1	 <e1>child</e1> was carefully wrapped and bound into the <e2>cradle</e2> by means of a cord."
Other
Comment:

2	 misty <e1>ridge</e1> uprises from the <e2>surge</e2>."
Other
Comment:

3	 is the sprawling <e1>complex</e1> that is Peru's largest <e2>producer</e2> of silver."
Other
Comment:

4	 current view is that the chronic <e1>inflammation</e1> in the distal part of the stomach caused by Helicobacter pylori <e2>infection</e2> results in an increased acid production from the non-infected upper corpus region of the stomach."
Cause-Effect(e2,e1)
Comment:

5	 <e1>composer</e1> has sunk into <e2>oblivion</e2>."
Other
Comment: violates b.1 and c.3

6	 <e1>burst</e1> has been caused by water hammer <e2>pressure</e2>."
Cause-Effect(e2,e1)
Comment:

7	 <e1>singer</e1>, who performed three of the nominated songs, also caused a <e2>commotion</e2> on the red carpet."
Cause-Effect(e1,e2)
Comment:

8	 intellectually engaging books and <e1>essays</e1> remain pertinent to illuminating contemporary <e2>history</e2>."
Other
Comment: "pertinent to" is not necessarily about

9	 sweet <e1>dress</e1> is made with a <e2>blend</e2> of cotton and silk, and the crochet flower necklace is the perfect accessory."
Other
Comment: the blend is the material out of which the dress is made; can't be Entity-Origin because the material is still present in the dre

10	 is one of the leading causes of <e2>death</e2> among pre-adolescents and teens, and victims of bullying are at an increased risk for committing suicide."
Cause-Effect(e1,e2)
Comment:

11	 had chest pains and <e1>headaches</e1> from <e2>mold</e2> in the bedrooms."
Cause-Effect(e2,e1)
Comment:

12	 Medicare buy-in <e1>plan</e1> ran into Senate <e2>resistance</e2>."
Other
Comment: violates c.3

13	 <e1>stress</e1> is one of the main causes of <e2>divorce</e2>."
Cause-Effect(e1,e2)
Comment:

14	 <e1>women</e1> that caused the <e2>accident</e2> was on the cell phone and ran thru the intersection without pausing on the median."
Cause-Effect(e1,e2)
Comment:

15	 are caused by improperly fitting shoes or by a <e2>skin abnormality</e2>."
Cause-Effect(e2,e1)
Comment:

16	 in the popular movie "Deep Impact", the action of the Perseid <e1>meteor shower</e1> is caused by a <e2>comet</e2>, in this case periodic comet Swift-Tuttle."
Cause-Effect(e2,e1)
Comment:

17	 following information appeared in the <e1>notes</e1> to consolidated financial <e2>statements</e2> of some corporate annual reports."
Other
Comment: We do not know what the notes are talking about; we only know that the notes are somehow connected to the statement.

18	 appropriates the symbols of a consumer society: oversized <e1>diamond</e1> <e2>colliers</e2> are worn."
Other
Comment:

19	 <e1>radiation</e1> from the atomic <e2>bomb explosion</e2> is a typical acute radiation."
Cause-Effect(e2,e1)
Comment:

20	 neoplastic <e1>recurrence</e1> arose from an extensive <e2>radiation</e2> induced ulceration."
Cause-Effect(e2,e1)
Comment:

21	 has a tattoo on his right arm and <e1>scars</e1> from <e2>stitches</e2> on his right elbow."
Cause-Effect(e2,e1)
Comment:

22	 bought a <e1>silver</e1> <e2>ring</e2> which he was so happy with and he keeps wearing it now even though its abit too big haha."
Other
Comment:

23	 major <e1>disagreement</e1> with Lyons concerns the <e2>causal part</e2> of his theory."
Other
Comment:

24	 infectious bacterial disease <e1>brucellosis</e1> has been found in a beef <e2>cow</e2> in eastern Idaho."
Other
Comment: diseases are not parts.

25	 the Anglo-Norman force sustained but little loss in this battle, their archers at the onset showered a hail of arrows upon the Irish host who were not protected with mail armour, and shot them down in hundreds before they could get to close quarters; and then the charge of the heavy Anglo-Norman cavalry of mail-clad knights, completed the havoc and <e1>rout</e1> of the undisciplined Gaelic <e2>hosts</e2>."
Other
Comment: The pattern is at fault -- "rout" is not the name of a grouping; negation is outside

26	 continuing Nigerian <e1>outbreak</e1> is the biggest ever caused by the <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

27	 <e1>fire</e1> inside WTC was caused by exploding <e2>fuel</e2>."
Cause-Effect(e2,e1)
Comment:

28	 <e1>suffering</e1> caused by the <e2>terrorists</e2> is the real torture."
Cause-Effect(e2,e1)
Comment:

29	 a poetic twist, the <e1>tsunami</e1> triggered by the rock <e2>band</e2> forced many American jazz and blues singers to seek work in the United Kingdom, which is where Anderson found a receptive audience in 1965."
Cause-Effect(e2,e1)
Comment:

30	 and fire caused due to <e2>corrosion</e2> of bypass piping for recirculation gas at a fuel oil desulphurization unit."
Cause-Effect(e2,e1)
Comment:

31	 metal <e1>ball</e1> makes a ding ding ding <e2>noise</e2> when it swings back and hits the metal body of the lamp."
Cause-Effect(e1,e2)
Comment:

32	 other fish, grunion come out of the water completely to lay their eggs in the wet <e1>sand</e1> of the <e2>beach</e2>."
Other
Comment:

33	 view of the <e1>damage</e1> caused by the 1693 Catania <e2>earthquake</e2> and the reconstruction activities."
Cause-Effect(e2,e1)
Comment:

34	 requested that the perpetrators be prosecuted to the fullest extent of the law, that adequate compensation be provided to the victims and that senior government and police officials offer apologies for the <e1>suffering</e1> caused by the responsible police <e2>officers</e2>."
Cause-Effect(e2,e1)
Comment:

35	 <e1>findings</e1> have been published in a special <e2>section</e2> of the academic journal Archives of Sexual Behavior."
Other
Comment: Location. It cannot be Content-Container since the Content should be removable. It also cannot be Component-Whole since it violates (d).

36	 Marshall Plan also provided a way of gaining public acceptance in Europe for the New Deal format that the United States had successfully used before the war to end the <e1>recession</e1> triggered by the 1929 Wall Street <e2>crash</e2>."
Cause-Effect(e2,e1)
Comment:

37	 they grow there, the <e1>swelling</e1> and inflammation caused by the <e2>infection</e2> closes off the sac, causing it not to "shed" bacteria, and protecting the bacteria inside from antibiotics and your body's own immune cells."
Cause-Effect(e2,e1)
Comment:

38	 are played acoustically; the <e1>tone</e1> is produced by the <e2>vibration</e2> of the strings which is amplified by the body of the guitar, which acts as a large hollow resonating chamber, or they may rely on an amplifier that can electronically manipulate tone."
Cause-Effect(e2,e1)
Comment:

39	 are reborn from the soil and the climate begins to warm, all set to a <e1>score</e1> improvised by an <e2>orchestra</e2> of birds."
Other
Comment: score is not a product

40	 Subtlety reduced the threat caused by Polymorph by 40% at max rank, though the <e1>threat</e1> caused by the <e2>spell</e2> is minimal."
Cause-Effect(e2,e1)
Comment:

41	 beautiful hydrothermal features in the park (geysers, hot springs, mud pots, etc.), the uplift and subsidence, and many of the <e1>earthquakes</e1> are caused by the <e2>movements</e2> of hydrothermal and/or magmatic fluids."
Cause-Effect(e2,e1)
Comment:

42	 parents bought her a <e1>silver</e1> <e2>necklace</e2> almost identical to the one pictured."
Other
Comment:

43	 <e1>motion</e1> of the vehicle through the air caused a <e2>suction</e2> on the road draft tube."
Cause-Effect(e1,e2)
Comment:

44	 Friedrich guides us through a <e1>babel</e1> of <e2>words</e2>, and worlds of the imagination ranging from his translations from five languages(notably the Russian of his literary studies) to the poetry of the Indian Mexico of his anthropological field work to America writ large -- super highways, a Vermont farm, father and child."
Other
Comment: Webster says: babel: 2 often not capitalized a: a confusion of sounds or voices b: a scene of noise or confusion --- so not a set.

45	 <e1>decision</e1> was also the subject of an unsuccessful <e2>legal challenge</e2>."
Other
Comment: "legal challenge" is not a Message

46	 <e1>malfunctions</e1> on Monday caused <e2>delays</e2> for patrons waiting to check out or renew books at the branches, and impeded access to personal accounts that allow users to renew or hold books online."
Cause-Effect(e1,e2)
Comment:

47	 <e1>train ride</e1> from <e2>station</e2> to station is approximate 30 minutes."
Other
Comment:

48	 <e1>maze</e1> of interlocking <e2>jurisdictions</e2> and levels of government confronts average citizens in trying to solve even the simplest of problems."
Other
Comment:This definitely is not a set: it is a pattern, an arrangement.

49	 <e1>damage</e1> from roof leaks, plumbing leaks or flooding lead to the <e2>growth</e2> of molds."
Cause-Effect(e1,e2)
Comment:

50	 weather is here, and with it comes the <e1>scourge</e1> of <e2>mosquitoes</e2>."
Other
Comment: Like infestation, it is not a set.

51	 <e1>formation</e1> of struvite <e2>stones</e2> is associated with the presence of urea-splitting bacteria, most commonly Proteus mirabilis (but also Klebsiella, Serratia, Providencia species)."
Other
Comment: A process.

52	 army was successfully engaged during the day with strong rearguards of all arms on the Petit Morin River, thereby materially assisting the progress of the French armies on our right and left, against whom the <e1>enemy</e1> was making his greatest <e2>efforts</e2>."
Other
Comment: Effort is not a concrete object.

53	 <e1>discomfort</e1> from the <e2>injury</e2> was now precluding him from his occupation which involved prolonged procedures in the standing position."
Cause-Effect(e2,e1)
Comment:

54	 always try to maintain the best <e1>environment</e1> for <e2>programmers</e2>, starting with good salary and conducive working environment."
Other
Comment: We cannot say the programmers actually/directly use the environment.

55	 <e1>water</e1> pushed to the coast resulted in <e2>tides</e2> as much as three feet above normal, with waves of 5-10 feet atop these tides."
Cause-Effect(e1,e2)
Comment:

56	 <e1>charge</e1> is the source of an electric <e2>field</e2>, which carries energy-the electrostatic self-energy."
Cause-Effect(e1,e2)
Comment:

57	 <e1>tardiness</e1> however has been caused by the <e2>arrival</e2> of my old man; who in true Bloodworth fashion has had me walking everywhere."
Cause-Effect(e2,e1)
Comment:

58	 river had now turned into full <e1>flood</e1> after the <e2>deluge</e2> of rain a few days ago."
Cause-Effect(e2,e1)
Comment:

59	 <e1>cultivation</e1> consisted of plowing the crop with a double-shovel <e2>plow</e2>."
Other
Comment: Purpose-Tool

60	 mentioned the <e1>scandal</e1> caused by a BBC <e2>documentary</e2> on the treatment of children in a special-needs home and asked how the state had responded to these."
Cause-Effect(e2,e1)
Comment:

61	 have placed the <e1>candidates</e1> into <e2>roles</e2>."
Other
Comment: violates b.

62	 agitations throw academic <e1>life</e1> into <e2>disarray</e2>."
Other
Comment: violates c.3

63	 in simple words, a <e1>tendon</e1> attaches a <e2>muscle</e2> to a bone."
Other
Comment:

64	 were denoted by <e2>black dots</e2> along the tracks, the adjacent numbers indicating the day of the month."
Other
Comment:

65	 World Health Organization(WHO) found that the <e1>radiation</e1> release from the Chernobyl <e2>accident</e2> was 200 times that of the Hiroshima and Nagasaki."
Cause-Effect(e2,e1)
Comment:

66	 in the midst of the <e1>confusion</e1> caused by the <e2>coup</e2>, the issuing of militant posters was a way for artists and organizations to declare their active engagement against the rebellion."
Cause-Effect(e2,e1)
Comment:

67	 <e1>accident</e1> caused a major traffic <e2>snarl</e2> on the arterial road."
Cause-Effect(e1,e2)
Comment:

68	 plane crash survivors have paid a special visit to the Hutt Hospital <e1>surgeon</e1> whose <e2>team</e2> helped to re-build their shattered faces eight years ago."
Other
Comment:The team is not a collection of surgeons.

69	 various forms of idealistic, materialistic and agnostic philosophies are subject to the <e1>tension</e1> caused by the indicated <e2>situation</e2>."
Cause-Effect(e2,e1)
Comment:

70	 damage and <e1>electrode</e1> <e2>corrosion</e2> are both associatcd with high charge density stimulation."
Other
Comment:

71	 of the diaphragm are caused by stimulation of the vagus nerve either by the brain or by <e2>irritation</e2> anywhere along the length of the nerve."
Cause-Effect(e2,e1)
Comment:

72	 Christmas, Daniel gave Kelly a Tiffany bracelet, and for Valentine's Day he bought a <e1>diamond</e1> <e2>necklace</e2>."
Other
Comment:

73	 <e1>warts</e1> are caused by a <e2>virus</e2> that infects the outer layer of skin on the soles of the feet."
Cause-Effect(e2,e1)
Comment:

74	 <e1>sensor</e1> was manufactured in a cost effective thin film <e2>process</e2>."
Other
Comment:

75	 putative left, we see, is just as eager as the nominal right to brand crime and violence with any hint of political motivation as terrorism, and therefore to remove it from the ordinary processes of criminal law and sanction, which are already quite draconian in these United States, and to animate parallel systems of harsher surveillance and punishment for the political <e1>compeers</e1> of such <e2>criminals</e2>."
Other
Comment: Compeer = peer (more or less). Not a set.

76	 process passes on a health <e1>gene</e1> to the next <e2>generation</e2>."
Other
Comment: violates c.3

77	 map to the left shows a snapshot of <e1>weather</e1> <e2>conditions</e2> in selected towns across Italy."
Other
Comment:

78	 retailers poured <e1>resources</e1> into promoting low-alcohol <e2>wine</e2>."
Other
Comment: resources go to promoting, not to wine=

79	 final <e1>part</e1> of the court is completed by the <e2>chapel</e2>, begun by Mary I in 1554 in memory of her father."
Other
Comment: part is not a producer

80	 <e1>hotel</e1> arose from the <e2>reconstruction</e2> of historical building."
Other
Comment:

81	 "all around immature nice guy" is, above all, a <e1>choreographer</e1>, having devised the <e2>moves</e2> to the film adaptation of Hairspray."
Other
Comment:

82	 <e1>state</e1> has assembled a $230 million incentive <e2>package</e2> to lure the project, which could mean as many as 9000 jobs."
Other
Comment: this is not a product-producer, the package is not a concrete object.

83	 stong <e1>earthquake</e1> caused a <e2>blackout</e2> on the sound stage and short-circuited some of the neon-tubed violins."
Cause-Effect(e1,e2)
Comment:

84	 <e1>solution</e1> comprises the <e2>creation</e2> of a decentralized Internet host name resolution system with flat hierarchy on the basis of Metrized Small World data structure."
Other
Comment:

85	 Release by Mega Food contains Sensoril, a clinically studied extract of a Ashwagandha that helps to inhibit fatigue and physical <e1>tension</e1> from everyday <e2>stress</e2>."
Cause-Effect(e2,e1)
Comment:

86	 an innate desire to know and to do, mankind has progressed past placing a dead fish in every <e1>hill</e1> of <e2>corn</e2>, beans and squash."
Other
Comment: figurative speech; possibly a location.

87	 special <e1>meeting</e1> of the <e2>shareholders</e2> of Lydia Diamond was held on December 23rd, 2009 and the Sale was approved by the shareholders."
Other
Comment: Participation, not belonging.

88	 aim of this study, therefore, was to examine the embryo <e1>quality</e1> obtained from vitrified, warmed <e2>oocytes</e2> in a standard infertility population."
Other
Comment:

89	 disease</e1> is one of the leading causes of <e2>morbidity</e2> and mortality in the UK, as well as in the developed and the developing world."
Cause-Effect(e1,e2)
Comment:

90	 level surface closest to the MSS, known as the <e1>geoid</e1>, departs from an <e2>ellipsoid</e2> by about 100 m in each direction."
Other
Comment:

91	 from nasal and <e2>sinus pressure</e2> usually can be seen on a good nasal examination and a CT of the sinuses."
Cause-Effect(e2,e1)
Comment:

92	 the 2006 campaign, the <e1>governor</e1> won the Hispanic vote with <e2>appearances</e2> such as one at Casa de Maryland."
Other
Comment:

93	 <e1>chair</e1> of the <e2>corporation</e2>, at the time of election, shall be either a former President, the retiring President, or a member (not emeritus) of the Corporation."
Other
Comment:

94	 <e1>hole</e1> was found in a <e2>piece</e2> of the package that was ripped off near its edge."
Other
Comment: There is no functional connection; the hole probably appeared by accident.

95	 <e1>meeting</e1> establishes the <e2>laws</e2> which govern the church and the priorities for the coming year."
Cause-Effect(e1,e2)
Comment: "laws" is a metonymy for "rule of law", which is a state

96	 also pointed out that on the Sabbath the <e1>priests</e1> broke the commandment with priestly <e2>work</e2>."
Other
Comment:

97	 like <e1>fear</e1> from <e2>crowd</e2>, fear from insects, fear from height etc all contribute in developing the anxiety disorder."
Cause-Effect(e2,e1)
Comment:

98	 a cloudless, new moon sky, a billion <e1>stars</e1> lit the <e2>heavens</e2>."
Other
Comment: heavens are not producer

99	 hidden preamble or timing signal is employed to mark the time of commencement of the <e1>transmission</e1> of information pulses from a <e2>transmitter</e2>."
Cause-Effect(e2,e1)
Comment:

100	 <e1>confrontation</e1> with the flight attendant caused a <e2>commotion</e2> on the plane, prolonged the flight's delay, and added to the aggravation already being felt by the passengers and crew."
Cause-Effect(e1,e2)
Comment:

101	 chronic myelogenous leukemia-specific P210 <e1>protein</e1> is the product of the bcr/abl hybrid <e2>gene</e2>."
Other
Comment:

102	 purpose of the <e1>audit</e1> was to report on the <e2>financial statements</e2>."
Other
Comment: Audit here is a process, not a message.

103	 increase of the signal might correspond to formation of the high-density excitons, while the <e1>reduction</e1> of the signal originates from the <e2>relaxation</e2>."
Cause-Effect(e2,e1)
Comment:

104	 estimate a wind speed associated with the <e1>devastation</e1> caused by the <e2>tornado</e2>."
Cause-Effect(e2,e1)
Comment:

105	 basic <e1>indicator</e1> of the health <e2>condition</e2> of trees, stands and forests is tree defoliation."
Cause-Effect(e2,e1)
Comment:

106	 <e1>deficits</e1> are caused by <e2>people</e2> saving too much of their money."
Cause-Effect(e2,e1)
Comment:

107	 my <e1>friend</e1> falls in <e2>love</e2> easily and breaks her heart all the time."
Other
Comment: violates b.1 and c.3

108	 <e1>wind</e1> and smoke cause flight <e2>delays</e2>."
Cause-Effect(e1,e2)
Comment:

109	 developing countries four-fifths of all the <e1>illnesses</e1> are caused by water-borne <e2>diseases</e2>, with diarrhoea being the leading cause of childhood death."
Cause-Effect(e2,e1)
Comment:

110	 completing the <e1>resetting</e1> through the reset <e2>signal</e2>, the bit period transmitted by the master module 30 is received."
Other
Comment: Purpose-Tool

111	 <e1>destruction</e1> caused by the <e2>bombing</e2> of Attorney General Palmer's home."
Cause-Effect(e2,e1)
Comment:

112	 second biggest factor affecting the <e1>sound</e1> produced by a <e2>drum</e2> is the tension at which the drum head is held against the shell of the drum."
Cause-Effect(e2,e1)
Comment:

113	 largest <e1>landslide</e1> triggered by the <e2>earthquake</e2> is located approximately 32 kilometers southeast of Muzafarrabad in a tributary valley of the Jhelum River."
Cause-Effect(e2,e1)
Comment:

114	 <e1>debris</e1> caused a <e2>crash</e2> on the Schuylkill, and it has been closed for hours because of the mishap."
Cause-Effect(e1,e2)
Comment:

115	 <e1>fire</e1> triggered by the <e2>blasts</e2> damaged eight buildings at the plant, including one that was burned down."
Cause-Effect(e2,e1)
Comment:

116	 his <e1>poem</e1>, written by the <e2>riverside</e2> near the battle-ground, Mr. Emerson alluded to "Yon stem headstone"."
Other
Comment:

117	 <e1>faults</e1> caused delays and <e2>cancellations</e2> on Wellington's suburban train services this morning."
Cause-Effect(e1,e2)
Comment:

118	 is a natural cure for <e2>cancer</e2>."
Other
Comment:

119	 spinal stenosis by enlarging the spinal canal to relieve <e1>pressure</e1> on the spinal cord that has been caused by a herniated or bulging <e2>disc</e2>."
Cause-Effect(e2,e1)
Comment:

120	 <e1>beer</e1> acts as a great hair of the <e2>dog</e2>."
Other
Comment:

121	 <e1>company</e1> has run into a financial <e2>problem</e2> over the last few years."
Other
Comment: violates b.

122	 <e1>girl</e1> plays her violin on a pogo <e2>stick</e2>."
Other
Comment: Locative relation.

123	 manages to escape and kidnaps the <e1>scientist</e1>'s <e2>niece</e2>."
Other
Comment: the niece is not a product of the scientist

124	 have rights in the event of a delay or <e1>cancellation</e1> that has been caused by the <e2>airline</e2>."
Cause-Effect(e2,e1)
Comment:

125	 screenplay by Patterson McNutt and Arthur J. Beckhard focuses on the adoption of a young <e1>orphan</e1> (Shirley Temple) by a wealthy <e2>bachelor</e2> (John Boles)."
Other
Comment: the orphan is not produced by the bachelor

126	 Susanoo was in <e1>sorrow</e1> after the <e2>loss</e2> of his mother and he was raging in his kingdom."
Cause-Effect(e2,e1)
Comment:

127	 the <e1>earthquake</e1> triggered by the <e2>eruption</e2> of Thera struck first."
Cause-Effect(e2,e1)
Comment:

128	 objective is to review <e1>advances</e1> in the molecular <e2>biology</e2> and pharmacogenomics of lung cancer and how they apply to personalizing medicine."
Other
Comment:

129	 mellitus</e1> is one of the leading causes of irreversible <e2>blindness</e2> worldwide, and, in the United States."
Cause-Effect(e1,e2)
Comment:

130	 <e1>crew</e1> assisted with the <e2>investigation</e2> and was in service for around an hour."
Other
Comment: Purpose-Tool

131	 <e1>data</e1> has been concerning primarily assembly <e2>operations</e2>."
Other
Comment:

132	 chief adds <e1>hurdles</e1> for <e2>drilling</e2> on public lands."
Other
Comment: Purpose-Tool

133	 is the most efficient and compact form of <e1>insulation</e1> in a <e2>carafe</e2>, and it's unbreakable."
Other
Comment:

134	 help has reduced the time to reverse all the <e1>irritation</e1> that had been caused by the <e2>fungus</e2>."
Cause-Effect(e2,e1)
Comment:

135	 the other hand, the higher the <e1>satisfaction</e1> from the <e2>purchase</e2>, the greater the benefit of word-of-mouth referrals and repeat purchasing."
Cause-Effect(e2,e1)
Comment:

136	 big city marathons offer great crowd support and a large <e1>camaraderie</e1> of <e2>runners</e2>, running in a big city marathon is not for everyone."
Other
Comment: Camaraderie is the spirit of community. Not a set.

137	 48% of the divorces, the <e1>kinship systems</e1> of <e2>grandparents</e2> expanded with divorce through one or more of the following four processes."
Other
Comment:

138	 Judge without a jury and judgment was entered for the defendants on the ground that the <e1>accident</e1> was caused by the plaintiff's own <e2>negligence</e2>."
Cause-Effect(e2,e1)
Comment:

139	 world is experiencing an unprecedented <e1>glut</e1> of <e2>savings</e2>, driving down real interest rates."
Other
Comment: Glut means many, a lot --- not a set.

140	 <e1>case</e1> centers on a <e2>tree</e2> at a high school that was a meeting place for white students."
Other
Comment:

141	 filled with <e1>rage</e1> after the <e2>fight</e2> with the Darkside, I rush at Ansem, light and dark energy overflowing from me."
Other
Comment:

142	 children descend the ladder after hearing the fire <e1>alarm</e1> which has been triggered by the wood work workshop catching <e2>fire</e2>."
Cause-Effect(e2,e1)
Comment:

143	 the best <e1>blogging</e1> is going on well away from the most visible <e2>places</e2>."
Other
Comment:

144	 <e1>incident</e1> caused a brief <e2>sensation</e2> on the Web among people suspicious that it was a political commentary."
Cause-Effect(e1,e2)
Comment:

145	 <e1>navy</e1> searched the vessel with the <e2>crew</e2> on board."
Other
Comment:

146	 sealed the cut after making a <e1>cut</e1> of the stem with a clean, sharp <e2>blade</e2>."
Other
Comment: Purpose-Tool

147	 workers locked themselves in the upstairs office and left the shocked <e1>managers</e1> downstairs in the <e2>shop</e2>."
Other
Comment:

148	 this is frequently cited as "proof" that saturated fats and <e1>cholesterol</e1> cause heart <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

149	 Water Information Program is a public information <e1>program</e1> sponsored by the water <e2>districts</e2>, organizations and agencies in the San Juan and Dolores watersheds of Southwestern Colorado."
Other
Comment: district is not a producer

150	 recently succeeded in wiping out a nasty <e1>memory</e1> from the mind of a genetically-engineered <e2>mouse</e2>."
Other
Comment: the mouse does not produce the memory

151	 commercial soap, shower gel or cleanser products contain <e1>preservatives</e1>, colorants and chemicals that cause dryness, rashes, <e2>itchiness</e2> and roughness on the skin."
Cause-Effect(e1,e2)
Comment:

152	 and Stockton Heath were called to the scene after <e1>pyrotechnics</e1> used during one of the performances caused a <e2>fire</e2> on the main stage."
Cause-Effect(e1,e2)
Comment:

153	 a catch-22 the worst part is that acne causes stress and <e1>stress</e1> triggers acne <e2>breakouts</e2>."
Cause-Effect(e1,e2)
Comment:

154	 US patent system is in a <e1>crisis</e1> that has been caused by the <e2>flood</e2> of patent applications being filed at the USPTO every year."
Cause-Effect(e2,e1)
Comment:

155	 many farmers did their <e1>plowing</e1> the land with a single furrow <e2>plow</e2>, some large-scale farmers began to use a multiple share or bukker plow."
Other
Comment: Purpose-Too

156	 were be submitted by 5 p.m. on the Wednesday before <e1>publication</e1> by <e2>mail</e2>."
Other
Comment: "by mail" modifies the submission, not the publication.

157	 gastroenteritis is a highly contagious <e1>infection</e1> of the intestines caused by one of several <e2>viruses</e2>."
Cause-Effect(e2,e1)
Comment:

158	 outer <e1>segment</e1> is comprised of a <e2>membrane</e2> which is folded into several layers of disks."
Other
Comment: It sounds like the membrane is the whole segment, not just part of it.

159	 fizzy <e1>drinks</e1> and meat cause heart disease and <e2>diabetes</e2>."
Cause-Effect(e1,e2)
Comment:

160	 explore the experience of <e1>grief</e1> after the <e2>loss</e2> of a parent and offers support; we also make simple suggestions, and we provide a place for sharing memories."
Cause-Effect(e2,e1)
Comment:

161	 war <e1>mentality</e1> was generated by the Iraq <e2>war</e2> in combination with the constant drum beat of fear at home."
Cause-Effect(e2,e1)
Comment:

162	 is still one of the leading causes of maternal <e2>mortality</e2>."
Cause-Effect(e1,e2)
Comment:

163	 no computers were then available to him, he hand-simulated the Boxes algorithm, using a <e1>device</e1> made from an assembly of <e2>matchboxes</e2>."
Other
Comment: matchboxes make the dev

164	 to running barefoot, <e1>running</e1> in conventional running <e2>shoes</e2> increases stress on the knee joints up to 38%."
Other
Comment: Purpose-Tool

165	 <e1>demolition</e1> was the cause of <e2>terror</e2> and communal divide is just a way of not letting truth prevail."
Cause-Effect(e1,e2)
Comment:

166	 <e1>outbreak</e1> resulted in 256 deaths and 3,402 <e2>injuries</e2>."
Cause-Effect(e1,e2)
Comment:

167	 postcard took the <e1>reader</e1> into the author's <e2>past</e2>."
Other
Comment: violates b.

168	 emotionally wrenching experiences encouraged the volunteers to seek the <e1>comradeship</e1> of fellow <e2>veterans</e2>."
Other
Comment: What's sought is company.

169	 County, a small but thriving colony grows in the seepage <e1>spring</e1> which is the source of the <e2>creek</e2>."
Other
Comment:

170	 portable electronic <e1>devices</e1> are running into temperature sensitivity <e2>issues</e2>."
Other
Comment: violates b.

171	 melting butter on the <e1>stove</e1> is the preferred <e2>method</e2>, because it gives you more control over the process, you can also melt butter in a microwave."
Other
Comment: Modality is outsid

172	 the tea slowly to reduce stomach <e1>pain</e1> from <e2>indigestion</e2>, bloating and feeling of fullness."
Cause-Effect(e2,e1)
Comment:

173	 substance abuse and poverty all lead to <e2>child abuse</e2>."
Cause-Effect(e1,e2)
Comment:

174	 ATM <e1>malfunction</e1> caused a <e2>rush</e2> on the ATM machine until the police sealed off the area."
Cause-Effect(e1,e2)
Comment:

175	 was focused on <e2>admission avoidance</e2>, prevention of deterioration after admission and facilitating early discharge."
Other
Comment:

176	 the knightly ethic was based on a sense of honour and reflected the ideal of a <e1>comradeship</e1> of <e2>arms</e2>."
Other
Comment: Ethics, not a set.

177	 <e1>sections</e1> have been denoted with an <e2>asterisk</e2>."
Other
Comment:

178	 <e1>corpse</e1> of a murderer was dangling from the <e2>noose</e2>, twisting in the wind."
Other
Comment:

179	 causes fluid <e2>retention</e2>, which can lead to edema (swelling), increased blood pressure, and in those susceptible patients, congestive heart failure."
Cause-Effect(e1,e2)
Comment:

180	 takes <e1>words</e1> into <e2>action</e2>."
Other
Comment: violates c.3

181	 businesses generally the third party claims for the <e1>damages</e1> that has been caused by the company <e2>vehicle</e2>."
Cause-Effect(e2,e1)
Comment:

182	 <e1>martyrs</e1> conquered the fears associated with <e2>persecution</e2> and always remained loyal to the Lord."
Other
Comment:

183	 Tim Geithner came along with a <e1>fistful</e1> of taxpayer <e2>dollars</e2>."
Other
Comment: Too metaphorical. Plus, a fistful is a quantity.

184	 <e1>law</e1> established a major <e2>redistribution</e2> of territorial sovereignty within the Empire."
Cause-Effect(e1,e2)
Comment: redistribution caused by law

185	 mononucleosis due to the Epstein-Barr <e1>virus</e1> causes exudative <e2>tonsillitis</e2> or pharyngitis in about one-half of cases."
Cause-Effect(e1,e2)
Comment:

186	 the trial, the prosecution presented "pictures of burning bodies and human remains as well as images of the <e1>explosion</e1> triggered by the Pentagon <e2>crash</e2>.""
Cause-Effect(e2,e1)
Comment:

187	 <e1>damage</e1> at the mine has been caused by the <e2>strikers</e2>."
Cause-Effect(e2,e1)
Comment:

188	 is the <e1>site</e1> deep inside the <e2>earth</e2> where fault movement begin."
Other
Comment: the site is not an entity of its own.

189	 we have set-up, early on, a familiar literary dynamic --- two <e1>compeers</e1> of different <e2>ages</e2> thrown together: Huck Finn and Nigger Jim, Holden Caufield and sister Phoebe, hell --- maybe even Dmitri Karamazov and Alyosha (or, if we stretch it far enough, Falstaff and Prince Hal)."
Other
Comment:

190	 too, get a <e1>headache</e1> from <e2>wine</e2>, and was always told that it was the sulfites."
Cause-Effect(e2,e1)
Comment: modality is outside

191	 most significant is a well-preserved black and white mosaic for which the <e1>authority</e1> has given a provisional <e2>translation</e2>."
Other
Comment:

192	 entered the <e1>patients</e1> into randomised controlled <e2>trials</e2>."
Other
Comment: violates b.1 and c.3

193	 <e1>interrogation</e1> covers von Neurath's <e2>activities</e2> during the years 1932 to 1938 and Hitler's policy of aggression during the late 1930s."
Other
Comment: Not a message -- a process or a procedure.

194	 all of the <e1>harm</e1> caused by the <e2>hurricane</e2> has filled entire books so this Web page summarizes the total damage and focuses on the damage incurred on Long Island, New York."
Cause-Effect(e2,e1)
Comment:

195	 is included on the <e1>disease</e1> caused by the <e2>organism</e2>, its transmission, geographical distribution, and hosts."
Cause-Effect(e2,e1)
Comment:

196	 <e1>star</e1> is landing into <e2>controversies</e2> because of thoughtless statements."
Other
Comment: violates b.1 and c.3

197	 political <e1>prisoner</e1> is falling into <e2>oblivion</e2>."
Other
Comment: violates b.1 and c.3

198	 is one of the commonest causes of <e2>death</e2> in burn patients, particularly."
Cause-Effect(e1,e2)
Comment:

199	 Vikings had become assimilated into a peaceable society, and <e1>monasteries</e1> at Chertsey and Abingdon were founded by the <e2>river</e2>."
Other
Comment: location, the river is not making monasterties

200	 was diagnosed with bipolar disorder following a <e1>breakdown</e1> triggered by the sudden <e2>death</e2> of my brother six years ago."
Cause-Effect(e2,e1)
Comment:

201	 years now my <e1>daughter</e1> has put up with verbal <e2>harssement</e2> from a girl."
Other
Comment: harssement is not a product of the daughter but of a girl

202	 longest serving <e1>spacecraft</e1> goes into <e2>retirement</e2>."
Other
Comment: violates b.1 and c.3

203	 <e1>baby</e1> is falling into a <e2>sleep</e2>."
Other
Comment: violates b.1 and c.

204	 reactor <e1>meltdown</e1> caused a chain <e2>reaction</e2> that destroyed all the towers in the network."
Cause-Effect(e1,e2)
Comment:

205	 that occur after DTaP are caused by a <e2>fever</e2>."
Cause-Effect(e2,e1)
Comment:

206	 a commercial Enigma, modified by Polish cryptanalysts to match a military Enigma, used phone plugs, the <e1>plugs</e1> in the <e2>plugboard</e2> of the actual Enigma had two prongs, but they still functioned electrically in the same way as phone plugs."
Other
Comment: The plugboard and plugs are separate parts of the machine.

207	 is marked by a <e1>sign</e1> indicating the <e2>length</e2> of the pause."
Other
Comment: Purpose.

208	 the vehicles caught <e1>fire</e1> after the <e2>collision</e2>, the transformers began to explode one after the other."
Cause-Effect(e2,e1)
Comment:

209	 or smoke cause <e2>irritation</e2> to those with respiratory sensitivity."
Cause-Effect(e1,e2)
Comment:

210	 <e1>professor</e1> portrays his students' term <e2>paper</e2> as his own."
Other
Comment: professor is not a producer

211	 <e1>team</e1>, has carefully devised an amended research <e2>methodology</e2>; it has also since found that further compromises will have to be made."
Other
Comment: the team is not producing the methodology; modality is outsid

212	 <e1>sinking</e1> resulted in the <e2>loss</e2> of 112 lives, including those of 28 Americans."
Cause-Effect(e1,e2)
Comment:

213	 <e1>team</e1> drafted a great <e2>player</e2> in 2002 when they chose Julius Peppers second overall."
Other
Comment: player is not a product

214	 daily headaches are tension headaches or <e1>headaches</e1> which are caused by taking too many <e2>pain killers</e2>."
Cause-Effect(e2,e1)
Comment:

215	 over time, indigenous <e1>students</e1> have been moving into more specialised and skill-intensive <e2>components</e2> within disciplines."
Other
Comment: violates b.

216	 <e1>month</e1> of snowy <e2>sundays</e2> in January had an adverse impact on Prospect's finances."
Other
Comment:

217	 necropsy a heavy <e1>infestation</e1> of Haematopinus <e2>lice</e2> was present, along with a polyserositis affecting the right hock, left elbow and peritoneum."
Other
Comment:

218	 <e1>meningitis</e1> is caused by pneumococcus <e2>bacteria</e2>, which also cause several diseases of the respiratory system, including pneumonia."
Cause-Effect(e2,e1)
Comment:

219	 shark attacks in 24 hours threw local <e1>people</e1> into <e2>panic</e2>."
Other
Comment: violates b.1 and c.3

220	 share a <e1>kinship</e1> of <e2>ideals</e2> with every man and woman on earth who struggles for their God-given rights."
Other
Comment:

221	 (on a proportional basis) the <e1>rainbow</e1> caused by the <e2>spray</e2> appeared smaller than that of the other rainbow."
Cause-Effect(e2,e1)
Comment:

222	 <e1>changes</e1> now seen in the endometrium are caused by a <e2>hormone</e2> called progesterone."
Cause-Effect(e2,e1)
Comment:

223	 <e1>waste</e1>, a mixture of gasoline, water and caustic soda, gave off toxic <e2>fumes</e2>."
Cause-Effect(e1,e2)
Comment:

224	 <e1>studies</e1>, some of them book long, have made a notable contribution to scientific <e2>medicine</e2>."
Other
Comment: the studies are published - (d) is satisfied. However, medicine is NOT their Topic

225	 ligaments</e1> are caused by <e2>problems</e2> with collagen (protein fibres in the ligaments)."
Cause-Effect(e2,e1)
Comment:

226	 puts <e1>creativity</e1> into <e2>use</e2>."
Other
Comment: violates c.3

227	 article discusses the ethics of the Soldier of Fortune's guns-for-hire <e1>advertisements</e1> that resulted in several <e2>murders</e2> across the United States."
Cause-Effect(e1,e2)
Comment:

228	 1905 the <e1>press</e1> reported extensively and vividly on the <e2>disorders</e2> in the cities and countryside, the clamor for basic reform, the political discussions."
Other
Comment: Press is an agent here.

229	 is used to indicate the <e2>words</e2> of another speaker or writer."
Other
Comment: Purpose.

230	 size of the thumbnails is changed with a sliding <e1>bar</e1> on the upper right <e2>corner</e2> of the window."
Other
Comment:

231	 evaluated maximum number of breached assemblies and exposed fuel area for a proposed <e1>shipment</e1> in a <e2>cask</e2> with a test leakage rate."
Other
Comment:

232	 <e1>battle</e1> caused a <e2>panic</e2> on the frontier, and settlers in the surrounding counties fled."
Cause-Effect(e1,e2)
Comment:

233	 decades, most of the nation's renewable <e1>power</e1> has come from <e2>dams</e2>, which supplied cheap electricity without requiring fossil fuels."
Cause-Effect(e2,e1)
Comment: Cause-Effect (satisfies c - Objects emitting radiation/heat/light... are regarded as Causers of such emissions)

234	 optical <e1>signal</e1> is generated by an externally modulated tunable <e2>laser</e2>, and introduced to the chip through a tapered fiber."
Cause-Effect(e2,e1)
Comment:

235	 <e1>byelection</e1> was caused by the <e2>resignation</e2> of Boris Johnson following his election as mayor of London in May."
Cause-Effect(e2,e1)
Comment:

236	 was a victim of the clandestine wealth-transfer plaguing the productive sector as a result of the falling interest-rate <e1>structure</e1> caused by bond <e2>speculation</e2>."
Cause-Effect(e2,e1)
Comment:

237	 end caps make <e1>pier</e1> piling sidewall <e2>forms</e2> function more efficiently by locking the forms together so they stay in place."
Other
Comment: I really don't understand this sentence.

238	 received reports from the residence hall presidents regarding <e1>evacuation</e1> after the fire <e2>drill</e2>."
Cause-Effect(e2,e1)
Comment:

239	 frog is the environmental <e1>indicator</e1> of the <e2>land</e2>, but University of Queensland researchers reckon when it comes to the sea, we should look to the turtle."
Other
Comment:

240	 <e1>tsunamis</e1> triggered by the massive <e2>earthquakes</e2> plunged those provinces into crisis: the number of people dead and missing has reached to 245,782 people."
Cause-Effect(e2,e1)
Comment:

241	 have to take into account the reality of the <e1>damage</e1> that has been caused by the <e2>deregulation</e2> of nutritional supplements."
Cause-Effect(e2,e1)
Comment:

242	 <e1>catastrophe</e1> is narrated through <e2>metaphor</e2>."
Other
Comment: Manner.

243	 Black-backed Gulls were capable of producing, on average, almost three times the normal <e1>clutch</e1> of three <e2>eggs</e2>."
Other
Comment: Quantification excludes the Member-Collection interpretation.

244	 Channel 4 <e1>drama</e1> set in a psychiatric unit has been criticised by a TV <e2>watchdog</e2> for its "offensive" title and for reinforcing prejudice against people with mental health problems."
Other
Comment:

245	 dominance</e1> is one of the main causes of <e2>osteoporosis</e2>, cancer, ovarian cysts, fibroids and a host of other female problems in the U.S."
Cause-Effect(e1,e2)
Comment:

246	 however, is a different <e1>kettle</e1> of <e2>drums</e2>."
Other
Comment: It's an idiom. Non-compositional reading makes no sense.

247	 is nominally a <e1>superfluity</e1> of <e2>goods</e2> required for subsistence, but the character of these goods varies with the use of wealth."
Other
Comment:

248	 <e1>wife</e1> is a participant in the <e2>blogosphere</e2>, and he doesn't want to ruin the surprise for her."
Other
Comment: modality and negation are outside

249	 <e1>scan</e1> started at the rest <e2>potential</e2> toward the positive direction."
Other
Comment:

250	 great news is that <e1>germs</e1> causing recreational water <e2>illnesses</e2> are killed by chlorine."
Cause-Effect(e1,e2)
Comment:

251	 EU inserted <e1>experts</e1> into the national <e2>defence</e2>."
Other
Comment: violates b.

252	 <e1>shop</e1> machined the part with a 1.25 inch <e2>diameter</e2>."
Other
Comment: diameter is not a tool, instead a property of the part.

253	 chance, Toe discovers a rainbow-coloured <e1>rock</e1> with hidden <e2>power</e2> to grant wishes."
Other
Comment: power is a property, cannot be Instrument.

254	 turbines are making an electricity <e1>system</e1> with low <e2>carbon</e2> emissions even greener - already, in Seattle, more than 90 percent of the power comes from renewable sources."
Other
Comment: carbon is not a product of the system

255	 <e1>disruption</e1> has been caused by a sensitivity reaction in the brain to an ingested <e2>substance</e2>."
Cause-Effect(e2,e1)
Comment:

256	 enormous <e1>landslide</e1>, which was triggered by an exceptionally heavy <e2>rainfall</e2> event (500 mm in 24 h) on 30 October 1998."
Cause-Effect(e2,e1)
Comment:

257	 the framework of a holistic approach to student development and support, Student Services are also the contact point for other functions such as student out-of-class involvement, <e1>student</e1> participation in the university <e2>governance</e2> as well as in the Student Union."
Other
Comment: Participation again -- not one of our relations.

258	 <e1>market</e1> is rooted in the <e2>structure</e2> of Zanzibar household economies, and therefore proides an indispensible function in daily life."
Other
Comment:

259	 complete <e1>examination process</e1> has been carried out according to the pertinent <e2>directives</e2>."
Other
Comment: "pertinent to" is not necessarily about

260	 heated <e1>gas</e1> caused a <e2>pyrolysis</e2> on the lower part of oil shale and produced shale oil and oil shale gas are escaped from the retort through exhaust pipe."
Cause-Effect(e1,e2)
Comment:

261	 signoff <e1>queue</e1> is used for <e2>reports</e2> that the user has not seen before."
Other
Comment: we have some Purpose-Tool relation here (the queue is used for reports); negation is outsid

262	 have inherited <e1>entitlements</e1> to <e2>property</e2>."
Other
Comment:

263	 libel <e1>claimant</e1> has proved that the <e2>statement</e2> was defamatory."
Other
Comment: the claimant is not the producer of the statement

264	 low oil <e1>prices</e1> caused the <e2>collapse</e2> of the wall and the Russian empire."
Cause-Effect(e1,e2)
Comment:

265	 charging odd amounts like 49 or 99 cents, the <e1>cashier</e1> very probably opened the <e2>till</e2>."
Other
Comment: The till is the object of the opening instead of the Instrument.

266	 <e1>pain</e1> was caused by the <e2>parasite</e2> entering the body through the skin during bathing or drinking of infested water."
Cause-Effect(e2,e1)
Comment:

267	 <e1>reaction</e1> starts at a rather low <e2>temperature</e2> ( + 5C), and the calorimeter is run from 40 to 130C."
Cause-Effect(e2,e1)
Comment:

268	 to Moll lived the celebrated actress Nancy Dawson, a former <e1>harlot</e1> made famous by her lascivious <e2>hornpipe</e2> in Gay's phenomenally popular The Beggar'ss Opera."
Other
Comment: no evidence that the pipe was made by the harlo

269	 we are not at all complacent and we are well aware of the <e1>challenges</e1> around <e2>recruitment</e2>."
Other
Comment: the negation is in the other clause, so we could keep the

270	 influential <e1>towns</e1> of Brownville and Fontanelle were founded that <e2>year</e2> as well."
Other
Comment: year is not a producer

271	 chance <e1>discovery</e1> made by a road <e2>worker</e2> in 1956 uncovered a rich find of 360 million year old fish fossils."
Other
Comment: (a) is satisfied

272	 Bank, which has only one retail location, was one of those opportunistic upstarts, a <e1>bank</e1> built on a <e2>bubble</e2>."
Other
Comment: bubble is not a producer

273	 <e1>helix</e1> runs away from the <e2>nucleotide</e2>."
Other
Comment:

274	 derive a tremendous amount of <e1>joy</e1> from <e2>teaching</e2> students in the research laboratory."
Cause-Effect(e2,e1)
Comment:

275	 study found that people who took the <e1>combination</e1> of cholinesterase <e2>inhibitors</e2> (Aricept, Razadyne, or Exelon) and Memantine, showed a significantly slower rate of cognitve decline than those who took only a cholinesterase inhibitor or no drug."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

276	 <e1>horns</e1> grows from the Southern California desert <e2>mountains</e2> across to Arkansas and up into Kansas."
Other
Comment:

277	 very serious <e1>problem</e1> ensued from the <e2>events</e2> of the day."
Cause-Effect(e2,e1)
Comment:

278	 sent the <e1>revellers</e1> into <e2>party mode</e2>."
Other
Comment: violates c.3

279	 first <e1>revolution</e1> was triggered by the growing use of reading and <e2>writing</e2>."
Cause-Effect(e2,e1)
Comment:

280	 US regulatory <e1>agency</e1> was investigating <e2>allegations</e2> that at least one plane was considered unsafe to fly."
Other
Comment:

281	 resulting <e1>biofilm</e1> grows from the <e2>inside</e2> out rather than planktonic organisms attaching and promoting the growth from the outside."
Other
Comment:

282	 <e1>vibration</e1> caused by a heavy goods <e2>train</e2> on the Metropolitan Railway, which runs under the Exhibition premises, had shaken the figure off its balance."
Cause-Effect(e2,e1)
Comment:

283	 also gives some of the history behind the <e1>formation</e1> of Wolf's <e2>dragoons</e2> and some of the battles and campaigns the mercenary regiment has fought."
Other
Comment: An arrangement, not a set; or maybe the process of forming.

284	 <e1>surges</e1> or spikes are caused by <e2>lightning</e2>, short circuits, power company equipment problems, and inductive spikes, among many other causes."
Cause-Effect(e2,e1)
Comment:

285	 recovery is weak and fragile, and the economic and social <e1>damage</e1> caused by the <e2>crisis</e2> is long-lasting."
Cause-Effect(e2,e1)
Comment:

286	 cutaneous <e1>mycoses</e1> are caused by a homogeneous group of keratinophilic <e2>fungi</e2> termed the dermatophytes."
Cause-Effect(e2,e1)
Comment:

287	 from the global economic <e1>crisis</e1> triggered by the <e2>collapse</e2> of Lehman Brothers was achieved with cooperation from Brazil, Russia, India and China."
Cause-Effect(e2,e1)
Comment:

288	 <e1>microphone</e1> converts sound into an electrical <e2>signal</e2>."
Cause-Effect(e1,e2)
Comment:

289	 trapped <e1>mass</e1> takes part in the <e2>movement</e2> and therefore contributes to the inertia of the system."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

290	 been a <e1>closet</e1> <e2>writer</e2> for a long time."
Other
Comment: closet is not a product

291	 of the resin is caused by the <e2>expansion</e2> of the structure as a result of water (or other liquid) molecules penetrating the matrix."
Cause-Effect(e2,e1)
Comment:

292	 were <e1>setbacks</e1> and technical problems that ensued from the location <e2>design</e2>, flooding, and moisture that plagued the winery and bumped up the investment cost beyond the initial budgetary estimates."
Cause-Effect(e2,e1)
Comment:

293	 find evidence that Ernst suffered a thrombotic cardiovascular event, i.e., a myocardial <e1>infraction</e1> triggered by a blood <e2>clot</e2>."
Cause-Effect(e2,e1)
Comment:

294	 was venting from the first floor of a multi-storeyed <e2>building</e2> in South Mumbai's Nariman point area on Monday."
Other
Comment:

295	 charcuterie was well portioned offering lots of variety, well textured, with a nice <e1>accompaniment</e1> of <e2>condiments</e2> and composed salads."
Other
Comment: As the words suggest, it is accompaniment, not belonging.

296	 <e1>protesters</e1> carefully chose a private <e2>road</e2> in order not to cause inconvenience to the public."
Other
Comment: the road is the location

297	 breakdown of the linear relation of J,1 D at peakeffect region indicates that the <e1>peakeffect</e1> originates from an addition pinning <e2>effect</e2>."
Cause-Effect(e2,e1)
Comment:

298	 gist of <e1>trespass</e1> is direct physical <e2>interference</e2> with another's exclusive possession of land."
Other
Comment:

299	 a <e1>headache</e1> from <e2>wine</e2> is often stronger and last longer due to several compounds."
Cause-Effect(e2,e1)
Comment:

300	 from various <e1>fields</e1> pertinent to the <e2>theme</e2> took part and presented specific aspects of the topic."
Other
Comment:

301	 <e1>container</e1> encloses a one-cup <e2>capacity</e2>, plus with the bonus lid it provides convenient storage of chopped foods."
Other
Comment: capacity is not a content

302	 Maze procedure crates new pathways for the electrical <e1>impulses</e1> that trigger the <e2>heartbeat</e2>."
Cause-Effect(e1,e2)
Comment:

303	 in the <e1>song</e1>, the background <e2>singers</e2> repeat the Christian and Jewish word of praise, "Hallelujah"."
Other
Comment: the singer is not creating the song it is just singing it

304	 discovered that my chronic <e1>migraines</e1> and neck pain were caused by the <e2>injuries</e2> I had sustained in my first car accident two and a half years ago."
Cause-Effect(e2,e1)
Comment:

305	 180 cm thick concrete <e1>shield</e1> starts at the <e2>radius</e2> of 600 cm."
Other
Comment:

306	 continuous <e1>rains</e1> had caused the <e2>overflow</e2> of Sulangaling River, a creek of the Muara Batang."
Cause-Effect(e1,e2)
Comment:

307	 and wind cause <e2>evaporation</e2> of water, causing rains, and this energy can be caught using hydroelectric power."
Cause-Effect(e1,e2)
Comment:

308	 has changed the way I think about the <e1>formation</e1> of <e2>parties</e2> and party systems."
Other
Comment: It's the forming of.

309	 schose the better approach: to be honest and understanding and to acknowledge the <e1>distress</e1> caused by the hallucinations or <e2>delusions</e2>."
Cause-Effect(e2,e1)
Comment:

310	 <e2>corrosion</e2> and stress corrosion are similar, as both are caused by external stresses applied to the pipe and occur inside of the pipe."
Cause-Effect(e1,e2)
Comment:

311	 <e1>fire</e1> started at the <e2>southeastern end</e2> of the Circus Maximus in shops selling flammable goods."
Other
Comment:

312	 assessed the efficacy of a recombinant <e1>vaccine</e1> consisting of <e2>outer-surface protein A</e2> (OspA) without adjuvant in subjects at risk for Lyme disease."
Other
Comment: outer-surface protein A is a substanc

313	 best kept secret for avoiding abdominal <e1>weight gain</e1> due to <e2>stress</e2> is the use of adaptogens."
Cause-Effect(e2,e1)
Comment:

314	 <e1>items</e1> advertised on TV simply melt the chocolate on the <e2>stovetop</e2>."
Other
Comment: Locativ

315	 <e1>sense</e1> was extended from the <e2>language</e2> to the people who spoke it."
Other
Comment:

316	 <e1>farmer</e1> produced a <e2>surplus</e2> despite the country's worst drought in 30 years by using conservation farming techniques."
Other
Comment: surplus is not a direct product

317	 is an Eden invented by the <e1>poet</e1>'s <e2>imagination</e2> into which external values are not disregarded, but have been absorbed and re-invented."
Other
Comment: Violation of "(f) Properties, capabilities, aptitutes, skills, attitutes etc. are not acceptable as Instruments.

318	 Island is a gripping pirate <e1>story</e1>, fast-paced by the <e2>standards</e2> of its time and full of action."
Other
Comment: standard is not a produc

319	 response on the <e1>toll</e1> caused by the <e2>earthquake</e2> in Sichuan, China."
Cause-Effect(e2,e1)
Comment:

320	 University of Colorado <e1>student</e1> died due to a <e2>jump</e2> from an overpass onto US 36."
Other
Comment: Other, because student cannot be effect.

321	 mile 17 the <e1>course</e1> went away from the <e2>water</e2> and onto streets with trees."
Other
Comment:

322	 the <e1>earth</e1> revolves around the <e2>sun</e2>, the place where light shines the brightest changes."
Other
Comment: That's location/orientation

323	 analysis demonstrates beyond any doubt that the <e1>problem</e1> of unemployment has been caused by the <e2>state</e2>, not by any inherent flaws or failures in a free market."
Cause-Effect(e2,e1)
Comment:

324	 <e1>inequality</e1> and poverty caused the <e2>riots</e2> in 2001."
Cause-Effect(e1,e2)
Comment:

325	 <e1>marshes</e1> have been drained into the <e2>farms</e2>."
Other
Comment: marches are wetlands; they do not move into the farms, only the water in them does

326	 were passed on to subsequent <e2>generations</e2> only through egg cells."
Other
Comment: violates b.

327	 <e1>analysis</e1> is used mainly to assess the monetary <e2>value</e2> of very large private and public sector projects."
Other
Comment: This is Purpose, which is not in our inventory.

328	 three <e1>companions</e1> reached the city by <e2>way</e2> of the river Selintan."
Other
Comment: e2 is a location rather than an Instrument.

329	 seems like the fever <e1>heat</e1> got pushed out from the <e2>body</e2> as rashes."
Cause-Effect(e2,e1)
Comment:

330	 <e1>series</e1> made a contribution to the <e2>development</e2> of museological thought."
Other
Comment:

331	 the left regular <e1>grammars</e1> generate exactly all regular <e2>languages</e2>."
Other
Comment: grammar is not actively involved

332	 feared <e1>ruler</e1> founded the largest land <e2>empire</e2> in history."
Other
Comment: the empire is not a real concrete object.

333	 connect the microcontroller to the Internet, one must implement a <e1>protocol</e1> <e2>stack</e2> on the device."
Other
Comment:

334	 <e1>technician</e1> assists the <e2>fishermen</e2> with this."
Other
Comment: Assistance, collaborative work.

335	 are therefore invited software engineering researchers to apply for research <e1>awards</e1> in all <e2>areas</e2> of software engineering."
Other
Comment: The sentence violates: "(a) The Message X has descriptive, significative or propositional content and has been produced to communicate this content.

336	 yellow <e1>discolouration</e1> has been caused by the damaging acidic <e2>properties</e2> of the low-grade mount used in the original frame."
Cause-Effect(e2,e1)
Comment:

337	 <e1>troops</e1> made their deepest <e2>incursion</e2> into Basra yesterday, "poking a toe" within four miles of the centre."
Other
Comment:

338	 <e1>damage</e1> caused by the <e2>tsunami</e2> - at least the physical damage - is barely visible in some places."
Cause-Effect(e2,e1)
Comment:

339	 Jung, the <e1>individual</e1> is a participant in a '<e2>collective unconscious</e2>'."
Other
Comment:

340	 <e1>gaps</e1> in the rings are caused by <e2>resonance</e2> between the particles in the rings and the moons orbiting nearby."
Cause-Effect(e2,e1)
Comment:

341	 followed a specific procedure for obtaining the <e1>engineer</e1>'s <e2>permit</e2> in Quebec and met certain requirements to receive an engineer's permit."
Other
Comment: This would be a permit that allows the engineer to do his/her work, probably produced by some bureaucrat. See for example http://www.oiq.qc.ca/practice/permits/eng-permit.html

342	 <e1>party</e1> starts in an <e2>hour</e2>."
Other
Comment:

343	 resulting <e1>conflict</e1> caused the <e2>destruction</e2> of the town, and The Conqueror, Wisecrack, Jackdaw and most of the citizens of the town were transported to a demon-dimension."
Cause-Effect(e1,e2)
Comment:

344	 discovered a good bit of published literature about <e1>modification</e1> of yeast with resveratrol-related <e2>genes</e2>."
Other
Comment: Purpose-Tool

345	 the right front wheel of Senna's car hit the wall, the violent <e1>impact</e1> caused a <e2>torsion</e2> on the steering column, causing it to break."
Cause-Effect(e1,e2)
Comment:

346	 above exceptions fully resolved the evaluation of a <e1>photograph</e1> by a <e2>court</e2> as a result of the claim."
Other
Comment:

347	 have successfully tested a <e1>system</e1> that translates brain waves into <e2>speech</e2>."
Other
Comment: speech is not a concrete obj

348	 <e1>company</e1> has assembled five independent food safety <e2>experts</e2> to serve on its newly formed Food Safety Advisory Council."
Other
Comment: the company is not the producer of experts

349	 <e1>weather</e1> resulted in several deaths and hundreds of <e2>accidents</e2>."
Cause-Effect(e1,e2)
Comment:

350	 <e1>fun run</e1> starts at <e2>noon</e2>."
Other
Comment:

351	 site welcomed to the premier industrial <e1>grinding</e1> <e2>wheels</e2> resource."
Other
Comment: Purpose-Tool

352	 five million years ago an <e1>asteroid</e1> caused the <e2>extinction</e2> of the dinosaurs."
Cause-Effect(e1,e2)
Comment:

353	 this afternoon the <e1>models</e1> have come into somewhat better <e2>agreement</e2>."
Other
Comment: violates c.

354	 expects a normal rush hour after a fatal <e1>accident</e1> near Baltimore caused <e2>delays</e2> along the Northeast corridor."
Cause-Effect(e1,e2)
Comment:

355	 we saw earlier, <e1>helicobacter</e1> is responsible for causing stomach <e2>ulcer</e2>."
Cause-Effect(e1,e2)
Comment:

356	 90% of the cases of <e1>ringworm</e1> of the scalp are caused by Trichophyton tonsurans, a <e2>fungus</e2> that infects the hairs and causes them to break."
Cause-Effect(e2,e1)
Comment:

357	 while naked, he stole a <e1>car</e1> with <e2>children</e2> inside, dropped one out of the window, and drove it through a fence."
Other
Comment: (d) is not satisfied, vehicles are not containers

358	 <e1>shoulder problems</e1> are caused by the <e2>breakdown</e2> of soft tissues in the shoulder region."
Cause-Effect(e2,e1)
Comment:

359	 <e1>mania</e1>, in the 1600s, was caused by the massive <e2>influx</e2> of newly discovered Gold into Amsterdam from the new world: in particular the capture of the Spanish Treasury fleet."
Cause-Effect(e2,e1)
Comment:

360	 there is no known cure for asbestos cancer but several mesothelioma treatment regimens have proven to be successful in helping the patient avoid <e1>pain</e1> and discomfort caused by the <e2>disease</e2>."
Cause-Effect(e2,e1)
Comment:

361	 denote the interest <e2>rate</e2>."
Other
Comment:

362	 <e1>president</e1> increased the fleet by the <e2>construction</e2> of one high-class cruiser."
Other
Comment: Here e2 is more of a single event than a method

363	 patient experiences displaced emotional and financial <e1>deprivation</e1> as well as anger after the <e2>divorce</e2>."
Cause-Effect(e2,e1)
Comment:

364	 we are beginning to understand how the <e1>brain</e1> works using brain-machine interface <e2>technology</e2>."
Other
Comment: The brain is the target object of the study that uses technology.

365	 limit the use of RFID <e1>technology</e1> for human <e2>tracking</e2>."
Other
Comment: Purpose-T

366	 was a little worried about making an <e1>ascent</e1> of the crux with a <e2>backpack</e2>."
Other
Comment:

367	 of this proposal is being discussed at the state <e2>level</e2>."
Other
Comment:

368	 is based on the notion that a human is basically a <e1>purpose</e1> driven <e2>animal</e2>."
Other
Comment: Purpose is a property.

369	 is one of the leading causes of <e2>kidney failures</e2>."
Cause-Effect(e1,e2)
Comment:

370	 are microscopic organisms that cause sickness or <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

371	 have just bought a <e1>silver</e1> <e2>necklace</e2> from a lady who makes her own jewellery with the fingerprints of my children on it."
Other
Comment:

372	 Earth's thin, rocky <e1>crust</e1> is composed of <e2>silicon</e2>, aluminum, calcium, sodium and potassium."
Other
Comment: Material

373	 <e1>fever</e1> is caused by infection with yellow fever <e2>virus</e2>, which is transmitted by the bite of infected mosquitoes."
Cause-Effect(e2,e1)
Comment:

374	 making <e1>observations</e1> of the microfossil through the binocular <e2>microscope</e2> or on a computer monitor, the investigator needed to manually move the specimen."
Other
Comment: Purpose-Too

375	 has done a thorough job of cutting through the <e1>thicket</e1> of <e2>contradictions</e2> and fantasies that surround the strategic bombing debate from 1914 to 1945."
Other
Comment: A thicket is a pattern, not a set.

376	 though his 16-month old suffered from severe <e1>burns</e1> on her body caused by <e2>boiling water</e2> spilled on her, father refuses to allow ambulance to take his daughter to Hadassah because 'rabbi advised otherwise'."
Cause-Effect(e2,e1)
Comment:

377	 study presents a comprehensive methodology for calculating the cost to <e1>society</e1> of various criminal <e2>acts</e2>."
Other
Comment:

378	 fad started when a certain <e1>brand</e1> of socks manufactured by an American <e2>company</e2> became popular among Japanese schoolgirls."
Other
Comment: brand is not a tangible object

379	 5 minutes or so, the <e1>problem</e1> went away from an operational <e2>perspective</e2>."
Other
Comment:

380	 theory of <e1>corn</e1> <e2>spirits</e2> and fertility and have thus needed to enquire no further, so their distribution and function remains unclear."
Other
Comment:

381	 <e1>author</e1> cites the <e2>case</e2> of an American citizen during the general war."
Other
Comment: the author is the communicator, not the message.

382	 army of Israel was utterly defeated and its camp ransacked, which terribly augmented the horrors and disasters of the <e1>rout</e1> of Saul's <e2>army</e2>."
Other
Comment: Here e1 is a subset of e2, not an individual item.

383	 <e1>dermatitis</e1>, the most common type of eczema, causes <e2>itchiness</e2> that's worse in the colder months."
Cause-Effect(e1,e2)
Comment:

384	 eyes have seen the defeat of my adversaries; my ears have heard the <e1>rout</e1> of my wicked <e2>foes</e2>."
Other
Comment: The pattern is at fault -- "rout" is not the name of a grouping.

385	 is a rare but serious paralytic <e1>illness</e1> caused by a nerve <e2>toxin</e2> that is produced by the bacterium Clostridium botulinum."
Cause-Effect(e2,e1)
Comment:

386	 <e1>benefits</e1> from <e2>inflation</e2> which Professor Mulligan cites (e.g., bailing out underwater mortgagers) are better understood as a government sponsored transfer of wealth from savers to speculators."
Cause-Effect(e2,e1)
Comment:

387	 <e1>concerto</e1> comes from the <e2>pop</e2> of gas bubbles escaping the joints, snapping tendons and ligaments, and rickety arthritic joints."
Cause-Effect(e2,e1)
Comment:

388	 misconception I see often is a fuzzy idea of the difference between the copy constructor and the <e1>assignment</e1> <e2>operator</e2>."
Other
Comment:

389	 urinary tract <e1>infection</e1> (UTI) is the most common cause of bladder <e2>irritation</e2>."
Cause-Effect(e1,e2)
Comment:

390	 <e1>protest</e1> resulted in hours of traffic <e2>jams</e2> on Guangzhou's major roads, such as Guangyuanxi Lu, Huangshidong Lu and Dongfeng Lu."
Cause-Effect(e1,e2)
Comment:

391	 with disabilities had a difficult time conveying the <e1>trauma</e1> caused by the unexpected <e2>arrival</e2> of uniformed officers who ordered them out of their homes and sometimes forcibly removed them."
Cause-Effect(e2,e1)
Comment:

392	 <e1>discharge</e1> started from the burst pulse <e2>corona</e2>."
Other
Comment:

393	 viscous <e1>lavas</e1> lead to a violent <e2>eruption</e2>."
Cause-Effect(e1,e2)
Comment:

394	 US <e1>aircraft</e1> was dropped into a difficult <e2>landing</e2> in Mali."
Other
Comment: violates b.1 and c.

395	 <e1>cysts</e1> are caused by chronic <e2>inflammation</e2> of the perichondrium with production of serous fluid between the perichondrium and cartilage."
Cause-Effect(e2,e1)
Comment:

396	 posters (e.g. number 18) encouraged the population of areas near the front to evacuate, thus avoiding the overcrowding and ensuing problems of food distribution and <e1>disease</e1> caused by the incoming <e2>refugees</e2>."
Cause-Effect(e2,e1)
Comment:

397	 a participant <e1>complaint</e1> is the source of an investigative <e2>lead</e2>, interim contact with the participant should be made by the investigator."
Cause-Effect(e1,e2)
Comment:

398	 <e1>violence</e1> has been caused by the Hutu <e2>militia</e2> who fled Rwanda after the genocide in that country and who have been in hiding in the forest in Congo."
Cause-Effect(e2,e1)
Comment:

399	 <e1>clock</e1> struck twelve with a loud <e2>chime</e2> that made me jump."
Cause-Effect(e1,e2)
Comment:

400	 work by using a <e2>base</e2> to neutralize the acid."
Other
Comment: e2 is a substance contained in e1.

401	 noted that the <e1>landscapes</e1> he painted - typically <e2>mountains</e2>, lakes, snow, and log cabin scenes - were strongly influenced by his years living in Alaska, where he was stationed for the majority of his Air Force career."
Other
Comment:

402	 placed at the flagpole island at the village square caused a <e2>stir</e2> on the Linglestown forum on PennLive.com."
Cause-Effect(e1,e2)
Comment:

403	 valuable <e1>book</e1> has arrived into my <e2>care</e2>."
Other
Comment: violates b.1 and c.

404	 Basilone, a cook at Camp Pendleton, was in the hospital recovering from a severe kitchen <e1>burn</e1> after the <e2>spilling</e2> of scalding liquid on her feet."
Cause-Effect(e2,e1)
Comment:

405	 <e1>revenues</e1> from the <e2>selling</e2> of crude oil in 2003 reached US$11.508 billion or some 112.85 percent of the amount targeted in the 2003 state budget."
Cause-Effect(e2,e1)
Comment:

406	 cough is another name for the pertussis, an <e1>infection</e1> of the airways caused by the <e2>bacteria</e2> bordetella pertussis."
Cause-Effect(e2,e1)
Comment:

407	 are a <e1>petroleum</e1> and petrochemical <e2>company</e2>."
Other
Comment: petroleum is raw material

408	 <e1>users</e1> are running into <e2>problems</e2> with the installer."
Other
Comment: violates b.1

409	 the <e1>path</e1> went away from the <e2>lake</e2> into some gorse."
Other
Comment:

410	 it is why we are even prouder to announce that the appeal - thanks to the generosity of our readers - has raised 26,000 pounds, despite the <e1>hardship</e1> that has been caused by the <e2>recession</e2>."
Cause-Effect(e2,e1)
Comment:

411	 <e1>problems</e1> are caused by buffer <e2>overflows</e2> when parsing an overly long parameter."
Cause-Effect(e2,e1)
Comment:

412	 rock 'n' roll <e1>business</e1> is falling into <e2>self-parody</e2>."
Other
Comment: violates c.3

413	 <e1>handful</e1> of <e2>countries</e2> blocked a legally binding deal on climate change in Copenhagen and the talks process needs urgent reform to prevent something similar happening again."
Other
Comment: This is a quantity.

414	 <e1>aspects</e1> are indicated with colour light <e2>signals</e2>."
Other
Comment:

415	 underlined the tiny <e1>sacrifices</e1> made by Western <e2>armies</e2> in comparison with those of the Red Army."
Other
Comment:

416	 of the <e1>types</e1> of tissue that makes up <e2>bone</e2> is the mineralized osseous tissue, also called bone tissue, that gives it rigidity and a honeycomb-like three-dimensional internal structure."
Other
Comment: type is not a producer

417	 ensued from the Florida <e2>contingent</e2> on the fact that very stringent landowner protection laws in Florida make it imperative that the highest supportable appraised vallue be offered first."
Cause-Effect(e2,e1)
Comment:

418	 1830, the New York Mirror described the area as a "loathsome <e1>den</e1> of <e2>murderers</e2>, thieves, abandoned women, ruined children, filth, drunkenness, and broils.""
Other
Comment: Location.

419	 sold a <e1>gold</e1> <e2>ring</e2> to another company online and they sent me a lousy check for $14.00."
Other
Comment:

420	 dome of the museum rotunda is made from an actual brewing kettle, and walking into it gives <e1>visitors</e1> the sense of being in a <e2>kettle</e2>."
Other
Comment: the kettle is not a container

421	 found that <e1>people</e1> from among a community who escaped an horrific <e2>accident</e2> had made little progress after two years."
Other
Comment:

422	 camp is more rugged than a hotel but comes with a great lake view and the <e1>comradeship</e1> of fellow chemistry <e2>teachers</e2>."
Other
Comment:

423	 utilized a critical eye and free <e1>inquiry</e1> into the <e2>conditions</e2> of life and issues of morality."
Other
Comment: a process

424	 old <e1>man</e1> went into diabetic <e2>coma</e2>."
Other
Comment: violates b.1 and c.3

425	 find the <e1>candle</e1> <e2>light</e2> creates a special atmosphere not only for food, but ambiance for a relaxing convivial meal as well."
Cause-Effect(e1,e2)
Comment:

426	 vary according to the degree of <e1>inflammation</e1> caused by the <e2>bacteria</e2>, ranging from slightly loose stools to bloody diarrhea, abdominal pain, and fever."
Cause-Effect(e2,e1)
Comment:

427	 <e1>winds</e1> caused delays and <e2>cancellations</e2> of some state ferries."
Cause-Effect(e1,e2)
Comment:

428	 front <e1>wheels</e1> are making a <e2>grinding noise</e2>."
Cause-Effect(e1,e2)
Comment:

429	 syndrome: a genetic <e1>disorder</e1> that results in selective cognitive <e2>impairment</e2>."
Cause-Effect(e1,e2)
Comment:

430	 Chowchilla man is behind bars, after a pipe <e1>bomb</e1> was discovered inside a mobile <e2>home</e2>."
Other
Comment:

431	 <e1>symbol</e1> denotes <e2>concatenation</e2>."
Other
Comment:

432	 the open air of the Sanz hotel, amid the music of the fountain and the <e1>glint</e1> of the <e2>goldfish</e2>, I almost forgot my nationality and imagined myself a great Spanish grandee, residing in an ancient Spanish mansion, and, no doubt, unconsciously adopted something of the stately walk and conversation suited to the part."
Other
Comment: It's to do with light reflected, not fish collected.

433	 was lucky enough to see with my own eyes the recent stock-market crash, where they lost several million dollars, a <e1>rabble</e1> of dead <e2>money</e2> that went sliding off into the sea."
Other
Comment: Too abstract: money can't be a member of anything...

434	 the economic <e1>crisis</e1> was generated due to the sub-prime mortgage <e2>mess</e2> brought about through government intervention in the market to promote progressive ideals (ie extending loans to low-income borrowers)."
Cause-Effect(e2,e1)
Comment:

435	 specific <e1>legacy</e1> has relation to the <e2>time</e2> of making the will."
Other
Comment:

436	 the late 1980s, however, the Bank was caught up in the debt <e1>crisis</e1> in the developing world caused by the <e2>recession</e2> and the dramatic rise in interest rates."
Cause-Effect(e2,e1)
Comment:

437	 aim of this <e1>study</e1> was the <e2>measurement</e2> of the intensity and circumstances of drug use."
Other
Comment: here study is an activity - violates (d)

438	 risks to housing and general corporate <e1>profits</e1> from <e2>inflation</e2> were quite clear and the defensive strategy over the long term has paid dividends."
Cause-Effect(e2,e1)
Comment:

439	 is relatively little <e1>discomfort</e1> from this <e2>surgery</e2> and most individuals rarely take more than Tylenol for their discomfort."
Cause-Effect(e2,e1)
Comment:

440	 from meat and dairy cause heart <e2>disease</e2>, the leading killer of people with diabetes."
Cause-Effect(e1,e2)
Comment:

441	 <e1>runners</e1> carried the torch through the <e2>streets</e2> of North Platte, the torch was again handed off to a Pony Express rider, who continued down the trail."
Other
Comment:

442	 <e1>contortions</e1> are caused by gravitational <e2>interactions</e2> with the small satellites Prometheus and Pandora."
Cause-Effect(e2,e1)
Comment:

443	 future Britain, charismatic delinquent Alex DeLarge is jailed and later volunteers for an experimental aversion <e1>therapy</e1> developed by the <e2>government</e2> in an effort to solve society's crime problem."
Other
Comment:

444	 <e1>smile</e1>, a true reflection of God's tenderness, is the source of an invincible <e2>hope</e2>."
Cause-Effect(e1,e2)
Comment:

445	 <e1>earthquake</e1> caused a bulrush <e2>marsh</e2> at West Point, on the Puget Sound shore in Seattle, to drop and the tsunami deposited sand on top of the marsh."
Cause-Effect(e1,e2)
Comment:

446	 greatest <e1>amazement</e1> was caused by the <e2>floats</e2>."
Cause-Effect(e2,e1)
Comment:

447	 <e1>input</e1> <e2>queue</e2> is used for processing events from an MFG/PRO application to a WebSphere-connected application."
Other
Comment: Type.

448	 of cardiovascular <e1>collapse</e1> from caffeine <e2>overdose</e2> with lidocaine, phenylephrine, and hemodialysis."
Cause-Effect(e2,e1)
Comment:

449	 forces fared so well that MacArthur gained Truman's permission to attempt a total <e1>rout</e1> of communist <e2>forces</e2>."
Other
Comment: The pattern is at fault -- "rout" is not the name of a grouping.

450	 <e1>strategy</e1> covers the period to 2016, with a strong <e2>focus</e2> on 2010."
Other
Comment:

451	 date, all <e1>outbreaks</e1> of the highly pathogenic form of avian influenza have been caused by <e2>viruses</e2> of the H5 and H7 subtypes."
Cause-Effect(e2,e1)
Comment:

452	 Anderson has made one classic comedy(The Royal Tenenbaums) fueled by the <e1>tension</e1> from the characters' <e2>longings</e2> to burst out of the trappings in which they are framed."
Cause-Effect(e2,e1)
Comment:

453	 is found that the <e1>polysilicon</e1> grows from an initial <e2>step</e2> of the deposition."
Other
Comment:

454	 general, the greatest hypocalcemic effect was achieved by those liposomal <e1>preparations</e1> that resulted in the most sustained <e2>increase</e2> of L-hCT and F-hCT in plasma."
Cause-Effect(e1,e2)
Comment:

455	 <e1>applet</e1> requires a <e2>browser</e2> that supports JDK 1.1.5 or above."
Other
Comment:

456	 is caused by <e2>overpopulation</e2>."
Cause-Effect(e2,e1)
Comment:

457	 new, improved active piezoelectric <e1>hydrophone</e1> is made with shielded clear waterproof <e2>cable</e2> and a copper acoustic chamber coated in non-toxic, durable black rubber."
Other
Comment: Cable is mentioned as a material, not a part.

458	 economic <e1>setbacks</e1> of 1893 had created <e2>unemployment</e2> and poverty which caused migration in search of new opportunities."
Cause-Effect(e1,e2)
Comment:

459	 this time the <e1>farm</e1> had three <e2>horses</e2> and a small tractor."
Other
Comment:

460	 are determined to pursue the <e1>conquest</e1> of evil with the <e2>good</e2>."
Other
Comment: Purpose-Tool

461	 <e1>people</e1>, knowing their place in the world, fulfill it with <e2>joy</e2> and attention."
Other
Comment:

462	 sees Kingdom coming with the help of the new <e2>president</e2>."
Other
Comment:

463	 <e1>software</e1> caused a pretty good <e2>drain</e2> on the CPU for some reason."
Cause-Effect(e1,e2)
Comment:

464	 <e1>harm</e1> has been caused by the invitation <e2>system</e2>."
Cause-Effect(e2,e1)
Comment:

465	 most of the experimental literature focuses on individual contributions, many real-world problems involve the <e1>formation</e1> of <e2>coalitions</e2>."
Other
Comment: Ditto.

466	 Nobel created his <e1>fortune</e1> from the <e2>selling</e2> of explosives that utilized nitroglycerin."
Cause-Effect(e2,e1)
Comment:

467	 washing and skin care can help to remove <e1>bacteria</e1> and oils which cause <e2>acne</e2>."
Cause-Effect(e1,e2)
Comment:

468	 coalition sprang up after the Tories released an economic <e1>statement</e1> lambasted by the opposition <e2>parties</e2>."
Other
Comment:

469	 <e1>system</e1> combined the hierarchical <e2>structure</e2> of decision trees with a clean probabilistic semantics."
Other
Comment: structure is a property

470	 <e1>lack</e1> of stability caused a strong <e2>reliance</e2> on the colonizers."
Cause-Effect(e1,e2)
Comment:

471	 <e1>child</e1> has been placed into foster <e2>care</e2>."
Other
Comment: violates b.

472	 then, millions of <e1>dollars</e1> have gone into <e2>reconstructions</e2> for victims of tsunami in 2004."
Other
Comment: violates b.1

473	 <e1>progenitor</e1> made his <e2>name</e2> with a wonderful non-fiction account of policing in Baltimore called Homicide."
Other
Comment: name is not a produc

474	 <e1>eruptions</e1> are caused by <e2>tectonic forces</e2> or by the compaction of sediments at the deltas of large rivers, such as the Mississippi."
Cause-Effect(e2,e1)
Comment:

475	 and the other leaders of the Soviet Union set about repairing the <e1>damage</e1> caused by the revolution and the civil <e2>war</e2>."
Cause-Effect(e2,e1)
Comment:

476	 <e1>reaction</e1> from the international <e2>press</e2>, which I am sure you here in Tokyo have noticed, has been very wide and detailed."
Cause-Effect(e2,e1)
Comment:

477	 <e1>houses</e1> are now built this <e2>way</e2>."
Other
Comment: manner; way is not a producer

478	 the first model sank in August 1991, the <e1>crash</e1> caused a <e2>seismic event</e2> registering 3.0 on the Richter scale, and left nothing but a pile of debris at 220m of depth."
Cause-Effect(e1,e2)
Comment:

479	 purpose of this <e1>test</e1> was to report to the American public on the academic <e2>achievement</e2> of individual students, schools, districts, and states."
Other
Comment: Purpos

480	 example, driving recklessly and causing an auto <e1>accident</e1> that result in the <e2>death</e2> of another driver or passenger could be qualified as manslaughter."
Cause-Effect(e1,e2)
Comment:

481	 coupled with the <e1>death</e1> and destruction caused by the <e2>storm</e2> was a very traumatic experience for these residents."
Cause-Effect(e2,e1)
Comment:

482	 been asking for a fizzy <e1>milk</e1> <e2>drink</e2> for a while."
Other
Comment:

483	 have traditionally been more concerned about <e2>factors</e2> like price, quality, or cycle time, and not as concerned over how much energy their manufacturing processes use."
Other
Comment: factors is not a prod

484	 <e1>infection</e1> came from a <e2>wound</e2>."
Cause-Effect(e2,e1)
Comment:

485	 emission of electromagnetic <e1>radiation</e1> from <e2>cell phones</e2> continues to become a growing concern."
Cause-Effect(e2,e1)
Comment:

486	 derive a pair of optimal weights on the <e1>dollar</e1> in a currency <e2>basket</e2> to stabilize their trade balances for both of the countries."
Other
Comment:

487	 (Yagasu) made a <e1>profit</e1> from the <e2>selling</e2> of women groups' handicrafts activities."
Cause-Effect(e2,e1)
Comment:

488	 ultimate D.C.-related work on this topic, in recent decades, anyway, may be Jerzy Kosinski's satirical Being There, the inspiration for a Peter Sellers <e1>film</e1> by the same <e2>name</e2>."
Other
Comment: the name does not produce the film

489	 threats, and conflicts cause <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

490	 of Guinness rolled off and then were grabbed and stacked up against the <e1>wall</e1> by the pub <e2>owner</e2>."
Other
Comment: no evidence that the wall was build by the owner

491	 this section are <e1>horses</e1> born in Tori <e2>stud</e2> that have made Tori breed famous and maintained that fame."
Other
Comment: Here stud is the location of the breeding

492	 squatter- A person who buys domain names, and holds them with the intent of making a <e1>profit</e1> from the <e2>selling</e2> of the domain name."
Cause-Effect(e2,e1)
Comment:

493	 muscular <e1>dystrophies</e1> are caused by genetic <e2>defects</e2>, which means they are inherited at birth."
Cause-Effect(e2,e1)
Comment:

494	 a two-mirror telescope equipped with an active optics system usually M2 is used to correct the <e1>aberrations</e1> originated by optical <e2>reasons</e2>, i.e. defocus and coma."
Cause-Effect(e2,e1)
Comment:

495	 <e1>addition</e1> of water to the tank caused a runaway chemical <e2>reaction</e2>, resulting in a rapid rise in pressure and temperature."
Cause-Effect(e1,e2)
Comment:

496	 new insulated pizza <e1>bag</e1> is delivered to the <e2>market</e2>."
Other
Comment: violates b.1

497	 and <e1>slugs</e1> cause <e2>damage</e2> to seedlings, flowers, vegetables and shrubs."
Cause-Effect(e1,e2)
Comment:

498	 in World War II, American <e1>soldiers</e1> targeted the men with the <e2>katanas</e2> first because their killing power was feared and respected."
Other
Comment: Agency is missing.

499	 delivered her charge, she had silently returned to her <e1>tree</e1> deep in the <e2>woods</e2>."
Other
Comment: A specific tree, somehow special, is _located_ deep in the woods.

500	 <e1>snowstorm</e1> caused a major <e2>catastrophe</e2> on the West Virginia Turnpike."
Cause-Effect(e1,e2)
Comment:

501	 is one of the leading causes for <e2>blindness</e2> and currently about 90 million patients worldwide are affected by the disease."
Cause-Effect(e1,e2)
Comment:

502	 Murphy's <e1>bedroom</e1> was filled with prescription <e2>drugs</e2>."
Other
Comment:

503	 are everyday actions that can help prevent the spread of <e1>germs</e1> that cause respiratory illnesses like <e2>influenza</e2>."
Cause-Effect(e1,e2)
Comment:

504	 <e1>outbreak</e1> was caused by the live polio <e2>virus</e2> that is used in vaccines given orally the preferred method in developing countries because it is cheaper and doesn't require medical training to dispense."
Cause-Effect(e2,e1)
Comment:

505	 vagina was sutured behind the neourethra; the <e1>vagina</e1> accommodated a size 12 <e2>dilator</e2>."
Other
Comment: the example violates (c)

506	 normally marks the arrival of the earliest <e1>run</e1> of <e2>fish</e2> into lake tributaries, and peak runs occur in October."
Other
Comment: It is what fish do. An activity, not a set.

507	 <e1>vehicle sales</e1> sink into <e2>muck</e2>."
Other
Comment: violates b.1 and c.3

508	 <e2>spirits</e2> in Asia are almost always female and regarded as a kind of mother figure (thus, the connection to fertility and tossing it at the bride)."
Other
Comment:

509	 there's you, floating a couple of thousand feet up in the <e1>sky</e1> in a tiny little <e2>basket</e2>."
Other
Comment: it is not the sky that is contained in the basket

510	 Union Side reiterated its <e1>concerns</e1> that the <e2>public sector</e2> was effectively subsidising these events and requested that this practice cease."
Other
Comment: Mental state: violates restriction (b).

511	 <e1>drugs</e1> also cause headaches and <e2>nausea</e2>, affect your internal organs and raise your bad cholesterol."
Cause-Effect(e1,e2)
Comment:

512	 I know quite a few people who get <e1>dissatisfaction</e1> from <e2>laughing</e2> at retards."
Cause-Effect(e2,e1)
Comment:

513	 deaminase</e1> converts purine riboside into an <e2>analog</e2> of a reactive intermediate."
Other
Comment: deaminase is a proc

514	 time passed, <e1>aluminum</e1> formed itself into a <e2>can</e2>, a lid, and a tab."
Other
Comment:

515	 accounted for more than half of Britain's <e2>population</e2> growth in recent years."
Cause-Effect(e1,e2)
Comment: growth is an event.

516	 soldiers inspect the <e1>damage</e1> after the <e2>explosion</e2> in a school in Baghdad."
Cause-Effect(e2,e1)
Comment:

517	 <e1>rule</e1> is the subject of a <e2>legal challenge</e2> brought by ABC and its coalition partners."
Other
Comment: "legal challenge" is not a Messag

518	 is a literary <e1>style</e1> which portrays <e2>crime</e2> and violence in an unsentimental way."
Other
Comment: A style is not a message.

519	 other words such people accept a <e1>form</e1> of mathematical <e2>platonists</e2>, whether or not they label themselves that way."
Other
Comment:

520	 Nepalese government sets up a <e1>committee</e1> to inquire into the alleged <e2>misuse</e2> of diplomatic passports."
Other
Comment:

521	 <e1>investigation</e1> was concerning a <e2>series</e2> of letters received at the House containing non-noxious white powder."
Other
Comment: A process (investigation) is not a message - violates (d)

522	 <e1>plasma</e1> was generated by an RF <e2>discharge</e2> between two parallel electrodes whose diameter was 100 mm and separation was 40 mm using pure silane gas."
Other
Comment:

523	 these two tools, the <e1>dataset</e1> was reduced from its original <e2>size</e2> of over 200 features into 17%."
Other
Comment:

524	 nests are used year after year by the <e1>carpenter</e1> <e2>bee</e2>."
Other
Comment: carpenter is not a product or producer

525	 <e1>world</e1> is governed by mathematical <e2>laws</e2>."
Other
Comment: No communication here.

526	 broker is entitled to <e1>commission</e1> from the <e2>selling</e2> of your property."
Cause-Effect(e2,e1)
Comment:

527	 is a group of neurodegenerative <e2>disorders</e2> characterized by the death of retinal ganglion cells and by a specific deformation of the optic nerve."
Other
Comment: Glaucoma is-a disorder.

528	 pressures of <e1>unemployment</e1> and poverty lead to drug abuse and <e2>alcoholism</e2> or stress and depression which have a profound effect on children."
Cause-Effect(e1,e2)
Comment:

529	 the car, <e1>keys</e1> were found in the <e2>ignition</e2> and Codario-Ferrino's license was discovered inside a purse on the passenger's seat."
Other
Comment: car is not a container according to (d)

530	 <e1>magnetic field</e1> is generated by an electric <e2>current</e2> circulating in the star's interior."
Cause-Effect(e2,e1)
Comment:

531	 <e1>species</e1> makes a squelching <e2>noise</e2>."
Cause-Effect(e1,e2)
Comment: the species are involved in the making of nois

532	 cuts</e1> for rich are thrown into <e2>doubt</e2>."
Other
Comment: violates c.

533	 is part of a furniture <e1>line</e1> conceived for Anthropologie by British interior <e2>designers</e2>."
Other
Comment:

534	 political <e1>unity</e1> of the Iroquois was the source of their <e2>power</e2>, but it was by no means perfect."
Cause-Effect(e1,e2)
Comment:

535	 Bade <e1>residents</e1> have been blown back into primitive <e2>lifestyle</e2>."
Other
Comment: violates c.

536	 are the news reports and photographs of the <e1>devastations</e1> caused by the <e2>storm</e2>."
Cause-Effect(e2,e1)
Comment:

537	 curious <e1>thinkers</e1> are keeping Ben's traditions alive by inventing new and improved <e2>ways</e2> to make things work."
Other
Comment: way is not a product

538	 <e1>movement</e1> of the flag on the surface of the moon was caused by the <e2>vaccum</e2>."
Cause-Effect(e2,e1)
Comment:

539	 hollow <e1>bar</e1> mounting the cameras encloses a wiring <e2>harness</e2> between the cameras."
Other
Comment: no evidence for content-container

540	 acnes, or P. acnes, are the <e1>bacteria</e1> responsible for acne <e2>breakouts</e2>."
Cause-Effect(e1,e2)
Comment:

541	 the <e1>poem</e1>, an <e2>albatross</e2> starts to follow a ship - being followed by an albatross was generally considered an omen of good luck."
Other
Comment: the albatross is not the producer of the poem

542	 <e1>extraction</e1> in the Amazon has already caused the <e2>extinction</e2> of the Tetete and Zaparo nationalities and continues to threaten indigenous peoples."
Cause-Effect(e1,e2)
Comment:

543	 100 MHz RF <e1>signal</e1> for the amplitude modulator was derived from a pulse pattern <e2>generator</e2> (PPG)."
Cause-Effect(e2,e1)
Comment:

544	 temperature <e1>distributions</e1> in a <e2>vial</e2> during freeze-drying of a skim milk solution were determined experimentally."
Other
Comment: no evidence for content-container, distributions is not a content

545	 first <e1>seismic arrival</e1> from an <e2>earthquake</e2> is the P wave, which is usually relatively low-amplitude."
Cause-Effect(e2,e1)
Comment:

546	 centres, along with appropriate educational and psychosocial interventions, helped children overcome the <e1>trauma</e1> and stress caused by the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

547	 skiier Lindsey Vonn denied downhill treble as <e1>fog</e1> caused <e2>cancellation</e2> in Val d'Isere."
Cause-Effect(e1,e2)
Comment:

548	 opposing <e1>party</e1> hid the anvil with a <e2>view</e2> to important consequences."
Other
Comment: opinion.

549	 also spoke about post-September 11 civil rights and civil liberties <e1>issues</e1> facing <e2>immigrants</e2>."
Other
Comment:

550	 judge directed the <e1>court</e1> to decide the preliminary issue raised by the <e2>petitioner</e2>."
Other
Comment:

551	 has been assumed that the <e1>quench</e1> starts at the middle <e2>cross-section</e2> of the magnet."
Other
Comment:

552	 <e1>cream</e1> was made by <e2>hand</e2> in a large bowl placed inside a tub filled with ice and salt."
Other
Comment: manner

553	 <e1>user</e1> is cooling a processor with a power <e2>usage</e2> of 35W, using a conventional heatsink."
Other
Comment:

554	 <e1>tsunami</e1> resulted in significant property <e2>damage</e2> but only two fatalities in RS."
Cause-Effect(e1,e2)
Comment:

555	 <e1>president</e1> has made <e2>taxes</e2> and spending the big issues again."
Other
Comment:

556	 the end of the work day, the <e1>anger</e1> was radiating from the <e2>city</e2>."
Cause-Effect(e2,e1)
Comment:

557	 Big Barn Farm friends discover a <e1>pile</e1> of <e2>junk</e2>."
Other
Comment: Quantity.

558	 view of the terrible <e1>destruction</e1> that was caused by the flood <e2>waves</e2>, we have to fear that a number of Germans, clearly in the three-digit numbers, will be among the dead."
Cause-Effect(e2,e1)
Comment:

559	 is wishful <e1>thinking</e1> by a <e2>scribe</e2> who is more blind to the reality than those he accuses of blindness."
Other
Comment: (a) is satisfied

560	 education systems have carried <e1>nations</e1> into <e2>prosperity</e2>."
Other
Comment: violates c.3

561	 and fitting <e1>horseshoes</e1> was only part of the life of a <e2>blacksmith</e2>."
Other
Comment: no evidence that blachsmith is the producer of the horseshoes

562	 hell in the hospitals where the amputees's <e1>screaming</e1> after the <e2>lapse</e2> of morphine is heard all the time."
Cause-Effect(e2,e1)
Comment:

563	 discovered that these <e1>drugs</e1> were related to heart valve <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

564	 is a natural wax produced in the bee <e1>hive</e1> of honey <e2>bees</e2> of the genus Apis."
Other
Comment: Location.

565	 <e1>varieties</e1> of this sort were grown on flat land by <e2>peasants</e2>."
Other
Comment: varieties is not a product

566	 <e1>criminals</e1> that caused the <e2>fire</e2> illegally entered our country."
Cause-Effect(e1,e2)
Comment:

567	 <e1>views</e1> were reflected in his building <e2>designs</e2>."
Other
Comment:

568	 certain texts do talk about English <e1>society</e1> of various <e2>ages</e2>."
Other
Comment: That is, at various times.

569	 create a good seal, manufacturers put a foam- or gel-filled seal between the <e1>ear</e1> <e2>cup</e2> and your head."
Other
Comment: The cup is part of the headphones, not part of the ear.

570	 file photo shows a microlight <e1>pilot</e1> flying with <e2>geese</e2>."
Other
Comment:

571	 <e1>deed</e1> of agreement was drawn up in the temple by a notary <e2>public</e2> and confirmed with an oath "by god and the king.""
Other
Comment: deed is not a product

572	 jack-knifed <e1>lorry</e1> caused <e2>delays</e2> on the A27 eastbound between Havant, Hampshire, and Chichester, West Sussex."
Cause-Effect(e1,e2)
Comment:

573	 that cause respiratory <e2>illness</e2> typically are capable of causing a range of clinical manifestations, and asymptomatic infections are possible."
Cause-Effect(e1,e2)
Comment:

574	 whole <e1>future</e1> is being thrown into <e2>disarray</e2>."
Other
Comment: violates c.3

575	 inherent RNA silencing <e1>mechanism</e1> in plants has been effectively manipulated as a tool for the targeted <e2>down-regulation</e2> of genes."
Other
Comment: Purpose-Tool

576	 <e1>wife</e1>, a successful corporate lawyer, has given up <e2>work</e2>."
Other
Comment:

577	 this method, <e1>multiword concepts</e1> are treated as <e2>single words</e2>."
Other
Comment:

578	 <e1>uncle</e1>, who was in the Russian army, liberated Auschwitz with Barry's <e2>uncle</e2>."
Other
Comment:

579	 of the CO2 <e1>emissions</e1> are caused by the <e2>lorries</e2>, but this is not fair so a different distribution method is needed."
Cause-Effect(e2,e1)
Comment: modality and negation are outside

580	 previously interpreted as precursory activity to the 1906 earthquake, they have been found to have a strong seasonal pattern and have been postulated to be due to large seasonal sediment loads in coastal bays that overlie faults as a result of the <e1>erosion</e1> caused by <e2>hydraulic mining</e2> in the later years of the California Gold Rush."
Cause-Effect(e2,e1)
Comment:

581	 exception is the <e1>player</e1> who drew the <e2>ace</e2>, who may stop whenever they want."
Other
Comment: ace is not a product; modality is outsid

582	 <e1>infant</e1> was born in a <e2>condition</e2> of shock and died in ten minutes."
Other
Comment:

583	 <e1>shortage</e1> of folate cause megaloblastic <e2>anemia</e2>, where red blood cells are large and pale."
Cause-Effect(e1,e2)
Comment:

584	 are drain openings on both sides of the street in the <e1>curbs</e1> of the <e2>sidewalks</e2>."
Other
Comment:

585	 and melting <e1>snow</e1> lead to Genesee County's biggest sewage <e2>spill</e2> of the year."
Cause-Effect(e1,e2)
Comment:

586	 stereo <e1>buss</e1> outputs the stereo buss <e2>signal</e2>; a record buss outputs the record buss signal."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

587	 breakdown is often attributed to unresolved <e1>grief</e1> from infertility, <e2>miscarriage</e2>, and the loss of a child."
Cause-Effect(e2,e1)
Comment:

588	 highway shield is a <e1>sign</e1> denoting the <e2>route number</e2> of a highway, usually in the form of a symbolic shape with the route number."
Other
Comment: to denote is not to be a message.

589	 addition, a brief <e1>biography</e1> establishing her <e2>credentials</e2> was included at the end of the report."
Cause-Effect(e1,e2)
Comment:

590	 <e1>defendants</e1> took advantage of Astor's diminished mental <e2>capacity</e2> to carry them out."
Other
Comment:

591	 <e1>man</e1> has journeyed into deeper level <e2>studies</e2> with sound masters."
Other
Comment: violates b.

592	 addition, soil and river systems have been contaminated by the harsh chemicals used in cocaine production and the air has been polluted by the <e1>smoke</e1> caused by the <e2>burning</e2> of jungle and forest for coca bush cultivation."
Cause-Effect(e2,e1)
Comment:

593	 bought a <e1>gold</e1> <e2>bracelet</e2> for $200."
Other
Comment:

594	 people buy pre-made <e1>candle</e1> <e2>wicks</e2> when making homemade candles."
Other
Comment: The wicks haven't been made into candles yet.

595	 <e1>removal</e1> duplicate songs is done with the user-friendly start-up <e2>wizard</e2>."
Other
Comment: Purpose-Tool

596	 <e1>recession</e1> caused by the <e2>stock bubble</e2> was relatively mild, but so was the recovery."
Cause-Effect(e2,e1)
Comment:

597	 thought sometimes I saw the flash of distant spires, the sunny gleam of upland pastures, the soft <e1>undulation</e1> of purple <e2>hills</e2>."
Other
Comment: A kind of movement, not set membership.

598	 the Senate, the <e1>sizzle</e1> comes from an issue ad <e2>bill</e2> from Dem Sen. Jon Erpenbach."
Cause-Effect(e2,e1)
Comment:

599	 Colombia, for their series of articles on the <e1>emergency</e1> caused by a <e2>landslide</e2> on the highway leading to the coast."
Cause-Effect(e2,e1)
Comment:

600	 financial <e1>losses</e1> caused by the <e2>earthquake</e2> were estimated at $7 million."
Cause-Effect(e2,e1)
Comment:

601	 December 26th <e1>tsunami</e1> <e2>disaster</e2> is an example of a tsunami which was triggered by an earthquake."
Cause-Effect(e1,e2)
Comment:

602	 <e1>violence</e1> resulted in the <e2>death</e2> of police "capo" Filippo Raciti, which caused widespread soul-searching and a week-long suspension of Italian football."
Cause-Effect(e1,e2)
Comment:

603	 from <e2>braces</e2> is similar to that of working out at the gym - the first few days you know you' done something different, but then the body adapts and the discomfort disappears."
Cause-Effect(e2,e1)
Comment: modality is outsid

604	 the <e1>fire</e1> was caused by <e2>fireworks</e2>, costs associated with suppressing the fire were also applied."
Cause-Effect(e2,e1)
Comment:

605	 Titan heats the dermis to cause collagen contraction while ensuring <e1>preservation</e1> the epidermis through continuous <e2>cooling</e2>."
Cause-Effect(e2,e1)
Comment:

606	 spiral <e1>light</e1> was caused by the <e2>missile</e2>."
Cause-Effect(e2,e1)
Comment:

607	 of these papers which was published in the journal Climate Research turned out to be so badly flawed that the <e1>scandal</e1> resulted in the <e2>resignation</e2> of the editor-in-chief."
Cause-Effect(e1,e2)
Comment:

608	 sores</e1> (also known as: pressure sores, decubitus ulcers or pressure ulcers) are caused by <e2>pressure</e2>, which cuts off blood flow to parts of the body."
Cause-Effect(e2,e1)
Comment:

609	 <e1>presentation</e1> generated <e2>debate</e2> and there was general discussion on how journalists can better equip themselves to handle the challenges."
Cause-Effect(e1,e2)
Comment: the presentation is causing a debat

610	 my backpacking trip, the <e1>insoles</e1> caused a hot <e2>spot</e2> on the left side of my right heel and a blister on the right side of my left heel."
Cause-Effect(e1,e2)
Comment:

611	 Code applies to all <e1>sponsorship</e1> related to <e2>corporate image</e2>, brands, products, services activities or events of any kind."
Other
Comment: The sponsorship is not a message.

612	 produce surprisingly low carbon <e2>emissions</e2> per capita."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

613	 tiny Serbian <e1>village</e1> has put up a <e2>statue</e2> in honour of its adopted patron - Sylvester Stallone's Rocky."
Other
Comment: not clear whether the statue was made by them

614	 <e1>pepper</e1> is a miracle cure for <e2>ulcers</e2> and so many other conditions, plus aids assimilation of nutrients and vitamins."
Other
Comment:

615	 the current <e1>outbreaks</e1> caused by the H5N1 <e2>virus</e2>, only 24 outbreaks of highly pathogenic avian influenza have been recorded worldwide since 1959."
Cause-Effect(e2,e1)
Comment:

616	 Reynold's brought his first barrel of flour from DeTour on a <e1>jumper</e1> drawn by an <e2>ox</e2>."
Other
Comment: the ox is not a producer

617	 generate <e2>electricity</e2> by the same principle as DC generators."
Cause-Effect(e2,e1)
Comment:

618	 pate is in fact easier to make than my <e1>grandmother</e1>'s chopped <e2>liver</e2>, which called for rendering chicken fat."
Other
Comment: grandmother is not a produ

619	 of the 550 <e1>deaths</e1> are directly and intentionally caused by the <e2>physician</e2> but not reported as euthanasia because they lacked consent."
Cause-Effect(e2,e1)
Comment: negation is outside

620	 Chaney is found home on the range herding <e1>cattle</e1> on his Clarksburg <e2>farm</e2>."
Other
Comment:

621	 <e1>plans</e1> are outlined for another wind <e2>farm</e2> in north Devon of no more than four turbines."
Other
Comment: just outlined, so not announced yet - violation of (d)

622	 <e1>universities</e1> entered in <e2>collaboration</e2> focusing on development of plant biotechnology."
Other
Comment: violates c.3

623	 cafe <e1>owner</e1> thought up an unlikely beverage that has created a 'miracle' <e2>cure</e2>."
Other
Comment: the bevearge is the producer not the owner

624	 <e1>actress</e1> went into <e2>cardiac arrest</e2>."
Other
Comment: violates b.1 and c.3

625	 boat <e1>rides</e1> leave from the <e2>harbour</e2> at Avoch, chugging out into the firth in search of bottle nose dolphins."
Other
Comment:

626	 readable <e1>book</e1> is the product of Darwin's amazing <e2>journey</e2> aboard the Beagle."
Other
Comment: Cannot be Cause-Effect or Product-Producer because of restrictions in those relations.

627	 puts a driver bit that fits the <e1>screw</e1> in the drill press <e2>chuck</e2>."
Other
Comment:

628	 <e1>defendant</e1> was acting from his own <e2>computer</e2> in London."
Other
Comment:

629	 from wood <e2>fires</e2> in Tutbury Castle in Nottingham was considered unendurable by Eleanor of Aquitaine, wife of Henry II, causing her to move out in 1157."
Cause-Effect(e2,e1)
Comment:

630	 <e1>increase</e1> is caused by the <e2>absorption</e2> of UV radiation by the oxygen and ozone."
Cause-Effect(e2,e1)
Comment:

631	 court sent the <e1>drug addict</e1> into <e2>hibernation</e2>."
Other
Comment: violates b.1 and c.

632	 medicine to reduce sneezing and <e1>coughing</e1> from <e2>allergies</e2>."
Cause-Effect(e2,e1)
Comment:

633	 interest in something is a large step towards <e1>happiness</e1> after <e2>depression</e2>."
Other
Comment:

634	 now, my <e1>friends</e1> are familiar with my almost english <e2>obsession</e2> with toast."
Other
Comment:

635	 <e1>charges</e1> originated in an attempted <e2>blackmail</e2> against Moti, a constitutional lawyer and Australian citizen, in Vanuatu in 1997-98."
Other
Comment:

636	 it appears that most of the <e1>damage</e1> was caused by the winds and the rough <e2>seas</e2>."
Cause-Effect(e2,e1)
Comment:

637	 is the branch or specialty of medicine that deals with the study and application of <e2>imaging technology</e2>."
Other
Comment:

638	 practices have shown that often local authorities are quicker to respond to the natural <e1>disasters</e1> caused by the climate <e2>change</e2>."
Cause-Effect(e2,e1)
Comment:

639	 are four locations of this restaurant, owned by the Buckley <e1>company</e1> of Dublin <e2>butchers</e2>."
Other
Comment: Company is here used in the sense of 'firm'.

640	 funds raised through this appeal have a direct impact on the people affected by the severe <e1>devastations</e1> caused by the <e2>storms</e2>."
Cause-Effect(e2,e1)
Comment:

641	 <e1>harness</e1> was in a <e2>chest</e2>."
Other
Comment:

642	 the group ventures deeper into the forest, the eerie <e1>realm</e1> unleashes its <e2>spirits</e2> unto the intruders, killing them one by one."
Other
Comment: it cannot be E-O because e1 is actively involved, cannot be P-P because e2 is not a concrete object, and spirits are not part of the realm, they live there.

643	 <e1>stream</e1> and riverbank <e2>erosion</e2> is one of the main focuses in riparian protection and restoration."
Other
Comment:

644	 caused by the oral vaccine's live <e2>virus</e2> have happened before."
Cause-Effect(e2,e1)
Comment:

645	 <e1>compromise</e1> resolved the crisis through a series of secret <e2>negotiations</e2> involving Republican and Democratic politicians and various interest groups."
Cause-Effect(e2,e1)
Comment:

646	 work inside a <e2>caisson</e2> while excavating for bridge foundations."
Other
Comment: people cannot be content

647	 the <e1>author</e1> departs from an <e2>explanation</e2> of what has transpired and the facts and forces pertaining to the action."
Other
Comment:

648	 <e1>band</e1> performs with a high level of <e2>musicality</e2>, energy and spirit while combining sensitive group interplay with dynamic solo improvisations."
Other
Comment: Musicality is a property, so can't be an Instrument.

649	 <e1>process</e1> builds many <e2>features</e2> into the product that translate into benefits for you."
Other
Comment:

650	 a worker works in a <e1>factory</e1> for more than nine <e2>hours</e2> in any day or for more than forty-eight hours in any week, he shall be entitled to wages at the rate of twice his ordinary rate of wages."
Other
Comment: factory does not produce tim

651	 <e1>work</e1> is rooted in an <e2>effort</e2> to demonstrate commonality between the arts by focusing on classical rhetoric as the main discursive agency."
Other
Comment:

652	 is a powerful fat <e1>burner</e1> that works with a combination of natural <e2>herbs</e2> such as White and Green Tea, Capsaicin, and Caffeine."
Other
Comment: The herbs etc. are ingredients of thermocerin; as they are no longer perceptibly distinguishable Component-Whole cannot hold, and as they are present in thermocerin Entity-Origin cannot hold.

653	 Wayner, a <e1>technology</e1> <e2>writer</e2>, struggles with how to respond to the widespread piracy of his books online."
Other
Comment: writer is not a produc

654	 solar thermal power generation works essentially the same as generation from fossil fuels except that instead of using steam produced from the combustion of fossil fuels, the <e1>steam</e1> is produced by the <e2>heat</e2> collected from sunlight."
Cause-Effect(e2,e1)
Comment:

655	 the <e1>problem</e1> requires a broader <e2>solution</e2> - one that is consistent with the new U.S. commitment to cross-border cooperation."
Other
Comment:

656	 size of the <e1>assemblies</e1> grows from the byssus substrate <e2>interface</e2> to the transition layer."
Other
Comment:

657	 imbalance</e1> is one of the multifactorial causes of essential <e2>hypertension</e2> currently."
Cause-Effect(e1,e2)
Comment:

658	 <e1>identity</e1> takes part in the story's <e2>movement</e2>, in the dialectic between order and disorder."
Other
Comment:

659	 I move closer to the kitchen, the steady <e1>hum</e1> of the <e2>refrigerator</e2> grows stronger."
Cause-Effect(e2,e1)
Comment:

660	 real <e1>output</e1> per capita is running into inherent <e2>barriers</e2>."
Other
Comment: violates b.1

661	 <e1>acid</e1> and phospholipid chlorohydrins cause cell stress and endothelial <e2>adhesion</e2>."
Cause-Effect(e1,e2)
Comment:

662	 Earth was the center of the universe, and the <e1>sky</e1> was enclosed in a <e2>dome</e2>."
Other
Comment:

663	 new <e1>cigarettes</e1> cause headaches and <e2>nausea</e2> and contain dangerous chemicals."
Cause-Effect(e1,e2)
Comment:

664	 has urged India to do away with <e1>visas</e1> for <e2>travel</e2> between the two neighbours to boost trade."
Other
Comment: Purpose-Too

665	 made sure that the end could still slide freely over the <e1>dowel</e1> <e2>rod</e2>."
Other
Comment: "A dowel is a solid cylindrical rod, usually made of wood, plastic or metal. In its original manufactured form, dowel is called dowel rod." (http://en.wikipedia.org/wiki/Dowel)

666	 the hour, the <e1>clock</e1> plays a <e2>melody</e2> with motion."
Cause-Effect(e1,e2)
Comment:

667	 example, a <e1>technology</e1> <e2>manufacturer</e2> undertook a seven-year, $200 million human resources outsourcing effort."
Other
Comment: technology is not a product

668	 <e1>militancy</e1> stemmed from two different kinds of <e2>experiences</e2>."
Cause-Effect(e2,e1)
Comment:

669	 <e1>publication</e1> is supported by a <e2>grant</e2> from Merck."
Other
Comment: Relation is more like Instrument-Product

670	 <e1>pollution</e1> from animal <e2>factories</e2> is also destroying parts of the world's oceans."
Cause-Effect(e2,e1)
Comment:

671	 O'Brien was proud of how his <e1>team</e1> finished a difficult <e2>season</e2>."
Other
Comment: season is not a produc

672	 <e1>achievements</e1> of Michael Phelps in the pool proved to be a major <e2>talking point</e2> for the riders."
Other
Comment:

673	 remarkable <e1>combination</e1> of favourable <e2>circumstances</e2> saw the technology progress from the innovation phase - its trial in prototype form - through to adoption and widespread use, in only a few years."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

674	 NNT and NNH are useful indices to describe the trade-off between the benefit and the <e1>harm</e1> produced by a new <e2>treatment</e2>."
Cause-Effect(e2,e1)
Comment:

675	 is caused by <e2>clogging</e2> of sebaceous (oil producing) glands on the skin."
Cause-Effect(e2,e1)
Comment:

676	 ordinance was a result of the <e1>bond</e1> of profit <e2>agents</e2> getting angry over the recent expansion of the Broward County Pretrial program."
Other
Comment: The bond here means a tight connection (between agents who share a feeling). Not a set.

677	 water enters the inside of the dishwasher, and the <e1>motor</e1> makes a <e2>sound</e2> as if under strain."
Cause-Effect(e1,e2)
Comment: negation and modality are outside

678	 vessel went down in a typhoon and the <e1>man</e1> was discovered inside a cork <e2>buffer</e2> used to prevent damage to the ship during docking."
Other
Comment:

679	 trails, fire pit and a tree <e1>fort</e1> in the <e2>woods</e2> have encouraged him to spend time outside."
Other
Comment: The fort is located in the woods.

680	 cutting tool of the <e1>sort</e1> used for deep hole <e2>drilling</e2> has a cutting head mounted on a shank."
Other
Comment: Purpose-Tool

681	 <e1>fluctuations</e1> are caused by state and federal <e2>taxes</e2>, distance from refineries to filling stations and environmental laws."
Cause-Effect(e2,e1)
Comment:

682	 is caused by a <e2>virus</e2> that is usually contracted through the saliva of an infected animal."
Cause-Effect(e2,e1)
Comment:

683	 <e1>accident</e1> has been caused by the <e2>fog</e2>."
Cause-Effect(e2,e1)
Comment:

684	 <e1>injury</e1> resulted in numerous <e2>operations</e2> to save his eyesight."
Cause-Effect(e1,e2)
Comment:

685	 time the <e1>lobster</e1> was full of its superb <e2>flavor</e2>, which suffused even into the buttered corn."
Other
Comment:

686	 <e1>mistress</e1> fries the <e2>rashers</e2> in a small china fryingpan over the lamp, passing to each person the hot slices as they are done."
Other
Comment: e2 is the Patient, not the Instrument of the frying event.

687	 Luxembourg, the <e1>majority</e1> of migrant <e2>workers</e2> are cross-border workers who maintain their residence in neighbouring countries such as Belgium, France and Germany; as a result, employers and public authorities recognise their diplomas rather easily."
Other
Comment: Measure.

688	 <e1>studies</e1> have been conducted with regard to the above <e2>phenomena</e2>."
Other
Comment: here we have a process; violates (d)

689	 address the longer-term budget <e1>imbalance</e1> that has been caused by the <e2>tax cuts</e2>."
Cause-Effect(e2,e1)
Comment:

690	 North America, about 58 percent of the <e1>wildfires</e1> are caused by <e2>humans</e2>."
Cause-Effect(e2,e1)
Comment:

691	 put <e1>fairness</e1> into <e2>copyright use</e2>."
Other
Comment: violates c.3

692	 shows that public <e1>concern</e1> about the <e2>economy</e2> has moved into the top five issues facing the country."
Other
Comment: This is a mental state, and nothing suggests its verbalisation. Restriction (b).

693	 <e1>quota</e1> was extended from six <e2>weeks</e2> to 10 weeks in 2009."
Other
Comment:

694	 cousins have some fun sliding down the <e1>steps</e1> in a laundry <e2>basket</e2>."
Other
Comment: the steps are not in the basket

695	 stores the <e1>information</e1> in a secure and protected <e2>environment</e2> for as long as they believe it will help the company understand how to serve its clients better."
Other
Comment: not a container; modality is outside

696	 about how Catholic Church <e1>dioceses</e1> dealt with <e2>allegations</e2> of child abuse are to emerge within the coming weeks."
Other
Comment:

697	 sure the child takes lots of fluids in spite of the oral discomfort to prevent high <e1>fever</e1> from <e2>dehydration</e2>."
Cause-Effect(e2,e1)
Comment:

698	 Tafawa Balewa Square (TBS) in Lagos hosted a <e1>galaxy</e1> of <e2>events</e2> with tourism and culture activities as center of attraction."
Other
Comment:

699	 rare and incurable congenital <e1>disease</e1> which causes <e2>blindness</e2> has been successfully treated for the first time using gene therapy."
Cause-Effect(e1,e2)
Comment:

700	 I pulled unit apart the small fan on top of light was caked with dust, the <e1>heat</e1> caused a little <e2>discoloration</e2> on the difusing lense."
Cause-Effect(e1,e2)
Comment:

701	 work has led to new treatments for addicts, tests for drug intoxication and understanding of how <e1>heroin</e1>, other opiates and cocaine cause dependence and <e2>withdrawal</e2>."
Cause-Effect(e1,e2)
Comment:

702	 troubles have dragged the infamous <e1>actress</e1> into <e2>chaos</e2>."
Other
Comment: violates b.1 and c.3

703	 Shakespeare Authorship Studies Conference is the world's largest <e1>convocation</e1> of <e2>academicians</e2> and scholars to gather annually for the purpose of sharing new research on the life and works of the Elizabethan era's premier poet, playwright and wordsmith."
Other
Comment: Participation.

704	 from <e2>washing</e2> has always been considered a serious problem for cotton knitted fabrics."
Cause-Effect(e2,e1)
Comment:

705	 article goes some wat towards, identifying some of the <e1>conflicts</e1> arose from the previous and present agricultural <e2>development</e2>."
Cause-Effect(e2,e1)
Comment:

706	 <e1>disruption</e1> caused by the latest Christmas <e2>terrorist</e2> has added too much to the weary trip home."
Cause-Effect(e2,e1)
Comment:

707	 figures in the sport expect the Brawn cars to be the subject of a technical protest over the design of their <e1>diffusers</e1> by rival <e2>teams</e2>."
Other
Comment: no evidence for product-produc

708	 <e1>exemption</e1> also applies to <e2>goods</e2> supplied for use on ships and aircraft."
Other
Comment:

709	 <e1>nun</e1> fulfills his fantasy with a <e2>kiss</e2> that would make a hooker blush."
Other
Comment: Here e2 denotes an event rather than a technique; the situation is paraphrasable by "the nun kissed him" without loss of information. Modality is outside.

710	 <e1>company</e1> has landed into great <e2>controversies</e2>."
Other
Comment: violates b.1 and c.3

711	 Barbarian <e1>invasions</e1> of the fifth century were triggered by the <e2>destruction</e2> of the Gothic kingdoms by the Huns in 372-375."
Cause-Effect(e2,e1)
Comment:

712	 form was printed and filled out before <e1>return</e1> by <e2>mail</e2>."
Other
Comment: Purpose-Tool

713	 in Malta and Jamaica, the <e1>couple</e1> made many <e2>friends</e2> by immersing themselves in the local culture."
Other
Comment: friends is not a produc

714	 the increased demand logically calls for expansion and modification of intake processes to reach the goal of pairing each potential member with a <e1>sorority</e1> of their <e2>choice</e2>."
Other
Comment:

715	 Chi Minh City and Hanoi are in <e1>floods</e1> after the <e2>rain</e2>."
Cause-Effect(e2,e1)
Comment:

716	 percent of the mortgage <e1>fraud</e1> has been caused by the banks and the lending <e2>institutions</e2>."
Cause-Effect(e2,e1)
Comment:

717	 solar electricity instead of conventional electricity sources helps to reduce <e1>pollution</e1> that causes <e2>smog</e2>, acid rain, respiratory illness and global warming."
Cause-Effect(e1,e2)
Comment:

718	 and local implementation of the $787 billion package has degenerated into a <e1>scrimmage</e1> of competing <e2>agendas</e2> among governors and legislatures, state capitals and city halls, and even between neighboring municipalities."
Other
Comment: Scrimmage is a game of a scuffle, not a set.

719	 gets a little bit "chicken first or egg first" on examination but the primary truth is that the <e1>attacks</e1> are caused by the <e2>fear</e2> of the attacks themselve."
Cause-Effect(e2,e1)
Comment:

720	 year student David Beer is one of those affected by the <e1>pay</e1> <e2>dispute</e2>."
Other
Comment: Argument -- not message.

721	 <e1>studies</e1> supplied exploratory <e2>details</e2> on some of the determinant attributes and provided a basis for the current research."
Other
Comment: a process - violates (d)

722	 big <e1>bang</e1> was caused by the <e2>collision</e2> of two parallel universes."
Cause-Effect(e2,e1)
Comment:

723	 <e1>increase</e1> in customers, though, caused a <e2>strain</e2> on the company servers."
Cause-Effect(e1,e2)
Comment:

724	 <e1>credit card bill</e1> is approaching its <e2>limits</e2>."
Other
Comment: violates (a)

725	 <e1>lymphomas</e1> are caused by neoplastic <e2>proliferation</e2> of cells in the lymphoid system."
Cause-Effect(e2,e1)
Comment:

726	 is caused by <e2>infections</e2> that occur when pores in the skin are filled with oil, dirt, or other substances."
Cause-Effect(e2,e1)
Comment:

727	 girl with a mitochondrial disorder who developed a neurodegenerative disorder with "features of autism" after getting a <e1>fever</e1> from <e2>vaccines</e2>."
Cause-Effect(e2,e1)
Comment:

728	 -- founded by the Cliff Kushler, the <e1>inventor</e1> of the T9 text input <e2>technology</e2> -- raised $1.3 million earlier this year."
Other
Comment:

729	 is no accident that the title of the exhibition is a homage to one of the classic figures of contemporaneity, Antoni Tapies, whose work breached all the boundaries imposed on artistic <e1>creation</e1> by the <e2>critics</e2>."
Other
Comment:

730	 <e1>storm</e1> caused a tremendous amount of <e2>damage</e2> on the landing beaches, and for the time completely isolated the troops at Anzac."
Cause-Effect(e1,e2)
Comment:

731	 on other stormy days the boy learned to whittle out a straight <e1>shaft</e1> for the long <e2>bow</e2>, and tip it with gray goose feathers."
Other
Comment: The shaft is part of an arrow, not of the bow. It's not being used in the scenario described.

732	 in 1993, Montalban had a 10-hour surgery to try to alleviate the pain and <e1>discomfort</e1> from this <e2>injury</e2>."
Cause-Effect(e2,e1)
Comment:

733	 have inherited <e1>predispositions</e1> to <e2>anxiety</e2>."
Other
Comment:

734	 notifies the commencement of the <e1>exclusion</e1> of hospitals from the <e2>definition</e2>."
Other
Comment:

735	 <e1>examination</e1> has been made of all <e2>articles</e2> published in the review from 1944 through 1953."
Other
Comment:

736	 <e1>disease</e1> (CD) is an inflammatory disorder of the upper small intestine triggered by the <e2>ingestion</e2> of wheat, rye, barley, and possibly oat products."
Cause-Effect(e2,e1)
Comment:

737	 Flu - Popular name for the <e1>illness</e1> caused by the H1N1 <e2>virus</e2>."
Cause-Effect(e2,e1)
Comment:

738	 is an eye which never blanched at danger, and it is the <e1>boast</e1> of his <e2>soldiers</e2> that he never looked unpityingly upon the sufferings of his followers."
Other
Comment: The boast is the soldiers' state of being proud. negation does not concern the relation

739	 Jungle Book, because of its moral tone, came to be used as a motivational <e1>book</e1> by the <e2>movement</e2>."
Other
Comment: the movement does not make the book it is using it

740	 <e1>shape</e1> of the vessel is seen in a <e2>ewer</e2> that has been in the Metropolitan Museum for many years."
Other
Comment:

741	 ships caught <e1>fire</e1> after the <e2>collision</e2> but the blazes were brought under control."
Cause-Effect(e2,e1)
Comment:

742	 leads to <e2>inspiration</e2>, so in this story of love and hate, respect and betrayal, learn about the history of the Mexican Wrestling Wars."
Cause-Effect(e1,e2)
Comment:

743	 <e1>cyclotron</e1> started from the <e2>beginning</e2> of January 2000."
Other
Comment:

744	 <e1>play</e1> of a game starts in an initial <e2>state</e2>, at which players collect payoffs only if they remain in that state so that it becomes the final."
Other
Comment:

745	 1965, a <e1>farmer</e1> dug up the lower <e2>jawbone</e2> of a mammoth while in the process of expanding his cellar."
Other
Comment: jawbone is not a product of the farmer

746	 immediate challenge posed by this method was that only a <e1>handful</e1> of <e2>images</e2> were viewable on a computer screen at the same time."
Other
Comment: This is a quantity.

747	 this paper, we introduce dynamic analysis and model transformations of longitudinal <e1>flight</e1> of hypersonic <e2>aircrafts</e2>."
Other
Comment: It's what planes do.

748	 the bar sold alcohol to a person that was already obviously intoxicated, it became liable for the subsequent <e1>harm</e1> that was caused by the drunk <e2>driver</e2>."
Cause-Effect(e2,e1)
Comment:

749	 <e2>stones</e2>, water stones or whetstones are used to grind and hone the edges of steel tools and implements."
Other
Comment: Purpose-Tool

750	 feels the <e1>pain</e1> caused by the <e2>crisis</e2> but could be poised for rapid recovery."
Cause-Effect(e2,e1)
Comment:

751	 <e1>boom</e1> and shaking was caused by the <e2>asteroid</e2> that passed Earth yesterday."
Cause-Effect(e2,e1)
Comment:

752	 the morning of May 25, many schools in northeast China were evacuated because of the <e1>earthquake</e1> caused by the North Korea <e2>nuclear test</e2>."
Cause-Effect(e2,e1)
Comment:

753	 in the <e2>shop</e2> are all left-handed themselves and are happy to demonstrate products, explain why they are left-handed and give helpful advice to left-handers of all ages."
Other
Comment:

754	 <e1>dermatitis</e1> is one of the causes for <e2>dandruff</e2>."
Cause-Effect(e1,e2)
Comment:

755	 Leone in the wake of the <e1>devastation</e1> caused by the decade old civil <e2>conflict</e2> in every sector of our society, the education sector, being key."
Cause-Effect(e2,e1)
Comment:

756	 theory in possession about leather-making shows that penetration and <e1>bond</e1> of tanning <e2>agents</e2> are supplement each other during the tanning process."
Other
Comment: Bond refers to the process of binding.

757	 B is a potentially life-threatening liver <e1>infection</e1> caused by the hepatitis B <e2>virus</e2>."
Cause-Effect(e2,e1)
Comment:

758	 <e1>unions</e1> are moving into <e2>politics</e2>."
Other
Comment: violates b.1

759	 investigation, however, it was found that all the <e1>noise</e1> was caused by the <e2>arrival</e2> of Fred Riemer with an ox-team load of flour."
Cause-Effect(e2,e1)
Comment:

760	 especially enjoyed Matthew Wells' bare arms waving his hockey stick at the <e1>umpire</e1> in the Australia-Canada <e2>match</e2> to dispute a decision."
Other
Comment:

761	 <e1>manor</e1> had <e2>lands</e2> in Old Thame, Moreton and North Weston and property in New Thame."
Other
Comment: Here it seems to be ownership rather than a part-whole relationship, though it's not 100% clear.

762	 meeting was called in response to a request of Eastern labor papers, but happened to fall amid the <e1>excitement</e1> caused by the Pittsburgh <e2>riot</e2>."
Cause-Effect(e2,e1)
Comment:

763	 commercial soap, shower gel or cleanser products contain preservatives, colorants and <e1>chemicals</e1> that cause dryness, rashes, itchiness and <e2>roughness</e2> on the skin."
Cause-Effect(e1,e2)
Comment:

764	 what's become a drug legend, he got woozy, dreamy and saw a <e1>kaleidoscope</e1> of dancing <e2>colours</e2>."
Other
Comment: This is not really a set. It's a pattern.

765	 <e1>infrastructure</e1> is falling into <e2>disrepair</e2>."
Other
Comment: violates c.3

766	 must be given to efforts to combat <e1>insecurity</e1> and thus poverty, major cause of <e2>violence</e2> most often experienced by poorest."
Cause-Effect(e1,e2)
Comment:

767	 situation called for peanut butter <e1>cookies</e1> baked from the simplest <e2>recipe</e2> imaginable."
Other
Comment:

768	 angry <e1>driver</e1> then demonstrated his displeasure by speeding around the other <e2>vehicle</e2>, cutting the other driver off."
Other
Comment:

769	 <e1>compromises</e1> contained in the agreement caused the civil <e2>war</e2> in the 26 counties in June 1922-April 1923, in which the pro-Treaty Provisional Government defeated the anti-Treaty Republican forces."
Cause-Effect(e1,e2)
Comment:

770	 <e1>disruption</e1> has been caused by <e2>work</e2> being carried out by track operator Network Rail."
Cause-Effect(e2,e1)
Comment:

771	 person with an intrinsic motivation to run gains <e1>satisfaction</e1> from a very long <e2>running</e2> around their favourite course on a calm, sunny day."
Cause-Effect(e2,e1)
Comment:

772	 real possibility of total engulfment by flame or <e1>suffocation</e1> from <e2>smoke</e2> was a constant threat."
Cause-Effect(e2,e1)
Comment:

773	 <e1>committee</e1> is approaching the final <e2>decision</e2>."
Other
Comment: violates c.2

774	 include pertinent <e2>people</e2> involved as well as interesting facts and production statistics."
Other
Comment:

775	 <e1>abuse</e1> is rooted in the perpetrator's mental <e2>illness</e2>."
Cause-Effect(e2,e1)
Comment:

776	 was a <e1>factory</e1> for destroying perfectly good <e2>pants</e2>."
Other
Comment: the factory destroys the plants it does not produce them

777	 <e1>birthmarks</e1> are caused by <e2>expansions</e2> (dilations) in tiny blood vessels called capillaries."
Cause-Effect(e2,e1)
Comment:

778	 household needs a <e1>nest</e1> of <e2>tables</e2> - functional and economic with space."
Other
Comment: An arrangement, not a collection.

779	 the <e1>builder</e1> is shifting the <e2>mud</e2> to some other place in closed vehicles."
Other
Comment:

780	 techniques are encouraged in all the work and volunteers benefit by getting away from the stress of modern day life and enjoying the spirit and <e1>fellowship</e1> of the skilled <e2>craftsmen</e2> of the past."
Other
Comment: This means a feeling of comradeship.

781	 <e1>dispute</e1> has resulted in major regional <e2>wars</e2> and two Palestinian Intifadas with tragedies on both sides."
Cause-Effect(e1,e2)
Comment:

782	 photograph shows the <e1>vortices</e1> created by the water strider's <e2>legs</e2> as it moves across the water."
Cause-Effect(e2,e1)
Comment:

783	 common <e1>cold</e1> and the flu are caused by different <e2>viruses</e2>, with symptoms of the flu presenting more quickly and with more severity than those of a cold."
Cause-Effect(e2,e1)
Comment:

784	 campaign laws include several <e1>restrictions</e1> on political <e2>speech</e2> that can seem arcane to outsiders, and even to some Brazilians."
Other
Comment: The modality is outside e1-e2. This is not a speech as a message. This is speech as a category of political activities.

785	 <e1>mother</e1> copes with that using <e2>humor</e2> as a shield."
Other
Comment: Violation of "(f) Properties, capabilities, aptitutes, skills, attitutes etc. are not acceptable as Instruments.

786	 stand here above the twisting gorge the <e1>winds</e1> have carved out of the <e2>sand</e2>."
Other
Comment: sand is not the product of winds

787	 <e1>author</e1> makes reference to all <e2>sciences</e2>, to many classical works in both psychology and biology."
Other
Comment: e1 is not the message, he is the communicator/creator.

788	 two <e1>countries</e1> finally entered into a code share <e2>agreement</e2>."
Other
Comment: violates c.3

789	 stimulation for PONV is a convincing case for the efficacy of acupuncture; to that were later added <e1>nausea</e1> from <e2>chemotherapy</e2> or pregnancy, and dental pain."
Cause-Effect(e2,e1)
Comment:

790	 <e1>geology</e1> comprises <e2>granite</e2> of the Mesozoic era as the bedrock."
Other
Comment: Geology is a property

791	 in equal parts with peppermint, Elder flowers help reduce the <e1>fevers</e1> and aches caused by <e2>colds</e2> and the flu."
Cause-Effect(e2,e1)
Comment:

792	 following pages are organized by subject, and investigate the root causes of <e1>damage</e1> caused by the <e2>quake</e2>."
Cause-Effect(e2,e1)
Comment:

793	 the <e1>chaos</e1> and urgency caused by the <e2>hurricanes</e2>, it was difficult to keep track of people with psychiatric disabilities."
Cause-Effect(e2,e1)
Comment:

794	 Arterial Hypertension clinical <e1>community</e1> builds order from <e2>chaos</e2>."
Other
Comment:

795	 two <e1>ports</e1> were specialized in the <e2>manufacture</e2> of luxury goods."
Other
Comment: Manufacture was located there.

796	 progress is steady and the <e1>builder</e1> has now established the <e2>location</e2> of offices on the future car park area along Forest Road."
Other
Comment: the location is not a prod

797	 the years passed, some of the <e1>invaders</e1> graduated from <e2>pity</e2> to an emotion resembling guilt."
Other
Comment:

798	 <e1>editors</e1> assembled many of the leading medical specialists, <e2>researchers</e2> and allied health professionals who have extensive clinical experience with polio survivors."
Other
Comment: researchers is not a product

799	 <e1>scars</e1> from <e2>stitches</e2> that were successfully put in but ripped out by the individual are also common."
Cause-Effect(e2,e1)
Comment:

800	 <e1>fighting</e1> resulted in hundreds of <e2>deaths</e2> and in the deployment of peace keepers into East Timor."
Cause-Effect(e1,e2)
Comment:

801	 of the <e1>streaks</e1> are caused by <e2>meteoroids</e2> about the size of a grain of sand, although meteoroids are porous and much less dense than sand."
Cause-Effect(e2,e1)
Comment:

802	 <e1>methods</e1> approaching the <e2>analysis</e2> of cells are described, with applications."
Other
Comment: Purpose-Tool, and thus Other.

803	 <e1>strategy</e1> departs from an overriding <e2>goal</e2>."
Other
Comment:

804	 brakes are secured by a <e1>cable</e1> clamp <e2>nut</e2>."
Other
Comment:

805	 expressive colour, contrasting with the blackness of an apocalyptic sky, the chiaroscuro that accentuates the insubstantial limbs, and the desert landscape and <e1>pile</e1> of <e2>excrement</e2> dominating the scene express Miro's profound pessimism."
Other
Comment: Quantity.

806	 large anti-neutrino <e1>component</e1> is the source of an irreducible <e2>background</e2>."
Cause-Effect(e1,e2)
Comment:

807	 <e1>mortality</e1> caused by the <e2>war</e2> is also high."
Cause-Effect(e2,e1)
Comment:

808	 now, this corner of the <e1>painter</e1>'s rambling private <e2>collection</e2> has been all but forgotten."
Other
Comment: Ownership and thus Other

809	 he leaves Ephesus, however, a <e1>riot</e1> breaks out, instigated by the <e2>silversmiths</e2> who manufacture idols of the goddess Artemis; they are afraid that Paul's evangelistic success will ruin their business."
Cause-Effect(e2,e1)
Comment: modality is outsid

810	 <e1>eruption</e1> resulted in massive lahar <e2>flows</e2> (a mixture of ash, lava, rock and water), primarily in the Rio Montana and Marker watersheds."
Cause-Effect(e1,e2)
Comment:

811	 seemingly orthodox <e1>person</e1> has departed into serious <e2>error</e2>."
Other
Comment: violates b.1 and c.3

812	 Philippine Airforce aerial shot shows residents standing on a rooftop to escape the <e1>floodwaters</e1> caused by continuous <e2>rains</e2> brought on by Typhoon Ketsana in Marikina city, metro Manila September 27, 2009."
Cause-Effect(e2,e1)
Comment:

813	 <e1>pressure</e1> was caused by the rapid power <e2>acceleration</e2> at the start."
Cause-Effect(e2,e1)
Comment:

814	 real <e1>man</e1> departs from <e2>holiness</e2>."
Other
Comment:

815	 of these <e1>data</e1> were presented in a <e2>paper</e2> read at the annual meeting."
Other
Comment: The problem in this sentence that only part of the data is presented in the paper.

816	 item is engraved with the English <e1>author</e1>'s <e2>initials</e2>."
Other
Comment: The initials are a property of the author. Other.

817	 addition to the Sudanese rebels, the <e1>bombing</e1> resulted in the <e2>deaths</e2> of several Chadian civilians and livestock."
Cause-Effect(e1,e2)
Comment:

818	 distinct <e1>formulations</e1> of valproic acid have been investigated in clinical <e2>trials</e2>."
Other
Comment: Here "clinical trials" refers to experiments, not to a public event. Violates (d).

819	 were <e1>stacks</e1> of Verizon's directories piled up by <e2>entrances</e2> of buldings."
Other
Comment: the entrance is not a product of the stacks

820	 I show that Adh-psi is actually a new, functional <e1>gene</e1> recently descended from an Adh <e2>duplication</e2>."
Other
Comment:

821	 <e1>governor</e1> is assisted by a vice <e2>governor</e2>."
Other
Comment: Assistance, collaborative work.

822	 noise <e1>signal</e1> was generated by a noise <e2>diode</e2> (ENR = 27 dB) and gated with a high-speed electronic switch."
Cause-Effect(e2,e1)
Comment:

823	 <e1>warts</e1> on the hands and feet are caused by <e2>viruses</e2>, which only affect humans."
Cause-Effect(e2,e1)
Comment:

824	 <e1>focus</e1> has largely been on the subject of <e2>ethics</e2>."
Other
Comment: The focus is not a message.

825	 has been caused by <e2>people</e2> who either knowingly or unknowingly have priced people out of jobs."
Cause-Effect(e2,e1)
Comment:

826	 <e1>noise</e1> and vibration caused by the <e2>passage</e2> of trains resulted in unacceptable conditions within the convention center as standard construction techniques had been used."
Cause-Effect(e2,e1)
Comment:

827	 of the ethics <e1>scandal</e1> that resulted in the <e2>impeachment</e2> of the state's Governor, there was real hope for real ethics reform in Illinois this year."
Cause-Effect(e1,e2)
Comment:

828	 <e1>origin</e1> of <e2>berserkers</e2> is unknown, although Tacitus mentions groups of Germanic warriors with berserk-like fury."
Other
Comment:

829	 storm ended up causing about a fraction of the <e1>damage</e1> caused by the Chesapeake Bay <e2>storm</e2>."
Cause-Effect(e2,e1)
Comment:

830	 wholesale markets are held in a fixed place and transact daily a large volume of <e1>business</e1> emanated from the village <e2>markets</e2>."
Cause-Effect(e2,e1)
Comment:

831	 the episode "My Future Self 'n' Me" the boys discover a joint and rolling papers on a tree <e1>stump</e1> in the <e2>woods</e2>."
Other
Comment: Location.

832	 opens with a group of diplomats having a <e1>discussion</e1> around a rectangular <e2>table</e2> covered with a green cloth."
Other
Comment: This is location.

833	 <e1>principles</e1> on which <e2>homoeopathy</e2> is based are very different to conventional medical beliefs."
Other
Comment:

834	 <e1>bears</e1> have gone into <e2>hibernation</e2>."
Other
Comment: violates b.1 and c.

835	 Bishop was also happy to talk about some of the contentious <e1>issues</e1> affecting the <e2>church</e2> at the moment."
Other
Comment:

836	 blood <e1>pressure</e1> is caused by a <e2>narrowing</e2> of the arteries, which means the heart has to work harder in order to push the blood through."
Cause-Effect(e2,e1)
Comment:

837	 genreal <e1>anesthetic</e1> cause unconsciousness and <e2>insensibility</e2> to paid and are used for major surgical procedures."
Cause-Effect(e1,e2)
Comment:

838	 or pimples are caused by <e2>hormonal changes</e2>, wrong food habits and improper skin care."
Cause-Effect(e2,e1)
Comment:

839	 July he was sent north to quell a <e1>rebellion</e1> instigated by the discontented <e2>people</e2> of Warwick."
Cause-Effect(e2,e1)
Comment:

840	 trends have thrown <e1>women</e1> into totally inhibiting <e2>situations</e2>."
Other
Comment: violates c.3

841	 the <e1>damage</e1> caused by the <e2>floods</e2>, and the subsequent insurance payout, were what prompted the restoration of the station building."
Cause-Effect(e2,e1)
Comment:

842	 wooden <e1>rod</e1> is attached to the <e2>arm</e2> of the chair, which on my chair has an L-shaped opening (corner) under the armrest."
Other
Comment:

843	 Shibnath, our <e1>protagonist</e1> too takes part in the freedom <e2>movement</e2> of India, faces the pangs of foreign rule, and is inspired by Sarojini Naidu and other notable figures like veteran communist leader Ravi Narayan Reddy."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

844	 <e1>process</e1> is assisted by benign <e2>intervention</e2> or neglect."
Other
Comment:

845	 court found proof that the fatal <e1>fire</e1> was caused by the <e2>dryer</e2>."
Cause-Effect(e2,e1)
Comment:

846	 students were evacuated from Conrad Residence for approximately 15 minutes after <e1>burnt food</e1> in one of the kitchens set off the fire <e2>alarm</e2>."
Cause-Effect(e1,e2)
Comment:

847	 is excellent in the reatment of <e1>headaches</e1> from fatigue and <e2>exhaustion</e2>."
Cause-Effect(e2,e1)
Comment:

848	 Archbishop of York, Dr John Sentamu, visited the stoneyard to survey the <e1>damage</e1> caused by the <e2>fire</e2>."
Cause-Effect(e2,e1)
Comment:

849	 of the most vivid portraits is that of Brookie Simmons, a white woman who fought to abolish child labor in a <e1>town</e1> <e2>factory</e2>."
Other
Comment: more like location, the town does not produce the factory

850	 first encounter in my luxurious hotels casino was the sound of a woman behind the roulette wheels screaming for <e1>joy</e1> after <e2>hitting</e2> the 12225.00 jackpot."
Cause-Effect(e2,e1)
Comment:

851	 is a branch of <e1>philosophy</e1> dealing with the <e2>nature</e2> of beauty, art, and taste, and with the creation and appreciation of beauty."
Other
Comment:

852	 future leaders are learning about <e1>economics</e1> and politics from the real <e2>world</e2>."
Other
Comment: violation of (a).

853	 <e1>style</e1> of music reflected <e2>feelings</e2> and situations experienced in daily life."
Other
Comment:

854	 at from one side, the <e1>wall</e1> enclosed a barren sixty-acre <e2>field</e2> called the Port of Anarres."
Other
Comment: the field is not contained by the wall

855	 <e1>antler</e1> grows from an <e2>attachment point</e2> on the skull called a pedicle."
Other
Comment:

856	 was a serious <e1>increase</e1> in the acidity of the seas caused by the acid <e2>rains</e2>."
Cause-Effect(e2,e1)
Comment:

857	 pulses</e1> are caused by the relatively low systemic <e2>arterial blood pressure</e2> due to the continuous runoff of blood from the aorta into the pulmonary artery."
Cause-Effect(e2,e1)
Comment:

858	 of the soil with liquid seaweed <e2>extract</e2> has just enough of an alkaline effect that slugs hate."
Other
Comment: Purpose-Tool

859	 <e1>deficits</e1> caused by the fiscal stimulus <e2>package</e2> end in 2011 and will help to sustain a fragile recovery in 2010, the deficits projected for the longer term are a threat to our economic future."
Cause-Effect(e2,e1)
Comment: modality is outsid

860	 <e1>suffering</e1> caused by the <e2>bleeding</e2> depends on where the arteriovenous malformation is located."
Cause-Effect(e2,e1)
Comment:

861	 banks, in order to employ the government deposits, gave unusual accommodation to their customers, until, moving in a <e1>circle</e1> of <e2>fallacies</e2>, the whole colony dreamed of growing rich by selling to each other land which produced nothing."
Other
Comment: Highly abstract and equally highly metaphorical.

862	 car manufacturers are launching more and more cars to attain the top position in this <e1>jungle</e1> of <e2>automotives</e2>."
Other
Comment:

863	 have taken this from my trousseau when something rustles beyond the staggering <e1>gambol</e1> of the shadow <e2>dancers</e2>."
Other
Comment: Not a collection! Gambolling = dancing.

864	 of placing the <e1>seeds</e1> in a strainer <e2>basket</e2>, they were placed in a wet muslin or cheesecloth and hung up."
Other
Comment:

865	 <e1>company</e1> has entered into the exclusive <e2>retail business</e2> and plans to open 60 retail stores in the country in the next 5 years."
Other
Comment: violates b.1

866	 overall <e1>damage</e1> caused by the <e2>destruction</e2> of land and property for the Wall's construction has taken many years to recover further."
Cause-Effect(e2,e1)
Comment:

867	 <e1>pain</e1> he felt was caused by the plant <e2>rubbing</e2> against his capillaries."
Cause-Effect(e2,e1)
Comment:

868	 <e1>loans</e1> are travelling into <e2>foreclosure</e2> significantly slower than conventional loans."
Other
Comment: violates c.3

869	 blocks of flats caught <e1>fire</e1> after the <e2>blaze</e2> spread from a building site in Sumner Road."
Cause-Effect(e2,e1)
Comment:

870	 Hawke's Bay Herald building was completely destroyed by the <e1>fire</e1> after the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

871	 seek to actually reverse the <e1>injury</e1> that has been caused by the <e2>heart attack</e2>."
Cause-Effect(e2,e1)
Comment:

872	 <e1>echoing</e1> you see is from an expect <e2>command</e2> running after send has run."
Cause-Effect(e2,e1)
Comment:

873	 were your <e1>run-of-the-mill</e1> poultry <e2>workers</e2> and janitors, people whose chief crime was to cross a border, an arbitrarily line that determines who is rich and who is poor, who has rights and who doesn't."
Other
Comment:

874	 the spring of 1950, the FCC issued a warning to the Hollywood motion picture studios against withholding product and <e1>talent</e1> from broadcast <e2>television</e2>, in what motion picture exhibitors denounced as "a bullying statement"."
Other
Comment:

875	 undernourished kittens were 'rehabilitated' with ad libitum access to <e1>food</e1> from six <e2>weeks</e2> of age onwards, and eventually achieved normal body size."
Other
Comment:

876	 is an abnormal build-up of fluid that causes <e2>swelling</e2>, most often in the arms or legs."
Cause-Effect(e1,e2)
Comment:

877	 has become the hottest <e2>topic</e2> of study for United States historians."
Other
Comment: here study is an activity - violates (d)

878	 the PN <e1>signal</e1> is generated by an <e2>algorithm</e2>, knowledge of the algorithm reveals the entire sequence."
Cause-Effect(e2,e1)
Comment:

879	 government views <e1>science</e1> simply as a tool for profit <e2>generation</e2>."
Other
Comment: Purpose-Tool

880	 was the <e1>destruction</e1> of the natural grasslands caused by the <e2>expansion</e2> of the cropping frontiers starting in 1875."
Cause-Effect(e2,e1)
Comment:

881	 dissertation examines four <e1>romances</e1> copied by the <e2>scribe</e2> himself."
Other
Comment: scribe is not a producer

882	 cabinet held a chilly outdoor <e1>meeting</e1> on a Mount Everest <e2>plateau</e2> today."
Other
Comment: This looks like location.

883	 Java <e1>developer</e1> has moved into Weblogic <e2>administration</e2>."
Other
Comment: violates b.1

884	 <e1>death</e1> of the rat caused the <e2>relocation</e2> of the flea, and if its next host just happened to be a human, then contagion was the result."
Cause-Effect(e1,e2)
Comment:

885	 planted the frozen <e2>scallops</e2> that led to Spike's elimination from Top Chef."
Other
Comment: scallops is not a product of the p

886	 <e1>firm</e1> assembled a project <e2>team</e2> consisting of the authors of this paper to develop its OnStar telematics business."
Other
Comment: team is not a product

887	 <e1>injury</e1> or death was caused by the <e2>intoxication</e2> and the employee shall be barred from receiving workers' compensation."
Cause-Effect(e2,e1)
Comment:

888	 suffer from <e1>headaches</e1> from <e2>perfume</e2> and any other toxic thing I get to smell."
Cause-Effect(e2,e1)
Comment:

889	 <e1>book</e1> departs from the <e2>movie</e2> in several respects, but Eggers does an excellent job taking us inside Max's head and motivations."
Other
Comment:

890	 opened to its tote bag form, it looks like a unsubstantial <e1>tote</e1> <e2>bag</e2> with a compartment for the umbrella."
Other
Comment: "The term tote, meaning "to carry" can be traced back to the 17th century but was not used to describe bags until 1900" (http://en.wikipedia.org/wiki/Tote_bag)

891	 changes can be caused by the tumor itself, by <e1>increased pressure</e1> within the skull caused by the presence of the <e2>tumor</e2>."
Cause-Effect(e2,e1)
Comment:

892	 the doctor had administered a <e1>drug</e1> which had caused the eventual <e2>death</e2> of the child."
Cause-Effect(e1,e2)
Comment:

893	 <e1>crashes</e1> resulted in the <e2>collapse</e2> of much of the World Trade Center complex, the destruction of part of the southwest side of the Pentagon."
Cause-Effect(e1,e2)
Comment:

894	 fact that you actually caused an <e1>accident</e1> that resulted in <e2>injury</e2> or death gives them the justification they need to prosecute you to the fullest extent of the law, and seek the toughest penalties possible."
Cause-Effect(e1,e2)
Comment:

895	 Bummer gone for the night the groms decide to surf at night with the help of floodlights, but the <e1>floodlights</e1> cause a <e2>power outage</e2> for the entire hotel."
Cause-Effect(e1,e2)
Comment:

896	 <e1>inflammation</e1> of the liver caused by the hepatitis A <e2>virus</e2> (HAV)."
Cause-Effect(e2,e1)
Comment:

897	 conclusion of the investigation was that the <e1>loss</e1> was caused by a <e2>failure</e2> in a cell wall, resulting in a serious crack and a leakage that the pumps were not able to cope with."
Cause-Effect(e2,e1)
Comment:

898	 <e1>tsunami</e1> was generated by an unusual type of <e2>earthquake</e2> that occurs near oceanic trenches."
Cause-Effect(e2,e1)
Comment:

899	 <e1>student</e1> is a participant in a web conferencing <e2>session</e2>."
Other
Comment: The session is not a collection of students.

900	 the globe, unique and fascinating species face <e1>extinction</e1> from <e2>hunting</e2> and habitat destruction, which affects vulnerable animals in every kind of environment."
Cause-Effect(e2,e1)
Comment:

901	 <e1>people</e1> are familiar with <e2>feelings</e2> of anxiety."
Other
Comment: Here feelings are not used by people, instead people feel them and are used to them.

902	 is the <e1>combination</e1> of human <e2>resources</e2> and institutions that permits countries to achieve their development goals."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

903	 <e1>team</e1> finishes the <e2>season</e2> with a 9-11 record, just short of tournament contention."
Other
Comment: season is not a product

904	 became an obsession but, frustrated at every turn, he eventually made do with a <e1>copy</e1> made by a family <e2>firm</e2> in Nottingham."
Other
Comment:

905	 the most <e1>damage</e1> has been caused by the corrosive <e2>effects</e2> of wind and water."
Cause-Effect(e2,e1)
Comment:

906	 <e1>city dwellers</e1> have sunk into <e2>abominations</e2>."
Other
Comment: violates b.1 and c.3

907	 model describes the relationship between a government and the <e1>manager</e1> of a <e2>firm</e2> which produces a pure public good, under private or public ownership."
Other
Comment:

908	 was an intrinsic part of <e2>plantation life</e2> and no child, however privileged or protected, could escape its ugliness or it savagery."
Other
Comment:

909	 <e1>police</e1> told an open government <e2>surveyor</e2> it "doesn't give out the records"."
Other
Comment: surveyor is not a product; negation is outsid

910	 <e1>movement</e1> developed from the <e2>rediscovery</e2> by European scholars of many Greek and Roman texts."
Cause-Effect(e1,e2)
Comment:

911	 vascular <e1>dilatation</e1> was caused by the sympathetic and the course of vaso-motor <e2>nerves</e2>."
Cause-Effect(e2,e1)
Comment:

912	 and <e1>rill</e1> <e2>erosion</e2> is considered to be the most harmful of all soil erosion forms since it may be unnoticed or ignored by the peasant."
Cause-Effect(e2,e1)
Comment:

913	 female constructs a <e1>nest</e1> of <e2>grass</e2> in a hollow on the ground."
Other
Comment: e2 is a material, not a component

914	 <e1>problem</e1> comes from the <e2>widgets</e2> resembling HTC's own Sense UI widgets."
Cause-Effect(e2,e1)
Comment:

915	 <e1>kids</e1> get to hop around in a <e2>sack</e2> or pillowcase."
Other
Comment: in this example, the sack is not a container

916	 important <e1>advantages</e1> are related to the <e2>position</e2> of a left-handed first baseman with respect to the base."
Other
Comment:

917	 <e1>fire</e1> is caused by <e2>overheating</e2> of connections, which is cause by its turn by poor ohmic contact."
Cause-Effect(e2,e1)
Comment:

918	 9 shows the average <e1>delays</e1> obtained with this <e2>policy</e2> as compared with those of the previous subsection."
Cause-Effect(e2,e1)
Comment:

919	 <e1>trip</e1> of two mountain <e2>goats</e2> to was also a subject for discussion."
Other
Comment: does trip here refer to 'journey' or group?

920	 shuttle science shows how 1908 Tunguska <e1>explosion</e1> was caused by a <e2>comet</e2>."
Cause-Effect(e2,e1)
Comment:

921	 metal <e1>fume</e1> and dust cause upper respiratory tract irritation, chronic interstitial pneumonitis, and skin <e2>sensitization</e2>."
Cause-Effect(e1,e2)
Comment:

922	 child and young person seen at Starship with <e1>intoxication</e1> from alcohol or illicit <e2>drug use</e2> had a social work assessment before leaving the hospital."
Cause-Effect(e2,e1)
Comment:

923	 original <e1>santur</e1> was made with tree <e2>bark</e2>, stones and stringed with goat intestines."
Other
Comment: tree bark is a substance not a part.

924	 <e1>place</e1> was in the <e2>desk</e2> in front of me."
Other
Comment: desk is not a container (a) is not satisfied

925	 time in 2002, the <e1>chief executive</e1> of this <e2>corporation</e2> sought and received board approval to construct a modern training school for its staff."
Other
Comment:

926	 much of the past decade, the <e1>leader</e1> has methodically fashioned the party into a re-election <e2>machine</e2>."
Other
Comment: the machine is not a real product

927	 the <e1>pollution</e1> caused by the <e2>buring</e2> of coal, the light-colored tree trunks became darker due to soot."
Cause-Effect(e2,e1)
Comment:

928	 stirred the oil, garlic and cumin seeds together in a <e1>dish</e1> large enough to hold the <e2>sardines</e2> in a single layer."
Other
Comment:

929	 <e1>exposure</e1> to higher concentrations of the gas cause disorientation, <e2>convulsions</e2>, unconsciousness and death."
Cause-Effect(e1,e2)
Comment:

930	 chemical <e1>studies</e1> were directed toward <e2>proof</e2> of structure of the indole components of the seeds."
Cause-Effect(e1,e2)
Comment:

931	 <e1>riot</e1> was instigated by the <e2>clergy</e2> of the Church of England with the active support and collaboration of the magistrates."
Cause-Effect(e2,e1)
Comment:

932	 <e1>farm</e1> is participant in <e2>forestry</e2> and there have already been planted around eight thousand plants."
Other
Comment: Participation is a relation generally different from all our Nine. Component-Whole may be close sometimes.

933	 the <e1>discomfort</e1> caused by the <e2>ointment</e2> and the duration of treatment often result in non-compliance."
Cause-Effect(e2,e1)
Comment:

934	 and PMS cause stress and <e2>anxiety</e2> even without imbalanced hormones."
Cause-Effect(e1,e2)
Comment:

935	 <e1>arrest</e1> completes a dismal past five <e2>weeks</e2> for the 25-year-old."
Other
Comment: weeks is not a product

936	 <e1>killings</e1> resulted in indiscriminate <e2>firing</e2> by unknown people in Garden area of the city."
Cause-Effect(e1,e2)
Comment:

937	 <e1>cow</e1> makes a <e2>sound</e2> called lowing, also known as mooing."
Cause-Effect(e2,e1)
Comment:

938	 are caused by the vitreous gel <e2>tugging</e2> on the retina."
Cause-Effect(e2,e1)
Comment:

939	 about Salmonellosis, an <e1>illness</e1> caused by a <e2>bacteria</e2> found in raw food, soil, or water."
Cause-Effect(e2,e1)
Comment:

940	 the <e1>book</e1>, a distinguished country <e2>gentleman</e2> becomes a knight after reading too many chivalric novels."
Other
Comment: gentleman is not a producer

941	 Liver Cirrhosis Treatment Liver cirrhosis is a degenerative inflammatory <e1>disease</e1> that results in <e2>hardening</e2> and scarring of liver cells."
Cause-Effect(e1,e2)
Comment:

942	 day-old <e1>baby</e1> was taken into <e2>intensive care</e2>."
Other
Comment: violates b.1

943	 these <e1>gases</e1> cause <e2>evaporation</e2> of water from sea and soil."
Cause-Effect(e1,e2)
Comment:

944	 <e1>clergy</e1> of various <e2>denominations</e2> were surveyed to assess their understanding and experience of trauma."
Other
Comment: Ditto.

945	 am currently taking a <e1>medication</e1> which causes <e2>tingling</e2> in my hands and feet, but I also have vitamin d deficiency r/t hyperparathyroidism and my calcium is up and down."
Cause-Effect(e1,e2)
Comment:

946	 by far the most frequent tsunami-maker is the <e1>buckling</e1> of the seafloor caused by an undersea <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

947	 magnetic bracelet helps the <e1>pain</e1> from <e2>stroke</e2> in your arm."
Cause-Effect(e2,e1)
Comment:

948	 R900-million and the tribe a further R80-billion in compensation for the <e1>humiliation</e1> caused by the monarch's criminal <e2>trial</e2>."
Cause-Effect(e2,e1)
Comment:

949	 sales <e1>cycle</e1> has shortened from several <e2>months</e2> to weeks."
Other
Comment:

950	 <e1>study</e1> on which this <e2>paper</e2> is based was prompted by concerns about marking standards."
Other
Comment: The study is the content of the paper, not the topic --- topic would be biology, history, standards etc.

951	 every <e1>employee</e1> who is a participant in the <e2>trust</e2> automatically has a beneficial interest in the ownership of the agency."
Other
Comment: Here 'trust' is not a collection of employees.

952	 of the task which the authors set themselves is the delineation and validation of the idea that a <e1>subculture</e1> of <e2>violence</e2> exists."
Other
Comment: A type of subculture.

953	 <e1>author</e1>'s <e2>name</e2> gives her work a brand image that informs consumers' choices of literary and artistic works."
Other
Comment: name is not a product

954	 the healthy heart, the left <e1>ventricle</e1> performs a systolic wringing motion, with a counterclockwise <e2>rotation</e2> at the apex."
Other
Comment: manner

955	 <e2>erosion</e2> is the detachment and removal of soil material by water."
Cause-Effect(e1,e2)
Comment:

956	 involving the medial part of the premotor cortex, the supplementary motor area (SMA) and the rear portion of the medial part of the precentral gyrus caused a contralateral, severe leg-predominant <e2>hemiplegia</e2>, distally predominant and a less severe proximal weakness of the arm."
Cause-Effect(e1,e2)
Comment:

957	 the <e1>disruption</e1> caused by pupil <e2>mobility</e2>."
Cause-Effect(e2,e1)
Comment:

958	 second <e1>injury</e1> also started from the aforementioned <e2>collision</e2>, but has only recently re-surfaced."
Cause-Effect(e2,e1)
Comment:

959	 and investigation of such a detector arose from an inadequate <e2>sensitivity</e2> of a commercial p-type Si detector."
Cause-Effect(e2,e1)
Comment:

960	 <e1>director</e1>, Robert Connolly, who co-wrote the script with David Williamson, assembles the pieces with great methodical <e2>logic</e2>."
Other
Comment: Violation of "(f) Properties, capabilities, aptitutes, skills, attitutes etc. are not acceptable as Instruments.

961	 apart from visual design elements, one also gets creative with the <e1>layout</e1> of the <e2>site</e2>."
Other
Comment: layout is a property

962	 consists of <e2>seeing</e2> what everybody else has seen and thinking what nobody else has thought."
Other
Comment: It could have been Component-Whole, but e1 does not comply with restriction (a); negation is outsid

963	 <e1>inflammation</e1> is caused by the <e2>growth</e2> of unusual bacteria, which usually results from antibiotic use."
Cause-Effect(e2,e1)
Comment:

964	 <e1>exhibition</e1> The Art of the Motorcycle caused a <e2>revolution</e2> on the museum scene with its presentation of the motorcycle as a metaphor of the 20th century."
Cause-Effect(e1,e2)
Comment:

965	 occur throughout life and those <e1>pressures</e1> cause <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

966	 of the best vantage <e1>points</e1> of the Boston skyline is from the <e2>water</e2>, in a boat heading toward the Boston Harbor Islands."
Other
Comment:

967	 iterpipes, python is ready to replace the bash <e1>shell</e1> for <e2>scripting</e2>."
Other
Comment: Purpose-Tool

968	 <e1>drugs</e1> cause <e2>unconsciousness</e2> and cardiac arrest separately."
Cause-Effect(e1,e2)
Comment:

969	 is an absorbing <e1>book</e1>, diminished by the choppy <e2>way</e2> Ackerman balances Antonina's account with the larger story of the Warsaw Holocaust."
Other
Comment: way is not a product or producer

970	 of the resulting mixture caused the <e2>reduction</e2> of the aluminum ions in the Al2O3."
Cause-Effect(e1,e2)
Comment:

971	 <e1>president</e1> of the <e2>bank</e2> has told us that most of the State banks exist by its forbearance."
Other
Comment: modality is outsid

972	 month, <e1>scientists</e1> sliced the <e2>brain</e2> into 2401 paper-thin sections, part of a project to create an open-access digital atlas."
Other
Comment:

973	 creates his <e1>work</e1> based on his <e2>life experiences</e2> and observations."
Other
Comment: based on -- not directly the topic

974	 include the tapping of the package, the way one holds their cigarette, the oral gratification, and the easy social <e1>camaraderie</e1> of <e2>smokers</e2> on a break."
Other
Comment:... or fellow smokers.

975	 <e1>meeting</e1> of devoted <e2>friends</e2> and lovers served as the foundation of the NAMES Project AIDS Memorial Quilt."
Other
Comment:

976	 become apparent in evolution as <e1>self-assemblage</e1> of the gene <e2>networks</e2> and cascades."
Other
Comment:

977	 different bacteria, <e1>protozoa</e1> and viruses cause food <e2>poisoning</e2>, but most cases are the result of just a few species of bacteria."
Cause-Effect(e1,e2)
Comment:

978	 boy learned how to protect the socket for making a picture <e1>light switch</e1> <e2>cover</e2> in this free home decorating video."
Other
Comment:

979	 concepts of <e1>psychoanalysis</e1> have been applied to <e2>films</e2> in various ways."
Other
Comment:

980	 sad (excuse the pun) consequence is that a winter of suffering from SAD adds to the <e1>weight gain</e1> caused by the <e2>antidepressants</e2>."
Cause-Effect(e2,e1)
Comment:

981	 poor management pushed the <e1>workers</e1> into <e2>depression</e2>."
Other
Comment: violates c.3

982	 to Mecca is a basic <e2>tenet</e2> of Islam."
Other
Comment:

983	 structural <e1>deficit</e1> has been caused by the series of <e2>tax cuts</e2>, not the recession or defense needs."
Cause-Effect(e2,e1)
Comment:

984	 <e1>hypermenorrhea</e1> was made worse by <e2>treatment</e2>."
Other
Comment: treatment is not a producer

985	 facing the hopelessness of the future, the <e1>poet</e1> sank into <e2>despair</e2>."
Other
Comment: violates b.1 and c.3

986	 final <e1>rules</e1> are under <e2>consideration</e2> and are expected by June 30."
Other
Comment:

987	 <e1>manager</e1> saw a black <e2>male</e2> fire two shots while beside his car in the parking lot."
Other
Comment: male is not a product

988	 the <e1>emperor</e1> took advantage of the <e2>gathering</e2> to determine the order and organization of the church."
Other
Comment: e2 is the temporal location.

989	 took a long time to undo the <e1>damage</e1> that has been caused by the <e2>crisis</e2> of confidence, damage whose effects are just now beginning to make themselves felt in a slow, glacial collapse."
Cause-Effect(e2,e1)
Comment:

990	 immediate origin of the <e1>pigment</e1> in circulation is from the <e2>breakdown</e2> of endodermal tissue."
Other
Comment:

991	 <e1>car</e1> definitely has snob <e2>appeal</e2> with its good looks and saloon functionality."
Other
Comment:

992	 have come into <e2>use</e2>."
Other
Comment: violates b.1 and c.3

993	 Lisbon <e1>treaty</e1> has come into <e2>force</e2>."
Other
Comment: violates c.

994	 rescue teams found 17 of the 25 crew thrown into the sea when the tanker caught <e1>fire</e1> after the <e2>collision</e2>."
Cause-Effect(e2,e1)
Comment:

995	 <e1>kids</e1> liberate the ponies with the <e2>help</e2> of a sympathetic groom."
Other
Comment:

996	 1,000 <e1>farm</e1> <e2>animals</e2> receive health and medical care each year in our Farm Animal Hospital."
Other
Comment:

997	 to the face and nasal area causes <e2>nosebleeds</e2>, such as getting punched or violently slapped."
Cause-Effect(e1,e2)
Comment:

998	 comments from readers highlight the <e1>frustration</e1> and inconvenience caused by the 3-pin <e2>system</e2>."
Cause-Effect(e2,e1)
Comment:

999	 <e1>observations</e1> from <e2>space</e2> reveal a number of fascinating natural phenomena of interest to meteorologists and aeronomists, such as aurorae, airglow, aerosol layers, lightning, and atmospheric refraction effects."
Other
Comment:

1000	 <e1>speech</e1> was delivered from the <e2>steps</e2> of Lincoln Memorial on August 28, 1963 as part of his famous March on Washington."
Other
Comment:

1001	 city accuses Wells Fargo of engaging in illegal "reverse redlining" - targeting black neighborhoods for bad <e1>loans</e1> that resulted in mass <e2>foreclosures</e2>."
Other
Comment:

1002	 once took a tin of her delicious <e1>cookies</e1> made from the following old <e2>recipe</e2>."
Other
Comment:

1003	 <e1>newsroom</e1> contains the latest <e2>developments</e2> in UK foreign policy and news on the work of the British Embassy and Consulates around the US."
Other
Comment: Location

1004	 is an <e1>inflammation</e1> of the lungs caused by bacteria, viruses, or chemical <e2>irritants</e2>."
Cause-Effect(e2,e1)
Comment:

1005	 <e1>blockages</e1> are caused by a build-up of <e2>fatty plaque</e2> along the artery walls."
Cause-Effect(e2,e1)
Comment:

1006	 <e1>attention</e1> has been directed toward the <e2>study</e2> of the motility of the stomach and its regulation by the extrinsic nerves."
Other
Comment: The sentence violates restriction (b).

1007	 <e1>demise</e1> of the bees has been caused by the globalization of <e2>commerce</e2>."
Cause-Effect(e2,e1)
Comment:

1008	 <e1>food poisoning</e1> is caused by <e2>eating</e2> food contaminated with Staphylococcus aureus."
Cause-Effect(e2,e1)
Comment:

1009	 former lover, the erstwhile hippie Shasta, has become entangled with a married, <e1>billionaire</e1> <e2>developer</e2>, Marty Wolfmann."
Other
Comment:

1010	 were engaged, at great odds, with the swarming <e1>rabble</e1> of the <e2>alleys</e2>."
Other
Comment: Metaphorical sentence, 'alleys' is not suitable as a member.

1011	 of the soils developed from the <e2>amphibolites</e2> of Santiago-Ponte Ulla, Spain."
Cause-Effect(e1,e2)
Comment:

1012	 Declaration urged that such <e1>strategies</e1> address the root <e2>causes</e2> and risk factors of crime and victimization."
Other
Comment: a strategy is a method of (prescription for) doing something

1013	 disturbances such as flares, prominences, and sunspots increase the amount of <e1>radiation</e1> from the <e2>sun</e2>."
Cause-Effect(e2,e1)
Comment:

1014	 results support the theoretical model conceptualizing alcohol use and misuse as being the product of <e1>stress</e1> caused by constraints and <e2>resources</e2> brought to bear simultaneously by agent personality, structures of daily life, and macro social structures."
Cause-Effect(e2,e1)
Comment:

1015	 the great <e1>union</e1> of the popular <e2>masses</e2> of France opposed the great union of the adherents of the monarchy and the victory of 'political reform' had been attained, many countries followed the French example and undertook all sorts of 'political reforms'."
Other
Comment: A union cannot possibly be an element of masses.

1016	 significant portion of head and neck <e1>cancers</e1>, anal cancers, and cancer of the larynx are caused by the human <e2>papillomavirus</e2>."
Cause-Effect(e2,e1)
Comment:

1017	 and poverty cause <e2>tension</e2> not only within communities and countries, but throughout the world."
Cause-Effect(e1,e2)
Comment:

1018	 great <e1>resume</e1> is the best tool for a successful career <e2>transition</e2>."
Other
Comment: Purpose-Tool

1019	 only <e1>light</e1> in the house was radiating from the TV <e2>screen</e2>."
Cause-Effect(e2,e1)
Comment:

1020	 economic terms, the ecological <e1>catastrophe</e1> caused by the Prestige oil <e2>spill</e2> is comparable with that caused by the Exxon Valdez."
Cause-Effect(e2,e1)
Comment:

1021	 is a temporal linguistic <e1>quality</e1> expressing the <e2>time</e2>."
Other
Comment:

1022	 beautiful <e1>outside</e1> of the <e2>store</e2> is complementary to the local surroundings and is designed to be a store of the community."
Other
Comment:

1023	 important aim concerning <e1>enamel</e1> and dentin <e2>erosion</e2> is to identify agents that might protect the tooth surface from demineralization."
Other
Comment:

1024	 representative is a technical guarantor, a partner or an <e1>officer</e1> of an enterprise who is a member of the <e2>corporation</e2> and who is designated as a representative for the enterprise in accordance with sections 79 and 80 of the Regulation respecting the internal management of the Corporation of Master Electricians of Quebec."
Other
Comment: Indirect membership: enterprise, not officer.

1025	 Research, in Arizona, makes a range of devices for neutralizing <e1>radiation</e1> from <e2>computers</e2> and other sources."
Cause-Effect(e2,e1)
Comment:

1026	 family members also get great <e1>joy</e1> from <e2>dogs</e2> doing tricks and great for family activities."
Cause-Effect(e2,e1)
Comment:

1027	 is an ingredient for making a distinct <e2>color</e2> called Egyptian blue."
Other
Comment:

1028	 US forces have withdrawn due to the <e1>damage</e1> caused by the eruption and the <e2>typhoon</e2>."
Cause-Effect(e2,e1)
Comment:

1029	 <e1>riot</e1> resulted in the <e2>deaths</e2> of 196 people, and led to a major reform in the country's economic policy favouring the Malays."
Cause-Effect(e1,e2)
Comment:

1030	 <e1>flea</e1> <e2>infestation</e2> is caused by fleas, which are small, wingless blood-sucking insects."
Cause-Effect(e1,e2)
Comment:

1031	 this case report we describe a young female with BCS, which was the result of a <e1>combination</e1> of risk <e2>factors</e2>, including the recently discovered G20210A."
Other
Comment: Combination here is a mix, the elements are not independent of each other.

1032	 went up to Oxford during the war to read English and, after war service in India, codirected The Tempest with Neville Coghill in an outdoor <e1>production</e1> by the Worcester College <e2>lake</e2>."
Other
Comment: lake is not a product

1033	 founded the Emmaus Program, an annual <e1>convocation</e1> of diocesan <e2>clergy</e2> for their continuing education and spiritual formation, in 1983."
Other
Comment: Participation.

1034	 Liebeck is the woman who sued McDonalds after she suffered a serious <e1>burn</e1> after the <e2>spilling</e2> of a cup of coffee on her lap."
Cause-Effect(e2,e1)
Comment:

1035	 <e1>bending</e1> caused a <e2>fracture</e2> on the tension side of the test specimen, but the UHMP fiber ribbon held the fractured parts together."
Cause-Effect(e1,e2)
Comment:

1036	 a decision made by the Typhoon Committee in cooperation with United Nations agencies and the League of Red Crescent Societies, ESCAP compiles every year region-wide statistics and reports on the <e1>harm</e1> caused by tropical cyclones, <e2>floods</e2>, droughts and other severe weather events."
Cause-Effect(e2,e1)
Comment:

1037	 <e2>attacks</e2> linked to heart disease and heart attacks."
Other
Comment:

1038	 in addition to Maori, other population <e1>groups</e1> need specific recognition in the Bill, including <e2>people</e2> with disabilities."
Other
Comment: People with disabilities are a KIND of group.

1039	 <e1>influx</e1> caused a further <e2>drain</e2> on the country's already scanty resources."
Cause-Effect(e1,e2)
Comment:

1040	 most of the world's unreached people live in the <e1>jungle</e1> of big <e2>cities</e2> and no longer in the real jungle."
Other
Comment: "Jungle" here is a quality (something is like a jungle), not a set of like things.

1041	 ingredient also repairs the <e1>damage</e1> that has been caused by the <e2>sun</e2>."
Cause-Effect(e2,e1)
Comment:

1042	 Patterson discusses the <e1>issues</e1> affecting daily <e2>life</e2> in the north-west."
Other
Comment:

1043	 picked up the latest issue of Woman's World magazine a few days ago because it had a head line about the effect of <e1>safflower</e1> on <e2>belly fat</e2>."
Other
Comment:

1044	 beyond the <e1>damage</e1> caused by the smoke and the <e2>water</e2>, the structure of the store itself it was not overly damaged."
Cause-Effect(e2,e1)
Comment:

1045	 with this change, or with similar mutations in the USH2A gene, develop moderate to severe hearing loss and retinitis pigmentosa, a <e1>disorder</e1> that results in <e2>loss</e2> of vision."
Cause-Effect(e1,e2)
Comment:

1046	 Olympic bobsleigh <e1>plans</e1> go into <e2>meltdown</e2>."
Other
Comment: violates c.3

1047	 had what it took to play the terrifying Ugandan dictator - but the other <e1>man</e1> convinced him with his <e2>passion</e2> for the part."
Other
Comment:

1048	 <e1>burglar</e1> forgot to log out before leaving the home with two diamond <e2>rings</e2>."
Other
Comment:

1049	 Germanic <e1>migrations</e1> of the fifth century were triggered by the <e2>destruction</e2> of the Gothic kingdoms by the Huns in 372-375."
Cause-Effect(e2,e1)
Comment:

1050	 <e1>country</e1> is sinking into <e2>turmoil</e2>."
Other
Comment: violates b.1 and c.3

1051	 the run-up to this match, a new <e1>war</e1> of words has erupted on the <e2>internet</e2> in yet another twist to the long-simmering saga."
Other
Comment: A collocation: "war of words". The Internet is the place of that war.

1052	 purpose of this <e1>thesis research</e1> was to examine <e2>social structure</e2>, culture, and gender as potential sources of variation in the seriousness of punishment recommended for everyday acts of wrongdoing."
Other
Comment: Research is a process, not a message - violation of (d). The modality is outside e1-e2.

1053	 reference <e1>signal</e1> was generated from an auxiliary <e2>photomultiplier</e2> (RCA 1P28) with a quantum counter."
Cause-Effect(e2,e1)
Comment:

1054	 who is also the governor of Punjab has been accused by the <e1>congress</e1> of various murky <e2>deals</e2> worth billions of rupees."
Other
Comment: Not the right syntax.

1055	 electromagnetic (EM) <e1>radiation</e1> from the <e2>sun</e2> arrives mostly in the form of visible and infrared wavelengths."
Cause-Effect(e2,e1)
Comment:

1056	 <e1>pseudolesion</e1> was caused by <e2>drainage</e2> of the paraumbilical vein."
Cause-Effect(e2,e1)
Comment:

1057	 article about Salmonellosis, the <e1>infection</e1> caused by Salmonella <e2>bacteria</e2>, leading to diarrhea, fever, vomiting, and abdominal cramps."
Cause-Effect(e2,e1)
Comment:

1058	 paper presents the results of a survey of the building <e1>damage</e1> caused by the ash fall from the cataclysmic <e2>eruption</e2> of Mount Pinatubo."
Cause-Effect(e2,e1)
Comment:

1059	 is an online <e1>radio</e1> <e2>tuner</e2> to listen, discover and share radios with your friends."
Other
Comment:

1060	 <e1>companies</e1> have gone into <e2>liquidation</e2>."
Other
Comment: violates b.1 and c.3

1061	 had indicated the <e1>fire</e1> started from the <e2>airconditioners</e2> because on arrival that was the area engulfed."
Other
Comment:

1062	 <e1>earthquake</e1> caused the <e2>failures</e2> of the electric power system, the water supply system, the sewer system, the telephone and telegraph systems."
Cause-Effect(e1,e2)
Comment:

1063	 <e1>guy</e1> put up a <e2>fight</e2>, so the mugger takes out a gun and shoots him, point blank."
Cause-Effect(e1,e2)
Comment:

1064	 are hedging bets on hosting the terror <e1>scum</e1> of different <e2>tripes</e2>."
Other
Comment: Tripes??!

1065	 is the oil that allows the <e1>radicalisation</e1> <e2>machine</e2>'s many cogs to turn."
Other
Comment: no evidence for product-producer

1066	 third <e1>book</e1> was requested by the <e2>editor</e2>, E.L. Doctorow but he changed jobs before the manuscript was completed."
Other
Comment: the editor does not produce the book

1067	 or furuncles are caused by staphylococcal bacterial <e2>infections</e2> of the hair follicles."
Cause-Effect(e2,e1)
Comment:

1068	 <e1>stations</e1> (and cable channels) have spawned imitation <e2>shows</e2>."
Other
Comment: stations are not producers in this cas

1069	 the coin-operated machine supplier a.k.a. the <e1>coin</e1> <e2>operator</e2>."
Other
Comment: the operator supplies machines that are coin-operated, so there's no direct link between the operator and the coins.

1070	 <e1>cancer</e1> is caused by <e2>infection</e2> with the human papillomavirus (HPV) and is one of the most common cancers in women in developing countries."
Cause-Effect(e2,e1)
Comment:

1071	 problems associated with screening, many of those <e1>cancers</e1> were caused by <e2>radiation exposures</e2> shortly after the accident."
Cause-Effect(e2,e1)
Comment:

1072	 corporate leaders have inherited Woodrow Wilson's <e1>commitment</e1> to <e2>scholarship</e2>."
Other
Comment:

1073	 year's Nobel Laureates in Physiology or Medicine made the remarkable and unexpected discovery that inflammation in the stomach (gastritis) as well as ulceration of the stomach or duodenum (peptic ulcer disease) is the result of an <e1>infection</e1> of the stomach caused by the <e2>bacterium</e2> Helicobacter pylori."
Cause-Effect(e2,e1)
Comment:

1074	 siding <e1>installer</e1> erroneously installed the siding with a 6" <e2>reveal</e2>, rather than a 7" reveal as required."
Other
Comment: The reveal is not a material but a measurement of the amount of raw material that is exposed.

1075	 usual, an <e1>asterisk</e1> denotes a censored <e2>observation</e2>."
Other
Comment:

1076	 thorough oral examination, which includes dental X-rays, determines that the <e1>toothache</e1> is coming from a <e2>jaw problem</e2>."
Cause-Effect(e2,e1)
Comment:

1077	 we note the <e1>convergence</e1> over the lakes caused by the land breeze <e2>circulation</e2>."
Cause-Effect(e2,e1)
Comment:

1078	 Court added to the <e1>debate</e1> pointing out the <e2>need</e2> for investment in primary care as part of the long term strategy."
Other
Comment: The addition makes it a negative example.

1079	 finds Jae-Young, but the <e1>striker</e1> blasts over the bar with only the <e2>keeper</e2> to beat."
Other
Comment:

1080	 severe <e1>recession</e1> triggered by the global <e2>crisis</e2> has bottomed out, thanks in part to a rebound in exports, although production remains the same."
Cause-Effect(e2,e1)
Comment:

1081	 the 1998 crisis, capital <e1>flight</e1> caused a <e2>crisis</e2> on the currency markets, as the removal of funds from Russia necessarily entailed the conversion of rubles to dollars."
Cause-Effect(e1,e2)
Comment:

1082	 used to get terrible <e1>headaches</e1> from sinus and <e2>infections</e2> that resulted in taking antibiotics a few times a year."
Cause-Effect(e2,e1)
Comment:

1083	 designed lampposts are spaced along the <e1>curbs</e1> of the <e2>roadway</e2>."
Other
Comment:

1084	 <e1>grief</e1> from <e2>infertility</e2> is at times so overwhelming that no one person can provide all the comfort and support that his or her partner needs."
Cause-Effect(e2,e1)
Comment:

1085	 & Castillo (1990) compared the root systems of three species of shrub or treelet with saplings of three tree <e1>species</e1> in the <e2>forest</e2> on Barro Colorado."
Other
Comment: A species is a taxonomic concept, so: a class of trees. A forest is not a collection of abstract classes of trees.

1086	 candida or yeast <e1>infections</e1> are caused by various species of <e2>candida</e2>, especially Candida albicans, and are very common in babies and young children."
Cause-Effect(e2,e1)
Comment:

1087	 elderly found it hard to cope with the high heat-humidity, which often causes nausea and <e1>dizziness</e1> from exhaustion and <e2>dehydration</e2>."
Cause-Effect(e2,e1)
Comment:

1088	 government and some private companies hold stakes in this <e1>export</e1> <e2>company</e2>."
Other
Comment: export is not a product

1089	 <e1>cowboy</e1> swiftly adjusted the halter with a <e2>turn</e2> of chain between the jaws."
Other
Comment:

1090	 they stood, he held out to them an endless scroll, filled with a <e1>maze</e1> of <e2>letters</e2>, words, the very stories they had been listening to."
Other
Comment: Mazes are configurations, not sets.

1091	 <e1>curvature</e1> of the piece was originally from a small <e2>bowl</e2> or cup."
Other
Comment:

1092	 involving <e2>legislation</e2>, technical innovation and international cooperation have been examined."
Other
Comment:

1093	 <e1>earthquake</e1> caused a massive <e2>avalanche</e2> on the northern slope of Mount Huascar."
Cause-Effect(e1,e2)
Comment:

1094	 calculated the exit positions of the backscattered <e1>electrons</e1> from a single-scattering <e2>approach</e2>."
Other
Comment:

1095	 are several scripts to shut down Windows, hibernate or put the <e1>computer</e1> to <e2>sleep</e2>."
Other
Comment: violates b.1 and c.3

1096	 <e1>president</e1> of the <e2>university</e2> of the Philippines is elected for a single six-year term by the University's twelve-member Board of Regents."
Other
Comment:

1097	 JFK baggage system <e1>malfunction</e1> caused <e2>delays</e2> for some flights and caused some passengers to simply travel without their things."
Cause-Effect(e1,e2)
Comment:

1098	 <e1>particles</e1>, grime and dirt cause friction and microscopic <e2>scratches</e2> that over time destroy the performance of equipment."
Cause-Effect(e1,e2)
Comment:

1099	 a <e1>tsunami</e1> is generated by a strong offshore <e2>earthquake</e2>, its first waves would reach the outer coast minutes after the ground stops shaking."
Cause-Effect(e2,e1)
Comment: modality is outsid

1100	 <e1>globules</e1> have moved into <e2>action</e2>."
Other
Comment: violates b.1 and c.3

1101	 deposit ages, soil formation, <e1>weathering</e1>, diagenetic processes, and earthquake shaking lead to consolidation and <e2>cementation</e2> of the sediment."
Cause-Effect(e1,e2)
Comment:

1102	 were two smiling and waving individuals hanging under the <e1>bun</e1> in a wicker <e2>basket</e2> equipped with the big Bunsen burner."
Other
Comment:

1103	 the <e1>hobo</e1> leaves the next <e2>morning</e2>, Dick notices that on the gate is a picture of a knife."
Other
Comment:

1104	 good salad calls for a <e1>cupful</e1> of <e2>shrimps</e2>, cut in small pieces; half a cupful of celery hearts diced small, and seasoning of pepper and salt."
Other
Comment: Cupful is a measurement.

1105	 cheering and <e1>screaming</e1> after the <e2>victory</e2> had hardly died down when Marilyn Kelly proclaimed "Party at my house!"."
Cause-Effect(e2,e1)
Comment:

1106	 counted almost thirty-three honorable punches and kicks thrown in this clip of little kid <e1>screaming</e1> after the terrible <e2>fight</e2>."
Cause-Effect(e2,e1)
Comment:

1107	 blind <e1>woman</e1> took the <e2>taxi</e2> driver to the Equality Tribunal."
Other
Comment:

1108	 umpiring pushed the <e1>test</e1> into <e2>controversy</e2>."
Other
Comment: violates b.1 and c.3

1109	 is several bulk sms software and the popular ones can be purchased online after making the <e1>payment</e1> through secured payment <e2>gateway</e2>."
Other
Comment:

1110	 <e1>countries</e1> are also sinking into <e2>recession</e2>."
Other
Comment: violates b.1 and c.3

1111	 restricted to the rear portion of the medial part of the precentral gyrus caused a contralateral predominantly distal <e2>leg weakness</e2>."
Cause-Effect(e1,e2)
Comment:

1112	 of the largest Internet piracy rings in the world has been shut down in a police <e1>operation</e1> that resulted in the <e2>arrest</e2> of 181 people."
Cause-Effect(e1,e2)
Comment:

1113	 <e1>conditions</e1> have relation to such matters as the <e2>magnitude</e2> and importance of the company."
Other
Comment:

1114	 initiated Federal SAR response activities for <e1>incidents</e1> that result in aeronautical <e2>distress</e2>."
Cause-Effect(e1,e2)
Comment:

1115	 looking at the picture aids "let-down," the <e1>release</e1> of milk normally triggered by the <e2>presence</e2> of the baby, its touch, its cry."
Cause-Effect(e2,e1)
Comment:

1116	 declarative sentence or <e1>declaration</e1>, the most common type, commonly makes a <e2>statement</e2>."
Other
Comment: statement is not a producer

1117	 at a Devon hospital are due to strike on 5 January for two days in a <e1>dispute</e1> over sick <e2>pay</e2>."
Other
Comment: violates (b)

1118	 focus on the <e2>content</e2> rather than struggling to see the words."
Other
Comment: Here we have Interpreter-Content relation.

1119	 <e1>inspiration</e1> for the multi-touch technology came from a decidedly non-digital <e2>event</e2>."
Cause-Effect(e2,e1)
Comment:

1120	 victim slipped off the gangway while attempting to close the <e1>lid</e1> of the <e2>tank</e2> trailer."
Other
Comment: Lid is part of the trailer, not the tank

1121	 that recovery and <e1>reconstruction</e1> after the <e2>tsunami</e2> are getting under way, we want to see people move into their new homes, communities resume their livelihoods and children back into their rebuilt schools."
Other
Comment: modality is outside

1122	 bond-insurance <e1>unit</e1> was placed into <e2>receivership</e2>."
Other
Comment: violates c.3

1123	 European Ombudsman, P. Nikiforos Diamandouros, has asked the European Commission to correct an administrative <e1>error</e1> concerning fishing <e2>quotas</e2> in the West of Scotland."
Other
Comment:

1124	 driven to <e1>rage</e1> after <e2>reading</e2> about yet another weirdly spelled Web 2.0 company is struggling on TechCrunch."
Cause-Effect(e2,e1)
Comment:

1125	 hotly anticipated new <e1>album</e1> has been leaked on to the <e2>public</e2>."
Other
Comment: violates b.

1126	 <e1>minister</e1> participated in a high level UN <e2>conference</e2> on financing for development."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1127	 described in this article investigated two <e2>questions</e2> about forgiveness."
Other
Comment: study here is activity - violation of (d)

1128	 team prepared GIS precipitation and contour maps of the area (approximately 777 square miles) depicting the landforms and identifying the <e1>flooding</e1> and landslides caused by the <e2>rainfall</e2>."
Cause-Effect(e2,e1)
Comment:

1129	 1906 San Francisco <e1>earthquake</e1> was caused by a <e2>rupture</e2> on the San Andreas Fault, a continental transform fault that forms part of the boundary between the Pacific Plate and the North American Plate."
Cause-Effect(e2,e1)
Comment:

1130	 <e1>relationship</e1> between funding source and study outcome was investigated in several other <e2>studies</e2>."
Other
Comment: here study is a process - violation of (d)

1131	 <e1>grief</e1> from sudden <e2>death</e2> is completely different from expected death, when families have time to prepare and say goodbye."
Cause-Effect(e2,e1)
Comment:

1132	 <e1>book</e1>, compiled by the <e2>poet</e2>'s daughter, includes memoirs by writers, poets, translators, critics, actors, and theater directors."
Other
Comment: daughter is not a producer

1133	 technique for <e1>combustion</e1> of organic compounds in a <e2>flask</e2> filled with oxygen is well known."
Other
Comment: does not express content-container relat

1134	 <e1>wounds</e1> caused by the scourging and the <e2>thorns</e2> are almost invisible."
Cause-Effect(e2,e1)
Comment:

1135	 series of steps takes you to the top of the falls where you get a wide and spectacular view of the stone bowl that the <e1>creek</e1> has carved over the <e2>ages</e2>."
Other
Comment: ages is not a producer

1136	 <e1>war</e1> was caused by the expansionist <e2>desires</e2> of Hitler, Mussolini and the Japanese imperialists."
Cause-Effect(e2,e1)
Comment:

1137	 <e1>narcs</e1> planted a <e2>rock</e2> of cocaine on me when they arrested my buddy with his stash."
Other
Comment: the rock is not made by the narcs

1138	 is caused by a sharp <e2>decrease</e2> in estrogen levels that leads to an increased rate of bone remodeling."
Cause-Effect(e2,e1)
Comment:

1139	 beautiful young <e1>girl</e1> is going into blissful <e2>trance</e2>."
Other
Comment: violates b.1 and c.

1140	 the <e1>background</e1> is a depiction of a <e2>city</e2> with angels that along a path that leads towards it."
Other
Comment: Background may be part of a medium, but it's a long shot.

1141	 economic <e1>collapse</e1> was caused by <e2>consumers</e2> buying mortgages they couldn't afford and the housing collapse."
Cause-Effect(e2,e1)
Comment:

1142	 that occur after DTaP are usually not caused directly by the vaccine, but by a <e1>fever</e1>, which in turn was triggered by the <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

1143	 determine, once and for all, how the <e1>manakin</e1> was making its bizarre <e2>sounds</e2>, Bostwick and colleagues decided to take feather samples."
Cause-Effect(e2,e1)
Comment:

1144	 opening <e1>angle</e1> of the Cherenkov cone measures the velocity with a <e2>resolution</e2> of 0.2%."
Other
Comment: manner

1145	 damaged some components of espresso machines and the <e1>plastics</e1> inside the <e2>machine</e2> absorbed it and started to pass on odour and taste to the espresso."
Other
Comment: the plastics are substances

1146	 <e1>implants</e1> were placed into <e2>function</e2>."
Other
Comment: violates b.1 and c.3

1147	 have three of the finest Hanoverian <e1>stallions</e1> in England standing at <e2>stud</e2>."
Other
Comment: Stud is the location of the breeding Location and thus Other

1148	 procedure</e1> refers to the <e2>legal process</e2> for adjudicating claims that someone has violated criminal law."
Other
Comment: procedure is a process here - violation of (d)

1149	 present invention relates to a method for producing battery electrodes, <e1>electrodes</e1> produced by this <e2>method</e2>, and batteries containing such electrodes."
Other
Comment: method is not a producer

1150	 and Permits are <e1>revenues</e1> from the <e2>selling</e2> of vendor and dog licenses and other items."
Cause-Effect(e2,e1)
Comment:

1151	 none of this was really necessary, because you just head for the largest <e1>building</e1> ever created by <e2>man</e2>."
Other
Comment: (a) is satisfied, however 'man' is not a concrete object here.

1152	 following <e1>activity</e1> involves surveying the child health <e2>resources</e2> available in your group's community."
Other
Comment:

1153	 of the work on continuous <e1>culture</e1> of <e2>bacteria</e2> has been carried out with aerobic bacteria, though little has been done with strict anaerobes."
Other
Comment: We interpret culture as 'growing'.

1154	 you age, the bones and <e1>cartilage</e1> that make up your <e2>backbone</e2> and neck gradually deteriorate, sometimes forming irregular bony outgrowths called bone spurs."
Other
Comment: cartilage is a substance

1155	 <e1>choice</e1> takes you forward by a more or less fixed number of pages at any given position in the <e2>book</e2>."
Other
Comment: choice is not a producer

1156	 a few <e1>congressmen</e1> attended that first <e2>party</e2> in 1977."
Other
Comment: In this context party refers to a festivity instead of the political party.

1157	 British prison <e1>escapee</e1> who taunted police over the internet has established a <e2>following</e2> of more than 32000 fans on Facebook."
Other
Comment:

1158	 purpose of the <e1>focus groups</e1> was to determine user <e2>needs</e2>, wants, and concerns early and progressively throughout the development of the prototype."
Other
Comment: People could not be messages.

1159	 port <e1>side</e1> of a vessel is indicated with a red navigation <e2>light</e2> at night."
Other
Comment:

1160	 than 4500 tons of nitrogen oxides annually -- a <e1>pollutant</e1> that causes smog, acid <e2>rain</e2>, and contributes to asthma attacks and other breathing problems."
Cause-Effect(e1,e2)
Comment:

1161	 and poverty lead to <e2>neglect</e2> and abuse."
Cause-Effect(e1,e2)
Comment:

1162	 had three of the eights against a <e1>flush</e1> of <e2>clubs</e2>."
Other
Comment: This is a five-card hand, not a set.

1163	 has inherited <e1>susceptibility</e1> to certain <e2>cancers</e2>."
Other
Comment:

1164	 <e1>swelling</e1> of the vocal fold mucosa is caused by <e2>smoking</e2>."
Cause-Effect(e2,e1)
Comment:

1165	 conclusion, <e1>incubation</e1> of the aorta produces a specific <e2>reduction</e2> in agonist-evoked contraction."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

1166	 <e1>celebrity</e1> arrived to crash the <e2>party</e2>."
Other
Comment: Purpos

1167	 <e1>stories</e1> range from near <e2>future</e2> predictions to far future, far space improvisations."
Other
Comment:

1168	 owe it to ourselves to separate the riffraff from <e1>riffraff</e1> of less unsavory <e2>characteristics</e2>."
Other
Comment: This is the characteristics of riffraf members.

1169	 <e1>tourism sector</e1> is sinking into deeper <e2>poverty</e2>."
Other
Comment: violates b.1 and c.3

1170	 recent years, the <e1>issue</e1> of experimentation upon nonhuman animals has become the subject of media <e2>attention</e2>."
Other
Comment:

1171	 the last day, in a small shop in the Plaka, the oldest quarter in Athens, I bought a <e1>silver</e1> <e2>ring</e2> with Athena's image carved on it."
Other
Comment:

1172	 Revealed (1993) is a <e1>science fiction</e1> <e2>novel</e2> by Arthur C. Clarke and Gentry Lee."
Other
Comment: A type of novel.

1173	 <e1>high humidity</e1> caused by the <e2>rainfall</e2> damaged the seed of PU already mature while the good soil moisture allowed the seed of SO, TO and OO to fill better."
Cause-Effect(e2,e1)
Comment:

1174	 the <e1>president</e1> won the Democratic nomination with the <e2>help</e2> of the super delegates."
Other
Comment:

1175	 superb <e1>location</e1> of this <e2>fortress</e2> allows us a great view over the surrounding mountains."
Other
Comment: changed e1 from "superb" to "location

1176	 <e1>defendant</e1>, in order to prove his plea of justification, produced a <e2>witness</e2> named Mary Dillon."
Other
Comment: the witness is not a product

1177	 the H5N1 <e1>virus</e1> has caused by far the greatest number of human cases of very severe <e2>disease</e2> and the greatest number of deaths."
Cause-Effect(e1,e2)
Comment:

1178	 <e1>symptoms</e1> of fight or flight are caused by <e2>chemical changes</e2> in the body, but these two symptoms of are caused by chronic, rapid, shallow breathing."
Cause-Effect(e2,e1)
Comment:

1179	 took this <e1>photo</e1> out of an airplane <e2>window</e2>."
Other
Comment:

1180	 <e1>teenagers</e1> return home with the help of family <e2>ties</e2>."
Other
Comment:

1181	 <e1>assassination</e1> resulted in extensive <e2>arrests</e2> of governmental, security, and criminal figures."
Cause-Effect(e1,e2)
Comment:

1182	 <e1>storm</e1> resulted in 31 deaths and 2.5 million dollars <e2>damage</e2>."
Cause-Effect(e1,e2)
Comment:

1183	 bought a <e1>silver</e1> <e2>ring</e2> from a Bass Pro Shops, a hunting/fishing chain store, for $53."
Other
Comment:

1184	 economic <e1>policies</e1> are turning into a global <e2>disaster</e2>."
Cause-Effect(e1,e2)
Comment:

1185	 utilities, and green businesses are turning to behavioral <e2>economics</e2>."
Other
Comment:

1186	 original <e1>play</e1> was inspired by a <e2>trip</e2> to Europe made by Murray Burnett in 1938."
Other
Comment: the trip itself is not actively involved in the production of the play

1187	 <e1>supreme court</e1> has applied the protections of this amendment to the <e2>states</e2> through the Due Process Clause of the Fourteenth Amendment."
Other
Comment:

1188	 the end what was left of the city was <e1>miles</e1> from the <e2>sea</e2>, and many of the inhabitants left swampy lowland to live in the surrounding hills."
Other
Comment:

1189	 evaluating capital punishment as a form of retribution is reduced by Sellin to merely estimating the proportion of capital <e1>murders</e1> that result in <e2>execution</e2>."
Cause-Effect(e1,e2)
Comment:

1190	 recent years there have been many advances in the use of <e1>opioids</e1> for cancer <e2>pain</e2>."
Other
Comment: Purpose-Tool

1191	 authors propose galaxy <e1>clusters</e1> as a tool for <e2>cosmology</e2>."
Other
Comment:Purpose-Tool

1192	 was caused by whiplash and head <e2>injury</e2>."
Cause-Effect(e2,e1)
Comment:

1193	 neighbors used snow blowers to clear the road ahead while the other <e1>neighbors</e1> dug out the <e2>snow</e2> around the ambulance with snow shovels."
Other
Comment: snow is not a product

1194	 <e1>hull</e1> caused a <e2>scratch</e2> on the eye and that is why it's not healing all the way."
Cause-Effect(e1,e2)
Comment:

1195	 <e1>massacre</e1> resulted in a local and international <e2>onslaught</e2>."
Cause-Effect(e1,e2)
Comment:

1196	 ancestors have passed on <e1>knowledge</e1> to <e2>descendants</e2>."
Other
Comment: violates b.

1197	 already offers a <e1>cornucopia</e1> of employment <e2>opportunities</e2> for anyone coming from a myriad of backgrounds, but they lack name recognition."
Other
Comment: This is a kind of measure. Not a whole. Not a container either. See "the horn of plenty". Highly metaphorical.

1198	 <e1>church</e1> is sinking into indolent <e2>obscurity</e2>."
Other
Comment: violates b.1 and c.3

1199	 <e1>colds</e1> and flu cause <e2>inflammation</e2> of the mucous membranes (found in the nose, throat and mouth)."
Cause-Effect(e1,e2)
Comment:

1200	 prepares for <e1>crush</e1> of <e2>executions</e2>."
Other
Comment: Executions are events. Events have a specific time point, seems odd to use them in the member-collection relation.

1201	 is the most common cause of <e2>abdominal pain</e2> in the pediatric population."
Cause-Effect(e1,e2)
Comment:

1202	 country is resolving the war and <e1>poverty</e1> caused by the previous <e2>administration</e2>."
Cause-Effect(e2,e1)
Comment:

1203	 traditional dancing <e1>ensembles</e1> participated in the <e2>festival</e2> of Razlog."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1204	 registration purposes, the <e1>property</e1> in a <e2>vessel</e2> is divided into 64 indivisible shares."
Other
Comment: (d) is violated as vehicles cannot be containers

1205	 Buffs once again lacked playmakers, the wide receivers couldn't get open, the <e1>offense</e1> went away from the running <e2>game</e2> early."
Other
Comment:

1206	 <e1>pain</e1> was radiating from the <e2>contraction</e2> out to my hips and back and then down both my legs all the way to my toes."
Cause-Effect(e2,e1)
Comment:

1207	 citizens remained in their houses, and only vagabonds, the <e1>scum</e1> of various <e2>nationalities</e2>, and spies were about; women were not to be seen, or only such as belonged to the dregs of society."
Other
Comment:'various nationalities' is a property of the scum

1208	 country cats are happy to live in the shed or the chicken house, or a nest deep inside a <e1>straw</e1> <e2>stack</e2>."
Other
Comment: Material.

1209	 fresh Muslim <e1>anger</e1> has been caused by the opening <e2>speech</e2> delivered by Pope Benedict XVI on September 12, 2006."
Cause-Effect(e2,e1)
Comment:

1210	 milked their <e1>evening</e1> <e2>drink</e2> for them and then found them asleep."
Other
Comment:

1211	 sores</e1> or fever blisters are caused by the herpes simplex <e2>virus</e2> and are usually relatively easy to identify."
Cause-Effect(e2,e1)
Comment:

1212	 <e1>parents</e1> have been dragged into his alleged life insurance <e2>fraud</e2>."
Other
Comment: violates b.

1213	 is the <e1>natural science</e1> concerned with the <e2>study</e2> of life and living organisms."
Other
Comment: study is an activity - violates (d)

1214	 of them breed in the rice-field, while other <e1>fish</e1> enter the field through <e2>tidal action</e2>."
Other
Comment:

1215	 <e1>gunman</e1> pumped a bullet into his right <e2>leg</e2> and fled his Northwest Side convenience store with several hundred dollars."
Other
Comment: the leg is not a product

1216	 <e1>quarrel</e1> during the night of the crime was caused by <e2>money</e2>."
Cause-Effect(e2,e1)
Comment:

1217	 <e1>manuscript</e1> has been the object of intense <e2>study</e2> by many professional and amateur cryptographers."
Other
Comment: here study is an activity - violates (d)

1218	 is the inflammation of the sinuses caused by a bacterial <e2>infection</e2>."
Cause-Effect(e2,e1)
Comment:

1219	 discoveries of dark matter a few decades ago and of dark energy a few years ago have thrown <e1>physics</e1> into <e2>turmoil</e2>."
Other
Comment: violates c.3

1220	 current study demonstrates that angiogenesis occurs early following transplantation, resulting in a <e1>hookup</e1> of donor and recipient <e2>vessels</e2>."
Other
Comment:

1221	 the face of each card is displayed, the <e1>subject</e1> identifies the name associated with the <e2>card</e2>."
Other
Comment:

1222	 the great <e1>fire</e1> of the <e2>aftershock</e2> in Tokyo in 1923 many Ginkgo trees survived while other trees died."
Cause-Effect(e2,e1)
Comment:

1223	 major <e1>product</e1> arose from an <e2>attack</e2> of aromatic compound."
Cause-Effect(e2,e1)
Comment:

1224	 of the missing samples repairs the waveform with a minimum of <e2>distortion</e2>."
Cause-Effect(e1,e2)
Comment:

1225	 DC-DC <e1>converter</e1> was manufactured in a 130nm bulk CMOS <e2>process</e2>."
Other
Comment:

1226	 <e1>house</e1> is going into <e2>foreclosure</e2>."
Other
Comment: violates b.1 and c.3

1227	 <e1>editor cum scientist</e1> approached the pod with <e2>reverence</e2>, and a remote control device."
Other
Comment: manner

1228	 worst <e1>devastation</e1> around us has been caused by the abject failure of religious <e2>education</e2>."
Cause-Effect(e2,e1)
Comment:

1229	 judge has ordered a woman to hand over her daughter's pet sheep to a rescue centre after a legal <e1>wrangle</e1> over <e2>ownership</e2> of the animal."
Other
Comment:

1230	 rasher of bacon was found in a returned <e1>book</e1> by a Worthing <e2>librarian</e2>."
Other
Comment: the librarian is not the producer

1231	 order to gather experimental data, researchers explicitly defined a <e1>model</e1> describing the <e2>process</e2>."
Other
Comment: The process is a subject, but the model is not a message.

1232	 dotted <e1>line</e1> refers to experimental and simulated <e2>data</e2>."
Other
Comment:

1233	 gets life sentence in kidnap, ransom case of <e1>woman</e1> he kept in makeshift <e2>casket</e2>."
Other
Comment:

1234	 among the heroin addicts especially, there is frequently a very severe depression, and <e1>depression</e1> is one of the main causes of <e2>suicide</e2>."
Cause-Effect(e1,e2)
Comment:

1235	 deeds have thrown thousands of <e1>people</e1> into eternal financial <e2>damnation</e2>."
Other
Comment: violates c.

1236	 and Ginger Marmalade was made from a <e1>glut</e1> of corella <e2>pears</e2>."
Other
Comment: I interpret glut as amount.

1237	 loan <e1>program</e1> is running into insurmountable <e2>difficulties</e2>."
Other
Comment: violates b.

1238	 we saw was a promising <e1>idea</e1> sabotaged by a muddled and undernourished <e2>script</e2>."
Other
Comment: script is not a producer

1239	 minimized excessive <e1>flows</e1> that cause flooding, bank <e2>erosion</e2>, and habitat loss."
Cause-Effect(e1,e2)
Comment:

1240	 final character was the brilliant <e1>scientist</e1> <e2>inventor</e2> and technology geek."
Other
Comment: scientist is not a product or producer

1241	 example, <e1>measles</e1> and chickenpox cause <e2>rashes</e2> along with other symptoms."
Cause-Effect(e1,e2)
Comment:

1242	 the planning <e1>proposal</e1> has generated <e2>opposition</e2> from locals who have voiced fears over health issues."
Cause-Effect(e1,e2)
Comment: (a) is satisfied

1243	 decreed joy and sadness, because <e1>joy</e1> results in <e2>laughter</e2> and sadness leads to crying."
Cause-Effect(e1,e2)
Comment:

1244	 <e1>arbiter</e1> of the <e2>game</e2> begins the game and requests a move from the first player."
Other
Comment:

1245	 the beginning, a <e1>fire</e1> started from the ring <e2>area</e2> of a crude oil storage tank(33000kl)."
Other
Comment:

1246	 is caused by infection with a <e2>parasite</e2> called Plasmodium that is transmitted by mosquitos."
Cause-Effect(e2,e1)
Comment:

1247	 <e1>arrows</e1> act as avatars of the <e2>students</e2>."
Other
Comment: This cannot be Message-Topic since it violates (h)

1248	 banded <e1>racer</e1> needs <e2>advice</e2> on accommodation."
Other
Comment: violates c.

1249	 catch <e1>happiness</e1> from friends and family <e2>members</e2> like an emotional virus."
Other
Comment:

1250	 years passed before I saw the ibex again, despite regular field trips to the area and the services of an NCWCD ranger who knew every bend in the <e1>maze</e1> of <e2>canyons</e2>."
Other
Comment: It's an arrangement, not a set. Elements are not interchangeable.

1251	 <e1>warmth</e1> was radiating from the <e2>fireplace</e2> to all corners of the room."
Cause-Effect(e2,e1)
Comment:

1252	 <e1>bakeries</e1> in the supermarket <e2>area</e2> also reduce the prices on their goods as closing time approaches."
Other
Comment:

1253	 reports regarding the casualties has been announced and the <e1>loss</e1> that has been caused by the <e2>quake</e2> is being estimated."
Cause-Effect(e2,e1)
Comment:

1254	 bought a whole <e1>cartload</e1> of <e2>groceries</e2>, and spent a fraction of what I would at any regular grocery store."
Other
Comment: A measure of quantity: as much as a cart will hold. Modality is outside

1255	 <e1>pollution</e1> from coal-fired power <e2>plants</e2> is large and varied and contributes to a significant number of negative environmental and health problems."
Cause-Effect(e2,e1)
Comment:

1256	 Safety-Service Director Rex Katterheinrich estimated the city collecting $2.16 million in 2009, who took into account for the economic <e1>slowdown</e1> caused by the national <e2>recession</e2>."
Cause-Effect(e2,e1)
Comment:

1257	 Marshall is the discoverer of Helicobacter (H. pylori), the <e1>germ</e1> that causes peptic <e2>ulcer</e2>."
Cause-Effect(e1,e2)
Comment:

1258	 recipes are culled from various restaurant chefs, magazines and Brother Victor-Antoine d'Avila-Latourrette, a <e1>monk</e1> and cookbook <e2>author</e2>."
Other
Comment: monk is not a producer.

1259	 dates for when the coral reefs had been living(125,000, 105,000, and 82,000 years ago) closely matched <e1>dates</e1> from Milankovitch <e2>cycles</e2> for times when the ice sheets should have been melted and the seas at their highest(127,000, 106,000, and 82,000 years ago)."
Other
Comment:

1260	 were brought into <e2>custody</e2> for questions."
Other
Comment: violates b.

1261	 <e1>sadness</e1> from <e2>divorce</e2> meant more if you were aware she was married very briefly to choreographer/director Michael Bennett, who shaped her career, then created the "Chorus Line" character around her in 1975."
Cause-Effect(e2,e1)
Comment:

1262	 (NonGonococcal Urethritis) is an <e1>infection</e1> of the urethra caused by <e2>pathogens</e2> ( germs ) other than gonorrhea."
Cause-Effect(e2,e1)
Comment:

1263	 of 5 succeeded with can-do <e2>attitude</e2>."
Other
Comment: attitudes, properties etc cannot be considered Instruments.

1264	 <e1>crash</e1> caused a <e2>gash</e2> on the west side of the Pentagon measuring 30 yards wide and 10 yards deep."
Cause-Effect(e1,e2)
Comment:

1265	 scientists injected <e1>fluids</e1> into the <e2>animals</e2>."
Other
Comment:

1266	 stimulant, <e1>nicotine</e1> causes a temporary <e2>increase</e2> in alertness and a calm feeling."
Cause-Effect(e1,e2)
Comment:

1267	 treated the <e1>pain</e1> from <e2>shingles</e2> as it persisted for long periods of time."
Cause-Effect(e2,e1)
Comment:

1268	 addition of a <e1>velocity</e1> <e2>stack</e2> on the carb inlet helps stop some fuel spray coming out the carb when the engine is running."
Other
Comment:

1269	 new research shows that the tree <e1>trunks</e1> in the <e2>forest</e2> act like hot water bottles."
Other
Comment: A forest is a collection of trees, not a collection of tree trunks.

1270	 <e1>matter</e1> became the subject of protracted <e2>legal action</e2>, from which the employer emerged victorious."
Other
Comment:

1271	 <e1>researches</e1> are making a valuable contribution to the <e2>history</e2> of logic in a period little known in the West."
Other
Comment:

1272	 are many types and causes of headaches, from <e1>tension</e1> <e2>headaches</e2> due to stress to migraines triggered by certain foods."
Cause-Effect(e1,e2)
Comment:

1273	 had their urethra and urachus ligated with a fine silastic <e2>tubing</e2>."
Other
Comment: e1 is not the Agent

1274	 with adenomyosis experience <e1>pain</e1> from this <e2>disease</e2> in the early 30's."
Cause-Effect(e2,e1)
Comment:

1275	 <e1>amenities</e1> such as <e2>kiosks</e2> create pedestrian-friendly spaces."
Other
Comment: A kiosk is a type of amenity.

1276	 <e1>splints</e1> are caused by the <e2>muscles</e2> on the front and sides of the leg."
Other
Comment:

1277	 chief safety <e1>officer</e1> announced the Gwinnett-Barrow-Jackson enforcement wave with the <e2>unveiling</e2> of a replica of new traffic warning signs that have been posted along I-85."
Other
Comment:

1278	 diagnosis has replaced <e1>simulation</e1> for the <e2>correction</e2> of simple design errors."
Other
Comment: Purpose-Tool

1279	 moves <e1>people</e1> into <e2>climate action</e2>."
Other
Comment: violates c.3

1280	 mobile <e1>meth</e1> was inside a <e2>van</e2> parked inside a storage unit at 4095 West Kearns."
Other
Comment:

1281	 <e1>tests</e1> establish baseline <e2>information</e2> on employees and help insure that they are appropriately matched to the physical demands of their jobs."
Cause-Effect(e1,e2)
Comment: information is an occurrenc

1282	 the <e1>disorders</e1> are caused by defective lysosomal <e2>enzymes</e2>, with the result being lysosomal accumulation of pathway intermediates, these are often referred to as lysosomal storage diseases."
Cause-Effect(e2,e1)
Comment:

1283	 UK <e1>economy</e1> has come out of <e2>recession</e2>, after figures showed it had grown by a weaker-than-expected 0.1% in the last three months of 2009."
Other
Comment:

1284	 current <e1>crisis</e1> was caused by the <e2>housing bubble</e2>, and the primary cause of the housing bubble was the Federal Reserve keeping interest rates at 1 percent."
Cause-Effect(e2,e1)
Comment:

1285	 read that interview you did with the <e1>guy</e1> who came up with flash <e2>mobs</e2>."
Other
Comment: no evidence for product-producer

1286	 of four straight games, the <e1>side</e1> has constructed the program's best <e2>start</e2> since 1979-80 and the third-best opening in school history."
Other
Comment: no evidence for Product-Produc

1287	 Tour of California raced through West Marin on Monday in a <e1>blur</e1> of speeding <e2>bicyclists</e2> and their caravan of support vehicles, once again sparking charges that it puts spectators in harm's way."
Other
Comment: A blur is an event.

1288	 song immediately segues into the maniacal "Red & Purple", a bewilderingly worded love <e1>song</e1> accompanied by a toy <e2>piano</e2> and fuzzy bass."
Other
Comment: the piano is not responsible for the production of the song

1289	 over-the-counter pain <e1>pills</e1> and prescription drugs cause medication-overuse <e2>headaches</e2>."
Cause-Effect(e1,e2)
Comment:

1290	 protein <e1>products</e1> encoded by this <e2>class</e2> of resistance gene are located within the plant cell cytoplasm."
Other
Comment: class is not a producer

1291	 <e1>deaths</e1> from the accident were caused by radiation <e2>poisoning</e2>."
Cause-Effect(e2,e1)
Comment:

1292	 <e1>prisoner</e1> was taken into preventive <e2>custody</e2> this morning."
Other
Comment: violates b.

1293	 were assessing the <e1>loss</e1> caused by the poor <e2>performance</e2> of Gartmore's 340m pounds IPO this week after it needed to be scaled down and its price slashed."
Cause-Effect(e2,e1)
Comment:

1294	 <e1>phrase</e1> was related in a <e2>preface</e2> of a 1904 collection of Drury's stories."
Other
Comment: The relation is unclear.

1295	 <e1>company</e1> has been dragged into a <e2>lawsuit</e2>."
Other
Comment: violates b.

1296	 abandoned national socio-cultural imperatives and rushed in to join the scandalous community and the <e1>camaraderie</e1> of the <e2>tyrants</e2>."
Other
Comment: That's how they feel -- as fellow tyrants.

1297	 <e1>pronouns</e1> are indicated with <e2>parentheses</e2> and are given for example purposes."
Other
Comment:

1298	 aim of <e1>ecophilosophy</e1> is a total or comprehensive <e2>view</e2> of our human and individual situation."
Other
Comment: Scientific disciplines are not messages.

1299	 <e1>embassy</e1> participated in <e2>opening</e2> of the unique exhibition about general Pika."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency

1300	 origin of the superficial <e1>extensors</e1> is from a flattened common extensor <e2>tendon</e2>."
Other
Comment:

1301	 first prototype of the new <e1>system</e1> is constructed from the preliminary <e2>design</e2>."
Other
Comment:

1302	 revealed a relationship between <e1>cracks</e1> caused by <e2>earthquakes</e2> and paddy fields."
Cause-Effect(e2,e1)
Comment:

1303	 reasonable <e1>approach</e1> was distilled from the initial <e2>shock</e2> at the conflicting data."
Other
Comment:

1304	 <e1>researcher</e1> approached the subjects and their experiences with an open <e2>mind</e2>."
Other
Comment:

1305	 presented very extensive and detailed report on greenhouse <e1>heating</e1> with <e2>compost</e2>."
Other
Comment: Purpose-Tool

1306	 <e1>bacteria</e1> cause <e2>mortality</e2> in target species via a lethal septicaemia as a result of spore germination."
Cause-Effect(e1,e2)
Comment:

1307	 is an <e1>inflammation</e1> of the pancreas caused by a <e2>malfunction</e2> involving the digestive enzymes that the pancreas makes."
Cause-Effect(e2,e1)
Comment:

1308	 direct <e1>catastrophe</e1> caused by the <e2>earthquake</e2> was estimated at 10.2 billion euro, clearly justifying European intervention."
Cause-Effect(e2,e1)
Comment:

1309	 <e1>damages</e1> caused by the <e2>fires</e2> that immediately broke out and raged for three days, were by far worse than those caused by the earthquake itself."
Cause-Effect(e2,e1)
Comment:

1310	 wears a <e1>kilt</e1> for the <e2>outing</e2>."
Other
Comment: Purpose-Tool

1311	 longtime publishers in the healthcare industry, we, too, are skeptical about the <e1>glut</e1> of <e2>startups</e2> in this area."
Other
Comment: Glut means many, a lot --- not a set.

1312	 <e1>citizenship</e1> and connection to Britain and Italy is shown in <e2>parentheses</e2>."
Other
Comment:

1313	 testified that cause of <e1>death</e1> was massive bleeding into the blood sac of the heart caused by a stab <e2>wound</e2> on the left chest."
Cause-Effect(e2,e1)
Comment:

1314	 scale of such landslides on natural slopes can be large enough to devastate entire villages or towns, such as the Huascaran Avalanche triggered by the Peru earthquake (1970, Mw = 7.8), or the complex <e1>slides</e1> caused by the Alaska <e2>earthquake</e2> in 1964 (Ms = 8.4)."
Cause-Effect(e2,e1)
Comment:

1315	 remote <e1>slope</e1> of Nevado Mismi, a 5316 m peak, is the ultimate source of the <e2>river</e2>."
Other
Comment:

1316	 <e1>composition</e1> forming the subject of the present <e2>invention</e2> included one or more fillers as defined above."
Other
Comment: Invention is much too little like a message.

1317	 daily headaches are <e1>tension</e1> <e2>headaches</e2> or headaches which are caused by taking too many pain killers."
Cause-Effect(e1,e2)
Comment:

1318	 immediate, down-to-earth <e1>impact</e1> of the poem is established in the first two <e2>lines</e2>."
Other
Comment: This is a form of effect, though maybe not exactly Cause-Effect.

1319	 soon as the <e1>lumberjack</e1> saw the <e2>thief</e2>, the lumberjack thought that "If I kill him and bring his head to the authorities, I will get a reward.""
Other
Comment:

1320	 <e1>trend</e1> has been caused by the growing absolute numbers of young people on the planet, and by the <e2>rising unemployment rate</e2>."
Cause-Effect(e2,e1)
Comment:

1321	 some reason, the <e1>star</e1> was blinded from his own <e2>insight</e2> about the incommensurability of time."
Other
Comment:

1322	 defects</e1> are caused by <e2>drugs</e2> that the persons have been exposed to before birth."
Cause-Effect(e2,e1)
Comment:

1323	 precautionary <e1>principle</e1> insists on <e2>certainty</e2> that a technology is not harmful before it can be used."
Other
Comment: The modality is outside e1-e2.

1324	 <e1>soils</e1> used for the <e2>growing</e2> of irrigated cotton in the Macquarie Valley of N.S.W. are variable and each soil type has its own characteristics and problems."
Other
Comment: Purpose-Tool

1325	 falls into special <e2>use</e2>."
Other
Comment: violates b.1 and c.

1326	 these cases of <e1>fever</e1> from <e2>constipation</e2> there are no local signs except, perhaps, a varying amount of tenderness over the sigmoid flexure of the colon, but only appreciable where the distension of gut is extreme."
Cause-Effect(e2,e1)
Comment:

1327	 the <e1>cleaner</e1> was down in a <e2>cistern</e2>, the children enjoyed looking down into the cistern to see him work."
Other
Comment:

1328	 <e1>cell line</e1> was derived from a macrophage-enriched <e2>cell culture</e2>."
Other
Comment:

1329	 is caused by infection with Toxoplasma gondii, an obligate intracellular <e2>parasite</e2>."
Cause-Effect(e2,e1)
Comment:

1330	 importantly, the <e1>shock</e1> and anger caused by the surprise <e2>attack</e2> on Pearl Harbor united a divided nation and was translated into a wholehearted commitment to victory in World War II."
Cause-Effect(e2,e1)
Comment:

1331	 <e1>neuroma</e1> is the most common cause of localized <e2>pain</e2> in the third interspace and these diagnostic tests produce good indications of the condition."
Cause-Effect(e1,e2)
Comment:

1332	 government of Iraq has established a <e1>committee</e1> to consider a proposed <e2>amendment</e2> to the Constitution of Iraq."
Other
Comment: Here we have Purpose-Tool relation - committee for amendment.

1333	 experiences throw <e1>neurons</e1> into <e2>reverse</e2>."
Other
Comment: violates c.

1334	 never seen anything like it in my life: they have a whole <e1>town</e1> of prarie <e2>dogs</e2>."
Other
Comment: A place, not a set; modality and negation are outsid

1335	 the substrate doping density at which impact <e1>ionization</e1> causes <e2>avalanche</e2> breakdown at the trench capacitor junction has been estimated."
Cause-Effect(e1,e2)
Comment:

1336	 <e1>man</e1> is falling into a drug <e2>addiction</e2> and needs help."
Other
Comment: violates b.1 and c.

1337	 disasters like <e1>cyclone</e1>, floods and the storm surges, drought are caused by <e2>climate change</e2>."
Cause-Effect(e2,e1)
Comment:

1338	 really got into using baking <e1>soda</e1> for <e2>cleaning</e2>, so I buy it in bulk."
Other
Comment: Purpose-Tool

1339	 <e1>injuries</e1> from <e2>running</e2> are treated and prevented by following tips and performing stretches from Runner's World.com."
Cause-Effect(e2,e1)
Comment:

1340	 <e1>zone</e1> is denoted with an <e2>icon</e2> indicating how difficult the zone is expected to be to conquer."
Other
Comment: violates (h)

1341	 s hard for me to fathom the <e1>craziness</e1> that has been caused by the H1N1 <e2>virus</e2>."
Cause-Effect(e2,e1)
Comment:

1342	 <e1>fit</e1> of this <e2>jacket</e2> is perfect, it is not bulky."
Other
Comment: fit is a property.

1343	 <e1>displacement</e1> comes from low <e2>atmospheric pressure</e2> within the centre of the depression."
Cause-Effect(e2,e1)
Comment:

1344	 fishing or <e1>dynamite</e1> <e2>fishing</e2> is the practice of using explosives to stun or kill fish."
Other
Comment: Purpose-Too

1345	 1993, international <e1>news agencies</e1> reported the <e2>murder</e2> of a four-year- old English boy, James Bulger."
Other
Comment: The agencies are the communicators not the message.

1346	 is caused by local <e2>infection</e2> of the lacrimal gland by bacteria or viruses."
Cause-Effect(e2,e1)
Comment:

1347	 of all, it is a source of specialist <e1>cadre</e1> of various <e2>specialties</e2>, such as monument and art renovation, foreign language teachers, economists, chemists, lawyers and IT specialists, just to name a few, who often stay in the city after graduating."
Other
Comment: Kinds of cadre.

1348	 after takeoff, an apparent systems <e1>malfunction</e1> has caused the inadvertent <e2>launch</e2> of an AIM-9 Sidewinder missile."
Cause-Effect(e1,e2)
Comment:

1349	 the war, as the Midway was preparing for retirement, she was called upon one last time to the Philippines to help with an <e1>evacuation</e1> after the <e2>eruption</e2> of Mt. Pinatubo."
Cause-Effect(e2,e1)
Comment:

1350	 <e1>palace</e1> was built by the <e2>lake</e2> during the reign of the Umayyad caliph al-Walid I (705-715 CE)."
Other
Comment: the lake is not a producer

1351	 <e1>vibrations</e1> caused a violent twisting <e2>motion</e2> on the bridge."
Cause-Effect(e1,e2)
Comment:

1352	 final <e1>round</e1> lets the last 2 <e2>contestants</e2> answer the question from a hint of a given qualification to find the last man standing."
Other
Comment:

1353	 help doctors to know and cure <e1>headaches</e1> from <e2>medication overuse</e2> a revised criteria was published by the International Headache Society."
Cause-Effect(e2,e1)
Comment:

1354	 debates <e1>proposal</e1> is still under <e2>consideration</e2>, although there are potential problems."
Other
Comment:

1355	 <e1>obedience</e1> was extracted from <e2>subjects</e2> in this case."
Other
Comment:

1356	 <e1>injuries</e1> are a common cause of <e2>unconsciousness</e2> and they occur in many sports like rugby and boxing."
Cause-Effect(e1,e2)
Comment:

1357	 <e1>pioneer</e1> builds home from <e2>scratch</e2>."
Other
Comment:

1358	 <e1>girlfriend</e1> was in a <e2>trunk</e2> and they drove over a bridge."
Other
Comment: restriction (d) is violated

1359	 <e1>tabernacle</e1> was inside a rectangular <e2>court</e2> whose entrance faced the East."
Other
Comment:

1360	 <e1>colouration</e1> has been caused by a blue <e2>dye</e2>."
Cause-Effect(e2,e1)
Comment:

1361	 the <e1>anger</e1>, <e2>sky</e2> was evolved, from the sky air was evolved, from the air fire was evolved and from the fire water was evolved."
Other
Comment:

1362	 a dream proffers no solution but portrays only the <e1>anxiety</e1> which is generated by the <e2>conflict</e2>."
Cause-Effect(e2,e1)
Comment:

1363	 the merchant was ready to come home, he had bought a <e1>diamond</e1> <e2>necklace</e2> for his first daughter."
Other
Comment:

1364	 Republican tax cut fetish has drained government <e1>surpluses</e1> into unprecedented <e2>deficits</e2>."
Other
Comment: violates c.

1365	 ordered <e1>vaccine</e1> made with a 50-year-old egg <e2>technology</e2> rather than experimental methods."
Other
Comment: the technology is not actively involved in the making of the vaccion

1366	 was meant to represent the resting of the <e1>maize</e1> <e2>spirits</e2> until the next harvesting period came around."
Other
Comment:

1367	 Pattinson wears a <e1>suit</e1> for a cemetery <e2>scene</e2> on location."
Other
Comment: Purpose-Tool

1368	 the product around the house killed <e1>germs</e1> that were causing flu, colds or <e2>sore throat</e2>."
Cause-Effect(e1,e2)
Comment:

1369	 charge a Carlisle man with eight <e1>offences</e1> in relation to the illegal <e2>trade</e2> of endangered tortoises."
Other
Comment:

1370	 Iraqi <e1>unit</e1> is sent to battle the <e2>cult</e2>."
Other
Comment:

1371	 Australia, fifty cent <e1>coins</e1> have been put into <e2>circulation</e2>."
Other
Comment: violates b.1 and c.

1372	 consensus paper describes the essential skills that clinicians need to help persons who are experiencing <e1>grief</e1> after the <e2>death</e2> of a loved one."
Cause-Effect(e2,e1)
Comment:

1373	 even more compelling, the <e1>design</e1> is rooted in an optimistic <e2>worldview</e2>."
Other
Comment:

1374	 making an <e1>impression</e1> the crowd with an a capella <e2>rendition</e2> of their national anthem, the South African were immediately under pressure."
Cause-Effect(e2,e1)
Comment:

1375	 delegates gather in Copenhagen for the UN climate summit, a new poll shows growing <e1>concern</e1> for <e2>climate change</e2>."
Other
Comment: It's a mental state, and nothing suggests its verbalisation. Restriction (b).

1376	 Washington <e1>sniper</e1> is put to <e2>death</e2>."
Other
Comment: violates b.1 and c.

1377	 16th Avenue, throngs of cars crowded the street forming a huge traffic <e1>jam</e1> of honking <e2>horns</e2> with people hanging out of windows and sunroofs, slapping high-fives to all who passed."
Other
Comment: Sounds are not suited as elements of a collection.

1378	 massive <e1>companies</e1> were bailed out of the <e2>recession</e2> earlier this year, an advantage to cardholders started to be there."
Other
Comment:

1379	 <e1>orchestra</e1> was in a <e2>box</e2> above the stage."
Other
Comment:

1380	 put the <e1>posts</e1> in <e2>chronological order</e2>."
Other
Comment: violates b.

1381	 <e1>marketing spending</e1> translated into <e2>revenue</e2>."
Cause-Effect(e1,e2)
Comment:

1382	 simple <e1>intervention</e1> in relation to local small-scale gold <e2>production</e2> was undertaken in the late 1980s."
Other
Comment:

1383	 reality, however, the <e1>drama</e1> has been caused by the erupting <e2>ash</e2> and smoke colliding with a lightning storm."
Cause-Effect(e2,e1)
Comment:

1384	 on the whole, given the constraints of sticking so closely to the original book, the <e1>developer</e1> has crafted a thoroughly pleasing puzzle <e2>adventure</e2>."
Cause-Effect(e1,e2)
Comment:

1385	 <e1>story</e1> is narrated in <e2>flashback</e2>."
Other
Comment: Manner.

1386	 <e1>subject</e1> was taken into <e2>custody</e2> for trespassing."
Other
Comment: violates b.

1387	 <e1>receipt</e1> of the invoice through the <e2>air-mail</e2> or the email, we send it the accounting department for payment procedures."
Other
Comment:

1388	 a decade, <e1>neighborhoods</e1> are sinking into <e2>disrepair</e2>."
Other
Comment: violates c.

1389	 plasma <e1>membrane</e1> is composed of a double layer (bilayer) of <e2>lipids</e2>, oily substances found in all cells (see Figure 1)."
Other
Comment: Material

1390	 is one of the main causes of a global <e2>crisis</e2> that deprives more than a billion people of access to safe drinking water and more than 2.6 billion of access to sanitation systems."
Cause-Effect(e1,e2)
Comment:

1391	 Frances was 13, she read an article about a <e1>woman</e1> who escaped an unhappy <e2>marriage</e2> and went to Kenya."
Other
Comment:

1392	 commercial soap, shower gel or cleanser products contain preservatives, <e1>colorants</e1> and chemicals that cause dryness, <e2>rashes</e2>, itchiness and roughness on the skin."
Cause-Effect(e1,e2)
Comment:

1393	 <e1>presentation</e1> of the data is rooted in an <e2>identity</e2> in which a nation's saving is equal to domestic investment plus net foreign investment."
Other
Comment:

1394	 her <e1>parents</e1> wind up accompanying her to the <e2>factory</e2>, though her mother disapproves of Violet's gum-chewing habit."
Other
Comment: factory and parents are not product-producer

1395	 all the <e1>pain</e1> caused by the great <e2>recession</e2>, the job market still was not in as bad shape as it had been during the depths of the early 1980s recession, until now."
Cause-Effect(e2,e1)
Comment:

1396	 where he saw firsthand the <e1>destruction</e1> caused by the <e2>hurricanes</e2> and the failure of the storm protection system."
Cause-Effect(e2,e1)
Comment:

1397	 <e1>breezes</e1> are caused by cool and more dense <e2>air</e2> moving inland off the water."
Cause-Effect(e2,e1)
Comment:

1398	 <e1>germs</e1> cause several kinds of illnesses, such as <e2>diarrhea</e2>, meningitis or a cold."
Cause-Effect(e1,e2)
Comment:

1399	 and <e1>coastal</e1> <e2>erosion</e2> is a good general discussion of these subjects."
Other
Comment:

1400	 <e1>soda</e1> safely tackles kitchen <e2>jobs</e2> above and beyond the legendary box at the back of the refrigerator."
Other
Comment: Purpose-Tool

1401	 the <e1>role</e1> is also under <e2>scrutiny</e2> in this affair."
Other
Comment:

1402	 the end of a long day, the <e1>teacher</e1> relaxed with a short <e2>nap</e2> on her sofa."
Other
Comment: e2 is a simple event and can't be an instrument.

1403	 <e1>road</e1> starts at an <e2>intersection</e2> with Melrose Avenue, East 165th Street, Brook Avenue and Park Avenue in Melrose."
Other
Comment:

1404	 <e1>artist</e1> hid the convulsion with a forced <e2>laugh</e2> and finished the performance, but went immediately to bed."
Other
Comment: simple event.

1405	 <e1>organisation</e1> campaigns against such things as <e2>child labour</e2>."
Other
Comment: this is against child labour

1406	 <e1>brown areas</e1> are caused by <e2>drought</e2>, brown patch, take-all-patch, chinch bugs or grubs."
Cause-Effect(e2,e1)
Comment:

1407	 in 2004 the <e1>rupture</e1> started at the <e2>southeast end</e2> of the segment and ran northwestward, the opposite direction from those that struck in '34 and '66."
Other
Comment:

1408	 other countries passed their own <e1>laws</e1> to establish local slave <e2>registries</e2>."
Other
Comment:

1409	 adults retain <e1>scars</e1> from <e2>acne breakouts</e2> during their teen years and feel marked for life."
Cause-Effect(e2,e1)
Comment:

1410	 Michigan towns hosts an <e1>array</e1> of Yuletide <e2>events</e2>."
Other
Comment: Events cannot be elements of a collection.

1411	 slow <e1>suffocation</e1> of the cells swiftly cause unconsciousness and <e2>shock</e2>, soon followed by death."
Cause-Effect(e1,e2)
Comment:

1412	 <e1>granules</e1> and the pebbles are caused by a <e2>magnetic force</e2> to collide with one another, thereby resulting in liberation of the oxygen molecules contained in the granules and the pebbles."
Other
Comment:

1413	 StyleSearch is a <e1>competition</e1> to establish the UK's most ethical <e2>dressers</e2>."
Other
Comment: To establish is a form of purposeful activity. No message here.

1414	 these cases, the <e1>disappointment</e1> from the <e2>purchase</e2> is not forgotten over time, but rather accumulates."
Cause-Effect(e2,e1)
Comment:

1415	 1805 merchants of the city formed a <e1>troop</e1> of <e2>cavalry</e2> in Montreal."
Other
Comment: It would be too big a stretch to assume that cavalry means individual riders. This describes really a kind of troop.

1416	 <e1>streaking</e1> was from the <e2>penguins</e2> doing what all animals do in the forests and woods, etc."
Other
Comment:

1417	 term "dung beetle" or Mistkaefer is in fact used in the <e1>novella</e1> by the cleaning <e2>lady</e2> near the end of the story, but it is not used in the narration."
Other
Comment: lady is not a producer

1418	 standards can apply to <e1>products</e1> covered by this <e2>document</e2>."
Other
Comment: the document is not a produc

1419	 <e1>debt</e1> and poverty cause enormous <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

1420	 <e1>earthquake</e1> was caused by the Anatolian plate and the Eurasian <e2>plate</e2> moving past each other."
Cause-Effect(e2,e1)
Comment:

1421	 it took only minutes for the Pacific <e1>tsunami</e1> and earthquake to cause <e2>havoc</e2> to the south coast of Samoa, the rebuilding and reconstruction efforts will take years."
Cause-Effect(e1,e2)
Comment: modality is outsid

1422	 more resources are required in order to stem the <e1>devastation</e1> that has been caused by the <e2>epidemic</e2> throughout sub-Saharan Africa."
Cause-Effect(e2,e1)
Comment:

1423	 responsibility of the <e1>carrier</e1> commences from the moment he receives the merchandise, personally or through a <e2>person</e2> charged for the purpose."
Other
Comment: e2 is employing e1.

1424	 one case, the <e1>waterjet</e1> caused a large <e2>gouge</e2> on the bottom side of a a copper/ wood/copper piece."
Cause-Effect(e1,e2)
Comment:

1425	 <e1>threats</e1>, and conflicts cause <e2>stress</e2>."
Cause-Effect(e1,e2)
Comment:

1426	 is an atlas of <e1>maps</e1> and graphic <e2>representations</e2> of the geographies of the new electronic territories of the Internet, the World-Wide Web and other emerging Cyberspaces."
Other
Comment:

1427	 <e1>damages</e1> caused by mudslides, <e2>tremors</e2>, subsidence, superficial or underground water were verified, as well as swelling clay soils."
Cause-Effect(e2,e1)
Comment:

1428	 sound <e1>machine</e1> contained 10 <e2>sounds</e2> that his dog loved."
Cause-Effect(e1,e2)
Comment:

1429	 <e1>guard</e1> participates in Veterans Day observance <e2>ceremony</e2> in Juneau."
Other
Comment: Participation in an event. We do not see it as a form of membership. It rather is a kind of agency or co-agency.

1430	 <e1>steam</e1> caused a <e2>backpressure</e2> on the VTD, resulting in the rupture disc opening."
Cause-Effect(e1,e2)
Comment:

1431	 campaign coincides with a government <e1>initiative</e1> to promote <e2>safer drinking</e2>."
Other
Comment: I cannot see initiative as a Message.

1432	 was the <e1>glitter</e1> of <e2>admirals</e2> and generals before the high altar, and the brighter colors of the representatives of powers and potentates."
Other
Comment: not su

1433	 the present invention includes a composition for <e1>treatment</e1> of disorders associated with or enhanced by an <e2>eosinophilia</e2>."
Other
Comment:

1434	 <e1>death</e1> during one of the Portuguese raids caused the <e2>abandonment</e2> of the settlement."
Cause-Effect(e1,e2)
Comment:

1435	 choosing to hold the <e1>ceremony</e1> in a public <e2>building</e2> and inviting guests you are recognizing both that your new life affects the lives of many other people."
Other
Comment: the ceremony itself is not contained in the building, the buildings more like a location

1436	 sculpture-like <e1>knitwear</e1> was inspired by the <e2>concept</e2> of 'Sculpture.'"
Other
Comment: concept is not a producer

1437	 <e1>eight-year-old boy</e1> was locked in a <e2>safe</e2> for a prank but had to be rescued when his air ran short."
Other
Comment:

1438	 this entire assembly is covered by a <e1>lid</e1> attached to the rear of the <e2>coffeemaker</e2> and latches in front."
Other
Comment: It doesn't sound like the lid is part of the coffeemaker, it's just attached to it

1439	 to vapor causes intense <e2>watering</e2> and irritation to eyes."
Cause-Effect(e1,e2)
Comment:

1440	 into the grill-charred, bronze-fleshed Copper River salmon fillet perched on a <e1>hill</e1> of crisp-tender green <e2>beans</e2> and roasted fingerling potatoes -- a dribble of mustard vinaigrette around the plate rim the only sauce it wanted -- I was back in San Francisco again."
Other
Comment: A hill is a spatial structure; modality is outside

1441	 are running into one <e2>problem</e2> after another trying to pass the health care bill in the Senate."
Other
Comment: violates b.

1442	 <e1>scandals</e1> are caused by the young female <e2>celebs</e2> who 'inadvertently' reveal glimpses of their naked faces as they get out of limousines."
Cause-Effect(e2,e1)
Comment:

1443	 <e1>infection</e1> was caused by the contaminated <e2>chopsticks</e2> used by the parent to feed her child."
Cause-Effect(e2,e1)
Comment:

1444	 time," he told her before turning to the <e1>boy</e1> who was in the <e2>desk</e2> next to him."
Other
Comment: the desk does not contain the boy; reported speech is OK here

1445	 <e1>convention</e1> took into account <e2>discharges</e2> of harmful substances from ships."
Other
Comment:

1446	 shows he's becoming a delightful comic <e1>actor</e1> with a highly flexible <e2>voice</e2>."
Other
Comment: Personal properties. qualities, skills cannot be Instruments.

1447	 unknown source brought an <e1>alien frog</e1> into our <e2>eco-system</e2>."
Other
Comment: violates b.

1448	 achieved the maximum possible <e1>flexibility</e1> in a crockery <e2>basket</e2> for receiving a plurality of different items of crockery."
Other
Comment: flexibility is not a content

1449	 <e1>emails</e1> have been leaked to the public <e2>broadcasting</e2>."
Other
Comment: violates b.

1450	 latter <e1>reports</e1> were subjected to intensive <e2>examination</e2>."
Other
Comment:

1451	 <e1>aircraft</e1> accommodated a <e2>pilot</e2> and copilot sitting side-by-side in a framed canopy."
Other
Comment:

1452	 University of Michigan study of 756 recently unemployed job seekers has found that medical and emotional <e1>fallout</e1>, including depression, from <e2>unemployment</e2> continued even after two years, when 71 percent were re-employed."
Cause-Effect(e2,e1)
Comment:

1453	 leaving Peter bought a <e1>silver</e1> star <e2>necklace</e2> for Tina."
Other
Comment:

1454	 <e1>accolade</e1> was decided upon after an intense <e2>discussion</e2> between about 200 members."
Cause-Effect(e2,e1)
Comment: This cannot be Message-Topic since (1) Cause-Effect is a stronger relation, according to the Guidelines, and (2) discussions, quarrels, etc. are accepted as Messages only when the information is spread outside the participants. Here we have "between".

1455	 infamous <e1>teacher</e1> has been dragged into another child abuse <e2>case</e2>."
Other
Comment: violates b.

1456	 <e1>poisoning</e1> is perhaps the commonest cause of <e2>abdominal pain</e2>, especially in the young dog or the scavenger type."
Cause-Effect(e1,e2)
Comment:

1457	 first days were frustrating as the winds were blowing for large sails, but the <e1>direction</e1> was from the <e2>north</e2>, and the bay was at low tide."
Other
Comment:

1458	 model was approved by as the top <e1>design</e1> by a professional <e2>panel</e2>; however, it was later exhibited for the public."
Other
Comment:

1459	 the <e1>success</e1> of the revolution is the reason for the <e2>celebration</e2>."
Cause-Effect(e1,e2)
Comment:

1460	 got a <e1>fever</e1> from <e2>exhaustion</e2> and it seems like I'm better but basically my body is suffering from major exhaustion so I'm always tired."
Cause-Effect(e2,e1)
Comment:

1461	 is one of the most abundant tree <e1>species</e1> in the whole <e2>forest</e2>, and with a maximum height of 14 m. the dominant tree species of the first canopy layer."
Other
Comment: A species is a taxonomic concept, so: a class of trees. A forest is not a collection of abstract classes of trees.

1462	 trio, the penguins, and a <e1>cartload</e1> of <e2>chimpanzees</e2> use the newly-fixed plane (which looks more like a helicopter) to come to the rescue."
Other
Comment: A measure of quantity: as much as a cart will hold.

1463	 author examines some <e1>issues</e1> connected to religious <e2>freedom</e2>."
Other
Comment: "connected to" is not necessarily about

1464	 <e1>hinge</e1> caused a <e2>crack</e2> on the left side of my kindle, and Amazon has been horrible about helping with this issue."
Cause-Effect(e1,e2)
Comment:

1465	 of patients of the Bikini accident has been caused by the <e2>radiation</e2> of the fallout in contrast to the atomic bomb injury at Hiroshima and Nagasaki."
Cause-Effect(e2,e1)
Comment:

1466	 abdominal <e1>distention</e1> caused by the <e2>worms</e2> was slightly asymmetrical when compared with the normal fright-induced swelling."
Cause-Effect(e2,e1)
Comment:

1467	 than thirty people lost their lives in June, in the <e1>disaster</e1> caused by torrential <e2>rains</e2> in Hiroshima Prefecture, and in September more than thirty people lost their lives in the damage caused by the typhoon that swept through various regions, centering on Kumamoto Prefecture."
Cause-Effect(e2,e1)
Comment:

1468	 sold a <e1>diamond</e1> <e2>ring</e2> that I bought at Zales for about $500 for $200 on craigslist."
Other
Comment:

1469	 introductory <e1>text</e1> makes a threefold contribution to the undergraduate <e2>literature</e2>."
Other
Comment: The document is about something, but that something is not named.

1470	 <e1>limits</e1> apply to many <e2>offices</e2> at both the federal and state level in the United States."
Other
Comment:

1471	 <e1>ideas</e1> insist on large <e2>gambles</e2> and conservatives rely on incremental small changes."
Other
Comment:

1472	 about the dynamics of addiction starts from repairing the <e1>damage</e1> that has been caused by the <e2>addiction</e2>."
Cause-Effect(e2,e1)
Comment:

1473	 first is that the <e1>ossicles</e1> are caused by an avulsion <e2>fracture</e2> 1,5 and the second is that the ossicles occur as a result of accessory ossification."
Other
Comment:

1474	 scientists have discovered a way of creating new <e1>brain cells</e1> in a <e2>dish</e2>."
Other
Comment: no evidence for Content-Cont

1475	 till now have negotiated with the <e2>market</e2> as individuals."
Other
Comment:

1476	 corporate <e1>regulator</e1> has been dragged into undertaker's <e2>inquiry</e2>."
Other
Comment: violates b.

1477	 febrile seizure is a <e1>convulsion</e1> in a child triggered by a <e2>fever</e2>."
Cause-Effect(e2,e1)
Comment:

1478	 merchant facilitates attacks using fake or modified terminals, towards tapping both the financial data stored on the <e1>cards</e1> as well as the <e2>pin</e2> of the cardsholders."
Other
Comment:

1479	 disruption of electricity and telecommunication lines have thrown the <e1>city</e1> into <e2>darkness</e2>."
Other
Comment: violates c.3

1480	 there is a <e1>movement</e1> afoot, instigated by the heterodox section of the <e2>community</e2>, as well as by the followers of the Gatha Alone Cultists to proselytise others to become "Zarthushtis"."
Cause-Effect(e2,e1)
Comment:

1481	 <e1>experiments</e1> reported in this article investigated two specific <e2>properties</e2> of the location probability effect."
Other
Comment: The Message is the article, not the experiments.

1482	 a recent tour of the handful of year-round farmers' markets in town turned up a <e1>cornucopia</e1> of fresh <e2>foods</e2>, from staples to rarities, sweets to meats."
Other
Comment: This is a kind of measure.

1483	 I got my life back, <e1>sadness</e1> from <e2>divorce</e2> is GONE I am thrilled I am not bleeding, dont need red shorts to walk my daughter to the park."
Cause-Effect(e2,e1)
Comment:

1484	 some time, the <e1>acids</e1> caused a white <e2>spot</e2> on the tooth where they dissolved some of the enamel."
Other
Comment:

1485	 is personally responsible for the <e1>carnage</e1> that has been caused by the <e2>fight</e2>."
Cause-Effect(e2,e1)
Comment:

1486	 has highlighted some important <e1>issues</e1> with regard to the <e2>abilities</e2> of firefighters."
Other
Comment:

1487	 has been used to promote many <e1>issues</e1> to do with <e2>animal welfare</e2> and has also helped raise funds for many of the service charities."
Other
Comment: Issues are not messages.

1488	 of years ago the <e1>island</e1> was almost discovered by an <e2>explorer</e2> called Marco Polo."
Other
Comment: island is not a product

1489	 <e1>decline</e1> of the old ideologies has made many of the old Left-Right <e2>arguments</e2> redundant."
Other
Comment: the arguments are not products of the declin

1490	 <e1>size</e1> of the issue was increased from its initial <e2>amount</e2> of US$750 million following strong market interest."
Other
Comment:

1491	 <e1>pain</e1> and symptoms were caused by the automobile <e2>accident</e2>."
Cause-Effect(e2,e1)
Comment:

1492	 has supported the development of a series of IFRC studies on rebuilding and <e1>reconstruction</e1> after the <e2>tsunami</e2> to identify lessons learned in promoting and strengthening community roles in the rebuilding process."
Other
Comment:

1493	 week the <e1>city</e1> had patched up the offending <e2>section</e2> of roadway."
Other
Comment: city is not a producer of the section

1494	 is the oldest and largest international research consortium aimed at understanding the <e1>challenges</e1> facing the global automotive <e2>industry</e2>."
Other
Comment:

1495	 goal of the <e1>project</e1> was to introduce environmentally efficient production <e2>technologies</e2>."
Other
Comment: Goal or purpose.

1496	 pets experience <e1>rashes</e1> and discomfort from ticks and <e2>fleas</e2>."
Cause-Effect(e2,e1)
Comment:

1497	 Sickness" is a bit of a misnomer, as <e1>nausea</e1> from <e2>pregnancy</e2>; it can happen at any time of the day."
Cause-Effect(e2,e1)
Comment: modality is outside

1498	 people took this as an indication that the <e1>increase</e1> was caused by the MMR <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

1499	 <e1>prisoner</e1> has departed into <e2>captivity</e2>."
Other
Comment: violates b.1 and c.3

1500	 it is beyond the power of the State to compel the Syme family to retain their shares or, more importantly, to oblige Mr Macdonald to remain the <e1>chief executive</e1> of this <e2>company</e2>."
Other
Comment:

1501	 <e1>wind</e1> caused a neat effect on the smoke clouds though, causing a <e2>corkscrew</e2> in the otherwise straight line."
Cause-Effect(e1,e2)
Comment:

1502	 women <e1>fear</e1> from darkness, insects, <e2>cockroaches</e2>, mice, lizards, spiders and more and more."
Cause-Effect(e2,e1)
Comment:

1503	 <e1>house</e1> was packed from that <e2>moment</e2> to past midnight."
Other
Comment:

1504	 have arrived in midland <e2>cars</e2>."
Other
Comment: Mann

1505	 and comedonal <e1>debris</e1> cause acne pimples or <e2>pustules</e2> (inflammatory lesions)."
Cause-Effect(e1,e2)
Comment:

1506	 <e1>chimps</e1> had tasted cooked <e2>food</e2> before, which may have influenced the outcome."
Other
Comment: food is not product of chimps

1507	 <e1>blood</e1> <e2>clot</e2> is useful to occlude and repair perforations in small side branches of the coronary artery without myocardial damage."
Other
Comment:

1508	 <e1>slope</e1> on a distance-time graph represents the <e2>speed</e2> of an object."
Other
Comment:

1509	 illustrators <e1>section</e1> has been brought into the new web <e2>format</e2>."
Other
Comment: violates c.3

1510	 are being thrown into <e2>poverty</e2> by our corrupt health care system."
Other
Comment: violates c.3

1511	 the earliest period of its history, the <e1>church</e1> made use of <e2>messengers</e2>, called "cursores," in order to communicate with the entire world."
Other
Comment: People are not usually classified as Instruments, unless they are clearly non-agentive in the situation, this is similar to employment.

1512	 oil <e1>spill</e1> caused by a <e2>collision</e2> between a ship and a barge closed the ship channel servicing the nation's second largest port."
Cause-Effect(e2,e1)
Comment:

1513	 America, one of <e1>dynamite</e1>'s first use was in the <e2>creation</e2> of trenches for irrigation systems."
Other
Comment: Purpose-Tool

1514	 anxiety, worry or <e1>fear</e1> are among the causes of <e2>heart attack</e2>."
Cause-Effect(e1,e2)
Comment:

1515	 <e1>builder</e1> who has mortgaged the <e2>land</e2> to raise money will have to spell this out in all advertisements and brochures."
Other
Comment: land is not a product; modality is outsid

1516	 <e1>bills</e1> make up half of <e2>bankruptcies</e2>."
Cause-Effect(e1,e2)
Comment:

1517	 <e1>cavalry</e1> observed the passing through the <e2>town</e2>."
Other
Comment:

1518	 reality, <e1>acne</e1> is caused by <e2>bacteria</e2> and oil on the skin."
Cause-Effect(e2,e1)
Comment:

1519	 he was freeing himself from the <e1>clutches</e1> of the <e2>dishwasher</e2>, he ripped off some of his skin, revealing his bionic arm."
Other
Comment:

1520	 locksmith copies and repairs car <e1>keys</e1> for modern <e2>vehicles</e2> at a lower cost."
Other
Comment:

1521	 the <e1>traveller</e1> drew up the <e2>blind</e2> the next morning, the sea opened before him joyously under the broad August sunlight."
Other
Comment: the blind is not produced by the traveller

1522	 77-year-old is <e1>suffering</e1> from <e2>exhaustion</e2> and he will undergo medical tests."
Cause-Effect(e2,e1)
Comment: modality is outsid

1523	 substrate treating apparatus for <e1>treatment</e1> of substrates with a treating <e2>liquid</e2> includes a treating tank having an inner tank for storing the treating liquid."
Other
Comment: Purpose-Tool

1524	 are <e1>symbols</e1> that indicate the <e2>structure</e2> and organization of written language."
Other
Comment:

1525	 <e1>company</e1> has moved into <e2>mobile software applications</e2>, which connect to enterprise databases."
Other
Comment:

1526	 <e1>students</e1> participated in the tutoring <e2>programs</e2> funded by the legislation, but the controversial element was not the options for public schools or the tutoring program (both of which where never challenged)."
Other
Comment: negation is outside

1527	 <e1>orders</e1> are shipped to foreign <e2>countries</e2> using US postal service delivery."
Other
Comment:

1528	 began to reverse the <e1>damage</e1> to one of the greatest rivers in the state caused by the <e2>construction</e2> of a dam nearly 70 years ago."
Cause-Effect(e2,e1)
Comment:

1529	 <e1>loop</e1> emiting short flashes of <e2>light</e2> is projected onto volunteer members of the audience."
Cause-Effect(e1,e2)
Comment:

1530	 are caused by <e2>movement</e2> of the earth's crust along this fault."
Cause-Effect(e2,e1)
Comment:

1531	 see that the <e1>universe</e1> starts at an initial <e2>epoch</e2> t0."
Other
Comment:

1532	 University and Houston-based MI SWACO, the world's largest producer of <e1>drilling</e1> <e2>fluids</e2> for the petrochemical industry, aim to develop a graphene additive."
Other
Comment: Purpose-Tool

1533	 tsunami was generated by an undersea <e1>landslide</e1>, which was triggered by the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

1534	 greatest <e1>plenitude</e1> of <e2>graces</e2> was conferred on him as man, and from him, as he was our head, derived to all the members of his Church."
Other
Comment: Measure.

1535	 the presence of Cuba's favorite son, Estrada Palma, who is to enjoy the honor of being the first <e1>chief executive</e1> of this <e2>republic</e2>."
Other
Comment:

1536	 shows how <e1>laws</e1> composed to incorporate rural <e2>workers</e2> in a controlled way became platforms for unexpected protest and political mobilization culminating in the 1963 Rural Laborer Statute (ETR)."
Other
Comment: the workers did not make the laws

1537	 decision to take the <e1>meeting</e1> on the <e2>road</e2> gave groups around the world the opportunity to host future Keele Meetings."
Other
Comment:

1538	 K.P. Kumar is the <e1>chairman</e1> of the <e2>college</e2> that strives to impart value education to students and guide them for excellent prospects in career making."
Other
Comment:

1539	 dancing <e1>duo</e1> caused a <e2>stir</e2> on the 2008 series of the show with their infusion of classic Michael Jackson songs and dance moves mixed with bangra."
Cause-Effect(e1,e2)
Comment:

1540	 Pacific Chorus <e1>frog</e1> was found in a Christmas <e2>tree</e2> being sold in Anchorage, Alaska."
Other
Comment: the tree is not a container

1541	 spreading riots threw the <e1>country</e1> into <e2>turmoil</e2>."
Other
Comment: violates c.3

1542	 National Ballet's new <e1>production</e1>, by the creative <e2>partnership</e2> of Rachel Beaujean and Ricardo Bustamante, is based on the original ballet by Jean Coralli and Jules Perrot."
Other
Comment: partnership is not a producer

1543	 was performed by <e1>illumination</e1> of the urethra with a <e2>candle</e2>."
Other
Comment:

1544	 <e1>companions</e1> have departed into <e2>eternity</e2>."
Other
Comment: violates b.1 and c.3

1545	 is the second Italian championship won by Woody with <e1>horses</e1> bred in his <e2>stud</e2>."
Other
Comment: Here stud is the location of the breeding - Other.

1546	 deeper <e1>currents</e1> are caused by <e2>heat</e2> from the sun."
Cause-Effect(e2,e1)
Comment:

1547	 this is a very dark <e1>novel</e1>, driven by an unsparing <e2>view</e2> of human nature and a clear-eyed analysis of the idea of human perfectibility."
Other
Comment: view is not a producer

1548	 arriving in Cairns, co-workers have thrown the new <e1>employee</e1> into local <e2>issues</e2>."
Other
Comment: violates b.

1549	 alert victim with a broken neck or severely torn ligament has enough <e1>discomfort</e1> from the <e2>injury</e2> and muscle spasm to force him to hold his neck still."
Cause-Effect(e2,e1)
Comment:

1550	 Affiliate Classroom promotes the direct sales and gets <e1>commission</e1> from the <e2>selling</e2> of products."
Cause-Effect(e2,e1)
Comment:

1551	 act of repeated hand washing is the compulsive behavior performed in an attempt to remove the <e1>anxiety</e1> caused by the obsessive <e2>thought</e2>."
Cause-Effect(e2,e1)
Comment:

1552	 basically just a shack with a fridge and some fosters <e1>beers</e1> stacked up the back <e2>wall</e2>."
Other
Comment: wall is not a produc

1553	 right boys and girls you read that correctly, you just shared a <e1>printer</e1> over the <e2>internet</e2>."
Other
Comment:

1554	 bought a <e1>gold</e1> <e2>bracelet</e2> for her sister."
Other
Comment:

1555	 have inherited a <e1>tendency</e1> to <e2>obesity</e2>."
Other
Comment:

1556	 stood at the great central window, which was wide open, and watched the <e1>whiteness</e1> of the <e2>swans</e2> moving vaguely over the surface of the canal in the oncoming twilight."
Other
Comment: Colour.

1557	 relation to the <e1>catastrophe</e1> caused by the <e2>rains</e2> of recent days in the Sierra and Coastal zones of Chiapas."
Cause-Effect(e2,e1)
Comment:

1558	 second primer <e1>set</e1> was derived from a specific variant surface glycoprotein(VSG) expression <e2>site</e2> where the SRA gene is expressed(R-ES)."
Other
Comment:

1559	 the police raid the catacombs, Shannyn's character hits her head while fleeing only to wake up alone in the <e1>maze</e1> of <e2>skulls</e2> and bones."
Other
Comment:This definitely is not a set: it is a pattern, an arrangement.

1560	 magnetic <e1>island</e1> grows from the resonant <e2>radius</e2> until the so-called mixing radius rmix and full reconnection are reached."
Other
Comment:

1561	 have blocked out the PIN <e1>code</e1> of the <e2>phone</e2> (Please do not give this code to the customer)."
Other
Comment:

1562	 <e1>research</e1>, performed at the Kyoto Prefectural University of Medicine, has been presented at a medical <e2>meeting</e2> in Japan."
Other
Comment: Meeting.

1563	 <e1>housing</e1> encloses a double sealed ball <e2>bearing</e2>, with a lower lip seal for additional protection."
Other
Comment:

1564	 new <e1>law</e1> has been brought into <e2>force</e2>."
Other
Comment: violates c.3

1565	 <e1>restaurant</e1> was filled with <e2>customers</e2>, most of them children and mothers."
Other
Comment:

1566	 <e1>development</e1> of oil palm plantations is one of the biggest causes of rainforest <e2>clearance</e2>."
Cause-Effect(e1,e2)
Comment:

1567	 <e1>terrorist</e1> has planted a <e2>bomb</e2> in a city centre and it is due to go off in one or two hours' time."
Other
Comment: not enough evidence to decide whetehr the bomb is a product of the terrorist

1568	 causes <e2>swelling</e2> and narrowing of the airways."
Cause-Effect(e1,e2)
Comment:

1569	 weekend <e1>snowstorm</e1> caused <e2>delays</e2> that had some passengers still stuck in Washington, DC on Monday night."
Cause-Effect(e1,e2)
Comment:

1570	 heaviest <e1>rain</e1> fell from an <e2>area</e2> from Roane and Clay Counties northeastward across Braxton, Gilmer and Lewis Counties and into Southern Harrison county."
Other
Comment:

1571	 hold the <e1>magnesium ribbon</e1> in <e2>tongs</e2>, and place one end in a Bunsen burner flame."
Other
Comment:

1572	 <e1>walk</e1> starts at an <e2>entry</e2> to Mealmore Forest."
Other
Comment:

1573	 <e1>man</e1> has already converted a room in the basement into an <e2>office</e2>."
Other
Comment:

1574	 warming <e1>pollution</e1> from <e2>cars</e2>, light trucks and SUV's is the single largest source of global warming pollution generated in Maine."
Cause-Effect(e2,e1)
Comment:

1575	 <e1>insert</e1> starts in the left <e2>column</e2> and only spans the left column."
Other
Comment:

1576	 strain results from the physical stresses of everyday life, including poor posture, muscle <e1>tension</e1> from psychologic stress or <e2>poor sleeping</e2>."
Cause-Effect(e2,e1)
Comment:

1577	 reference clock <e1>signal</e1> originates from an internal clock <e2>source</e2>."
Cause-Effect(e2,e1)
Comment:

1578	 morning session of the <e1>symposium</e1> ends with a reunion lunch for the <e2>attendees</e2>."
Other
Comment:

1579	 chemical <e1>reaction</e1> in the water caused a bubbling <e2>affect</e2> on the surface."
Cause-Effect(e1,e2)
Comment:

1580	 <e1>research</e1> has been published in a <e2>paper</e2> by the Scottish Records Association."
Other
Comment: Location. It cannot be Content-Container since the Content should be removable. It also cannot be Component-Whole since it violates (d).

1581	 <e1>conflict</e1> is rooted in an ongoing <e2>refusal</e2> by the Palestinians and the Arab world to recognize the right of the Jewish people."
Cause-Effect(e2,e1)
Comment:

1582	 spot <e1>fire</e1> is caused by burning <e2>embers</e2> being blown away by high winds that occur during bushfires."
Cause-Effect(e2,e1)
Comment:

1583	 gummy savers with a little frosting in between to make a <e1>smoke</e1> <e2>stack</e2> on the engine."
Other
Comment: Type of stack, and the same three times below.

1584	 <e1>rock</e1> in the road caused an <e2>accident</e2> by breaking the rear wheel on the wagon."
Cause-Effect(e1,e2)
Comment:

1585	 for his funny turn as a <e1>man</e1> who instigates the <e2>kidnapping</e2> of his own wife in E Niwas's Love Ke Liye Kuch Bhi Karega."
Cause-Effect(e1,e2)
Comment:

1586	 <e1>explosion</e1> caused a <e2>gas leak</e2> on the pipeline near the village of Pouce Coupe, south of Dawson Creek."
Cause-Effect(e1,e2)
Comment:

1587	 spaghetti <e1>pie</e1> served at a church dinner had caused the <e2>poisoning</e2> of one hundred people."
Cause-Effect(e1,e2)
Comment:

1588	 seeking their fortune in the Colorado gold fields traveled to Denver on the Smoky Hill <e2>trail</e2> from Kansas and points east."
Other
Comment: locations cannot be instruments in this case.

1589	 commercial <e1>pasta</e1> is made by this <e2>method</e2>."
Other
Comment: it is more like manner, the method is not a producer

1590	 marriages do not recover from affairs at all, but at least one-third do find some way to rebuild trust and <e1>happiness</e1> after an <e2>affair</e2>."
Other
Comment:

1591	 dog has a <e1>fever</e1> from <e2>allergies</e2> he was given clavamox and a shot."
Cause-Effect(e2,e1)
Comment:

1592	 sold a <e1>diamond</e1> <e2>ring</e2> on consignment through a jeweller who also dealt in second hand jewellery."
Other
Comment:

1593	 is also when a <e1>parent</e1> manipulates a <e2>child</e2>."
Other
Comment:

1594	 <e1>shooting</e1> stemmed from an <e2>argument</e2> the two students had "in the community" over the weekend."
Cause-Effect(e2,e1)
Comment:

1595	 <e1>chemicals</e1> used for screen <e2>reclamation</e2> are some of the most hazardous products in a screen printing facility."
Other
Comment: Purpose-Tool

1596	 four <e1>men</e1> are being dragged into the criminal <e2>underworld</e2>."
Other
Comment: violates b.

1597	 the curved shape resembles the gentle <e1>undulation</e1> of sand <e2>dunes</e2>, two raised starfish accent the border."
Other
Comment:

1598	 of the <e1>problem</e1> is rooted in an ill-conceived state <e2>law</e2>."
Cause-Effect(e2,e1)
Comment:

1599	 important challenge for the new administration was to address the <e1>insecurity</e1> and poverty caused by civil <e2>war</e2>."
Cause-Effect(e2,e1)
Comment:

1600	 old <e1>man</e1> fixed the children with a firm <e2>stare</e2>."
Other
Comment:

1601	 Afghan handed over innocent <e1>people</e1> into <e2>torture</e2>."
Other
Comment: violates b.1 and c.3

1602	 good taste for good cheese leads to the <e1>factory</e1>'s commercial <e2>success</e2>."
Other
Comment: success is not a product

1603	 <e1>masts</e1> for the high-tech third generation mobile phones cause headaches and <e2>nausea</e2>."
Cause-Effect(e1,e2)
Comment:

1604	 to have better FM reception than the previous model, this <e1>radio</e1> <e2>tuner</e2> works with both Windows and Mac systems."
Other
Comment: modality is outside

1605	 <e1>diapir</e1> uprises from the upward-convex silicone <e2>dome</e2>, intruding within the sand."
Other
Comment:

1606	 acoustic <e1>instrumental</e1> (which has always been one of my favorites), makes an abrupt departure from the band's <e2>signature</e2> and dark-sounding metal riffs."
Other
Comment:

1607	 <e1>laptop</e1> was in the <e2>desk</e2>."
Other
Comment: it is not inside the desk

1608	 <e1>findings</e1> were from two years of DNA <e2>testing</e2> and CT scans on 16 mummies, including those of Tutankhamun and his family, the team that carried out the study said in an article to be published Wednesday in the Journal of the American Medical Association."
Other
Comment:

1609	 immediate post-war years were a <e1>hive</e1> of <e2>ideas</e2> at Glyndebourne, some worked and others did not."
Other
Comment: Here hive refers to location or place.

1610	 hormonal, bacterial and inflammatory <e1>disturbances</e1> cause <e2>acne</e2>."
Cause-Effect(e1,e2)
Comment:

1611	 Gateway DX-4822-01 <e1>computer</e1> makes a convincing pitch with the performance <e2>numbers</e2> and features to earn its place in your home."
Other
Comment:

1612	 or convulsions are caused by hormone deficiencies and <e2>imbalances</e2>."
Cause-Effect(e2,e1)
Comment:

1613	 probably refers to the <e1>artist</e1>'s <e2>assistant</e2>, Suzanne Miller."
Other
Comment: People are not usually classified as Instruments, unless they are clearly non-agentive in the situation. This is a collaborative work.

1614	 sharp marginal <e1>rim</e1> starts at the anterior <e2>dorsal angle</e2> and continues around the anterior and ventral margins to the posterior-ventral angle."
Other
Comment:

1615	 <e1>estate</e1> builds itself out of <e2>downturn</e2>."
Other
Comment:

1616	 detailed estimate is built up of many <e1>component</e1> <e2>parts</e2> which may result in cumulative errors."
Other
Comment: Kind of parts.

1617	 had caused the <e2>collapse</e2> of the Somali Republic."
Cause-Effect(e1,e2)
Comment:

1618	 concise, comprehensive style is- a great ornament in narration; and a <e1>superfluity</e1> of unnecessary <e2>words</e2>, altogether improper."
Other
Comment: A kind of measurement.

1619	 <e1>vowel length</e1> was denoted by the <e2>acute accent</e2>."
Other
Comment:

1620	 fatal <e1>mistake</e1> caused a <e2>quarrel</e2> between different companies."
Cause-Effect(e1,e2)
Comment:

1621	 <e1>disorders</e1> of the stomach and intestines cause nausea and <e2>vomiting</e2>."
Cause-Effect(e1,e2)
Comment:

1622	 are all symptoms of the muscle <e1>paralysis</e1> caused by the bacterial <e2>toxin</e2>."
Cause-Effect(e2,e1)
Comment:

1623	 makeup <e1>artist</e1> applies the finishing <e2>touches</e2> to Marquesa Lawrence before the taping of a segment of "The Scholar.""
Other
Comment: We decided that e2 is an event rather than an entity.

1624	 <e1>families</e1> recover from three <e2>weeks</e2> of war."
Other
Comment:

1625	 detect defect sites by chemical <e1>modification</e1> of the sites with <e2>polymers</e2>."
Other
Comment:

1626	 was drizzling lightly in late October when the midnight <e1>shift</e1> started at the Owls Head Water pollution control <e2>plant</e2>."
Other
Comment:

1627	 was the <e1>destruction</e1> of the gold standard by the government that caused the unprecedented <e2>collapse</e2> in the world economy."
Cause-Effect(e1,e2)
Comment:

1628	 from <e2>asthma</e2> is worse at night or early in the morning, making it hard to sleep."
Cause-Effect(e2,e1)
Comment:

1629	 lbs of <e1>clay</e1> made into a <e2>canister</e2> hold a 5 lb bag of flour."
Other
Comment: clay is the material out of which the canister is made.

1630	 Obama administration supports ending the use of <e1>antibiotics</e1> for <e2>growth</e2> and feed efficiency in food animals."
Cause-Effect(e1,e2)
Comment:

1631	 <e1>concerns</e1> were related to property <e2>taxes</e2>, sewage systems, property values, and control of school districts."
Other
Comment: Violation of (b).

1632	 <e1>machine</e1> needs user <e2>confirmation</e2> EACH time the camera is turned on."
Other
Comment: confirmation is not a product

1633	 primary electron <e1>beam</e1> was generated by an electrostatically focused electron <e2>gun</e2>, with a rhenium strip cathode."
Cause-Effect(e2,e1)
Comment:

1634	 designs <e1>qualifications</e1> in the <e2>care</e2> and education of children and young people."
Other
Comment:

1635	 doses of <e1>cocaine</e1> cause convulsions, severe maternal weight loss and increased maternal <e2>mortality</e2>."
Cause-Effect(e1,e2)
Comment:

1636	 <e1>dog</e1> loose on the carriageway caused a five-vehicle <e2>crash</e2> on the M25 on Wednesday morning."
Cause-Effect(e1,e2)
Comment:

1637	 <e1>microprocessor cluster</e1> has been migrated into high-end embedded <e2>applications</e2>."
Other
Comment: violates b.

1638	 economic terms, <e1>pollution</e1> from fossil <e2>fuels</e2> is regarded as a negative externality and should be taxed."
Cause-Effect(e2,e1)
Comment:

1639	 air and water <e1>pollution</e1> from fossil <e2>fuels</e2> are a huge problem in China."
Cause-Effect(e2,e1)
Comment:

1640	 of Water, Kuttimuratov's other piece I photographed for you, shows the Zoroastrian <e1>goddess</e1> of water with a <e2>fish</e2>."
Other
Comment:

1641	 1880, there was a strong <e1>typhoon</e1> and an earthquake that lead to the <e2>destruction</e2> of the instrument."
Cause-Effect(e1,e2)
Comment:

1642	 extra-time goals sent the <e1>team</e1> into the Carling <e2>final</e2>."
Other
Comment: violates b.

1643	 foreign <e1>company</e1> has entered into the insurance <e2>market</e2> in China."
Other
Comment: violates b.

1644	 included is our Commission Authorization form, which collects the <e1>author</e1>'s contact <e2>information</e2> and authorizes us to retain our standard 5% commission."
Other
Comment: information is not product if the author

1645	 is one of the more obvious causes of pedestrian <e2>accidents</e2>."
Cause-Effect(e1,e2)
Comment:

1646	 <e1>high temperature</e1> caused a <e2>decomposition reaction</e2>, increased the inner pressure of the reactor, and resulted in a rupture."
Cause-Effect(e1,e2)
Comment:

1647	 to Two Gateway Center is gained from a <e2>doorway</e2> just inside the Liberty Avenue vehicle entrance."
Other
Comment:

1648	 <e1>deterioration</e1> has been caused by an apparently endless <e2>recession</e2>."
Cause-Effect(e2,e1)
Comment:

1649	 scientific, yet understandable reasons of why the L*Bo Aid is so effective in eliminating and preventing <e1>elbow pain</e1> due to epicondylitis commonly referred to as "Tennis Elbow" and <e2>tendinitis</e2>."
Cause-Effect(e2,e1)
Comment:

1650	 principal hazard facing the publisher with respect to reviews is getting panned by an honest <e1>book</e1> <e2>reviewer</e2> or scammed by a phony book reviewer."
Other
Comment: the reviewer is not a producer

1651	 <e1>process</e1> departs from an <e2>inspiration</e2> and idea generation phase based on challenges the company faces in the coming years."
Cause-Effect(e2,e1)
Comment:

1652	 <e1>decline</e1> has been caused by the <e2>immigration</e2> of lower ability immigrants."
Cause-Effect(e2,e1)
Comment:

1653	 <e1>criminal law</e1> is set out in a diverse <e2>range</e2> of statutes and court decisions."
Cause-Effect(e2,e1)
Comment: The statutes and court decisions cause law (which means "the rule of law" - a state).

1654	 the <e1>coast</e1> comprises coastal <e2>lowlands</e2> that receive the many small rivers flowing from the lake-studded plains of the island's western half."
Other
Comment:

1655	 <e1>conjunctivitis</e1> is the most common cause of <e2>pinkeye</e2> around the world."
Cause-Effect(e1,e2)
Comment:

1656	 <e1>singing</e1> comes from the substantial <e2>figure</e2> of Mole - Paul Smith in the normal world - who crams into his days a full-time job."
Cause-Effect(e2,e1)
Comment:

1657	 <e1>bacon</e1> is home cured by our local <e2>butcher</e2> who also supplies the award winning sausages."
Other
Comment: butcher is not a producer, bacon is raw material

1658	 damage in Washington was so much less than the <e1>damage</e1> caused by the 1994 Northridge <e2>earthquake</e2>, despite that their magnitudes were so similar-- 6.8 vs. 6.7."
Cause-Effect(e2,e1)
Comment:

1659	 we analysed changes in heterozygosity over time in an insular mouflon (Ovis aries) <e1>population</e1> founded by two <e2>individuals</e2> in 1957."
Other
Comment: indirect relation: the individuals started the population but they were others involved in the act of increasing the population

1660	 early 2007 renewed a coal mining <e1>activity</e1> in the region triggered the <e2>earthquake</e2>, although earthquake activity has been present in the area at least since white settlement first occurred."
Cause-Effect(e1,e2)
Comment:

1661	 last year, many <e1>people</e1> are sinking into <e2>debt</e2>."
Other
Comment: violates b.1 and c.3

1662	 <e1>bacteria</e1> causes skin infections, colds, or <e2>diarrhea</e2>."
Cause-Effect(e1,e2)
Comment:

1663	 the air with both hands and <e1>coughing</e1> from the <e2>dust</e2>, it settled on both vehicles."
Cause-Effect(e2,e1)
Comment:

1664	 said that the creation of such <e2>facilities</e2> contributes to strengthening the city's position as one of eastern Cuba's major tourist destinations."
Other
Comment: experts are not produc

1665	 leads to <e2>aggressions</e2> towards colleagues."
Cause-Effect(e1,e2)
Comment:

1666	 former <e1>emission</e1> arose from the primary collisional <e2>excitation</e2>."
Cause-Effect(e2,e1)
Comment:

1667	 solar calendar is a calendar whose <e1>dates</e1> indicate the <e2>position</e2> of the earth on its revolution around the sun."
Other
Comment:

1668	 sweet satisfaction was only troubled by the <e1>sorrow</e1> caused by the horrible <e2>attack</e2> on the person of a representative of the nation."
Cause-Effect(e2,e1)
Comment:

1669	 love the sweet and salty <e1>combo</e1> of the watermelon <e2>salads</e2> that have been all over the food world lately."
Other
Comment: This is not a set: we are talking about a complex taste.

1670	 is exciting to see the <e1>windsurfers</e1> conquer the water body with their impressive <e2>control</e2> and skills."
Other
Comment:

1671	 the <e1>quality</e1> inside a fertilizer <e2>bag</e2>."
Other
Comment: quality is not a conten

1672	 depression sufferers and their physicians revealed that <e1>insomnia</e1> was caused by <e2>depression</e2>."
Cause-Effect(e2,e1)
Comment:

1673	 wears a <e1>brace</e1> for her left <e2>ankle</e2>, has restricted use of her left hand, still has vision problems and continues with therapy."
Other
Comment: we interpret here that she is using the brace not the ankle.

1674	 increased <e1>spending</e1> caused a <e2>strain</e2> on the state treasury as the Sultan was spending increasing amounts of time in the harem rather than leading the people."
Cause-Effect(e1,e2)
Comment:

1675	 earliest research <e1>interest</e1> stemmed from an <e2>internship</e2> at Tall Timbers."
Cause-Effect(e2,e1)
Comment:

1676	 are some ways to avoid mindless eating and boost your weight <e1>loss</e1> from <e2>running</e2>."
Cause-Effect(e2,e1)
Comment:

1677	 <e1>figures</e1> show <e2>unemployment</e2> in Wales is rising again despite falls in the previous two months."
Other
Comment:

1678	 <e1>tides</e1> caused by the <e2>sun</e2> follow the exact same methods as those by the moon."
Cause-Effect(e2,e1)
Comment:

1679	 <e1>organizers</e1> of the retreat near Lake Placid threw together a <e2>group</e2> of people on a hunch."
Other
Comment: group is not a product

1680	 <e1>study</e1> aimed at assessing the <e2>processing time</e2> of a natural scene in a fast categorization task of its context or 'gist'."
Other
Comment: Here the study is a process; it is NOT written work. Violates (d).

1681	 in his time, was strictly a portion of feudal Europe, and the <e1>chivalry</e1> of Athenian <e2>dukes</e2> was familiar to those for whom he wrote, and wherever chivalry was in esteem; and when he described a fatal battle in the plain of Thebes, the slaughter of knights, the despair of their ladies, he recalled a great catastrophe recent in men's memories."
Other
Comment: It's a character trait, a code -- not a set.

1682	 has announced that they have pulled the <e1>film</e1> from its release <e2>date</e2>, but as of yet have not announced when we can expect to dee the movie in theaters."
Other
Comment: the negation is outsid

1683	 forgot to shut the bathroom door before showering and the <e1>steam</e1> set off the smoke <e2>alarm</e2> on the wall between the bathroom and my bedroom."
Cause-Effect(e1,e2)
Comment:

1684	 of a vacuum <e1>spark</e1> triggered by the transient hollowcathode discharge electron <e2>beam</e2>."
Cause-Effect(e2,e1)
Comment:

1685	 sliding bar <e1>assembly</e1> is attached to the removable <e2>panel</e2> and the bush is mounted to the panel's stationary support."
Other
Comment:

1686	 <e1>electrician</e1> carries out audibility <e2>checks</e2> throughout the building during the drill."
Other
Comment:

1687	 <e1>dehydrator</e1> is best for the <e2>drying</e2> of high moisture herbs."
Other
Comment: Purpose-Tool

1688	 year, many infants and toddlers die due to <e1>suffocation</e1> from <e2>breathing</e2> small objects into their breathing passages and lungs."
Cause-Effect(e2,e1)
Comment:

1689	 of the <e1>suffering</e1> caused by the <e2>destruction</e2> of life, I am committed to cultivating compassion and learning ways to protect the lives of people, animals, plants, and minerals."
Cause-Effect(e2,e1)
Comment:

1690	 way back in the San Francisco earthquake, most of the damage was caused by <e1>fire</e1> after the <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

1691	 <e1>company</e1> has entered into a reseller <e2>agreement</e2>."
Other
Comment: violates c.3

1692	 <e1>people</e1> are falling into <e2>poverty</e2>, especially those already struggling to make ends meet."
Other
Comment: violates b.1 and c.3

1693	 <e1>decade</e1> produced a bumper <e2>crop</e2> of great movies."
Other
Comment: decade is not a producer

1694	 <e1>trail</e1> starts at an <e2>elevation</e2> of 5600' and steadily climbs to the top of a 6850' promontory overlooking Pine and Juniper Canyons."
Other
Comment:

1695	 <e1>smile</e1> runs away from the kid's <e2>face</e2>."
Other
Comment:

1696	 are navigational <e1>maps</e1> based on realistic <e2>descriptions</e2> of harbours and coasts."
Other
Comment: Descriptions are the source of/for maps.

1697	 <e1>bottom</e1> is welded into each monoseal <e2>casket</e2> using a continuous weld aldong the entire seam."
Other
Comment: no indication for Content-Container relation

1698	 stuffed <e1>pork</e1> into <e2>defense</e2> and homeland security."
Other
Comment: This CANNOT be Entity-Destination; it violates E-D's b.1.

1699	 <e1>cancer</e1> caused by HBV <e2>virus</e2> is among the first three causes of death from cancer in men, and a major cause of cancer in women."
Cause-Effect(e2,e1)
Comment:

1700	 common side effect of strict elimination after extended periods of use is <e1>headaches</e1> from <e2>caffeine withdrawal</e2>, which is also a clear sign of the addiction."
Cause-Effect(e2,e1)
Comment:

1701	 <e1>war</e1> resulted in other collateral imperial <e2>conquests</e2> as well."
Cause-Effect(e1,e2)
Comment:

1702	 hear it, too, in the lovely expansiveness of his work as a <e1>chamber</e1> <e2>musician</e2>."
Other
Comment: chamber is not a product

1703	 teenager fell seriously ill after receiving the <e1>injection</e1>, along with thousands of other <e2>pupils</e2> across Northern Ireland last Friday."
Other
Comment:

1704	 <e1>light</e1> that is currently reaching the Earth was generated in the <e2>sun</e2> approximately 100000 years ago."
Cause-Effect(e2,e1)
Comment:

1705	 bounded <e1>applicability</e1> of the Perceptron arose from the <e2>linearity</e2> of its modifiable decision rule."
Cause-Effect(e2,e1)
Comment:

1706	 shock <e1>wave</e1> was generated by an <e2>explosive</e2> made from RDX."
Cause-Effect(e2,e1)
Comment:

1707	 that time there was also a Renaissance <e1>building</e1> founded by the <e2>wall</e2>."
Other
Comment: wall is not a producer

1708	 are vascular plants in the class Lycopodiopsida, a division of vascular plants known as Pteridophytes (the <e1>ferns</e1> and their <e2>allies</e2>)."
Other
Comment: This relation is symmetric in a way that Instrument-Agency isn't.

1709	 <e1>department</e1> achieved the goal with a 75% <e2>reduction</e2> in accidents."
Other
Comment:

1710	 a literature review of 875 cases of Merkel cell carcinoma, the <e1>tumor</e1> was the cause of <e2>death</e2> in 34% of these patients."
Cause-Effect(e1,e2)
Comment:

1711	 <e1>instability</e1> grows from an <e2>perturbation</e2> whose initial amplitude is small."
Cause-Effect(e2,e1)
Comment:

1712	 <e1>praise</e1> and blame cause <e2>concern</e2>, for they bring people hope and fear."
Cause-Effect(e1,e2)
Comment:

1713	 article is about pre-existing <e1>conditions</e1> with respect to <e2>health insurance</e2>."
Other
Comment: If the sentence was annotated: This <e1>article<e2> is about pre-existing <e2>conditions</e2> with respect to health insurance., then we would have had have Message-Topic.

1714	 dreary tenement scene is architecturally reminiscent of the neighbourhood of Fagin's <e1>den</e1> of <e2>child-thieves</e2> in Oliver Twist."
Other
Comment: Location, as per Dickens (but there is sense ambiguity here; see Webster: 4: a subdivision of a Cub Scout pack made up of two or more boys).

1715	 method of mitigating the effect of a market <e1>spike</e1> caused by the triggering and the <e2>election</e2> of a conditional order includes monitoring conditional orders."
Cause-Effect(e2,e1)
Comment:

1716	 <e1>friend</e1> has entered into a new <e2>relationship</e2>."
Other
Comment: violates c.3

1717	 <e1>deaths</e1> of Israelis caused by <e2>terror</e2> are permanent and irreversible whereas the hardships faced by the Palestinians are temporary and reversible."
Cause-Effect(e2,e1)
Comment:

1718	 dissatisfaction</e1> is one of the main causes of <e2>stress</e2> and stress is one of the main causes of illness."
Cause-Effect(e1,e2)
Comment:

1719	 <e1>stroke</e1>, which was triggered by a <e2>bout</e2> of chicken pox, also weakened her arteries so much that doctors said she had the brain 'of an 80-year-old'."
Cause-Effect(e2,e1)
Comment:

1720	 and holiday <e1>travellers</e1> are running into heavy <e2>delays</e2> on Route 128 in Weston this morning."
Other
Comment: violates b.1 and c.3

1721	 <e1>aerosol</e1> was generated from an oxalic <e2>acid solution</e2> containing only the tracer."
Other
Comment:

1722	 <e1>delay</e1> in the progression of these applications has been caused by the original <e2>applicants</e2>."
Cause-Effect(e2,e1)
Comment:

1723	 two hours later, officers got an anonymous tip that the <e1>gunman</e1> was inside a nearby <e2>apartment building</e2>."
Other
Comment: this example states the location of the gunman

1724	 executioners have carried the <e1>scholar</e1> into <e2>exile</e2>."
Other
Comment: violates c.3

1725	 and colleagues achieved fame more than a decade ago by accurately predicting that that the <e1>fireball</e1> caused by the <e2>intersection</e2> of the comet Shoemaker-Levy 9 with Jupiter is observable from Earth."
Cause-Effect(e2,e1)
Comment:

1726	 oil revenues have dragged this poor <e1>country</e1> into even deeper <e2>recession</e2>."
Other
Comment: violates c.3

1727	 are reside meningococcal bacilli in the vaccine and it is accessible to bolt the ache or become a carrier of the <e1>ache</e1> from the <e2>vaccine</e2>."
Cause-Effect(e2,e1)
Comment:

1728	 <e1>student</e1> demonstrates his/her understanding through active <e2>participation</e2> in the learning process."
Other
Comment: The feeling here is that e2 is not a method, just an event. It's a bit wooly.

1729	 <e1>lawyers</e1> entered into a <e2>scuffle</e2> over the division of AP."
Other
Comment: violates b.1 and c.3

1730	 <e1>slope</e1> is going away from the <e2>house</e2>."
Other
Comment:

1731	 are <e1>charts</e1> for all <e2>land masses</e2> on Earth, and long-distance charts for trans-oceanic travel."
Other
Comment: This is Purpose-Tool and thus Other; note "for". Charts communicate structure, if at all, not land masses.

1732	 <e1>initiative</e1>, called The Big Switch Off, aims to reduce <e2>energy consumption</e2> by turning off lights and unused appliances."
Other
Comment: initiative are not Messages.

1733	 <e1>breeding</e1> consists of <e2>concealing</e2> how much we think of ourselves and how little we think of the other person."
Cause-Effect(e1,e2)
Comment: Good breeding causes certain behaviour. (It is an iffy diagnosis.)

1734	 <e1>bruises</e1> are caused by the attacker's <e2>fingertips</e2> pressing into the skin."
Cause-Effect(e2,e1)
Comment:

1735	 rain, darkness, and or blowing snow lead to <e2>disorientation</e2>."
Cause-Effect(e1,e2)
Comment:

1736	 growth and aflatoxin <e1>contamination</e1> are caused by the following factors: warm temperature, high <e2>humidity</e2> and poor soil condition."
Cause-Effect(e2,e1)
Comment:

1737	 <e1>tides</e1> are caused by the <e2>gravitational force</e2> of the Moon."
Cause-Effect(e2,e1)
Comment:

1738	 now an SEO-minded <e1>attendee</e1> has journeyed deep into advanced SEO <e2>concepts</e2>."
Other
Comment: violates b.

1739	 the <e1>harm</e1> caused by the <e2>War</e2> on Drugs is a big task."
Cause-Effect(e2,e1)
Comment:

1740	 recently decided to work a bit outside of Visual Studio and configure a plain text <e1>editor</e1> to work with the C# <e2>compiler</e2>."
Other
Comment: e1 and e2 are interacting, but neither is really using the other

1741	 ancient <e1>temples</e1> have fallen into <e2>disrepair</e2>."
Other
Comment: violates b.1 and c.3

1742	 request to alter the voice to a great extent has resulted in exaggerated deviations from the "normally" accepted opera <e1>singer</e1>'s <e2>timbre</e2>."
Other
Comment: e2 is a property of e1.

1743	 <e1>reindeer</e1> made his television <e2>debut</e2> on NBC in 1964, when Rankin/Bass produced a stop-motion animated TV special."
Other
Comment:

1744	 yesterday in Hong Kong sold a <e1>diamond</e1> <e2>ring</e2> containing a 8.74 carat blue diamond for 3.5m pounds."
Other
Comment:

1745	 these fuels are burned, they create air <e1>pollution</e1> that contributes to global warming and causes smog, acid rain and respiratory <e2>disease</e2>."
Cause-Effect(e1,e2)
Comment:

1746	 Financial Regulator today amended the code of conduct of mortgage arrears by increasing the <e1>moratorium</e1> from six <e2>months</e2> to 12 months."
Other
Comment:

1747	 psychology, Eysenck Personality Questionnaire (EPQ) is a <e1>questionnaire</e1> to assess the personality <e2>traits</e2> of a person."
Other
Comment: Purpose.

1748	 friend got a <e1>rash</e1> from a mosquito <e2>bite</e2> and Westcort helped her but it left a scar so she also put on Mederma after the rash went away."
Cause-Effect(e2,e1)
Comment:

1749	 really underscores everything in the pro-life movement, that <e1>abortion</e1> is part of a very sad <e2>story</e2> for women."
Other
Comment:

1750	 floating zenith <e1>telescope</e1> has come into formal observatory <e2>routine</e2> since September."
Other
Comment: violates b.1 and c.3

1751	 <e1>germs</e1> cause illnesses ranging from common ailments, like the cold and <e2>flu</e2>, to disabling."
Cause-Effect(e1,e2)
Comment:

1752	 greatest impact of the tsunami was generally in an east-west direction, so the <e1>havoc</e1> caused by the <e2>tsunami</e2> along the southwestern shores of Sri Lanka was not as severe as along the eastern coast."
Cause-Effect(e2,e1)
Comment:

1753	 <e1>blisters</e1> are caused by <e2>moisture</e2> that was actually trapped in between the layers of paint."
Other
Comment:

1754	 is towards the future, and <e1>satisfaction</e1> is gained from <e2>feelings</e2> of progress."
Other
Comment:

1755	 is a disease of the body's connective tissue that causes thickening and <e2>hardening</e2> of the skin."
Cause-Effect(e1,e2)
Comment:

1756	 developmental <e1>bureaucracy</e1> has come into <e2>being</e2>."
Other
Comment: violates c.3

1757	 <e1>cramps</e1> are caused by the <e2>anxiety reaction</e2> but because the sufferer has high anxiety, they can be interpreted in other ways; fears grow and the anxiety worsens."
Cause-Effect(e2,e1)
Comment:

1758	 18 of the <e1>men</e1> assist that <e2>season</e2>."
Other
Comment:

1759	 <e1>website</e1> is concerned with the <e2>dissemination</e2> and exchange of information about the EnCoRe project."
Other
Comment: Purpose.

1760	 produced many of the bottle stopper <e1>marbles</e1> made by this <e2>method</e2>."
Other
Comment: method is not a producer and it is not actively involved in the productio

1761	 <e1>fuel leak</e1> in one of the C-17s caused a <e2>delay</e2> on the morning of Nov. 7 as the crew was preparing for departure for Cairo, Egypt."
Cause-Effect(e1,e2)
Comment:

1762	 <e2>infestation</e2> is very rarely fatal; death and morbidity are from secondary infection."
Cause-Effect(e1,e2)
Comment:

1763	 <e1>lava</e1> has been blown into great <e2>bubbles</e2>."
Other
Comment: violates c.

1764	 accounts detail the routine and perfunctory nature of arrest and proceedings against the <e1>riffraff</e1> of the "criminal <e2>classes</e2>" (Friedman and Percival)."
Other
Comment:

1765	 advance <e1>visit</e1> was made by <e2>staff</e2> to arrange the visits."
Other
Comment:

1766	 <e1>drugs</e1> he sold had caused the overdose <e2>death</e2> of Matthew Lessard, 19, of Lowell."
Cause-Effect(e1,e2)
Comment:

1767	 <e1>jar</e1> from the fall had caused a subdural <e2>hematoma</e2> on the right front side of my brain that shows up in the CT."
Cause-Effect(e1,e2)
Comment:

1768	 Hip Hop National <e1>interschool</e1> is rescheduled to the 1st <e2>week</e2> of July."
Other
Comment:

1769	 the <e1>writer</e1> behind award-winning BBC <e2>adaptations</e2> of Bleak House, Little Dorrit and Pride and Prejudice, blamed what he called a "new breed" of BBC executives."
Other
Comment:

1770	 February of 1885 the <e1>news</e1> reached the city by <e2>telegraph</e2> that Indians and half breeds had massacred a number of white people at Duck Lake."
Other
Comment: e1 is not an Agent.

1771	 his inauguration in November, he pledged a fresh start after an election marred by fraud and violence, but disappointed many by presenting a <e1>cabinet</e1> of familiar <e2>names</e2>."
Other
Comment: Double metonymy, a bit much. People are members of a government, but names are not members of a cabinet of ministers.

1772	 are caused by the <e2>discharge</e2> of accumulated along geologic faults."
Cause-Effect(e2,e1)
Comment:

1773	 <e1>outdoor unit</e1> is going into <e2>defrost</e2>."
Other
Comment: violates c.

1774	 of the lever caused by the <e2>swinging</e2> of the pendulum."
Cause-Effect(e2,e1)
Comment:

1775	 according to claim 1, characterized in that the time duration of the quality reduction is limited at least to the duration of the <e1>interference</e1> triggered by the switching <e2>process</e2>."
Cause-Effect(e2,e1)
Comment:

1776	 <e1>protests</e1> are turning into a Twitter <e2>revolution</e2> in Moldova."
Cause-Effect(e1,e2)
Comment:

1777	 <e1>landscapes</e1> are parts of the <e2>earth</e2> that were covered by glaciers during the last Ice Age."
Other
Comment:

1778	 Twitter is a powerful social <e1>medium</e1> for spreading <e2>news</e2> and information, some government agencies fear it could also be used by terrorists as a tool for communication."
Other
Comment: Purpose-Tool, so - Other; the modality is outside e1-e2

1779	 <e1>dryness</e1> causes nosebleeds, <e2>coughing</e2>, wheezing, and other short-term respiratory problems."
Cause-Effect(e1,e2)
Comment:

1780	 <e1>building</e1> was surrounded by <e2>police</e2> who arrested three people as they tried to gain access."
Other
Comment: the police is not the producer of the building

1781	 and <e1>flu</e1> cause <e2>inflammation</e2> of the mucous membranes of the nose, throat and mouth."
Cause-Effect(e1,e2)
Comment:

1782	 internal <e1>payoff</e1> is rooted in the psychological <e2>cost</e2> of preference falsification."
Other
Comment:

1783	 government has spended the following 18 months before the elections in a similar vein - shooting a whole <e1>lead</e1> of Conservative <e2>foxes</e2>, to extend the metaphor - namely Heathrow and Royal Mail privatisation."
Other
Comment: Too metaphorical.

1784	 identified the different <e1>noises</e1> made by <e2>dogs</e2> and the meanings behind them."
Cause-Effect(e1,e2)
Comment:

1785	 is a <e1>legal procedure</e1> for declaring a <e2>marriage</e2> null and void."
Other
Comment: It's a procedure, not a message - violates (d)

1786	 stored the <e1>wine</e1> in a cool <e2>temperature</e2>."
Other
Comment: temperature is not a container for wine and vice versa; nor is it Destination

1787	 <e1>company</e1> moved into the music <e2>business</e2>."
Other
Comment: violates b.

1788	 Maryland Department of the Environment has already worked to reduce the amount of <e1>pollution</e1> from sources like cars and <e2>factories</e2>."
Cause-Effect(e2,e1)
Comment:

1789	 farming</e1> is one of the main causes of tropical <e2>deforestation</e2>, which currently produces a fifth of global climate change."
Cause-Effect(e1,e2)
Comment:

1790	 encroaching <e1>darkness</e1> has been caused by the twin horrors of war and a mysterious <e2>plague</e2>."
Cause-Effect(e2,e1)
Comment:

1791	 the <e1>complex</e1> was built in <e2>stages</e2>, discrepancies exist in completion dates due to differing opinions on "completion"."
Other
Comment:

1792	 <e1>mason</e1> has removed the original left and right <e2>edges</e2> and in their place has prepared a simple moulding on each side."
Other
Comment: edges is not a product

1793	 disease is a degenerative brain <e1>disorder</e1> that results in <e2>memory loss</e2>, impaired thinking, difficulty finding the right word when speaking, and personality changes (see "Warning signs of Alzheimer's disease," below)."
Cause-Effect(e1,e2)
Comment:

1794	 clock <e1>signal</e1> was generated from an external cavity semiconductor <e2>laser</e2>."
Cause-Effect(e2,e1)
Comment:

1795	 a <e1>minority</e1> of Armenian <e2>physicians</e2> felt well prepared to counsel patients to quit smoking."
Other
Comment: Measure.

1796	 <e1>team</e1> captured the provincial title with a convincing 6-1 <e2>victory</e2> over their adversaries, the Pas Huskies."
Other
Comment: victory is an event and can't be an Instrument.

1797	 University of Washington system named Hubble looks for these black holes and maps them on a Web site, providing an ever-changing <e1>constellation</e1> of the Internet's weak <e2>points</e2>."
Other
Comment: A constellation is a spatial arrangement.

1798	 <e1>landslides</e1> caused by these earthquakes and <e2>aftershocks</e2> were concentrated along the mudstone and sandstone surfaces."
Cause-Effect(e2,e1)
Comment:

1799	 desperate <e1>man</e1> who had clung to the stump had battered the rocks with a shuddering <e2>thump</e2>."
Cause-Effect(e1,e2)
Comment: the man action has caused the thump (noise).

1800	 <e1>document</e1> makes a significant contribution into further <e2>clarification</e2> of the access to drinking water as a human right."
Other
Comment: There is a contribution to clarification, but not clarification itself. The document is about "access to drinking water". But given the e2, Other is right.

1801	 dust and <e1>fume</e1> cause irritation of the upper respiratory tract, metallic taste and <e2>nausea</e2>."
Cause-Effect(e1,e2)
Comment:

1802	 <e1>dust</e1>, noise, and sleep deprivation produced by the <e2>construction</e2> are intolerable."
Cause-Effect(e2,e1)
Comment:

1803	 NRMA's president, Wendy Machin, and the chief executive, Tony Stuart, were among members of the <e1>party</e1> which viewed the concert in a private <e2>box</e2>."
Other
Comment:

1804	 picture at the top shows a <e1>farmer</e1> with a genetically engineered cotton <e2>plant</e2> in South Africa in 2003."
Other
Comment: Product-Producer might be implicit, but there's no direct evidence.

1805	 <e1>production schemes</e1> are spreading into various <e2>crops</e2> and may have relevance for sectors such as dairy production."
Other
Comment: the crops are not the destination of the schemes - rather their object; modality is outsi

1806	 <e1>transmitter</e1> sends a radio <e2>signal</e2> to the doorbell radio receiver inside the building."
Cause-Effect(e1,e2)
Comment:

1807	 are all in on it and the same <e1>people</e1> who caused the <e2>destruction</e2> of the economy are still running the show so they can keep us down and buy up the country cheap."
Cause-Effect(e1,e2)
Comment:

1808	 two of the cases reported in the media, an older woman's baby was stillborn because of an abnormal placeta, and one of the <e1>miscarriages</e1> was caused by the umbilical <e2>chord</e2> encircling the fetus."
Cause-Effect(e2,e1)
Comment:

1809	 it was closer she saw the <e1>light</e1> was coming from a <e2>flashlight</e2> being carried in the mouth of a large black Scottie dog, its muzzle gray with age."
Cause-Effect(e2,e1)
Comment:

1810	 <e1>building</e1> leaked from every conceivable <e2>place</e2>."
Other
Comment:

1811	 goals were addressed, but the primary goal of the <e1>street</e1> <e2>furniture</e2> was to enhance the quality of life for people in Phildaelphia and the secondary goal was to increase revenue for the City of Philadelphia."
Other
Comment: Seems more "located in" than "part of

1812	 jury's <e1>deliberations</e1> were reported weekly on <e2>air</e2>."
Other
Comment: Air is a medium.

1813	 is the cause of chronic <e2>vulval pain</e2> in the absence of skin disease and infection."
Cause-Effect(e1,e2)
Comment:

1814	 movie has thrown <e1>viewers</e1> into <e2>confusion</e2>."
Other
Comment: violates b.1 and c.3

1815	 chiefs are worried about the environmental <e1>damage</e1> caused by the Olympic <e2>flame</e2>."
Cause-Effect(e2,e1)
Comment:

1816	 log truck caught <e1>fire</e1> after the <e2>collision</e2>, but the 35-year-old driver escaped before the cab became engulfed in flames."
Cause-Effect(e2,e1)
Comment:

1817	 <e1>aeroplane</e1> was withdrawn from that <e2>duty</e2> and confined to low-level flying, where it became a success."
Other
Comment:

1818	 have an additional concern about body exposure to any electromagnetic <e1>radiation</e1>, from <e2>computers</e2> and cell phones held next to the body."
Cause-Effect(e2,e1)
Comment:

1819	 <e1>spill</e1> was caused by a <e2>leak</e2> in a Kuwaiti tanker carrying 160,000 tonnes of crude, after it collided with a dredger further south on December 14."
Cause-Effect(e2,e1)
Comment:

1820	 Cormier, succumbed to peer pressure and now hangs out with the popular <e1>crowd</e1> that often instigates the <e2>harassment</e2>."
Cause-Effect(e1,e2)
Comment:

1821	 had visited Myer's during the afternoon and bought a <e1>gold</e1> <e2>bracelet</e2> for $300."
Other
Comment:

1822	 saving from the introduction of a single <e1>machine</e1> for flange hole <e2>drilling</e2> was 15500 rubles."
Other
Comment: Purpose-Tool

1823	 unexpected <e1>elimination</e1> caused a <e2>riot</e2> on the Internet, and one blog site (SOHH.com) referred to her elimination episode as the one where the show lost all credibility."
Cause-Effect(e1,e2)
Comment:

1824	 standard variable <e1>rates</e1> are still under <e2>review</e2>."
Other
Comment: a process

1825	 changed the balance of the flavours through my selection of bread, and got an <e1>increase</e1> in the sweetness with a choice of <e2>raisin bread</e2>."
Cause-Effect(e2,e1)
Comment: Why not Cause-Effect?

1826	 in rural Southern areas fell into <e2>poverty</e2> faster than those in cities in 2008."
Other
Comment: violates b.1 and c.3

1827	 <e1>inquiry</e1> into the city's job creation funding came from a reader's <e2>tip</e2>."
Cause-Effect(e2,e1)
Comment:

1828	 is very natural and normal to feel grief and <e1>sorrow</e1> after the <e2>loss</e2> of a pet."
Cause-Effect(e2,e1)
Comment:

1829	 dog, owned by Steve Abbott, the singer's manager, is stranger to music and has reacted to the <e1>sounds</e1> made by any other of Universal's top <e2>names</e2>."
Other
Comment: the names are not actively involved in the production. "... performance of previously-existing works are not considered to be creative acts.

1830	 <e1>irritation</e1> from the <e2>chemicals</e2> in the tobacco is considered to be the number one contributing factor."
Cause-Effect(e2,e1)
Comment:

1831	 exit portion of the <e1>runway</e1> is cantilevered from the support <e2>stanchion</e2>."
Other
Comment:

1832	 <e1>smell</e1> was radiating from all directions, from every <e2>tree</e2> and branch."
Cause-Effect(e2,e1)
Comment:

1833	 town's population is approximately four, the school closed years ago and <e1>birds</e1> have turned the church into a poop-caked <e2>aviary</e2>."
Other
Comment: aviary is not a product

1834	 <e1>party</e1> has made the <e2>crazies</e2> into mainstream Republicans."
Other
Comment: crazies is not a product

1835	 <e1>lymphomas</e1> are divided into two major categories: Hodgkin lymphoma and all other <e2>lymphomas</e2>, called non-Hodgkin lymphomas."
Other
Comment: The Member-Collection definition calls this "Class-Member

1836	 children sent their <e1>marriage</e1> into a <e2>downward spiral</e2>."
Other
Comment: violates c.

1837	 of women suffer <e1>headaches</e1> from <e2>caffeine withdrawal</e2> as a result of this study."
Cause-Effect(e2,e1)
Comment:

1838	 again, the infamous <e1>politician</e1> has landed into a nepotism <e2>controversy</e2>."
Other
Comment: violates b.1 and c.

1839	 to 85% of <e1>viruses</e1> that cause respiratory <e2>illness</e2> are identified by the technology."
Cause-Effect(e1,e2)
Comment:

1840	 recent years, considerable <e1>attention</e1> has been focused on regenerative <e2>medicine</e2> because of its applicability to a wide range of medical fields."
Other
Comment: violation of (a)

1841	 <e1>study</e1> is making a valuable contribution to determining the <e2>levels</e2> of sustainable tourism in this country."
Other
Comment: The study is about something, but that something is not named.

1842	 recovery plan was the commencement of a captive breeding <e1>program</e1> from a small wild <e2>population</e2>."
Other
Comment:

1843	 <e1>disruption</e1> has been caused by the freak storms and flash <e2>floods</e2> overnight."
Cause-Effect(e2,e1)
Comment:

1844	 organization with the mission of allowing a safe haven for parents to share their <e1>grief</e1> after the <e2>death</e2> of a child."
Cause-Effect(e2,e1)
Comment:

1845	 have been talking extensively here about the <e1>disruption</e1> that has been caused by the Brazilian Air Traffic Controllers white <e2>strike</e2>."
Cause-Effect(e2,e1)
Comment:

1846	 <e1>detectives</e1> have been dragged into a mysterious <e2>case</e2>."
Other
Comment: violates b.

1847	 are considering new <e1>limits</e1> on <e2>stem cell research</e2>."
Other
Comment:

1848	 <e1>pollution</e1> from <e2>coal</e2> fired sources is so serious we can not afford a policy that backslides in any way."
Cause-Effect(e2,e1)
Comment:

1849	 <e1>satellite</e1> has been placed into <e2>service</e2>."
Other
Comment: violates b.1 and c.3

1850	 these cases, marriages performed in the <e1>temple</e1> by a duly authorized temple <e2>sealer</e2> are recognized by the government."
Other
Comment: the sealer is not a producer of the temple

1851	 viral <e1>infections</e1> that cause <e2>rash</e2> resolve within several days and require no medication."
Cause-Effect(e1,e2)
Comment:

1852	 kind of treatments necessary to kill the <e1>bacteria</e1> which cause acne <e2>breakouts</e2> must be prescribed or administered by a medical professional."
Cause-Effect(e1,e2)
Comment:

1853	 <e1>opposition leader</e1> has gone into <e2>hiding</e2>."
Other
Comment: violates b.1 and c.

1854	 had another <e1>idea</e1> to do with <e2>child care</e2> that was stroller related."
Other
Comment: violation of (b).

1855	 just sold a <e1>gold</e1> <e2>ring</e2>, which was my last asset and now we have nothing left for a better life."
Other
Comment:

1856	 is caused by the <e2>eyelids</e2> sliding down over the positively charged cornea, whereas saccade potentials are caused by changes in the orientation of the corneoretinal dipole."
Cause-Effect(e2,e1)
Comment:

1857	 surprise <e1>visit</e1> caused a <e2>frenzy</e2> on the already chaotic trading floor."
Cause-Effect(e1,e2)
Comment:

1858	 I am trying to get a week <e1>number</e1> from a given <e2>date</e2>."
Other
Comment:

1859	 agenda of deeper reforms can boost public confidence even as it undoes a lot of the <e1>distress</e1> caused by the financiers and <e2>bankers</e2>."
Cause-Effect(e2,e1)
Comment:

1860	 sure to drink plenty of water to prevent running a <e1>fever</e1> from <e2>dehydration</e2>."
Cause-Effect(e2,e1)
Comment:

1861	 first <e1>sighting</e1> of the mighty Mount Kinabalu was from quite a <e2>distance</e2> and it was still extremely impressive."
Other
Comment:

1862	 consequences of the <e1>injuries</e1> caused by the <e2>bike-accident</e2> in February, fractures in the area of head and neck, unfortunately have turned out to be still too severe."
Cause-Effect(e2,e1)
Comment:

1863	 <e1>agency</e1> also provides a third of the region's power <e2>supply</e2>, drawn mostly from generators inside big dams."
Other
Comment: agency is not a producer

1864	 people know and understand their <e1>rights</e1> on issues such as <e2>benefits</e2>, housing and employment."
Other
Comment: A kind of.

1865	 passenger set off the <e1>devices</e1> at Detroit Metropolitan Airport, causing a <e2>commotion</e2> and some injuries."
Other
Comment:

1866	 <e1>association</e1> keeps teachers informed about current <e2>developments</e2>."
Other
Comment:

1867	 amide-linked local <e1>anesthetics</e1>, bupivacaine and ropivacaine, cause <e2>depression</e2> of cardiac contractility and dysrhythmias."
Cause-Effect(e1,e2)
Comment:

1868	 the transistor radio you listened to under the <e1>pillow</e1> of your <e2>bed</e2> to streamcasts on the Net, Fisher covers it all, and extremely well."
Other
Comment:

1869	 functionalist <e1>approach</e1> tries to explain the <e2>convergence</e2> of modern welfare states."
Other
Comment: Internalized -- see restriction (b).

1870	 of the <e1>suffering</e1> caused by unmindful <e2>drinking</e2>, I am committed to cultivate good health, both physical and mental, for myself, my family, and my society."
Cause-Effect(e2,e1)
Comment:

1871	 <e1>configuration</e1> of <e2>dominoes</e2> is called the layout, string, or line of play."
Other
Comment:

1872	 executive director for life of the Eclipse Foundation (just kidding Mike) broke the <e1>news</e1> today in his <e2>blog</e2>."
Other
Comment: A blog is a communication channel.

1873	 root and chamomile provide a gentle astringent that helps reduce inflammation and calms skin <e1>irritation</e1> from the <e2>sun</e2> and environmental pollutants."
Cause-Effect(e2,e1)
Comment:

1874	 <e1>colitis</e1> usually is caused by taking <e2>antibiotics</e2>."
Cause-Effect(e2,e1)
Comment:

1875	 lowly structure is preserved and protected from decay by having built over it an outer <e1>structure</e1> surmounted by a great <e2>dome</e2> of glass."
Other
Comment: dome is not a producer

1876	 <e1>protein molecule</e1> has come into <e2>existence</e2> by natural processes."
Other
Comment: violates c.3

1877	 halting of easy <e1>profits</e1> from <e2>inflation</e2> brought on a banking crisis, which resulted in a complete restructuring of the industry during the late 1990s."
Cause-Effect(e2,e1)
Comment:

1878	 the <e1>fire</e1> after the <e2>earthquake</e2> burned out 7456 houses in over 530 localities."
Cause-Effect(e2,e1)
Comment:

1879	 <e1>hero</e1> initially attempts to stop the train with his own <e2>strength</e2>, but fails miserably and doesn't slow the train down."
Other
Comment:

1880	 under the same influence, it was in the natural <e1>order</e1> of <e2>events</e2> that John, a little later, recorded his awakening into the new life at a religious meeting at a quarter before nine o'clock on the evening of May 24th 1738."
Other
Comment:

1881	 northwest <e1>swell</e1> was generated by a powerful <e2>storm</e2> off Japan on Jan. 5 and gained strength last week."
Cause-Effect(e2,e1)
Comment:

1882	 the same way that diet and <e1>stress</e1> effect facial <e2>acne</e2> they also effect body acne therefore the basic "clear skin rules" of cutting out greasy, fatty foods, and sugary foods as well as trying to reduce everyday stress apply to body acne as well."
Cause-Effect(e1,e2)
Comment:

1883	 latest <e1>adventure</e1> from the animation <e2>wizards</e2> at Pixar is beautiful, masterly, inspired - and delivers a powerful ecological message."
Other
Comment: no product-producer is involved

1884	 with <e2>color</e2> has become a common trend these days."
Other
Comment:Purpose-Tool

1885	 height-time profiles revealed that the <e1>downflow</e1> started at <e2>times</e2> of the deceleration phase of the CME core."
Other
Comment:

1886	 <e1>team</e1> won the Association's championship with some <e2>regularity</e2>."
Other
Comment:

1887	 <e1>wire</e1> had caused a slight <e2>injury</e2> on the ventral side of the neck and at the base of horns."
Cause-Effect(e1,e2)
Comment:

1888	 industrial chemical <e1>melamine</e1> was found in a <e2>sample</e2> of infant formula made in the USA."
Other
Comment: not a container (so cannot be C-C), and substances can't be components (so cannot be C-W)

1889	 buys all these glittering <e1>diamond</e1> <e2>colliers</e2>, rings, pendants, etc., eto., is. a mystery."
Other
Comment:

1890	 Communications is an advertising <e1>agency</e1> specialized in TV <e2>ads</e2>, outdoors, media, marketing, consulting, press, etc..."
Other
Comment:

1891	 spread is mainly airborne, via the virus-laden <e1>droplets</e1> produced by coughing and <e2>sneezing</e2>."
Other
Comment: sneezing is a process

1892	 articles specifically on gas corrosion and <e1>stress</e1> <e2>corrosion</e2> are also available in the literature."
Cause-Effect(e1,e2)
Comment:

1893	 also uses the <e1>intranet</e1> to inform staff about <e2>training opportunities</e2> or forthcoming staff events."
Other
Comment: Here we have a channel rather than a message.

1894	 kiosk was placed at a statewide <e1>convention</e1> of science <e2>teachers</e2> and in a high school science classroom."
Other
Comment: Participants -- not members: participants as agents or co-agents in an event.

1895	 built forts and tree <e1>houses</e1> in the <e2>woods</e2> out of materials swiped from the construction sites that would eventually render those woods someone's back yard."
Other
Comment: Houses are located in the woods. modality is outside

1896	 <e1>woman</e1> was recovering from a bullet <e2>wound</e2> after she was caught in the cross-fire of a shootout."
Other
Comment:

1897	 was digging up the <e1>earth</e1> to throw into the <e2>cradle</e2>, when I turned up a lump of ore about the size of a small walnut, which I knew at once was a piece of gold."
Other
Comment: modality is outside

1898	 Mary found a pocketknife in the compartment and a straw from her <e1>soda</e1> <e2>drink</e2> now spilled everywhere."
Other
Comment:

1899	 four superb performers - and at the end it's almost impossible to believe there have been so few of them - present a wordless show that is like a <e1>circus</e1> of human <e2>dreams</e2> and nightmares."
Other
Comment: Dreams are events and cannot be regarded as part of a collection; modality and negation are outsid

1900	 <e1>trawl</e1> through ancient copies of the Herts Advertiser threw up a treasure <e2>trove</e2> of information about the early days of the city's first ever cinema."
Other
Comment:

1901	 unwillingness to fund on a secured basis placed stress on the <e1>liquidity</e1> of the <e2>firm</e2>."
Other
Comment: Liquidity is a state or property.

1902	 sold a <e1>gold</e1> <e2>ring</e2> she received as a gift from her company and her old '80s style chains."
Other
Comment:

1903	 <e1>dialect</e1> spoken in the South Karelian Region of Finland is part of the South Eastern dialects of the Finnish <e2>language</e2>."
Other
Comment:

1904	 change</e1> is the topic of the <e2>day</e2>."
Other
Comment: This is time, or period -- not a message.

1905	 promised bride was already in great <e1>peril</e1> from the twisted love of an insane <e2>suitor</e2>."
Other
Comment:

1906	 <e1>bees</e1> eating ordinary <e2>honey</e2> live only four to six weeks."
Other
Comment: honey is not being produced

1907	 report the second case of ureteropelvic junction <e1>obstruction</e1> after radiofrequency <e2>ablation</e2> that resulted in nephrectomy."
Other
Comment:

1908	 <e1>lighting</e1> in the <e2>shop</e2> was dim and the walls were covered with shelves which were covered with shoes."
Other
Comment:

1909	 statement threw <e1>people</e1> into <e2>chaos</e2>."
Other
Comment: violates c.3

1910	 concert closes with the young <e1>composer</e1>'s take on another <e2>aria</e2> from Guilio Cesare, the notoriously tricky Al lampo dell'armi."
Other
Comment: aria is not a product of the composer

1911	 younger <e1>female</e1> got out rather easily from the <e2>cuffs</e2> and massaged her wrists."
Other
Comment:

1912	 hand-cranked <e1>churn</e1> produced smoother <e2>ice cream</e2> than the pot freezer and did it quicker."
Other
Comment: the churn itself is not actively involved in the making of ice cream

1913	 is the way of <e1>deliverance</e1> from vicious <e2>cycles</e2> of anger and insult."
Other
Comment:

1914	 <e1>kids</e1> dug into the Baked Ziti with <e2>gusto</e2>."
Other
Comment: manner.

1915	 <e1>cockpit</e1> accommodated a <e2>crew</e2> of three, including pilot, radar operator, and sensor operator."
Other
Comment: no evidence for content-container

1916	 geography</e1> examines the <e2>natural environment</e2> and how the climate, vegetation & life, soil, water, and landforms are produced and interact."
Other
Comment: Sciences are not messages.

1917	 the <e1>man</e1> was put into an Interpol red flag <e2>list</e2>."
Other
Comment: This cannot be Entity-Destination since it violates E-D's b.

1918	 <e1>continent</e1> has sunk into deep economic <e2>abyss</e2>."
Other
Comment: violates b.1 and c.3

1919	 are under way to establish the <e2>identity</e2> of human remains found by police in woodland in Surrey."
Other
Comment: here "investigation" is an activity/process - violation of (d)

1920	 managed to squeeze decent <e1>photos</e1> out of an <e2>iPhone</e2>."
Other
Comment:

1921	 <e1>auction</e1> started at the ungodly <e2>hour</e2> of 10 am, which I'm guessing ensures no one will show up after hitting the bars and bid drunk."
Other
Comment: modality and negatio are outsid

1922	 the <e1>buttonhole</e1> accommodated a <e2>button</e2> sewn to the underside of the opposite lapel, thus allowing a man to button all the way up in brisk weather."
Other
Comment: modality is outside

1923	 established a new administrative system, sent a regiment of regular troops which quelled the lroquois, and then invested vast sums in economicdevelopment, establishing new industries such as lumbering and shipbuilding and subsidizing the immigration of skilled and unskilled labor, and marriageable girls for the <e1>superfluity</e1> of <e2>bachelors</e2>."
Other
Comment:

1924	 store the <e1>information</e1> in the <e2>variable</e2> in your source code."
Other
Comment:

1925	 <e1>scepticism</e1> in regard to the <e2>liberal reforms</e2> of the sixties made him very unpopular among the more progressive writers of that time."
Other
Comment: attitude, not communication

1926	 the Fifties, they developed a <e1>technique</e1> for treating blood with <e2>ozone</e2> called 'major autohemotherapy'."
Other
Comment: Purpose-Tool

1927	 have thrown <e1>mankind</e1> into deeper <e2>bondage</e2> than ever."
Other
Comment: violates c.3

1928	 attacking the Walthers <e1>kit</e1> with a razor <e2>saw</e2>, however, let's take care of some other important layout details."
Other
Comment:

1929	 LEAST 140000 <e1>homeowners</e1> have fallen into negative <e2>equity</e2>."
Other
Comment: violates b.1 and c.3

1930	 <e1>parties</e1> were taken into <e2>confidence</e2> over Swat offensive."
Other
Comment: violates c.3

1931	 CCCB is an institution that organizes contemporary cultural <e1>events</e1> and exhibitions with regard to <e2>music</e2>, dance, debates and readings."
Other
Comment: To be in relation to, or have a relation with, does not mean to be a topic of

1932	 <e1>azithromycin</e1> -induced <e2>ototoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1933	 while Paget's bone disease was present, and perhaps enhanced activation of <e1>dihydrotachysterol</e1> by rifampicin, could have led to <e2>increased calcium-release</e2> into the circulation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1934	 severe <e1>hypercalcemia</e1> in a patient treated for hypoparathyroidism with <e2>dihydrotachysterol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1935	 We report two cases of <e1>pseudoporphyria</e1> caused by <e2>naproxen</e2> and oxaprozin."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1936	 We report two cases of <e1>pseudoporphyria</e1> caused by naproxen and <e2>oxaprozin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1937	 the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating <e2>erythropoietic protoporphyria</e2> in the pediatric population."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1938	 A 44-year-old man taking <e1>naproxen</e1> for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and <e2>cutaneous fragility</e2> on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1939	 A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on <e1>oxaprozin</e1> for rheumatoid arthritis presented with tense bullae and <e2>cutaneous fragility</e2> on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1940	 A 44-year-old man taking <e1>naproxen</e1> for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with <e2>tense bullae</e2> and cutaneous fragility on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1941	 A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on <e1>oxaprozin</e1> for rheumatoid arthritis presented with <e2>tense bullae</e2> and cutaneous fragility on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1942	 How to best treat psychotic patients who have had past <e1>clozapine</e1> -induced agranulocytosis or <e2>granulocytopenia</e2> remains a problem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1943	 The results suggest that olanzapine may be useful in treating patients with <e1>clozapine</e1> -induced <e2>granulocytopenia</e2> without the risk of recurrence of hematologic side effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1944	 severe <e1>5-fluorouracil</e1> -associated <e2>neurotoxicity</e2> in a patient with dihydropyrimidine dehydrogenase deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1945	 describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and <e2>neurologic toxicity</e2> that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1946	 describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, <e2>prolonged myelosuppression</e2>, and neurologic toxicity that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1947	 describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered <e2>severe mucositis</e2>, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1948	 case suggests that <e1>BH-AC</e1>, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible <e2>encephalopathy syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1949	 report a case of reversible <e1>encephalopathy syndrome</e1> in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of <e2>BH-AC</e2> (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1950	 report a case of reversible <e1>encephalopathy syndrome</e1> in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and <e2>idarubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1951	 one case, the readministration of <e1>riluzole</e1> was followed by the relapse of <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1952	 report the cases of two patients who developed acute <e1>hepatitis</e1> after taking <e2>riluzole</e2> at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1953	 syndrome</e1> caused by <e2>5-aminosalicylic acid</e2> in patients with inflammatory bowel disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1954	 the two local anesthetics usually do not cause <e1>methemoglobinemia</e1>, we suspect that the displacement of <e2>lidocaine</e2> from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1955	 after axillary block with <e2>bupivacaine</e2> and additional injection of lidocaine in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1956	 after axillary block with bupivacaine and additional injection of <e2>lidocaine</e2> in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1957	 report a patient with chronic renal failure and ischemic heart disease who developed clinically significant <e1>methemoglobinemia</e1> after an axillary block with <e2>bupivacaine</e2> and additional injection of lidocaine in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1958	 report a patient with chronic renal failure and ischemic heart disease who developed clinically significant <e1>methemoglobinemia</e1> after an axillary block with bupivacaine and additional injection of <e2>lidocaine</e2> in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1959	 of activated eosinophils in nasal polyps of an <e1>aspirin</e1> -induced <e2>asthma</e2> patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1960	 episode of subacute <e1>encephalopathy</e1> after the infusion of a moderate dose of <e2>methotrexate</e2> (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1961	 believe that this represents an unusual case of moderate-dose <e1>MTX</e1> -induced <e2>neurotoxicity</e2> in a patient with gastric cancer, which has not previously been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1962	 describe a life threatening side effect of acute <e1>epoprostenol</e1> infusion (<e2>pulmonary edema</e2>) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1963	 14-year-old girl with newly diagnosed SLE developed a <e1>pruritic bullous eruption</e1> while on <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1964	 -induced <e2>acute interstitial pneumonitis</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1965	 clinical course suggests that the <e1>interstitial pneumonitis</e1> was induced by <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1966	 is the first case of <e1>hydroxyurea</e1> -induced <e2>acute interstitial pneumonitis</e2> reported in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1967	 and <e1>irritant contact dermatitis</e1> to <e2>calcipotriol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1968	 (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas <e2>allergic reactions</e2> are less common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1969	 (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause <e2>irritation of the skin</e2>, whereas allergic reactions are less common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1970	 present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an <e1>irritant type of reaction</e1> after treatment with <e2>calcipotriol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1971	 associated with sarcoidosis: marked exacerbation with <e2>pravastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1972	 is associated with <e2>myotonia</e2> in animals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1973	 case suggests that sarcoidosis and <e1>pravastatin</e1>, two entities not frequently associated with <e2>myotonia</e2>, may interact in a synergistic manner to produce severe clinical <e2>myotonia</e2> in humans."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1974	 to <e1>aspirin</e1> can be manifested as acute asthma, urticaria and/or <e2>angioedema</e2>, or a systemic anaphylactoid reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1975	 to <e1>aspirin</e1> can be manifested as acute asthma, urticaria and/or angioedema, or a <e2>systemic anaphylactoid reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1976	 to <e1>aspirin</e1> can be manifested as acute asthma, <e2>urticaria</e2> and/or angioedema, or a systemic anaphylactoid reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1977	 Fixed drug <e1>eruption</e1> is associated with many drugs but this is the first such report with <e2>omeprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1978	 drug <e1>eruption</e1> in hands caused by <e2>omeprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1979	 objective of this report is to describe a case of fixed drug <e1>eruption</e1> that occurred during <e2>omeprazole</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1980	 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with <e1>diffuse erythema</e1> and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1981	 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and <e1>fever up to 39 degrees C</e1> one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1982	 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, <e1>malaise</e1>, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1983	 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and <e1>pustules</e1> on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1984	 generalized exanthematous pustulosis</e1> induced by <e2>salazosulfapyridine</e2> in a patient with ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1985	 report a case of <e1>acute generalized exanthematous pustulosis</e1> (AGEP) induced by <e2>salazosulfapyridine</e2> in a patient with ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1986	 SUMMARY: A 39-year-old white Jewish schizophrenic man treated with <e1>olanzapine</e1> developed an <e2>elevated serum CK concentration</e2> with a peak concentration of 4000 IU/L (normal < 230)."
DRUG-ADE(e1,e2)
Comment: DRUG-

1987	 <e1>Olanzapine</e1>, like other atypical antipsychotic drugs, may cause <e2>muscle injury with concomitant elevations of serum CK</e2> of muscle origin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1988	 <e1>elevation of serum creatine kinase</e1> associated with <e2>olanzapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1989	 To report a case of marked <e1>elevation of serum creatine kinase</e1> (CK) associated with <e2>olanzapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1990	 -associated <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1991	 patient, who had a history of osteoarthritis, had severe <e1>hepatitis</e1> 5 weeks after being started on <e2>diclofenac</e2> for increasing pain in the joints."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1992	 induces <e2>lymphocytopenia</e2>, which may explain the improvement in this patient's psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1993	 case of <e1>priapism</e1> occurred during <e2>heparin</e2> therapy for a previous surgical operation to the knee is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1994	 as a complication of <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1995	 association between <e1>heparin</e1> and priapism is often recognized; <e2>abnormal platelet aggregation</e2> could play a role in the pathogenesis of this side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1996	 association between <e1>heparin</e1> and <e2>priapism</e2> is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1997	 carries a well-known risk of neutropenia and <e1>agranulocytosis</e1>, which necessitates the immediate discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1998	 carries a well-known risk of <e1>neutropenia</e1> and agranulocytosis, which necessitates the immediate discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1999	 We report a patient who developed neutropenia on <e1>clozapine</e1>, but behind the cell count decrease showed to be a <e2>diurnal variation of the white blood cells</e2> (WBC)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2000	 neutrophilic dermatosis</e1> induced by <e2>all-trans-retinoic acid</e2> treatment for acute promyelocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2001	 on discontinuation and rechallenge supported the assumption that the <e1>hair loss</e1> was a side effect of the <e2>paroxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2002	 loss</e1> associated with <e2>paroxetine</e2> treatment: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2003	 report on a 37-year-old female who complained of moderate <e1>hair loss</e1> during <e2>paroxetine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2004	 Patients with <e1>insulin</e1> allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant <e2>protamine allergy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2005	 The patient required <e1>insulin</e1> desensitization for severe urticaria, <e2>angioedema</e2>, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2006	 The patient required <e1>insulin</e1> desensitization for severe urticaria, <e2>angioedema</e2>, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2007	 The patient required <e1>insulin</e1> desensitization for <e2>severe urticaria</e2>, angioedema, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2008	 The patient required <e1>insulin</e1> desensitization for <e2>severe urticaria</e2>, angioedema, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2009	 The patient required <e1>insulin</e1> desensitization for severe urticaria, angioedema, and occasional <e2>wheezing</e2> resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2010	 The patient required <e1>insulin</e1> desensitization for severe urticaria, angioedema, and occasional <e2>wheezing</e2> resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2011	 The purpose of this study was to determine whether desensitization to NPH <e1>insulin</e1>, as well as standard <e1>insulin</e1> desensitization, could control <e2>allergic symptoms</e2> in a patient allergic to both NPH and regular <e1>insulin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2012	 The purpose of this study was to determine whether desensitization to <e1>NPH insulin</e1>, as well as standard insulin desensitization, could control <e2>allergic symptoms</e2> in a patient allergic to both NPH and regular insulin."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2013	 receiving <e1>neutral protamine Hagedorn (NPH) insulin</e1> are at increased risk for the development of <e2>protamine hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2014	 allergy</e1> as a complication of <e2>insulin</e2> hypersensitivity: A case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2015	 continued to receive regular <e1>insulin</e1> 4 times per day over the following 3 years with only occasional <e2>hives</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2016	 patient had recurrence of urticaria and <e1>angioedema</e1> a year and a half later, at which point the NPH was stopped and she was desensitized to regular <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2017	 patient had recurrence of urticaria and <e1>angioedema</e1> a year and a half later, at which point the <e2>NPH</e2> was stopped and she was desensitized to regular insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2018	 patient had recurrence of <e1>urticaria</e1> and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2019	 patient had recurrence of <e1>urticaria</e1> and angioedema a year and a half later, at which point the <e2>NPH</e2> was stopped and she was desensitized to regular insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2020	 5-month-old infant became <e1>lethargic</e1> and poorly responsive after receiving 1 drop of <e2>brimonidine</e2> in each eye."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2021	 5-month-old infant became lethargic and <e1>poorly responsive</e1> after receiving 1 drop of <e2>brimonidine</e2> in each eye."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2022	 11-day-old infant became lethargic and <e1>apneic</e1> after a single drop of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2023	 11-day-old infant became <e1>lethargic</e1> and apneic after a single drop of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2024	 <e1>central nervous system depression</e1> in infants after the use of topical <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2025	 Topical <e1>brimonidine</e1> may be associated with <e2>central nervous system depression</e2> in infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2026	 To report two cases in which topical <e1>brimonidine</e1> resulted in apparent <e2>central nervous system depression</e2> and unresponsiveness in an infant."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2027	 was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of <e1>ceftriaxone</e1> with <e2>elevated hepato-biliary enzymes</e2> and transient biliary stasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2028	 was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of <e1>ceftriaxone</e1> with elevated hepato-biliary enzymes and <e2>transient biliary stasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2029	 abnormalities</e1> secondary to <e2>ceftriaxone</e2> use: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2030	 lumbosacral radiculopathy</e1> after intrathecal <e2>methotrexate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2031	 are three children who developed <e1>progressive paraparesis</e1> after intrathecal <e2>methotrexate</e2> administration followed by complete or partial recovery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2032	 the first days of <e1>arsenic trioxide</e1> treatment a rapid <e2>decrease in the D-dimers</e2> was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2033	 the first days of <e1>arsenic trioxide</e1> treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a <e2>slight decrease in peripheral blood leukocytes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2034	 22-year-old black man developed fever, <e1>chills</e1>, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2035	 22-year-old black man developed fever, chills, <e1>fatigue</e1>, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2036	 22-year-old black man developed <e1>fever</e1>, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2037	 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a <e1>generalized, pruritic, macular eruption</e1> 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2038	 22-year-old black man developed fever, chills, fatigue, <e1>night sweats</e1>, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2039	 the negative viral serologies, the clinical picture was most consistent with an infectious <e1>mononucleosis-like syndrome</e1> produced by the<e2> minocycline</e2> ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2040	 conclude that the presence of this metabolic defect combined with topical <e1>5-FU</e1> (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of <e2>life-threatening toxicity</e2> after treatment with a topical drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2041	 now report the first known cancer patient who developed <e1>life-threatening complications</e1> after treatment with topical <e2>5-FU</e2> and was shown subsequently to have profound DPD deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2042	 <e1>acute ischaemic event</e1> associated with the use of <e2>venlafaxine</e2>: a case report and proposed pathophysiological mechanisms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2043	 association of <e1>venlafaxine</e1> treatment with <e2>ischaemic events</e2> could be explained by its unique pharmacological and haemodynamic properties."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2044	 is the first report of a possible association between an <e1>acute cardiovascular event</e1> and <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2045	 present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with <e1>venlafaxine</e1>, and developed <e2>acute myocardial ischaemia</e2> within the first week of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2046	 <e1>cyclophosphamide</e1> (cytoxan) <e2>embryopathy</e2>: a distinct phenotype?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2047	 purpose of this report is to document a new case of in utero <e1>CP</e1> exposure with multiple congenital anomalies and to establish an apparent <e1>CP</e1> <e2>embryopathy</e2> phenotype."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2048	 purpose of this report is to document a new case of in utero <e1>CP</e1> exposure with <e2>multiple congenital anomalies</e2> and to establish an apparent <e1>CP</e1> embryopathy phenotype."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2049	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, <e2>blepharophimosis</e2>, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2050	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, <e2>craniosynostosis</e2>, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2051	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, <e2>developmental delay</e2>, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2052	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and <e2>distal limb defects</e2> including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2053	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, <e2>flat nasal bridge</e2>, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2054	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including <e2>hypoplastic thumbs</e2> and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2055	 reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and <e2>oligodactyly</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2056	 conclude that (a) <e1>cyclophosphamide</e1> is a <e2>human teratogen</e2>, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2057	 all cases, <e1>seizures</e1> were controlled by withdrawal of <e2>phenytoin</e2> and reduction of drug levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2058	 <e1>seizures</e1> in <e2>phenytoin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2059	 present three patients with paradoxical <e1>seizures</e1>; their serum <e2>phenytoin</e2> levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2060	 This case suggests that <e1>losartan</e1> can induce late-onset <e2>angioedema</e2> in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2061	 -induced <e2>angioedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2062	 To report a case of <e1>angioedema</e1> associated with <e2>losartan</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2063	 incidence of <e1>angioedema</e1> secondary to <e2>losartan</e2>, an angiotensin II receptor antagonist, is unknown."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2064	 report the case of a female acromegalic patient in whom multiple <e1>hepatic adenomas</e1> appeared soon after <e2>danazol</e2> treatment for uterine fibromatosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2065	 -induced <e2>thrombocytopenia</e2> is a rare and serious complication of anticoagulation therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2066	 <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>: management with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2067	 remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>, especially in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2068	 report the successful treatment of <e1>heparin</e1> -induced thrombocytopenia and subsequent <e2>hemorrhagic complications</e2> postoperatively in a 2-year-old child with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2069	 report the successful treatment of <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2070	 -induced <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2071	 report a case of <e1>glaucoma</e1> induced by <e2>doxetaxel</e2> therapy for metastatic breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2072	 <e1>hyperphosphatemia</e1> caused by <e2>sodium phosphate</e2> enema in a patient with liver dysfunction and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2073	 report a case of acute <e1>hyperphosphatemia</e1> secondary to rectal administration of sodium phosphate and <e2>sodium biphosphate</e2> (Fleet enema)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2074	 report a case of acute <e1>hyperphosphatemia</e1> secondary to rectal administration of <e2>sodium phosphate</e2> and sodium biphosphate (Fleet enema)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2075	 of the QT interval</e1> and ventricular tachyarrhymias have been described in patients on <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2076	 of the QT interval and <e1>ventricular tachyarrhymias</e1> have been described in patients on <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2077	 report a case of recurrent <e1>torsades de pointes</e1> following treatment with pentavalent antimonial drugs and <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2078	 is given to the differentiation of <e1>diphenylhydantoin</e1> induced <e2>gingival hyperplasia</e2> from the angiomatous enlargement of the gingiva before any treatment is planned."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2079	 66-year-old Japanese woman with severe scleroderma developed <e1>anemia</e1> and thrombocytopenia due to D-penicillamine (<e2>D-Pen</e2>) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2080	 66-year-old Japanese woman with severe scleroderma developed <e1>anemia</e1> and thrombocytopenia due to <e2>D-penicillamine</e2> (D-Pen) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2081	 66-year-old Japanese woman with severe scleroderma developed anemia and <e1>thrombocytopenia</e1> due to D-penicillamine (<e2>D-Pen</e2>) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2082	 66-year-old Japanese woman with severe scleroderma developed anemia and <e1>thrombocytopenia</e1> due to <e2>D-penicillamine</e2> (D-Pen) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2083	 of <e1>D-Pen</e1> and the start of corticosteroid therapy were followed by recovery from <e2>bicytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2084	 vitro <e1>inhibition of hematopoiesis</e1> in a patient with systemic sclerosis treated with <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2085	 findings suggest that <e1>bicytopenia</e1> in this patient was caused by <e2>D-Pen</e2> and may be due to different sensitivities in the hematopoietic lineage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2086	 48-year-old woman who was treated for thyrotoxicosis with <e1>methimazole</e1> developed <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2087	 <e1>hypocalcemic tetany</e1> caused by fleet phospho-soda preparation in a patient taking <e2>alendronate sodium</e2>: report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2088	 <e1>hypocalcemic tetany</e1> caused by <e2>fleet phospho-soda</e2> preparation in a patient taking alendronate sodium: report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2089	 case report describes a patient who was previously prescribed <e1>alendronate</e1> (Fosamax) and presented with postoperative hypophosphatemia and <e2>hypocalcemic tetany</e2> after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2090	 case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and <e1>hypocalcemic tetany</e1> after bowel preparation with <e2>Fleet Phospho-Soda</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2091	 case report describes a patient who was previously prescribed alendronate (<e1>Fosamax</e1>) and presented with postoperative hypophosphatemia and <e2>hypocalcemic tetany</e2> after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2092	 case report describes a patient who was previously prescribed <e1>alendronate</e1> (Fosamax) and presented with postoperative <e2>hypophosphatemia</e2> and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2093	 case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative <e1>hypophosphatemia</e1> and hypocalcemic tetany after bowel preparation with <e2>Fleet Phospho-Soda</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2094	 case report describes a patient who was previously prescribed alendronate (<e1>Fosamax</e1>) and presented with postoperative <e2>hypophosphatemia</e2> and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2095	 here are 2 patients who developed <e1>thrombotic microangiopathy</e1> of the kidneys after receiving high cumulative doses of the new anticancer drug <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2096	 microangiopathy with <e1>renal failure</e1> in two patients undergoing <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2097	 microangiopathy</e1> with renal failure in two patients undergoing <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2098	 first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom <e1>B-cell non-Hodgkin's lymphoma</e1> was diagnosed 9 months after treatment with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2099	 relationship between <e1>infliximab</e1> treatment and <e2>lymphoma</e2> in Crohn's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2100	 second is a 29-year-old man with CD in whom <e1>nodular sclerosing Hodgkin's lymphoma</e1> was diagnosed 3 weeks after infusion with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2101	 describe the clinical course of 2 patients with Crohn's disease (CD) in whom <e1>lymphoma</e1> was diagnosed after treatment with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2102	 intoxication in the neonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2103	 report a case of <e2>codeine</e2> intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2104	 (HU) and sodium phenylbutyrate (SPB) have been shown to <e2>increase fetal hemoglobin</e2> (Hb F) levels in patients with thalassemia intermedia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2105	 (HU) and <e1>sodium phenylbutyrate</e1> (SPB) have been shown to <e2>increase fetal hemoglobin</e2> (Hb F) levels in patients with thalassemia intermedia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2106	 the four patients who responded to <e1>HU</e1> with an <e2>increase in total Hb</e2>, all reported symptomatic improvement and three have not required further transfusions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2107	 responses were achieved with low doses of <e1>HU</e1> (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or <e2>hepatic toxicity</e2> and no further increases in Hb."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2108	 responses were achieved with low doses of <e1>HU</e1> (3-10 mg/kg/day) and higher doses were associated with <e2>mild reversible hematologic</e2> or hepatic toxicity and no further increases in Hb."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2109	 phenylbutyrate was added to treatment with <e1>HU</e1> in two patients, but failed to produce an increase in total Hb despite <e2>increasing Hb F</e2> levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2110	 phenylbutyrate</e1> was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite <e2>increasing Hb F</e2> levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2111	 conclude that low-dose <e1>HU</e1> therapy in patients with thalassemia intermedia may <e2>increase total Hb</e2> levels sufficiently to eliminate the need for transfusions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2112	 describe the clinical response, as determined by <e1>increases in total Hb</e1> and decreased transfusion needs, in five patients with thalassemia intermedia treated with <e2>HU</e2> alone or in combination with SPB."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2113	 describe the clinical response, as determined by <e1>increases in total Hb</e1> and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with <e2>SPB</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2114	 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of <e1>oolong tea</e1> that eventually reached 15 L each day, became <e2>delirious</e2> and was admitted to a psychiatric hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2115	 abstinence from <e1>oolong tea</e1> his <e2>delirium</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2116	 rhabdomyolysis following massive ingestion of oolong tea: <e2>caffeine</e2> intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2117	 rhabdomyolysis following massive ingestion of <e1>oolong tea</e1>: <e2>caffeine intoxication</e2> with coexisting hyponatremia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2118	 <e1>rhabdomyolysis</e1> following massive ingestion of oolong tea: <e2>caffeine</e2> intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2119	 <e1>rhabdomyolysis</e1> following massive ingestion of <e2>oolong tea</e2>: caffeine intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2120	 clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the <e2>delirium</e2>, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2121	 clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe <e2>hyponatremia</e2> has been reported to cause rhabdomyolysis on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2122	 clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the <e2>rhabdomyolysis</e2> as well as the delirium, although severe hyponatremia has been reported to cause <e2>rhabdomyolysis</e2> on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2123	 clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the <e2>rhabdomyolysis</e2> as well as the delirium, although severe hyponatremia has been reported to cause <e2>rhabdomyolysis</e2> on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2124	 possibility of severe <e1>rhabdomyolysis</e1> should be considered in a patient with water intoxication due to massive ingestion of <e2>caffeine</e2> -containing beverages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2125	 possibility of severe rhabdomyolysis should be considered in a patient with <e1>water intoxication</e1> due to massive ingestion of <e2>caffeine</e2> -containing beverages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2126	 hypothesize that <e2>caffeine</e2> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2127	 hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the <e2>coexisting hyponatremia</e2>, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2128	 hypothesize that <e1>caffeine</e1> toxicity <e2>injured the muscle cells</e2>, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2129	 hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the <e2>potassium depletion</e2> induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2130	 hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2131	 the addition of <e1>citalopram</e1>, a desmethylclomipramine plasma level increase and an <e2>8-hydroacy-desmethylclomipramine plasma level decrease</e2> were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2132	 the addition of <e1>citalopram</e1>, a <e2>desmethylclomipramine plasma level increase</e2> and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2133	 report 3 cases of HIV-1 infected patients who experienced symptomatic <e1>angiolipomas</e1> shortly after starting antiretroviral therapy including the protease inhibitor <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2134	 serum triglycerides</e1> with <e2>clozapine</e2> resolved with risperidone in four patients."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2135	 two patients <e1>clozapine</e1> was reinstated after risperidone was discontinued; <e2>serum triglyceride levels increased</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2136	 increase when <e1>clozapine</e1> was switched to risperidone and vice versa is consistent with our previous report of <e2>elevated serum triglyceride levels</e2> in <e1>clozapine</e1> -treated patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2137	 <e1>valproate</e1> associated with significant <e2>hypotension</e2> in the treatment of status epilepticus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2138	 our knowledge, this is the first report of significant <e1>hypotension</e1> associated with intravenous <e2>valproate</e2> in the treatment of status epilepticus in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2139	 report a case of severe <e1>hypotension</e1> associated with intravenous <e2>valproate</e2> used to treat status epilepticus in an 11-year-old girl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2140	 both patients the <e1>rippling phenomena worsened</e1> with <e2>pyridostigmine</e2> treatment but markedly improved after immunosuppression with azathioprine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2141	 diagnosis of masked <e2>theophylline</e2> poisoning should be considered in similar situations involving a rapid decrease of insulin requirements."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2142	 <e1>intoxication</e1> was excluded, and <e2>theophylline</e2> was finally incriminated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2143	 intoxication mimicking diabetic ketoacidosis in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2144	 compound, used by adults in the child's home, had caused accidental <e2>theophylline</e2> poisoning, mimicking diabetic ketoacidosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2145	 blue in the treatment and prevention of <e2>ifosfamide</e2> -induced encephalopathy: report of 12 cases and a review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2146	 to 15% of patients treated with <e1>ifosfamide</e1> develop an <e2>encephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2147	 conclude that MB is an effective treatment for <e2>ifosfamide</e2> -induced encephalopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2148	 vein thrombosis</e1> in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of <e2>F VIII</e2> after intramural jejunal bleeding--successful thrombolysis under heparin therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2149	 report on a 14-year-old boy with severe haemophilia A who developed a <e1>portal vein thrombosis</e1> during continuous infusion of <e2>F VIII</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2150	 60-year-old woman with diabetes mellitus (type 2) developed an <e1>acute icteric hepatitis-like illness</e1> 6 weeks after the initiation of <e2>gliclazide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2151	 -induced <e2>acute hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2152	 conclusion, this case strongly suggests that <e1>gliclazide</e1> can induce <e2>acute icteric liver necro-inflammation</e2> which may be misdiagnosed clinically as acute viral hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2153	 believe that this is the first description of <e1>acute hepatitis</e1> caused by an idiosyncratic adverse reaction to <e2>gliclazide</e2> or to one of its metabolites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2154	 describe the case of <e1>acute hepatitis</e1> induced by <e2>gliclazide</e2>, a second generation sulfonylurea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2155	 is, therefore, needed to prevent undesired accumulation of <e1>TCA</e1> that may lead to protracted <e2>Cushing's syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2156	 syndrome</e1> persisted more than 6 months while <e2>TCA</e2> concentrations remained detectable for at least 80 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2157	 presented patient was treated with 200 mg <e1>TCA</e1> and developed <e2>Cushing's syndrome</e2> 6 weeks later (cortisol and ACTH concentrations were below limits of detection, <e1>TCA</e1> concentrations were > 3 micrograms/l)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2158	 had impaired lung function and <e1>abnormal computed tomographic scans</e1>, and their condition improved when <e2>nitrofurantoin</e2> was withdrawn and corticosteroid treatment commenced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2159	 had <e1>impaired lung function</e1> and abnormal computed tomographic scans, and their condition improved when <e2>nitrofurantoin</e2> was withdrawn and corticosteroid treatment commenced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2160	 obliterans organising pneumonia</e1> associated with the use of <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2161	 case histories are presented of two patients who developed lung disease associated with the use of <e1>nitrofurantoin</e1> with histological features of bronchiolitis obliterans organising pneumonia (<e2>BOOP</e2>), a rare but recognised form of drug induced injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2162	 case histories are presented of two patients who developed lung disease associated with the use of <e1>nitrofurantoin</e1> with histological features of <e2>bronchiolitis obliterans organising pneumonia</e2> (BOOP), a rare but recognised form of drug induced injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2163	 case histories are presented of two patients who developed <e1>lung disease</e1> associated with the use of <e2>nitrofurantoin</e2> with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2164	 favourable outcome in these two patients contrasts with the <e1>fatal outcome</e1> of the two other reported cases of <e2>nitrofurantoin</e2> induced BOOP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2165	 favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of <e2>nitrofurantoin</e2> induced BOOP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2166	 spectrum of <e1>nitrofurantoin</e1> <e2>lung injury</e2> continues to widen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2167	 two middle aged women presented with <e1>respiratory symptoms</e1> after prolonged treatment with <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2168	 suggest that the previous classification of <e2>nitrofurantoin</e2> induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2169	 administration of levodopa ameliorated a refractory <e1>akathisia</e1> case induced by <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2170	 present report illustrates a rare case of refractory <e1>akathisia</e1> after <e2>interferon-alpha</e2> treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2171	 present report illustrates a rare case of refractory akathisia after <e1>interferon-alpha</e1> treatment and also that levodopa treatment would be theoretically and practically useful in reducing the <e2>neurotoxicity</e2> associated with <e1>interferon-alpha</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2172	 erythroid leukemia</e1> after <e2>cyclophosphamide</e2> therapy for multiple myeloma: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2173	 development of erythroid leukemia plus <e1>carcinoma</e1> in these two men suggests mutagenic change secondary to <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2174	 reaction</e1> induced by uracil-tegafur (<e2>UFT</e2>), a second-generation anticancer agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2175	 reaction</e1> induced by <e2>uracil-tegafur</e2> (UFT), a second-generation anticancer agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2176	 is the first report of <e2>UFT</e2> -induced scleroderma-like reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2177	 report a case of a <e1>scleroderma-like reaction</e1> induced by long-term administration of <e2>UFT</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2178	 nervous system manifestations</e1> of an <e2>ibuprofen</e2> overdose reversed by naloxone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2179	 overdose is usually characterized by GI upset, <e2>dizziness</e2>, and mild sedation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2180	 overdose is usually characterized by <e2>GI upset</e2>, dizziness, and mild sedation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2181	 overdose is usually characterized by GI upset, dizziness, and <e2>mild sedation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2182	 treatment of acute <e2>ibuprofen</e2> intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2183	 report the case of an 11-month-old female infant with a <e1>depressed level of consciousness</e1> after ingestion of <e2>ibuprofen</e2> whose mental status markedly improved with administration of naloxone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2184	 -associated pneumonitis with <e2>acute respiratory failure</e2> in a patient with the LEOPARD syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2185	 -associated <e2>pneumonitis</e2> with acute respiratory failure in a patient with the LEOPARD syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2186	 is a rare cause of <e2>hypersensitivity pneumonitis</e2>, and few cases have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2187	 describe a case of <e1>interstitial hypoxaemiant pneumonitis</e1> probably related to <e2>flecainide</e2> in a patient with the LEOPARD syndrome, a rare congenital disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2188	 sinus thrombosis</e1> associated with transient free protein S deficiency after <e2>L-asparaginase</e2> treatment: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2189	 sinus thrombosis associated with <e1>transient free protein S deficiency</e1> after <e2>L-asparaginase</e2> treatment: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2190	 report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a <e1>seizure</e1> during consolidation treatment with <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2191	 report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated <e1>transient ischemic attacks</e1> followed by a seizure during consolidation treatment with <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2192	 report on a young adolescent with <e1>benign intracranial hypertension</e1> which we attribute to the use of <e2>minocycline</e2> for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2193	 report 2 patients who developed <e1>polyarteritis nodosa</e1> following <e2>vaccination against hepatitis B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2194	 this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose <e1>methotrexate</e1> therapy might have promoted the development of <e2>lung cancer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2195	 case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with <e1>cocaine</e1> -induced <e2>refractory coronary vasospasm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2196	 as illustrated by these and other cases reported to date, the onset of <e1>troglitazone</e1> -induced <e2>liver injury</e2> is insidious and temporally variable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2197	 remains to be seen whether the <e1>hepatotoxicity</e1> associated with <e2>troglitazone</e2> is a drug-class effect or specific to <e2>troglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2198	 remains to be seen whether the <e1>hepatotoxicity</e1> associated with <e2>troglitazone</e2> is a drug-class effect or specific to <e2>troglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2199	 thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of <e1>troglitazone</e1> without significant <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2200	 three reported cases demonstrate that <e1>troglitazone</e1> is an idiosyncratic hepatotoxin that can lead to <e2>irreversible liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2201	 -induced <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2202	 -induced <e2>lung disease</e2>: two cases demonstrating resolution of apparently irreversible CT abnormalities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2203	 present two cases of <e1>nitrofurantoin</e1> -induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated <e2>distortion of the lung parenchyma</e2>, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2204	 present two cases of <e1>nitrofurantoin</e1> -induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established <e2>fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2205	 present two cases of <e1>nitrofurantoin</e1> -induced <e2>pulmonary toxicity</e2> in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2206	 present two cases of <e1>nitrofurantoin</e1> -induced pulmonary toxicity in which the initial HRCT showed a <e2>widespread reticular pattern</e2> and associated distortion of the lung parenchyma, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2207	 -related <e2>death</e2> in a child with cytochrome P-450 2D6 genetic deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2208	 medical examiner's report indicated <e1>death</e1> caused by <e2>fluoxetine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2209	 medical examiner's report indicated death caused by <e2>fluoxetine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2210	 is the first report of a <e1>fluoxetine</e1> -related <e2>death</e2> in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2211	 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a <e1>spinal cord lesion</e1> following the use of <e2>zolmitriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2212	 cord infarction</e1> during use of <e2>zolmitriptan</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2213	 temporal relationship suggests that the <e1>spinal cord infarction</e1> may be related to the use of <e2>zolmitriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2214	 SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a <e1>hypersensitivity</e1> reaction to <e2>carboplatin</e2> after nine courses."
DRUG-ADE(e2,e1)
Comment: DRUG-

2215	 regimen could prove useful for other patients who develop <e1>hypersensitivity</e1> reactions to <e2>carboplatin</e2> and allow therapy to continue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2216	 vasoconstrictive <e1>renal insufficiency</e1> associated with maternal <e2>nimesulide</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2217	 is the first report of an <e1>adverse effect of fetal renal circulation</e1> by maternal ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2218	 the <e1>t-AML</e1> developed following oral <e2>etoposide</e2> therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2219	 leukemia</e1> in a child with neuroblastoma while on oral <e2>etoposide</e2>: what is the cause?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2220	 authors present a case of <e1>t-AML</e1> that developed in a child with metastatic neuroblastoma 18 months after he received oral <e2>etoposide</e2>, given for palliation purpose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2221	 <e1>Cyanamide</e1>, an aversive agent widely used in Japan, is known to induce various degrees of <e2>hepatic lesion with ground-glass inclusion bodies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2222	 2: A 43-year-old male alcoholic remained completely abstinent with <e1>cyanamide</e1> treatment for 5 years and complained of <e2>general fatigue</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2223	 3: A 29-year-old female alcoholic complained of general <e1>fatigue</e1> and a slight fever after 1.5 years of abstinence with <e2>cyanamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2224	 3: A 29-year-old female alcoholic complained of general fatigue and a slight <e1>fever</e1> after 1.5 years of abstinence with <e2>cyanamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2225	 4: A 61-year-old male alcoholic who remained completely abstinent while taking <e1>cyanamide</e1> for 3 years showed slight <e2>elevation of serum transaminases</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2226	 In some abstainers who take <e1>cyanamide</e1> for several years, thin septum-like liver fibrosis progresses along with the emergence of <e2>ground-glass hepatocytes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2227	 In some abstainers who take <e1>cyanamide</e1> for several years, thin <e2>septum-like liver fibrosis</e2> progresses along with the emergence of ground-glass hepatocytes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2228	 -induced <e2>liver dysfunction</e2> after abstinence in alcoholics: a long-term follow-up study on four cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2229	 <e1>cyanamide</e1> -treated alcoholics relapse into drinking, more severe <e2>inflammation</e2> develops in the liver."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2230	 patient with an allergy to a macrolide antibiotic was given <e1>tacrolimus</e1> and developed a <e2>sudden cutaneous reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2231	 77-year-old woman with no history of epilepsy presented a probable <e1>nonconvulsive status epilepticus</e1> while receiving continuous intravenous <e2>morphine</e2> for back pain relating to vertebral metastasis of a malignant lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2232	 <e1>generalized tonic-clonic seizure</e1> occurred a few minutes after injection of the morphine antagonist <e2>naloxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2233	 status epilepticus</e1>: the role of <e2>morphine</e2> and its antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2234	 <e1>bacterial peritonitis</e1> induced by intraarterial <e2>vasopressin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2235	 the literature on the use of <e1>risperidone</e1> in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (<e2>EPS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2236	 the literature on the use of <e1>risperidone</e1> in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of <e2>extrapyramidal symptoms</e2> (EPS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2237	 months following splenectomy, <e1>multiple abscesses</e1> occurred in the muscles of both thighs while the patient was receiving the third course of the <e2>CHOP</e2> regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2238	 seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, rash and hepatitis in association with <e2>anti-native DNA antibodies</e2> and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2239	 seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, rash and <e2>hepatitis</e2> in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2240	 seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed <e2>polyarthritis</e2>, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2241	 seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, <e2>rash</e2> and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2242	 hepatitis and <e1>anti-native DNA antibodies</e1> after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2243	 hepatitis and <e1>anti-native DNA antibodies</e1> after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2244	 <e1>hepatitis</e1> and anti-native DNA antibodies after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2245	 <e1>hepatitis</e1> and anti-native DNA antibodies after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2246	 hepatitis and anti-native DNA antibodies after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2247	 hepatitis and anti-native DNA antibodies after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2248	 case of <e1>normotensive scleroderma renal crisis</e1> after high-dose <e2>methylprednisolone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2249	 has been reported after several anticancer chemotherapies and most often after <e2>mitomycin C</e2> -based chemotherapy regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2250	 hemolytic uremic syndrome</e1> in an advanced ovarian cancer patient treated with <e2>carboplatin</e2> and gemcitabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2251	 hemolytic uremic syndrome</e1> in an advanced ovarian cancer patient treated with carboplatin and <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2252	 present a case of <e1>HUS</e1> in an advanced ovarian cancer patient treated with <e2>carboplatin</e2> and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2253	 present a case of <e1>HUS</e1> in an advanced ovarian cancer patient treated with carboplatin and <e2>gemcitabine</e2>, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2254	 evaluation of ovarian structure and function should be considered in women of reproductive age being treated with <e1>valproate</e1> for epilepsy, especially if they develop <e2>menstrual cycle disturbances</e2> during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2255	 Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and <e1>hyperandrogenism</e1> seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2256	 Reproductive endocrine disorders characterized by <e1>menstrual disorders</e1>, polycystic ovaries, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2257	 Reproductive endocrine disorders characterized by menstrual disorders, <e1>polycystic ovaries</e1>, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2258	 <e1>Reproductive endocrine disorders</e1> characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2259	 The 3 cases presented here illustrate the development of <e1>reproductive endocrine disorders</e1> after the initiation of <e2>valproate</e2> therapy in women with epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2260	 To describe the development of <e1>valproate</e1> -related <e2>reproductive endocrine disorders</e2> in women with epilepsy."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2261	 Three patients developed a <e1>reproductive endocrine disorder</e1> during treatment with <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

2262	 Replacing <e1>valproate</e1> with lamotrigine resulted in a decrease in <e2>serum testosterone</e2> concentrations in all 3 women."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2263	 polycystic changes disappeared from the ovaries in 2 of the women after <e1>valproate</e1> therapy was discontinued, and the 2 women who had gained weight and developed <e2>amenorrhea</e2> while being treated with <e1>valproate</e1> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2264	 polycystic changes disappeared from the ovaries in 2 of the women after <e1>valproate</e1> therapy was discontinued, and the 2 women who had <e2>gained weight</e2> and developed amenorrhea while being treated with <e1>valproate</e1> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2265	 <e1>polycystic changes</e1> disappeared from the ovaries in 2 of the women after <e2>valproate</e2> therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with <e2>valproate</e2> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2266	 recurrent <e1>staphylococcus aureus sepsis</e1> developed during <e2>CyA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2267	 septicemia with <e1>lethal</e1> outcome during and after <e2>cyclosporine</e2> therapy in severe ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2268	 <e1>septicemia</e1> with lethal outcome during and after <e2>cyclosporine</e2> therapy in severe ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2269	 60 year-old woman with chronic renal failure developed acute <e1>proximal muscle weakness</e1> after receiving a regular dosage of <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2270	 -induced <e2>myopathy</e2> in renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2271	 biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of <e1>colchicine</e1> -induced <e2>myopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2272	 biopsy revealed variation in muscle fiber size and few <e1>vacuolated fibers</e1> which were features of <e2>colchicine</e2> -induced myopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2273	 biopsy revealed <e1>variation in muscle fiber size</e1> and few vacuolated fibers which were features of <e2>colchicine</e2> -induced myopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2274	 third patient experienced <e1>disabling neurotoxicity</e1> in the extremity of a prior ulnar nerve and tendon transposition after receiving <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2275	 limb pain as a manifestation of <e1>paclitaxel</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2276	 limb pain</e1> as a manifestation of <e2>paclitaxel</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2277	 should be aware that <e1>PLP</e1> can occur after initiation of <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2278	 describe 2 patients with prior amputation who experienced <e1>phantom limb pain</e1> (PLP) after receiving <e2>paclitaxel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2279	 describe 2 patients with prior amputation who experienced phantom limb pain (<e1>PLP</e1>) after receiving <e2>paclitaxel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2280	 manifestations of a case of <e1>phenylbutazone</e1> -induced <e2>serum sickness-like reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2281	 manifestations</e1> of a case of <e2>phenylbutazone</e2> -induced serum sickness-like reactions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2282	 experience supports hemodialysis for ESRF patients with <e2>atenolol</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2283	 reaction to <e1>gemfibrozil</e1> manifesting as <e2>eosinophilic gastroenteritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2284	 describe a case of <e1>EGE</e1> manifested as an allergy to <e2>gemfibrozil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2285	 is the second report of <e1>lactic acidosis</e1> in a patient on stavudine and <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2286	 is the second report of <e1>lactic acidosis</e1> in a patient on <e2>stavudine</e2> and lamivudine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2287	 present an AIDS patient with severe and prolonged <e1>lactic acidosis</e1> on stavudine and <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2288	 present an AIDS patient with severe and prolonged <e1>lactic acidosis</e1> on <e2>stavudine</e2> and lamivudine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2289	 caused by <e2>propafenone</e2> has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2290	 wide variety of <e1>adverse central nervous system effects</e1> have been reported in association with <e2>propafenone</e2>; dizziness is the most common."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2291	 wide variety of adverse central nervous system effects have been reported in association with <e1>propafenone</e1>; <e2>dizziness</e2> is the most common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2292	 -induced <e2>ataxia</e2>: report of three cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2293	 describe 3 elderly patients with moderate to severe <e1>ataxia</e1> that occurred while they were taking <e2>propafenone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2294	 74-year-old man received oral administration of <e1>pilsicainide</e1>, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed <e2>loss of consciousness</e2> two days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2295	 <e1>pilsicainide</e1> is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid <e2>life-threatening arrhythmias</e2> due to high plasma concentrations of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2296	 cases are important in documenting that drug-induced <e1>dystonia</e1>s do occur in patients with dementia, that <e2>risperidone</e2> appears to have contributed to <e1>dystonia</e1> among elderly patients, and that the categorization of dystonic reactions needs further clarification."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2297	 of <e1>non-convulsive status epilepticus</e1> by <e2>tiagabine</e2> in three adolescent patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2298	 events of <e1>non-convulsive status epilepticus</e1> subsided following reduction in <e2>tiagabine</e2> dosages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2299	 is the first report of <e1>non-convulsive status epilepticus</e1> provoked by <e2>tiagabine</e2> in adolescent patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2300	 have been many reports of probable <e1>lithium</e1> -induced <e2>organic brain syndromes</e2> occurring when serum <e1>lithium</e1> levels are within or close to the therapeutic range."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2301	 the acute manic state is characterized by marked psychotic symptoms and <e1>intense anxiety</e1>, it may be associated with increased vulnerability to the development of severe <e2>lithium</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2302	 the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe <e1>lithium</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2303	 the acute manic state is characterized by marked <e1>psychotic symptoms</e1> and intense anxiety, it may be associated with increased vulnerability to the development of severe <e2>lithium</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2304	 inhibitor-induced <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2305	 inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2306	 inhibitors (<e1>ritonavir</e1> and saquinavir) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2307	 inhibitors (ritonavir and <e1>saquinavir</e1>) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2308	 inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed <e1>progressive ataxia</e1> related to <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2309	 inhibitors (<e1>ritonavir</e1> and saquinavir) were added to the treatment and the patient developed <e2>progressive ataxia</e2> related to carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2310	 inhibitors (ritonavir and <e1>saquinavir</e1>) were added to the treatment and the patient developed <e2>progressive ataxia</e2> related to carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2311	 acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and <e2>clinical toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2312	 acted as a CYP3A4 inhibitor, <e2>diminishing carbamazepine metabolism</e2> and provoking an increase in serum levels and clinical toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2313	 acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an <e2>increase in serum levels</e2> and clinical toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2314	 patient was diagnosed with <e2>carbamazepine</e2> toxicity related to the introduction of ritonavir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2315	 patient was diagnosed with <e1>carbamazepine toxicity</e1> related to the introduction of <e2>ritonavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2316	 to <e2>calcitonin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2317	 We have introduced a case of <e1>anaphylaxis </e1>by <e2>calcitonin</e2> that suggest an IgE mediated hypersensitivity reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2318	 intramuscular challenge test with 25 UI of <e1>Miacalcic</e1> was positive with an immediate <e2>anaphylactic reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2319	 introduce a case of a sixty years old woman with several previous episodes of rhinitis, <e1>conjunctivitis</e1> and perspiration immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2320	 introduce a case of a sixty years old woman with several previous episodes of rhinitis, <e1>conjunctivitis</e1> and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2321	 introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and <e1>perspiration</e1> immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2322	 introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and <e1>perspiration</e1> immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2323	 introduce a case of a sixty years old woman with several previous episodes of <e1>rhinitis</e1>, conjunctivitis and perspiration immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2324	 introduce a case of a sixty years old woman with several previous episodes of <e1>rhinitis</e1>, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2325	 as a cause of drug-induced <e2>autoimmune hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2326	 -induced <e2>autoimmune hepatitis</e2> is usually identical to sporadic <e2>autoimmune hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2327	 describe the clinical and liver biopsy morphologic features for 4 patients with <e1>minocycline</e1> -induced <e2>autoimmune hepatitis</e2> (group 1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2328	 -provoked seizures as singular expression of <e2>central nervous toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2329	 -provoked <e2>seizures</e2> as singular expression of central nervous toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2330	 treated with <e1>L-asparaginase</e1> may present with <e2>hemorrhagic</e2> and thrombotic cerebrovascular events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2331	 treated with <e1>L-asparaginase</e1> may present with hemorrhagic and <e2>thrombotic cerebrovascular events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2332	 report a case of <e1>seizure</e1> associated with <e2>L-asparaginase</e2> therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2333	 patients with various malignancies who received imipenem/<e1>cilastatin</e1> 143 times for <e2>neutropenic fever</e2> between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2334	 patients with various malignancies who received <e1>imipenem</e1>/cilastatin 143 times for <e2>neutropenic fever</e2> between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2335	 of <e1>seizures</e1> in pediatric cancer patients treated with imipenem/<e2>cilastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2336	 of <e1>seizures</e1> in pediatric cancer patients treated with <e2>imipenem</e2>/cilastatin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2337	 tendency of imipenem/<e2>cilastatin</e2> is one of its well-known side effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2338	 tendency of <e2>imipenem</e2>/cilastatin is one of its well-known side effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2339	 of these patients had <e1>convulsions</e1> attributed to imipenem/<e2>cilastatin</e2>; 3.6% of the patients had seizure, or 2% of imipenem/<e2>cilastatin</e2> administrations was followed by a seizure attack."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2340	 of these patients had <e1>convulsions</e1> attributed to <e2>imipenem</e2>/cilastatin; 3.6% of the patients had seizure, or 2% of <e2>imipenem</e2>/cilastatin administrations was followed by a seizure attack."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2341	 of these patients had convulsions attributed to imipenem/<e1>cilastatin</e1>; 3.6% of the patients had <e2>seizure</e2>, or 2% of imipenem/<e1>cilastatin</e1> administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2342	 of these patients had convulsions attributed to <e1>imipenem</e1>/cilastatin; 3.6% of the patients had <e2>seizure</e2>, or 2% of <e1>imipenem</e1>/cilastatin administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2343	 of these patients had convulsions attributed to imipenem/<e1>cilastatin</e1>; 3.6% of the patients had <e2>seizure</e2>, or 2% of imipenem/<e1>cilastatin</e1> administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2344	 of these patients had convulsions attributed to <e1>imipenem</e1>/cilastatin; 3.6% of the patients had <e2>seizure</e2>, or 2% of <e1>imipenem</e1>/cilastatin administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2345	 -induced mood changes with <e2>hypomanic</e2> features in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2346	 -induced <e2>mood changes</e2> with hypomanic features in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2347	 report two adults who received <e1>gabapentin</e1> (GBP) and subsequently developed <e2>behavioural side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2348	 report two adults who received gabapentin (<e1>GBP</e1>) and subsequently developed <e2>behavioural side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2349	 pancreatitis</e1> in a child with idiopathic ulcerative colitis on long-term <e2>5-aminosalicylic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2350	 describe a 10-year-old boy with ulcerative colitis who developed <e1>acute pancreatitis</e1> while on long-term treatment with <e2>5-aminosalicylic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2351	 Marked <e1>visual field constriction</e1> appears to be associated with <e2>vigabatrin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2352	 electroretinography, visual evoked potentials, and multifocal electroretinography in patients with <e1>vigabatrin</e1> -attributed <e2>visual field constriction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2353	 Symptomatic <e1>visual field constriction</e1> thought to be associated with <e2>vigabatrin</e2> has been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2354	 current study investigated the visual fields and visual electrophysiology of eight patients with known <e1>vigabatrin</e1> -attributed <e2>visual field loss</e2>, three of whom were reported previously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2355	 <e1>field defects</e1> and some electrophysiological abnormalities persist when <e2>vigabatrin</e2> therapy is withdrawn."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2356	 symptoms</e1> disappeared after <e2>interferon</e2> therapy was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2357	 of chronic hepatitis C with interferon alpha (<e1>IFN-alpha</e1>) is relatively contraindicated in patients with psychiatric disorders because of possible severe <e2>psychiatric side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2358	 of chronic hepatitis C with <e1>interferon alpha</e1> (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe <e2>psychiatric side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2359	 for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent <e1>changes in serotonergic or noradrenergic neurotransmission</e1> caused by <e2>IFN-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2360	 high-flux hemodiafiltration is often used in the management of <e2>vancomycin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2361	 of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of <e2>vancomycin</e2> toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2362	 describe 2 children with cerebral palsy who suffered significant <e1>morbidity</e1> immediately after treatment with <e2>hyperbaric oxygen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2363	 33-year-old male presented with <e1>brown discolouration of the fingernails</e1> following the application of 4% hydroquinone in sorbolene cream and <e2>0.1% tretinoin cream</e2> to the face intermittently for 9 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2364	 33-year-old male presented with <e1>brown discolouration of the fingernails</e1> following the application of <e2>4% hydroquinone in sorbolene cream</e2> and 0.1% tretinoin cream to the face intermittently for 9 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2365	 staining</e1> from <e2>hydroquinone</e2> cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2366	 of the fingertips after <e2>bleomycin</e2> and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2367	 of the fingertips after bleomycin and <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2368	 supports the well-reported potential of <e1>bleomycin</e1> to trigger <e2>acral vascular toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2369	 describe a 57-year-old man with acral erythrocyanosis progressing to <e1>acute digital ischemia</e1> and gangrene that developed after combined chemotherapy (<e2>bleomycin</e2> and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2370	 describe a 57-year-old man with acral erythrocyanosis progressing to <e1>acute digital ischemia</e1> and gangrene that developed after combined chemotherapy (bleomycin and <e2>methotrexate</e2>) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2371	 describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and <e1>gangrene</e1> that developed after combined chemotherapy (<e2>bleomycin</e2> and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2372	 describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and <e1>gangrene</e1> that developed after combined chemotherapy (bleomycin and <e2>methotrexate</e2>) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2373	 over-anticoagulation</e1> in a patient taking <e2>warfarin</e2>: therapeutic role of cholestyramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2374	 present a case of significant over-anticoagulation temporally associated with a bout of protracted <e1>diarrhea</e1> in a patient on <e2>warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2375	 present a case of significant <e1>over-anticoagulation</e1> temporally associated with a bout of protracted diarrhea in a patient on <e2>warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2376	 related to the use of activated and non-activated <e2>PCCs</e2> predominantly affects young patients who often have no preceding history of, or risk factors for, <e1>MI</e1> and tends to be associated with large cumulative doses of concentrate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2377	 VIIa concentrate in the management of bleeding following <e1>prothrombin complex concentrate</e1> -related <e2>myocardial infarction</e2> in patients with haemophilia and inhibitors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2378	 have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following <e1>PCC</e1> -related <e2>MI</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2379	 after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2380	 after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2381	 after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2382	 <e1>quinine</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2383	 after three subsequent episodes of severe, symptomatic <e1>thrombocytopenia</e1> over the next four weeks did he say, upon repeat questioning, that he had continued to take <e2>quinine</e2> for night leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2384	 8-year-old child with familial Mediterranean fever exhibited signs of <e2>colchicine</e2> intoxication while receiving prophylactic doses of the drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2385	 To the best of our knowledge, this is the first time <e2>colchicine</e2> intoxication in this age group has been described in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2386	 fatal acute <e2>colchicine</e2> intoxication in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2387	 fatal</e1> acute <e2>colchicine</e2> intoxication in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2388	 myeloid leukemia</e1> and lung cancer occurring in a chronic lymphocytic leukemia patient treated with <e2>fludarabine</e2> and autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2389	 myeloid leukemia and <e1>lung cancer</e1> occurring in a chronic lymphocytic leukemia patient treated with <e2>fludarabine</e2> and autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2390	 describe the exceptional development of <e1>AML</e1> and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after <e2>fludarabine</e2> treatment followed by autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2391	 describe the exceptional development of AML and <e1>lung cancer</e1> in a patient with previously diagnosed CLL in minimal residual disease status after <e2>fludarabine</e2> treatment followed by autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2392	 2 of the 3 cases the patients were also taking <e1>lithium carbonate</e1> and beta-blockers, both of which could have contributed to the <e2>incontinence</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2393	 the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors <e2>paroxetine</e2> and sertraline, as well as a third who developed this side effect on venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2394	 the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors paroxetine and <e2>sertraline</e2>, as well as a third who developed this side effect on venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2395	 the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2396	 concerns 2 male patients who experienced <e1>incontinence</e1> while taking <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2397	 studies in <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2398	 points illustrated are, (1) occurrence of <e1>HIT</e1> with any dose or form of <e2>heparin</e2>; (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to <e2>heparin</e2> and disappearance of <e1>HIT</e1> antibodies over time."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2399	 II <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT) is an immunological disorder characterized by antibodies to <e1>heparin</e1> -platelet factor 4 complexes and a high risk of thrombotic complications."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2400	 several unrevealing medical work-ups, he was found to have a high blood <e2>lead</e2> level (122 microg/dL); he has a history of scraping and sanding <e2>lead</e2> paint without adequate protective measures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2401	 also highlights a current major etiologic question, that is, whether and to what degree <e1>lead</e1> exposure contributes to the development of <e2>hypertension</e2>, and raises the issue of whether <e1>lead</e1> -induced <e2>hypertension</e2> constitutes a subset of <e2>hypertension</e2> that is especially amenable to therapy with dietary calcium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2402	 also highlights a current major etiologic question, that is, whether and to what degree <e1>lead</e1> exposure contributes to the development of hypertension, and raises the issue of whether <e1>lead</e1> -induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2403	 controlled hypertension in a painter with chronic <e2>lead</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2404	 case demonstrates an occupational activity (construction) that has now become the dominant source of <e1>lead</e1> exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic <e1>lead</e1> toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2405	 rash</e1>, including the Stevens-Johnson syndrome (SJS), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2406	 rash, including the Stevens-Johnson syndrome (<e1>SJS</e1>), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2407	 rash, including the <e1>Stevens-Johnson syndrome</e1> (SJS), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2408	 syndrome</e1> caused by the antiretroviral drug <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2409	 physicians treating large populations of patients with HIV are well aware of this complication, only one other report of <e1>nevirapine</e1> -associated <e2>SJS</e2> has been documented in the dermatology literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2410	 describe 2 cases of <e1>SJS</e1> related to <e2>nevirapine</e2> use and review the literature on this newly recognized association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2411	 intake and <e1>acarbose</e1> were withheld and the <e2>ileus</e2> spontaneously resolved after 2 days."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2412	 is evidence that the angiotensin II receptor antagonist, <e1>losartan</e1>, <e2>increases urate excretion</e2> by reducing reabsorption of urate in the renal proximal tubule."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2413	 fibrillation</e1> occurring in a patient taking <e2>etanercept</e2> plus methotrexate for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2414	 fibrillation</e1> occurring in a patient taking etanercept plus <e2>methotrexate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2415	 review of the literature revealed two other cases of <e1>hepatic angiosarcoma</e1> in patients after long-term <e2>cyclophosphamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2416	 angiosarcoma</e1> occurring after <e2>cyclophosphamide</e2> therapy: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2417	 propose that <e1>cyclophosphamide</e1> be added to the list of exposures potentially associated with <e2>hepatic angiosarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2418	 is frequently associated with <e2>dermatologic toxicity</e2>, but this is only the second case of toxic epidermal necrolysis described in connection with this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2419	 is frequently associated with dermatologic toxicity, but this is only the second case of <e2>toxic epidermal necrolysis</e2> described in connection with this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2420	 the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed <e2>bullous lesions on the hands and soles that disseminated, evolving to necrosis</e2>, sepsis, and death on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2421	 the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and <e2>death</e2> on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2422	 the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, <e2>sepsis</e2>, and death on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2423	 epidermal necrolysis</e1> after the use of high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2424	 report a fatal case of toxic epidermal necrolysis (<e1>TEN</e1>) resulting from a high dose of cytosine arabinoside (<e2>ARA-C</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2425	 report a fatal case of toxic epidermal necrolysis (<e1>TEN</e1>) resulting from a high dose of <e2>cytosine arabinoside</e2> (ARA-C)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2426	 report a fatal case of <e1>toxic epidermal necrolysis</e1> (TEN) resulting from a high dose of cytosine arabinoside (<e2>ARA-C</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2427	 report a fatal case of <e1>toxic epidermal necrolysis</e1> (TEN) resulting from a high dose of <e2>cytosine arabinoside</e2> (ARA-C)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2428	 and <e2>obsessive-compulsive symptoms</e2> (OCS): case report and review of atypical antipsychotic-induced OCS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2429	 and obsessive-compulsive symptoms (<e2>OCS</e2>): case report and review of atypical antipsychotic-induced <e2>OCS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2430	 and obsessive-compulsive symptoms (<e2>OCS</e2>): case report and review of atypical antipsychotic-induced <e2>OCS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2431	 first known report of <e1>quetiapine</e1> <e2>exacerbating OCS</e2> in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2432	 was diagnosed with possible <e1>serotonin syndrome</e1>; his symptoms resolved after <e2>clomipramine</e2> was stopped but before clozapine was restarted eight days later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2433	 To report on the possible development of <e1>serotonin syndrome</e1> in a patient receiving <e2>clomipramine</e2> after clozapine was withdrawn from the treatment regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2434	 To report on the possible development of <e1>serotonin syndrome</e1> in a patient receiving clomipramine after <e2>clozapine</e2> was withdrawn from the treatment regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2435	 <e1>serotonin syndrome</e1> associated with <e2>clomipramine</e2> after withdrawal of clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2436	 <e1>serotonin syndrome</e1> associated with clomipramine after withdrawal of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2437	 day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, <e2>agitated</e2>, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2438	 day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, <e2>agitated</e2>, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2439	 day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began <e2>behaving oddly</e2>, started sweating profusely, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2440	 day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began <e2>behaving oddly</e2>, started sweating profusely, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2441	 day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and <e2>confused</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2442	 day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and <e2>confused</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2443	 day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, <e2>shivering</e2>, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2444	 day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, <e2>shivering</e2>, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2445	 day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started <e2>sweating profusely</e2>, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2446	 day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started <e2>sweating profusely</e2>, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2447	 day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became <e2>tremulous</e2>, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2448	 day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became <e2>tremulous</e2>, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2449	 induced <e2>coagulopathy</e2> --a near fatal experience."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2450	 cause of his bleeding was a <e1>severe thrombocytopoaenia</e1>, induced by chronic ingestion of <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2451	 <e1>olanzapine</e1> -associated <e2>leukopenia</e2>: three case reports."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2452	 cases suggest the possibility that, in some patients, leukopenia or <e1>agranulocytosis</e1> during <e2>olanzapine</e2> treatment might be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2453	 cases suggest the possibility that, in some patients, <e1>leukopenia</e1> or agranulocytosis during <e2>olanzapine</e2> treatment might be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2454	 report three cases of patients who developed <e1>leukopenia</e1> during <e2>olanzapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2455	 This case illustrates a potential link between dermatologic and ocular <e2>5-FU</e2> toxicities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2456	 diagnoses included ocular rosacea with cicatrizing conjunctivitis and <e1>5-FU</e1> -induced <e2>ectropion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2457	 Patients with <e1>5-FU</e1> -induced <e2>ectropion</e2> experience tender, red, scaled lids, making contact lens wear difficult."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2458	 Patients with <e1>5-FU</e1> -induced ectropion experience <e2>tender, red, scaled lids</e2>, making contact lens wear difficult."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2459	 secondary to bolus injection of <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2460	 of <e1>5-FU</e1> <e2>dermatologic toxicities</e2> in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2461	 is a case of <e1>acute renal failure</e1> induced by <e2>acetazolamide</e2> therapy for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2462	 failure</e1> associated with <e2>acetazolamide</e2> therapy for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2463	 sulfonamide like nephropathy should be differentiated from <e1>acetazolamide</e1> -related <e2>calcium phosphate nephrolithiasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2464	 colitis</e1> in a patient taking <e2>meloxicam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2465	 and <e1>endoscopic lesions</e1> quickly regressed within 1 week of <e2>meloxicam</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2466	 describe a patient who presented with <e1>bloody diarrhoea</e1> after 15 mg <e2>meloxicam</e2> daily for 10 days for osteoarthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2467	 suggest that <e1>meloxicam</e1> might have <e2>intestinal toxic effects</e2> when taken in high doses, because of reduced COX-2 selectivity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2468	 these cases revealed, close monitoring of blood chemistry is mandatory after starting <e1>spironolactone</e1>, and patients should be advised to stop <e1>spironolactone</e1> immediately if <e2>diarrhoea</e2> develops."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2469	 patients with chronic heart failure, <e1>spironolactone</e1> added to conventional treatment may lead to <e2>serious and, occasionally, fatal hyperkalaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2470	 some cases this seems to happen because <e1>spironolactone</e1> causes <e2>diarrhoea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2471	 adverse events</e1> experienced by patients with chronic heart failure taking <e2>spironolactone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2472	 report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with <e1>oxaliplatin</e1> and developed a peculiar <e2>dermnatitis</e2> in the irradiated field after being exposed to subsequent chemotherapy with <e1>oxaliplatin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2473	 11-year-old boy developed a <e1>severe enteropathy</e1> 2 years after initiation of <e2>clofazimine</e2> treatment for graft-versus-host disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2474	 <e2>enteropathy</e2> caused by crystal deposition can be life-threatening."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2475	 enteropathy caused by crystal deposition can be <e2>life-threatening</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2476	 <e2>enteropathy</e2> in a pediatric bone marrow transplant recipient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2477	 developed a <e1>severe urticarial rash</e1> 3 weeks following initiation of therapy with <e2>Enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2478	 cared for a patient with progressive renal impairment who presented with <e1>blurred vision</e1>, QRS broadening and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2479	 cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and <e1>cardiac failure</e1> due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2480	 cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2481	 cared for a patient with progressive renal impairment who presented with blurred vision, <e1>QRS broadening</e1> and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2482	 <e1>aspergillus arthritis</e1> complicating <e2>fludarabine</e2> -based non-myeloablative stem cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2483	 describe two patients with <e1>aspergillus arthritis of the knee joint</e1> following <e2>fludarabine</e2> -based non-myeloablative stem cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2484	 The present findings suggest that <e1>fluvoxamine</e1> can cause <e2>increased libido</e2> in some patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2485	 libido</e1> in a woman treated with <e2>fluvoxamine</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2486	 The aim of this paper is to describe a case of <e1>increased libido</e1> during <e2>fluvoxamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2487	 The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an <e1>increased libido</e1> with the administration of <e2>fluvoxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2488	 <e1>increased libido</e1> disappeared after <e2>fluvoxamine</e2> was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2489	 infant who developed <e1>pancreatitis</e1> during <e2>meglumine antimoniate</e2> treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2490	 treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed <e1>pancreatitis</e1> caused by <e2>meglumine antimoniate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2491	 This case report showed that the clinical appearance of <e1>Hashimoto's disease</e1> after <e2>IFN-alpha</e2> therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2492	 studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop <e1>autoimmune thyroiditis</e1>, in order to make a early diagnosis of thyroid disorders during the <e2>IFN-alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2493	 studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of <e1>thyroid disorders</e1> during the <e2>IFN-alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2494	 disease</e1> during <e2>interferon-alpha</e2> therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2495	 The authors described a case of <e1>Hashimoto's disease</e1> during interferon-alpha (<e2>IFN-alpha</e2>) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2496	 The authors described a case of <e1>Hashimoto's disease</e1> during <e2>interferon-alpha</e2> (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2497	 dose-finding studies for intravenous proton pump inhibitors <e1>omeprazole</e1> and pantoprazole, three of six young female volunteers receiving <e1>omeprazole</e1> and two young female volunteers receiving pantoprazole developed <e2>peripheral edema</e2> within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2498	 dose-finding studies for intravenous proton pump inhibitors omeprazole and <e1>pantoprazole</e1>, three of six young female volunteers receiving omeprazole and two young female volunteers receiving <e1>pantoprazole</e1> developed <e2>peripheral edema</e2> within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2499	 edema</e1> was observed in five female patients after taking proton pump inhibitors omeprazole, <e2>lansoprazole</e2>, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2500	 edema</e1> was observed in five female patients after taking proton pump inhibitors <e2>omeprazole</e2>, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2501	 edema</e1> was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or <e2>pantoprazole</e2> for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2502	 fluctuations</e1> appear after 2-3 years of <e2>levodopa</e2> treatment, and affect at least 50% of patients after five years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2503	 Significant <e1>weight loss</e1> is a potential adverse event in patients with rheumatoid arthritis treated with <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2504	 -associated <e2>weight loss</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2505	 We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if <e1>weight loss</e1> had occurred as an adverse event in patients treated with <e2>leflunomide</e2> between November 1998 and January 2000."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2506	 To determine the frequency of <e1>weight loss</e1> in patients treated with <e2>leflunomide</e2> for rheumatoid arthritis at an arthritis referral center."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2507	 Five of 70 patients who had begun <e1>leflunomide</e1> therapy had significant <e2>weight loss</e2> that could not be linked to other identifiable etiologies."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2508	 is increasingly recognized that dose adjustment of oral <e1>valacyclovir</e1> in renal failure is necessary to avoid <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2509	 of <e2>valacyclovir</e2> in peritoneal dialysis: a pharmacokinetic study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2510	 developed <e1>neurotoxicity</e1> with an adjustment dosage of <e2>valacyclovir</e2> for a cutaneous zoster infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2511	 necrosis of the femoral head</e1> in patients with prostate cancer treated with <e2>cyproterone acetate</e2> and radiotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2512	 report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of <e1>cyproterone acetate</e1> prior to radical or palliative pelvic irradiation, and who subsequently developed <e2>femoral head avascular necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2513	 induced <e2>polymorphic ventricular tachycardia</e2> with normal QT interval."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2514	 report the first case of <e1>polymorphic ventricular tachycardia</e1> with normal QT interval associated with the oral use of <e2>levofloxacin</e2> in the absence of other etiologies known to cause these arrhythmias."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2515	 far, few cases of <e1>pulmonary side effects</e1> caused by <e2>ticlopidine</e2> have been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2516	 care should be taken when <e1>pulmonary symptoms</e1> appear in association with <e2>ticlopidine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2517	 -induced <e2>interstitial pulmonary disease</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2518	 report a case of <e1>interstitial pulmonary disease</e1> that occurred together with lymphocytic colitis during treatment with <e2>ticlopidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2519	 report a case of interstitial pulmonary disease that occurred together with <e1>lymphocytic colitis</e1> during treatment with <e2>ticlopidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2520	 patient that received <e1>methadone</e1> for cancer-associated pain developed <e2>myoclonus</e2> as a side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2521	 -induced <e2>myoclonus</e2> in advanced cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2522	 To report a case of <e1>fatal hyperkalemia</e1> owing to <e2>succinylcholine</e2> administration in a patient with mucositis secondary to chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2523	 -induced <e2>hyperkalemia</e2> in a patient with mucositis secondary to chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2524	 believe that mucositis was a contributing factor to this case of <e1>fatal hyperkalemia</e1> after administration of <e2>succinylcholine</e2>, with a mechanism similar to that reported with thermal injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2525	 seeding</e1> after ultrasound-guided percutaneous <e2>ethanol injection</e2> for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2526	 describe a case of needle-track <e1>cutaneous seeding</e1> of hepatocellular carcinoma (HCC) after sonographically guided percutaneous <e2>ethanol injection</e2> (PEI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2527	 -induced <e2>ventricular fibrillation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2528	 <e1>adenosine</e1> shortens the antegrade refractoriness of accessory atrioventricular connections and may cause <e2>acceleration of the ventricular rate</e2> during atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2529	 observed <e1>ventricular fibrillation</e1> in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of <e2>adenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2530	 the dose of <e1>methylprednisolone</e1> was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the <e2>psychotic reaction</e2> disappeared a few hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2531	 EEG monitoring is helpful in managing <e1>seizures</e1> that occur as a complication of <e2>CBZ</e2> OD, after the course of recovery or worsening, and in providing assistance with prognosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2532	 <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes <e2>cortical hyperexcitability</e2>, a profound burst-suppression EEG pattern, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2533	 <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and <e2>cranial nerve areflexia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2534	 <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a <e2>profound burst-suppression EEG pattern</e2>, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2535	 <e1>CBZ</e1> OD may produce a <e2>reversible encephalopathy</e2> that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2536	 plasmocytosis due to <e1>methimazole</e1> -induced <e2>bone marrow toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2537	 plasmocytosis</e1> due to <e2>methimazole</e2> -induced bone marrow toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2538	 our knowledge this is the first report of pancytopenia due to <e1>MMI</e1>, where the usual hypoplasia found is replaced by <e2>massive plasmocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2539	 our knowledge this is the first report of <e1>pancytopenia</e1> due to <e2>MMI</e2>, where the usual hypoplasia found is replaced by massive plasmocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2540	 report a case of <e1>fulminant hepatic failure</e1> associated with <e2>didanosine</e2> and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2541	 report details a case of <e1>bilateral avascular necrosis of the femoral heads</e1> in a patient receiving 'standard' doses of <e2>dexamethasone</e2> as part of the antiemetic regimen used in cisplatin-based combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2542	 no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following <e1>hemorrhage</e1> may have been favored by <e2>metformin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2543	 obese patient, not diabetic, treated with <e1>metformin</e1> for some weeks, was referred to us with <e2>severe inferior digestive hemorrhage</e2>, diagnosed with Meckel's diverticulum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2544	 hemorrhage</e1> caused by a Meckel's diverticulum in a <e2>metformin</e2> -treated patient: is there any connection?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2545	 became worse</e1> after tobramycin and <e2>gentamycin</e2> treatment for 2 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2546	 became worse</e1> after <e2>tobramycin</e2> and gentamycin treatment for 2 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2547	 linkage of <e1>amprenavir</e1> with <e2>intracranial bleeding</e2> in an HIV-infected hemophiliac."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2548	 <e1>bleeding</e1> resolved on discontinuation of <e2>APV</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2549	 report the occurrence of spontaneous <e1>intracranial bleeding</e1> in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving <e2>amprenavir</e2> (APV)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2550	 to the Naranjo probability scale, the relationship of <e1>gemcitabine</e1> treatment with <e2>cutaneous eruption</e2> in our patient is possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2551	 We report the first case of <e1>gemcitabine</e1> -induced <e2>LABD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2552	 immunoglobulin A bullous dermatosis</e1> induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2553	 To report a case of linear immunoglobulin (Ig) A bullous dermatosis (<e1>LABD</e1>) induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2554	 To report a case of <e1>linear immunoglobulin (Ig) A bullous dermatosis</e1> (LABD) induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2555	 hours after the administration of <e1>gemcitabine</e1>, a <e2>symmetric, bullous, herpetiform eruption</e2> appeared on his trunk and upper limbs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2556	 is the most frequently implicated drug, but other agents have been reported to cause <e2>LABD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2557	 <e1>taxol</e1> has shown significant activity in advanced ovarian cancer, <e2>peripheral neuropathy</e2> is likely to become the major dose-limiting toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2558	 rare case of advanced ovarian carcinoma who developed <e1>difficulty walking</e1> 25 days after treatment with weekly <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2559	 describe a case of advanced ovarian carcinoma who developed <e1>difficulty walking</e1> because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2560	 describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and <e1>loss of proprioception</e1> 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2561	 describe a case of advanced ovarian carcinoma who developed difficulty walking because of <e1>marked pain</e1> in the lower extremities and loss of proprioception 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2562	 by naloxone of <e1>morphine</e1> -induced <e2>spasm</e2> of the sphincter of Oddi in a post-cholecystectomy patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2563	 present the case of a patient who had undergone cholecystectomy previously, but in whom <e1>morphine</e1> given in the Emergency Department precipitated pain consistent with <e2>biliary colic</e2>; the pain resolved promptly after administration of naloxone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2564	 present the case of a patient who had undergone cholecystectomy previously, but in whom <e1>morphine</e1> given in the Emergency Department precipitated <e2>pain</e2> consistent with biliary colic; the <e2>pain</e2> resolved promptly after administration of naloxone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2565	 gravis</e1> during low-dose <e2>IFN-alpha</e2> therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2566	 patient with rheumatoid arthritis developed an acute <e1>intrahepatic cholestasis</e1> after 100 mg of <e2>sodium aurothiomalate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2567	 lung injury</e1> associated with <e2>5-fluorouracil</e2> and oxaliplatinum combined chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2568	 lung injury</e1> associated with 5-fluorouracil and <e2>oxaliplatinum</e2> combined chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2569	 T-CD4+ lymphopenia and <e1>bilateral patchy pulmonary infiltrates</e1> developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2570	 T-CD4+ lymphopenia and <e1>bilateral patchy pulmonary infiltrates</e1> developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2571	 T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2572	 T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2573	 <e1>T-CD4+ lymphopenia</e1> and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2574	 <e1>T-CD4+ lymphopenia</e1> and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2575	 is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a <e1>pulmonary adverse reaction</e1>, a feature never previously associated with oxaliplatinum and <e2>5-fluorouracil</e2> regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2576	 is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a <e1>pulmonary adverse reaction</e1>, a feature never previously associated with <e2>oxaliplatinum</e2> and 5-fluorouracil regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2577	 <e1>Accutane</e1> a <e2>teratogenic</e2> prescription drug licensed to treat severe, recalcitrant nodular acne."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2578	 The estimated number of <e1>Accutane</e1> prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used <e2>teratogenic</e2> drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to <e1>Accutane</e1> in 1999."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2579	 62-year-old woman treated with <e1>pranlukast</e1> for 2 months developed interstitial pneumonitis with a <e2>high fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2580	 62-year-old woman treated with <e1>pranlukast</e1> for 2 months developed <e2>interstitial pneumonitis</e2> with a high fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2581	 <e1>interstitial pneumonia</e1> induced by <e2>ONO-1078</e2> (pranlukast), a leukotriene receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2582	 <e1>interstitial pneumonia</e1> induced by ONO-1078 (<e2>pranlukast</e2>), a leukotriene receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2583	 asymptomatic HIV-infected woman experienced right-sided <e1>renal colicky pain</e1> during treatment with <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2584	 -associated nephrolithiasis and chronic <e2>interstitial nephritis</e2> were the only possible causes identified in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2585	 -associated <e2>nephrolithiasis</e2> and chronic interstitial nephritis were the only possible causes identified in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2586	 necrosis</e1> associated with the HIV protease inhibitor <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2587	 should be aware that <e1>indinavir</e1> <e2>nephrolithiasis</e2> may cause papillary necrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2588	 should be aware that <e1>indinavir</e1> nephrolithiasis may cause <e2>papillary necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2589	 HIV protease inhibitor <e1>indinavir</e1> may cause nephrolithiasis and <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2590	 HIV protease inhibitor <e1>indinavir</e1> may cause <e2>nephrolithiasis</e2> and interstitial nephritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2591	 renal consequences of <e1>indinavir</e1> -associated <e2>nephrotoxicity</e2> are uncertain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2592	 report a case of <e1>papillary necrosis</e1> in a patient treated with <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2593	 describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked <e1>decline in glomerular filtration rate</e1> in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2594	 <e1>LTG</e1> overdose may result in a severe but reversible <e2>encephalopathy</e2>, a previously undescribed phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2595	 revealed elevated serum <e2>LTG</e2> levels and no other etiology for encephalopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2596	 A 55-year-old woman became <e1>stuporous</e1> after overdose with <e2>lamotrigine</e2> (LTG) and valproic acid (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2597	 A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (<e2>LTG</e2>) and valproic acid (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2598	 A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (LTG) and <e2>valproic acid</e2> (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2599	 A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (LTG) and valproic acid (<e2>VPA</e2>) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2600	 To report that acute <e1>lamotrigine</e1> poisoning may result in severe <e2>encephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2601	 from <e2>lamotrigine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2602	 cause of death was determined to be <e1>acute intoxication</e1> by <e2>olanzapine</e2>, and the manner of death was accidental."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2603	 article describes the case of a 25-year-old man found <e1>dead</e1> at home who had been prescribed <e2>olanzapine</e2> for schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2604	 drug eruption</e1> to <e2>salsalate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2605	 <e1>eruption</e1> emerged after 1 month of therapy with <e2>salsalate</e2>, persisted for as long as <e2>salsalate</e2> was administered, and cleared within 3 weeks of discontinuing the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2606	 describe a patient who experienced a <e1>lichenoid eruption</e1> after the initiation of <e2>salsalate</e2> for relief of arthritic pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2607	 B</e1> -induced <e2>seizures</e2> in a patient with AIDS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2608	 SUMMARY: A 46-year-old African-American man experienced recurrent <e1>grand mal seizures</e1> during intravenous infusion of <e2>amphotericin B</e2>, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time."
DRUG-ADE(e2,e1)
Comment: DRUG-

2609	 <e1>Amphotericin B</e1> seems to be the probable cause of the <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2610	 administration of phenytoin and lorazepam, the <e1>seizures</e1> persisted and occurred only during <e2>amphotercin B</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2611	 also has a potential for inducing <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2612	 To report a case of multiple episodes of <e1>seizure</e1> activity in an AIDS patent following <e2>amphotericin B</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2613	 time course of events suggested that <e1>amphotericin B</e1> was the cause of the <e2>seizures</e2> in this AIDS patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2614	 date, only three cases of <e1>seizures</e1> associated with <e2>amphotericin B</e2> have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2615	 cord paralysis</e1> as a consequence of peritonsillar infiltration with <e2>bupivacaine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2616	 present the case of a 5-year-old girl who developed <e1>bilateral vocal cord paralysis</e1> following preoperative peritonsillar <e2>bupivacaine</e2> infiltration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2617	 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete <e1>right bundle branch block</e1> after ingestion of 10 g and 4 g of <e2>carbamazepine</e2> respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2618	 induced <e2>right bundle branch block</e2> in a Greenlandic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2619	 entropion</e1> associated with chronic <e2>dipivefrin</e2> application."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2620	 Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including <e1>dipivefrin</e1> is a possible mechanism of action for <e2>entropion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2621	 eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of <e1>cicatricial entropion</e1> after at least 2 years of twice-a-day application of <e2>dipivefrin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2622	 To report patients who presented to the oculoplastics department for repair of <e1>cicatrical entropion</e1> after topical use of <e2>dipivefrin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2623	 34-year-old lady developed a <e1>constellation of dermatitis</e1>, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2624	 34-year-old lady developed a constellation of dermatitis, <e1>fever</e1>, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2625	 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and <e1>hepatitis</e1>, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2626	 34-year-old lady developed a constellation of dermatitis, fever, <e1>lymphadenopathy</e1> and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2627	 is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often <e2>fatal</e2>, immunoallergic reaction to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2628	 is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often <e2>fatal</e2>, immunoallergic reaction to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2629	 is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often fatal, <e2>immunoallergic reaction</e2> to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2630	 is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often fatal, <e2>immunoallergic reaction</e2> to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2631	 is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e2>sulphasalazine</e2> syndrome", a rare, but often fatal, immunoallergic reaction to <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2632	 is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e2>sulphasalazine</e2> syndrome", a rare, but often fatal, immunoallergic reaction to <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2633	 3-week <e2>sulphasalazine</e2> syndrome strikes again."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2634	 the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the <e1>SIADH</e1> was most likely to have been induced by administration of <e2>CDDP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2635	 of inappropriate secretion of ADH (<e1>SIADH</e1>) following <e2>cisplatin</e2> administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2636	 of inappropriate secretion of ADH</e1> (SIADH) following <e2>cisplatin</e2> administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2637	 report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (<e2>CDDP</e2>) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2638	 report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with <e2>cisplatin</e2> (CDDP) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2639	 report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (CDDP) and vindesine (<e2>VDS</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2640	 report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (CDDP) and <e2>vindesine</e2> (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2641	 report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (<e2>CDDP</e2>) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2642	 report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with <e2>cisplatin</e2> (CDDP) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2643	 report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (<e2>VDS</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2644	 report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (CDDP) and <e2>vindesine</e2> (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2645	 extensive neurological 'work up', we realized that the <e1>anisocoria</e1> was related to the transdermal <e2>scopolamine</e2> patch that we had prescribed for weaning off the opioid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2646	 from transdermal <e2>scopolamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2647	 novo absence status</e1> of late onset following withdrawal of <e2>lorazepam</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2648	 aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a <e1>nonconvulsive generalized status epilepticus</e1> following acute withdrawal of <e2>lorazepam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2649	 recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2650	 early signs of HMSN, such as areflexia and pes cavus deformity, can prevent <e1>severe neurotoxicity</e1> of polychemotherapy by avoiding <e2>vincristine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2651	 disease predisposes to severe <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2652	 report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed <e1>severe motor neuropathy</e1> 3 weeks after the first cycle of treatment including 2 mg of <e2>vincristine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2653	 <e1>asymptomatic hepatitis</e1> in a healthy normal volunteer exposed to 2 oral doses of <e2>amodiaquine</e2> and artesunate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2654	 <e1>asymptomatic hepatitis</e1> in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and <e2>artesunate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2655	 report describes an unexpected drug-induced <e1>hepatitis</e1> in a previously healthy young woman exposed to 2 doses of <e2>amodiaquine</e2> and artesunate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2656	 report describes an unexpected drug-induced <e1>hepatitis</e1> in a previously healthy young woman exposed to 2 doses of amodiaquine and <e2>artesunate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2657	 allergic contact dermatitis</e1> to <e2>8-methoxypsoralen</e2> (8-MOP)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2658	 allergic contact dermatitis</e1> to 8-methoxypsoralen (<e2>8-MOP</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2659	 describe a patient who had a <e1>systemic allergic contact dermatitis</e1> to <e2>8-MOP</e2> develop during her second course of PUVA treatment for psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2660	 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with confusion, <e2>abdominal pain</e2>, and distention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2661	 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with <e2>confusion</e2>, abdominal pain, and distention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2662	 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with confusion, abdominal pain, and <e2>distention</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2663	 and granulocytopenia associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2664	 and <e1>granulocytopenia</e1> associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2665	 Although a definite association has not been proven, clinicians should be aware of the possibility of <e1>agranulocytosis</e1> while using <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2666	 We describe three case-reports concerning <e1>haematological adverse effects</e1> of <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2667	 <e1>Quetiapine</e1> was associated with leucopenia in two patients and clinically apparent <e2>agranulocytosis</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2668	 <e1>Quetiapine</e1> was associated with <e2>leucopenia</e2> in two patients and clinically apparent agranulocytosis in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2669	 There is very little published information regarding <e1>ofloxacin</e1> -induced <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2670	 a large case-control study included three cases of either <e1>Stevens-Johnson syndrome</e1> or toxic epidermal necrolysis associated with <e2>ofloxacin</e2> use, but no details of the cases were given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2671	 a large case-control study included three cases of either Stevens-Johnson syndrome or <e1>toxic epidermal necrolysis</e1> associated with <e2>ofloxacin</e2> use, but no details of the cases were given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2672	 is hoped that this case report creates awareness that <e1>ofloxacin</e1> -induced <e2>toxic epidermal necrolysis</e2> is possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2673	 To report a fatal case of <e1>toxic epidermal necrolysis</e1> in a man who was treated with oral <e2>ofloxacin</e2> for epididymitis."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2674	 a probable cause of <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2675	 report rules out other causes of <e1>toxic epidermal necrolysis</e1> and implicates <e2>ofloxacin</e2> in what appears to be an atypical presentation of drug-induced <e1>toxic epidermal necrolysis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2676	 report rules out other causes of <e1>toxic epidermal necrolysis</e1> and implicates <e2>ofloxacin</e2> in what appears to be an atypical presentation of drug-induced <e1>toxic epidermal necrolysis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2677	 boy with chronic neutropenia and recurrent inflammatory skin lesions developed <e1>multiple erythematous nodules</e1> following administration of <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2678	 girl with cystic fibrosis and cyclic neutropenia developed an <e1>erythematous papular eruption</e1> without fever or neutrophilia 7 months after commencing therapy with <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2679	 dermatoses</e1> in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (<e2>G-CSF</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2680	 dermatoses</e1> in two children with idiopathic neutropenia: association with <e2>granulocyte colony-stimulating factor</e2> (G-CSF) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2681	 <e1>neutrophilic skin lesions</e1> were observed in two children receiving granulocyte colony-stimulating factor (<e2>G-CSF</e2>) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2682	 <e1>neutrophilic skin lesions</e1> were observed in two children receiving <e2>granulocyte colony-stimulating factor</e2> (G-CSF) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2683	 neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (<e2>G-CSF</e2>) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2684	 neutrophilic skin lesions were observed in two children receiving <e2>granulocyte colony-stimulating factor</e2> (G-CSF) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2685	 believe that these skin eruptions belong to a spectrum of <e1>neutrophilic dermatoses</e1> that can be induced or aggravated by <e2>G-CSF</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2686	 believe that these <e1>skin eruptions</e1> belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by <e2>G-CSF</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2687	 is a putative role of <e1>liothyronine</e1> administration in precipitating or activating <e2>hyperthyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2688	 -induced <e2>thyrotoxicosis</e2> in ophthalmic Graves disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2689	 case report describes the development of asymptomatic visual field defects (<e1>VFDs</e1>) in a psychiatric patient with bipolar disorder receiving adjunctive <e2>tiagabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2690	 case report describes the development of asymptomatic <e1>visual field defects</e1> (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive <e2>tiagabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2691	 toxicity</e1> with <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2692	 is the second report of <e1>acute lung injury</e1> and diffuse alveolar damage caused by <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2693	 is the second report of acute lung injury and <e1>diffuse alveolar damage</e1> caused by <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2694	 report presents a case of <e1>acute lung injury</e1> developing within hours after administration of <e2>mefloquine</e2> for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2695	 adult male presented with <e1>central blindness</e1> after ingesting <e2>methanol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2696	 of severe <e1>methanol</e1> -induced <e2>visual impairment</e2>: no evidence of retinal toxicity due to fomepizole."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2697	 caution should be taken in using <e1>octreotide</e1> or its long-acting analog in patients otherwise predisposed to <e2>intrahepatic bile stasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2698	 and <e1>bile sludge</e1> are common side effects of <e2>octreotide</e2> therapy but rarely become symptomatic or require treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2699	 and bile sludge are common side effects of <e2>octreotide</e2> therapy but rarely become symptomatic or require treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2700	 (intrahepatic stone) during <e2>octreotide</e2> therapy for acromegaly: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2701	 addition to its known effect on gallbladder stasis, <e1>octreotide</e1> <e2>alters bile acid composition</e2> and may thus hasten intrahepatic sludge and stone formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2702	 addition to its known effect on <e1>gallbladder stasis</e1>, <e2>octreotide</e2> alters bile acid composition and may thus hasten intrahepatic sludge and stone formation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2703	 addition to its known effect on gallbladder stasis, <e1>octreotide</e1> alters bile acid composition and may thus <e2>hasten intrahepatic sludge</e2> and stone formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2704	 addition to its known effect on gallbladder stasis, <e1>octreotide</e1> alters bile acid composition and may thus hasten intrahepatic sludge and <e2>stone formation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2705	 is the first reported case of <e1>hepatolithiasis</e1> during <e2>octreotide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2706	 report a case of <e1>hepatolithiasis</e1> (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with <e2>octreotide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2707	 in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between <e1>tamoxifen</e1> therapy in women with breast cancer and the development of <e2>endometrial carcinoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2708	 this healthy population, the relative risk of developing <e1>endometrial carcinoma</e1> in the <e2>tamoxifen</e2> arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2709	 which is a leading cause of <e2>drug eruptions</e2> in the above group of drugs was withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2710	 acid hydrazide</e1> induced <e2>anagen effluvium</e2> and associated lichenoid eruption."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2711	 acid hydrazide</e1> induced anagen effluvium and associated <e2>lichenoid eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2712	 <e1>anagen effluvium</e1> with lichenoid eruption following <e2>INH</e2> therapy has not been observed previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2713	 anagen effluvium with <e1>lichenoid eruption</e1> following <e2>INH</e2> therapy has not been observed previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2714	 IgA bullous dermatosis</e1> occurring after <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2715	 report a patient who experienced <e1>LABD</e1> shortly after starting <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2716	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, <e2>agitation</e2>, fever, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2717	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with <e2>confusion</e2>, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2718	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, <e2>diaphoresis</e2>, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2719	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, <e2>fever</e2>, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2720	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and <e2>hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2721	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, <e2>tachycardia</e2>, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2722	 a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, <e2>tachypnea</e2>, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2723	 Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving sertraline or venlafaxine when <e2>metoclopramide</e2> is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2724	 Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving <e2>sertraline</e2> or venlafaxine when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2725	 Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving sertraline or <e2>venlafaxine</e2> when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2726	 Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when <e2>metoclopramide</e2> is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2727	 Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving <e2>sertraline</e2> or venlafaxine when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2728	 Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving sertraline or <e2>venlafaxine</e2> when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2729	 To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when <e2>metoclopramide</e2> was coadministered with sertraline or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2730	 To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when metoclopramide was coadministered with <e2>sertraline</e2> or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2731	 To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when metoclopramide was coadministered with sertraline or <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2732	 To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when <e2>metoclopramide</e2> was coadministered with sertraline or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2733	 To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with <e2>sertraline</e2> or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2734	 To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2735	 syndrome</e1> caused by selective serotonin reuptake-inhibitors-<e2>metoclopramide</e2> interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2736	 was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed <e2>agitation</e2>, dysarthria, diaphoresis, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2737	 was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, dysarthria, <e2>diaphoresis</e2>, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2738	 was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, <e2>dysarthria</e2>, diaphoresis, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2739	 was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a <e2>movement disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2740	 was admitted following a fall and, after being given <e1>metoclopramide</e1>, developed <e2>movement disorder</e2> and a period of unresponsiveness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2741	 was admitted following a fall and, after being given <e1>metoclopramide</e1>, developed movement disorder and a period of <e2>unresponsiveness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2742	 patient suffering from a rare enzyme deficiency developed a <e1>malignant neuroleptic syndrome</e1> after having been treated with one single dose of <e2>haloperidol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2743	 reports on <e1>delated cutaneous reactions</e1> to <e2>captopril</e2> have been seldom reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2744	 is an angiotensin-converting enzyme (ACE) inhibitor and their <e2>cutaneous side-effects</e2> are documented, but little has been published concerning the usefulness of patch test when they occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2745	 to <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2746	 presented the case of a patient who developed a <e1>cutaneous reaction</e1> induced by <e2>captopril</e2> with positive patch test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2747	 62-year-old Caucasian man with atrial fibrillation who was taking <e1>warfarin</e1> reported an episode of <e2>hematochezia</e2>; his international normalized ratio (INR) was 1.74."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2748	 -associated <e2>bleeding</e2> complication saved life."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2749	 -associated <e2>bleeding</e2> generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2750	 case of polymyositis with <e1>dilated cardiomyopathy</e1> associated with <e2>interferon alpha</e2> treatment for hepatitis B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2751	 case of <e1>polymyositis</e1> with dilated cardiomyopathy associated with <e2>interferon alpha</e2> treatment for hepatitis B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2752	 this case, <e1>interferon alpha</e1> induced polymyositis and <e2>cardiomyopathy</e2> is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2753	 this case, <e1>interferon alpha</e1> induced <e2>polymyositis</e2> and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2754	 is a rare complication of <e2>interferon alpha</e2> treatment as a result of immune-modulating role of the drug itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2755	 treat hepatitis B, <e1>interferon alpha</e1> was administered until the proximal <e2>muscle weakness</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2756	 follow-up after <e1>neoplastic seeding</e1> complicating percutaneous <e2>ethanol</e2> injection for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2757	 describe a case of <e1>subcutaneous metastasis</e1> along the needle track after percutaneous <e2>ethanol</e2> injection (PEI) for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2758	 endometrial carcinoma</e1> in a breast cancer patient treated with <e2>tamoxifen</e2> with normal transvaginal ultrasonography."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2759	 <e1>tamoxifen</e1> therapy can induce <e2>endometrial disorders</e2>, surveillance schemes of women taking <e1>tamoxifen</e1> have been recommended."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2760	 <e1>tamoxifen</e1> therapy can induce <e2>endometrial disorders</e2>, surveillance schemes of women taking <e1>tamoxifen</e1> have been recommended."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2761	 described a very atypical case of a high stage, high grade <e1>endometrial cancer</e1> associated with <e2>tamoxifen</e2> in a 64-year-old woman with a past history of breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2762	 ductopenia was present in two, suggesting that <e1>itraconazole</e1> might be responsible for the occurrence of prolonged drug-induced <e2>cholangiopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2763	 <e1>ductopenia</e1> was present in two, suggesting that <e2>itraconazole</e2> might be responsible for the occurrence of prolonged drug-induced cholangiopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2764	 <e1>Itraconazole</e1> -induced liver injury presents with a <e2>cholestatic pattern of injury</e2> with damage to the interlobular bile ducts, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2765	 <e1>Itraconazole</e1> -induced liver injury presents with a cholestatic pattern of injury with <e2>damage to the interlobular bile ducts</e2>, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2766	 <e1>Itraconazole</e1> -induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to <e2>ductopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2767	 <e1>Itraconazole</e1> -induced <e2>liver injury</e2> presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2768	 related to <e2>itraconazole</e2>: report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2769	 Three patients with apparent <e1>itraconazole</e1> -induced <e2>liver injury</e2> were studied."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2770	 occurrence of acute <e1>hepatitis</e1> is best known for <e2>ketoconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2771	 report on three patients who developed acute <e1>liver damage</e1> during therapy with <e2>itraconazole</e2>, and in whom liver biopsy specimens were obtained."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2772	 suggest that <e1>itraconazole</e1> should be added to the list of drugs that may be responsible for a drug-induced <e2>vanishing bile duct syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2773	 <e1>itraconazole</e1>, <e2>hepatotoxic</e2> reactions have only very rarely been reported, and histologic data are lacking."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2774	 stroke</e1> associated with the use of <e2>porcine factor VIII</e2> in a patient with acquired haemophilia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2775	 have recently encountered a patient with acquired haemophilia who developed a <e1>thrombotic left middle cerebral artery distribution stroke</e1> while being treated with <e2>pFVIII</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2776	 speculate that platelet activation induced by <e1>pFVIII</e1> may have contributed to <e2>thrombosis</e2> and suggest that <e1>pFVIII</e1> be used with caution in elderly patients with pre-existing cardiovascular risk factors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2777	 sarcoidosis</e1> during <e2>interferon alfa</e2> and ribavirin treatment of hepatitis C virus infection: two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2778	 sarcoidosis</e1> during interferon alfa and <e2>ribavirin</e2> treatment of hepatitis C virus infection: two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2779	 have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with <e2>interferon alfa</e2> and more recently with the combination of <e2>interferon alfa</e2> plus ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2780	 have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with <e2>interferon alfa</e2> and more recently with the combination of <e2>interferon alfa</e2> plus ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2781	 have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with interferon alfa and more recently with the combination of interferon alfa plus <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2782	 report two new cases of <e1>sarcoidosis</e1> in two patients with hepatitis C virus infection treated with <e2>interferon alfa</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2783	 report two new cases of <e1>sarcoidosis</e1> in two patients with hepatitis C virus infection treated with interferon alfa and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2784	 Although <e1>mirtazapine</e1> offers clinicians a combination of strong efficacy and good safety, we suggest bearing <e2>SS</e2> in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2785	 A review of the cases of <e1>SS</e1> with implication of <e2>mirtazapine</e2> as the cause was performed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2786	 To document a case of <e1>serotonin syndrome</e1> (SS) associated with <e2>mirtazapine</e2> monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2787	 To document a case of serotonin syndrome (<e1>SS</e1>) associated with <e2>mirtazapine</e2> monotherapy, review the previously reported cases of <e1>SS</e1> associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2788	 <e1>serotonin syndrome</e1> induced by <e2>mirtazapine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2789	 toxicity</e1> secondary to <e2>procarbazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2790	 64-year-old man presented with <e1>proteinuria</e1> during postoperative <e2>interferon (IFN)-beta</e2> therapy against malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2791	 change nephrotic syndrome</e1> developing during postoperative <e2>interferon-beta</e2> therapy for malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2792	 our knowledge this is the first report that demonstrates <e1>histological abnormalities of the glomerulus</e1> associated with postoperative <e2>IFN-beta</e2> therapy for the malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2793	 authors report two cases of <e1>delayed elimination</e1> of methotrexate in patients receiving <e2>ciprofloxacin</e2>, with severe toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2794	 authors report two cases of <e1>delayed elimination</e1> of <e2>methotrexate</e2> in patients receiving ciprofloxacin, with severe toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2795	 authors report two cases of delayed elimination of methotrexate in patients receiving <e1>ciprofloxacin</e1>, with severe <e2>toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2796	 Clinicians should be aware of the possible association of <e1>thrombocytopenia</e1> with <e2>lansoprazole</e2> and discontinue the drug if <e1>thrombocytopenia</e1> becomes apparent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2797	 After exclusion of other causes, the onset of <e1>thrombocytopenia</e1> after administration of <e2>lansoprazole</e2>, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2798	 After exclusion of other causes, the onset of thrombocytopenia after administration of <e1>lansoprazole</e1>, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic <e2>thrombocytopenic</e2> response to <e1>lansoprazole</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2799	 was started on oral <e1>lansoprazole</e1> 60 mg twice daily and, on hospital day 2, his <e2>platelet count decreased</e2> to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2800	 -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2801	 To describe a case of <e1>thrombocytopenia</e1> associated with the administration of <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2802	 date, this is the first reported case of what appears to be isolated <e1>thrombocytopenia</e1> associated with <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2803	 <e1>anaphylactoid reaction</e1> to <e2>amifostine</e2> used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2804	 most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, hypotension, hypocalcemia and <e2>allergic reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2805	 most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, hypotension, <e2>hypocalcemia</e2> and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2806	 most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, <e2>hypotension</e2>, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2807	 most common side effects associated with <e1>amifostine</e1> are <e2>nausea</e2>, vomiting, hypotension, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2808	 most common side effects associated with <e1>amifostine</e1> are nausea, <e2>vomiting</e2>, hypotension, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2809	 patient suffered a <e1>life-threatening anaphylactoid reaction</e1> to <e2>amifostine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2810	 during <e2>clozapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2811	 and <e1>agranulocytosis</e1> are considered among the most dangerous adverse effects of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2812	 and agranulocytosis are considered among the most dangerous adverse effects of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2813	 female patient received <e1>clozapine</e1> in a daily dose of 400 mg, which induced <e2>agranulocytosis</e2> after 2 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2814	 male patient was treated with 225-mg/day <e1>clozapine</e1> and the time to the diagnosis of <e2>agranulocytosis</e2> was 6 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2815	 53-year-old man developed <e1>NMS</e1> without rigidity while taking <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2816	 <e1>neuroleptic malignant syndrome</e1> associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2817	 SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral <e1>zuclopenthixol</e1>, an antipsychotic from the thioxanthene family, who developed an acute, <e2>painful erection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

2818	 <e1>Priapism</e1> is an uncommon but potentially serious adverse effect of <e2>zuclopenthixol</e2> that practitioners, as with many other antipsychotics, should be aware of."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2819	 The occurrence of <e1>priapism</e1> in our patient was related to <e2>zuclopenthixol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2820	 To present a single case of <e1>zuclopenthixol</e1> -induced <e2>priapism</e2> and a literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2821	 associated with <e2>zuclopenthixol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2822	 capacity of <e1>zuclopenthixol</e1> to induce <e2>priapism</e2> is thought to be due to its antagonist activity on alpha-adrenergic receptors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2823	 identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming <e1>sepsis</e1> associated with <e2>metamizole</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2824	 a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of <e2>agranulocytosis</e2> but is widely used in Mexico and other countries."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2825	 is beneficial in <e1>mitomycin</e1> -induced <e2>hemolytic-uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2826	 describe a patient who developed <e1>HUS</e1> after treatment with <e2>mitomycin C</e2> (total dose 144 mg/m2) due to a carcinoma of the ascending colon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2827	 -induced <e2>toxic epidermal necrolysis</e2> in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2828	 our knowledge, this case is the first published report of <e1>levofloxacin</e1> -induced <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2829	 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with cisplatin, vinblastine and <e2>bleomycin</e2> for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2830	 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with <e2>cisplatin</e2>, vinblastine and bleomycin for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2831	 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with cisplatin, <e2>vinblastine</e2> and bleomycin for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2832	 leukoencephalopathy</e1> following cisplatin, <e2>bleomycin</e2> and vinblastine therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2833	 leukoencephalopathy</e1> following <e2>cisplatin</e2>, bleomycin and vinblastine therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2834	 leukoencephalopathy</e1> following cisplatin, bleomycin and <e2>vinblastine</e2> therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2835	 5 days of treatment with <e1>IL-2</e1>, the patient developed a <e2>hemorrhagic lesion</e2> that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2836	 5 days of treatment with <e1>IL-2</e1>, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 <e2>pancytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2837	 5 days of treatment with <e1>IL-2</e1>, the patient developed a hemorrhagic lesion that progressed to <e2>toxic epidermal necrolysis</e2>, as well as grade 4 pancytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2838	 To report a case of <e1>cutaneous and hematologic toxicity</e1> in a patient treated with <e2>IL-2</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2839	 <e1>IL-2</e1> is safe and well tolerated, with a <e2>mortality rate <3</e2>%."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2840	 epidermal necrolysis</e1> associated with <e2>interleukin-2</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2841	 case of <e1>anaphylactoid reaction</e1> due solely to the use of <e2>Gelofusine</e2> in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2842	 allergy--the need for identification jewellery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2843	 authors describe <e1>valproate</e1> -induced <e2>hyperammonemia</e2> and mental status changes in an 88-year-old man, the first known reported case in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2844	 authors describe <e1>valproate</e1> -induced hyperammonemia and <e2>mental status changes</e2> in an 88-year-old man, the first known reported case in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2845	 -induced hyperammonemia as a cause of <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2846	 -induced <e2>hyperammonemia</e2> as a cause of altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2847	 in urinary bladder after <e2>cyclophosphamide</e2> therapy for retinoblastoma and review of bladder sarcomas."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2848	 epivodes of <e1>NMS</e1> occured under treatment with clozapine, risperidone, and <e2>amisulpride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2849	 epivodes of <e1>NMS</e1> occured under treatment with <e2>clozapine</e2>, risperidone, and amisulpride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2850	 epivodes of <e1>NMS</e1> occured under treatment with clozapine, <e2>risperidone</e2>, and amisulpride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2851	 73-year-old woman presented with fever and <e1>cough</e1> 2 weeks after completing the third cycle of <e2>fludarabine</e2> for chronic lymphocytic leukemia (CLL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2852	 73-year-old woman presented with <e1>fever</e1> and cough 2 weeks after completing the third cycle of <e2>fludarabine</e2> for chronic lymphocytic leukemia (CLL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2853	 induced lung toxicity must be considered in all patients who develop unexplained <e2>lung disease</e2> while receiving fludarabine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2854	 induced lung toxicity must be considered in all patients who develop unexplained <e1>lung disease</e1> while receiving <e2>fludarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2855	 induced <e2>lung toxicity</e2> must be considered in all patients who develop unexplained lung disease while receiving fludarabine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2856	 pulmonary nodules</e1>: an unusual presentation of <e2>fludarabine</e2> pulmonary toxicity: case report and review of literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2857	 pulmonary nodules: an unusual presentation of <e1>fludarabine</e1> <e2>pulmonary toxicity</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2858	 case extends the spectrum of <e1>fludarabine</e1> pulmonary toxicity to include <e2>pulmonary nodules</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2859	 case extends the spectrum of <e1>fludarabine</e1> <e2>pulmonary toxicity</e2> to include pulmonary nodules."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2860	 our knowledge, four cases of <e1>interstitial pneumonitis</e1> associated with <e2>fludarabine</e2> have been reported in medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2861	 may be associated rarely with severe <e2>erythroderma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2862	 <e1>erythroderma</e1> as a complication of continuous <e2>epoprostenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2863	 report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, nausea and vomiting, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2864	 report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, <e2>nausea</e2> and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2865	 report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with <e2>rapidly progressive erythema</e2>, scaling, nausea and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2866	 report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, <e2>scaling</e2>, nausea and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2867	 report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, nausea and <e2>vomiting</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2868	 50-year-old diabetic and hypertensive male patient is reported who had <e1>ticlopidine</e1> -induced <e2>marrow aplasia</e2> partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2869	 is no consensus on the treatment of <e1>ticlopidine</e1> -induced <e2>marrow aplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2870	 -induced <e2>marrow aplasia</e2> treated with cyclosporine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2871	 53-year-old man developed <e1>lower leg edema</e1> 4 weeks after <e2>rosiglitazone</e2> was increased from 4 mg once/day to 4 mg twice/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2872	 75-year-old man developed <e1>bilateral lower leg edema</e1> 6 months after switching from troglitazone to <e2>pioglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2873	 77-year-old man developed <e1>ankle, hand, and facial swelling</e1> 2 weeks after starting <e2>rosiglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2874	 cases of <e1>polymorphic ventricular tachycardia</e1> induced by the administration of <e2>verapamil</e2> against paroxysmal supraventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2875	 is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little <e2>proarrhythmic effect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2876	 describe two cases of PSVT that changed to <e1>non-sustained polymorphic ventricular tachycardia</e1> after administration of <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2877	 acid</e1> and <e2>renal complications</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2878	 <e1>mydriasis</e1>: intravenous <e2>lidocaine</e2> adverse reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2879	 present a neonate with a seizure disorder who acutely developed <e1>pupillary mydriasis</e1> secondary to <e2>lidocaine</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2880	 suggest adding this side effect to the list of untoward effects of <e1>lidocaine</e1> and to the differential diagnosis of fixed <e2>dilated pupils</e2> in neonates treated with <e1>lidocaine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2881	 terminating in <e1>acute myeloid leukemia</e1> in a hairy cell leukemia patient treated with <e2>2-deoxycoformycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2882	 terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with <e2>2-deoxycoformycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2883	 the best of our knowledge only two previous cases of <e1>AML</e1> have been linked to treatment of HCL with purine analogs, both with <e2>2-chlorodeoxyadenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2884	 Peripheral administration of low-dose <e1>vasopressin</e1> for septic shock should be discouraged because of the risk of <e2>ischemic skin complications</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2885	 To describe a case of severe <e1>skin necrosis</e1> resulting from peripheral intravenous administration of low-dose <e2>vasopressin</e2> in a patient with catecholamine-resistant septic shock."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2886	 necrosis</e1> after extravasation of low-dose <e2>vasopressin</e2> administered for septic shock."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2887	 induced <e2>hemolytic uremic syndrome</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2888	 is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of <e2>hemolytic uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2889	 <e1>vasculitis</e1> has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of <e2>cladribine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2890	 vasculitis</e1> complicating hairy cell leukaemia treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2891	 describe a 73-year-old woman who developed serious <e1>systemic vasculitis</e1> with associated thrombocytopenia in the course of treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2892	 describe a 73-year-old woman who developed serious systemic vasculitis with associated <e1>thrombocytopenia</e1> in the course of treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2893	 <e1>mammary hyperplasias</e1> have been reported as rare complications of <e2>D-penicillamine</e2> and Neothetazone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2894	 <e1>mammary hyperplasias</e1> have been reported as rare complications of D-penicillamine and <e2>Neothetazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2895	 induced by <e2>bucillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2896	 <e1>bucillamine</e1> was believed to be the cause of the <e2>giant hypertrophy</e2> because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2897	 bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to <e1>D-penicillamine</e1>, which was the subject of an abundance of reports of <e2>mammary hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2898	 authors report the first case of <e1>bucillamine</e1> -induced <e2>giant mammary hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2899	 authors describe three families in whom the occurrence of <e1>FVS</e1> in all the siblings strongly suggests hereditary susceptibility to <e2>valproic acid</e2> -induced adverse outcome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2900	 fetal <e1>valproate</e1> syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and <e2>developmental delay</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2901	 fetal <e1>valproate</e1> syndrome (FVS) is characterized by <e2>distinctive facial appearance</e2>, major and minor malformations, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2902	 fetal <e2>valproate</e2> syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2903	 fetal <e1>valproate</e1> syndrome (<e2>FVS</e2>) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2904	 fetal <e1>valproate</e1> syndrome (FVS) is characterized by distinctive facial appearance, <e2>major and minor malformations</e2>, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2905	 embryopathy in three sets of siblings: further proof of hereditary susceptibility."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2906	 pustular psoriasis</e1> induced by <e2>cyclosporin a</e2> withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2907	 report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of <e1>cyclosporin A</e1> induced a generalised pustular exacerbation and a <e2>aggravation of the joint condition</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2908	 report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of <e1>cyclosporin A</e1> induced a <e2>generalised pustular exacerbation</e2> and a aggravation of the joint condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2909	 first case concerns a 70-year-old man who developed severe <e1>aplastic anemia</e1> 7 weeks after treatment with 500 mg of <e2>ticlopidine</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2910	 second was an 82-year-old man receiving <e1>ticlopidine</e1> for 2 years when, during a febrile episode, he was found neutropenic with <e2>marrow aplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2911	 second was an 82-year-old man receiving <e1>ticlopidine</e1> for 2 years when, during a febrile episode, he was found <e2>neutropenic</e2> with marrow aplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2912	 -induced <e2>aplastic anemia</e2> (TIAA) is considered very uncommon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2913	 -induced aplastic anemia (<e2>TIAA</e2>) is considered very uncommon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2914	 -induced <e2>aplastic anemia</e2>: two new case reports, review, and meta-analysis of 55 additional cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2915	 the data of the 57 patients are evaluated, a reversible direct <e1>cytotoxic effect</e1> of <e2>ticlopidine</e2> on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2916	 drug eruption</e1> to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2917	 used for dysmenorrhea, caused a <e2>herpetiform fixed drug eruption</e2> predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2918	 used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a <e2>red-brown lesion</e2> on the dorsal hand."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2919	 patient who had been treated with large doses of <e1>thyroid hormone</e1> for several years developed features of secondary <e2>hypothyroidism</e2> after <e1>thyroid hormone</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2920	 Gemcitabine has mild renal toxicity, but cases of <e1>gemcitabine</e1> -associated <e2>hemolytic-uremic syndrome</e2> (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2921	 <e1>Gemcitabine</e1> has mild renal toxicity, but cases of gemcitabine-associated <e2>hemolytic-uremic syndrome</e2> (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2922	 Gemcitabine has mild renal toxicity, but cases of <e1>gemcitabine</e1> -associated hemolytic-uremic syndrome (<e2>HUS</e2>) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2923	 <e1>Gemcitabine</e1> has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (<e2>HUS</e2>) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2924	 <e1>Gemcitabine</e1> has mild <e2>renal toxicity</e2>, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2925	 There are only a few confirmed cases of <e1>gemcitabine</e1> -associated <e2>HUS</e2> despite the widespread use of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2926	 -associated <e2>hemolytic-uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2927	 time between initiation of <e1>gemcitabine</e1> therapy and onset of <e2>HUS</e2> was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of <e1>gemcitabine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2928	 time between initiation of <e1>gemcitabine</e1> therapy and onset of <e2>HUS</e2> was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of <e1>gemcitabine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2929	 A case is presented of a 45-year-old woman on prolonged <e1>gemcitabine</e1> treatment for ovarian cancer who developed <e2>HUS</e2> and recovered after drug discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2930	 Including our own patient, a total of 26 cases of <e1>gemcitabine</e1> -associated <e2>HUS</e2> were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-A

2931	 <e1>amiodarone</e1> <e2>optic neuropathy</e2> has been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2932	 revealed <e1>amiodarone</e1> <e2>corneal deposits</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2933	 REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, <e2>color vision anomalies</e2>, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-

2934	 REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually <e2>decreased vision</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

2935	 REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," <e2>glare</e2>, color vision anomalies, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-

2936	 REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of <e2>visual "shining</e2>," glare, color vision anomalies, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-

2937	 changes</e1> secondary to initiation of <e2>amiodarone</e2>: a case report and review involving ocular management in cardiac polypharmacy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2938	 both <e1>amiodarone</e1> and digoxin can cause permanent visual changes, the <e2>ocular effects</e2> are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2939	 both amiodarone and <e1>digoxin</e1> can cause permanent visual changes, the <e2>ocular effects</e2> are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2940	 both <e1>amiodarone</e1> and digoxin can cause permanent <e2>visual changes</e2>, the ocular effects are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2941	 both amiodarone and <e1>digoxin</e1> can cause permanent <e2>visual changes</e2>, the ocular effects are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2942	 twins sustained severe <e1>circumoral and pharyngeal burns</e1> from a concentrated solution of <e2>benzalkonium</e2> (Zephiran) chloride prescribed for treatment of candidiasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2943	 twins sustained severe <e1>circumoral and pharyngeal burns</e1> from a concentrated solution of benzalkonium (<e2>Zephiran</e2>) chloride prescribed for treatment of candidiasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2944	 Long-term treatment with <e1>rifabutin</e1> may have a reversible and previously undescribed <e2>side-effect on retinal function</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2945	 To describe the clinical and electrophysiological findings in a young boy with <e1>decreased vision</e1> possibly due to retinal damage by <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2946	 To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to <e1>retinal damage</e1> by <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2947	 dysfunction and <e1>anterior segment deposits</e1> in a patient treated with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2948	 dysfunction</e1> and anterior segment deposits in a patient treated with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2949	 suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with <e1>visual disturbance</e1> during treatment with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2950	 case is presented of a patient who experienced <e1>benzodiazepine withdrawal symptoms</e1> on discontinuation of <e2>nefazodone</e2>, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2951	 case of <e1>SIADH</e1> induced by <e2>mizoribin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2952	 hypersecretion</e1> in relation to plasma osmolality was reversed by <e2>mizoribin</e2> withdrawal, suggesting that bredinin might adversely induce SIADH."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2953	 hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that <e1>bredinin</e1> might adversely induce <e2>SIADH</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2954	 summary, we report herein the first case of <e1>SIADH</e1> believed to be an adverse effect of <e2>mizoribin</e2>, which may therefore needed to be added to the list of drugs which can induce <e1>SIADH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2955	 summary, we report herein the first case of <e1>SIADH</e1> believed to be an adverse effect of <e2>mizoribin</e2>, which may therefore needed to be added to the list of drugs which can induce <e1>SIADH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2956	 describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) 1.5 months after commencement of <e2>mizoribin</e2> prescription when his arthritis was improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2957	 describe a 74-year-old man with rheumatoid arthritis (RA) who developed <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) 1.5 months after commencement of <e2>mizoribin</e2> prescription when his arthritis was improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2958	 disease-modifying drugs he was taking, <e1>cyclosporin</e1> and methotrexate, were stopped, and the <e2>lymphoma</e2> resolved spontaneously without the use of chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2959	 disease-modifying drugs he was taking, cyclosporin and <e1>methotrexate</e1>, were stopped, and the <e2>lymphoma</e2> resolved spontaneously without the use of chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2960	 onset of <e1>nephrotic syndrome</e1> during <e2>interferon-alpha</e2> retreatment for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2961	 herein report this rare case of acute onset of <e1>nephrotic syndrome</e1> during <e2>interferon-alpha</e2> retreatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2962	 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced <e1>seizures</e1> after receiving therapy with <e2>interferon beta-1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2963	 and <e1>extrapyramidal symptoms</e1> in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and <e2>clomipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2964	 and <e1>extrapyramidal symptoms</e1> in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <e2>interferon beta-1a</e2> and clomipramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2965	 and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and <e2>clomipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2966	 and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <e2>interferon beta-1a</e2> and clomipramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2967	 68-year-old female patient with advanced ovarian carcinoma <e1>collapsed</e1> whilst receiving a <e2>carboplatin</e2> and cyclophosphamide infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2968	 68-year-old female patient with advanced ovarian carcinoma <e1>collapsed</e1> whilst receiving a carboplatin and <e2>cyclophosphamide</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2969	 hypersensitivity presenting as <e2>coronary vasospasm</e2> - a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2970	 to <e1>carboplatin</e1> is a rare but real complication of therapy and should be considered in patients presenting with <e2>hyperacute changes on ECG</e2> whilst receiving <e1>carboplatin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2971	 to <e2>carboplatin</e2> is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving <e2>carboplatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2972	 60-year-old white man with chronic bronchitis was noted to develop <e1>acute respiratory failure</e1> and metabolic acidosis four days after being started on <e2>methazolamide</e2> (Neptazane) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2973	 60-year-old white man with chronic bronchitis was noted to develop <e1>acute respiratory failure</e1> and metabolic acidosis four days after being started on methazolamide (<e2>Neptazane</e2>) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2974	 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and <e1>metabolic acidosis</e1> four days after being started on <e2>methazolamide</e2> (Neptazane) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2975	 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and <e1>metabolic acidosis</e1> four days after being started on methazolamide (<e2>Neptazane</e2>) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2976	 was discontinued and the <e2>allergic reactions</e2> resolved after the woman took diphenhydramine for 1 week."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2977	 The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2978	 for <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2979	 was postulated that the <e1>allergic reaction</e1> was most likely caused by <e2>capecitabine</e2> or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2980	 To report the safe use of fluorouracil in a patient with breast cancer who had <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

2981	 developed a generalized rash and itching, sore throat, and <e1>dizziness</e1> approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2982	 developed a <e1>generalized rash</e1> and itching, sore throat, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2983	 developed a generalized rash and <e1>itching</e1>, sore throat, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2984	 developed a generalized rash and itching, <e1>sore throat</e1>, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2985	 five and six weeks of continuous oral administration of <e1>methylprednisolone</e1>, the boys developed <e2>steroid diabetes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2986	 of <e1>methylprednisolone</e1> dosage rather than insulin therapy resulted in better control of <e2>glycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2987	 to previous recommendations, our experience cautions against the further use of high-dose <e1>cytarabine</e1> in patients who develop <e2>PPE</e2>, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2988	 has been suggested that <e1>PPE</e1> caused by <e2>cytarabine</e2> does not recur with subsequent <e2>cytarabine</e2> re-challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2989	 <e1>palmar-plantar erythrodysaesthesia</e1> following high-dose <e2>cytarabine</e2> treatment for acute lymphoblastic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2990	 report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe <e1>bullous eruption</e1>, following successive cycles of high-dose <e2>cytarabine</e2> for the treatment of acute lymphoblastic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2991	 report a patient with recurrent, increasingly severe episodes of <e1>PPE</e1>, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose <e2>cytarabine</e2> for the treatment of acute lymphoblastic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2992	 endometriosis may act as a precancerous lesion in the process of <e1>tamoxifen</e1> -induced <e2>malignant transformation of endometriosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2993	 <e1>Ovarian cancer</e1> arising from an endometriotic cyst in a postmenopausal woman under <e2>tamoxifen</e2> therapy is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2994	 <e1>Tamoxifen</e1> may cause <e2>malignant transformation of endometriosis</e2> through atypical endometriosis even in the postmenopausal state."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2995	 endometrioid adenocarcinoma</e1> arising from an endometriotic cyst in a postmenopausal woman under <e2>tamoxifen</e2> therapy for breast cancer: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2996	 spectroscopic, and imaging abnormalities</e1> resolved with discontinuation of <e2>metronidazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2997	 MRS examination demonstrated a persistent <e1>lactate elevation</e1> during <e2>metronidazole</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2998	 MR imaging and MR spectroscopy abnormalities</e1> in association with <e2>metronidazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2999	 nine previous uncomplicated cycles she developed severe <e1>anaphylaxis</e1> to <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3000	 to <e2>cisplatin</e2> following nine previous uncomplicated cycles."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3001	 to <e2>cisplatin</e2> is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3002	 <e1>isradipine</e1> has been associated with <e2>hepatocellular injury</e2>, there are no reports of fulminant liver failure with this agent, and our patient had been treated for >2 years without signs of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3003	 second possibility is an interaction between <e1>clarithromycin</e1> and isradipine, potentially <e2>increasing the hepatic toxicity</e2> of isradipine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3004	 second possibility is an interaction between clarithromycin and <e1>isradipine</e1>, potentially <e2>increasing the hepatic toxicity</e2> of <e1>isradipine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3005	 second possibility is an interaction between clarithromycin and <e1>isradipine</e1>, potentially <e2>increasing the hepatic toxicity</e2> of <e1>isradipine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3006	 SUMMARY: A 58-year-old white woman developed <e1>fulminant liver failure</e1> while being treated with the macrolide antibiotic <e2>clarithromycin</e2> for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-

3007	 <e1>Clarithromycin</e1> may be a cause of <e2>fulminant liver failure</e2> either alone or by inhibiting the metabolism of other drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3008	 liver failure</e1> associated with <e2>clarithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3009	 To report a patient developing <e1>fulminant liver failure</e1> while being treated with <e2>clarithromycin</e2> for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3010	 most likely cause of liver failure in this patient was, therefore, <e1>clarithromycin</e1>, which undergoes hepatic metabolism and has been reported to cause <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3011	 most likely cause of <e1>liver failure</e1> in this patient was, therefore, <e2>clarithromycin</e2>, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3012	 <e1>paradoxical ocular effect</e1> of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3013	 Under certain circumstances topical <e1>brimonidine</e1> can cause <e2>paradoxical raised IOP</e2> necessitating vigilance in follow-up of patients on topical <e1>brimonidine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3014	 We report an unusual <e1>paradoxical effect</e1> of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3015	 <e1>Brimonidine</e1> was observed to cause <e2>IOP elevation</e2>, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3016	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of <e2>anxiety</e2>, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3017	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, <e2>diaphoresis</e2>, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3018	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with <e2>generalized seizures</e2> and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3019	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with <e2>generalized seizures</e2> and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3020	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and <e2>palpitations</e2>, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3021	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and <e2>status epilepticus</e2> secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3022	 <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and <e2>status epilepticus</e2> secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3023	 withdrawal presenting as <e2>status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3024	 visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and <e1>altered mental status</e1> after <e2>zonisamide</e2> treatment was begun or its dosage increased."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3025	 <e1>visual hallucinations</e1> have not been reported as an adverse effect of this agent, we describe three patients who experienced complex <e1>visual hallucinations</e1> and altered mental status after <e2>zonisamide</e2> treatment was begun or its dosage increased."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3026	 hallucinations</e1> associated with <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3027	 -induced <e2>hypoglycemia</e2> in a nondiabetic young man."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3028	 report the first case of <e1>doxycycline</e1> -induced <e2>hypoglycemia</e2> in a young nondiabetic man."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3029	 patients who suffer from osteogenic sarcoma and have <e1>anaphylactic reactions</e1> to <e2>MTX</e2>, this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3030	 had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, facial swelling, cough, and <e2>chest tightness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3031	 had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, facial swelling, <e2>cough</e2>, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3032	 had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with <e2>diffuse urticaria</e2>, facial swelling, cough, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3033	 had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, <e2>facial swelling</e2>, cough, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3034	 had an immediate <e1>hypersensitivity reaction</e1> during the initiation of the <e2>MTX</e2> infusion with diffuse urticaria, facial swelling, cough, and chest tightness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3035	 was later skin tested to confirm <e1>allergy</e1> to <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3036	 desensitization to high-dose <e1>methotrexate</e1> after <e2>systemic anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3037	 successful development and implementation of this protocol will have impact on patients who have <e1>anaphylactic reactions</e1> to <e2>MTX</e2> but require this medication for specific diseases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3038	 authors report a case of <e1>Balint syndrome</e1> with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3039	 authors report a case of <e1>Balint syndrome</e1> with irreversible posterior leukoencephalopathy on MRI following intrathecal <e2>methotrexate</e2> and cytarabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3040	 authors report a case of Balint syndrome with irreversible <e1>posterior leukoencephalopathy</e1> on MRI following intrathecal methotrexate and <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3041	 authors report a case of Balint syndrome with irreversible <e1>posterior leukoencephalopathy</e1> on MRI following intrathecal <e2>methotrexate</e2> and cytarabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3042	 present a unique case of <e1>GTBM</e1> in a patient with myeloma following treatment with <e2>Melphalan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3043	 with lymphoblastic lymphoma who had treatment with <e1>L-asparaginase</e1> and steroid are predisposed to the development of <e2>cortical venous thrombosis</e2> and may have this syndrome in addition to a dural puncture headache."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3044	 with lymphoblastic lymphoma who had treatment with <e1>L-asparaginase</e1> and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a <e2>dural puncture headache</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3045	 pneumonitis</e1> associated with <e2>sirolimus</e2>: a dilemma for lung transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3046	 <e2>pneumonitis</e2> has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3047	 -induced <e2>pneumonitis</e2> has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3048	 pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e2>pulmonary infiltrate</e2> that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3049	 -induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e2>pulmonary infiltrate</e2> that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3050	 pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e1>pulmonary infiltrate</e1> that reversed after ceasing <e2>SR</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3051	 (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3052	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3053	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3054	 (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3055	 (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3056	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3057	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3058	 (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3059	 (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3060	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3061	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3062	 (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3063	 (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3064	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3065	 (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3066	 (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3067	 16-year-old boy developed <e1>fever</e1>, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3068	 16-year-old boy developed <e1>fever</e1>, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3069	 16-year-old boy developed fever, <e1>generalized rigidity</e1>, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3070	 16-year-old boy developed fever, <e1>generalized rigidity</e1>, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3071	 16-year-old boy developed fever, generalized rigidity, leukocytosis, and <e1>increased serum transaminase and creatine kinase</e1> levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3072	 16-year-old boy developed fever, generalized rigidity, leukocytosis, and <e1>increased serum transaminase and creatine kinase</e1> levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3073	 16-year-old boy developed fever, generalized rigidity, <e1>leukocytosis</e1>, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3074	 16-year-old boy developed fever, generalized rigidity, <e1>leukocytosis</e1>, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3075	 administration of <e1>lithium</e1> with olanzapine may place patients at risk for <e2>NMS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3076	 administration of lithium with <e1>olanzapine</e1> may place patients at risk for <e2>NMS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3077	 malignant syndrome</e1> in an adolescent receiving olanzapine-<e2>lithium</e2> combination therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3078	 malignant syndrome</e1> in an adolescent receiving <e2>olanzapine</e2> -lithium combination therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3079	 <e1>6-MP</e1> and AZA are widely used and are known to cause <e2>hepatotoxicity</e2> in a proportion of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3080	 6-MP and <e1>AZA</e1> are widely used and are known to cause <e2>hepatotoxicity</e2> in a proportion of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3081	 associated with <e2>6-thioguanine</e2> therapy for Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3082	 case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of <e1>thiopurine</e1> -induced <e2>hepatic injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3083	 believe the temporal association of the <e1>abnormal liver enzymes</e1> in this patient, in the absence of other offending agents, argues strongly in favor of <e2>6-TG</e2> as a cause of liver enzyme abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3084	 believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of <e1>6-TG</e1> as a cause of <e2>liver enzyme abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3085	 describe a case of significant <e1>elevation of serum transaminases</e1> in a patient treated with <e2>6-TG</e2> for a flare of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3086	 peritoneal dialysis has not previously been reported for <e1>lisinopril</e1> induced <e2>multiorgan failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3087	 observed transient <e1>panhypogammaglobulinaemia</e1> in a patient with neuropsychiatric SLE after treatment with prednisolone and <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3088	 observed transient <e1>panhypogammaglobulinaemia</e1> in a patient with neuropsychiatric SLE after treatment with <e2>prednisolone</e2> and cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3089	 hepatic failure</e1> developed in a 24-year-old black woman who had been treated with propylthiouracil and <e2>propranolol</e2> for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3090	 hepatic failure</e1> developed in a 24-year-old black woman who had been treated with <e2>propylthiouracil</e2> and propranolol for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3091	 hepatitis</e1> and lymphocyte sensitization due to <e2>propylthiouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3092	 observations indicate that submassive hepatic necrosis may result from treatment with <e1>propylthiouracil</e1> and are consistent with the notion that sensitization mechanisms may be responsible for the <e2>hepatic injury</e2> induced by this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3093	 observations indicate that <e1>submassive hepatic necrosis</e1> may result from treatment with <e2>propylthiouracil</e2> and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3094	 diagnosis of <e1>hypothermia</e1> was delayed until it was apparent for several days but resolved with the discontinuation of <e2>risperidone</e2> and continuation of clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3095	 is a case report of subtle, mild <e1>hypothermia</e1> in a 54-year old female patient receiving <e2>risperidone</e2> for schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3096	 is a relatively rare side effect with the newer atypical antipsychotic agents, particularly <e2>clozapine</e2>, and is easily misdiagnosed in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3097	 -induced <e2>akathisia</e2> in children with schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3098	 cases of childhood-onset schizophrenia associated with <e1>clozapine</e1> -induced <e2>akathisia</e2> responsive to beta-blocker treatment are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3099	 reviewing the literature we suggest the CPM was a complication of <e1>lithium</e1> toxicity which affected the lateral geniculate nucleus which produced <e2>blindness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3100	 reviewing the literature we suggest the <e1>CPM</e1> was a complication of <e2>lithium</e2> toxicity which affected the lateral geniculate nucleus which produced blindness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3101	 pontine myelinolysis</e1> manifested by temporary blindness: a possible complication of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3102	 pontine myelinolysis manifested by <e1>temporary blindness</e1>: a possible complication of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3103	 treatment with <e1>propylthiouracil</e1> (PTU) resulted in <e2>elevated hepatic enzymes</e2> and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3104	 treatment with propylthiouracil (<e1>PTU</e1>) resulted in <e2>elevated hepatic enzymes</e2> and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3105	 treatment with carbimazole of a hyperthyroid pregnancy with <e1>hepatic impairment</e1> after <e2>propylthiouracil</e2> administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3106	 (<e1>IFN-alpha</e1>) may precipitate or exacerbate the occurrence of <e2>MPGN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3107	 (IFN-alpha) may precipitate or exacerbate the occurrence of <e2>MPGN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3108	 change disease</e1> in a patient receiving <e2>IFN-alpha</e2> therapy for chronic hepatitis C virus infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3109	 58-yr-old male patient with essential thrombocythaemia (ET) developed <e1>chronic myeloid leukaemia</e1> (CML) after continuous uneventful treatment with <e2>hydroxyurea</e2> for 18 yr."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3110	 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (<e1>CML</e1>) after continuous uneventful treatment with <e2>hydroxyurea</e2> for 18 yr."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3111	 of <e1>Philadelphia positive chronic myeloid leukaemia</e1> during treatment with <e2>hydroxyurea</e2> for Philadelphia negative essential thrombocythaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3112	 are no previous reports in the literature about the emergence of <e1>CML</e1> during treatment with <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3113	 fever resolved, but he developed symptoms consistent with those of <e2>chloroquine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3114	 To report a case of severe <e2>chloroquine</e2> toxicity in the presence of high-grade <e2>chloroquine</e2> -resistant Plasmodium vivax."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3115	 related to <e2>chloroquine</e2> treatment of resistant vivax malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3116	 72-year-old woman with a history of thyrotoxicosis presented with sore throat and <e1>fever</e1> two weeks after starting <e2>carbimazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3117	 72-year-old woman with a history of thyrotoxicosis presented with <e1>sore throat</e1> and fever two weeks after starting <e2>carbimazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3118	 of <e1>carbimazole</e1> -induced <e2>agranulocytosis</e2> and sepsis with granulocyte colony stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3119	 of <e1>carbimazole</e1> -induced agranulocytosis and <e2>sepsis</e2> with granulocyte colony stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3120	 present the management of <e1>agranulocytosis</e1> and neutropenic sepsis secondary to <e2>carbimazole</e2> with recombinant human granulocyte colony stimulating factor (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3121	 present the management of agranulocytosis and <e1>neutropenic sepsis</e1> secondary to <e2>carbimazole</e2> with recombinant human granulocyte colony stimulating factor (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3122	 perforation</e1> after pterygium excision and intraoperative <e2>mitomycin C</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3123	 the best of our knowledge, <e1>corneoscleral melting</e1> in the first postoperative week after a single intraoperative application of <e2>mitomycin C</e2> has not been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3124	 71-year-old man, who had a history of a previous <e1>bullous drug reaction</e1> to a <e2>sulfonamide</e2>, began receiving an ophthalmic preparation that contained sulfacetamide sodium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3125	 patient received only the ophthalmic <e1>sulfonamide</e1>, and it was used for one day, but he developed <e2>Stevens-Johnson syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3126	 <e1>sulfonamides</e1> are the best verified drug-trigger for <e2>erythema multiforme</e2> and Stevens-Johnson syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3127	 <e1>sulfonamides</e1> are the best verified drug-trigger for erythema multiforme and <e2>Stevens-Johnson syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3128	 on these findings, the patient was diagnosed with <e1>diabetes insipidus</e1> secondary to <e2>lithium</e2> therapy and was treated successfully with amiloride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3129	 have been aware of <e2>lithium</e2> toxicity for many years and traditionally have administered thiazide diuretics for <e2>lithium</e2> -induced polyuria and nephrogenic diabetes insipidus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3130	 have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced polyuria and <e2>nephrogenic diabetes insipidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3131	 have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced polyuria and <e2>nephrogenic diabetes insipidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3132	 have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced <e2>polyuria</e2> and nephrogenic diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3133	 have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1> -induced <e2>polyuria</e2> and nephrogenic diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3134	 of <e1>lithium</e1> -induced <e2>diabetes insipidus</e2> with amiloride."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3135	 capillary leak syndrome</e1> after granulocyte colony-stimulating factor (<e2>G-CSF</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3136	 capillary leak syndrome</e1> after <e2>granulocyte colony-stimulating factor</e2> (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3137	 present two cases in which both patients suffered with <e1>CLS</e1>, which we believe was caused following administration of <e2>granulocyte colony-stimulating factor</e2>, to our knowledge not described in the intensive care patient previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3138	 which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before <e2>neurologic abnormalities</e2> began."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3139	 identification of <e1>speech loss</e1> linked to <e2>FK506</e2> may be important because reduction or cessation of the drug may be associated with reverse of <e1>speech loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3140	 (<e1>FK506</e1>), an immunosuppressant, has been associated with <e2>mutism</e2> in adults after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3141	 (FK506), an immunosuppressant, has been associated with <e2>mutism</e2> in adults after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3142	 (<e1>FK506</e1>)-induced <e2>mutism</e2> after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3143	 (FK506)-induced <e2>mutism</e2> after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3144	 the use of <e1>insulin</e1> in a patient with liver dysfunction increase water retention in the body, i.e. cause <e1>insulin</e1> <e2>oedema</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3145	 after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked peripheral oedema, <e2>ascites</e2> and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3146	 after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked <e2>peripheral oedema</e2>, ascites and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3147	 after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked peripheral oedema, ascites and <e2>pleural effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3148	 after introduction of <e1>insulin</e1> therapy, she developed <e2>severe anasarca</e2>, including marked peripheral oedema, ascites and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3149	 induced hyperglycaemia could not be controlled sufficiently, despite a high dose of <e1>insulin</e1> (> 110 units/day), suggesting the existence of <e1>insulin</e1> insensitivity and hyper<e1>insulin</e1>aemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3150	 induced hyperglycaemia could not be controlled sufficiently, despite a high dose of <e1>insulin</e1> (> 110 units/day), suggesting the existence of <e1>insulin</e1> insensitivity and hyper<e1>insulin</e1>aemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3151	 conjectured that the side effects of <e1>insulin</e1>, such as <e2>anti-natriuresis</e2> and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3152	 conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3153	 conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and <e2>hypoalbuminaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3154	 conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and <e2>increased vascular permeability</e2>, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3155	 conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3156	 40 mg/day of <e1>prednisolone</e1> improved hepatic dysfunction dramatically, her <e2>diabetic milieu deteriorated</e2> seriously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3157	 <e1>methotrexate</e1> -induced <e2>acute cerebellar syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3158	 describe a patient who developed <e1>acute cerebellar syndrome</e1> after prophylactic intrathecal <e2>methotrexate</e2> administration and recovered spontaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3159	 lymphadenopathy with dysproteinemia</e1> following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3160	 report a case of <e1>AILD</e1> in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3161	 report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and <e1>fever</e1> following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3162	 report a case of AILD in an 80-year-old male who presented with a <e1>generalized pruritic maculopapular eruption</e1> and fever following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3163	 from <e2>isoniazid</e2> is a possible side effect to this commonly prescribed antibiotic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3164	 -induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3165	 case is reported in which severe hypocalcemia, with a <e1>low plasma parathyroid hormone</e1> (PTH) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3166	 case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (<e1>PTH</e1>) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3167	 case is reported in which <e1>severe hypocalcemia</e1>, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3168	 -related <e2>hyponatremia</e2> following cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3169	 discuss the association between <e1>carbamazepine</e1> and <e2>hyponatremia</e2> and the causes of <e2>hyponatremia</e2> after cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3170	 <e1>5-ASA</e1> was discontinued, the <e2>polyneuropathy</e2> symptoms recovered gradually."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3171	 polyneuropathy</e1> with <e2>5-aminosalicylic acid</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3172	 clinical course suggests that the <e1>sensorimotor polyneuropathy</e1> may have been caused by <e2>5-ASA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3173	 SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and <e2>atrophy</e2> in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3174	 SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and <e2>atrophy</e2> in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3175	 SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and <e2>gait disturbance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3176	 SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and <e2>gait disturbance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3177	 SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed <e2>weakness</e2> and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3178	 SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed <e2>weakness</e2> and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3179	 SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive <e2>worsening of the dysesthesia</e2> in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3180	 SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive <e2>worsening of the dysesthesia</e2> in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3181	 cellulitic cryptococcosis</e1> in the setting of <e2>prednisone</e2> monotherapy for pemphigus vulgaris."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3182	 both cases, high fever, skin rash, liver dysfunction and <e1>atypical lymphocytosis</e1> developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3183	 both cases, <e1>high fever</e1>, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3184	 both cases, high fever, skin rash, <e1>liver dysfunction</e1> and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3185	 both cases, high fever, <e1>skin rash</e1>, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3186	 acetylator genotypes as a possible risk factor for <e1>infectious mononucleosis-like syndrome</e1> induced by <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3187	 report two patients with <e1>infectious mononucleosis-like syndrome</e1> induced by <e2>salazosulfapyridine</e2> (SASP)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3188	 report two patients with <e1>infectious mononucleosis-like syndrome</e1> induced by salazosulfapyridine (<e2>SASP</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3189	 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance <e1>infliximab</e1> infusions and methotrexate, developed a <e2>lupus-like syndrome</e2> eight months after her initial infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3190	 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and <e1>methotrexate</e1>, developed a <e2>lupus-like syndrome</e2> eight months after her initial infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3191	 <e1>lupus-like syndrome</e1> associated with <e2>infliximab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3192	 therapy may cause a <e2>lupus-like syndrome</e2> that is reversible upon discontinuing this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3193	 report in detail an unusual adverse reaction to <e1>infliximab</e1> therapy, a drug-induced <e2>lupus-like clinical syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3194	 myelogenous leukemia (CML), hepatitis C, and interferon alpha (<e1>IFNalpha</e1>) have all been associated with <e2>renal dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3195	 myelogenous leukemia (CML), hepatitis C, and <e1>interferon alpha</e1> (IFNalpha) have all been associated with <e2>renal dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3196	 the underlying hepatitis C, this case represents <e1>renal abnormalities</e1> consistent with <e2>IFNalpha</e2> therapy for CML."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3197	 -induced <e2>focal segmental glomerulosclerosis</e2> in chronic myelogenous leukemia: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3198	 renal biopsy showed <e1>focal segmental glomerulosclerosis</e1>, which has only been previously reported in two cases of CML treated with <e2>IFNalpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3199	 <e1>autoimmune hemolytic anemia</e1> following <e2>rituximab</e2> therapy in a patient with a lymphoproliferative disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3200	 pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after <e1>destruction of CD20 positive cells</e1> by <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3201	 pathophysiological mechanisms remain unknown, although the drug could act through <e1>massive cytokines liberation</e1> after destruction of CD20 positive cells by <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3202	 report the first case, to our knowledge, of <e1>rituximab</e1> -related <e2>autoimmune hemolytic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3203	 <e1>acute transverse myelitis</e1> following <e2>hepatitis B vaccination</e2> and respiratory infection: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3204	 this paper, we report a case of 3 years-old boy who developed <e1>acute onset tetraparesia</e1> following a viral respiratory infecction and <e2>hepatitis B vaccination</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3205	 it would be expected that, like other type IA toxicities, <e1>diphenhydramine</e1> -induced <e2>cardiotoxicity</e2> could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3206	 -induced wide complex <e2>dysrhythmia</e2> responds to treatment with sodium bicarbonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3207	 because <e1>diphenhydramine</e1> also exhibits type IA sodium channel blockade, <e2>cardiac toxicity</e2> is also possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3208	 describe 3 cases of <e1>diphenhydramine</e1> -induced <e2>cardiac toxicity</e2> that were responsive to bicarbonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3209	 describe a patient with extranodal non-Hodgkin lymphoma who developed <e1>systemic candidiasis</e1> after treatment with a <e2>cyclophosphamide</e2> -based chemotherapy regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3210	 syndrome</e1> in a boy with nephrotic syndrome during <e2>prednisolone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3211	 report a case of <e1>SJS</e1> in a 14-year-old male with nephrotic syndrome, who was treated with oral <e2>prednisolone</e2> for 6 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3212	 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a <e1>reversal reaction</e1> after starting <e2>dapsone</e2> and rifampin therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3213	 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a <e1>reversal reaction</e1> after starting dapsone and <e2>rifampin</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3214	 in order to avoid <e1>neuropathic side effects</e1>, patients under <e2>thalidomide</e2> therapy should be monitored every 6 months with nerve conduction studies while taking the drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3215	 a two-month interruption of interferon administration, natural <e1>interferon alpha</e1> was given but followed by another episode of the same <e2>neurological manifestations</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3216	 1, a 62-year-old woman, developed <e1>bilateral optic neuritis</e1> with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3217	 1, a 62-year-old woman, developed bilateral optic neuritis with <e1>decreased sensation of vibration</e1> and increased deep tendon reflex in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3218	 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and <e1>increased deep tendon reflex</e1> in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3219	 2, a 29-year-old woman, developed <e1>bilateral optic neuritis</e1> combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3220	 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as <e1>bowel and bladder dysfunction</e1> after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3221	 2, a 29-year-old woman, developed bilateral optic neuritis combined with <e1>numbness of the lower extremities</e1> as well as bowel and bladder dysfunction after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3222	 Optic neuritis in combination with other <e1>neurological signs</e1>, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3223	 <e1>Optic neuritis</e1> in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3224	 sclerosis-like disease</e1> secondary to <e2>alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3225	 To describe <e1>bilateral optic neuritis</e1> that occurred as an adverse effect of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3226	 abdomen</e1> due to endometriosis in a premenopausal woman taking <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3227	 abdomen due to <e1>endometriosis</e1> in a premenopausal woman taking <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3228	 describe a premenopausal woman who, while having <e1>tamoxifen</e1> due to a diagnosis of in situ ductal carcinoma, developed <e2>endometriosis</e2> requiring surgery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3229	 case report of fatal <e1>dapsone</e1> -induced <e2>agranulocytosis</e2> in an Indian mid-borderline leprosy patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3230	 agranulocytosis</e1> in an Indian male receiving 100mg of <e2>dapsone</e2> daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3231	 case reports concerning <e1>dapsone</e1> -induced <e2>agranulocytosis</e2> are reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3232	 pulmonary embolism</e1> due to late-onset <e2>heparin</e2> -induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3233	 pulmonary embolism due to late-onset <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> following coronary artery bypass graft surgery: successful treatment with lepirudin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3234	 cardiac surgical patients have had previous exposure to <e1>heparin</e1> for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT) postoperatively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3235	 psychosis</e1> associated with <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3236	 twelve year-old-girl with idiopathic partial epilepsy with secondary generalization, developed <e1>acute psychosis</e1> 10 days after the administration of <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3237	 <e1>psychotic behavior</e1> resolved completely soon after the discontinuation of <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3238	 "A" was an 8-year-old boy with attention deficit and chronic tic disorder who developed <e1>obsessive-compulsive symptoms</e1> within 2 weeks of starting <e2>risperidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

3239	 symptoms</e1> suddenly emerged 10 days after starting <e2>risperidone</e2> and resolved within 3 days of discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3240	 -induced <e2>obsessive-compulsive symptoms</e2> in two children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3241	 of abnormal bone marrow histiocytes</e1>, an undesired effect of <e2>granulocyte macrophage-colony-stimulating factor</e2> therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3242	 <e1>heart failure exacerbation</e1> associated with <e2>rosiglitazone</e2>: case report and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3243	 -induced <e2>generalized exanthem</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3244	 one case of a <e1>generalized maculopapular rash</e1> with <e2>enoxaparin</e2> has been reported in Europe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3245	 our knowledge, this is the first case reported in the English literature of a <e1>generalized exanthem</e1> due to subcutaneous injection of <e2>enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3246	 side effects associated with <e1>clonazepam</e1> may include agitation, <e2>aggression</e2>, hyperactivity, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3247	 side effects associated with <e1>clonazepam</e1> may include <e2>agitation</e2>, aggression, hyperactivity, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3248	 side effects associated with <e1>clonazepam</e1> may include agitation, aggression, <e2>hyperactivity</e2>, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3249	 side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, <e2>irritability</e2>, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3250	 side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, irritability, <e2>property destruction</e2>, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3251	 side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, irritability, property destruction, and <e2>temper tantrums</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3252	 report describes an individual with mental retardation who experienced <e1>behavioral exacerbation</e1> associated with <e2>clonazepam</e2> prescribed at 2 mg/day (0.02 mg/kg/day) to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3253	 -induced <e2>immune hemolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3254	 report the first case of <e1>IHA</e1> associated with <e2>cefuroxime</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3255	 39 hours on <e1>argatroban</e1>, the infusion was stopped when minor <e2>bleeding</e2> was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3256	 for <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> in hepato-renal failure and CVVHD."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3257	 is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in <e2>hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3258	 To report a case of significant <e1>hepatic and renal failure</e1> with the use of <e2>argatroban</e2> in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3259	 To report a case of significant hepatic and renal failure with the use of argatroban in a patient with <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT) requiring continuous veno-veno hemodialysis (CVVHD)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3260	 first-rank symptoms</e1> associated with <e2>fluvoxamine</e2> treatment: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3261	 patient, a 28-year-old man suffering from panic disorder, developed several <e1>first-rank symptoms</e1> during <e2>fluvoxamine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3262	 communication describes a patient who developed <e1>Schneiderian first-rank symptoms</e1> in the course of treatment with <e2>fluvoxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3263	 finding suggests that <e1>fluvoxamine</e1> can precipitate <e2>Schneiderian first-rank symptoms</e2> in some susceptible patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3264	 present a surprising case of a woman schizophrenic patient treated with <e1>clozapine</e1> suffering from <e2>EPS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3265	 during <e2>interferon-alpha</e2> therapy for chronic hepatitis C virus infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3266	 <e1>skin lesions</e1> may be induced or worsened during antiviral therapy with interferon-alpha (<e2>IFN</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3267	 <e1>skin lesions</e1> may be induced or worsened during antiviral therapy with <e2>interferon-alpha</e2> (IFN)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3268	 describe two dark-skinned patients who developed <e1>hyperpigmented skin</e1> and tongue lesions during combination therapy with <e2>IFN</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3269	 describe two dark-skinned patients who developed <e1>hyperpigmented skin</e1> and tongue lesions during combination therapy with IFN and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3270	 describe two dark-skinned patients who developed hyperpigmented skin and <e1>tongue lesions</e1> during combination therapy with <e2>IFN</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3271	 describe two dark-skinned patients who developed hyperpigmented skin and <e1>tongue lesions</e1> during combination therapy with IFN and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3272	 is concluded that simultaneous administration of <e1>ciprofloxacin</e1> and tazobactam/piperacillin may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3273	 is concluded that simultaneous administration of ciprofloxacin and tazobactam/<e1>piperacillin</e1> may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3274	 is concluded that simultaneous administration of ciprofloxacin and <e1>tazobactam</e1>/piperacillin may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3275	 the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of <e2>ciprofloxacin</e2> and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3276	 the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/<e2>piperacillin</e2> and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3277	 the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and <e2>tazobactam</e2>/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3278	 under <e2>ciprofloxacin</e2> and tazobactam/piperacillin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3279	 under ciprofloxacin and tazobactam/<e2>piperacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3280	 under ciprofloxacin and <e2>tazobactam</e2>/piperacillin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3281	 after the injection of <e2>chymopapain</e2> occurs in about 1% of such cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3282	 patients suddenly became <e1>hypotensive</e1> after injection of <e2>chymopapain</e2> into a disk."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3283	 in a newborn: <e2>lithium</e2> toxicity or lab error?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3284	 in a newborn: <e2>lithium</e2> toxicity or lab error?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3285	 newborn manifested a four day course of <e1>lethargy</e1> with unexplained high <e2>lithium</e2> levels in the adult toxic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3286	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3287	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3288	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3289	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3290	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3291	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3292	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3293	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3294	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3295	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3296	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3297	 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3298	 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3299	 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3300	 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3301	 -induced <e2>systemic lupus erythematosus-like disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3302	 cases of <e1>CBZ</e1> -induced <e2>SLE</e2> reported in the literature were reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3303	 four months, while receiving <e1>RH</e1>, he developed painful <e2>bilateral gynaecomastia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3304	 is a rarely reported adverse drug reaction due to <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3305	 associated, painful, <e2>bilateral gynaecomastia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3306	 patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), recurrent arteriothromboses, and <e2>acute renal failure</e2> after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3307	 patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), recurrent arteriothromboses, and <e2>acute renal failure</e2> after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3308	 patient suffering from <e1>heparin</e1> -associated thrombocytopenia (<e2>HAT</e2>), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3309	 patient suffering from <e1>heparin</e1> -associated thrombocytopenia (<e2>HAT</e2>), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3310	 patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), <e2>recurrent arteriothromboses</e2>, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3311	 patient suffering from <e1>heparin</e1> -associated thrombocytopenia (HAT), <e2>recurrent arteriothromboses</e2>, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3312	 patient suffering from <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3313	 patient suffering from <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3314	 means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine <e2>Clexane</e2> (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3315	 means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins <e2>Fragmin</e2> and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3316	 means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and <e2>Fraxiparin</e2> (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3317	 means of the in vitro <e1>heparin</e1> -induced <e2>platelet activation</e2> (HIPA) assay it was shown that standard <e1>heparin</e1> and the LMW <e1>heparin</e1>s Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e2>platelet activation</e2> with the patient's serum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3318	 -associated <e2>thrombocytopenia</e2>: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3319	 collapse</e1> following <e2>labetalol</e2> administration in preeclampsia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3320	 patient with Parkinson's disease, initially treated with <e1>bromocriptine</e1> and subsequently with cabergoline, developed progressive <e2>pleuropulmonary abnormalities</e2> during the latter therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3321	 patient with Parkinson's disease, initially treated with bromocriptine and subsequently with <e1>cabergoline</e1>, developed progressive <e2>pleuropulmonary abnormalities</e2> during the latter therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3322	 changes</e1> during treatment of Parkinson's disease with a long-acting ergot derivative, <e2>cabergoline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3323	 cabergoline may cause similar <e1>pleuropulmonary abnormalities</e1> to <e2>bromocriptine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3324	 <e1>cabergoline</e1> may cause similar <e2>pleuropulmonary abnormalities</e2> to bromocriptine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3325	 myopathy</e1> with selective degeneration of myosin filaments following status asthmaticus treated with <e2>methylprednisolone</e2> and vecuronium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3326	 myopathy</e1> with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3327	 myopathy with selective <e1>degeneration of myosin filaments</e1> following status asthmaticus treated with <e2>methylprednisolone</e2> and vecuronium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3328	 myopathy with selective <e1>degeneration of myosin filaments</e1> following status asthmaticus treated with methylprednisolone and <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3329	 quadriparesis</e1> was noted after discontinuation of <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3330	 entity is probably related to a combination of high doses of corticosteroids, <e1>vecuronium</e1> administration and metabolic abnormalities associated with <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3331	 patient with ulcerative colitis developed skin pigmentation and <e1>diffuse pulmonary shadowing</e1> without respiratory symptomatology, while taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3332	 patient with ulcerative colitis developed <e1>skin pigmentation</e1> and diffuse pulmonary shadowing without respiratory symptomatology, while taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3333	 infiltrates</e1> and skin pigmentation associated with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3334	 infiltrates and <e1>skin pigmentation</e1> associated with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3335	 -induced <e2>lung disorder</e2> is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3336	 -induced lung disorder is an extremely rare entity which must be considered in all <e2>ulcerative colitis</e2> patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3337	 lung disorder is an extremely rare entity which must be considered in all <e1>ulcerative colitis</e1> patients while on <e2>sulfasalazine</e2> therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3338	 <e1>sclerotic changes of lumbar spine and femur</e1> due to long-term oral <e2>isotretinoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3339	 an association between exposure to <e1>bleomycin</e1> and the development of <e2>scleroderma</e2> has been suspected, few cases are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3340	 series of 3 patients supports a causal connection between <e1>bleomycin</e1> and <e2>scleroderma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3341	 in association with the use of <e2>bleomycin</e2>: a report of 3 cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3342	 describe the development of <e1>cutaneous scleroderma</e1> in 3 patients coincident with the use of <e2>bleomycin</e2> in low cumulative doses of less than 100 U."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3343	 patient presented with <e1>dilated cardiomyopathy</e1> after many years of overusing an <e2>adrenaline</e2> inhaler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3344	 cardiomyopathy</e1> associated with chronic overuse of an <e2>adrenaline</e2> inhaler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3345	 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (<e1>SLE</e1>) with characteristic laboratory findings, 18 months after starting <e2>carbamazepine</e2> maintenance treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3346	 21-year-old woman suffering from bipolar affective disorder developed <e1>systemic lupus erythematosus</e1> (SLE) with characteristic laboratory findings, 18 months after starting <e2>carbamazepine</e2> maintenance treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3347	 both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3348	 both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3349	 both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3350	 -induced <e2>systemic lupus erythematosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3351	 receded after withdrawal of <e2>carbamazepine</e2> and treatment with anti-inflammatory drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3352	 report a case of <e1>acne fulminans</e1> occurring during treatment with <e2>13-cis-retinoic acid</e2> for cystic acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3353	 phosphate synthetase-1 deficiency discovered after <e1>valproic acid</e1> -induced <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3354	 acid</e1> induced <e2>coma</e2> is presented in an adult patient without a history of metabolic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3355	 induced by <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3356	 this report we present four patients treated with a combination of different psychotropic drugs, in whom <e1>asterixis</e1> was triggered either by adding <e2>carbamazepine</e2> (CBZ) to a treatment regimen, or by increasing its dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3357	 this report we present four patients treated with a combination of different psychotropic drugs, in whom <e1>asterixis</e1> was triggered either by adding carbamazepine (<e2>CBZ</e2>) to a treatment regimen, or by increasing its dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3358	 consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e2>CBZ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3359	 consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e2>clozapine</e2> are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3360	 consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as <e2>lithium</e2> or clozapine are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3361	 consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e2>CBZ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3362	 consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e2>clozapine</e2> are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3363	 consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as <e2>lithium</e2> or clozapine are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3364	 and seizures induced by intravesical <e2>alum</e2> irrigations."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3365	 and <e1>seizures</e1> induced by intravesical <e2>alum</e2> irrigations."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3366	 cystitis</e1> is a significant toxic effect of <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3367	 report four cases of encephalopathy coincident with elevated <e2>alum</e2>inum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with <e2>alum</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3368	 report four cases of <e1>encephalopathy</e1> coincident with elevated <e2>alum</e2>inum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with <e2>alum</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3369	 report four cases of encephalopathy coincident with elevated <e1>alum</e1>inum levels as well as one patient who developed <e2>seizures</e2> while receiving continuous bladder irrigations with <e1>alum</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3370	 with <e1>hyponatremia</e1> in a child prescribed <e2>desmopressin</e2> for nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3371	 with hyponatremia in a child prescribed <e2>desmopressin</e2> for nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3372	 report a case of hyponatremia associated with a <e1>grand mal seizure</e1> in a 28 month-old child after intra-nasal <e2>desmopressin</e2> administration for high fluid intake with nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3373	 report a case of <e1>hyponatremia</e1> associated with a grand mal seizure in a 28 month-old child after intra-nasal <e2>desmopressin</e2> administration for high fluid intake with nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3374	 case report describes a 38-year-old male in whom <e1>SIADH</e1> was strongly suspected secondary to <e2>Tegretol</e2> therapy to control a seizure disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3375	 diabetes</e1> was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with <e2>norethisterone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3376	 follow-up revealed that gestational diabetes when associated with <e1>norethisterone</e1> had a lesser risk of emerging <e2>diabetes mellitus</e2> and impaired glucose tolerance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3377	 follow-up revealed that <e1>gestational diabetes</e1> when associated with <e2>norethisterone</e2> had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3378	 follow-up revealed that gestational diabetes when associated with <e1>norethisterone</e1> had a lesser risk of emerging diabetes mellitus and <e2>impaired glucose tolerance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3379	 a single practice during the 21 years 1971-1991, the incidence of <e1>gestational diabetes</e1> in pregnancies in which <e2>norethisterone</e2> was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take <e2>norethisterone</e2> (137 of 1,684) (p < 0.001)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3380	 of a female fetus occurred in 5 of 39 (12.8%) exposed to <e1>norethisterone</e1>; all were cases of <e2>clitoral hypertrophy</e2> not requiring surgical treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3381	 of a female fetus</e1> occurred in 5 of 39 (12.8%) exposed to <e2>norethisterone</e2>; all were cases of clitoral hypertrophy not requiring surgical treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3382	 in these 69 pregnancies accounted for 33.3% (5 of 15) cases of <e2>clitoral hypertrophy</e2> diagnosed in 100,756 consecutive births."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3383	 adverse reaction to <e1>IFN</e1> was strongly suspected as the cause of <e2>CHF</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3384	 myeloma complicated by <e1>congestive heart failure</e1> following first administration of <e2>recombinant alpha-interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3385	 hours after the first administration of <e1>IFN</e1>, <e1>IFN</e1> was suspended by the symptoms of congestive heart failure (<e2>CHF</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3386	 hours after the first administration of <e1>IFN</e1>, <e1>IFN</e1> was suspended by the symptoms of <e2>congestive heart failure</e2> (CHF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3387	 eccrine hidradenitis</e1> mimicking cutaneous vasculitis in a lupus patient: a complication of <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3388	 report a case of <e1>NEH</e1> masquerading as cutaneous vasculitis in a woman receiving <e2>cyclophosphamide</e2> for lupus nephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3389	 cutaneous rash</e1> associated with <e2>ganciclovir</e2> therapy has rarely been reported in literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3390	 rash</e1> and splinter hemorrhages from <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3391	 rash and <e1>splinter hemorrhages</e1> from <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3392	 roxithromycin and <e1>betamethasone</e1> induce <e2>acute pancreatitis</e2>? A case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3393	 <e1>roxithromycin</e1> and betamethasone induce <e2>acute pancreatitis</e2>? A case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3394	 REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and <e1>betamethasone</e1>, manifested <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

3395	 REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with <e1>roxithromycin</e1> and betamethasone, manifested <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

3396	 tubular acidosis</e1> secondary to <e2>FK506</e2> in living donor liver transplantation: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3397	 is one type of <e1>nephrotoxicity</e1> induced by <e2>FK506</e2>, and it is reversible in mild cases when appropriately treated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3398	 is one type of nephrotoxicity induced by <e2>FK506</e2>, and it is reversible in mild cases when appropriately treated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3399	 and physicians should therefore be aware of the potential for <e1>RTA</e1> to occur with <e2>FK506</e2> after any organ transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3400	 mechanism of <e1>RTA</e1> induced by <e2>FK506</e2> has not yet been clearly elucidated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3401	 treatment for acidosis and hyperkalaemia should be started as soon as <e1>RTA</e1> is diagnosed, and the dosage of <e2>FK506</e2> should also be reduced if possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3402	 report a case of <e1>RTA</e1> secondary to <e2>FK506</e2> administration in liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3403	 74-year-old patient with idiopathic Parkinson's disease was evaluated for <e1>unintended sleep episodes</e1> that occurred after long-term treatment with 400 mg/day of <e2>L-dopa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3404	 -induced excessive <e2>daytime sleepiness</e2> in PD: a placebo-controlled case with MSLT assessment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3405	 authors' results suggest that <e1>L-dopa</e1> may cause <e2>daytime somnolence</e2> in some patients with Parkinson's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3406	 of intrathecal <e2>methotrexate</e2>: MR imaging findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3407	 attribute the clinical and radiographic findings to <e1>cytotoxic edema</e1> secondary to intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3408	 report a case of intrathecal <e1>methotrexate</e1> neurotoxicity manifesting as left arm weakness and <e2>aphasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3409	 report a case of intrathecal <e1>methotrexate</e1> neurotoxicity manifesting as <e2>left arm weakness</e2> and aphasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3410	 report a case of intrathecal <e1>methotrexate</e1> <e2>neurotoxicity</e2> manifesting as left arm weakness and aphasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3411	 this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential teratogenicity, and it has been implicated in <e2>Epstein's anomaly</e2>, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3412	 this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential teratogenicity, and it has been implicated in <e2>Epstein's anomaly</e2>, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3413	 this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential <e2>teratogenicity</e2>, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3414	 this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential <e2>teratogenicity</e2>, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3415	 present a case of a 20-year-old woman who ingested 900 mg of <e1>glyburide</e1> causing refractory <e2>hypoglycemia</e2> resistant to treatment with intravenous dextrose, glucagon, and diazoxide."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3416	 <e2>ethambutol</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3417	 most commonly recognized toxic effect of <e1>ethambutol</e1> is <e2>optic neuropathy</e2>, which generally is considered uncommon and reversible in medical literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3418	 case and a review of the literature show the severe and unpredictable nature of <e2>ethambutol</e2> toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3419	 case and a review of the literature show the severe and unpredictable nature of <e1>ethambutol</e1> toxicity and its potential for irreversible <e2>vision loss</e2> despite careful ophthalmologic monitoring."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3420	 describe a 43-year-old man who developed signs and symptoms of <e1>bilateral optic neuropathy</e1> during treatment with <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3421	 case history and toxicological findings of an infant <e1>fatality</e1> involving pseudoephedrine, <e2>brompheniramine</e2>, and dextromethorphan are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3422	 case history and toxicological findings of an infant <e1>fatality</e1> involving pseudoephedrine, brompheniramine, and <e2>dextromethorphan</e2> are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3423	 case history and toxicological findings of an infant <e1>fatality</e1> involving <e2>pseudoephedrine</e2>, brompheniramine, and dextromethorphan are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3424	 <e1>overanticoagulation</e1> with <e2>acenocoumarol</e2> due to a genetic polymorphism of cytochrome P450 CYP2C9."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3425	 report the case of a young healthy woman who presented an early <e1>overanticoagulation</e1> when receiving <e2>acenocoumarol</e2> for a first thromboembolic episode."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3426	 -induced <e2>myopathy</e2> in a teenager with familial Mediterranean fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3427	 <e1>Colchicine</e1> -induced <e2>myopathy</e2> should be excluded in patients with FMF who present with generalized muscle weakness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3428	 <e1>Colchicine</e1>, the most important drug in treatment of FMF, can cause <e2>myopathy</e2> in patients with impaired renal and hepatic function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3429	 our patient, an objective causality scale showed that therapeutic doses of <e1>colchicine</e1> for FMF were the definite cause of <e2>myopathy</e2>, even though his renal and hepatic function were normal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3430	 To report a case of <e1>colchicine</e1> -induced <e2>myopathy</e2> in a teenager with familial Mediterranean fever (FMF)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3431	 and dysphagia caused by contact allergy to inhaled <e2>budesonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3432	 and <e1>dysphagia</e1> caused by contact allergy to inhaled <e2>budesonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3433	 report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and <e1>dysphagia</e1>, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3434	 report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and <e1>dysphagia</e1>, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3435	 report a 43-year-old woman who developed <e1>sore throat</e1>, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3436	 report a 43-year-old woman who developed <e1>sore throat</e1>, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3437	 report a 43-year-old woman who developed sore throat, <e1>swelling of the lips and oral cavity</e1> and dysphagia, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3438	 report a 43-year-old woman who developed sore throat, <e1>swelling of the lips and oral cavity</e1> and dysphagia, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3439	 toxicity</e1> of <e2>dexamethasone</e2> during all remission-induction chemotherapy: report of two cases and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3440	 describe the infectious toxicities experienced by the first two patients in our institution treated with <e1>dexamethasone</e1> (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the <e1>dexamethasone</e1> arm of BFM 2000 and review the relevant literature that suggests an increased risk of <e2>infectious complications</e2> with <e1>dexamethasone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3441	 describe the <e1>infectious toxicities</e1> experienced by the first two patients in our institution treated with <e2>dexamethasone</e2> (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the <e2>dexamethasone</e2> arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with <e2>dexamethasone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3442	 describe a patient who developed <e1>NEH</e1> on three separate occasions provoked by two different chemotherapeutic agents--<e2>cytarabine</e2> and mitoxantrone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3443	 describe a patient who developed <e1>NEH</e1> on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and <e2>mitoxantrone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3444	 diagnosis of <e1>infliximab</e1> -induced <e2>lupus</e2> was made and the drug treatment was withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3445	 -induced <e2>lupus</e2> in Crohn's disease: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3446	 is the first case, to our knowledge, of onset of prolonged <e1>infliximab</e1> -induced <e2>lupus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3447	 with <e1>infliximab</e1> is known to produce an increase of autoantibodies (antinuclear antibodies, <e2>anti-double-stranded DNA</e2>), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3448	 with <e1>infliximab</e1> is known to produce an increase of autoantibodies (<e2>antinuclear antibodies</e2>, anti-double-stranded DNA), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3449	 with <e1>infliximab</e1> is known to produce an <e2>increase of autoantibodies</e2> (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3450	 Raynaud's phenomenon</e1> with <e2>yohimbine</e2> therapy for erectile dysfunction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3451	 describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced <e1>worsening of Raynaud's phenomenon</e1> when using <e2>yohimbine</e2> for ED."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3452	 initiation of topical <e1>vitamin D3</e1> ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the <e2>serum level of calcium and urinary excretion of calcium increased</e2> gradually."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3453	 <e1>hypercalcemia</e1> due to vitamin D3 ointment (<e2>1,24(OH)2D3</e2>) combined with thiazide diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3454	 <e1>hypercalcemia</e1> due to vitamin D3 ointment (1,24(OH)2D3) combined with <e2>thiazide</e2> diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3455	 <e1>hypercalcemia</e1> due to <e2>vitamin D3</e2> ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3456	 present case is the first report of <e1>hypercalcemia</e1> induced by vitamin D3 ointment and <e2>thiazide</e2> simultaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3457	 present case is the first report of <e1>hypercalcemia</e1> induced by <e2>vitamin D3</e2> ointment and thiazide simultaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3458	 experienced a male patient with psoriasis and hypertension whose conditions were treated with <e1>tacalcitol</e1> ointment and thiazide, respectively, resulting in hypercalciuria and <e2>hypercalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3459	 experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and <e1>thiazide</e1>, respectively, resulting in hypercalciuria and <e2>hypercalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3460	 experienced a male patient with psoriasis and hypertension whose conditions were treated with <e1>tacalcitol</e1> ointment and thiazide, respectively, resulting in <e2>hypercalciuria</e2> and hypercalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3461	 experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and <e1>thiazide</e1>, respectively, resulting in <e2>hypercalciuria</e2> and hypercalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3462	 typically causes a long-lasting state of <e2>immunodeficiency</e2> and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3463	 typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of <e2>secondary neoplasms</e2> after its use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3464	 induces durable complete remission in Castleman's disease but may accelerate its transformation to <e2>non-Hodgkin's lymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3465	 it is reasonable to conclude that: 1) <e1>2-CdA</e1> can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that <e1>2-CdA</e1> may accelerate the <e2>transformation of MCD to NHL</e2> cannot be ruled out."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3466	 this amount of FAB was insufficient to bind all <e1>DGTX</e1> present in the serum, cardiac <e1>DGTX</e1> toxicity (total AV-block) persisted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3467	 this amount of FAB was insufficient to bind all <e1>DGTX</e1> present in the serum, cardiac <e1>DGTX</e1> toxicity (<e2>total AV-block</e2>) persisted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3468	 patients had taken <e1>phenytoin</e1> for variable time periods (range 16-80 days; mean: 40) and were on the medication when the <e2>skin lesions</e2> first appeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3469	 multiforme</e1> associated with <e2>phenytoin</e2> and cranial radiation therapy: a report of three patients and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3470	 conclusion, <e1>RSDS</e1> is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (<e2>CyA</e2> or tacrolimus), even under monotherapy or with a low steroid dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3471	 conclusion, <e1>RSDS</e1> is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or <e2>tacrolimus</e2>), even under monotherapy or with a low steroid dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3472	 sympathetic dystrophy syndrome</e1> in renal transplanted patients under immunosuppression with <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3473	 now present four cases of <e1>RSDS</e1> in kidney transplant recipients treated with <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3474	 <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in <e2>acute myopia</e2> and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3475	 <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and <e2>angle-closure glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3476	 <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and <e2>anterior chamber shallowing</e2>, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3477	 <e1>Topiramate</e1> may be associated with <e2>ciliochoroidal effusion</e2> with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3478	 <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward <e2>displacement of the lens-iris diaphragm</e2> and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3479	 of <e1>topiramate</e1> -induced <e2>acute-onset myopia</e2> and angle closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3480	 of <e1>topiramate</e1> -induced acute-onset myopia and <e2>angle closure glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3481	 In an institutional practice setting, two women, aged 25 and 45, developed <e1>acute myopia</e1> after starting <e2>topiramate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3482	 -induced <e2>photo-onycholysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3483	 present a case of <e1>photo-onycholysis</e1> in a patient treated with <e2>doxycycline</e2> for acne vulgaris."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3484	 new type of <e1>minocycline</e1> -induced <e2>cutaneous hyperpigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3485	 disorders</e1> are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3486	 fourth type of cutaneous <e1>minocycline</e1> <e2>hyperpigmentation</e2> may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3487	 distinct types of <e1>minocycline</e1> -induced <e2>cutaneous pigmentation</e2> have been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3488	 report two patients with acne vulgaris with a fourth type of <e1>minocycline</e1> -induced <e2>cutaneous pigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3489	 -induced <e2>toxic epidermal necrolysis</e2> in a patient with systemic lupus erythematosus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3490	 report here a case of <e1>TEN</e1> after administration of <e2>ciprofloxacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3491	 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed <e1>fever</e1> concurrent with the administration of <e2>amifostine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3492	 -induced <e2>fever</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3493	 receiving <e1>amifostine</e1> who develop only <e2>fever</e2> should be evaluated for an adverse drug reaction, as well as for sepsis and <e2>fever</e2>s of neutropenia, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3494	 receiving <e1>amifostine</e1> who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and <e2>fevers of neutropenia</e2>, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3495	 receiving <e1>amifostine</e1> who develop only fever should be evaluated for an adverse drug reaction, as well as for <e2>sepsis</e2> and fevers of neutropenia, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3496	 our knowledge, this is the first case report that demonstrates the occurrence of <e1>fever</e1> with low-dose <e2>amifostine</e2> therapy without the manifestation of accompanying rash or hypotension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3497	 interstitial nephritis</e1> due to <e2>pantoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3498	 5 weeks of therapy, she stopped taking <e1>pantoprazole</e1> due to <e2>general malaise</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3499	 To describe what is believed, as of November 4, 2003, to be the first case published in the literature of <e1>acute interstitial nephritis</e1> (AIN) due to <e2>pantoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3500	 Naranjo probability scale suggests a highly probable relationship between <e1>AIN</e1> and <e2>pantoprazole</e2> therapy in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3501	 have been several reported cases of <e1>omeprazole</e1> -induced <e2>AIN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3502	 was highly suspected that <e1>finasteride</e1> was associated with the <e2>anterior subcapsular opacity on the lens</e2>, and the patient therefore discontinued use of <e1>finasteride</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3503	 was highly suspected that <e1>finasteride</e1> was associated with the <e2>anterior subcapsular opacity on the lens</e2>, and the patient therefore discontinued use of <e1>finasteride</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3504	 -associated <e2>bilateral cataract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3505	 the best of the authors' knowledge, this is the first reported case of <e1>Propecia</e1> -associated <e2>cataract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3506	 in a patient with multiple sclerosis and monoclonal gammopathy on <e2>interferon beta-1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3507	 SUMMARY: Two children with attention deficit disorder treated with <e1>methylphenidate</e1> as a simple drug developed <e2>fixed drug eruption of the scrotum</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

3508	 <e1>Fixed drug rash</e1> induced by <e2>methylphenidate</e2> is a possible but rare phenomenon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3509	 drug eruption of the scrotum</e1> due to <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3510	 To report two cases of <e1>fixed drug eruption</e1> induced by <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3511	 <e2>pneumonitis</e2> in nonsurgical treatment of ectopic pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3512	 describe a case of <e1>pneumonitis</e1> following local administration of <e2>methotrexate</e2> for nonsurgical termination of an ectopic pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3513	 The risk/benefit ratio of <e1>warfarin</e1> therapy changes in the over 75s, when <e2>haemorrhagic side-effects</e2> become more common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3514	 REPORT: A woman of 80 years, on long-term <e1>warfarin</e1> therapy presented with an <e2>acute dissecting thoracic aortic aneurysm</e2>; on investigation the only precipitating factor found was an international normalised ratio of 4.8."
DRUG-ADE(e1,e2)
Comment: DRUG-

3515	 -associated <e2>thoracic aortic dissection</e2> in an elderly woman."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3516	 vasculitis</e1> secondary to <e2>ramipril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3517	 we report <e1>ramipril</e1> -induced <e2>cutaneous vasculitis</e2> in a patient who required steroid therapy to control it."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3518	 -induced <e2>cutaneous vasculitis</e2> is particularly rare and our case was atypical because the patient had tolerated lisinopril before."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3519	 This is, to our knowledge, the first report of <e1>severe myelopathy</e1> following accidental intrathecal administration of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3520	 improvement and rehabilitation potential following <e1>toxic myelopathy</e1> due to intrathecal injection of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3521	 Evidence of neurological improvement and rehabilitation potential after <e1>severe myelopathy</e1> due to intrathecal injection of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3522	 DESIGN: Case report of a 31-year-old woman who presented with <e1>toxic myelopathy</e1> due to intrathecal administration of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3523	 <e1>infliximab</e1> treatment, additional sleep studies revealed an <e2>increase in the number of apneic events</e2> and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3524	 <e1>infliximab</e1> treatment, additional sleep studies revealed an increase in the number of apneic events and <e2>SaO2 dips</e2> suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3525	 clinical recognition of <e1>sleep disordered breathing</e1> should be taken into account when rheumatoid arthritis patients are to be treated with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3526	 induced by sodium polystyrene sulphonate (<e2>Kayexalate</e2>) in two extremely low birth weight newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3527	 induced by <e2>sodium polystyrene sulphonate</e2> (Kayexalate) in two extremely low birth weight newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3528	 describe two ELBW infants affected by hyperkalaemia, treated with <e1>Kayexalate</e1>, who developed serious <e2>hypernatraemia</e2>, that has never been reported before in preterm infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3529	 maculopathy</e1> associated with <e2>quinacrine</e2> therapy for malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3530	 Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe <e1>maculopathy</e1> indistinguishable from <e2>chloroquine</e2> <e1>maculopathy</e1> in certain patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3531	 Low dosages of <e1>quinacrine</e1> used for malaria prophylaxis can be associated with a delayed, <e2>severe maculopathy</e2> indistinguishable from chloroquine maculopathy in certain patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3532	 A patient developed a <e1>bilaterally symmetric bull's-eye maculopathy</e1> 45 years after taking <e2>quinacrine</e2> for 18 months as prophylaxis against malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3533	 clinical picture was identical to that of <e1>chloroquine</e1> and hydroxy<e1>chloroquine</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3534	 clinical picture was identical to that of chloroquine and <e1>hydroxychloroquine</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3535	 infarcts</e1> in a pediatric patient secondary to <e2>phenylpropanolamine</e2>, a recalled medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3536	 (PPA) recently has been publicly implicated as a cause of stroke and other <e2>neurologic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3537	 (<e1>PPA</e1>) recently has been publicly implicated as a cause of stroke and other <e2>neurologic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3538	 (PPA) recently has been publicly implicated as a cause of <e2>stroke</e2> and other neurologic events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3539	 (<e1>PPA</e1>) recently has been publicly implicated as a cause of <e2>stroke</e2> and other neurologic events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3540	 patient developed occipital infarcts and was found to have extremely elevated levels of <e2>PPA</e2> in his blood and dialysis fluid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3541	 patient developed <e1>occipital infarcts</e1> and was found to have extremely elevated levels of <e2>PPA</e2> in his blood and dialysis fluid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3542	 present a case of <e1>stroke</e1> after <e2>PPA</e2> ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3543	 nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and <e2>hallucinations</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3544	 nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or <e2>mild headache</e2>, although rare occurrences of seizures and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3545	 nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of <e2>minor dizziness</e2> or mild headache, although rare occurrences of seizures and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3546	 nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of <e2>seizures</e2> and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3547	 -induced <e2>psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3548	 SYNTHESIS: A 49-year-old man developed symptoms of <e1>severe psychosis</e1> concomitant with <e2>ciprofloxacin</e2> (250 mg bid) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3549	 To report a case of <e1>ciprofloxacin</e1> -induced <e2>psychosis</e2> and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3550	 induced by <e2>vancomycin</e2> in an ESRD patient on CAPD."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3551	 is a rare adverse effect associated with prolonged <e2>vancomycin</e2> therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3552	 describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed <e1>vancomycin</e1> -induced <e2>agranulocytosis</e2> during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3553	 is very likely that the <e1>dexamethasone</e1> used in the antiemetic drug regimen contributed to the development of <e2>osteonecrosis</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3554	 is a serious side effect of antiemetic treatment with <e2>dexamethasone</e2> and this serious complication should be incorporated in the current guidelines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3555	 should be informed about the risk of <e1>osteonecrosis</e1> when taking <e2>dexamethasone</e2> as an antiemetic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3556	 of <e1>Peyronie's disease</e1> during long-term <e2>colchicine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3557	 here we reported two patients, presenting with <e1>PD</e1> during high dose <e2>colchicine</e2> treatment for familiar mediterranean fever (FMF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3558	 patient developed <e1>cholestatic hepatitis</e1> while being treated with <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3559	 second episode of <e1>jaundice</e1> followed the intravaginal administration of a mixture of <e2>furazolidone</e2> and nifuroxime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3560	 second episode of <e1>jaundice</e1> followed the intravaginal administration of a mixture of furazolidone and <e2>nifuroxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3561	 case of <e1>phenobarbital</e1> <e2>exacerbation of a preexisting maladaptive behavior</e2> partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3562	 years of behavioral data are presented to support the hypothesis that <e1>phenobarbital</e1> was exacerbating <e2>maladaptive behaviors</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3563	 profile should trigger a "red flag" as to the possibility of <e1>phenobarbital</e1> <e2>behavioral side effects</e2> or exacerbation of preexisting maladaptive behaviors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3564	 profile should trigger a "red flag" as to the possibility of <e1>phenobarbital</e1> behavioral side effects or <e2>exacerbation of preexisting maladaptive behaviors</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3565	 toxicity and the treatment of xerostomia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3566	 report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in <e2>bradycardia</e2>, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3567	 report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in bradycardia, <e2>mild hypotension</e2>, and muscarinic symptoms in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3568	 report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in bradycardia, mild hypotension, and <e2>muscarinic symptoms</e2> in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3569	 combinations of <e1>belladonna</e1>, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3570	 combinations of belladonna, <e1>ergotamine</e1>, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3571	 combinations of belladonna, ergotamine, and <e1>phenobarbital</e1> have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3572	 hypersensitivity syndrome</e1> associated with <e2>Bellamine S</e2>, a therapy for menopausal symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3573	 report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (<e2>belladonna alkaloids</e2>; ergotamine; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3574	 report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking <e2>Bellamine S</e2> (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3575	 report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (belladonna alkaloids; <e2>ergotamine</e2>; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3576	 report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (belladonna alkaloids; ergotamine; <e2>phenobarbital</e2>) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3577	 case of <e1>heatstroke</e1> is reported in a 32-year-old man diagnosed with schizophrenia and on <e2>clozapine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3578	 stroke</e1> in schizophrenia during <e2>clozapine</e2> treatment: rapid recognition and management."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3579	 -related <e2>radiation recall</e2> preferentially involves internal tissue and organs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3580	 authors also determined that their case of <e1>myositis</e1> developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3581	 authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of <e1>radiation recall</e1>, thereby bringing the number of patients who developed <e1>radiation recall</e1> to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3582	 authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of <e1>radiation recall</e1>, thereby bringing the number of patients who developed <e1>radiation recall</e1> to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3583	 literature search found 12 cases of <e1>radiation recall</e1> caused by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3584	 majority of <e1>radiation recall reactions</e1> attributed to <e2>gemcitabine</e2> are reported to affect internal tissue or organs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3585	 macular edema</e1> in a low-risk patient after switching from latanoprost to <e2>bimatoprost</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3586	 macular edema</e1> in a low-risk patient after switching from <e2>latanoprost</e2> to bimatoprost."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3587	 A 68-year-old man developed intense conjunctival hyperemia and <e1>cystoid macula edema</e1> after switching from latanoprost to <e2>bimatoprost</e2> 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3588	 A 68-year-old man developed intense conjunctival hyperemia and <e1>cystoid macula edema</e1> after switching from <e2>latanoprost</e2> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3589	 A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to <e1>bimatoprost</e1> 9 months after cataract surgery in an eye at low-risk for this <e2>cystoid macular edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3590	 A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from <e1>latanoprost</e1> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this <e2>cystoid macular edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3591	 A 68-year-old man developed <e1>intense conjunctival hyperemia</e1> and cystoid macula edema after switching from latanoprost to <e2>bimatoprost</e2> 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3592	 A 68-year-old man developed <e1>intense conjunctival hyperemia</e1> and cystoid macula edema after switching from <e2>latanoprost</e2> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3593	 To report a case of angiographically documented <e1>cystoid macula edema</e1> occurring after switching a pseudophakic patient from latanoprost to <e2>bimatoprost</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3594	 To report a case of angiographically documented <e1>cystoid macula edema</e1> occurring after switching a pseudophakic patient from <e2>latanoprost</e2> to bimatoprost."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3595	 immediate <e1>hemolytic reaction</e1> induced by repeated administration of <e2>oxaliplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3596	 REPORT: We report a patient who developed a <e1>DAT-positive hemolytic episode</e1> after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of <e2>oxaliplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

3597	 neurotoxicity is a frequent complication of <e1>methotrexate</e1> therapy, <e2>fatal acute neurotoxicity</e2> is extremely uncommon, especially in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3598	 <e1>neurotoxicity</e1> is a frequent complication of <e2>methotrexate</e2> therapy, fatal acute <e1>neurotoxicity</e1> is extremely uncommon, especially in adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3599	 should be aware of the signs and symptoms of <e1>neurotoxicity</e1> during treatment, as well as predisposing factors that put patients receiving <e2>methotrexate</e2> at risk for neurotoxic effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3600	 acute encephalomyelitis</e1> after a single dose of intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3601	 day after <e1>methotrexate</e1> administration, the patient complained of <e2>severe back pain</e2> and urinary retention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3602	 day after <e1>methotrexate</e1> administration, the patient complained of severe back pain and <e2>urinary retention</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3603	 patient rapidly progressed from mild neurotoxicity to <e1>fatal encephalopathy</e1> after one dose of intrathecal <e2>methotrexate</e2> during his third cycle of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3604	 patient rapidly progressed from <e1>mild neurotoxicity</e1> to fatal encephalopathy after one dose of intrathecal <e2>methotrexate</e2> during his third cycle of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3605	 report a third case of a 6-week-old infant with Escherichia coli sepsis who received <e1>ampicillin</e1> and other antibiotics and subsequently developed <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3606	 patient developed <e1>large intramural esophageal hematoma</e1> as a complication of <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3607	 cystitis</e1> after bladder instillation with <e2>dimethyl sulfoxide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3608	 report the first case of an acute flare of <e1>eosinophilic cystitis</e1> in a 51-year-old woman after bladder instillation with <e2>dimethyl sulfoxide</e2> (DMSO) for presumed interstitial cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3609	 report the first case of an acute flare of <e1>eosinophilic cystitis</e1> in a 51-year-old woman after bladder instillation with dimethyl sulfoxide (<e2>DMSO</e2>) for presumed interstitial cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3610	 dystonia</e1> during <e2>pegylated interferon alpha</e2> therapy in a case with chronic hepatitis B infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3611	 this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed <e1>acute dystonia</e1> soon after the first dose of <e2>pegylated interferon alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3612	 with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, <e2>akathisia</e2>, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3613	 with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and <e2>depressive disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3614	 with <e1>IFN-alpha</e1> may be associated with a number of <e2>neuropsychiatric symptoms</e2>, such as Parkinsonism, akathisia, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3615	 with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as <e2>Parkinsonism</e2>, akathisia, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3616	 with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, <e2>seizure</e2>, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3617	 patient developed <e1>restless legs symptoms</e1> paralleling the course of interferon-alpha (<e2>IFN alpha</e2>) therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3618	 patient developed <e1>restless legs symptoms</e1> paralleling the course of <e2>interferon-alpha</e2> (IFN alpha) therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3619	 legs syndrome</e1> due to <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3620	 legs syndrome</e1> may thus be an adverse effect of <e2>IFN alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3621	 clinicians appear to be concerned about the potential <e1>hepatotoxicity</e1> of the opiate antagonist <e2>naltrexone</e2> (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3622	 clinicians appear to be concerned about the potential <e1>hepatotoxicity</e1> of the opiate antagonist naltrexone (<e2>NTX</e2>) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3623	 describe a heroin abuser in whom clinical and laboratory manifestations of <e1>acute hepatitis B and C</e1> appeared a few days after the insertion of a subcutaneous <e2>naltrexone</e2> implant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3624	 syndrome</e1> associated with <e2>sargramostim</e2> (granulocyte-macrophage colony stimulating factor) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3625	 syndrome is an <e1>acute febrile neutrophilic dermatosis</e1> that is a known complication of the administration of <e2>filgrastim</e2>, a drug that causes increased neutrophil proliferation and differentiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3626	 syndrome</e1> is an acute febrile neutrophilic dermatosis that is a known complication of the administration of <e2>filgrastim</e2>, a drug that causes increased neutrophil proliferation and differentiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3627	 report a case of <e1>Sweet's syndrome</e1> in association with <e2>sargramostim</e2> treatment following chemotherapy for acute myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3628	 cardiac death due to <e1>hypersensitivity myocarditis</e1> during <e2>clozapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3629	 cardiac death</e1> due to hypersensitivity myocarditis during <e2>clozapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3630	 autopsy findings and a detailed medical history supported the conclusion that <e1>clozapine</e1> -induced <e2>hypersensitivity myocarditis</e2> was the most likely cause of death."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3631	 case concerns the <e1>sudden death</e1> of a 29-year-old male during <e2>clozapine</e2> therapy started 2 weeks before."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3632	 glove syndrome, named for its distinctive <e1>purple discoloration</e1> and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3633	 glove syndrome</e1>, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3634	 glove syndrome, named for its distinctive purple discoloration and <e1>swelling of the hands</e1> in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3635	 findings were judged to be consistent with soft-tissue injury associated with intravenous administration of <e1>phenytoin</e1>, also termed <e2>purple glove syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3636	 findings were judged to be consistent with <e1>soft-tissue injury</e1> associated with intravenous administration of <e2>phenytoin</e2>, also termed purple glove syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3637	 patient was a 72-year-old man with advanced Parkinson's disease (PD) who received <e1>levodopa</e1> and anti-cholinergic drugs and whose head had become almost <e2>completely bald</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3638	 patient with monocular open-angle glaucoma had <e1>trichiasis</e1>, a condition associated with the use of a <e2>prostaglandin</e2> analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3639	 lash length</e1>, thickness, and pigmentation are well-documented side effects of <e2>prostaglandin</e2> analog glaucoma drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3640	 lash length, thickness, and <e1>pigmentation</e1> are well-documented side effects of <e2>prostaglandin</e2> analog glaucoma drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3641	 associated with <e2>prostaglandin</e2> analog use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3642	 pulmonary fibrosis</e1> associated with <e2>BCNU</e2>: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3643	 fibrosis</e1> is a severe complication associated with bis-chloronitrosourea (<e2>BCNU</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3644	 fibrosis</e1> is a severe complication associated with <e2>bis-chloronitrosourea</e2> (BCNU) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3645	 novel findings may offer specific therapeutic targets in the treatment of <e1>BCNU</e1> -associated <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3646	 further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of <e1>BCNU</e1> -related <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3647	 report here a 26-year-old female with diffuse large B-cell lymphoma who died of <e1>severe pulmonary fibrosis</e1> 81 days after the administration of high-dose <e2>BCNU</e2> (600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3648	 -induced <e2>choroidal detachment</e2> in a surgically untreated eye."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3649	 A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a <e1>choroidal detachment</e1> 12 hours after initiation of therapy with <e2>dorzolamide</e2> eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3650	 document the abrupt development of an extensive <e1>choroidal detachment</e1> after initiation of <e2>dorzolamide</e2> therapy in a surgically untreated eye with primary open-angle glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3651	 of lid sulcus</e1> from topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3652	 each of the three reported patients, <e1>alteration of eyelid appearance</e1> with deepening of the lid sulcus was evident as the result of topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3653	 each of the three reported patients, alteration of eyelid appearance with <e1>deepening of the lid sulcus</e1> was evident as the result of topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3654	 planus</e1> induced by <e2>hepatitis B vaccination</e2>: a new case and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3655	 report: <e1>life-threatening hypoglycaemia</e1> associated with <e2>sulfadoxine-pyrimethamine</e2>, a commonly used antimalarial drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3656	 this report, we present a case of <e1>hypoglycaemic coma</e1> associated with <e2>SP</e2>, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of <e2>SP</e2> increases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3657	 this report, we present a case of <e1>hypoglycaemic coma</e1> associated with <e2>SP</e2>, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of <e2>SP</e2> increases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3658	 treatment with <e1>heparin</e1> was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by <e2>fatal intracerebral haemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3659	 forearm deep venous thrombosis</e1> following a severe <e2>infliximab</e2> infusion reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3660	 we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (<e2>IIR</e2>), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3661	 we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (<e2>IIR</e2>), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3662	 we describe a patient with Crohn's disease who developed a severe <e2>infliximab</e2> infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e2>infliximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3663	 we describe a patient with Crohn's disease who developed a severe <e2>infliximab</e2> infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e2>infliximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3664	 we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (IIR), complicated 1 day later by <e2>severe swelling of the forearm and hand ipsilateral</e2> to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3665	 we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (IIR), complicated 1 day later by <e2>severe swelling of the forearm and hand ipsilateral</e2> to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3666	 site of thrombosis and the chronological relationship with the IIR implicates a <e1>hypersensitivity</e1> to <e2>infliximab</e2> in the causation of the venous thrombosis in this case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3667	 site of thrombosis and the chronological relationship with the <e1>IIR</e1> implicates a hypersensitivity to <e2>infliximab</e2> in the causation of the venous thrombosis in this case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3668	 site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to <e1>infliximab</e1> in the causation of the <e2>venous thrombosis</e2> in this case."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3669	 3- to 13-month period of therapy without <e1>indapamide</e1>, glucose levels of all patients decreased and <e2>diabetes</e2> disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3670	 stopping <e1>indapamide</e1>, <e2>glucose tolerance impairing</e2> may be reversed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3671	 Therapy with <e1>indapamide</e1> may induce <e2>diabetes</e2> in essential hypertension patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3672	 To study therapy with <e1>indapamide</e1> impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of <e2>diabetes</e2> induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3673	 To study therapy with <e1>indapamide</e1> impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of <e2>diabetes</e2> induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3674	 To study therapy with <e1>indapamide</e1> <e2>impairing carbohydrate metabolism</e2> in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3675	 induction of <e1>diabetes</e1> by treatment of hypertension with <e2>indapamide</e2> (with four case reports)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3676	 After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and <e1>fosinopril</e1> (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3677	 After 4- to 14-month period of therapy with the combination of <e1>indapamide</e1> (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with <e1>indapamide</e1> (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3678	 After 4- to 14-month period of therapy with the combination of <e1>indapamide</e1> (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with <e1>indapamide</e1> (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3679	 Previous investigators have reported <e1>discrepancies between hematologic, marrow morphologic, and cytogenetic responses</e1> to <e2>imatinib mesylate</e2> among patients with chronic myeloid leukemia (CML)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3680	 a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to <e1>blast crisis</e1> at 7 to 10 months of <e2>imatinib</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3681	 addition to disease refractoriness, rare instances of disease progression from chronic phase to <e1>blast crisis</e1> during <e2>imatinib</e2> therapy have recently been anecdotally reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3682	 To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to <e1>blast crisis</e1> while taking <e2>imatinib</e2> and to perform a review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3683	 findings suggest that significant <e1>progression of marrow reticulin fibrosis</e1> during <e2>imatinib</e2> therapy can be an indicator for a return or progression of CML and, in some patients with CML, <e2>imatinib</e2> may promote cytogenetic clonal evolution, resulting in a poor response to treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3684	 of chronic myeloid leukemia to <e1>blast crisis</e1> during treatment with <e2>imatinib mesylate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3685	 reversible hypoxemia and <e1>hypotension</e1> induced by <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3686	 reversible <e1>hypoxemia</e1> and hypotension induced by <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3687	 this paper we report a case of <e1>nimodipine</e1> overdosage resulting in prolonged hypotension and <e2>hypoxemia</e2>, which was successfully treated with calcium gluconate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3688	 this paper we report a case of <e1>nimodipine</e1> overdosage resulting in <e2>prolonged hypotension</e2> and hypoxemia, which was successfully treated with calcium gluconate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3689	 hypoglycemia</e1> from <e2>ciprofloxacin</e2> and glyburide interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3690	 hypoglycemia</e1> from ciprofloxacin and <e2>glyburide</e2> interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3691	 present a case of a diabetic patient taking glyburide who was prescribed <e1>ciprofloxacin</e1> and developed <e2>prolonged hypoglycemia</e2>, which persisted for over 24 hours."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3692	 present a case of a diabetic patient taking <e1>glyburide</e1> who was prescribed ciprofloxacin and developed <e2>prolonged hypoglycemia</e2>, which persisted for over 24 hours."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3693	 hypersensitivity apparently due to ethylenediamine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3694	 hypersensitivity</e1> apparently due to <e2>ethylenediamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3695	 present a case of ethylenediamine-induced <e1>delayed hypersensitivity reaction</e1> in a 46-year-old woman who received parenteral <e2>aminophylline</e2> for an acute asthma exacerbation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3696	 present a case of <e1>ethylenediamine</e1> -induced <e2>delayed hypersensitivity reaction</e2> in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3697	 -induced pancreatitis is an uncommon but potential <e2>lethal complication</e2> of the treatment of leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3698	 -induced <e2>pancreatitis</e2> is an uncommon but potential lethal complication of the treatment of leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3699	 -induced <e2>severe necrotizing pancreatitis</e2> successfully treated with percutaneous drainage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3700	 cases of <e1>pancreatitis</e1> associated with <e2>L-asparaginase</e2> toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3701	 has been noted to be a complication in 2-16% of patients undergoing treatment with <e2>L-asparaginase</e2> for a variety of pediatric neoplasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3702	 present a pediatric patient with leukemia and a severe, <e1>L-asparaginase</e1> -induced <e2>necrotizing pancreatitis</e2>, treated successfully with percutaneous drainage used to flush the infected necrotic parts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3703	 -induced <e2>fulminant hepatic failure</e2> in an active duty soldier."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3704	 hepatic failure</e1> is a rare complication of <e2>disulfiram</e2> treatment for alcoholism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3705	 case describes <e1>fulminant hepatic failure</e1> in a patient taking <e2>disulfiram</e2> with no previous liver disease and report of being compliant with alcohol abstinence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3706	 overdose causes an <e2>unusual array of neurological symptoms</e2>, many similar to reported adverse effects during therapeutic use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3707	 case of <e1>sideroblastic anemia</e1> is presented in a patient with a left ventricular assist device drive-line infection who was receiving <e2>linezolid</e2>, an antibiotic used for serious infections with gram-positive organisms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3708	 <e1>linezolid</e1> has been shown to have <e2>hematologic side effects</e2>, blood count monitoring is recommended in patients receiving this drug for long-term therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3709	 anemia</e1> due to <e2>linezolid</e2> in a patient with a left ventricular assist device."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3710	 this report, two newborns with congenital heart anomalies demonstrated the <e1>harlequin color change</e1>, one whose skin findings showed a course related to the dose of systemic <e2>prostaglandin E1</e2>, suggesting a possible association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3711	 <e1>harlequin color change</e1> and association with <e2>prostaglandin E1</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3712	 renal insufficiency</e1> is known to occur in patients who are taking <e2>ciprofloxacin</e2>, particularly the elderly."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3713	 -induced <e2>renal insufficiency</e2> in cystic fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3714	 mechanisms for <e1>ciprofloxacin</e1> -induced <e2>nephrotoxicity</e2> have been proposed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3715	 report two young patients with cystic fibrosis who presented with <e1>acute renal insufficiency</e1> after 2-3 weeks of oral <e2>ciprofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3716	 neuropathy revealing <e1>necrotizing vasculitis</e1> during <e2>infliximab</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3717	 neuropathy</e1> revealing necrotizing vasculitis during <e2>infliximab</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3718	 describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with peripheral neuropathy due to <e2>necrotizing vasculitis</e2> in one patient and to progression of preexisting mononeuritis multiplex in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3719	 describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with <e2>peripheral neuropathy</e2> due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3720	 describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to <e2>progression of preexisting mononeuritis multiplex</e2> in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3721	 anemia</e1> following combination therapy with <e2>interferon-alpha</e2> and interleukin-2 in a patient with metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3722	 anemia</e1> following combination therapy with interferon-alpha and <e2>interleukin-2</e2> in a patient with metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3723	 report a case of <e1>severe anemia</e1>, which responded well to steroid therapy, in a patient receiving IL-2 plus <e2>IFN-alpha</e2> for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3724	 report a case of <e1>severe anemia</e1>, which responded well to steroid therapy, in a patient receiving <e2>IL-2</e2> plus IFN-alpha for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3725	 objective causality assessment indicated a probable relationship between <e1>clotting abnormality</e1> and <e2>warfarin</e2> administration, although the degree of elevation of the INR was unusual in the light of the daily <e2>warfarin</e2> dose and duration of its exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3726	 on the clinical status of the patient, it was suspected that several conditions contributed to the <e1>abnormal hypersensitivity</e1> to <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3727	 the low dosage of <e1>warfarin</e1>, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and <e2>bleeding symptoms</e2> concurrently developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3728	 view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid <e1>fatal haemorrhage</e1> after initiating <e2>warfarin</e2> therapy regardless of the dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3729	 <e1>hypersensitivity</e1> to <e2>warfarin</e2> in a critically ill patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3730	 report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with ganciclovir, foscarnet, and <e2>cidofovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3731	 report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with ganciclovir, <e2>foscarnet</e2>, and cidofovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3732	 report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with <e2>ganciclovir</e2>, foscarnet, and cidofovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3733	 (5-FU)-associated <e2>peripheral neuropathy</e2> is an uncommon event."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3734	 (<e1>5-FU</e1>)-associated <e2>peripheral neuropathy</e2> is an uncommon event."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3735	 analysis of 28 patients receiving <e1>CAP</e1> with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with <e2>peripheral neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3736	 regarding potential adverse effects of <e1>CAP</e1> is paramount and dose modification is indicated with development of <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3737	 symptoms</e1> resolved after stopping <e2>CAP</e2> for 4 weeks in Patient A, with no recurrence after reinitiating <e2>CAP</e2> alone at 2000 mg/m2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3738	 symptoms</e1> resolved after stopping <e2>CAP</e2> for 4 weeks in Patient A, with no recurrence after reinitiating <e2>CAP</e2> alone at 2000 mg/m2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3739	 A reported right leg weakness (<e1>foot drop</e1>) during week 4 of <e2>CAP-XRT</e2> (1600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3740	 A reported <e1>right leg weakness</e1> (foot drop) during week 4 of <e2>CAP-XRT</e2> (1600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3741	 B developed <e1>perioral and upper extremity paresthesias</e1> during the fourth cycle of <e2>CAP</e2> alone (2500 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3742	 neuropathy</e1> associated with <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3743	 conclude <e1>peripheral neuropathy</e1> with <e2>5-FU</e2> is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3744	 hypo-alpha-lipoproteinemia</e1> during treatment with <e2>rosiglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3745	 report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound <e1>reduction in plasma HDL cholesterol and apolipoprotein AI levels</e1> soon after the initiation of <e2>rosiglitazone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3746	 leukopenia associated with <e1>mild hepatotoxicity</e1> in an HIV carrier treated with <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3747	 leukopenia</e1> associated with mild hepatotoxicity in an HIV carrier treated with <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3748	 report an HIV-infected woman who developed mild <e1>leukopenia</e1> as the first sign of a <e2>nevirapine</e2> -related adverse event, which was followed by skin and hepatic toxicity associated with a more severe <e1>leukopenia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3749	 report an HIV-infected woman who developed mild <e1>leukopenia</e1> as the first sign of a <e2>nevirapine</e2> -related adverse event, which was followed by skin and hepatic toxicity associated with a more severe <e1>leukopenia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3750	 report an HIV-infected woman who developed mild leukopenia as the first sign of a <e1>nevirapine</e1> -related adverse event, which was followed by <e2>skin and hepatic toxicity</e2> associated with a more severe leukopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3751	 all cases, drugs in addition to <e1>quetiapine</e1> were detected, but in cases #1 and #2, the cause of <e2>death</e2> was considered to be a <e1>quetiapine</e1> overdose and the other drugs were not considered to be contributory."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3752	 cases were chosen for study because they were all <e1>deaths</e1> as a result of suicidal ingestion of drugs in which <e2>quetiapine</e2> was considered a significant factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3753	 present three cases from the Provincial Toxicology Center of British Columbia, Canada in which <e1>suicidal overdose deaths</e1> were associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3754	 approximately two weeks of <e1>sertraline</e1> treatment he noted an <e2>intense itching sensation</e2> in his scalp after eating a piece of chocolate cake."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3755	 and skin rash from chocolate during <e2>fluoxetine</e2> and sertraline treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3756	 and skin rash from chocolate during fluoxetine and <e2>sertraline</e2> treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3757	 and <e1>skin rash</e1> from chocolate during <e2>fluoxetine</e2> and sertraline treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3758	 and <e1>skin rash</e1> from chocolate during fluoxetine and <e2>sertraline</e2> treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3759	 lymphohistiocytic reactions</e1> temporally related to <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3760	 report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of <e1>pulmonary signs and symptoms with alveolar infiltrates</e1> temporally related to the institution of <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3761	 cerebral cortical hyperexcitability</e1> following <e2>flupirtine</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3762	 report the case of a patient with <e1>increased cerebral cortical excitability</e1> following intoxication with <e2>flupirtine</e2>, a centrally acting analgesic and antispastic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3763	 Report of a case of a woman patient who developed <e1>celiac disease</e1> after <e2>pegylated interferon alpha-2a</e2> and ribavirin use for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3764	 Report of a case of a woman patient who developed <e1>celiac disease</e1> after pegylated interferon alpha-2a and <e2>ribavirin</e2> use for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3765	 disease</e1> onset after <e2>pegylated interferon</e2> and ribavirin treatment of chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3766	 disease</e1> onset after pegylated interferon and <e2>ribavirin</e2> treatment of chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3767	 AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving <e1>pegylated interferon alpha-2a</e1> and ribavirin for 6 months, developed progressive malaise and <e2>anemia</e2> 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-

3768	 AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and <e1>ribavirin</e1> for 6 months, developed progressive malaise and <e2>anemia</e2> 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-

3769	 AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving <e1>pegylated interferon alpha-2a</e1> and ribavirin for 6 months, developed <e2>progressive malaise</e2> and anemia 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-

3770	 AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and <e1>ribavirin</e1> for 6 months, developed <e2>progressive malaise</e2> and anemia 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-

3771	 present two cases of <e1>anaphylaxis</e1> under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist <e2>metaraminol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3772	 this article, we describe another case of subcutaneous changes following repeated <e1>glatiramer acetate</e1> injection, presented as <e2>localized panniculitis</e2> in the area around the injection sites, in a 46-year-old female patient who was treated with <e1>glatiramer acetate</e1> for 18 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3773	 this article, we describe another case of subcutaneous changes following repeated <e1>glatiramer acetate</e1> injection, presented as <e2>localized panniculitis</e2> in the area around the injection sites, in a 46-year-old female patient who was treated with <e1>glatiramer acetate</e1> for 18 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3774	 this article, we describe another case of <e1>subcutaneous changes</e1> following repeated <e2>glatiramer acetate</e2> injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with <e2>glatiramer acetate</e2> for 18 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3775	 panniculitis and subsequent <e1>lipoatrophy</e1> with subcutaneous glatiramer acetate (<e2>Copaxone</e2>) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3776	 panniculitis and subsequent <e1>lipoatrophy</e1> with subcutaneous <e2>glatiramer acetate</e2> (Copaxone) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3777	 panniculitis</e1> and subsequent lipoatrophy with subcutaneous glatiramer acetate (<e2>Copaxone</e2>) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3778	 panniculitis</e1> and subsequent lipoatrophy with subcutaneous <e2>glatiramer acetate</e2> (Copaxone) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3779	 a postoperative patient with pre-existent myasthenia gravis, oral <e1>verapamil</e1> caused a marked <e2>exacerbation in myasthenic weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3780	 four patients, thrombosis occurred 2-45 days after severe <e1>hepatic veno-occlusive disease</e1> (HVOD) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3781	 four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (<e1>HVOD</e1>) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3782	 four patients, <e1>thrombosis</e1> occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3783	 during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing <e1>busulfan</e1> and to be associated with <e2>HVOD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3784	 during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing <e2>busulfan</e2> and to be associated with HVOD."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3785	 we describe a case of <e1>Vogt-Koyanagi-Harada disease</e1> occurring 4 months after the start of <e2>interferon</e2> alpha treatment, probably induced by the immunomodulatory effects of <e2>interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3786	 we describe a case of <e1>Vogt-Koyanagi-Harada disease</e1> occurring 4 months after the start of <e2>interferon alpha</e2> treatment, probably induced by the immunomodulatory effects of interferon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3787	 abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3788	 abnormalities</e1>, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3789	 abnormalities, including <e1>retinal hemorrhage</e1> and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3790	 disease</e1> occurring during <e2>interferon alpha</e2> therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3791	 hepatic failure</e1> is a rare and potentially lethal complication of <e2>propylthiouracil</e2> (PTU) use for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3792	 hepatic failure</e1> is a rare and potentially lethal complication of propylthiouracil (<e2>PTU</e2>) use for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3793	 an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with <e1>PTU</e1> -induced <e2>fulminant hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3794	 treatment of hyperthyroidism with amiodarone in a patient with <e1>propylthiouracil</e1> -induced <e2>acute hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3795	 present a 20-year-old woman with Basedow-Graves' disease who developed <e1>PTU</e1> -induced <e2>fulminant hepatitis</e2>, which progressed to acute hepatic failure with grade III hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3796	 virus-associated lymphoproliferative disorder</e1> in a patient with rheumatoid arthritis on <e2>methotrexate</e2> and rofecoxib: idiosyncratic reaction or pharmacogenetics?"
DRUG-ADE(e2,e1)
Comment: DRUG-A

3797	 virus-associated lymphoproliferative disorder</e1> in a patient with rheumatoid arthritis on methotrexate and <e2>rofecoxib</e2>: idiosyncratic reaction or pharmacogenetics?"
DRUG-ADE(e2,e1)
Comment: DRUG-A

3798	 (MTX) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in MTX-treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3799	 (<e1>MTX</e1>) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in <e1>MTX</e1> -treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3800	 (<e1>MTX</e1>) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in <e1>MTX</e1> -treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3801	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including <e2>acute renal failure</e2>, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3802	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, <e2>diarrhea</e2>, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3803	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, <e2>elevated liver transaminases</e2>, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3804	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, <e2>jaundice</e2>, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3805	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, <e2>mucosal ulcerations</e2>, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3806	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, <e2>pancytopenia</e2>, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3807	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and <e2>pyrexia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3808	 studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, <e2>vomiting</e2>, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3809	 hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the <e2>EBV-associated lymphoproliferative disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3810	 hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced <e2>hematopoietic toxicity</e2> and immunosuppression causing the EBV-associated lymphoproliferative disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3811	 hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and <e2>immunosuppression</e2> causing the EBV-associated lymphoproliferative disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3812	 We observed <e1>aggravation and spreading of a psoriatic plaque</e1> when treated topically with the toll-like receptor (TLR) 7 agonist <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

3813	 triggered by toll-like receptor 7 agonist <e2>imiquimod</e2> in the presence of dermal plasmacytoid dendritic cell precursors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3814	 <e1>imiquimod</e1> induces <e2>large amounts of type I interferon production</e2> from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3815	 <e1>exacerbation of psoriasis</e1> was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3816	 declined</e1> after treatment with <e2>methylprednisolone</e2>, after which fundus examination became consistent with progressive outer retinal necrosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3817	 side effects of <e1>AZA</e1> are rare, and reported <e2>allergic skin eruptions</e2> from <e1>AZA</e1> are very limited in Japan."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3818	 side effects of <e1>AZA</e1> are rare, and reported <e2>allergic skin eruptions</e2> from <e1>AZA</e1> are very limited in Japan."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3819	 is a good diagnostic tool for <e1>AZA</e1> <e2>allergy</e2>, especially for severe drug <e2>allergy</e2> cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3820	 eruption</e1> caused by <e2>azathioprine</e2>: value of using the drug-induced lymphocytes stimulation test for diagnosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3821	 report <e1>AZA</e1> -induced <e2>drug eruption</e2> that developed in two cases of systemic scleroderma with polymyositis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3822	 dyskinesia</e1> in 2 patients treated with <e2>ziprasidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3823	 of our patients developed <e1>TD</e1> after 23 months and 34 months of <e2>ziprasidone</e2> monotherapy, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3824	 is an atypical antipsychotic drug that is believed to have a low propensity for inducing <e2>extrapyramidal symptoms</e2>, including tardive dyskinesia (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3825	 is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including <e2>tardive dyskinesia</e2> (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3826	 is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (<e2>TD</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3827	 possible association with long-term exposure to an anti-epileptic drug of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3828	 patient was found to have <e1>no motile sperm</e1> with a normal sperm count, while taking a dose of 400 mg/day of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3829	 ulceration</e1> induced by all-trans <e2>retinoic acid</e2> in a patient with acute promyelocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3830	 <e1>ulcer</e1> did not respond to antibiotic treatment and healed shortly after withholding <e2>ATRA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3831	 report the development of <e1>scrotal ulcer</e1> in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with <e2>ATRA</e2> at a dose of 40 mg orally twice daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3832	 case of <e1>clozapine</e1> -induced <e2>tonic-clonic seizures</e2> managed with valproate: implications for clinical care."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3833	 discontinuation of <e1>clozapine</e1>, she was rechallenged and again was observed to have <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3834	 findings suggest that <e1>clozapine</e1> -induced <e2>seizures</e2> can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of <e2>seizures</e2> and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3835	 describe a case of <e1>clozapine</e1> -induced <e2>seizures</e2> in a patient with treatment-resistant schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3836	 Symptoms and pathologic changes of <e1>colitis</e1> are associated with exposure to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3837	 To describe clinical and pathologic findings in patients noted to develop <e1>lower gastrointestinal symptoms</e1> when exposed to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3838	 Three patients who developed symptoms of inflammatory bowel disease (<e1>IBD</e1>) during <e2>rofecoxib</e2> exposure are described along with pathology findings."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3839	 Three patients who developed symptoms of <e1>inflammatory bowel disease</e1> (IBD) during <e2>rofecoxib</e2> exposure are described along with pathology findings."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3840	 administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3841	 administration of Oxybutynin concomitantly with an increase in the dose of <e1>Dantrolene</e1>, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3842	 administration of <e1>Oxybutynin</e1> concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3843	 toxicity following Oxybutynin and Dantrolene administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3844	 toxicity</e1> following Oxybutynin and <e2>Dantrolene</e2> administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3845	 toxicity</e1> following <e2>Oxybutynin</e2> and Dantrolene administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3846	 To report a case of <e2>Carbamazepine</e2> toxicity following the administration of Oxybutynin and Dantrolene."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3847	 To report a case of <e1>Carbamazepine toxicity</e1> following the administration of Oxybutynin and <e2>Dantrolene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3848	 To report a case of <e1>Carbamazepine toxicity</e1> following the administration of <e2>Oxybutynin</e2> and Dantrolene."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3849	 the best of our knowledge, this is the first reported patient with <e1>captopril</e1> -induced <e2>pemphigus</e2> in whom no new lesions developed after subsequent treatment with enalapril."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3850	 report a case of drug-induced <e1>pemphigus</e1> caused by an angiotensin-converting enzyme inhibitor, <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3851	 is a significant side effect of <e2>thalidomide</e2> therapy, which may limit its clinical use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3852	 <e2>neuropathy</e2> in childhood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3853	 <e2>neuropathy</e2> is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3854	 neuropathy is often associated with <e2>proximal weakness</e2> and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3855	 was withdrawn from world markets in 1961 following recognition of its <e2>teratogenic effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3856	 report four cases of <e1>sensorimotor axonal neuropathy</e1> in children aged 10-15 years, treated with <e2>thalidomide</e2> for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3857	 edema</e1> associated with <e2>Gliadel</e2> wafers: two case studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3858	 are two clinical case reports demonstrating profound <e1>cerebral edema</e1> associated with implantation of <e2>Gliadel</e2> wafers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3859	 the introduction of <e1>carmustine</e1> wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant <e2>cerebral edema</e2> is a potential adverse effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3860	 the introduction of carmustine wafers (<e1>Gliadel</e1> wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant <e2>cerebral edema</e2> is a potential adverse effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3861	 acid</e1> (RA) may further increase the risk of developing <e2>BMTN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3862	 acid (<e1>RA</e1>) may further increase the risk of developing <e2>BMTN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3863	 is likely that <e1>RA</e1> contributed to the <e2>deterioration in renal function</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3864	 acid</e1> may increase the risk of <e2>bone marrow transplant nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3865	 occurrence of <e1>BMTN</e1> in two children treated with <e2>RA</e2> in our unit is unlikely to be coincidental."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3866	 developed a late <e1>secondary infection</e1> in some sites treated with <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3867	 64-year-old man with schizophrenia developed <e1>myoclonic jerks</e1> when given higher doses of <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3868	 -induced <e2>myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3869	 report a case of <e1>myoclonus</e1> induced by <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3870	 <e1>myelodysplastic syndrome</e1> after <e2>temozolomide</e2> for recurrent high-grade glioma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3871	 report a 44-year-old woman with t-MDS (<e1>refractory anemia with excess blasts</e1>) following treatment of recurrent anaplastic astrocytoma with <e2>temozolomide</e2> (TMZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3872	 report a 44-year-old woman with t-MDS (<e1>refractory anemia with excess blasts</e1>) following treatment of recurrent anaplastic astrocytoma with temozolomide (<e2>TMZ</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3873	 drug-induced <e1>neutropenia</e1> occurs in a patient receiving a semisynthetic <e2>penicillin</e2> for two weeks or more."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3874	 reticularis</e1> associated with <e2>interferon alpha</e2> therapy in two melanoma patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3875	 cases highlight the occurrence of <e1>livedo reticularis</e1> as an uncommon side-effect of <e2>interferon alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3876	 report two patients who developed intense <e1>livedo reticularis</e1> clearly related to the administration of <e2>interferon alpha 2b</e2> as an adjuvant therapy for melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3877	 This rare case of <e1>PTU</e1> -induced <e2>ANCA-associated vasculitis</e2> manifested with ototoxicity in combination with systemic involvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3878	 This rare case of <e1>PTU</e1> -induced ANCA-associated vasculitis manifested with <e2>ototoxicity</e2> in combination with systemic involvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3879	 To report the case of a young woman with Graves' disease in whom ototoxicity developed because of <e1>propylthiouracil</e1> (PTU)-induced <e2>antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3880	 To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (<e1>PTU</e1>)-induced <e2>antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3881	 To report the case of a young woman with Graves' disease in whom <e1>ototoxicity</e1> developed because of <e2>propylthiouracil</e2> (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3882	 To report the case of a young woman with Graves' disease in whom <e1>ototoxicity</e1> developed because of propylthiouracil (<e2>PTU</e2>)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3883	 -induced sensorineural hearing loss associated with <e2>antineutrophil cytoplasmic antibodies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3884	 -induced <e2>sensorineural hearing loss</e2> associated with antineutrophil cytoplasmic antibodies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3885	 In a 22-year-old Thai woman with Graves' disease, tinnitus, <e1>hearing impairment in the left ear (with progression to the right ear)</e1>, and vertigo developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3886	 In a 22-year-old Thai woman with Graves' disease, <e1>tinnitus</e1>, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3887	 In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and <e1>vertigo</e1> developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3888	 <e1>hearing impairment</e1> and tinnitus were gradually reduced after <e2>PTU</e2> withdrawal and corticosteroid and azathioprine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3889	 hearing impairment and <e1>tinnitus</e1> were gradually reduced after <e2>PTU</e2> withdrawal and corticosteroid and azathioprine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3890	 drugs had been stopped on the 2nd day of therapy due to development of <e1>optic neuritis</e1> secondary to <e2>ethambutol</e2> administration at another hospital."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3891	 the anti-tuberculous therapy, <e1>visual loss</e1> can be related to <e2>ethambutol</e2> toxicity or the tuberculosis infection itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3892	 addition, <e1>ethambutol</e1> rarely causes <e2>visual loss</e2> during the early period or when given at lower doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3893	 -induced <e2>aplastic anaemia</e2> and liver failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3894	 -induced aplastic anaemia and <e2>liver failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3895	 is well-recognized that <e1>flucloxacillin</e1> may occasionally result in <e2>fatal hepatic injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3896	 report the case of a 40-year-old woman who developed fulminant hepatic failure and <e1>aplastic anaemia</e1> following a course of oral <e2>flucloxacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3897	 report the case of a 40-year-old woman who developed <e1>fulminant hepatic failure</e1> and aplastic anaemia following a course of oral <e2>flucloxacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3898	 days after intravenous <e1>Zoledronic acid</e1>, the patient presented to emergency room with complaints of carpopedal spasm and <e2>bronchospasm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3899	 days after intravenous <e1>Zoledronic acid</e1>, the patient presented to emergency room with complaints of <e2>carpopedal spasm</e2> and bronchospasm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3900	 acid</e1> -induced <e2>severe hypocalcaemia</e2> in a prostate cancer patient with extensive osteoblastic bone metastases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3901	 case report describes an adolescent with <e1>severe lupus erythematosus</e1> who received cyclophosphamide (<e2>CY</e2>) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3902	 case report describes an adolescent with <e1>severe lupus erythematosus</e1> who received <e2>cyclophosphamide</e2> (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3903	 pigmentation</e1> after oral lichen planus treatment with topical <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3904	 relation between <e1>tacrolimus</e1> treatment and staining was suggested by the appearance of <e2>pigmentation</e2> during topical <e1>tacrolimus</e1> treatment and its clinical disappearance when treatment was stopped."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3905	 relation between <e1>tacrolimus</e1> treatment and staining was suggested by the appearance of <e2>pigmentation</e2> during topical <e1>tacrolimus</e1> treatment and its clinical disappearance when treatment was stopped."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3906	 report the first histopathologically documented case of <e1>oral mucosa pigmentation</e1> after OLP treatment with topical <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3907	 some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with <e1>Methotrexate</e1> (MTX) and <e2>malignant lymphoma</e2> developing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3908	 some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (<e1>MTX</e1>) and <e2>malignant lymphoma</e2> developing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3909	 is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including <e2>tardive dyskinesia</e2> (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3910	 is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia (<e2>TD</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3911	 withdrawal-related <e2>respiratory dyskinesia</e2>: a case diagnosed by spirography and fibroscopy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3912	 authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], <e1>limb dyskinesia</e1>, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3913	 authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and <e1>orofacial dyskinesia</e1>) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3914	 authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [<e1>RD</e1>], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3915	 authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including <e1>respiratory dyskinesia</e1> [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3916	 authors present an elderly patient with mixed dementia who developed <e1>TD</e1> at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3917	 clinicians should pay close attention to possible onset of <e1>RD</e1> in patients with multiple risk factors for TD, even when <e2>SDA</e2> therapy is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3918	 this study, we report on three individual patients who received <e1>BTX-B</e1> and who subsequently developed <e2>parasympathetic dysfunction of the visual system</e2> after injections of <e1>BTX-B</e1> at remote sites."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3919	 this study, we report on three individual patients who received <e1>BTX-B</e1> and who subsequently developed <e2>parasympathetic dysfunction of the visual system</e2> after injections of <e1>BTX-B</e1> at remote sites."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3920	 date, there have been few reports of <e1>visual disturbances</e1> associated with <e2>BTX-B</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3921	 system side effects caused by <e1>parasympathetic dysfunction</e1> after <e2>botulinum toxin type B</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3922	 system side effects</e1> caused by parasympathetic dysfunction after <e2>botulinum toxin type B</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3923	 -induced <e2>anemia</e2> in two kidney transplant recipients."
DRUG-ADE(e1,e2)
Comment: DRUG-A

3924	 renal transplant patients developed <e1>anemia</e1> during treatment of hypertension with <e2>enalapril</e2> medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3925	 74-year-old hypercholestrerolaemic woman taking <e1>cerivastatin</e1> (0.15 mg/day) for 22 days complained of general muscle weakness and <e2>muscle pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3926	 74-year-old hypercholestrerolaemic woman taking <e1>cerivastatin</e1> (0.15 mg/day) for 22 days complained of general <e2>muscle weakness</e2> and muscle pain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3927	 rates of <e1>cerivastatin</e1> metabolites in a patient with <e1>cerivastatin</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3928	 report on a patient who developed <e1>acute rhabdomyolysis</e1> after taking <e2>cerivastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3929	 <e2>hypersensitivity</e2> induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3930	 <e1>hypersensitivity</e1> induced by low-dose paclitaxel/<e2>carboplatin</e2> in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3931	 <e1>hypersensitivity</e1> induced by low-dose <e2>paclitaxel</e2>/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3932	 one patient exhibited severe hypersensitivity reactions including cardiac arrest and <e1>apnea</e1>, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3933	 one patient exhibited severe hypersensitivity reactions including <e1>cardiac arrest</e1> and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3934	 one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed <e1>eruptions</e1>, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3935	 one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, <e1>hypotension</e1>, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3936	 one patient exhibited <e1>severe hypersensitivity reactions</e1> including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3937	 one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and <e1>tachycardia</e1> soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3938	 report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3939	 report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3940	 report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3941	 report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3942	 report five cases of <e1>carboplatin</e1> (CBDCA) <e2>hypersensitivity</e2> after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3943	 report five cases of carboplatin (<e1>CBDCA</e1>) <e2>hypersensitivity</e2> after weekly low-dose paclitaxel (60 mg/m2)/<e1>CBDCA</e1> (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3944	 report five cases of carboplatin (CBDCA) <e1>hypersensitivity</e1> after weekly low-dose <e2>paclitaxel</e2> (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3945	 Standard anti-tuberculosis therapy was administered but was complicated by interaction with <e1>cyclosporine</e1> and drug-induced <e2>cholestasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

3946	 <e1>fentanyl</e1> application induces <e2>adrenocortical insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3947	 report a case of a 64-year-old man with secondary <e1>adrenocortical insufficiency</e1> who has been on a chronic transdermal <e2>fentanyl</e2> treatment because of sciatic pain syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3948	 -induced <e2>neuroleptic malignant syndrome</e2> in a schizophrenic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3949	 To report a case of <e1>neuroleptic malignant syndrome</e1> (NMS) associated with <e2>fluphenazine</e2> in a schizophrenic patient and review the literature related to this condition."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3950	 To report a case of neuroleptic malignant syndrome (<e1>NMS</e1>) associated with <e2>fluphenazine</e2> in a schizophrenic patient and review the literature related to this condition."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3951	 <e1>vancomycin</e1> -induced <e2>cerebrospinal fluid eosinophilia</e2>: report of two patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3952	 propose a mechanism of <e1>vancomycin</e1> -induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of <e2>CSFE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3953	 report two cases of <e1>cerebrospinal fluid eosinophilia</e1> (CSFE) secondary to the intraventricular administration of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3954	 report two cases of cerebrospinal fluid eosinophilia (<e1>CSFE</e1>) secondary to the intraventricular administration of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3955	 recovery from <e1>interstitial pneumonitis</e1>, induced by <e2>bicalutamide</e2> and leuprorelin acetate given as treatment for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3956	 recovery from <e1>interstitial pneumonitis</e1>, induced by bicalutamide and <e2>leuprorelin acetate</e2> given as treatment for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3957	 report a case of <e1>interstitial pneumonitis</e1> induced by <e2>bicalutamide</e2> and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3958	 report a case of <e1>interstitial pneumonitis</e1> induced by bicalutamide and/or <e2>leuprorelin acetate</e2> given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3959	 In these 3 cases, the unique positive ocular finding was <e1>corneal endothelial deposits</e1>, which may be related to the use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3960	 endothelial deposits</e1> associated with <e2>rifabutin</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3961	 The aim of this study was to report on the possible development of <e1>corneal endothelial deposits</e1> resulting from the use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3962	 All cases developed <e1>corneal endothelial deposits</e1> after previous use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

3963	 A <e1>malignant mixed mesodermal tumor</e1> was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking <e2>raloxifene</e2> for osteoporosis prevention."
DRUG-ADE(e2,e1)
Comment: DRUG-

3964	 There may be an association between <e1>raloxifene</e1> and the development of <e2>malignant mixed mesodermal tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3965	 mixed mullerian tumor of the uterus</e1> in a patient taking <e2>raloxifene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3966	 report a case of a women in whom a <e1>malignant mixed mesodermal tumor</e1> was diagnosed while she was taking <e2>raloxifene</e2>, which is also a selective estrogen receptor modulator."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3967	 we report four patients who underwent liver transplantation and developed <e1>neutropenia</e1> while receiving <e2>MMF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3968	 mofetil</e1> -induced <e2>neutropenia</e2> in liver transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3969	 mean time from starting <e1>MMF</e1> to the development of <e2>neutropenia</e2> was 4 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3970	 side effects of <e1>MMF</e1>, such as <e2>bone marrow toxicity</e2>, have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3971	 previous review described data on 15 patients who experienced <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP or secondary thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3972	 previous review described data on 15 patients who experienced acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>anti-D IGIV</e2> administration for ITP or secondary thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3973	 intravascular coagulation associated with <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3974	 intravascular coagulation</e1> associated with acute hemoglobinemia or hemoglobinuria following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3975	 intravascular coagulation associated with acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3976	 review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (<e2>DIC</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3977	 review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of hemoglobinemia, particularly <e2>disseminated intravascular coagulation</e2> (DIC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3978	 review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of <e2>hemoglobinemia</e2>, particularly disseminated intravascular coagulation (DIC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3979	 purpose of this review is to increase awareness among physicians and other health care professionals that <e1>DIC</e1> may be a rare but potentially severe complication of <e2>anti-D IGIV</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3980	 review presents the first case series of DIC associated with <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3981	 review presents the first case series of <e1>DIC</e1> associated with acute hemoglobinemia or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3982	 review presents the first case series of DIC associated with acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3983	 the second <e1>infliximab</e1> infusion, he was found to have a <e2>severe transient neutropenia</e2> (0.5 x 10(9)/L)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3984	 <e1>agranulocytosis</e1> during treatment with <e2>infliximab</e2> in enteropathic spondyloarthropathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3985	 data indicated that <e1>infliximab</e1> possibly triggered production of granulocyte and neutrophil autoantibodies with resultant <e2>autoimmune agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3986	 data indicated that <e1>infliximab</e1> possibly triggered <e2>production of granulocyte and neutrophil autoantibodies</e2> with resultant autoimmune agranulocytosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3987	 peripheral neuropathy and <e1>bone marrow depression</e1> led to <e2>linezolid</e2> withdrawal in seven patients, and neuropathy may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3988	 peripheral <e1>neuropathy</e1> and bone marrow depression led to <e2>linezolid</e2> withdrawal in seven patients, and <e1>neuropathy</e1> may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3989	 <e1>peripheral neuropathy</e1> and bone marrow depression led to <e2>linezolid</e2> withdrawal in seven patients, and neuropathy may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3990	 patients developed peripheral neuropathy and five patients <e1>bone marrow depression</e1>, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of <e2>linezolid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3991	 patients developed <e1>peripheral neuropathy</e1> and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of <e2>linezolid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3992	 case of <e1>high-grade endometrial stromal sarcoma</e1>, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3993	 case of high-grade endometrial stromal sarcoma, confined into an <e1>intrauterine polypoid growth</e1>, in a woman with a history of breast cancer who was treated with adjuvant <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3994	 endometrial stromal sarcoma</e1> after <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3995	 deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including <e2>endometrial adenocarcinoma</e2> or uterine sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3996	 deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including <e2>endometrial adenocarcinoma</e2> or uterine sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3997	 deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including endometrial adenocarcinoma or <e2>uterine sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3998	 deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including endometrial adenocarcinoma or <e2>uterine sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3999	 only the third dose of <e1>pentamidine</e1>, it was noted that the patient's <e2>heart rate had decreased</e2> to 48 beats/minute."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4000	 various manifestations of <e1>pentamidine</e1> -induced <e2>cardiotoxicity</e2> have been reported, to our knowledge, second-degree heart block associated with this agent has not been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4001	 various manifestations of <e1>pentamidine</e1> -induced cardiotoxicity have been reported, to our knowledge, <e2>second-degree heart block</e2> associated with this agent has not been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4002	 should be vigilant when monitoring for <e1>cardiotoxicity</e1> in patients receiving <e2>pentamidine</e2> throughout the duration of therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4003	 <e1>pentamidine</e1> -associated <e2>second-degree heart block</e2> and sinus bradycardia: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4004	 <e1>pentamidine</e1> -associated second-degree heart block and <e2>sinus bradycardia</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4005	 backward</e1> in two elderly patients taking <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4006	 Both patients experienced a previously unreported side effect--<e1>falling backward</e1> --associated with <e2>bupropion</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4007	 and neurologic findings</e1> in two children exposed to <e2>vigabatrin</e2> in utero."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4008	 knowledge concerning <e1>VGB</e1> -associated <e2>visual dysfunction</e2> in pediatric patients, particularly in those who have been exposed to <e1>VGB</e1> in utero is limited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4009	 -induced <e2>visual field defects</e2> are at present the most important safety issue in the use of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4010	 explored <e1>ophthalmic and neurologic findings</e1> in two children who have been exposed prenatally to <e2>VGB</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4011	 Interferon (<e1>IFN</e1>)-associated retinopathy is typically characterized by retinal hemorrhages and <e2>cotton wool spots</e2> at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4012	 <e1>Interferon</e1> (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and <e2>cotton wool spots</e2> at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4013	 Interferon (<e1>IFN</e1>)-associated retinopathy is typically characterized by <e2>retinal hemorrhages</e2> and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4014	 <e1>Interferon</e1> (IFN)-associated retinopathy is typically characterized by <e2>retinal hemorrhages</e2> and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4015	 Interferon (<e1>IFN</e1>)-associated <e2>retinopathy</e2> is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4016	 <e1>Interferon</e1> (IFN)-associated <e2>retinopathy</e2> is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4017	 course of <e1>macular edema</e1> in two cases of <e2>interferon</e2> -associated retinopathy observed by optical coherence tomography."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4018	 course of macular edema in two cases of <e1>interferon</e1> -associated <e2>retinopathy</e2> observed by optical coherence tomography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4019	 During and after <e1>IFN</e1> therapy, OCT is a useful examination technique for revealing macular edema in patients who have <e2>decreased vision</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4020	 During and after <e1>IFN</e1> therapy, OCT is a useful examination technique for revealing <e2>macular edema</e2> in patients who have decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4021	 should be aware of the ocular side effects of <e1>IFN</e1> therapy and carefully monitor patients for the possible occurrence of <e2>hypoalbuminemia</e2> and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4022	 should be aware of the <e1>ocular side effects</e1> of <e2>IFN</e2> therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4023	 should be aware of the ocular side effects of <e1>IFN</e1> therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4024	 former patient had complained once that his <e1>visual acuity had decreased</e1> after the termination of <e2>IFN</e2> therapy, and the latter patient complained twice during <e2>IFN</e2> therapy that his <e1>visual acuity had decreased</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4025	 former patient had complained once that his <e1>visual acuity had decreased</e1> after the termination of <e2>IFN</e2> therapy, and the latter patient complained twice during <e2>IFN</e2> therapy that his <e1>visual acuity had decreased</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4026	 the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed <e2>macular edema</e2> and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4027	 the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed <e2>macular edema</e2> and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4028	 the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed macular edema and <e2>reduced visual acuity</e2> during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4029	 the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated retinopathy who had developed macular edema and <e2>reduced visual acuity</e2> during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4030	 the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated <e2>retinopathy</e2> who had developed macular edema and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4031	 the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1> -associated <e2>retinopathy</e2> who had developed macular edema and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4032	 development of <e1>diabetes mellitus</e1> after <e2>interferon-alfa</e2> and ribavirin therapy for chronic hepatitis C: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4033	 development of <e1>diabetes mellitus</e1> after interferon-alfa and <e2>ribavirin</e2> therapy for chronic hepatitis C: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4034	 To report the late development of <e1>immune-mediated diabetes mellitus</e1> after completion of <e2>alfa-interferon</e2> therapy for hepatitis C in an Asian patient."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4035	 necrosis</e1> after injection of polyethylene glycol-modified <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4036	 necrosis</e1> as a result of <e2>interferon alfa</e2> is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4037	 report 5 patients (3 patients with chronic hepatitis C treated with <e1>pegylated interferon alfa-2b</e1> in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of <e1>pegylated interferon alfa-2b</e1> at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4038	 report 5 patients (3 patients with chronic hepatitis C treated with <e1>pegylated interferon alfa-2b</e1> in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of <e1>pegylated interferon alfa-2b</e1> at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4039	 report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral <e1>ribavirin</e1> and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4040	 review the literature on previously reported cases of <e1>cutaneous necrosis</e1> after injection of standard <e2>interferon alfa</e2> or pegylated <e2>interferon alfa</e2> -2b and discuss the different pathophysiologic mechanisms that might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4041	 review the literature on previously reported cases of <e1>cutaneous necrosis</e1> after injection of standard interferon alfa or <e2>pegylated interferon alfa-2b</e2> and discuss the different pathophysiologic mechanisms that might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4042	 mechanisms involved in the occurrence of <e1>ischemic colitis</e1> in patients receiving <e2>tegaserod</e2> are also discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4043	 -associated <e2>ischemic colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4044	 describe the development of ischemic colitis in a woman who was treated with <e1>tegaserod</e1> and review the relationship among ischemic colitis, <e1>tegaserod</e1> use, and <e2>irritable bowel syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4045	 describe the development of ischemic colitis in a woman who was treated with <e1>tegaserod</e1> and review the relationship among ischemic colitis, <e1>tegaserod</e1> use, and <e2>irritable bowel syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4046	 describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4047	 describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4048	 describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4049	 describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4050	 57-year-old man developed <e1>chronic, watery diarrhea</e1> four weeks after Helicobacter pylori eradication therapy including <e2>lansoprazole</e2> followed by <e2>lansoprazole</e2> monotherapy for gastroesophageal reflux disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4051	 57-year-old man developed <e1>chronic, watery diarrhea</e1> four weeks after Helicobacter pylori eradication therapy including <e2>lansoprazole</e2> followed by <e2>lansoprazole</e2> monotherapy for gastroesophageal reflux disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4052	 -associated <e2>collagenous colitis</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4053	 reported case represents an unusual association between medication with the proton pump inhibitor <e1>lansoprazole</e1> and the development of <e2>collagenous colitis</e2> suggesting the importance of evaluation of drug use in patients with microscopic colitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4054	 woman developed <e1>painful ulcers</e1> over her lower abdomen in the form of reticulate erythema after injecting <e2>interferon beta-1b</e2> subcutaneously for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4055	 woman developed painful ulcers over her lower abdomen in the form of <e1>reticulate erythema</e1> after injecting <e2>interferon beta-1b</e2> subcutaneously for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4056	 wall ulceration</e1> and mucinosis secondary to <e2>recombinant human interferon-beta-1b</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4057	 wall ulceration and <e1>mucinosis</e1> secondary to <e2>recombinant human interferon-beta-1b</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4058	 -related increased <e2>vincristine neurotoxicity</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4059	 increased <e2>vincristine</e2> neurotoxicity: case report and review of literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4060	 cases of unusual enhanced vincristine <e1>neurotoxicity</e1> related to <e2>itraconazole</e2> have been reported in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4061	 cases of unusual enhanced <e1>vincristine</e1> <e2>neurotoxicity</e2> related to itraconazole have been reported in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4062	 days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and <e2>absence of deep reflexes</e2>, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4063	 days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, <e2>mild left ptosis</e2>, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4064	 days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and <e2>mild weakness of the upper extremities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4065	 days after <e1>itraconazole</e1> was started, he developed paralytic ileus, <e2>neurogenic bladder</e2>, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4066	 days after <e1>itraconazole</e1> was started, he developed <e2>paralytic ileus</e2>, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4067	 days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with <e2>severe paralysis of the lower extremities</e2> and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4068	 authors suggest that in the absence of any proven benefit of <e1>itraconazole</e1> prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially <e2>fatal toxicities</e2>, the combination use of these drugs should be avoided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4069	 authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with <e1>vincristine</e1> leading to severe and even potentially <e2>fatal toxicities</e2>, the combination use of these drugs should be avoided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4070	 REPORT: We report a case of <e1>intracerebral hemorrhage</e1> occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting <e2>pseudoephedrine</e2> daily for one year."
DRUG-ADE(e2,e1)
Comment: DRUG-

4071	 one report links <e1>phenylpropanolamine</e1> consumption to an <e2>intracerebral hemorrhage</e2> in a patient with an AVM."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4072	 -induced hemorrhage associated with a <e2>cerebral vascular malformation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4073	 -induced <e2>hemorrhage</e2> associated with a cerebral vascular malformation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4074	 1979, over 30 published case reports have documented the relationship between <e1>phenylpropanolamine</e1> and <e2>stroke</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4075	 is a case of <e1>pseudoephedrine</e1> -induced <e2>intracerebral hemorrhage</e2> in a patient with an underlying vascular malformation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4076	 onset of <e1>quetiapine</e1> -induced <e2>diabetic ketoacidosis</e2> in an elderly patient: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4077	 report a case of reversible <e1>DKA</e1> and new-onset DM that developed in a demented patient who was treated with <e2>quetiapine</e2> for 14 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4078	 report a case of reversible DKA and new-onset <e1>DM</e1> that developed in a demented patient who was treated with <e2>quetiapine</e2> for 14 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4079	 leukostasis</e1> secondary to <e2>all-trans retinoic acid</e2> in the treatment of acute promyelocytic leukemia in first relapse."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4080	 epidermoid cysts</e1> resulting from treatment with <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4081	 A 79-year-old woman being treated with <e1>imiquimod</e1> 5 days per week for a nodular basal cell developed a <e2>verrucous plaque</e2> over the treatment area after 7 weeks of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4082	 <e1>multiple comedones</e1> and ruptured epidermoid cysts are newly reported adverse effects of <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4083	 multiple comedones and <e1>ruptured epidermoid cysts</e1> are newly reported adverse effects of <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4084	 report an unusual case of massive <e1>fluoxetine</e1> ingestion resulting in neurological and cardiovascular toxicity resulting in <e2>death</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4085	 report an unusual case of massive <e1>fluoxetine</e1> ingestion resulting in <e2>neurological and cardiovascular toxicity</e2> resulting in death."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4086	 damage</e1> following therapeutic intravenous <e2>iron sucrose</e2> infusion in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4087	 case reported here is of a child given a large dose of intravenous <e1>iron sucrose</e1> (16 mg/kg) over 3 hours, who subsequently developed features of <e2>systemic iron toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4088	 personal observations of an <e1>acute amnestic episode</e1> in younger individuals after intake of <e2>clioquinol</e2> are described together with three observations from the medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4089	 clinical aspect closely resembled classical transient global amnesia but the episode after <e1>clioquinol</e1> lasted longer (24 hours to three days) and a more or less extensive <e2>retrograde amnesia</e2> persisted permanently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4090	 clinical aspect closely resembled classical <e1>transient global amnesia</e1> but the episode after <e2>clioquinol</e2> lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4091	 global amnesia</e1> after <e2>clioquinol</e2>: five personal observations from outside Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4092	 the other patient, a 78-year-old woman, <e1>Neisseria mucosa knee arthritis</e1> occurred after a single <e2>sodium hyaluronate</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4093	 patient was an 80-year-old woman who was admitted for <e1>Staphylococcus aureus knee arthritis</e1> after several intraarticular injections of sodium hyaluronate and <e2>corticosteroids</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4094	 patient was an 80-year-old woman who was admitted for <e1>Staphylococcus aureus knee arthritis</e1> after several intraarticular injections of <e2>sodium hyaluronate</e2> and corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4095	 knee arthritis</e1> after intra-articular <e2>hyaluronate</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4096	 dystonia</e1> induced by <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4097	 induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of <e2>lamivudine</e2> -induced <e1>ADR</e1> in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4098	 authors report two cases of <e1>acute dystonic reactions</e1> (ADRs) as a side effect of <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4099	 authors report two cases of acute dystonic reactions (<e1>ADRs</e1>) as a side effect of <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4100	 authors think that although <e1>lamivudine</e1> is widely used and well tolerated, it can cause <e2>ADRs</e2>, which are reversible after drug withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4101	 fibrosis</e1> after long-term treatment with the dopamine agonist <e2>pergolide</e2> for Parkinson Disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4102	 This observation of "on-off" <e1>risperidone</e1> treatment suggests that <e1>risperidone</e1> may have worsened both <e2>psychiatric and physical manifestations</e2> of the mitochondrial disorder in this adolescent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4103	 This observation of "on-off" <e1>risperidone</e1> treatment suggests that <e1>risperidone</e1> may have worsened both <e2>psychiatric and physical manifestations</e2> of the mitochondrial disorder in this adolescent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4104	 To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and <e1>increased mood symptoms</e1> during treatment with <e2>risperidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4105	 -induced psychosis and <e2>depression</e2> in a child with a mitochondrial disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4106	 -induced <e2>psychosis</e2> and depression in a child with a mitochondrial disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4107	 radiation myelopathy</e1> after high-dose <e2>busulfan</e2> and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4108	 radiation myelopathy</e1> after high-dose busulfan and <e2>melphalan</e2> chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4109	 -induced <e2>pericardial effusion</e2> and tamponade after unblocked cardiac irradiation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4110	 -induced pericardial effusion and <e2>tamponade</e2> after unblocked cardiac irradiation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4111	 therapy has been associated with <e2>radiation recall reactions</e2> when used in the treatment of carcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4112	 should be aware of the potential for developing a <e1>gemcitabine</e1> -induced radiation recall reaction resulting in hemodynamically significant <e2>pericardial effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4113	 should be aware of the potential for developing a <e1>gemcitabine</e1> -induced <e2>radiation recall reaction</e2> resulting in hemodynamically significant pericardial effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4114	 report four cases of hemodynamically significant <e1>pericardial effusion</e1> in patients with refractory lymphoma who were receiving <e2>gemcitabine</e2>, all of whom had a history of mediastinal radiation without subcarinal blocking."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4115	 patient with generalized MG was effectively managed with <e1>MM</e1> but developed <e2>CNS lymphoma</e2> after 3 years of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4116	 minimal short-term side effects and apparent efficacy, chronic treatment of MG with <e1>MM</e1> may be associated with increased risk of <e2>lymphoproliferative disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4117	 <e1>CNS lymphoma</e1> complicating treatment of myasthenia gravis with <e2>mycophenolate mofetil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4118	 <e1>CNS lymphoma</e1> regressed on withdrawal of <e2>MM</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4119	 withdrawal: a cause of prolonged <e2>fever</e2> in the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4120	 <e2>withdrawal syndrome</e2> resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4121	 <e1>withdrawal syndrome</e1> resulting from underdosing of oral <e2>baclofen</e2> should be considered as a potential source of prolonged fever in the intensive care unit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4122	 patient continued to have fever and <e1>autonomic instability</e1> without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral <e2>baclofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4123	 patient continued to have <e1>fever</e1> and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral <e2>baclofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4124	 report a case of <e1>baclofen</e1> <e2>withdrawal syndrome</e2> resulting from oral <e1>baclofen</e1> underdosing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4125	 report a case of <e1>baclofen</e1> <e2>withdrawal syndrome</e2> resulting from oral <e1>baclofen</e1> underdosing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4126	 discontinuing <e1>captopril</e1> and starting systemic steroids, her symptomatology rapidly improved, and her <e2>eosinophilia</e2> and radiographic abnormalities both resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4127	 discontinuing <e1>captopril</e1> and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and <e2>radiographic abnormalities</e2> both resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4128	 -induced <e2>pulmonary infiltrates with eosinophilia</e2> in an infant with congenital heart disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4129	 report a case of an infant with complex congenital heart disease who was placed on <e1>captopril</e1> for afterload reduction following cardiac surgery and subsequently developed <e2>pulmonary infiltrates with eosinophilia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4130	 <e1>propofol</e1> precipitate <e2>pancreatitis</e2> in patients with Cushing's syndrome?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4131	 elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to <e1>acute pancreatitis</e1> following <e2>propofol</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4132	 recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a <e1>focal seizure</e1>) of severe <e2>lithium</e2> -induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4133	 recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a <e1>prolonged seizure</e1>, a serotonin syndrome and a focal seizure) of severe <e2>lithium</e2> -induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4134	 recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a <e1>serotonin syndrome</e1> and a focal seizure) of severe <e2>lithium</e2> -induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4135	 T-cell-rich B-cell lymphoma</e1> as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with <e2>rituximab</e2>: a molecular analysis using laser capture microdissection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4136	 <e1>CD20-negative tumors</e1> have been described after <e2>Rituximab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4137	 51-year old physically fit woman experienced <e1>angio-oedema</e1> and hypotensive shock after <e2>irbesartan</e2> ingestion requiring noradrenaline infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4138	 51-year old physically fit woman experienced angio-oedema and <e1>hypotensive shock</e1> after <e2>irbesartan</e2> ingestion requiring noradrenaline infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4139	 our knowledge, our report is one of the first on shock and <e1>angio-oedema</e1> from <e2>irbesartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4140	 our knowledge, our report is one of the first on <e1>shock</e1> and angio-oedema from <e2>irbesartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4141	 died within six weeks of developing <e1>congestive heart failure</e1> coupled with liver failure due to haemosiderosis despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4142	 died within six weeks of developing congestive heart failure coupled with liver failure due to <e1>haemosiderosis</e1> despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4143	 died within six weeks of developing congestive heart failure coupled with <e1>liver failure</e1> due to haemosiderosis despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4144	 haemosiderosis</e1> inspite of regular use of <e2>desferrioxamine</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4145	 of the side-effects of intravitreal <e1>triamcinolone</e1> is the development of <e2>cataract</e2>, and it is known that <e2>cataract</e2> extraction can exacerbate macular degeneration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4146	 loss of vision after removal of <e1>cataract</e1> caused by intravitreal <e2>triamcinolone</e2> in combination with photodynamic therapy for exudative age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4147	 loss of vision</e1> after removal of cataract caused by intravitreal <e2>triamcinolone</e2> in combination with photodynamic therapy for exudative age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4148	 caused by tocolysis with oral <e2>ritodrine hydrochloride</e2> in a pregnant patient with myotonic dystrophy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4149	 has been recognized as a complication of tocolytic therapy with <e2>ritodrine hydrochloride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4150	 report here a rare case of <e1>ritodrine-hydrochloride</e1> -induced <e2>rhabdomyolysis</e2> in a pregnant patient with myotonic dystrophy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4151	 myocardial ischemia</e1> following accidental intravenous administration of <e2>epinephrine</e2> in high concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4152	 and accidental <e1>epinephrine</e1> overdose might result in potentially <e2>lethal complications</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4153	 present a case of acute <e1>epinephrine</e1> toxicity resulting in <e2>acute myocardial ischemia</e2> in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4154	 present a case of acute <e1>epinephrine</e1> toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed <e2>severe allergic reaction</e2> to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4155	 present a case of acute <e1>epinephrine</e1> toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed <e2>severe allergic reaction</e2> to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4156	 and pharmacokinetic findings in <e1>levodopa</e1> -induced augmentation of <e2>restless legs syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4157	 and signs of <e1>augmentation</e1> were related to low plasma <e2>levodopa</e2> levels, abating 75 minutes after oral <e2>levodopa</e2> administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma <e2>levodopa</e2> concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4158	 and signs of <e1>augmentation</e1> were related to low plasma <e2>levodopa</e2> levels, abating 75 minutes after oral <e2>levodopa</e2> administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma <e2>levodopa</e2> concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4159	 and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with <e2>anarchic discharges of motor unit potentials</e2>, tonic grouped discharges and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4160	 and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and <e2>flexor spasms</e2>, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4161	 and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated <e2>marked motor hyperactivity</e2> during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4162	 and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with <e2>painful dysesthesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4163	 and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, <e2>tonic grouped discharges</e2> and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4164	 describe a patient with idiopathic RLS who developed <e1>augmentation</e1> after 8 months of <e2>levodopa</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4165	 major side effect of <e1>infliximab</e1> is <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4166	 report describes a probable case of <e1>infliximab</e1> -induced <e2>membranous nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4167	 -induced <e2>dyserythropoiesis</e2>: chloramphenicol toxicity revisited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4168	 report here two cases of <e1>dyserythropoietic anaemia</e1> associated with long-term <e2>linezolid</e2> use that share striking similarities to chloramphenicol-associated myelotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4169	 report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to <e1>chloramphenicol</e1> -associated <e2>myelotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4170	 selective association between <e1>fluoxetine</e1> and extensive, prominent <e2>eye movements in nonrapid eye movement (NREM) sleep</e2> was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4171	 addition, a 31-year-old man with obsessive-compulsive disorder developed <e1>RBD</e1> soon after starting <e2>fluoxetine</e2> therapy, which persisted at PSG study 19 months after <e2>fluoxetine</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4172	 addition, a 31-year-old man with obsessive-compulsive disorder developed <e1>RBD</e1> soon after starting <e2>fluoxetine</e2> therapy, which persisted at PSG study 19 months after <e2>fluoxetine</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4173	 eye movements during NREM sleep</e1> and REM sleep behavior disorder associated with <e2>fluoxetine</e2> treatment of depression and obsessive-compulsive disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4174	 eye movements during NREM sleep and <e1>REM sleep behavior disorder</e1> associated with <e2>fluoxetine</e2> treatment of depression and obsessive-compulsive disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4175	 of serious side effects of an <e1>increase in the QT interval</e1> causing torsades de pointes, <e2>dofetilide</e2> must be initiated with close monitoring of the QT interval in an inpatient setting."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4176	 of serious side effects of an increase in the QT interval causing <e1>torsades de pointes</e1>, <e2>dofetilide</e2> must be initiated with close monitoring of the QT interval in an inpatient setting."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4177	 QT prolongation and torsades de pointes secondary to <e1>acute ischemia</e1> in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4178	 QT prolongation</e1> and torsades de pointes secondary to acute ischemia in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4179	 QT prolongation and <e1>torsades de pointes</e1> secondary to acute ischemia in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4180	 report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from <e1>acute myocardial ischemia</e1> in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4181	 report marked QT prolongation and torsades de pointes in a setting of <e1>flash pulmonary edema</e1> resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4182	 report marked <e1>QT prolongation</e1> and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4183	 report marked QT prolongation and <e1>torsades de pointes</e1> in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4184	 <e1>positive U waves</e1> appearing with high-dose intravenous <e2>phenylephrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4185	 on a maximal dose of <e1>phenylephrine</e1> she developed prominent <e2>positive U waves</e2>, which disappeared with the cessation of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4186	 is a rare complication of <e2>SRL</e2> therapy and may be connected with some diagnostic and/or therapeutic problems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4187	 -associated <e2>hepatotoxicity</e2> in the kidney graft recipient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4188	 aim of our paper was to describe <e1>hepatotoxicity</e1> of <e2>sirolimus</e2> (SRL) in a kidney graft recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4189	 REPORT: We present a case of a 28-yr-old male who developed a severe case of <e1>nephrotic syndrome</e1> while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of <e2>interferon beta 1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4190	 syndrome</e1> in a multiple sclerosis patient treated with <e2>interferon beta 1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4191	 COURSE: The <e1>nephrosis</e1> resolved almost completely once the <e2>interferon</e2> was stopped and after immunosuppressive treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4192	 latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential <e1>renal toxicity</e1> of <e2>interferons</e2> in MS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4193	 -induced <e2>multifocal leukoencephalopathy</e2>: a report of five cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4194	 authors report five additional cases of <e1>capecitabine</e1> -induced <e2>multifocal leukoencephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4195	 56-year-old white woman with a diagnosis of reactive depression developed severe <e1>UI</e1> after a 30 days' treatment with <e2>venlafaxine</e2> 75 mg/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4196	 authors report a case of urinary incontinence (<e1>UI</e1>) that occurred in a woman after administration of <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4197	 authors report a case of <e1>urinary incontinence</e1> (UI) that occurred in a woman after administration of <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4198	 -induced <e2>urinary incontinence</e2> resolved after switching to sertraline."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4199	 of <e1>hypothyroidism</e1> during treatment can be difficult because of the common side effects of <e2>alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4200	 hypothyroidism</e1> induced by <e2>recombinant alpha interferon</e2> in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4201	 dysfunction</e1> has been reported in patients with malignant disease treated with <e2>recombinant alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4202	 cases of <e1>hypothyroidism</e1> in patients with chronic hepatitis C treated with <e2>recombinant alpha interferon</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4203	 fibrillation</e1> after <e2>vardenafil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4204	 report a case admitted with a first-detected, <e1>symptomatic paroxysmal atrial fibrillation</e1> in a healthy patient after self-medication with <e2>vardenafil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4205	 describe a case of infection with <e1>Mycobacterium abscessus</e1> in a 67-year-old woman receiving <e2>infliximab</e2> as a component of her therapy for RA."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4206	 <e1>Interferon alpha-2b</e1> -induced <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4207	 cardiomyopathy</e1> caused by administration of <e2>interferon alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4208	 this case <e1>senna</e1> was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4209	 this case <e1>senna</e1> was likely the cause of a <e2>subacute cholestatic hepatitis</e2> exemplifying again the potential role of herbal related liver injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4210	 cholestatic hepatitis</e1> likely related to the use of <e2>senna</e2> for chronic constipation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4211	 report a case of <e1>senna</e1> -induced <e2>cholestatic hepatitis</e2> which was not diagnosed at presentation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4212	 on the history and clinical features, a diagnosis of <e1>insulin</e1> -induced <e2>lipohypertrophy</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4213	 -induced <e2>lipohypertrophy</e2>: report of a case with histopathology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4214	 the possible in vivo effects of <e1>insulin</e1> on adipocytes were clearly observed in this case of <e1>insulin</e1> -induced <e2>lipohypertrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4215	 our knowledge, this is the first report of <e1>insulin</e1> -induced <e2>lipohypertrophy</e2> with detailed histological examinations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4216	 7-year-old girl developed <e1>diabetes mellitus</e1> and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with <e2>azathioprine</e2> and/or prednisone for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4217	 7-year-old girl developed <e1>diabetes mellitus</e1> and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or <e2>prednisone</e2> for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4218	 7-year-old girl developed diabetes mellitus and <e1>exocrine pancreatic insufficiency</e1> after 3.5 years of almost continuous treatment with <e2>azathioprine</e2> and/or prednisone for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4219	 7-year-old girl developed diabetes mellitus and <e1>exocrine pancreatic insufficiency</e1> after 3.5 years of almost continuous treatment with azathioprine and/or <e2>prednisone</e2> for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4220	 objective causality assessment suggests that the <e1>JHR</e1> in our patient was probably related to <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4221	 SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with <e1>JHR</e1> after an initial intravenous dose of <e2>penicillin G</e2> for presumed neurosyphilis."
DRUG-ADE(e2,e1)
Comment: DRUG-

4222	 -induced <e2>Jarisch-Herxheimer reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4223	 patient described feeling cold with worsening headache and <e1>chills</e1> approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4224	 patient described <e1>feeling cold</e1> with worsening headache and chills approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4225	 patient described feeling cold with <e1>worsening headache</e1> and chills approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4226	 respiratory distress syndrome</e1> after <e2>rituximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4227	 has been associated with the administration of other monoclonal antibodies, such as infliximab, <e2>gemtuzumab ozogamicin</e2>, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4228	 has been associated with the administration of other monoclonal antibodies, such as <e2>infliximab</e2>, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4229	 has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and <e2>OKT3</e2> and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4230	 is rarely associated with <e2>rituximab</e2> infusion for lympho-proliferative disorders, but it should be considered by those administering <e2>rituximab</e2>, especially when a patient develops severe pulmonary symptoms soon after infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4231	 is rarely associated with <e2>rituximab</e2> infusion for lympho-proliferative disorders, but it should be considered by those administering <e2>rituximab</e2>, especially when a patient develops severe pulmonary symptoms soon after infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4232	 is rarely associated with <e1>rituximab</e1> infusion for lympho-proliferative disorders, but it should be considered by those administering <e1>rituximab</e1>, especially when a patient develops <e2>severe pulmonary symptoms</e2> soon after infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4233	 hypoxemia, and pleuritic chest pain occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4234	 <e1>hypoxemia</e1>, and pleuritic chest pain occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4235	 hypoxemia, and <e1>pleuritic chest pain</e1> occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4236	 hypoxemia</e1> mandated endotracheal intubation 1 week after <e2>rituximab</e2> administration and led to death 4 weeks after admission."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4237	 report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed <e1>acute respiratory distress syndrome</e1> (ARDS) after a single infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4238	 report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (<e1>ARDS</e1>) after a single infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4239	 hypocalcaemia and <e1>renal impairment</e1> associated with <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4240	 hypocalcaemia</e1> and renal impairment associated with <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4241	 report three cases of <e1>severe hypocalcaemia</e1> associated with i.v. <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4242	 -related <e2>radiation recall</e2> in a patient with pancreatic cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4243	 should be added to the list of drugs known to cause <e2>radiation recall</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4244	 recall</e1> from <e2>gemcitabine</e2> is rare, but can potentially arise in any site that has been previously irradiated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4245	 recall</e1> related to <e2>gemcitabine</e2> has been reported in lung and breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4246	 report a patient with inoperable pancreatic cancer who developed <e1>gastrointestinal bleeding</e1> secondary to radiation-recall related to <e2>gemcitabine</e2> and review literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4247	 report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to <e1>radiation-recall</e1> related to <e2>gemcitabine</e2> and review literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4248	 suggest discontinuing <e1>gemcitabine</e1> if <e2>radiation recall</e2> is observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4249	 17-year-old boy with acute lymphoblastic leukemia developed <e1>acute renal failure</e1> within 48 h of an intravenous high-dose <e2>methotrexate</e2> (5 g/m2) infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4250	 <e1>methotrexate</e1> -associated <e2>acute renal failure</e2> may be an avoidable complication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4251	 -associated <e2>nephropathy</e2> is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4252	 <e1>prolapse of the urethral mucosa</e1> following periurethral injection of <e2>calcium hydroxylapatite</e2> for stress urinary incontinence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4253	 authors present a case report of a <e1>granulomatous reaction</e1> leading to urethral prolapse, 3 months after the transurethral injection of <e2>calcium hydroxylapatite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4254	 authors present a case report of a granulomatous reaction leading to <e1>urethral prolapse</e1>, 3 months after the transurethral injection of <e2>calcium hydroxylapatite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4255	 our knowledge, this is the first <e1>granulomatous reaction</e1> described after <e2>calcium hydroxylapatite</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4256	 SUMMARY: A 57-year-old female with cardiomyopathy and "sulfa" (trimethoprim/sulfamethoxazole) allergy documented as <e1>pancreatitis</e1> presented with symptoms consistent with <e1>pancreatitis</e1> after use of <e2>furosemide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4257	 addition, while cases of loop diuretic-induced <e1>pancreatitis</e1>, including <e2>furosemide</e2>, have been published, the allergic manifestations with both sulfonamide antibiotics and non-antibiotics in our patient suggest possible cross-reactivity between these 2 drug classes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4258	 appears to also be a part of a long list of agents that can cause <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4259	 -induced thrombocytopenia complicated with <e2>massive thrombosis of the inferior vena cava</e2> after filter placement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4260	 -induced <e2>thrombocytopenia</e2> complicated with massive thrombosis of the inferior vena cava after filter placement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4261	 the 3rd day, an inferior vena cava (IVC) filter was placed with a <e1>heparin</e1> flush, after which massive <e2>IVC thrombosis</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4262	 patient was positive for antibody against complexes of <e1>heparin</e1> and platelet factor 4, and was diagnosed as <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> with thrombosis syndrome (HITTS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4263	 patient was positive for antibody against complexes of <e1>heparin</e1> and platelet factor 4, and was diagnosed as <e1>heparin</e1> -induced thrombocytopenia with <e2>thrombosis syndrome</e2> (HITTS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4264	 <e1>thrombosis</e1> develops during <e2>heparin</e2> treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4265	 <e1>gastric-outlet obstruction</e1> was recognized in several infants who received <e2>prostaglandin E1</e2>, we studied the association between the drug and this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4266	 The administration of <e1>prostaglandin E1</e1> to neonates can cause gastric-outlet obstruction due to <e2>antral hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4267	 The administration of <e1>prostaglandin E1</e1> to neonates can cause <e2>gastric-outlet obstruction</e2> due to antral hyperplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4268	 treatment with immunosuppressive drugs such as cyclosporine, <e1>cisplatin</e1>, tacrolimus, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4269	 treatment with immunosuppressive drugs such as <e1>cyclosporine</e1>, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4270	 treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and <e1>interferon-alpha</e1> can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4271	 treatment with immunosuppressive drugs such as cyclosporine, cisplatin, <e1>tacrolimus</e1>, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4272	 posterior leukoencephalopathy syndrome</e1> in systemic lupus erythematosus with thrombocytopenia treated with <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4273	 report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, <e1>headache</e1>, and seizure after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4274	 report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and <e1>seizure</e1> after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4275	 report a case of a young woman with SLE and thrombocytopenia, who developed <e1>severe perspiration</e1>, headache, and seizure after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4276	 To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between <e2>lopinavir</e2>/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4277	 To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/<e2>ritonavir</e2> and valproic acid (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4278	 To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/ritonavir and <e2>valproic acid</e2> (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4279	 To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/ritonavir and valproic acid (<e2>VPA</e2>) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4280	 interaction between <e1>lopinavir</e1>/ritonavir and valproic Acid exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4281	 interaction between lopinavir/<e1>ritonavir</e1> and valproic Acid exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4282	 interaction between lopinavir/ritonavir and <e1>valproic Acid</e1> exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4283	 intravitreal injection of <e1>triamcinolone acetonide</e1>, <e2>cataract</e2> may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4284	 and bursitis in multiple sclerosis patients treated with <e2>interferon-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4285	 and <e1>bursitis</e1> in multiple sclerosis patients treated with <e2>interferon-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4286	 literature review revealed an additional six cases of onset of <e1>inflammatory arthritis</e1> in MS patients receiving <e2>IFN-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4287	 first patient developed a <e1>monoarthritis</e1> 2 weeks after initiation of <e2>IFN-beta</e2>, which persisted during the 14 months of therapy and resolved with discontinuation of the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4288	 with <e1>IFN-beta</e1> has rarely been associated with the development of <e2>autoimmune disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4289	 second patient developed both <e1>autoimmune thyroid disease</e1> and a refractory pre-patellar bursitis after 50 months of <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4290	 second patient developed both autoimmune thyroid disease and a <e1>refractory pre-patellar bursitis</e1> after 50 months of <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4291	 present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed <e1>inflammatory musculoskeletal manifestations</e1>, following <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4292	 -induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4293	 present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/sulfamethoxazole (TMP/<e2>SMX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4294	 present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/<e2>sulfamethoxazole</e2> (TMP/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4295	 present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/sulfamethoxazole (<e2>TMP</e2>/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4296	 present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using <e2>trimethoprim</e2>/sulfamethoxazole (TMP/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4297	 reviewed the literature in an attempt to characterize the pattern and predictors of TMP/<e1>SMX</e1> -induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4298	 reviewed the literature in an attempt to characterize the pattern and predictors of <e1>TMP</e1>/SMX-induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4299	 this paper, we report a patient with primary anti-phospholipid syndrome treated by <e1>corticosteroid</e1>, who developed <e2>disseminated nocardiosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4300	 -induced <e2>bilateral ptosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4301	 occurring 24 h after <e2>chloroquine</e2> therapy, with full recovery 48 h after cessation of <e2>chloroquine</e2>, has not been described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4302	 occurring 24 h after <e2>chloroquine</e2> therapy, with full recovery 48 h after cessation of <e2>chloroquine</e2>, has not been described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4303	 report describes a case of <e1>bilateral ptosis</e1> induced by <e2>chloroquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4304	 We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a <e1>central neurological syndrome</e1> within days of intrathecal <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4305	 MRI correlates of subacute <e1>methotrexate</e1> -related <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4306	 A delayed <e1>stroke-like leukoencephalopathy</e1> has been observed in patients receiving <e2>methotrexate</e2> (MTX) for childhood leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4307	 A delayed <e1>stroke-like leukoencephalopathy</e1> has been observed in patients receiving methotrexate (<e2>MTX</e2>) for childhood leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4308	 objective is to present a retrospective analysis of the DWI findings in four patients who suffered <e1>subacute neurotoxicity</e1> after intrathecal <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4309	 is a rare case of <e1>ARDS</e1> associated with <e2>lithium</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4310	 The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the "indirect" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced <e1>dyskinesias</e1> may differ from those involved in <e2>L-dopa</e2> induced <e1>dyskinesias</e1>; (iii) <e1>dyskinesias</e1> induced by STN surgery resolve spontaneously as compensatory mechanisms develop."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4311	 to surgery, <e1>levodopa</e1> induced <e2>dyskinesia</e2> had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4312	 combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent <e1>triazolam</e1> -induced <e2>eating disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4313	 -induced nocturnal bingeing with <e2>amnesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4314	 -induced <e2>nocturnal bingeing</e2> with amnesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4315	 interferon gamma has been implicated in the pathogenesis of <e1>sarcoidosis</e1>, only a few cases of <e1>sarcoidosis</e1> associated with <e2>interferon alpha</e2> therapy have been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4316	 of <e1>sarcoidosis</e1> during <e2>interferon alpha 2b</e2> and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4317	 of <e1>sarcoidosis</e1> during interferon alpha 2b and <e2>ribavirin</e2> combination therapy for chronic hepatitis C--a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4318	 report a case with chronic hepatitis C (CHC) who developed <e1>sarcoidosis</e1> after the treatment by <e2>interferon alpha</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4319	 report a case with chronic hepatitis C (CHC) who developed <e1>sarcoidosis</e1> after the treatment by interferon alpha and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4320	 suggest that <e1>sarcoidosis</e1> may develop in chronic hepatitis C patients during <e2>interferon alpha</e2> and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4321	 suggest that <e1>sarcoidosis</e1> may develop in chronic hepatitis C patients during interferon alpha and/or <e2>ribavirin</e2> treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4322	 colitis</e1> during standard dose combination chemotherapy with nedaplatin and <e2>irinotecan</e2> for testicular cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4323	 colitis</e1> during standard dose combination chemotherapy with <e2>nedaplatin</e2> and irinotecan for testicular cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4324	 this paper, we report a case of <e1>severe hypercalcemia</e1> of immobilization in a 40-year-old hemodialyzed woman treated by <e2>cinacalcet HCl</e2> for a severe HPTH-II (PTH>1,000 pg/mL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4325	 we present a case of <e1>sirolimus</e1> -associated <e2>interstitial pneumonitis</e2> in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4326	 <e1>sirolimus</e1> -associated <e2>pneumonitis</e2> after heart transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4327	 cases of <e1>sirolimus</e1> -associated <e2>pneumonitis</e2> have been reported after cardiac transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4328	 objective causality assessment by use of the Naranjo probability scale revealed that <e1>NCSE</e1> due to <e2>ifosfamide</e2> was probable."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4329	 SUMMARIES: Two patients who received <e1>ifosfamide</e1> -containing chemotherapy developed <e2>NCSE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

4330	 Among the many presentations of <e1>ifosfamide</e1> <e2>neurotoxicity</e2>, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4331	 an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4332	 status epilepticus</e1> due to <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4333	 To report 2 cases of nonconvulsive status epilepticus (<e1>NCSE</e1>) following infusion of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4334	 To report 2 cases of <e1>nonconvulsive status epilepticus</e1> (NCSE) following infusion of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4335	 describe a case of intraoperative <e1>gelatine</e1> -induced <e2>anaphylaxis</e2> whose diagnosis was delayed as the use of <e1>gelatine</e1> during surgical procedures was omitted for two times in patient's medical records."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4336	 describe a case of intraoperative <e1>gelatine</e1> -induced <e2>anaphylaxis</e2> whose diagnosis was delayed as the use of <e1>gelatine</e1> during surgical procedures was omitted for two times in patient's medical records."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4337	 mycobacterial infection</e1> post intravesical <e2>BCG</e2> installation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4338	 tuberculous lesions</e1> post intravesical <e2>BCG</e2> therapy are rare but need to be identified and treated quickly."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4339	 patients develop <e1>hypersensitivity rash</e1> in response to <e2>HCQ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4340	 of <e1>sumatriptan</e1> in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce <e2>symptomatic cerebral vasospasm</e2> with potentially dangerous consequences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4341	 We describe two patients who presented with <e1>diabetic ketoacidosis</e1> after treatment with <e2>quetiapine</e2> and risperidone, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4342	 We describe two patients who presented with <e1>diabetic ketoacidosis</e1> after treatment with quetiapine and <e2>risperidone</e2>, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4343	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4344	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4345	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4346	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4347	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4348	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4349	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4350	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4351	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4352	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4353	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4354	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4355	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4356	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4357	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4358	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4359	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4360	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4361	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4362	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4363	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4364	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4365	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4366	 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4367	 is the first case of <e1>TMP-SMX</e1> -induced <e2>hypersensitivity syndrome</e2> associated with the reactivation of a latent viral infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4368	 -induced <e2>hypersensitivity syndrome</e2> associated with reactivation of human herpesvirus-6."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4369	 To report a case of severe <e1>corticosteroid</e1> -induced <e2>glaucoma</e2> after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4370	 To report a case of severe corticosteroid-induced <e1>glaucoma</e1> after intravitreal injection of <e2>triamcinolone acetate</e2> in a 34-year-old man without a history of <e1>glaucoma</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4371	 A 34-year-old man acquired visual field defects and <e1>severe vision loss</e1> in both eyes after intravitreal injection of <e2>triamcinolone</e2> for diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4372	 A 34-year-old man acquired <e1>visual field defects</e1> and severe vision loss in both eyes after intravitreal injection of <e2>triamcinolone</e2> for diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4373	 <e1>steroid</e1> -induced <e2>glaucoma</e2> following intravitreal injection of triamcinolone acetonide."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4374	 steroid-induced <e1>glaucoma</e1> following intravitreal injection of <e2>triamcinolone acetonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4375	 treatment has the potential to cause severe vision loss as a result of intractable <e1>corticosteroid</e1> -induced <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4376	 treatment has the potential to cause <e1>severe vision loss</e1> as a result of intractable <e2>corticosteroid</e2> -induced glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4377	 thyroid disease</e1> is a common side-effect of interferon-alpha (<e2>IFN-alpha</e2>) treatment of viral hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4378	 thyroid disease</e1> is a common side-effect of <e2>interferon-alpha</e2> (IFN-alpha) treatment of viral hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4379	 thyrotoxicosis appeared 4-6 months after starting <e1>IFN-alpha</e1>, followed by <e2>Graves' hyperthyroidism</e2> within 8 to 11 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4380	 <e1>thyrotoxicosis</e1> appeared 4-6 months after starting <e2>IFN-alpha</e2>, followed by Graves' hyperthyroidism within 8 to 11 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4381	 <e1>hyperthyroidism</e1> induced by <e2>IFN-alpha</e2> could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4382	 -induced <e2>hyperthyroidism</e2>: a three-stage evolution from silent thyroiditis towards Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4383	 have described three patients with hepatitis C for whom <e1>IFN-alpha</e1> and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by <e2>hyperthryroidism</e2> relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4384	 have described three patients with hepatitis C for whom IFN-alpha and <e1>ribavirin</e1> were prescribed and who developed two successive phases of silent thyroiditis followed by <e2>hyperthryroidism</e2> relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4385	 have described three patients with hepatitis C for whom <e1>IFN-alpha</e1> and ribavirin were prescribed and who developed two successive phases of silent <e2>thyroiditis</e2> followed by hyperthryroidism relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4386	 have described three patients with hepatitis C for whom IFN-alpha and <e1>ribavirin</e1> were prescribed and who developed two successive phases of silent <e2>thyroiditis</e2> followed by hyperthryroidism relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4387	 also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4388	 also known as <e1>metamizole</e1>, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4389	 -induced <e2>granulocytopenia</e2>: a case for awareness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4390	 describe a patient who developed <e1>granulocytopenia</e1> and fever after taking <e2>dipyrone</e2> and discuss the available literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4391	 we describe 2 patients who developed unusual <e1>CD8+ cutaneous lymphoproliferative disorders</e1> after treatment with <e2>efalizumab</e2> and infliximab."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4392	 we describe 2 patients who developed unusual <e1>CD8+ cutaneous lymphoproliferative disorders</e1> after treatment with efalizumab and <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4393	 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, <e2>abdominal pain</e2> and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4394	 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, <e2>abdominal pain</e2> and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4395	 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed <e2>fever</e2>, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4396	 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed <e2>fever</e2>, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4397	 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, <e2>severe cutaneous involvement</e2>, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4398	 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, <e2>severe cutaneous involvement</e2>, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4399	 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, <e2>swelling</e2>, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4400	 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, <e2>swelling</e2>, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4401	 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and <e2>transaminitis</e2>, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4402	 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and <e2>transaminitis</e2>, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4403	 <e1>sulfadiazine</e1> <e2>hypersensitivity</e2> in a child with reactivated congenital toxoplasmic chorioretinitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4404	 case underscores problems in clinical management with <e1>sulfadiazine</e1> <e2>hypersensitivity</e2>, potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4405	 lung fibrosis</e1> caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and <e2>carboplatin</e2> as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4406	 lung fibrosis</e1> caused by <e2>paclitaxel</e2> toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of <e2>paclitaxel</e2> and carboplatin as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4407	 lung fibrosis</e1> caused by <e2>paclitaxel</e2> toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of <e2>paclitaxel</e2> and carboplatin as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4408	 pulmonary fibrosis</e1> induced by <e2>paclitaxel</e2>: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4409	 should keep in mind that taxanes such as <e1>paclitaxel</e1> have the potential to cause pneumonitis and <e2>lung fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4410	 should keep in mind that taxanes such as <e1>paclitaxel</e1> have the potential to cause <e2>pneumonitis</e2> and lung fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4411	 fibrosis</e1> is a complication of <e2>paclitaxel</e2> therapy that may occur despite treatments with corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4412	 are a major adverse effect during the treatment with <e2>anti-TNF-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4413	 this case report, we have described a patient with Crohn's disease who developed <e1>subfulminant hepatitis B</e1> after the fourth infusion of <e2>infliximab</e2> due to an unrecognized HBs-antigen carrier state."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4414	 hepatitis B</e1> after <e2>infliximab</e2> in Crohn's disease: need for HBV-screening?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4415	 unilateral total visual loss</e1> after retrogasserian <e2>phenol</e2> injection for the treatment of trigeminal neuralgia: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4416	 visual loss in this patient seems to result from <e1>phenol</e1> <e2>neurotoxicity</e2> rather than mechanical compression of the intraorbital optic nerve."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4417	 <e1>visual loss</e1> in this patient seems to result from <e2>phenol</e2> neurotoxicity rather than mechanical compression of the intraorbital optic nerve."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4418	 report a 78-year-old man who had <e1>acute unilateral total visual loss</e1> after retrogasserian <e2>phenol</e2> injection for the treatment of trigeminal neuralgia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4419	 induced <e1>liver injury</e1> secondary to interferon-beta (<e2>IFN-beta</e2>) in multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4420	 induced <e1>liver injury</e1> secondary to <e2>interferon-beta</e2> (IFN-beta) in multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4421	 3 hepatotoxicity</e1> (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on <e2>IFN beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4422	 marketing studies of Interferon-beta (<e1>IFN beta</e1>) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4423	 marketing studies of <e1>Interferon-beta</e1> (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4424	 report three cases of <e1>IFN beta</e1> induced <e2>hepatitis</e2> in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4425	 report three cases of <e1>IFN beta</e1> induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4426	 55-year-old woman presented an episode of <e1>acute urticaria</e1> and labial angioedema 60 minutes after ingesting 500 mg of <e2>cloxacillin</e2> for a skin abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4427	 55-year-old woman presented an episode of acute urticaria and <e1>labial angioedema</e1> 60 minutes after ingesting 500 mg of <e2>cloxacillin</e2> for a skin abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4428	 to <e2>cloxacillin</e2> with normal tolerance to amoxicillin and cefuroxime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4429	 <e1>hypersensitivity</e1> reactions to <e2>cloxacillin</e2> have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with <e2>cloxacillin</e2> allergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4430	 hypersensitivity reactions to <e1>cloxacillin</e1> have been reported, although <e2>IgE-mediated allergic reactions</e2> to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with <e1>cloxacillin</e1> allergy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4431	 toxicity</e1> related to <e2>BCNU</e2> has not been described well."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4432	 ischemia</e1> associated with high-dose <e2>carmustine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4433	 patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of <e1>myocardial ischemia</e1> during and immediately after <e2>BCNU</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4434	 reaction in a patient with <e1>aspirin</e1> -induced <e2>asthma</e2> treated with zafirlukast."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4435	 present a case of <e1>hypereosinophilia</e1> related to <e2>zafirlukast</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4436	 after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, rapidly progressive erythema, <e2>edema</e2>, and pain in his right forearm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4437	 after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, rapidly progressive erythema, edema, and <e2>pain in his right forearm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4438	 after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, <e2>rapidly progressive erythema</e2>, edema, and pain in his right forearm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4439	 few recent individual case reports have suggested that a <e1>myasthenic syndrome</e1> may be associated with <e2>statin</e2> treatment, but this association is not well described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4440	 -associated <e2>myasthenia gravis</e2>: report of 4 cases and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4441	 report 4 patients who developed symptoms of <e1>myasthenia gravis</e1> within 2 weeks of starting treatment with a <e2>statin</e2> drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4442	 of cytomegalovirus</e1> probably followed the treatment of Wegener's granulomatosis with corticosteroids and <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4443	 excluding other causes of long QT syndrome, the <e1>HCQ</e1> was suspected as the cause of her <e2>ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4444	 <e1>hydroxychloroquine</e1> use associated with <e2>QT prolongation</e2> and refractory ventricular arrhythmia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4445	 <e1>hydroxychloroquine</e1> use associated with QT prolongation and <e2>refractory ventricular arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4446	 The chronic use of <e1>HCQ</e1> for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal <e2>cardiac arrhythmias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4447	 report a case of chronic use of <e1>HCQ</e1> associated with <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4448	 The increasing prevalence of Type 2 diabetes and its treatment with <e1>metformin</e1> might result in more cases of <e2>lactic acidosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4449	 acidosis</e1> in patients taking <e2>metformin</e2> --rapid reversal and survival despite high APACHE score."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4450	 report: lack of control of <e1>diabetes</e1> and weight gain in a patient on initiation and rechallenge of therapy with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4451	 report: lack of control of diabetes and <e1>weight gain</e1> in a patient on initiation and rechallenge of therapy with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4452	 following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of <e1>olanzapine</e1> to metabolic changes manifested as <e2>uncontrolled diabetes mellitus</e2> and weight gain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4453	 following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of <e1>olanzapine</e1> to metabolic changes manifested as uncontrolled diabetes mellitus and <e2>weight gain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4454	 patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, <e1>olanzapine</e1> was discontinued because of weight gain and <e2>uncontrolled diabetes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4455	 patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, <e1>olanzapine</e1> was discontinued because of <e2>weight gain</e2> and uncontrolled diabetes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4456	 To report a case of traumatic flap dehiscence and <e1>Enterobacter keratitis</e1> 34 months after <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4457	 To report a case of <e1>traumatic flap dehiscence</e1> and Enterobacter keratitis 34 months after <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4458	 late flap dehiscence and <e1>Enterobacter keratitis</e1> following <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4459	 late flap dehiscence</e1> and Enterobacter keratitis following <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4460	 report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with <e1>BOOP</e1> after chemotherapy with <e2>docetaxel</e2> and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4461	 report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with <e1>BOOP</e1> after chemotherapy with docetaxel and <e2>gemcitabine</e2> producing severe respiratory insufficiency, and simulating a progression of the tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4462	 report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with <e1>docetaxel</e1> and gemcitabine producing severe respiratory insufficiency, and simulating a <e2>progression of the tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4463	 report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and <e1>gemcitabine</e1> producing severe respiratory insufficiency, and simulating a <e2>progression of the tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4464	 report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with <e1>docetaxel</e1> and gemcitabine producing <e2>severe respiratory insufficiency</e2>, and simulating a progression of the tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4465	 report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and <e1>gemcitabine</e1> producing <e2>severe respiratory insufficiency</e2>, and simulating a progression of the tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4466	 65-year-old man on <e1>warfarin</e1> therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with <e2>bloody tears</e2> was assessed in the clinic following a referral from an optometrist."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4467	 65-year-old man on <e1>warfarin</e1> therapy with a sudden spontaneous onset of <e2>sub-conjunctival haematoma</e2> associated with bloody tears was assessed in the clinic following a referral from an optometrist."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4468	 unusual presentation of spontaneous <e1>sub-conjunctival haematoma</e1> in a patient receiving <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4469	 to discomfort, <e1>diplopia</e1> and lagophthalmos, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4470	 to <e1>discomfort</e1>, diplopia and lagophthalmos, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4471	 to discomfort, diplopia and lagophthalmos, the <e1>haematoma</e1> necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4472	 to discomfort, diplopia and <e1>lagophthalmos</e1>, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4473	 <e1>sub-conjunctival haematoma</e1> in a patient receiving <e2>warfarin</e2> can pose a significant management challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4474	 and maculopapular eruptions associated with <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4475	 and <e1>maculopapular eruptions</e1> associated with <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4476	 a rare side effect of <e2>carbamazepine</e2>, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4477	 eruptions</e1> occur in 3% of individuals administered <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4478	 rashes</e1> and eruptions can be caused by many medications, including <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4479	 rashes and <e1>eruptions</e1> can be caused by many medications, including <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4480	 report the case of a 27-year-old Indian woman who developed maculopapular rash and <e1>angioedema</e1> secondary to <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4481	 report the case of a 27-year-old Indian woman who developed <e1>maculopapular rash</e1> and angioedema secondary to <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4482	 adenovirus pneumonia (<e1>AVP</e1>) following <e2>infliximab</e2> infusion for the treatment of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4483	 adenovirus pneumonia</e1> (AVP) following <e2>infliximab</e2> infusion for the treatment of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4484	 report a case of <e1>severe AVP</e1> three weeks following the administration of <e2>infliximab</e2> for the treatment of Crohn's disease (CD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4485	 case of <e1>ivermectin</e1> -induced <e2>severe hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4486	 our knowledge, this is the first case of <e1>ivermectin</e1> -induced <e2>severe liver disease</e2> published in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4487	 report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed <e1>severe hepatitis</e1>, identified 1 month after a single dose of <e2>ivermectin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4488	 REPORT: We hereby report a case of radiation recall dermatitis and <e1>myositis</e1> occurring on <e2>gemcitabine</e2> monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-

4489	 REPORT: We hereby report a case of <e1>radiation recall dermatitis</e1> and myositis occurring on <e2>gemcitabine</e2> monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-

4490	 This is the second case report that describes <e1>gemcitabine</e1> -induced <e2>radiation recall</e2> in rectus abdominus muscles after <e1>gemcitabine</e1> -based radiation therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4491	 -induced <e2>rectus abdominus radiation recall</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4492	 rippling muscle disease</e1> unmasked by <e2>simvastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4493	 report a 53-year-old-man who developed <e1>rippling muscle disease</e1> (RMD) 2 months after starting <e2>simvastatin</e2> therapy for hypercholesterolemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4494	 report a 53-year-old-man who developed rippling muscle disease (<e1>RMD</e1>) 2 months after starting <e2>simvastatin</e2> therapy for hypercholesterolemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4495	 coronary syndrome</e1> induced by <e2>capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4496	 case highlights the possible development of <e1>acute coronary syndrome</e1> as a side effect of <e2>Capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4497	 severe intoxication with <e1>carbamazepine</e1> is associated with seizures, <e2>coma</e2> and respiratory depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4498	 severe intoxication with <e1>carbamazepine</e1> is associated with seizures, coma and <e2>respiratory depression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4499	 severe intoxication with <e1>carbamazepine</e1> is associated with <e2>seizures</e2>, coma and respiratory depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4500	 rechallenge with monotherapy <e1>pegvisomant</e1>, however, the <e2>hepatic enzyme disturbances</e2> reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4501	 rechallenge with monotherapy <e1>pegvisomant</e1>, however, the <e2>hepatic enzyme disturbances</e2> reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4502	 rechallenge with monotherapy <e1>pegvisomant</e1>, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4503	 <e1>hepatitis</e1> in an acromegalic patient during combined treatment with pegvisomant and <e2>octreotide</e2> long-acting repeatable attributed to the use of pegvisomant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4504	 <e1>hepatitis</e1> in an acromegalic patient during combined treatment with <e2>pegvisomant</e2> and octreotide long-acting repeatable attributed to the use of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4505	 <e1>hepatitis</e1> in an acromegalic patient during combined treatment with <e2>pegvisomant</e2> and octreotide long-acting repeatable attributed to the use of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4506	 <e1>hepatic enzyme disturbances</e1> normalized after discontinuation of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4507	 report on a patient with acromegaly who developed severe drug-induced <e1>hepatitis</e1> during combined treatment with the long-acting somatostatin-analog <e2>octreotide</e2> and the GH receptor antagonist pegvisomant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4508	 report on a patient with acromegaly who developed severe drug-induced <e1>hepatitis</e1> during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4509	 B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, <e2>anaemia</e2>, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4510	 B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, <e2>anaemia</e2>, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4511	 B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, <e2>fever</e2>, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4512	 B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, <e2>fever</e2>, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4513	 B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and <e2>hypokalaemia</e2> are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4514	 B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and <e2>hypokalaemia</e2> are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4515	 B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, <e2>malaise</e2>, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4516	 B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, <e2>malaise</e2>, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4517	 B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: <e2>renal impairment</e2>, anaemia, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4518	 B</e1> (AmB) is effective, but its use is limited by toxicity: <e2>renal impairment</e2>, anaemia, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4519	 Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, <e2>brain abscess with Listeria monocytogenes</e2>, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4520	 Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and <e2>cutaneous Kaposi's sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4521	 Severe <e1>temozolomide</e1> -induced <e2>immunosuppression</e2>, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4522	 Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic <e2>infections with Pneumocystis jiroveci pneumonia</e2>, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4523	 Severe <e1>temozolomide</e1> -induced immunosuppression, exacerbated by corticosteroids, with profound <e2>T-cell lymphocytopenia</e2> and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4524	 brain abscess, Pneumocystis pneumonia and <e1>Kaposi's sarcoma</e1> after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4525	 brain abscess</e1>, Pneumocystis pneumonia and Kaposi's sarcoma after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4526	 brain abscess, <e1>Pneumocystis pneumonia</e1> and Kaposi's sarcoma after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4527	 <e1>Topiramate</e1> -induced <e2>angle-closure glaucoma</e2> (TiACG) is believed to be related to its sulfonamide moiety."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4528	 resolution of topiramate-induced <e1>angle-closure glaucoma</e1> with methylprednisolone and <e2>mannitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4529	 resolution of topiramate-induced <e1>angle-closure glaucoma</e1> with <e2>methylprednisolone</e2> and mannitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4530	 resolution of <e1>topiramate</e1> -induced <e2>angle-closure glaucoma</e2> with methylprednisolone and mannitol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4531	 splenic infarction</e1> associated with <e2>sumatriptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4532	 they are generally considered safe, there have been a few reports of <e1>myocardial infarction</e1> and stroke associated with <e2>triptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4533	 they are generally considered safe, there have been a few reports of myocardial infarction and <e1>stroke</e1> associated with <e2>triptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4534	 report a patient who developed <e1>spontaneous splenic infarction</e1> after the use of <e2>sumatriptan</e2> for the treatment of migraine headache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4535	 myocardial infarction</e1> during high-dose <e2>methylprednisolone</e2> therapy for Graves' ophthalmopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4536	 <e1>hypothyroidism</e1> after <e2>radioiodine</e2> treatment (euthyroid under substitutional therapy), she suffered from no other diseases."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4537	 we present the case of a woman who received high doses of <e1>methylprednisolone</e1> (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by <e2>myocardial infarction</e2> on the fifth day of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4538	 we present the case of a woman who received high doses of <e1>methylprednisolone</e1> (1 g iv daily) for active Graves' ophthalmopathy, and developed <e2>severe hypertension</e2> followed by myocardial infarction on the fifth day of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4539	 conclude that <e1>myocardial infarction</e1> may develop in patients treated with high-dose <e2>glucocorticoids</e2> for Graves' ophthalmopathy, and increased blood pressure may herald this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4540	 is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (<e1>SASP</e1>) therapy developed a severe and lasting <e2>psoriasis-like skin reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4541	 is a case story of a woman with classical rheumatoid arthritis, who during introduction of <e1>sulphasalazine</e1> (SASP) therapy developed a severe and lasting <e2>psoriasis-like skin reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4542	 skin reaction</e1> in a patient with rheumatoid arthritis after <e2>sulphasalazine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4543	 days after the fourth dose of <e1>vincristine</e1>, she presented with <e2>bilateral ptosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4544	 induced <e2>cranial polyneuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4545	 describe a 5-year-old girl showed recovery of <e1>vincristine</e1> induced <e2>cranial polyneuropathy</e2> with pyridoxine and pyridostigmine treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4546	 generalized exanthematous pustulosis</e1> caused by <e2>morphine</e2>, confirmed by positive patch test and lymphocyte transformation test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4547	 an opium alkaloid, frequently causes side effects such as hyperhidrosis and <e2>facial flushing</e2>, but serious cutaneous adverse drug reactions are seldom observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4548	 an opium alkaloid, frequently causes side effects such as <e2>hyperhidrosis</e2> and facial flushing, but serious cutaneous adverse drug reactions are seldom observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4549	 describe a case of a man treated with an EGFR-inhibitor (<e1>erlotinib</e1>) for a cell lung cancer who developed <e2>skin manifestations</e2> localized in an uncommon area and with an atypical evolution."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4550	 -associated <e2>neuroleptic malignant syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4551	 contact angioedema</e1> to <e2>benzoyl peroxide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4552	 that suggested an association between the <e1>severe angioedematous reaction</e1> and <e2>BP</e2> topical application include the strong reaction to <e2>BP</e2> in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4553	 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of <e1>5-fluorouracil</e1> as episodes of <e2>acute confusional state</e2> and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4554	 35-year-old woman presented with <e1>neurotoxicity</e1> correlated to an i.v. regimen of <e2>5-fluorouracil</e2> as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4555	 findings of restricted diffusion in <e1>5-fluorouracil</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4556	 present the case of a 58-year-old woman who ingested more than 35 g of <e1>caffeine</e1> in a <e2>suicide attempt</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4557	 may cause a severe adverse drug reaction with multiorgan involvement known as <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4558	 <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4559	 report the case of a 21-year-old female patient with <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4560	 to intrathecal <e2>diamorphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4561	 believe this is the first report of intrathecal <e1>diamorphine</e1> causing <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4562	 highlight two instances of <e1>systemic allergic reaction</e1>, and discuss the potential side effects of local <e2>aprotinin</e2> injections in the orthopaedic setting as well as the evidence base for its use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4563	 Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and <e1>carbamazepine</e1>) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4564	 Case analysis of a poly-drug overdose (venlafaxine, topiramate, <e1>divalproex sodium</e1>, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4565	 Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, <e1>risperidone</e1>, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4566	 Case analysis of a poly-drug overdose (venlafaxine, <e1>topiramate</e1>, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4567	 Case analysis of a poly-drug overdose (<e1>venlafaxine</e1>, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4568	 Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and <e1>carbamazepine</e1>) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4569	 Case analysis of a poly-drug overdose (venlafaxine, topiramate, <e1>divalproex sodium</e1>, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4570	 Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, <e1>risperidone</e1>, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4571	 Case analysis of a poly-drug overdose (venlafaxine, <e1>topiramate</e1>, divalproex sodium, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4572	 Case analysis of a poly-drug overdose (<e1>venlafaxine</e1>, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4573	 and maculopapular rashes appeared at 10 days after <e2>phenytoin</e2> initiation, and then the drug was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4574	 and <e1>maculopapular rashes</e1> appeared at 10 days after <e2>phenytoin</e2> initiation, and then the drug was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4575	 purpura</e1> associated with <e2>lamotrigine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4576	 case study is the second report of <e1>localized purpura</e1> after prolonged <e2>lamotrigine</e2> treatment suggesting this may be an atypical <e2>lamotrigine</e2> -induced drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4577	 report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed <e1>localized purpura</e1> after 23 months of <e2>lamotrigine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4578	 renal failure</e1> during <e2>lisinopril</e2> and losartan therapy for proteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4579	 renal failure</e1> during lisinopril and <e2>losartan</e2> therapy for proteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4580	 report describes a case of acute compromise of renal function associated with <e1>hypotension</e1> in a 7-year-old boy treated with the ACE inhibitor <e2>lisinopril</e2> and the ARB losartan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4581	 report describes a case of acute compromise of renal function associated with <e1>hypotension</e1> in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB <e2>losartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4582	 corneal keratinization</e1> following trabeculectomy and treatment with <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4583	 obliterans with organizing pneumonia</e1> after <e2>rituximab</e2> therapy for non-Hodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4584	 these findings suggest that the incidence of <e1>BOOP</e1> following <e2>rituximab</e2> therapy may be higher than has been previously appreciated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4585	 is the first reported case of <e1>BOOP</e1> associated with single-agent <e2>rituximab</e2>, and along with two other patients we describe, as well as two prior reports of <e1>BOOP</e1> in NHL patients receiving <e2>rituximab</e2> -based combinations, strengthens the possibility of a causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4586	 is the first reported case of <e1>BOOP</e1> associated with single-agent <e2>rituximab</e2>, and along with two other patients we describe, as well as two prior reports of <e1>BOOP</e1> in NHL patients receiving <e2>rituximab</e2> -based combinations, strengthens the possibility of a causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4587	 describe a case of an NHL patient who received <e1>rituximab</e1> and developed symptomatic, biopsy-proven multinodular <e2>bronchiolitis obliterans with organizing pneumonia</e2> (BOOP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4588	 a very low complication rate, several <e1>severe arterial thrombotic events</e1> have been reported following <e2>thrombin</e2> injection of pseudoaneurysms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4589	 extremity <e1>arterial thrombosis</e1> following sonographically guided <e2>thrombin</e2> injection of a femoral pseudoaneurysm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4590	 <e1>arterial thrombosis</e1>, though recognized as a severe complication of <e2>thrombin</e2> injection, has not been well described in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4591	 report a case of successful surgical management of <e1>arterial thrombosis</e1> after percutaneous <e2>thrombin</e2> injection of a femoral artery pseudoaneurysm in a 69-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4592	 small number of <e1>oxaliplatin</e1> -related <e2>hemolytic and/or thrombocytopenic reactions</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4593	 uremic syndrome</e1> following the infusion of <e2>oxaliplatin</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4594	 present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with oxaliplatin, <e2>5-fluorouracil</e2> and leucovorin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4595	 present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and <e2>leucovorin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4596	 present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with <e2>oxaliplatin</e2>, 5-fluorouracil and leucovorin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4597	 a review of the literature produced 41 anecdotic cases of neutropenia or <e1>agranulocytosis</e1> during treatment with <e2>olanzapine</e2> (Zyprexa) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4598	 a review of the literature produced 41 anecdotic cases of neutropenia or <e1>agranulocytosis</e1> during treatment with olanzapine (<e2>Zyprexa</e2>) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4599	 a review of the literature produced 41 anecdotic cases of <e1>neutropenia</e1> or agranulocytosis during treatment with <e2>olanzapine</e2> (Zyprexa) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4600	 a review of the literature produced 41 anecdotic cases of <e1>neutropenia</e1> or agranulocytosis during treatment with olanzapine (<e2>Zyprexa</e2>) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4601	 and <e1>agranulocytosis</e1> are risks known to occur with phenothiazines and <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4602	 and <e1>agranulocytosis</e1> are risks known to occur with <e2>phenothiazines</e2> and clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4603	 and agranulocytosis are risks known to occur with phenothiazines and <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4604	 and agranulocytosis are risks known to occur with <e2>phenothiazines</e2> and clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4605	 we report a case of <e1>neutropenia</e1>, which proved to be fatal in a schizophrenia patient receiving <e2>olanzapine</e2> and thiazide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4606	 we report a case of <e1>neutropenia</e1>, which proved to be fatal in a schizophrenia patient receiving olanzapine and <e2>thiazide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4607	 any case of <e1>severe neutropenia</e1> occurring in a patient receiving <e2>olanzapine</e2> is alarming to clinicians."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4608	 present a depressive patient who developed mild parkinsonian signs and <e1>camptocormia</e1> after the introduction of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4609	 present a depressive patient who developed <e1>mild parkinsonian signs</e1> and camptocormia after the introduction of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4610	 months after initiating <e1>mirtazapine</e1> therapy, she developed <e2>symptomatic hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4611	 this case, unlike those previously reported, <e1>hyponatremia</e1> recurred 5 months after switching from <e2>citalopram</e2> to mirtazapine, which is believed to be a safe antidepressant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4612	 this case, unlike those previously reported, <e1>hyponatremia</e1> recurred 5 months after switching from citalopram to <e2>mirtazapine</e2>, which is believed to be a safe antidepressant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4613	 hyponatremia</e1> associated with <e2>citalopram</e2> and mirtazapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4614	 hyponatremia</e1> associated with citalopram and <e2>mirtazapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4615	 43-year-old woman with multiple sclerosis (MS) had <e1>nephrotic syndrome</e1> 21 months after starting treatment with <e2>interferon (IFN)-beta-1b</e2> (subcutaneous administration)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4616	 <e1>nephrotic syndrome</e1> may be induced by <e2>IFN</e2> therapy, the <e2>IFN</e2> was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4617	 <e1>nephrotic syndrome</e1> may be induced by <e2>IFN</e2> therapy, the <e2>IFN</e2> was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4618	 syndrome</e1> associated with <e2>interferon-beta-1b</e2> therapy for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4619	 proteinuria and <e1>nephrotic syndrome</e1> is a rare adverse effect of <e2>IFN-beta-1b</e2> therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4620	 <e1>proteinuria</e1> and nephrotic syndrome is a rare adverse effect of <e2>IFN-beta-1b</e2> therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4621	 70-year-old man was admitted to our hospital because of <e1>dyspnea</e1> after taking an antihistaminic agent (<e2>homochlorcyclizine hydrochloride</e2>) for itching."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4622	 eosinophilic pneumonia</e1> caused by <e2>calcium stearate</e2>, an additive agent for an oral antihistaminic medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4623	 we concluded that this patient's <e1>pulmonary disease</e1> was caused by <e2>calcium stearate</e2>, an additive for an antihistaminic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4624	 complicating <e2>zoledronic acid</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4625	 present a case of <e1>severe unilateral posterior scleritis</e1> associated with <e2>zoledronic acid</e2> administration that was recognized and treated in a timely manner."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4626	 lethal <e1>hepatitis B virus reactivation</e1> after <e2>rituximab</e2> treatment of low-grade cutaneous B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4627	 such <e1>HBV reactivations</e1> were reported after combined <e2>rituximab</e2> and multiagent chemotherapy for B-cell lymphomas."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4628	 is the first case of <e1>HBV reactivation</e1> occurring during the year following <e2>rituximab</e2> monotherapy in the absence of any other immunosuppressive factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4629	 is a case report of fatal <e1>cryptococcal meningitis</e1> in a child with systemic lupus erythematosus being treated with prednisolone and <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4630	 is a case report of fatal <e1>cryptococcal meningitis</e1> in a child with systemic lupus erythematosus being treated with <e2>prednisolone</e2> and azathioprine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4631	 <e1>intertrigo-like eruption</e1> from pegylated liposomal <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4632	 <e1>eruption</e1> appears to be a distinct cutaneous toxicity of <e2>PLD</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4633	 report the case of a 60-year-old woman who developed erythema and <e1>erosions in the axilla and groin</e1> while on <e2>PLD</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4634	 report the case of a 60-year-old woman who developed <e1>erythema</e1> and erosions in the axilla and groin while on <e2>PLD</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4635	 is reported an unusual case of coexistent <e1>warfarin</e1> -induced <e2>skin necrosis</e2> and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4636	 is reported an unusual case of coexistent warfarin-induced skin necrosis and <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4637	 -induced <e2>skin necrosis</e2> and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4638	 skin necrosis and <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> following mitral valve replacement for marantic endocarditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4639	 of the fetus to <e1>indomethacin</e1> by administration of the drug to the mother may cause many side effects, including <e2>premature closure of the ductus arteriosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4640	 is a predisposing factor for premature ductal closure and often occurs after maternal <e2>indomethacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4641	 is a predisposing factor for <e1>premature ductal closure</e1> and often occurs after maternal <e2>indomethacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4642	 closure of the ductus arteriosus</e1>: variable response among monozygotic twins after in utero exposure to <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4643	 selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to <e1>ductal closure</e1> in response to <e2>indomethacin</e2> exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4644	 selective closure of the ductus arteriosus suggests that the affected twin was predisposed to <e1>hypoxia</e1> and thus was more susceptible to ductal closure in response to <e2>indomethacin</e2> exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4645	 These cases suggest that <e1>moxifloxacin</e1> may interfere with the healing of <e2>corneal ulcers</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4646	 Both cases presented here describe <e1>corneal ulcers</e1> that persisted and showed signs of worsening during weeks of frequent topical dosing with <e2>moxifloxacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4647	 corneal toxicity</e1> after topical <e2>fluoroquinolone</e2> therapy: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4648	 generalized exanthematous pustulosis</e1> induced by <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4649	 report a case of <e1>acute generalized exanthematous pustulosis</e1> (AGEP) in a 50-year-old woman that was attributed to the ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4650	 report a case of acute generalized exanthematous pustulosis (<e1>AGEP</e1>) in a 50-year-old woman that was attributed to the ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4651	 <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and <e2>bradycardia</e2> reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4652	 <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant <e2>cardiac toxicity</e2>, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4653	 <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant cardiac toxicity, with <e2>ventricular arrhythmias</e2> and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4654	 To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a <e1>fatal cardiac arrhythmia</e1> after an acute overdose of <e2>amphotericin B</e2> and to review its toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4655	 of the Naranjo probability scale indicated a highly probable relationship between the observed <e1>cardiac toxicity</e1> and <e2>amphotericin B deoxycholate</e2> therapy in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4656	 authors describe a case of <e1>valvular heart disease</e1> in a 48-year-old woman receiving <e2>benfluorex</e2> (150 mg t.i.d. for 8 years) and leading to surgical mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4657	 heart disease</e1> in a patient taking <e2>benfluorex</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4658	 main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, localized pain, myelo-suppression and <e2>liver dysfunction</e2>, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4659	 main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, <e2>localized pain</e2>, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4660	 main side-effects of <e1>Lp-TAE</e1> combined with HT were <e2>low-grade fever</e2>, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4661	 main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, localized pain, <e2>myelo-suppression</e2> and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4662	 -induced HUS: an unusual cause of <e2>acute renal failure</e2> in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4663	 -induced <e2>HUS</e2>: an unusual cause of acute renal failure in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4664	 <e1>tacrolimus</e1> -induced HUS is a rare cause of <e2>ARF</e2> in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4665	 <e1>tacrolimus</e1> -induced <e2>HUS</e2> is a rare cause of ARF in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4666	 transplantation for <e1>fulminant hepatitis</e1> related to <e2>nevirapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4667	 describe a detailed case of <e1>fulminant hepatitis</e1> induced by <e2>nevirapine</e2> (Viramune) and treated by liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4668	 describe a detailed case of <e1>fulminant hepatitis</e1> induced by nevirapine (<e2>Viramune</e2>) and treated by liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4669	 and thrombosis of the central retinal vein in a renal transplant recipient treated with <e2>cyclosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4670	 and <e1>thrombosis of the central retinal vein</e1> in a renal transplant recipient treated with <e2>cyclosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4671	 this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and <e1>azathioprine</e1>, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4672	 this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of <e1>cyclosporin</e1>, prednisone and azathioprine, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4673	 this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, <e1>prednisone</e1> and azathioprine, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4674	 use of <e1>cyclosporin</e1> has been associated with the development of <e2>cholelithiasis</e2> in transplant recipients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4675	 induced by <e2>cyproterone acetate</e2>: a report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4676	 male patients aged 78-83 years are presented, in whom <e1>severe hepatotoxic reactions</e1> emerged after <e2>CPA</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4677	 PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (<e1>CS</e1>)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with <e1>CS</e1> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after <e2>cutaneous leishmaniasis</e2> in a man receiving <e1>CS</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-

4678	 PRESENTATION: Three cases of <e1>Leishmania infantum leishmaniasis</e1> in <e2>corticosteroid</e2> (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS."
DRUG-ADE(e2,e1)
Comment: DRUG-

4679	 PRESENTATION: Three cases of <e1>Leishmania infantum leishmaniasis</e1> in corticosteroid (<e2>CS</e2>)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with <e2>CS</e2> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving <e2>CS</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4680	 PRESENTATION: Three cases of Leishmania infantum leishmaniasis in <e1>corticosteroid</e1> (CS)-treated patients are reported: an isolated <e2>lingual leishmaniasis</e2> in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS."
DRUG-ADE(e1,e2)
Comment: DRUG-

4681	 PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (<e1>CS</e1>)-treated patients are reported: an isolated <e2>lingual leishmaniasis</e2> in a farmer treated with <e1>CS</e1> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving <e1>CS</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-

4682	 infantum leishmaniasis</e1> in <e2>corticosteroid</e2> --treated patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4683	 an association of <e1>Ritalin</e1> with <e2>glaucoma</e2> has been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4684	 dose of <e1>methylphenidate</e1> may cause <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4685	 dose of <e1>methylphenidate</e1> may cause cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4686	 (Ritalin)-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4687	 (<e1>Ritalin</e1>)-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4688	 (Ritalin)-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4689	 (<e1>Ritalin</e1>)-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4690	 report a case of <e1>Ritalin</e1> -associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4691	 report a case of <e1>Ritalin</e1> -associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4692	 We report a typical symptoms of Charles-Bonnet syndrome (<e1>CBS</e1>) in patients with severe AMD after intravitreal <e2>Avastin</e2> -injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4693	 We report a typical symptoms of <e1>Charles-Bonnet syndrome</e1> (CBS) in patients with severe AMD after intravitreal <e2>Avastin</e2> -injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4694	 To describe <e1>transient structured visual hallucinations</e1> in a patient with vascular age-related macular degeneration (AMD), following an intravitreal <e2>Avastin</e2> -injection."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4695	 hallucinations</e1> after intravitreal injection of <e2>bevacizumab</e2> in vascular age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4696	 case of <e1>metoclopramide</e1> -induced <e2>oculogyric crisis</e2> in a 16-year-old girl with cystic fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4697	 case of <e1>oculogyric crisis</e1> induced by <e2>metoclopramide</e2> is described in this paper."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4698	 <e1>cyclosporine</e1> dependency is associated with the risk of <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4699	 is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to <e2>prolonged hypotension</e2> and, less frequently, transient renal impairment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4700	 is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, <e2>transient renal impairment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4701	 after widely separated courses of adriamycin exacerbated by <e2>actinomycin-D</e2> and mithramycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4702	 after widely separated courses of <e2>adriamycin</e2> exacerbated by actinomycin-D and mithramycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4703	 after widely separated courses of adriamycin exacerbated by actinomycin-D and <e2>mithramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4704	 of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics <e2>actinomycin-D</e2> (NSC-3053) and mithramycin (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4705	 of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and <e2>mithramycin</e2> (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4706	 of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (<e2>NSC-24559</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4707	 of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (<e2>NSC-3053</e2>) and mithramycin (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4708	 pathogenic mechanisms involved in the development of <e1>adriamycin</e1> <e2>cardiomyopathy</e2> are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4709	 hypersensitivity</e1> and myopericarditis have been reported during long-term treatment with <e2>mesalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4710	 hypersensitivity and <e1>myopericarditis</e1> have been reported during long-term treatment with <e2>mesalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4711	 report the case of a man, treated with <e1>mesalazine</e1> for Crohn's disease who developed drug-induced <e2>pericarditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4712	 drug induced <e1>hepatitis</e1> due to <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4713	 REPORT: We report a case of <e1>acute severe hepatitis</e1> resulting from <e2>erlotinib</e2> monotherapy in a patient with locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-

4714	 <e1>Acute severe hepatitis</e1> though rare is occasionally observed with EGFR inhibitors gefitinib or <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4715	 <e1>Acute severe hepatitis</e1> though rare is occasionally observed with EGFR inhibitors <e2>gefitinib</e2> or erlotinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4716	 resolved once <e2>erlotinib</e2> was discontinued and serum transaminases returned to baseline normal values."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4717	 -associated <e2>thrombocytopenia</e2> and thrombosis is a severe complication of systemic heparin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4718	 <e1>thrombocytopenia</e1> and thrombosis is a severe complication of systemic <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4719	 -associated thrombocytopenia and <e2>thrombosis</e2> is a severe complication of systemic heparin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4720	 thrombocytopenia and <e1>thrombosis</e1> is a severe complication of systemic <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4721	 experience supports the hypothesis that <e1>heparin</e1> can be readministered early to patients with <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis, provided antiplatelet therapy is given."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4722	 experience supports the hypothesis that <e1>heparin</e1> can be readministered early to patients with <e1>heparin</e1> -associated thrombocytopenia and <e2>thrombosis</e2>, provided antiplatelet therapy is given."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4723	 of antiplatelet drugs in the management of <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4724	 of antiplatelet drugs in the management of <e1>heparin</e1> -associated thrombocytopenia and <e2>thrombosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4725	 A clinical diagnosis of <e1>fixed drug eruption</e1> owing to use of the PDE5 inhibitor tadalafil (<e2>Cialis</e2>) was made."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4726	 A clinical diagnosis of <e1>fixed drug eruption</e1> owing to use of the PDE5 inhibitor <e2>tadalafil</e2> (Cialis) was made."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4727	 though only a few cases of this adverse event have been reported in the literature, severe <e1>docetaxel</e1> -induced <e2>pulmonary toxicity</e2> needs to be considered in the differential diagnosis when such patients present with respiratory symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4728	 interstitial pneumonitis</e1> associated with <e2>docetaxel</e2> administration in a patient with hormone-refractory prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4729	 case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 <e1>docetaxel</e1> who developed <e2>subacute interstitial pneumonitis-related pulmonary fibrosis</e2> after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4730	 patient presented with <e1>fulminant microangiopathic hemolytic anemia</e1> and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4731	 patient presented with <e1>fulminant microangiopathic hemolytic anemia</e1> and thrombocytopenia within 48 hr of initiating therapy with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4732	 patient presented with fulminant microangiopathic hemolytic anemia and <e1>thrombocytopenia</e1> within 48 hr of initiating therapy with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4733	 patient presented with fulminant microangiopathic hemolytic anemia and <e1>thrombocytopenia</e1> within 48 hr of initiating therapy with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4734	 thrombocytopenic purpura</e1> induced by trimethoprim-<e2>sulfamethoxazole</e2> in a Jehovah's Witness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4735	 thrombocytopenic purpura</e1> induced by <e2>trimethoprim</e2> -sulfamethoxazole in a Jehovah's Witness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4736	 report a case of <e1>Thrombotic Thrombocytopenic Purpura</e1> occurring as an allergic response to trimethoprim-<e2>sulfamethoxazole</e2> therapy (Bactrim, Septra) in a Jehovah's Witness patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4737	 report a case of <e1>Thrombotic Thrombocytopenic Purpura</e1> occurring as an allergic response to <e2>trimethoprim</e2> -sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4738	 absence epilepsy</e1> exacerbated by <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4739	 report describes a case of <e1>paradoxical</e1>, intravenous valproic acid-induced <e2>seizure exacerbation</e2> in a child with juvenile absence epilepsy, documented by video-electroencephalography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4740	 report describes a case of paradoxical, intravenous <e1>valproic acid</e1> -induced <e2>seizure exacerbation</e2> in a child with juvenile absence epilepsy, documented by video-electroencephalography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4741	 endophthalmitis</e1> following intravitreal bevacizumab (<e2>Avastin</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4742	 endophthalmitis</e1> following intravitreal <e2>bevacizumab</e2> (Avastin) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4743	 <e1>Infectious endophthalmitis</e1> is a potential complication of intravitreal <e2>bevacizumab</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4744	 Two patients with exudative <e1>age-related macular degeneration</e1> were treated sequentially with an intravitreal injection of <e2>bevacizumab</e2> and developed signs of severe but painless infectious endophthalmitis 2 days later."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4745	 Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of <e1>bevacizumab</e1> and developed signs of severe but <e2>painless infectious endophthalmitis</e2> 2 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4746	 To report two cases of <e1>acute endophthalmitis</e1> following intravitreal <e2>bevacizumab</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4747	 hypertension</e1> during <e2>lithium</e2> therapy: clinical case study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4748	 authors presented a case of <e1>pulmonary hypertension</e1> during <e2>lithium</e2> therapy, while she has been on <e2>lithium</e2> for 6 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4749	 is the first report of <e1>pulmonary hypertension</e1> in an adult patient during <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4750	 patient's <e1>arthritis</e1> flared after the second infusion of <e2>infliximab</e2>, which was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4751	 32-year-old man with a family history of type 2 diabetes mellitus presented with <e1>circulatory collapse</e1> and deep coma after 9 days of treatment with <e2>perospirone hydrochloride</e2>, a recently developed atypical antipsychotic agent available only in Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4752	 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and <e1>deep coma</e1> after 9 days of treatment with <e2>perospirone hydrochloride</e2>, a recently developed atypical antipsychotic agent available only in Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4753	 risk of new-onset <e1>diabetic ketoacidosis</e1> in patients with diabetic risk factors who are taking <e2>perospirone hydrochloride</e2> or other atypical antipsychotics should be kept in mind."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4754	 venous thrombembolism</e1> complicating <e2>imatinib</e2> therapy in a patient with metastatic gastrointestinal stromal tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4755	 possibility of <e1>deep vein thrombosis</e1> caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4756	 describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed <e1>status epilepticus</e1> shortly after receiving <e2>cisplatin</e2> and gemcitabine chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4757	 describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed <e1>status epilepticus</e1> shortly after receiving cisplatin and <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4758	 particular interest in this patient is the <e1>fluctuation of the QT interval</e1> at a stable dose of <e2>methadone</e2>, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4759	 present a case report of a patient who developed a <e1>prolonged QT</e1> while being treated with oral <e2>methadone</e2> for a chronic pain syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4760	 To present a case of <e1>piloerection</e1> after replacing <e2>fluvoxamine maleate</e2> with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4761	 To present a case of <e1>piloerection</e1> after replacing fluvoxamine maleate with <e2>milnacipran hydrochloride</e2>, and to analyse this effect based on receptor occupancy theory."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4762	 The <e1>piloerection</e1> observed after the replacement of <e2>fluvoxamine</e2> with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4763	 The <e1>piloerection</e1> observed after the replacement of fluvoxamine with <e2>milnacipran</e2> in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by <e2>milnacipran</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4764	 induced by replacing <e2>fluvoxamine</e2> with milnacipran."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4765	 induced by replacing fluvoxamine with <e2>milnacipran</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4766	 PRESENTATION: We report a patient with CF who developed <e1>recurrent eosinophilia</e1> and severe persistent bronchospasm following repeated administration of preservative-free <e2>tobramycin</e2> by inhalation, beginning at 16 months of age."
DRUG-ADE(e2,e1)
Comment: DRUG-

4767	 PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and <e1>severe persistent bronchospasm</e1> following repeated administration of preservative-free <e2>tobramycin</e2> by inhalation, beginning at 16 months of age."
DRUG-ADE(e2,e1)
Comment: DRUG-

4768	 Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and <e1>deterioration of pulmonary function</e1> following the use of <e2>tobramycin</e2> by inhalation or by intravenous administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4769	 Hypersensitivity reaction should be considered in patients who develop <e1>recurrent eosinophilia</e1> and deterioration of pulmonary function following the use of <e2>tobramycin</e2> by inhalation or by intravenous administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4770	 <e1>tobramycin</e1> solution-associated <e2>recurrent eosinophilia</e2> and severe persistent bronchospasm in a patient with cystic fibrosis: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4771	 <e1>tobramycin</e1> solution-associated recurrent eosinophilia and <e2>severe persistent bronchospasm</e2> in a patient with cystic fibrosis: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4772	 most serious dental side effect of <e1>bisphosphonate</e1> treatment (particularly when it is administered intravenously) is, paradoxically, <e2>osteonecrosis of the mandible</e2> or the maxilla represented by exposed nonhealing bone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4773	 effects of <e1>amiodarone</e1> including pulmonary toxicity, hepatotoxicity, <e2>aggravation of arrhythmia</e2>, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4774	 effects of <e1>amiodarone</e1> including pulmonary toxicity, <e2>hepatotoxicity</e2>, aggravation of arrhythmia, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4775	 effects of <e1>amiodarone</e1> including <e2>pulmonary toxicity</e2>, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4776	 effects of <e1>amiodarone</e1> including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and <e2>thyroid diseases</e2> are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4777	 is a very rare adverse effect associated with the use of <e2>amiodarone</e2>, and only four cases of <e2>amiodarone</e2> -induced pancreatitis have been reported in literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4778	 is a very rare adverse effect associated with the use of <e1>amiodarone</e1>, and only four cases of <e1>amiodarone</e1> -induced <e2>pancreatitis</e2> have been reported in literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4779	 the suspicion of <e1>amiodarone</e1> -induced <e2>acute pancreatitis</e2>, <e1>amiodarone</e1> was substituted by propafenone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4780	 report a patient who developed <e1>acute pancreatitis</e1> during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4781	 To our knowledge this is the first reported case of <e1>tuberculous uveitis</e1> following treatment with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4782	 uveitis</e1> after treatment with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4783	 report the first case of <e1>tuberculous uveitis</e1> due to <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4784	 complex pattern of <e1>melanonychia</e1> and onycholysis after treatment with <e2>pemetrexed</e2> for lung cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4785	 complex pattern of melanonychia and <e1>onycholysis</e1> after treatment with <e2>pemetrexed</e2> for lung cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4786	 and its serious adverse effects are discussed, and other cases of <e2>osteomyelitis</e2> with infliximab use are also reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4787	 and its serious adverse effects are discussed, and other cases of <e1>osteomyelitis</e1> with <e2>infliximab</e2> use are also reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4788	 occurring during <e2>infliximab</e2> treatment of severe psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4789	 on the Naranjo probability scale, <e1>serotonin syndrome</e1> was a probable adverse reaction associated with co-administration of <e2>citalopram</e2> and fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4790	 on the Naranjo probability scale, <e1>serotonin syndrome</e1> was a probable adverse reaction associated with co-administration of citalopram and <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4791	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, <e2>agitation</e2>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4792	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, <e1>agitation</e1>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4793	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, <e1>agitation</e1>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4794	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed <e2>confusion</e2>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4795	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed <e1>confusion</e1>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4796	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed <e1>confusion</e1>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4797	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, <e2>myoclonic jerks</e2> and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4798	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, <e1>myoclonic jerks</e1> and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4799	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, <e1>myoclonic jerks</e1> and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4800	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e2>serotonin syndrome</e2>, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4801	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e1>serotonin syndrome</e1>, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4802	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e1>serotonin syndrome</e1>, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4803	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, <e2>tachycardia</e2>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4804	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, <e1>tachycardia</e1>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4805	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, <e1>tachycardia</e1>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4806	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, <e2>tremors</e2>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4807	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, <e1>tremors</e1>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4808	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, <e1>tremors</e1>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4809	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e2>unsteady gait</e2>, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-

4810	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e1>unsteady gait</e1>, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4811	 SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e1>unsteady gait</e1>, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

4812	 Healthcare professionals should be aware of the possible development of <e1>serotonin syndrome</e1> as a complication of initiation of <e2>fentanyl</e2> and other phenylpiperidine opioids in patients treated with SSRIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4813	 To report a case of <e1>serotonin syndrome</e1> associated with interaction between fentanyl and <e2>citalopram</e2>, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4814	 To report a case of <e1>serotonin syndrome</e1> associated with interaction between <e2>fentanyl</e2> and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4815	 To report a case of <e1>serotonin syndrome</e1> associated with interaction between <e2>fentanyl</e2> and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4816	 syndrome</e1> caused by interaction between <e2>citalopram</e2> and fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4817	 syndrome</e1> caused by interaction between citalopram and <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4818	 failure</e1> after high-dose <e2>methotrexate</e2> in a child homozygous for MTHFR C677T polymorphism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4819	 report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented <e1>renal failure</e1> following the second cycle of high-dose methotrexate (<e2>HDMTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4820	 report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented <e1>renal failure</e1> following the second cycle of high-dose <e2>methotrexate</e2> (HDMTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4821	 induced <e2>Meibomian duct inflammation and blockage</e2> is the likely cause of this presentation in a patient with no history of eyelid masses in the past."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4822	 -induced Meibomian duct inflammation and blockage leading to <e2>chalazion</e2> formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4823	 -induced <e2>Meibomian duct inflammation and blockage</e2> leading to chalazion formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4824	 report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly <e1>docetaxel</e1> for 12 weeks and developed significant <e2>eye irritation and dryness</e2> during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4825	 case of <e1>recall pneumonitis</e1> induced by <e2>gemcitabine</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4826	 having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed <e2>dry cough</e2>, subfebrile temperatures and dyspnea within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4827	 having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and <e2>dyspnea</e2> within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4828	 having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed dry cough, <e2>subfebrile temperatures</e2> and dyspnea within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4829	 <e1>Gemcitabine</e1> -induced <e2>recall pneumonitis</e2> is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4830	 recall pneumonitis</e1> induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4831	 For all patients with <e1>vancomycin</e1> -induced <e2>neutropenia</e2>, possible cross-reactivity of teicoplanin should be monitored."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4832	 a new episode of <e1>neutropenia</e1>, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after <e2>teicoplanin</e2> initiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4833	 To report <e1>teicoplanin</e1> -related <e2>neutropenia</e2> that developed after an episode of <e2>neutropenia</e2> induced by vancomycin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4834	 To report teicoplanin-related <e1>neutropenia</e1> that developed after an episode of <e1>neutropenia</e1> induced by <e2>vancomycin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

4835	 -induced <e2>agranulocytosis</e2> that followed vancomycin-induced <e2>agranulocytosis</e2> suggests a possible cross-reactivity between the 2 drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4836	 <e1>agranulocytosis</e1> that followed <e2>vancomycin</e2> -induced <e1>agranulocytosis</e1> suggests a possible cross-reactivity between the 2 drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4837	 ulceration</e1>: an unusual complication of intravenous <e2>pentamidine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4838	 is a report of a renal transplant patient with Pneumocystis pneumonia who developed <e1>chemical cellulitis</e1> and ulceration following the extravasation of intravenous <e2>pentamidine</e2> into the soft tissues of the left hand and forearm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4839	 is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and <e1>ulceration</e1> following the extravasation of intravenous <e2>pentamidine</e2> into the soft tissues of the left hand and forearm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4840	 A 48-year-old woman presented with <e1>disfiguring facial edema</e1> 10 weeks after she began antiviral therapy with <e2>peginterferon alfa-2a</e2> and ribavirin for chronic hepatitis C infection."
DRUG-ADE(e2,e1)
Comment: DRUG-

4841	 A 48-year-old woman presented with <e1>disfiguring facial edema</e1> 10 weeks after she began antiviral therapy with peginterferon alfa-2a and <e2>ribavirin</e2> for chronic hepatitis C infection."
DRUG-ADE(e2,e1)
Comment: DRUG-

4842	 increase</e1> at beginning of primary treatment with topical <e2>interferon alpha 2-beta</e2> in a case of conjunctiva-cornea intraepithelial neoplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4843	 overdose can rapidly result in profound <e2>cardiovascular collapse</e2>, and is associated with a relatively high mortality."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4844	 <e1>cardiovascular collapse</e1> in severe <e2>flecainide</e2> overdose without recourse to extracorporeal therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4845	 -induced <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4846	 its FDA approval in 2002, there are no known citations of <e1>ezetimibe</e1> -induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4847	 estrogen receptor modulator <e1>raloxifene</e1> -associated <e2>aggravation of nonalcoholic steatohepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4848	 is the first histologically confirmed case of <e1>NASH</e1> that was aggravated by <e2>raloxifene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4849	 case of <e1>liver damage</e1> following treatment with <e2>Danazol</e2> for fibrocystic breast disease is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4850	 damage</e1> after <e2>danazol</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4851	 pneumonitis-like syndrome</e1> associated with the use of <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4852	 this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, fever, hypoxia, and <e2>diffuse pulmonary infiltrates</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4853	 this report, we describe a patient receiving <e1>lenalidomide</e1> in whom <e2>dyspnea</e2>, fever, hypoxia, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4854	 this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, <e2>fever</e2>, hypoxia, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4855	 this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, fever, <e2>hypoxia</e2>, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4856	 should be cognizant of this potential complication in patients receiving <e1>thalidomide</e1> or <e1>thalidomide</e1> -like drugs who present with <e2>fever</e2> and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4857	 should be cognizant of this potential complication in patients receiving <e1>thalidomide</e1> or <e1>thalidomide</e1> -like drugs who present with fever and <e2>pulmonary infiltrates</e2> and fail to improve despite treatment with broad-spectrum antibiotics."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4858	 the patient's clinical course and workup strongly support a diagnosis of <e1>lenalidomide</e1> -induced <e2>hypersensitivity pneumonitis-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4859	 <e1>triamcinolone</e1> may have had an influence on the <e2>exacerbation of retinochoroiditis</e2> in the posterior pole of the patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4860	 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced <e1>rapid cognitive decline</e1> after commencement of <e2>ethambutol</e2>, and symptoms fully resolved with cessation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4861	 toxicity manifesting as <e2>acute onset psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4862	 induced by <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4863	 human interferon-alpha</e1> has been used in the treatment of several cancers, but there have been several reports that it may <e2>exacerbate psoriasis or trigger off its onset</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4864	 report four patients, three of whom first developed <e1>psoriasis</e1> and one who had an aggravation of the condition during treatment with <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4865	 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed <e1>generalized erythema</e1> with high fever 3 weeks after taking <e2>sulfamethoxazole</e2>/trimethoprim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4866	 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed <e1>generalized erythema</e1> with high fever 3 weeks after taking sulfamethoxazole/<e2>trimethoprim</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4867	 We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and <e1>raised intracranial pressure</e1> (ICP) after severe <e2>sodium valproic acid</e2> (VPA) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4868	 We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and <e1>raised intracranial pressure</e1> (ICP) after severe sodium valproic acid (<e2>VPA</e2>) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4869	 We describe the neurointensive care (NIC) management of a patient with <e1>severe cerebral swelling</e1> and raised intracranial pressure (ICP) after severe <e2>sodium valproic acid</e2> (VPA) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4870	 We describe the neurointensive care (NIC) management of a patient with <e1>severe cerebral swelling</e1> and raised intracranial pressure (ICP) after severe sodium valproic acid (<e2>VPA</e2>) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4871	 care management of <e1>raised intracranial pressure</e1> caused by severe <e2>valproic acid</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4872	 induced <e2>hyperpigmentation</e2> with yolk sac tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4873	 hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the <e1>skin toxicity</e1> of <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4874	 report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included cisplatin, etoposide and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4875	 report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included <e2>cisplatin</e2>, etoposide and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4876	 report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included cisplatin, <e2>etoposide</e2> and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4877	 cause-effect relationship to <e1>capecitabine</e1> was suggested due to resolution of <e2>headache</e2> with <e1>capecitabine</e1> withdrawal and reappearance with <e1>capecitabine</e1> rechallenge."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4878	 <e1>Headaches</e1> have been reported as a potential side effect of <e2>capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4879	 -induced <e2>headache</e2> responding to diltiazem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4880	 should be considered in the treatment of <e1>5-FU</e1> or capecitabine-induced <e2>headaches</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4881	 should be considered in the treatment of 5-FU or <e1>capecitabine</e1> -induced <e2>headaches</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4882	 patient developed grade 3 <e1>capecitabine</e1> -induced <e2>headache</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4883	 hypothesize that <e1>capecitabine</e1> -induced <e2>headache</e2> is vascular in nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4884	 type electrocardiographic changes</e1> induced by concomitant use of <e2>lithium</e2> and propafenone in patient with Wolff-Parkinson-White syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4885	 type electrocardiographic changes</e1> induced by concomitant use of lithium and <e2>propafenone</e2> in patient with Wolff-Parkinson-White syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4886	 report a case of <e1>ST elevation in right precordial leads</e1> compatible with type 1 Brugada syndrome following administration of <e2>propafenone</e2> in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4887	 report a case of ST elevation in right precordial leads compatible with <e1>type 1 Brugada syndrome</e1> following administration of <e2>propafenone</e2> in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4888	 postulate that <e1>gastritis</e1> caused by <e2>dexamethasone</e2>, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4889	 postulate that gastritis caused by dexamethasone, <e1>mucositis</e1> caused by <e2>doxorubicin</e2>, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4890	 -induced paralytic ileus is a potential <e2>gastrointestinal side effect</e2> of this first-in-class anticancer proteasome inhibitor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4891	 -induced <e2>paralytic ileus</e2> is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4892	 ileus</e1> in patients undergoing <e2>bortezomib</e2> treatment has been reported, although a definite attribution to <e2>bortezomib</e2> administration has not been established."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4893	 report a myeloma patient who developed <e1>severe paralytic ileus</e1> during <e2>bortezomib</e2> therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4894	 woman developed <e1>delusional parasitosis</e1> when taking <e2>phenelzine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4895	 parasitosis</e1> associated with <e2>phenelzine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4896	 pneumonitis and <e1>alveolar hemorrhage</e1> complicating use of <e2>rituximab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4897	 pneumonitis</e1> and alveolar hemorrhage complicating use of <e2>rituximab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4898	 use of <e1>rituximab</e1> has been uncommonly associated with <e2>delayed pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4899	 <e1>metoclopramide</e1> induced <e2>neuroleptic malignant syndrome</e2> rapidly responsive to intravenous dantrolene."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4900	 report a case of fulminant <e1>neuroleptic malignant syndrome</e1> in a man aged 70 developing within 12 hours of starting six-hourly intravenous <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4901	 clinical symptoms of <e1>gastric mucosa foveolar hyperplasia</e1> due to long-term <e2>PGE1</e2> therapy simulate hypertrophic pyloric stenosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4902	 results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of <e1>gastric mucosa foveolar hyperplasia</e1> due to prolonged <e2>PGE1</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4903	 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of <e1>fatigue</e1>, myalgia, and leg weakness, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4904	 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and <e1>leg weakness</e1>, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4905	 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, <e1>myalgia</e1>, and leg weakness, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4906	 case of <e1>colchicine</e1> -induced <e2>rhabdomyolysis</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4907	 -induced <e2>rhabdomyolysis</e2> is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4908	 -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4909	 confirmed the diagnosis of rhabdomyolysis, and discontinuation of <e1>colchicine</e1> resulted in resolution of clinical and biochemical features of <e2>rhabdomylysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4910	 <e2>cardiotoxicity</e2> complicating treatment of stage IIB cervical cancer--case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4911	 <e1>Acetic acid</e1> is corrosive and may cause <e2>vagina bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4912	 of <e1>systemic lupus erythematosus</e1> by <e2>interferon-gamma</e2> in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4913	 development of systemic lupus erythematosus (<e1>SLE</e1>) after 38 months of therapy with <e2>recombinant human interferon gamma</e2> (rIFN-gamma) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4914	 development of systemic lupus erythematosus (<e1>SLE</e1>) after 38 months of therapy with recombinant human interferon gamma (<e2>rIFN-gamma</e2>) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4915	 development of <e1>systemic lupus erythematosus</e1> (SLE) after 38 months of therapy with <e2>recombinant human interferon gamma</e2> (rIFN-gamma) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4916	 development of <e1>systemic lupus erythematosus</e1> (SLE) after 38 months of therapy with recombinant human interferon gamma (<e2>rIFN-gamma</e2>) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4917	 assume that <e1>rIFN-gamma</e1> induced the de novo development of <e2>SLE</e2> in our patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4918	 induced <e2>osteochemonecrosis of the jaw</e2> mimicking a tumour."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4919	 -induced <e2>eosinophilia</e2> and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4920	 <e1>eosinophilia</e1> is a non-dose-dependent side effect of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4921	 despite good therapeutic response, <e1>clozapine</e1> must be stopped due to dangerous side effects such as <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4922	 <e1>lactic acidosis</e1> (MALA) is a serious metabolic complication that occurs because of <e2>metformin</e2> accumulation in patients who become dehydrated or developed acute renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4923	 -associated <e2>lactic acidosis</e2> (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4924	 -associated <e2>lactic acidosis</e2> precipitated by diarrhea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4925	 apparent link is described between the use of <e1>MMF</e1> with prednisone to treat pemphigus vulgaris and the development of <e2>red blood cell anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4926	 apparent link is described between the use of MMF with <e1>prednisone</e1> to treat pemphigus vulgaris and the development of <e2>red blood cell anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4927	 blood cell anemia</e1> in a patient with pemphigus vulgaris induced by the use of <e2>mycophenolate mofetil</e2> and prednisone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4928	 blood cell anemia</e1> in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4929	 dermatology literature heretofore has not noted that <e1>anemia</e1> is a side effect of patients taking <e2>MMF</e2> to treat pemphigus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4930	 report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, <e2>cyclosporine</e2> and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4931	 report suggests that <e1>anemia</e1> can occur due to <e2>MMF</e2>, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of <e2>MMF</e2>, cyclosporine and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4932	 report suggests that <e1>anemia</e1> can occur due to <e2>MMF</e2>, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of <e2>MMF</e2>, cyclosporine and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4933	 report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with <e2>prednisone</e2>, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and <e2>prednisone</e2> is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4934	 report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with <e2>prednisone</e2>, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and <e2>prednisone</e2> is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4935	 search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of <e1>oxcarbazepine</e1> -associated <e2>angioedema</e2> in pediatric patients aged 16 years and younger."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4936	 profile of <e1>oxcarbazepine</e1> -related <e2>angioneurotic edema</e2>: case report and review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4937	 -associated <e2>angioedema</e2> manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4938	 describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced <e1>angioedema</e1> during treatment with <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4939	 we describe another case of <e1>VOD</e1> occurring after LT, but in which the causative role was played by <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4940	 case of <e1>tacrolimus</e1> -induced <e2>hepatic VOD</e2> developing after lung transplantation (LT) has been recently reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4941	 <e2>hypersensitivity syndrome</e2> is a rare, life-threatening condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4942	 patient with chronic myelomonocytic leukemia developed drug-induced <e1>pulmonary toxicity</e1> after using low dose oral <e2>etoposide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4943	 <e1>etoposide</e1> -induced <e2>pulmonary toxicity</e2> is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4944	 scintigraphy of <e1>etoposide</e1> -induced <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4945	 of antineutrophil cytoplasmic antibody in a patient with <e1>L-tryptophan</e1> induced <e2>eosinophilia-myalgia syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4946	 Center for Disease Control has received numerous reports of an <e1>eosinophilia-myalgia syndrome</e1> related to products containing <e2>L-tryptophan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4947	 we report a case of <e1>RFP</e1> -induced <e2>hypothyroidism</e2> without underlying thyroid disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4948	 -induced <e2>hypothyroidism</e2> without underlying thyroid disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4949	 (<e1>RFP</e1>) increases hepatic microsomal enzyme activity, and there are case reports of <e1>RFP</e1> -induced hypothyroidism, all associated with <e2>Hashimoto's thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4950	 (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with <e2>Hashimoto's thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4951	 (<e1>RFP</e1>) increases hepatic microsomal enzyme activity, and there are case reports of <e1>RFP</e1> -induced <e2>hypothyroidism</e2>, all associated with Hashimoto's thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4952	 (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced <e2>hypothyroidism</e2>, all associated with Hashimoto's thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4953	 patient is described who developed a rapid onset of <e1>pulmonary fibrosis</e1> following treatment with a new non-steroidal anti-inflammatory drug, <e2>nabumetone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4954	 fibrosis</e1> associated with <e2>nabumetone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4955	 is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4956	 is a potent inhibitor of <e1>simvastatin</e1> metabolism, and may therefore facilitate <e1>simvastatin</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4957	 of simvastatin and <e1>cyclosporine</e1> resulted in resolution of <e2>rhabdomyolysis</e2> and normalization of renal function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4958	 of <e1>simvastatin</e1> and cyclosporine resulted in resolution of <e2>rhabdomyolysis</e2> and normalization of renal function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4959	 <e1>rhabdomyolysis</e1> following <e2>cyclosporine</e2> treatment for uveitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4960	 -induced <e2>rhabdomyolysis</e2> following cyclosporine treatment for uveitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4961	 lichen nitidus</e1> with involvement of the palms following <e2>interferon alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4962	 we present the case of a <e1>generalized lichen nitidus</e1> with involvement of the palms in a patient with hepatitis C after systemic treatment with <e2>interferon alpha</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4963	 we present the case of a <e1>generalized lichen nitidus</e1> with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4964	 is tempting to speculate that <e1>interferon alpha</e1> may be involved in the pathogenesis of <e2>lichen nitidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4965	 stent thrombosis</e1> several years after <e2>clopidogrel</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4966	 of APL in pregnancy is controversial as the use of <e1>ATRA</e1> has been questioned due to the <e2>teratogenic effect</e2> of retinoids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4967	 lung disease (<e1>ILD</e1>) related to therapy with the drug <e2>gefitinib</e2> has been well reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4968	 lung disease</e1> (ILD) related to therapy with the drug <e2>gefitinib</e2> has been well reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4969	 toxicity</e1> associated with <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4970	 to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known <e1>pulmonary fibrosis</e1> may be at particular risk for <e2>erlotinib</e2> pulmonary toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4971	 to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for <e1>erlotinib</e1> <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4972	 case and other published evidence should alert physicians to the possibility of fatal <e1>erlotinib</e1> -induced <e2>ILD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4973	 report a case of <e1>fatal pulmonary toxicity</e1> in a patient with advanced non-small cell lung cancer who received <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4974	 has been reported that <e1>fluoroquinolone</e1> antimicrobials prolong the corrected QT interval but rarely cause <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4975	 de pointes</e1> associated with <e2>moxifloxacin</e2>: a rare but potentially fatal adverse event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4976	 To report three cases of extensive <e1>skin necrosis</e1> in cirrhotic patients treated with the vasoconstrictor agent terlipressin (<e2>Glypressin</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4977	 To report three cases of extensive <e1>skin necrosis</e1> in cirrhotic patients treated with the vasoconstrictor agent <e2>terlipressin</e2> (Glypressin)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4978	 <e1>colchicine</e1> and statin therapy may be associated with <e2>myopathy</e2>, which usually occurs after several months of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4979	 colchicine and <e1>statin</e1> therapy may be associated with <e2>myopathy</e2>, which usually occurs after several months of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4980	 onset of <e1>muscle weakness</e1> (rhabdomyolysis) associated with the combined use of simvastatin and <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4981	 onset of <e1>muscle weakness</e1> (rhabdomyolysis) associated with the combined use of <e2>simvastatin</e2> and colchicine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4982	 onset of muscle weakness (<e1>rhabdomyolysis</e1>) associated with the combined use of simvastatin and <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4983	 onset of muscle weakness (<e1>rhabdomyolysis</e1>) associated with the combined use of <e2>simvastatin</e2> and colchicine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4984	 concomitant use, however, of <e1>colchicine</e1> and statin has been associated with the rapid onset of <e2>muscle weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4985	 concomitant use, however, of colchicine and <e1>statin</e1> has been associated with the rapid onset of <e2>muscle weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4986	 report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed <e1>acute weakness</e1> within 3 weeks after the start of treatment with <e2>colchicine</e2> for acute gouty bursitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4987	 report a case of a patient with mild chronic renal insufficiency who had been taking <e1>simvastatin</e1> for over a year and developed <e2>acute weakness</e2> within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4988	 report a case of a patient with <e1>mild chronic renal insufficiency</e1> who had been taking <e2>simvastatin</e2> for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4989	 carinii pneumonia</e1> as a complication of <e2>methotrexate</e2> treatment of asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4990	 pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with <e2>fever</e2>, pulmonary infiltrates, and hypoxia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4991	 pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with fever, pulmonary infiltrates, and <e2>hypoxia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4992	 pneumonia</e1> should be considered in asthmatic patients taking <e2>methotrexate</e2> who present with fever, pulmonary infiltrates, and hypoxia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4993	 pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with fever, <e2>pulmonary infiltrates</e2>, and hypoxia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4994	 REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a <e1>unilateral hearing loss</e1> shortly after commencing <e2>desferrioxamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-

4995	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), <e2>abdominal sepsis</e2> (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4996	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), <e2>cellulitis</e2> (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4997	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), <e2>disseminated herpes zoster</e2> (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4998	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and <e2>gastroenteritis</e2> (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

4999	 patients developed <e1>infection</e1> requiring hospitalization while taking <e2>leflunomide</e2> including: lower respiratory tract <e1>infection</e1>s (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5000	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: <e2>lower respiratory tract infections</e2> (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5001	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), <e2>mycotic aneurysm</e2> (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5002	 patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable <e2>TB liver</e2> (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5003	 -associated <e2>infections</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5004	 NZ Pharmacovigilance Centre has received 7 additional reports of <e1>severe infections</e1> in patients with RA taking <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5005	 58-year-old woman with rheumatoid arthritis (RA) developed <e1>fever</e1>, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5006	 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, <e1>leukocytopenia</e1>, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5007	 58-year-old woman with rheumatoid arthritis (RA) developed fever, <e1>skin eruptions</e1>, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5008	 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and <e1>thrombocytopenia</e1>, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5009	 -induced hypersensitivity syndrome and <e2>hemophagocytic syndrome</e2> associated with reactivation of Epstein-Barr virus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5010	 -induced <e2>hypersensitivity syndrome</e2> and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5011	 case illustrates that the <e1>hemophagocytic syndrome</e1> associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5012	 goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (OXC), as part of a switch off from <e2>carbamazepine</e2> (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5013	 goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (<e2>CBZ</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5014	 goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (<e2>OXC</e2>), as part of a switch off from carbamazepine (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5015	 goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of <e2>oxcarbazepine</e2> (OXC), as part of a switch off from carbamazepine (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5016	 <e1>headache</e1> induced by <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5017	 A patient with CHF and ESRD developed <e1>myoclonic muscle spasms</e1> after receiving <e2>dobutamine</e2> by continuous i.v. infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5018	 associated with continuous <e2>dobutamine</e2> infusion in a patient with end-stage renal disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5019	 The occurrence of <e1>myoclonus</e1> associated with continuous i.v. infusion of <e2>dobutamine</e2> in a patient with end-stage renal disease (ESRD) is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5020	 of <e1>colonic perforation</e1> as a result of the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5021	 of <e1>colonic perforation</e1> as a result of the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2> are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5022	 concluded that the <e1>colonic ulcer</e1> and the sigmoidovesical fistula had been caused by the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5023	 concluded that the <e1>colonic ulcer</e1> and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5024	 concluded that the colonic ulcer and the <e1>sigmoidovesical fistula</e1> had been caused by the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5025	 concluded that the colonic ulcer and the <e1>sigmoidovesical fistula</e1> had been caused by the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5026	 in a 12-year-old HIV-positive girl with an increased serum concentration of <e2>efavirenz</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5027	 report (to our knowledge, for the first time in a child) the emergence of <e1>psychosis</e1> in a 12-year old white girl with an increased <e2>efavirenz</e2> concentration and heterozygous gene polymorphism of the CYP2B6-G516T."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5028	 marinum infection</e1> complicating Crohn's disease, treated with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5029	 monomorphic ventricular tachycardia</e1> after <e2>adenosine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5030	 present a case of a <e1>sustained monomorphic ventricular tachycardia</e1> following <e2>adenosine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5031	 we found that three patients appeared to develop <e1>tardive OGC</e1> while taking <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5032	 oculogyric crisis</e1> during treatment with <e2>clozapine</e2>: report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5033	 <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5034	 patients are described who developed <e1>sensory neuropathy</e1> after the ingestion of 30.6 and 114 g <e2>metronidazole</e2> respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5035	 report a case of a patient with rheumatoid arthritis treated with low-dose <e1>methotrexate</e1> (15 mg/week) who developed <e2>infection with both M. tuberculosis and M. chelonae</e2> after the revision of a prosthetic hip."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5036	 <e1>Sustained ventricular tachycardia</e1> possibly owing to <e2>thalidomide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5037	 syncopal episodes</e1> started to occur during <e2>thalidomide</e2> treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5038	 syncopal episodes started to occur during <e1>thalidomide</e1> treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of <e2>sustained ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5039	 ventricular tachycardia</e1> in a <e2>thalidomide</e2> -treated patient with primary plasma-cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5040	 patient developed typical <e1>ECM</e1> after subcutaneous selfinjection of <e2>glatiramer acetate</e2> for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5041	 cutis medicamentosa</e1> following subcutaneous injection of <e2>glatiramer acetate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5042	 case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) <e1>glatiramer acetate</e1> can induce <e2>skin necrosis</e2> as a side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5043	 it is difficult to be certain of the direct link of <e1>amiodarone</e1> on the basis of a single case, it is reasonable to presume that this histopathology is associated with <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2> and that involution changes represent the hypofunctional status of this drug-induced disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5044	 is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause <e2>thyroid dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5045	 of the thyroid in <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5046	 is the first report on the histopathological findings of thyroid tissue from a patient with <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5047	 adverse effects are usually mild, the author reports here a case of <e1>leucocytopenia</e1> and thrombocytopenia with <e2>quetiapine</e2> treatment that required its discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5048	 adverse effects are usually mild, the author reports here a case of leucocytopenia and <e1>thrombocytopenia</e1> with <e2>quetiapine</e2> treatment that required its discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5049	 -induced <e2>leucopenia</e2> and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5050	 -induced leucopenia and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5051	 B</e1> -induced <e2>cutaneous leucocytoclastic vasculitis</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5052	 purpuric skin lesions</e1> on the anterior surface of both legs appeared on the 55th day of <e2>amphotericin B</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5053	 present a case of <e1>cutaneous leucocytoclastic vasculitis</e1> in which <e2>amphotericin B</e2> might presumably be the aetiological factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5054	 incidence of <e1>5-fluorouracil</e1> (5-FU)-related <e2>cardiotoxicity</e2> seems to be dosage and schedule dependent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5055	 incidence of 5-fluorouracil (<e1>5-FU</e1>)-related <e2>cardiotoxicity</e2> seems to be dosage and schedule dependent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5056	 asymptomatic bradycardia</e1> in patients on infusional <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5057	 report such a series of patients who had <e1>transient asymptomatic bradycardia</e1> after being treated with continuous infusion <e2>5-FU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5058	 to the Naranjo probability scale, the <e1>papular eruption</e1> was probably caused by <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5059	 The pathogenesis of <e1>methotrexate</e1> -induced <e2>papular eruption</e2> in collagen vascular diseases may suggest cutaneous small-vessel vasculitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5060	 <e1>Methotrexate</e1> -induced <e2>papular eruption</e2> is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5061	 -induced <e2>papular eruption</e2> following treatment of psoriasis has not been previously reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5062	 -induced <e2>papular eruption</e2> following treatment of psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5063	 To report a case of a <e1>diffuse papular eruption</e1> following treatment of psoriasis with <e2>methotrexate</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5064	 of <e1>methotrexate</e1> -induced papular eruption in psoriasis may involve immune mechanisms other than those of <e1>methotrexate</e1> -induced <e2>cutaneous vasculitis</e2> in collagen vascular disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5065	 of <e1>methotrexate</e1> -induced <e2>papular eruption</e2> in psoriasis may involve immune mechanisms other than those of <e1>methotrexate</e1> -induced cutaneous vasculitis in collagen vascular disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5066	 hours after the second <e1>methotrexate</e1> injection, the patient experienced a <e2>diffuse pruritic papular eruption</e2> located mainly on the limbs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5067	 acidosis</e1> induced by <e2>acetazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5068	 hemorrhage</e1> due to <e2>acetylsalicylic acid</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5069	 authors describe <e1>pericardial hemorrhage</e1>, which is related to the use of low-dose <e2>acetylsalicylic acid</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5070	 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), <e1>nelfinavir</e1> (<e2>cutaneous rash</e2>), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5071	 1996 to 2002 several medications were changed due to their adverse effects: <e1>indinavir</e1> (renal colic and <e2>fever</e2>), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5072	 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and <e1>efavirenz</e1> (<e2>nausea</e2> and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5073	 1996 to 2002 several medications were changed due to their adverse effects: <e1>indinavir</e1> (<e2>renal colic</e2> and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5074	 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and <e1>efavirenz</e1> (nausea and <e2>temporary memory loss</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5075	 and diffusion-weighted MRI findings of <e1>methotrexate</e1> related <e2>sub-acute neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5076	 case demonstrates the value of DWI in evaluation and diagnosis of <e1>sub-acute toxic leukoencephalopathy</e1> in patients being treated with <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5077	 describe longitudinal diffusion-weighted MRI findings of <e1>sub-acute leukoencephalopathy</e1> following <e2>methotrexate</e2> therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5078	 onset of <e1>CD</e1> may be considered as an immune-mediated injury induced by <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5079	 onset of CD may be considered as an <e1>immune-mediated injury</e1> induced by <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5080	 onset of <e1>Crohn's disease</e1> during treatment of active ankylosing spondylitis with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5081	 symptoms of active <e1>CD</e1> occurred 11, 12, and 26 months after start of <e2>etanercept</e2> therapy, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5082	 describe 3 AS patients treated with <e1>etanercept</e1> for active AS who developed new onset of <e2>CD</e2> while AS related symptoms responded well to <e1>etanercept</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5083	 gastrointestinal haemorrhage</e1> is a serious complication of <e2>aspirin</e2> and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5084	 gastrointestinal haemorrhage</e1> is a serious complication of aspirin and <e2>clopidogrel</e2> (dual) anti-platelet therapy with a high morbidity and mortality."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5085	 <e1>doxorubicin</e1> was administered, the patient presented thoracic pain and <e2>breathing distress</e2> due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5086	 <e1>doxorubicin</e1> was administered, the patient presented <e2>thoracic pain</e2> and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5087	 hepatocellular dysfunction</e1> following <e2>cyproterone acetate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5088	 report 3 patients with severe hepatocellular damage due to <e1>CPA</e1> therapy, 2 with <e2>fatal fulminant hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5089	 report 3 patients with <e1>severe hepatocellular damage</e1> due to <e2>CPA</e2> therapy, 2 with fatal fulminant hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5090	 was treated with <e1>acyclovir</e1> and subsequently developed <e2>VZV antigen-positive zoster</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5091	 to the Naranjo adverse drug reaction probability scale, the likelihood that <e1>temozolomide</e1> was responsible for the adverse drug reaction of <e2>fever</e2> was probable (score of 6)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5092	 should be aware that an erythematous and <e1>exfoliative rash</e1> may be induced by <e2>temozolomide</e2>, and be familiar with the pharmacologic and supportive measures necessary for its treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5093	 to the severity of the <e1>rash</e1>, <e2>temozolomide</e2> was permanently discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5094	 -induced <e2>desquamative skin rash</e2> in a patient with metastatic melanoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5095	 was restarted 2 months later; the patient again developed a <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5096	 dermatitis</e1> secondary to <e2>tobramycin sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5097	 report a case of <e1>exfoliative dermatitis</e1> clearly linked to intravenous and intraperitoneal administration of <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5098	 induced <e2>interstitial pneumonitis</e2> in patients with disseminated extranodal marginal zone B cell lymphoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5099	 toxicity: an easily missed cause of <e2>cerebellar syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5100	 diagnosis of <e1>trastuzumab</e1> -induced <e2>pneumonitis</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5101	 female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a <e1>plural effusion dyspnoea</e1> after several months of <e2>trastuzumab</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5102	 female patient with HER2 positive, metastatic breast cancer presented with <e1>pulmonary infiltrates</e1>, and a plural effusion dyspnoea after several months of <e2>trastuzumab</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5103	 <e1>interstitial lung disease</e1> associated with <e2>trastuzumab</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5104	 30-year-old pharmacist suffered from <e1>acute allergic contact dermatitis</e1> due to <e2>4-chloro-7-nitrobenzofurazan</e2> (NBD-Cl)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5105	 30-year-old pharmacist suffered from <e1>acute allergic contact dermatitis</e1> due to 4-chloro-7-nitrobenzofurazan (<e2>NBD-Cl</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5106	 contact dermatitis</e1> from <e2>4-chloro-7-nitrobenzofurazan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5107	 caused by olanzapine and <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5108	 caused by <e2>olanzapine</e2> and aripiprazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5109	 report the case of a woman who developed <e1>photo-onycholysis</e1> on multiple nails after uptake of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5110	 alveolar hemorrhage</e1> after <e2>leflunomide</e2> therapy in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5111	 report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, <e1>hemoptysis</e1>, and severe weakness, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5112	 report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and <e1>severe weakness</e1>, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5113	 report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset <e1>short-of-breath</e1>, hemoptysis, and severe weakness, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5114	 developed after rechallenge with controlled release <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5115	 during low-dose <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5116	 report the syndrome of inappropriate <e1>antidiuresis</e1> as a much earlier side-effect of <e2>carbamazepine</e2> administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5117	 the present paper, we describe two patients with active UC who developed a <e1>severe systemic CMV infection</e1> during a treatment with an oral microemulsion form of <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5118	 short review on <e1>imatinib</e1> -related <e2>hepatotoxicity</e2> is also presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5119	 mesylate</e1> -related <e2>fatal acute hepatic failure</e2> in a patient with chronic myeloid leukaemia and chronic hepatitis B infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5120	 to four percent of patients treated with <e1>imatinib</e1> may develop <e2>hepatotoxicity</e2>, which usually resolves with discontinuation of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5121	 report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on <e1>imatinib</e1> treatment, presenting with herpetic rash and <e2>acute liver failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5122	 report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on <e1>imatinib</e1> treatment, presenting with <e2>herpetic rash</e2> and acute liver failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5123	 Clinicians treating elderly patients with <e1>olanzapine</e1> should be aware of the potential for rapidly developing <e2>hyperglycemia</e2> and monitor such patients accordingly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5124	 To report a case of rapidly occurring <e1>hyperglycemia</e1> that occurred in a geriatric patient 3 days after treatment with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5125	 developing <e1>hyperglycemia</e1> during treatment with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5126	 he developed <e1>hyperglycemia</e1> (fasting blood glucose 138 mg/dL) that resolved when <e2>olanzapine</e2> was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with <e2>olanzapine</e2> 2.5 mg twice daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5127	 have been numerous case reports of <e1>hyperglycemia</e1> with <e2>olanzapine</e2> in the literature, but none reported <e1>hyperglycemia</e1> within days of initiation of the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5128	 respiratory distress syndrome</e1> after treatment with <e2>pegylated interferon alpha-2a</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5129	 respiratory distress syndrome</e1> after treatment with pegylated interferon alpha-2a and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5130	 report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with pegylated interferon alpha-2a (<e2>pegIFNalpha-2a</e2>) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5131	 report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with <e2>pegylated interferon alpha-2a</e2> (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5132	 report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and <e2>ribavirin</e2> use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5133	 report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with pegylated interferon alpha-2a (<e2>pegIFNalpha-2a</e2>) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5134	 report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with <e2>pegylated interferon alpha-2a</e2> (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5135	 report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and <e2>ribavirin</e2> use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5136	 anterior uveitis</e1> associated with <e2>clomiphene citrate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5137	 To report a case of <e1>bilateral anterior uveitis</e1> associated with ovulation induction therapy using <e2>clomiphene citrate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5138	 of <e1>tics</e1> in a thirteen-year-old male following <e2>atomoxetine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5139	 are, however, case studies describing patients experiencing recurrences of <e1>tics</e1> following treatment with <e2>atomoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5140	 51-year-old man developed <e1>type 1 diabetes mellitus</e1> following 24 weeks of treatment with recombinant <e2>alpha-2b peginterferon</e2> plus ribavirin for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5141	 51-year-old man developed <e1>type 1 diabetes mellitus</e1> following 24 weeks of treatment with recombinant alpha-2b peginterferon plus <e2>ribavirin</e2> for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5142	 clinical course suggested that <e1>recombinant alpha-2b peginterferon</e1> plus ribavirin provoked <e2>type 1 diabetes mellitus</e2>, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5143	 clinical course suggested that recombinant alpha-2b peginterferon plus <e1>ribavirin</e1> provoked <e2>type 1 diabetes mellitus</e2>, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5144	 1 diabetes mellitus</e1> provoked by <e2>peginterferon alpha-2b</e2> plus ribavirin treatment for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5145	 1 diabetes mellitus</e1> provoked by peginterferon alpha-2b plus <e2>ribavirin</e2> treatment for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5146	 To describe the occurrence of <e1>ocular hypertension</e1> in four patients following injection of <e2>ranibizumab</e2> intravitreally."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5147	 Severe and <e1>sustained ocular hypertension</e1> may occur after intravitreal <e2>ranibizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5148	 hypertension</e1> occurred 1 month after the second <e2>ranibizumab</e2> injection in patients 1 and 3, and 1 month after the first <e2>ranibizumab</e2> in patient 2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5149	 ocular hypertension</e1> following intravitreal <e2>ranibizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5150	 and <e1>dextroamphetamine</e1> -induced <e2>peripheral vasculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5151	 and dextroamphetamine-induced <e2>peripheral vasculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5152	 report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with <e2>acral cyanosis</e2>, livedo reticularis, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5153	 report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with <e2>acral cyanosis</e2>, livedo reticularis, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5154	 report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with acral cyanosis, <e2>livedo reticularis</e2>, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5155	 report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with acral cyanosis, <e2>livedo reticularis</e2>, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5156	 report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with acral cyanosis, livedo reticularis, or <e2>Raynaud phenomenon</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5157	 report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or <e2>Raynaud phenomenon</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5158	 eruptive giant mollusca contagiosa</e1> in an adult psoriasis patient during <e2>efalizumab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5159	 report a 45-year-old psoriasis patient who developed <e1>eruptive mollusca contagiosa</e1> during an antipsoriatic treatment with <e2>efalizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5160	 tumor, endometrial carcinoma and <e1>cervical adenocarcinoma</e1> in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5161	 tumor, <e1>endometrial carcinoma</e1> and cervical adenocarcinoma in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5162	 tumor</e1>, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5163	 posterior hyaloid detachment</e1> after intravitreal <e2>pegaptanib</e2> injection in diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5164	 authors report one case of <e1>incomplete posterior hyaloid detachment</e1> (PHD) following intravitreal <e2>pegaptanib</e2> to treat DME."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5165	 induced <e2>acute parotitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5166	 present here a female patient who developed <e1>acute bilateral parotitis</e1> within minutes of i.v. <e2>enalaprilat</e2> injection and recovered within 24 hours of stopping the drug and with symptomatic treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5167	 report a 4-year-old girl who presented with <e1>acute bilateral blindness</e1>, a focal seizure and hypertension 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5168	 report a 4-year-old girl who presented with acute bilateral blindness, a <e1>focal seizure</e1> and hypertension 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5169	 report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and <e1>hypertension</e1> 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5170	 symptomatic hyponatremia</e1> during <e2>sibutramine</e2> therapy: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5171	 known side effects of <e1>sibutramine</e1>, ie, <e2>hypertension</e2> and tachycardia, depend on its adrenergic and serotoninergic effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5172	 known side effects of <e1>sibutramine</e1>, ie, hypertension and <e2>tachycardia</e2>, depend on its adrenergic and serotoninergic effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5173	 describe a case of life-threatening <e1>hyponatremia</e1> associated with <e2>sibutramine</e2> use in an obese woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5174	 findings reveal that even in patients without a history of seizures, <e1>pregabalin</e1> can cause a <e2>cortical negative myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5175	 -induced <e2>cortical negative myoclonus</e2> in a patient with neuropathic pain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5176	 describe a patient who, after receiving his first dose of <e1>pregabalin</e1> to relieve neuropathic pain, presented with a <e2>negative myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5177	 -induced <e2>severe neuromyeloencephalopathy</e2>: report of seven cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5178	 report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic <e1>muzolimine</e1> (range 240 to 1440 mg per day) <e2>fatal neuromyeloencephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5179	 -induced <e2>posterior reversible encephalopathy</e2> syndrome during acute lymphoblastic leukemia treatment in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5180	 purpose of this article is to present the first case-series of <e1>posterior reversible encephalopathy syndrome</e1> (PRES) associated with <e2>L-asparaginase</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5181	 purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (<e1>PRES</e1>) associated with <e2>L-asparaginase</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5182	 report 3 cases of children with acute lymphoblastic leukemia who developed seizures and <e1>altered sensorium</e1> after <e2>L-asparaginase</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5183	 report 3 cases of children with acute lymphoblastic leukemia who developed <e1>seizures</e1> and altered sensorium after <e2>L-asparaginase</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5184	 -associated <e2>sclerosing glomerulonephritis</e2> in a patient with breast cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5185	 <e1>Anastrozole</e1> may be the causative factor in patients with <e2>sclerosing glomerulonephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5186	 of <e1>sclerosing glomerulonephritis</e1> occurred in this patient during <e2>anastrozole</e2> use, suggesting a newly defined side effect of <e2>anastrozole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5187	 injury</e1> due to <e2>anastrozole</e2> has not been published in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5188	 are major side effects of <e1>anastrozole</e1> including <e2>decrease in both lumbar spine</e2> and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5189	 are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and <e2>increase in the cholesterol level</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5190	 are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, <e2>increase in the incidence of all bone fractures</e2> (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5191	 are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), <e2>joint disorders</e2> and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5192	 believe that the <e1>acute renal failure</e1> in our patient was associated with <e2>anastrozole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5193	 SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed <e1>acute hepatitis</e1> one week after the final dose of a long-term course of pulse <e2>itraconazole</e2> therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis."
DRUG-ADE(e2,e1)
Comment: DRUG-

5194	 Prolonged exposure to <e1>itraconazole</e1>, administered either continuously or intermittently, may precipitate <e2>severe and irreversible hepatotoxic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5195	 hepatitis</e1> after long-term pulse <e2>itraconazole</e2> treatment for onychomycosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5196	 To report the occurrence of <e1>acute cytolytic hepatitis</e1> in a patient exposed to pulse <e2>itraconazole</e2> therapy for 24 weeks and provide a concise review of the literature on cases of <e2>itraconazole</e2> -induced hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5197	 To report the occurrence of acute cytolytic <e1>hepatitis</e1> in a patient exposed to pulse <e2>itraconazole</e2> therapy for 24 weeks and provide a concise review of the literature on cases of <e2>itraconazole</e2> -induced <e1>hepatitis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5198	 one case of <e1>severe symptomatic hepatitis</e1> occurring after pulse therapy with <e2>itraconazole</e2> for onychomycosis and requiring transplantation has been reported previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5199	 Intrathecal <e1>baclofen</e1> can <e2>impair sexual function</e2> and ejaculation in some patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5200	 A male and a female patient with spasticity treated with intrathecal <e1>baclofen</e1> were recognized to have <e2>sexual dysfunction</e2> side effects from treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5201	 dysfunction</e1> associated with intrathecal <e2>baclofen</e2> use: a report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5202	 reaction</e1> to <e2>recombinant insulin-like growth factor-I</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5203	 report a 13 year-old male who developed life-threatening <e1>anaphylaxis</e1> early in the course of <e2>Increlex</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5204	 the <e1>olanzapine</e1> dosage severely aggravated the symptoms of <e2>RLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5205	 legs syndrome and <e1>periodic limb movements during sleep</e1> probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5206	 legs syndrome</e1> and periodic limb movements during sleep probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5207	 fifth patient exhibited paraesthesia and <e1>agitation</e1> caused by <e2>olanzapine</e2> that was misdiagnosed as psychotic <e1>agitation</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5208	 fifth patient exhibited <e1>paraesthesia</e1> and agitation caused by <e2>olanzapine</e2> that was misdiagnosed as psychotic agitation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5209	 fourth patient showed <e1>RLS symptoms</e1> that were initially caused by a 20-mg daily <e2>olanzapine</e2> dosage and were later mitigated when <e2>olanzapine</e2> was reduced and ropinirole was administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5210	 second patient exhibited sudden <e1>PLMS</e1> following <e2>olanzapine</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5211	 third patient had been suffering from serious <e1>akathisia</e1> while on risperidone, and was cured after switching to <e2>olanzapine</e2>, but thereafter the patient suffered from RLS at nighttime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5212	 third patient had been suffering from serious <e1>akathisia</e1> while on <e2>risperidone</e2>, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5213	 third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to <e1>olanzapine</e1>, but thereafter the patient suffered from <e2>RLS</e2> at nighttime."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5214	 third patient had been suffering from serious akathisia while on <e1>risperidone</e1>, and was cured after switching to olanzapine, but thereafter the patient suffered from <e2>RLS</e2> at nighttime."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5215	 report five cases of restless legs syndrome (RLS) and <e1>periodic limb movements during sleep</e1> (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5216	 report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (<e1>PLMS</e1>) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5217	 report five cases of <e1>restless legs syndrome</e1> (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5218	 report five cases of restless legs syndrome (<e1>RLS</e1>) and periodic limb movements during sleep (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5219	 <e1>Alendronate</e1> led to <e2>nodular scleritis</e2> and rechallenge caused recurrence of scleritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5220	 <e1>Alendronate</e1> led to nodular <e2>scleritis</e2> and rechallenge caused recurrence of <e2>scleritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5221	 scleritis</e1> following <e2>alendronate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5222	 To report a case of <e1>nodular scleritis</e1> following <e2>alendronate sodium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5223	 weeks following rechallenge with <e1>alendronate sodium</e1> resulted in recurrence of his <e2>scleritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5224	 addition, there is a report on <e1>prolonged ECT seizure</e1> related to <e2>ciprofloxacin</e2>, which has an epileptogenic property with a similar action to beta-lactam antibiotics."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5225	 <e1>tardive seizures</e1> in our cases are thought to be related to piperacillin and <e2>cefotiam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5226	 <e1>tardive seizures</e1> in our cases are thought to be related to <e2>piperacillin</e2> and cefotiam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5227	 delirium</e1> resulting from <e2>levofloxacin</e2> therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5228	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5229	 The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5230	 The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5231	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5232	 The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5233	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5234	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5235	 The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5236	 The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5237	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5238	 The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5239	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5240	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5241	 The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5242	 The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5243	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5244	 The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5245	 The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5246	 we describe <e1>levofloxacin</e1> -induced <e2>delirium with psychotic features</e2> in a relatively young, otherwise healthy female."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5247	 -induced <e2>delirium with psychotic features</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5248	 A previously healthy 42-year-old woman presented with <e1>acute-onset delirium with psychotic features</e1> as a consequence of <e2>levofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5249	 Clinicians should be aware that <e1>Crohn's disease</e1> is a potential novel adverse drug effect of <e2>Copaxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5250	 of <e1>Crohn's disease</e1> in a patient with multiple sclerosis treated with <e2>copaxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5251	 Our patient developed <e1>Crohn's disease</e1> while on <e2>Copaxone</e2> treatment as a consequence of long-term immunosuppression."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5252	 Our patient developed Crohn's disease while on <e1>Copaxone</e1> treatment as a consequence of <e2>long-term immunosuppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5253	 had been on <e1>Copaxone</e1> 20 mg/day treatment for 2 years when she first exhibited <e2>gastrointestinal symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5254	 authors present a case study of a mentally healthy man who repeatedly experienced short-lived, <e1>obsessional-like suicidal ideas and images</e1> after ingestion of the anti-fungal drug <e2>ketoconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5255	 intravenous treatment with <e1>terlipressin</e1> for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly <e2>prolonged QT interval</e2> and torsade de pointes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5256	 intravenous treatment with <e1>terlipressin</e1> for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5257	 -induced <e2>ventricular arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5258	 nasal septal perforation</e1> with antiangiogenic <e2>bevacizumab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5259	 case describes a 52-year-old white woman who developed a <e1>spontaneous nasal septal perforation</e1> after given the antiangiogenic drug, <e2>bevacizumab</e2>, for metastatic ovarian cancer treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5260	 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous <e1>VRC</e1> and developed <e2>angio-oedema</e2> 10 days after starting therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5261	 as an unusual tolerable side effect of <e2>voriconazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5262	 we report a case of <e1>angio-oedema</e1> associated with <e2>VRC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5263	 our knowledge, this is the first report of an <e1>angio-oedema</e1> associated with <e2>VRC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5264	 (VRC) has not previously been reported to cause <e2>angio-oedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5265	 (<e1>VRC</e1>) has not previously been reported to cause <e2>angio-oedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5266	 seizures</e1> after <e2>bupropion</e2> overdose in a small child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5267	 patient experienced hallucinations, <e1>agitation</e1>, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5268	 patient experienced <e1>hallucinations</e1>, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5269	 patient experienced hallucinations, agitation, vomiting, tachycardia and <e1>seizures</e1> after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5270	 patient experienced hallucinations, agitation, vomiting, <e1>tachycardia</e1> and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5271	 patient experienced hallucinations, agitation, <e1>vomiting</e1>, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5272	 report a case of pediatric <e1>bupropion</e1> ingestion resulting in <e2>multiple seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5273	 -associated <e2>enuresis</e2> in attention deficit hyperactivity disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5274	 is a case report of possible association of <e1>methylphenidate</e1> and <e2>enuresis</e2> in an 11-year-old boy with attention deficit hyperactivity disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5275	 -induced <e2>leukopenia</e2> following rechallenge with cefoxitin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5276	 <e1>Cefazolin</e1> was a probable cause of this patient's <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5277	 To describe a case of <e1>cefazolin</e1> -induced <e2>leukopenia</e2> in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5278	 of the Naranjo probability scale determined the association between <e1>cephalosporin</e1> use and <e2>leukopenia</e2> to be probable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5279	 reversible encephalopathy syndrome (<e1>PRES</e1>) induced by <e2>cyclosporine</e2> use in a patient with collapsing focal glomeruloesclerosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5280	 reversible encephalopathy syndrome</e1> (<e2>PRES</e2>) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5281	 describe a case of <e1>PRES</e1> in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (<e2>CSA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5282	 describe a case of <e1>PRES</e1> in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of <e2>cyclosporine</e2> (CSA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5283	 priapism</e1> complicating <e2>warfarin</e2> therapy in a patient with protein C deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5284	 therapy was also complicated by <e1>Warfarin</e1> -induced <e2>skin necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5285	 report a rare case of recurrent (stuttering) <e1>priapism</e1> in a patient with protein C deficiency while maintained on <e2>Warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5286	 report a rare case of recurrent (<e1>stuttering</e1>) priapism in a patient with protein C deficiency while maintained on <e2>Warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5287	 patient expired after seven cycles of treatment had been completed because of <e1>pulmonary fibrosis</e1> and the drug toxicity of <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5288	 SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for <e1>mild cognitive impairment</e1>, had been taking <e2>propafenone</e2> 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects."
DRUG-ADE(e2,e1)
Comment: DRUG-

5289	 This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked <e2>coronary artery disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5290	 This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, dizziness, falls) and mimicked <e2>coronary artery disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5291	 This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, <e2>dizziness</e2>, falls) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5292	 This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, <e2>dizziness</e2>, falls) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5293	 This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, dizziness, <e2>falls</e2>) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5294	 This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, dizziness, <e2>falls</e2>) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5295	 months after starting <e1>citalopram</e1>, she experienced episodes of <e2>chest tightness</e2> and dizziness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5296	 months after starting <e1>citalopram</e1>, she experienced episodes of chest tightness and <e2>dizziness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5297	 Clinicians should be aware of this adverse reaction when facing similar complex <e1>neurologic symptoms</e1> in patients who are receiving the antibiotic treatment described here, especially <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5298	 To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, tobramycin, and <e2>piperacillin</e2>/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5299	 To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/<e2>tazobactam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5300	 To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, <e2>tobramycin</e2>, and piperacillin/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5301	 To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics <e2>vancomycin</e2>, tobramycin, and piperacillin/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5302	 and transient blindness following intravenous pulse <e2>methylprednisolone</e2> in children with primary glomerulonephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5303	 and <e1>transient blindness</e1> following intravenous pulse <e2>methylprednisolone</e2> in children with primary glomerulonephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5304	 children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of <e1>seizures</e1> and transient blindness at different times after i.v. pulse <e2>methylprednisolone</e2> (IVPMP) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5305	 children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and <e1>transient blindness</e1> at different times after i.v. pulse <e2>methylprednisolone</e2> (IVPMP) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5306	 <e1>Hydroxyurea</e1> is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with <e2>mucocutaneous adverse events</e2> and nail hyperpigmentation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5307	 <e1>Hydroxyurea</e1> is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and <e2>nail hyperpigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5308	 on the Naranjo algorithm, the adverse reaction observed was probably related to the <e1>hydroxyurea</e1> treatment (score = 6); however, the <e1>hydroxyurea</e1> chemotherapy could not be discontinued because of the <e2>myeloproliferative disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5309	 the <e1>longitudinal melanonychia</e1> and the multiple skin cancers first appeared after approximately 6 months of <e2>hydroxyurea</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5310	 the longitudinal melanonychia and the <e1>multiple skin cancers</e1> first appeared after approximately 6 months of <e2>hydroxyurea</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5311	 We report this case of the concomitant appearance of <e1>multiple skin cancers</e1> and nail changes associated with <e2>hydroxyurea</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5312	 We report this case of the concomitant appearance of multiple skin cancers and <e1>nail changes</e1> associated with <e2>hydroxyurea</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5313	 associated with concomitant occurrence of <e2>diffuse longitudinal melanonychia</e2> and multiple squamous cell carcinomas in an elderly subject."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5314	 associated with concomitant occurrence of diffuse longitudinal melanonychia and <e2>multiple squamous cell carcinomas</e2> in an elderly subject."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5315	 The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and <e1>diffuse nail hyperpigmentation</e1> associated with <e2>hydroxyurea</e2> treatment, and to describe a successful therapeutic approach using imiquimod 5%."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5316	 The purpose of this study was to report the concomitant occurrence of <e1>multiple squamous cell carcinomas</e1> and diffuse nail hyperpigmentation associated with <e2>hydroxyurea</e2> treatment, and to describe a successful therapeutic approach using imiquimod 5%."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5317	 patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a <e1>painful hand ulcer</e1>, possibly associated with the <e2>hydroxyurea</e2>, and new skin cancers were observed at the last follow-up visit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5318	 patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the <e1>hydroxyurea</e1>, and new <e2>skin cancers</e2> were observed at the last follow-up visit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5319	 is the first case of <e1>ciprofloxacin</e1> -induced <e2>VBDS</e2> successfully treated with tacrolimus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5320	 bile duct and <e1>Stevens-Johnson syndrome</e1> associated with <e2>ciprofloxacin</e2> treated with tacrolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5321	 bile duct</e1> and Stevens-Johnson syndrome associated with <e2>ciprofloxacin</e2> treated with tacrolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5322	 report a case of a patient with <e1>ciprofloxacin</e1> -induced <e2>SJS</e2> and acute onset of VBDS, and reviewed the related literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5323	 report a case of a patient with <e1>ciprofloxacin</e1> -induced SJS and acute onset of <e2>VBDS</e2>, and reviewed the related literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5324	 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for <e1>intracranial bleeding</e1> while receiving <e2>aspirin</e2> and clopidogrel."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5325	 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for <e1>intracranial bleeding</e1> while receiving aspirin and <e2>clopidogrel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5326	 salmonellosis</e1> in a patient treated with <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5327	 describe the first case of <e1>disseminated salmonellosis</e1> in a patient treated with <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5328	 -induced <e2>fixed drug eruption</e2>: first report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5329	 from <e2>cephalosporins</e2> has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced <e1>FDE</e1> in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5330	 from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of <e2>ceftriaxone</e2> -induced <e1>FDE</e1> in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5331	 report the first case of a 54-year-old Turkish woman who presented with <e1>ceftriaxone</e1> -induced <e2>FDE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5332	 All doctors need to be aware of the need to review the indications for <e1>gabapentin</e1> use during periods of acute illness, especially with regard to <e2>renal impairment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5333	 toxicity in <e2>renal failure</e2>: the importance of dose adjustment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5334	 This case report outlines a significant type of morbidity due to continued use of <e1>gabapentin</e1> during an episode of <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5335	 syphilitic posterior placoid chorioretinitis</e1> following intravitreal <e2>triamcinolone acetonide</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5336	 We describe the ophthalmic features and clinical course of two cases of <e1>acute syphilitic posterior placoid chorioretinitis</e1> (ASPPC) that developed after intravitreal triamcinolone acetonide (<e2>IVTA</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5337	 We describe the ophthalmic features and clinical course of two cases of <e1>acute syphilitic posterior placoid chorioretinitis</e1> (ASPPC) that developed after intravitreal <e2>triamcinolone acetonide</e2> (IVTA) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5338	 We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (<e1>ASPPC</e1>) that developed after intravitreal triamcinolone acetonide (<e2>IVTA</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5339	 We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (<e1>ASPPC</e1>) that developed after intravitreal <e2>triamcinolone acetonide</e2> (IVTA) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5340	 The fundus picture shown in these cases may be typical of <e1>ASPPC</e1> after <e2>IVTA</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5341	 Two patients with ocular inflammation of unknown origin developed <e1>severe chorioretinitis</e1> after <e2>IVTA</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5342	 it is difficult to solely attribute <e1>intratumoral hemorrhage</e1> to <e2>aspirin</e2>, we have to be careful when prescribing <e2>aspirin</e2> for patients who have asymptomatic meningioma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5343	 from a falx meningioma after internal use of low-dose <e2>aspirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5344	 the other hand, <e1>aspirin</e1> may have promoted the <e2>enlargement of spontaneous hemorrhage</e2> from meningioma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5345	 case is the second one in which <e1>hemorrhage</e1> from a meningioma may have been induced by <e2>aspirin</e2> prophylaxis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5346	 report a case in which <e1>hemorrhage</e1> occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose <e2>aspirin</e2> for 16 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5347	 coronary syndromes</e1> can be associated with the infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5348	 coronary syndromes</e1> complicating the first infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5349	 aim of this study was to describe the occurrence of <e1>acute coronary syndromes</e1> in 3 cases of <e2>rituximab</e2> infusions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5350	 occurrence of symptoms that could be ascribed to an <e1>acute coronary syndrome</e1> should always be taken seriously during the first <e2>rituximab</e2> infusion and investigated aggressively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5351	 reviewed the records of 3 patients with lymphoproliferative disorders who experienced <e1>acute coronary syndromes</e1> associated with their initial infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5352	 This report describes a case of a probable interaction between topical econazole lotion 1% and <e1>acenocoumarol</e1> that resulted in overanticoagulation and a life-threatening <e2>laryngeal hematoma</e2> in this elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5353	 This report describes a case of a probable interaction between topical <e1>econazole</e1> lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening <e2>laryngeal hematoma</e2> in this elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5354	 dyspnea</e1> in relation to an interaction between <e2>acenocoumarol</e2> and topical econazole lotion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5355	 dyspnea</e1> in relation to an interaction between acenocoumarol and topical <e2>econazole</e2> lotion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5356	 suppression in a fetus</e1> due to administration of <e2>methylprednisolone</e2> has hitherto been rarely published."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5357	 Life-threatening <e1>adrenal suppression</e1>, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose <e2>methylprednisolone</e2> in late pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5358	 <e1>methylprednisolone</e1> in a pregnant woman with Crohn's disease and <e2>adrenal suppression</e2> in her newborn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5359	 10-year-old asthmatic boy began to suffer from urticarial rash and <e1>moderately severe bronchospasm</e1> after 8 weeks' treatment with <e2>disodium cromoglycate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5360	 10-year-old asthmatic boy began to suffer from <e1>urticarial rash</e1> and moderately severe bronchospasm after 8 weeks' treatment with <e2>disodium cromoglycate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5361	 and urticaria during <e2>disodium cromoglycate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5362	 and <e1>urticaria</e1> during <e2>disodium cromoglycate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5363	 <e1>DSCG</e1> was withdrawn, <e2>urticaria</e2> vanished and the child remained symptom-free."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5364	 the first oral dose of <e1>propranolol</e1>, syncope developed together with <e2>atrioventricular block</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5365	 the first oral dose of <e1>propranolol</e1>, <e2>syncope</e2> developed together with atrioventricular block."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5366	 induced by <e2>propranolol</e2> in hypertrophic cardiomyopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5367	 -induced <e2>hyperglycaemic coma</e2> and neuroleptic malignant syndrome: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5368	 -induced hyperglycaemic coma and <e2>neuroleptic malignant syndrome</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5369	 The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and <e2>allergic skin reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5370	 The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, hypertension, <e2>alopecia</e2>, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5371	 The main adverse effects of <e1>leflunomide</e1> consist of <e2>diarrhea</e2>, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5372	 The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, <e2>hypertension</e2>, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5373	 The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, <e2>liver enzyme elevation</e2>, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5374	 The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, <e2>nausea</e2>, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5375	 -induced <e2>toxic epidermal necrolysis</e2> in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5376	 this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), <e1>mediastinal lymphadenopathy</e1> and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5377	 this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and <e1>pleurisy</e1> associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5378	 this report we described a case of juvenile idiopathic arthritis patient who developed <e1>thymic enlargement</e1> (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5379	 this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true <e1>thymic hyperplasia</e1>), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5380	 enlargement</e1> in a patient with juvenile idiopathic arthritis during <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5381	 -induced Drug Reaction with Eosinophilia and Systemic Symptoms (<e2>DRESS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5382	 -induced <e2>Drug Reaction with Eosinophilia and Systemic Symptoms</e2> (DRESS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5383	 is an image and brief case report of a 13-year-old boy who presented with <e1>severe rash</e1> and systemic symptoms after starting <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5384	 treatment with a beta-sympathomimetic drug (<e1>Partusisten</e1>) one fetus developed <e2>supraventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5385	 eruption</e1> induced by <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5386	 aim of this paper is to report the case of <e1>rosaceiform eruption</e1> induced by <e2>erlotinib</e2> in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5387	 patients with <e1>methotrexate</e1> -induced <e2>anaphylaxis</e2>, discontinuation of treatment may increase the risk of death due to cancer progression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5388	 and successful desensitization in <e1>methotrexate</e1> -induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5389	 we confirm that desensitization may be a safe procedure in patients with cancer who experience <e1>methotrexate</e1> -induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5390	 report the case of a child with metastatic osteosarcoma, who experienced an <e1>anaphylactic/anaphylactoid reaction</e1> to <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5391	 <e1>fever</e1> due to <e2>diltiazem</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5392	 <e1>fever</e1> should be considered in patients who have unexplained high temperatures during <e2>diltiazem</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5393	 our knowledge, drug-induced <e1>fever</e1> has not been reported with the use of <e2>diltiazem hydrochloride</e2>, a commonly prescribed calcium channel blocker."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5394	 case of <e1>congestive heart failure</e1> in a child with Wilms' tumor treated <e2>Adriamycin</e2> is presented and discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5395	 recognition of <e1>adriamycin</e1> <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5396	 role of <e1>Adriamycin</e1> in the production of <e2>cardiotoxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5397	 -induced <e2>Diabetes mellitus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5398	 Mellitus</e1> was observed in a patient given <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5399	 present study describes a patient who had <e1>unusual weight fluctuation</e1> under corticosteroid and psychotropic treatment such as mianserin and <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5400	 present study describes a patient who had <e1>unusual weight fluctuation</e1> under corticosteroid and psychotropic treatment such as <e2>mianserin</e2> and aripiprazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5401	 <e1>heparin</e1> -dependent antibodies (HDAs) typically manifest with <e2>thrombocytopenia</e2> as in <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> (HIT), they may also manifest with preserved platelet counts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5402	 should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing <e1>thrombosis</e1> who are receiving <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5403	 antibodies and thrombosis without <e1>heparin</e1> -induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5404	 these antithrombotic effects, the patient developed repeated <e1>venous thromboembolism</e1> during treatment with low-molecular-weight <e2>heparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5405	 months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for <e1>progressive liver failure</e1> and severe hepatocellular necrosis thought to be due to <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5406	 months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and <e1>severe hepatocellular necrosis</e1> thought to be due to <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5407	 of <e1>posaconazole</e1> led to clinical improvement until the patient's demise from bacteremic vancomycin-resistant <e2>enterococcal peritonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5408	 Cushing syndrome</e1> after epidural <e2>triamcinolone</e2> injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5409	 report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed <e1>Cushing syndrome</e1> with profound complications after epidural <e2>triamcinolone</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5410	 22-year-old drug-abuser injected <e1>flunitrazepam</e1> tablets dissolved in tap water into her left femoral artery and presented with clinical signs of <e2>acute ischaemia of the left leg</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5411	 ischaemia of the leg</e1> following accidental intra-arterial injection of dissolved <e2>flunitrazepam</e2> tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5412	 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a <e1>syringotropic hypersensitivity reaction</e1> after 9 months of therapy with <e2>infliximab</e2> and leflunomide is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5413	 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a <e1>syringotropic hypersensitivity reaction</e1> after 9 months of therapy with infliximab and <e2>leflunomide</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5414	 hypersensitivity reaction</e1> associated with <e2>infliximab</e2> and leflunomide combination therapy in a child with psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5415	 hypersensitivity reaction</e1> associated with infliximab and <e2>leflunomide</e2> combination therapy in a child with psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5416	 case of <e1>severe aplastic anemia</e1> secondary to treatment with <e2>lenalidomide</e2> for multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5417	 moderate myelosuppression is not uncommonly seen in patients treated with <e1>lenalidomide</e1>, <e2>aplastic anemia</e2> has not previously been reported to be associated with this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5418	 describe a case of severe aplastic anemia (<e1>AA</e1>) that was probably induced by <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5419	 describe a case of <e1>severe aplastic anemia</e1> (AA) that was probably induced by <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5420	 cessation of <e1>amantadine</e1>, the <e2>edema</e2> resolved, and the endothelial cell densities were <or=600/mm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5421	 <e1>Amantadine</e1> can cause <e2>reversible corneal edema</e2> but can irreversibly reduce the density of endothelial cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5422	 edema</e1> recurred when the administration of <e2>amantadine</e2> was resumed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5423	 endothelial dysfunction</e1> associated with <e2>amantadine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5424	 To describe <e1>bilateral corneal endothelial dysfunction</e1> in a patient with Parkinson disease who was treated with long-term <e2>amantadine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5425	 A 52-year-old woman with Parkinson disease who had taken <e1>amantadine</e1> for 6 years had <e2>bilateral corneal edema</e2> for 2 months at baseline."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5426	 <e1>amantadine</e1> was permanently discontinued and the <e2>cornea</e2> cleared again."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5427	 <e1>acute interstitial nephritis</e1> associated with the tyrosine kinase inhibitor <e2>sunitinib</e2>: a class effect?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5428	 report the first biopsy confirmed occurrence of <e1>acute interstitial nephritis</e1> in a patient receiving treatment with <e2>Sunitinib</e2> for metastatic renal cell cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5429	 symptoms</e1> are well-documented complications of therapy with <e2>haloperidol</e2>, even when small doses are used."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5430	 report highlights a case of drug-induced <e1>dysphagia</e1> in a patient receiving <e2>haloperidol</e2> for obsessive nocturnal thoughts and auditory disturbances."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5431	 52 year-old male patient diagnosed of ankylosing spondylitis presented with an <e1>iron deficiency anemia</e1> after a ten-month treatment of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5432	 induced <e2>sprue-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5433	 3 cases of <e1>imatinib</e1> -induced <e2>tumor lysis syndrome</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5434	 herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed <e1>tumor lysis syndrome</e1> after 10-day treatment with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5435	 -induced recurrence of <e2>Graves' disease</e2> ten years after thyroidectomy in chronic viral hepatitis C."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5436	 contrast to chronic or subacute thyroiditis, <e1>Graves' disease</e1> rarely complicates <e2>IFN-alpha</e2> therapy for chronic viral C hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5437	 contrast to chronic or <e1>subacute thyroiditis</e1>, Graves' disease rarely complicates <e2>IFN-alpha</e2> therapy for chronic viral C hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5438	 report the case of a 51-year-old man in whom <e1>IFN-alpha</e1> treatment was followed by recurrence of <e2>Graves' disease</e2> 10 years after thyroidectomy was performed and the patient was declared cured."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5439	 granulomatous dermatitis</e1> associated with <e2>darifenacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5440	 authors describe a case of <e1>interstitial granulomatous dermatitis</e1> associated with <e2>darifenacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5441	 is a known risk factor for <e2>hemolytic uremic syndrome</e2> (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5442	 is a known risk factor for hemolytic uremic syndrome (<e2>HUS</e2>), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5443	 A retrospective report of the first case of <e1>gemcitabine</e1> -related <e2>HUS</e2>, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5444	 therapy for <e1>gemcitabine</e1> -induced <e2>hemolytic uremic syndrome</e2> in a patient with metastatic pancreatic adenocarcinoma: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5445	 rash with eosinophilia and systemic symptoms</e1> after <e2>chlorambucil</e2> treatment in chronic lymphocytic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5446	 developed recurrent skin rash, fever, hypereosinophilia, and <e1>acute renal failure</e1> after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5447	 developed recurrent skin rash, <e1>fever</e1>, hypereosinophilia, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5448	 developed recurrent skin rash, fever, <e1>hypereosinophilia</e1>, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5449	 developed recurrent <e1>skin rash</e1>, fever, hypereosinophilia, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5450	 report the first case of <e1>chlorambucil</e1> -induced <e2>DRESS syndrome</e2> in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5451	 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e1>methotrexate</e1> (MTX) (12 g/m2), and went on to develop <e2>acute renal failure</e2> with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5452	 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e1>MTX</e1>) (12 g/m2), and went on to develop <e2>acute renal failure</e2> with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5453	 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme <e1>elevation of aspartate aminotrasferase</e1> and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e2>methotrexate</e2> (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5454	 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme <e1>elevation of aspartate aminotrasferase</e1> and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e2>MTX</e2>) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5455	 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending <e1>renal toxicity</e1> and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e2>methotrexate</e2> (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5456	 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending <e1>renal toxicity</e1> and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e2>MTX</e2>) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5457	 his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of <e1>renal toxicity</e1> may be present as early as 2 hours after the completion of a 4-hour <e2>MTX</e2> infusion, and to suggest that monitoring for <e2>MTX</e2> toxicity should perhaps begin within a few hours after the completion of 4-hour <e2>MTX</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5458	 recognition of <e1>renal toxicity</e1> of high-dose <e2>methotrexate</e2> therapy: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5459	 electroretinographic abnormalities in <e1>ethambutol</e1> -induced <e2>visual loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5460	 are the first reported patients to show mfERG abnormalities that correspond to <e1>bitemporal visual field defects</e1> and add to the growing evidence that <e2>ethambutol</e2> damages the retina."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5461	 are the first reported patients to show <e1>mfERG abnormalities</e1> that correspond to bitemporal visual field defects and add to the growing evidence that <e2>ethambutol</e2> damages the retina."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5462	 patients who developed decreased visual acuity after several months of <e1>ethambutol</e1> treatment for Mycobacterium avium-intracellulare infection had <e2>bitemporal visual field defects</e2> that suggested optic chiasm damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5463	 patients who developed <e1>decreased visual acuity</e1> after several months of <e2>ethambutol</e2> treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5464	 -associated <e2>nephrotoxicity</e2> in two HIV-infected adolescent males."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5465	 our knowledge, these cases represent the first reports of <e1>TDF</e1> -associated <e2>irreversible renal failure</e2> and rickets in pediatric patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5466	 our knowledge, these cases represent the first reports of <e1>TDF</e1> -associated irreversible renal failure and <e2>rickets</e2> in pediatric patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5467	 report two cases of tenofovir (<e1>TDF</e1>)-associated <e2>nephrotoxicity</e2> in perinatally HIV-infected adolescents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5468	 report two cases of <e1>tenofovir</e1> (TDF)-associated <e2>nephrotoxicity</e2> in perinatally HIV-infected adolescents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5469	 this case, discontinuing <e1>piroxicam</e1>, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's <e2>ulcers</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5470	 renal failure</e1> following intravenous <e2>immunoglobulin</e2> therapy in a HIV-infected patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5471	 renal failure</e1> is a rare complication following the administration of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5472	 exact mechanism of <e1>IVIG</e1> -associated <e2>acute renal failure</e2> remains unclear."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5473	 58-year-old man with advanced renal cell carcinoma developed grade 3 <e1>proteinuria</e1> (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after <e2>temsirolimus</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5474	 -induced <e2>glomerulopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5475	 can be a serious side effect of <e2>etanercept</e2> in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5476	 can be a serious side effect of <e1>etanercept</e1> in patients already on antidiabetic medications known to cause <e2>hypoglycemia</e2>, such as sulfonylureas, meglitinides, and insulin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5477	 can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as sulfonylureas, meglitinides, and <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5478	 can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as sulfonylureas, <e2>meglitinides</e2>, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5479	 can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as <e2>sulfonylureas</e2>, meglitinides, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5480	 hypoglycemia</e1> in a patient with diabetes taking <e2>etanercept</e2> for the treatment of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5481	 report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent <e1>etanercept</e1> for severe plaque psoriasis, experienced <e2>persistent hypoglycemia</e2> requiring the lowering and eventual elimination of his previous insulin regimen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5482	 report on three cases wherein treatment of <e1>dexmedetomidine</e1> -induced <e2>bradycardia</e2> with i.v. glycopyrrolate (5.0 microg/kg) not only resulting in resolution of <e2>bradycardia</e2> but also resulting in an exaggerated increase of arterial blood pressure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5483	 report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. <e1>glycopyrrolate</e1> (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an <e2>exaggerated increase of arterial blood pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5484	 -related <e2>osteonecrosis of the jaw</e2> (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5485	 -related <e2>osteonecrosis of the skull base</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5486	 previous study of patients with "<e1>quinine</e1> -associated <e2>TTP/HUS</e2>" found that ADAMTS13 activities were not abnormal in 12/12 patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5487	 retrospective review of TTP patients with <e1>quinine</e1> -associated <e2>thrombotic microangiopathy</e2> (TMA) for whom ADAMTS13 was measured before plasma exchange was performed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5488	 retrospective review of TTP patients with <e1>quinine</e1> -associated thrombotic microangiopathy (<e2>TMA</e2>) for whom ADAMTS13 was measured before plasma exchange was performed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5489	 with or without microangiopathy following <e2>quinine</e2> is often referred to as <e2>quinine</e2> "hypersensitivity." When schistocytes are present it is frequently termed "<e2>quinine</e2> -associated TTP/HUS." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5490	 with or without microangiopathy following <e1>quinine</e1> is often referred to as <e1>quinine</e1> "hypersensitivity." When schistocytes are present it is frequently termed "<e1>quinine</e1> -associated <e2>TTP/HUS</e2>." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5491	 conclude that while thrombocytopenia and <e1>schistocytosis</e1> can be seen in <e2>quinine</e2> -associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5492	 conclude that while <e1>thrombocytopenia</e1> and schistocytosis can be seen in <e2>quinine</e2> -associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5493	 conclude that while thrombocytopenia and schistocytosis can be seen in <e1>quinine</e1> -associated <e2>TTP/HUS</e2>, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5494	 recommend that a TMA in association with <e1>quinine</e1> be consistently referred to as <e1>quinine</e1> -associated <e2>thrombotic microangiopathy</e2> (<e1>quinine</e1> -TMA) to better distinguish this entity from idiopathic TTP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5495	 associated with <e1>primary and secondary perforation of the bladder</e1> following immediate instillations of <e2>epirubicin</e2> after transurethral resection of superficial urothelial tumours."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5496	 AND METHODS: We present two cases of significant morbidity related to <e1>primary and secondary perforation of the bladder</e1> following two instillations of <e2>epirubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

5497	 -associated <e2>acute renal failure</e2> with hyperkalemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5498	 report the first case of <e1>acute renal failure</e1> with hyperkalemia associated with the recently marketed direct renin inhibitor <e2>aliskiren</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5499	 report the first case of acute renal failure with <e1>hyperkalemia</e1> associated with the recently marketed direct renin inhibitor <e2>aliskiren</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5500	 case of <e1>acute cardiomyopathy</e1> and pericarditis associated with <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5501	 case of acute cardiomyopathy and <e1>pericarditis</e1> associated with <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5502	 <e1>acute cardiomyopathy</e1> and pericarditis secondary to <e2>methylphenidate</e2> use has been rarely reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5503	 acute cardiomyopathy and <e1>pericarditis</e1> secondary to <e2>methylphenidate</e2> use has been rarely reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5504	 report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and <e1>acute left ventricular dysfunction</e1> following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5505	 report the case of a 17-year-old male who developed <e1>chest pain</e1>, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5506	 report the case of a 17-year-old male who developed chest pain, <e1>elevated cardiac biomarkers</e1>, and acute left ventricular dysfunction following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5507	 to the Naranjo et al. adverse-reaction probability scale, <e1>enoxaparin</e1> was the probable cause of <e2>hepatotoxicity</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5508	 A woman receiving <e1>enoxaparin</e1> every 12 hours developed signs and symptoms of <e2>hepatotoxicity</e2> after the second dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5509	 <e1>enoxaparin</e1> -induced <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5510	 A case of probable <e1>enoxaparin</e1> -induced <e2>hepatotoxicity</e2> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5511	 reversible encephalopathy syndrome</e1> associated with <e2>methotrexate</e2> neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5512	 addition of intrathecal <e1>methotrexate</e1> to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5513	 describe a 15-year-old female patient diagnosed with <e1>acute lymphoblastic leukemia</e1> presenting with status epilepticus after receiving intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5514	 -induced <e2>pain syndrome</e2> in a child undergoing hematopoietic stem cell transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5515	 this case, <e1>CIPS</e1> was considered to be probably associated with <e2>cyclosporine</e2> according to the Naranjo probability scale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5516	 To report a case of <e1>calcineurin</e1> -induced <e2>pain syndrome</e2> (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5517	 the first <e1>cyclosporine</e1> dose, the patient complained of <e2>leg pain</e2> that was most severe during the <e1>cyclosporine</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5518	 the first <e1>cyclosporine</e1> dose, the patient complained of <e2>leg pain</e2> that was most severe during the <e1>cyclosporine</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5519	 malignant syndrome</e1> due to <e2>risperidone</e2> treatment in a child with Joubert syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5520	 report describes a case of <e1>neuroleptic malignant syndrome</e1> due to <e2>risperidone</e2> in a child with Joubert syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5521	 case of <e1>tuberculosis</e1> in a patient on <e2>Efalizumab</e2> and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5522	 case of <e1>tuberculosis</e1> in a patient on Efalizumab and <e2>Etanercept</e2> for treatment of refractory palmopustular psoriasis and psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5523	 most common complication of <e1>warfarin</e1> use is adverse <e2>bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5524	 REPORT: We describe here a case of a 60 year old female that experienced a relapse of <e1>symptomatic hyperlactatemia</e1> after being switched from <e2>stavudine</e2> to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda."
DRUG-ADE(e2,e1)
Comment: DRUG-

5525	 REPORT: We describe here a case of a 60 year old female that experienced a relapse of <e1>symptomatic hyperlactatemia</e1> after being switched from stavudine to <e2>zidovudine</e2> and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda."
DRUG-ADE(e2,e1)
Comment: DRUG-

5526	 This case shows that switching to <e1>zidovudine</e1> potentially can lead to a <e2>hyperlactatemia relapse</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5527	 In resource limited settings patients on antiretroviral treatment who develop <e1>stavudine</e1> induced <e2>hyperlactatemia</e2> are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5528	 reaction</e1> to <e2>bacitracin</e2> ointment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5529	 report a case of an 11-year-old boy who experienced an <e1>anaphylactic reaction</e1> after administration of <e2>bacitracin</e2> ointment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5530	 we present a patient with severe and <e1>prolonged hypoglycemia</e1> after long-acting <e2>octreotide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5531	 induced by long-acting <e2>somatostatin</e2> analogues in a patient with nonfunctional neuroendocrine tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5532	 these patients, long-acting <e1>octreotide</e1> may trigger <e2>serious hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5533	 due to parvovirus B19 in a Crohn's disease patient using <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5534	 uncomplicated long-term use of adequately-dosed <e1>AZA</e1> and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5535	 present the case of an adult Crohn's disease patient with a parvovirus B19 infection and <e1>leukopenia</e1> during long-term <e2>AZA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5536	 causing <e2>breast tissue enlargement</e2> has been very rarely reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5537	 induced <e2>gynaecomastia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5538	 neoformans fatal sepsis</e1> in a chronic lymphocytic leukemia patient treated with <e2>alemtuzumab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5539	 international literature regarding opportunistic infections after immunosuppressive therapy with <e1>alemtuzumab</e1> with particular attention on <e2>fungal infections</e2> has also been reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5540	 international literature regarding <e1>opportunistic infections</e1> after immunosuppressive therapy with <e2>alemtuzumab</e2> with particular attention on fungal infections has also been reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5541	 <e1>acute myeloid leukemia</e1> after <e2>etoposide</e2> therapy for haemophagocytic lymphohistiocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5542	 risk of developing <e1>sAML</e1> is estimated to be between 1% and 5%, 2-20 years after exposure to <e2>etoposide</e2> but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5543	 patients with HLH developed <e1>etoposide</e1> -related secondary acute myeloid leukemia (<e2>sAML</e2>) following therapy for HLH."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5544	 patients with HLH developed <e1>etoposide</e1> -related <e2>secondary acute myeloid leukemia</e2> (sAML) following therapy for HLH."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5545	 seizure</e1> resulting from accidental injection of <e2>tranexamic acid</e2> in spinal anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5546	 following <e2>clarithromycin</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5547	 report the first case of <e1>rhabdomyolysis</e1> related to the administration of <e2>clarithromycin</e2> without concurrent use of other medications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5548	 the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the <e2>development of abnormally large mammary glands</e2> associated with pain and peri-areolar erythema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5549	 the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the development of abnormally large mammary glands associated with <e2>pain</e2> and peri-areolar erythema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5550	 the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the development of abnormally large mammary glands associated with pain and <e2>peri-areolar erythema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5551	 re-initiation of <e1>sunitinib</e1> treatment was followed by <e2>bilateral breast enlargement</e2> again."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5552	 of male <e1>gynaecomastia</e1> in a patient treated with <e2>sunitinib</e2> for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5553	 mechanism by which <e1>sunitinib</e1> induces <e2>gynaecomastia</e2> is thought to be associated with an unknown direct action on breast hormonal receptors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5554	 more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, hand-foot syndrome, <e2>elevated lipase</e2> and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5555	 more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, <e2>fatigue</e2>, hand-foot syndrome, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5556	 more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, <e2>hand-foot syndrome</e2>, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5557	 more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include <e2>hypertension</e2>, fatigue, hand-foot syndrome, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5558	 more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, hand-foot syndrome, elevated lipase and <e2>lymphopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5559	 sodium</e1> -induced <e2>eosinophilic pleural effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5560	 report a case of 48-year-old woman with seizure disorder on divalproex sodium (<e1>Depakote</e1>) who presented with <e2>dyspnea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5561	 report a case of 48-year-old woman with seizure disorder on <e1>divalproex sodium</e1> (Depakote) who presented with <e2>dyspnea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5562	 of <e1>Depakote</e1> resulted in resolution of the <e2>effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5563	 -associated <e2>acute tubulointerstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5564	 report a case of biopsy-proven <e1>acute tubulointerstitial nephritis</e1> associated with a second course of <e2>flurbiprofen</e2>, a nonsteroidal anti-inflammatory drug of the propionic acid class."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5565	 and fast activity on electroencephalography in a child treated with <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5566	 case of a 4-year-old girl with <e1>valproate</e1> -induced <e2>stupor</e2> and electroencephalographic pattern of increased fast activity is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5567	 dyskeratotic plaque</e1> with milia associated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5568	 dyskeratotic plaque with <e1>milia</e1> associated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5569	 article presents a case of an <e1>atypical localized cutaneous eruption</e1> with an unusual course and protracted resolution time associated with <e2>sorafenib</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5570	 to the Naranjo adverse drug reaction probability scale, <e1>tigecycline</e1> was the probable cause of her <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5571	 7 days of <e1>tigecycline</e1> she developed severe abdominal pain and elevated pancreatic enzymes suggesting <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5572	 7 days of <e1>tigecycline</e1> she developed severe abdominal pain and <e2>elevated pancreatic enzymes</e2> suggesting acute pancreatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5573	 7 days of <e1>tigecycline</e1> she developed <e2>severe abdominal pain</e2> and elevated pancreatic enzymes suggesting acute pancreatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5574	 has been associated with the tetracycline class of antibiotics and concerns about <e1>tigecycline</e1> -induced <e2>acute pancreatitis</e2> have recently been raised."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5575	 -induced <e2>acute pancreatitis</e2>: case report and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5576	 recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including <e1>abdominal pain</e1>, during treatment with <e2>tigecycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5577	 recommend that clinicians monitor patients for signs and symptoms of <e1>pancreatitis</e1>, including abdominal pain, during treatment with <e2>tigecycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5578	 induced <e1>polymyositis</e1> secondary to <e2>leuprolide acetate</e2> (Lupron) therapy for prostate carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5579	 induced <e1>polymyositis</e1> secondary to leuprolide acetate (<e2>Lupron</e2>) therapy for prostate carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5580	 report a case of biopsy proven <e1>myositis</e1> whose symptoms began within 10 days of receiving <e2>leuprolide acetate</e2> therapy for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5581	 -induced <e2>hiccups</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5582	 report a patient of organic bipolar affective disorder who developed <e1>hiccups</e1> with the atypical antipsychotic <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5583	 This patient's <e1>rhabdomyolysis</e1> was probably induced by <e2>sertraline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5584	 The Naranjo probability scale indicated a probable relationship between <e1>sertraline</e1> treatment and the onset of <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5585	 To describe a case of <e1>sertraline</e1> -induced <e2>rhabdomyolysis</e2> in an elderly patient with dementia and comorbidities."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5586	 -induced <e2>rhabdomyolysis</e2> in an elderly patient with dementia and comorbidities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5587	 patient's other comorbidities and medications have not been suggested as possible interactions with <e1>sertraline</e1> that can cause <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5588	 lysis syndrome</e1> after transcatheter arterial infusion of <e2>cisplatin</e2> and embolization therapy for liver metastases of melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5589	 had <e1>priapism</e1> following the use of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5590	 associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5591	 <e1>ketamine</e1> prescribed for pain cause <e2>damage to the urinary tract</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5592	 mechanisms for <e1>damage to the urothelium</e1> by <e2>ketamine</e2> are suggested."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5593	 of three palliative care patients who were given <e1>ketamine</e1> as an analgesic and subsequently developed significant and debilitating <e2>urological symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5594	 two cases highlight the importance of considering <e1>lopinavir</e1>/ritonavir induced <e2>arrhythmias</e2> when dealing with HIV-positive individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5595	 two cases highlight the importance of considering lopinavir/<e1>ritonavir</e1> induced <e2>arrhythmias</e2> when dealing with HIV-positive individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5596	 cardiac arrhythmias</e1> related to <e2>lopinavir</e2>/ritonavir in two patients with HIV infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5597	 cardiac arrhythmias</e1> related to lopinavir/<e2>ritonavir</e2> in two patients with HIV infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5598	 as a manifestation of <e2>infliximab</e2> -associated disseminated cryptococcosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5599	 as a manifestation of <e1>infliximab</e1> -associated <e2>disseminated cryptococcosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5600	 three weeks of <e1>carbamazepine</e1> therapy, the patient arrived at the emergency department (ED) with severe agitation and <e2>aggressive behavior</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5601	 three weeks of <e1>carbamazepine</e1> therapy, the patient arrived at the emergency department (ED) with <e2>severe agitation</e2> and aggressive behavior."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5602	 -induced <e2>hyperammonemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5603	 A 26-year-old man with bipolar disorder developed <e1>hyperammonemia</e1> three weeks after initiating <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5604	 had also developed <e1>elevated serum ammonia levels</e1> while on <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5605	 A case of <e1>carbamazepine</e1> -induced <e2>hyperammonemia</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5606	 -induced <e2>cardiomyopathy</e2> aggravated by cis-platinum nephrotoxicity requiring dialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5607	 cardiomyopathy aggravated by <e1>cis-platinum</e1> <e2>nephrotoxicity</e2> requiring dialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5608	 of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and <e1>adriamycin</e1> <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5609	 of chemotherapy for a synovial sarcoma in an eight-year old boy included <e1>cisplatinum</e1> <e2>nephrotoxicity</e2> and adriamycin cardiotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5610	 65-year-old female patient presented with <e1>jaundice</e1> followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5611	 65-year-old female patient presented with jaundice followed 2 days later by <e1>severe dyspnea</e1> and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5612	 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and <e1>tachypnea</e1> which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5613	 case of <e1>acute respiratory failure</e1> due to diaphragmatic weakness following <e2>adalimumab</e2> therapy for psoriasis is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5614	 bilateral phrenic neuropathy</e1> following treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5615	 potential development of <e1>SJS</e1>/TEN, a severe life-threatening illness, emphasizes the need for judicious use of <e2>TMP-Sx</e2> and close monitoring and follow-up for patients who were given <e2>TMP-Sx</e2> for SSTIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5616	 potential development of SJS/<e1>TEN</e1>, a severe life-threatening illness, emphasizes the need for judicious use of <e2>TMP-Sx</e2> and close monitoring and follow-up for patients who were given <e2>TMP-Sx</e2> for SSTIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5617	 report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (<e1>SJS</e1>/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5618	 report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (<e1>SJS</e1>/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5619	 report a case of <e1>Stevens-Johnson syndrome</e1>/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5620	 report a case of <e1>Stevens-Johnson syndrome</e1>/toxic epidermal necrolysis (SJS/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5621	 report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/<e1>TEN</e1>) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5622	 report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/<e1>TEN</e1>) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5623	 report a case of Stevens-Johnson syndrome/<e1>toxic epidermal necrolysis</e1> (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5624	 report a case of Stevens-Johnson syndrome/<e1>toxic epidermal necrolysis</e1> (SJS/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5625	 <e1>Spontaneous hemothorax</e1> is a rare phenomenon in conjunction with <e2>LMWH</e2> but should be considered in cases of acute respiratory distress following commencement of <e2>LMWH</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5626	 day 4, following 3 doses of <e1>dalteparin</e1>, the patient developed <e2>acute respiratory distress</e2> attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5627	 hemothorax</e1> following anticoagulation with low-molecular-weight <e2>heparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5628	 ocular ischemic change</e1> may be associated with intravitreal injection of <e2>bevacizumab</e2> in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5629	 vision loss</e1> after intravitreal injection of bevacizumab (<e2>avastin</e2>) associated with ocular ischemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5630	 vision loss</e1> after intravitreal injection of <e2>bevacizumab</e2> (avastin) associated with ocular ischemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5631	 vision loss after intravitreal injection of bevacizumab (<e1>avastin</e1>) associated with <e2>ocular ischemic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5632	 vision loss after intravitreal injection of <e1>bevacizumab</e1> (avastin) associated with <e2>ocular ischemic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5633	 To report a patient with diabetic rubeosis who suffered from <e1>acute retinal ischemic change</e1> and stroke after intravitreal injection of <e2>bevacizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5634	 To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and <e1>stroke</e1> after intravitreal injection of <e2>bevacizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5635	 Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as <e2>carotid insufficiency</e2>, coagulopathy and poorly controlled diabetes mellitus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5636	 Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as carotid insufficiency, <e2>coagulopathy</e2> and poorly controlled diabetes mellitus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5637	 Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and <e2>poorly controlled diabetes mellitus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5638	 days after intravitreal injection of <e1>bevacizumab</e1>, <e2>acute ocular ischemic syndrome</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5639	 days after receiving intravitreal injection of <e1>bevacizumab</e1> (1.25 mg in 0.1 ml), he developed <e2>acute vision loss</e2> and change of consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5640	 days after receiving intravitreal injection of <e1>bevacizumab</e1> (1.25 mg in 0.1 ml), he developed acute vision loss and <e2>change of consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5641	 we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, <e2>cyclophosphamide</e2>, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5642	 we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, <e2>doxorubicin</e2>, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5643	 we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with <e2>etoposide</e2>, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5644	 we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, <e2>prednisone</e2>, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5645	 we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and <e2>rituximab</e2> (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5646	 we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, <e2>vincristine</e2>, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5647	 outcome of de novo <e1>hepatitis B infection</e1> after liver transplantation with lamivudine and <e2>adefovir</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5648	 outcome of de novo <e1>hepatitis B infection</e1> after liver transplantation with <e2>lamivudine</e2> and adefovir therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5649	 -associated <e2>acute interstitial nephritis</e2> and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5650	 -associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5651	 -associated acute interstitial nephritis and <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5652	 day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, <e2>eosinophilia</e2>, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5653	 day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, <e2>facial edema</e2>, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5654	 day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, <e2>macular rash</e2>, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5655	 day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, <e2>marked increase in serum creatinine level</e2>, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5656	 day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and <e2>mild hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5657	 day 7 of <e1>linezolid</e1> treatment, the patient developed <e2>severe pruritus</e2>, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5658	 case of <e1>linezolid</e1> -associated <e2>acute interstitial nephritis</e2> within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5659	 case of <e1>linezolid</e1> -associated <e2>acute interstitial nephritis</e2> within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5660	 case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5661	 case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5662	 case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5663	 case of <e1>linezolid</e1> -associated acute interstitial nephritis within the context of a <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5664	 awareness is needed on the possible occurrence of <e1>LPD</e1> resembling gastric cancer in rheumatoid arthritis patients treated with <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5665	 <e1>methotrexate</e1> -associated <e2>lymphoproliferative disorder</e2> resembling advanced gastric cancer in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5666	 was diagnosed with <e1>Epstein-Barr virus-associated polymorphic lymphoproliferative disorder</e1> (LPD) due to immunodeficiency caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5667	 was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to <e1>immunodeficiency</e1> caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5668	 was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (<e1>LPD</e1>) due to immunodeficiency caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5669	 our knowledge, this is the first case of spontaneous remission of <e1>MTX</e1> -associated <e2>gastric LPD</e2> after discontinuation of <e1>MTX</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5670	 he developed <e1>acute renal failure</e1>, hyperkalemia, and hyperuricemia 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5671	 he developed acute renal failure, <e1>hyperkalemia</e1>, and hyperuricemia 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5672	 he developed acute renal failure, hyperkalemia, and <e1>hyperuricemia</e1> 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5673	 induced <e2>tumor lysis syndrome</e2> in an advanced hepatocellular carcinoma patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5674	 nasal decongestants safer than rhinitis? A case of <e1>oxymetazoline</e1> -induced <e2>syncope</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5675	 report here a case of cardiovascular and <e1>neurological depression</e1> induced by <e2>oxymetalzoline</e2> in a toddler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5676	 that discontinuation of <e1>nitrofurantoin</e1> and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of <e2>toxic liver damage</e2> caused by <e1>nitrofurantoin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5677	 -induced <e2>acute liver damage</e2> in pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5678	 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (<e1>PCNSL</e1>) after having received 21 doses of <e2>natalizumab</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5679	 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed <e1>primary central nervous system lymphoma</e1> (PCNSL) after having received 21 doses of <e2>natalizumab</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5680	 central nervous system lymphoma</e1> in a patient treated with <e2>natalizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5681	 first patient is undergoing hemodialysis and, though responding to <e1>sunitinib</e1>, is having significant <e2>fatigue</e2> and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5682	 first patient is undergoing hemodialysis and, though responding to <e1>sunitinib</e1>, is having significant fatigue and <e2>hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5683	 To report a case of <e1>severe apnea</e1> in an infant exposed to <e2>lamotrigine</e2> through breast-feeding."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5684	 apnea</e1> in an infant exposed to <e2>lamotrigine</e2> in breast milk."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5685	 Naranjo probability scale indicated a probable relationship between <e1>apnea</e1> and exposure to <e2>lamotrigine</e2> through breast-feeding in this infant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5686	 there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with <e1>dasatinib</e1> -induced <e2>pleural effusion</e2> with complete pleural fluid analysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5687	 -induced <e2>pleural effusions</e2>: a lymphatic network disorder?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5688	 One case of recurrent primary peritoneal carcinoma previously treated with a <e1>carboplatin</e1> -based regimen, developed a <e2>platinum hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5689	 week after the initial-dose of <e1>adalimumab</e1> (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a <e2>fulminant cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5690	 cardiomyopathy</e1> following treatment with the tumour necrosis factor-alpha inhibitor <e2>adalimumab</e2> for Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5691	 -induced type 5 Bartter-like syndrome with <e2>severe hypocalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5692	 -induced <e2>type 5 Bartter-like syndrome</e2> with severe hypocalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5693	 of the <e1>tubular dysfunction</e1> took 15 days following cessation of the offending drug, <e2>Amikacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5694	 discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, <e2>hypocalcemia</e2>, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5695	 discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, <e2>hypomagnesemia</e2>, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5696	 discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, <e2>metabolic alkalosis</e2>, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5697	 discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5698	 discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in <e2>refractory hypokalemia</e2>, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5699	 discuss a patient who developed <e1>severe renal tubular dysfunction</e1> secondary to short-term therapy with <e2>Amikacin</e2>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5700	 the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and <e2>multiple infarcts</e2> on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5701	 the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were <e2>slow to awaken</e2>; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5702	 the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were slow to awaken; one had evidence of <e2>vasospasm</e2> by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5703	 is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the <e2>cerebral infarctions</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5704	 -induced <e2>hemorrhagic vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5705	 -induced <e2>hemorrhagic vasculitis</e2> is a rare side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5706	 is among the standard treatments for infected ischemic ulcers; in the rare case of <e1>ciprofloxacin</e1> -induced <e2>hemorrhagic vasculitis</e2>, it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5707	 one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a <e2>below-knee amputation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5708	 one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced <e2>hemorrhagic vasculitis</e2> was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5709	 one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to <e2>progressive gangrene</e2> and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5710	 one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1> -induced hemorrhagic vasculitis was superimposed on a <e2>severe forefoot infection</e2>, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5711	 one patient the <e1>vasculitis</e1> resolved after termination of the <e2>ciprofloxacin</e2> therapy; in the other patient the <e2>ciprofloxacin</e2> -induced hemorrhagic <e1>vasculitis</e1> was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5712	 a recent post-marketing survey in Japan revealed that <e1>interstitial pneumonia</e1> occurred in 4 among approximately 2 000 Japanese patients treated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5713	 pneumonia</e1> probably associated with <e2>sorafenib</e2> treatment: An alert of an adverse event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5714	 this article, we describe a Japanese patient with <e1>severe interstitial pneumonia</e1> probably caused by <e2>sorafenib</e2> treatment for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5715	 supervising future clinical trials for lung cancer should be alert to the fact that <e1>sorafenib</e1> can potentially induce serious <e2>interstitial lung disease</e2>, although this might depend on racial differences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5716	 <e1>gemcitabine</e1> -induced <e2>pulmonary toxicity</e2> in metastatic   gallbladder adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5717	 -induced <e2>pulmonary toxicity</e2> is usually a dramatic condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5718	 this report, we describe a fatal <e1>gemcitabine</e1> -induced <e2>pulmonary toxicity</e2> in a patient with gallbladder metastatic adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5719	 had <e1>hypokalemia</e1> (K 2.3 mmol/L) induced by <e2>licorice</e2> and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5720	 although <e1>garenoxacin</e1> reportedly causes fewer adverse reactions for <e2>cardiac rhythms</e2> than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5721	 although <e1>garenoxacin</e1> reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during <e2>hypokalemia</e2> in order to prevent TdP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5722	 de Pointes</e1> induced by a combination of garenoxacin and <e2>disopyramide</e2> and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5723	 de Pointes</e1> induced by a combination of <e2>garenoxacin</e2> and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5724	 report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (<e1>TdP</e1>) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5725	 report an 82-year-old man who developed ventricular tachycardia and <e1>Torsades de Pointes</e1> (TdP) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5726	 report an 82-year-old man who developed <e1>ventricular tachycardia</e1> and Torsades de Pointes (TdP) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5727	 371 patients treated with <e1>8MOP</e1>, three (0.8%) developed an <e2>acute dermatitis</e2> in the PUVA-treated areas."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5728	 after high-dose <e2>methylprednisolone</e2> for demyelinating disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5729	 observed 2 cases of <e1>hepatotoxicity</e1> after a high-dose <e2>methylprednisolone</e2> treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5730	 mucosal necrosis</e1> following administration of <e2>calcium polystryrene sulfonate</e2> (Kalimate) in a uremic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5731	 mucosal necrosis</e1> following administration of calcium polystryrene sulfonate (<e2>Kalimate</e2>) in a uremic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5732	 necrosis</e1> is known as a rare complication following the administration of <e2>Kayexalate</e2> (sodium polystryrene sulfonate) in sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5733	 necrosis</e1> is known as a rare complication following the administration of Kayexalate (<e2>sodium polystryrene sulfonate</e2>) in sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5734	 days after administration of <e1>Kalimate</e1> enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse <e2>colonic mucosal necrosis in the rectum</e2> and sigmoid colon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5735	 days after administration of <e1>Kalimate</e1> enema, he had <e2>profuse hematochezia</e2>, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5736	 report a rare case of <e1>colonic mucosal necrosis</e1> following Kalimate (<e2>calcium polystryrene sulfonate</e2>), an analogue of Kayexalate without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5737	 report a rare case of <e1>colonic mucosal necrosis</e1> following <e2>Kalimate</e2> (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5738	 report a rare case of <e1>colonic mucosal necrosis</e1> following Kalimate (calcium polystryrene sulfonate), an analogue of <e2>Kayexalate</e2> without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5739	 -induced <e2>tardive dyskinesia</e2> in schizophrenic patients taking clozapine as a first-line antipsychotic drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5740	 These results suggest that <e1>clozapine</e1> may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported <e2>discomfort</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5741	 These results suggest that <e1>clozapine</e1> may cause <e2>TD</e2>; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5742	 several case reports have suggested that <e1>clozapine</e1> could also cause <e2>TD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5743	 <e1>Clozapine</e1> causes few <e2>extrapyramidal symptoms</e2> and is recommended as a treatment drug for severe tardive dyskinesia (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5744	 retinoic acid</e1> -induced <e2>focal myositis</e2>, synovitis, and mononeuritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5745	 retinoic acid</e1> -induced focal myositis, synovitis, and <e2>mononeuritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5746	 retinoic acid</e1> -induced focal myositis, <e2>synovitis</e2>, and mononeuritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5747	 we report a patient with newly diagnosed acute promyelocytic leukemia who developed <e1>acute focal myositis</e1>, synovitis, and possible vasculitis, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5748	 we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and <e1>possible vasculitis</e1>, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5749	 we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, <e1>synovitis</e1>, and possible vasculitis, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5750	 To assess the nature, incidence, and risk factors of <e1>retinopathy</e1> associated with <e2>pegylated interferon</e2> and ribavirin combination therapy in chronic hepatitis C patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5751	 To assess the nature, incidence, and risk factors of <e1>retinopathy</e1> associated with pegylated interferon and <e2>ribavirin</e2> combination therapy in chronic hepatitis C patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5752	 Significant ocular complications such as an <e1>irreversible decrease of visual acuity</e1> may develop in patients treated with <e2>pegylated interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5753	 Significant <e1>ocular complications</e1> such as an irreversible decrease of visual acuity may develop in patients treated with <e2>pegylated interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5754	 in hepatitis C patients due to combination therapy with <e2>pegylated interferon</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5755	 in hepatitis C patients due to combination therapy with pegylated interferon and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5756	 of cisplatin in three patients with <e1>carboplatin</e1> <e2>hypersensitivity</e2>: is skin testing useful?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5757	 to <e2>carboplatin</e2> has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5758	 tests and intradermal tests with a series of dilutions of <e1>carboplatin</e1> and cisplatin were performed on three patients who had exhibited medium and <e2>severe hypersensitivity</e2> reactions to <e1>carboplatin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5759	 meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5760	 meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5761	 meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5762	 meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5763	 meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5764	 meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5765	 meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5766	 meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> in a patient treated with <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5767	 A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and <e1>aseptic meningitis</e1> simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5768	 A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and <e1>aseptic meningitis</e1> simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5769	 A 37-year-old African- American man with G6PD deficiency developed <e1>hemolytic anemia</e1>, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5770	 A 37-year-old African- American man with G6PD deficiency developed <e1>hemolytic anemia</e1>, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5771	 A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, <e1>hepatitis</e1>, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5772	 A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, <e1>hepatitis</e1>, orthostatic hypotension, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5773	 A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, <e1>orthostatic hypotension</e1>, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5774	 A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, <e1>orthostatic hypotension</e1>, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5775	 had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, <e2>difficulty with speech</e2>, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5776	 had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, <e2>difficulty with speech</e2>, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5777	 had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, <e2>dizziness</e2>, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5778	 had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, <e2>dizziness</e2>, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5779	 had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of <e2>headaches</e2>, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5780	 had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of <e2>headaches</e2>, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5781	 had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and <e2>itching on the trunk</e2> of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5782	 had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and <e2>itching on the trunk</e2> of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5783	 had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a <e2>maculopapular rash</e2> was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5784	 had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a <e2>maculopapular rash</e2> was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5785	 had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, <e2>weakness</e2>, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5786	 had been taking <e1>trimethoprim</e1> -sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, <e2>weakness</e2>, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5787	 The case of a patient who developed <e1>aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5788	 The case of a patient who developed <e1>aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5789	 The case of a patient who developed aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5790	 The case of a patient who developed aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5791	 The case of a patient who developed aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5792	 The case of a patient who developed aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5793	 The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5794	 The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> simultaneously during treatment with <e2>trimethoprim</e2> -sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5795	 patient, while on intravenous <e1>ritodrine</e1> therapy for preterm labor, experienced an episode of <e2>acute chest pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5796	 electrocardiogram (ECG), which was read as normal prior to <e1>ritodrine</e1> infusion, demonstrated a <e2>type I second-degree AV block</e2> which disappeared upon discontinuation of <e1>ritodrine</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5797	 electrocardiogram (ECG), which was read as normal prior to <e1>ritodrine</e1> infusion, demonstrated a <e2>type I second-degree AV block</e2> which disappeared upon discontinuation of <e1>ritodrine</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5798	 I second-degree AV block (<e1>Mobitz type I</e1>, Wenckebach AV block) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5799	 I second-degree AV block</e1> (Mobitz type I, Wenckebach AV block) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5800	 I second-degree AV block (Mobitz type I, <e1>Wenckebach AV block</e1>) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5801	 of <e1>anthracycline</e1> -induced <e2>early chronic cardiomyopathy</e2> with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5802	 report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of daunomycin and <e2>all-trans retinoic acid</e2> (ATRA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5803	 report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (<e2>ATRA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5804	 report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of <e2>daunomycin</e2> and all-trans retinoic acid (ATRA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5805	 We present a case of a patient with CML who developed <e1>KS</e1> 12 months after starting treatment with <e2>imatinib</e2> 400 mg/d."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5806	 of <e1>Kaposi's sarcoma</e1> (KS) is well described in immunosuppressed patients treated with corticosteroids and <e2>rituximab</e2>, but has not yet been reported during treatment with imatinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5807	 of Kaposi's sarcoma (<e1>KS</e1>) is well described in immunosuppressed patients treated with corticosteroids and <e2>rituximab</e2>, but has not yet been reported during treatment with imatinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5808	 sarcoma</e1> in a patient treated with <e2>imatinib mesylate</e2> for chronic myeloid leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5809	 We report a case of <e1>cutaneous KS lesions</e1> in a patient affected by CML treated with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

5810	 and pseudobulbar palsy complicating therapy with high-dose <e2>cytosine arabinoside</e2> in children with leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5811	 and <e1>pseudobulbar palsy</e1> complicating therapy with high-dose <e2>cytosine arabinoside</e2> in children with leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5812	 -based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including <e2>neuropsychiatric symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5813	 -induced <e2>psychosis</e2> as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5814	 The authors followed a patient with chronic HCV who received <e1>interferon</e1> and ribavirin and who developed <e2>hallucinations</e2> ultimately requiring psychiatric hospitalization."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5815	 The authors followed a patient with chronic HCV who received interferon and <e1>ribavirin</e1> and who developed <e2>hallucinations</e2> ultimately requiring psychiatric hospitalization."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5816	 The authors described a case of <e1>interferon</e1> -induced <e2>psychosis</e2> as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5817	 <e1>Zidovudine</e1> is well a known cause of <e2>anaemia</e2> and thus should be used with caution in the initiation of antiretroviral therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5818	 report a case of <e1>Zidovudine</e1> induced <e2>anaemia</e2> and bone marrow aplasia in a patient infected with HIV."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5819	 report a case of <e1>Zidovudine</e1> induced anaemia and <e2>bone marrow aplasia</e2> in a patient infected with HIV."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5820	 induced <e2>pure red cell aplasia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5821	 SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from <e1>hydroxychloroquine</e1> toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or <e2>objective visual field loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5822	 SD-OCT and AO detected abnormalities that correlate topographically with <e1>visual field loss</e1> from <e2>hydroxychloroquine</e2> toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective <e1>visual field loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5823	 To describe spectral-domain optical coherence tomography (SD-OCT) and adaptive optics (AO) imaging in <e1>hydroxychloroquine</e1> <e2>retinal toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5824	 optical coherence tomography and adaptive optics may detect <e1>hydroxychloroquine</e1> <e2>retinal toxicity</e2> before symptomatic vision loss."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5825	 <e1>trazodone</e1> -induced <e2>hypomanic symptoms</e2> occurred in three depressed patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5826	 -induced <e2>transient hypomanic symptoms</e2> and their management."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5827	 of <e1>etanercept</e1> was also clinically effective but followed by development of <e2>severe heart failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5828	 heart failure</e1> in a patient receiving <e2>etanercept</e2> for ankylosing spondylitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5829	 <e1>methylephedrine</e1> and Chinese herbal drugs might carry a risk of <e2>stroke</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5830	 describe a patient who experienced <e1>chronic nausea</e1> and an episode of confusion while treated with a small, stable dose of oral <e2>morphine</e2> in the setting of mild renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5831	 describe a patient who experienced chronic nausea and an episode of <e1>confusion</e1> while treated with a small, stable dose of oral <e2>morphine</e2> in the setting of mild renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5832	 adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, <e2>ataxia</e2>, diplopia, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5833	 adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, <e2>diplopia</e2>, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5834	 adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., <e2>dizziness</e2>, ataxia, diplopia, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5835	 adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and <e2>somnolence</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5836	 case of <e1>aseptic pleuropericarditis</e1> in a patient with chronic plaque psoriasis under <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5837	 may rarely provoke <e2>serositis</e2>, even with low doses and after just a few weeks of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5838	 report here a rare case of <e1>pleuropericarditis</e1> due to <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5839	 authors report five cases of <e1>tremor</e1> related to <e2>itraconazole</e2> therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following <e2>itraconazole</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5840	 authors report five cases of <e1>tremor</e1> related to <e2>itraconazole</e2> therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following <e2>itraconazole</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5841	 a newly described adverse event with long-term <e2>itraconazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5842	 kidney injury</e1> caused by <e2>zonisamide</e2> -induced hypersensitivity syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5843	 kidney injury caused by <e1>zonisamide</e1> -induced <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5844	 to <e2>zonisamide</e2> was confirmed by the skin patch test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5845	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, <e2>acute kidney injury</e2>, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5846	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and <e2>an increase in antihuman herpesvirus-6 immunoglobulin G titer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5847	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, <e2>eosinophilia</e2>, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5848	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, <e2>high-grade fever</e2>, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5849	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, <e2>liver dysfunction</e2>, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5850	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, <e2>lymphadenopathy</e2> and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5851	 current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread <e2>skin rash</e2>, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5852	 is the first report of <e1>acute kidney injury</e1> due to <e2>zonisamide</e2> -induced DRESS/DIHS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5853	 is the first report of acute kidney injury due to <e1>zonisamide</e1> -induced DRESS/<e2>DIHS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5854	 is the first report of acute kidney injury due to <e1>zonisamide</e1> -induced <e2>DRESS</e2>/DIHS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5855	 two case reports of adults with <e1>allergic contact dermatitis</e1> to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential <e1>allergic contact dermatitis</e1> to <e2>bisabolol</e2> - a component of the Aquaphor emollient they were using to treat their atopic dermatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5856	 report: <e1>acute renal failure</e1> after administering intravenous <e2>immunoglobulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5857	 hospital course of the <e1>acute renal failure</e1> is presented with a review of the literature on cases of <e1>acute renal failure</e1> after <e2>IVIG</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5858	 report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, <e1>azotemia</e1>, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5859	 report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, <e1>azotemia</e1>, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5860	 report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and <e1>hyperkalemia</e1> shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5861	 report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and <e1>hyperkalemia</e1> shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5862	 report the case of an 87-year-old white woman with myasthenia gravis who presented with <e1>nausea</e1>, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5863	 report the case of an 87-year-old white woman with myasthenia gravis who presented with <e1>nausea</e1>, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5864	 report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, <e1>shortness of breath</e1>, azotemia, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5865	 report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, <e1>shortness of breath</e1>, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5866	 the use of <e1>lithium</e1> should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of <e2>cardiac toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5867	 the use of <e1>lithium</e1> should be avoided with any patient who is purging, since it may exacerbate the <e2>loss of intracellular potassium</e2>, thereby increasing the risk of cardiac toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5868	 <e1>vancomycin</e1> -induced <e2>anaphylactic reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5869	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an <e2>anaphylactoid</e2> reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5870	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5871	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, <e2>blood disorders</e2>, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5872	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, <e2>gastrointestinal disturbances</e2>, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5873	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of <e2>hypersensitivity reactions</e2> - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5874	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as <e2>nephrotoxicity</e2>, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5875	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, <e2>ototoxicity</e2>, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5876	 is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "<e2>red man syndrome</e2>" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5877	 report a case of a 23-year-old man who developed a <e1>vancomycin</e1> -induced <e2>anaphylactic reaction</e2> in the treatment of methicillin-resistant Staphylococcus aureus infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5878	 patients in whom <e1>pulmonary oedema</e1> developed during tocolysis with <e2>hexoprenaline</e2> are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5879	 oedema</e1> after <e2>hexoprenaline</e2> administration in preterm labour."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5880	 interstitial lung disease</e1> after <e2>erlotinib</e2> administration in a patient with radiation fibrosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5881	 computed tomography scan findings were consistent with <e1>ILD</e1>, which was sufficient to diagnose as <e2>erlotinib</e2> -induced <e1>ILD</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5882	 Although <e1>gefitinib</e1> used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (<e2>ILD</e2>), few case reports on erlotinib-induced <e2>ILD</e2> have been issued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5883	 Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (<e1>ILD</e1>), few case reports on <e2>erlotinib</e2> -induced <e1>ILD</e1> have been issued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5884	 Although <e1>gefitinib</e1> used for the treatment of non-small-cell lung cancer is a well-known cause of <e2>interstitial lung disease</e2> (ILD), few case reports on erlotinib-induced ILD have been issued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5885	 We recently experienced a case of fatal <e1>erlotinib</e1> -induced <e2>ILD</e2>, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5886	 case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of <e1>ILD</e1> in patients taking <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5887	 patient suffered <e1>coronary artery vasospasm</e1>, attributed to the use of topical 1:1000 <e2>epinephrine</e2> during surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5888	 other patient developed <e1>transient intraoperative hypertension</e1> immediately after inadvertent submucosal injection of concentrated <e2>epinephrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5889	 -induced syndrome of inappropriate antidiuretic hormone (<e2>SIADH</e2>) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5890	 -induced <e2>syndrome of inappropriate antidiuretic hormone</e2> (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5891	 present a case of the syndrome of inappropriate antidiuretic hormone (<e1>SIADH</e1>) secondary to <e2>cisplatin</e2> therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5892	 present a case of the <e1>syndrome of inappropriate antidiuretic hormone</e1> (SIADH) secondary to <e2>cisplatin</e2> therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5893	 to our knowledge, in newborns there have been no reported cases to date of <e1>thrombocytosis</e1> induced by <e2>enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5894	 associated with <e2>enoxaparin</e2>: A very rare cause in newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5895	 induced by <e2>enoxaparin</e2> has been reported as a rare adverse effect of this medication in adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5896	 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, pancytopenia, splenomegaly, and <e2>extreme hyperferritinemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5897	 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed <e2>fever</e2>, pancytopenia, splenomegaly, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5898	 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, <e2>pancytopenia</e2>, splenomegaly, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5899	 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, pancytopenia, <e2>splenomegaly</e2>, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-A

5900	 leishmaniasis and <e1>macrophagic activation syndrome</e1> in a patient with rheumatoid arthritis under treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5901	 leishmaniasis</e1> and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5902	 case presentation is of a patient who had the clinical appearance of <e1>epiglottitis</e1>, but actually had an oro-pharyngeal dystonic reaction to <e2>prochlorperazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5903	 case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an <e1>oro-pharyngeal dystonic reaction</e1> to <e2>prochlorperazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5904	 of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe <e1>hydroxychloroquine</e1> <e2>retinopathy</e2> with 19 years follow-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5905	 other potential causes of liver toxicity were excluded, <e1>TMP-SMX</e1> was determined to be the cause of his <e2>acute liver toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5906	 other potential causes of <e1>liver toxicity</e1> were excluded, <e2>TMP-SMX</e2> was determined to be the cause of his acute <e1>liver toxicity</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5907	 this combination agent has been associated with a hypersensitivity syndrome involving <e1>cutaneous skin eruptions</e1>, pediatric cases of <e2>TMP-SMX</e2> -induced hepatotoxicity are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5908	 this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of <e1>TMP-SMX</e1> -induced <e2>hepatotoxicity</e2> are rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5909	 this combination agent has been associated with a <e1>hypersensitivity syndrome</e1> involving cutaneous skin eruptions, pediatric cases of <e2>TMP-SMX</e2> -induced hepatotoxicity are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5910	 to the increasing use of <e1>TMP-SMX</e1> in children, clinicians should be aware of this potentially life-threatening, <e2>immunemediated hypersensitivity reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5911	 -induced <e2>hepatotoxicity</e2> in a pediatric patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5912	 of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of <e1>hepatotoxicity</e1> and the <e2>TMP-SMX</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5913	 describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and <e1>soft tissue infection</e1> and was treated with <e2>TMP-SMX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5914	 was discontinued, and <e2>thyrotoxicosis</e2> gradually abated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5915	 and hypothyroidism during re-treatment with <e2>amiodarone</e2> in a patient who previously experienced <e2>amiodarone</e2> -induced thyrotoxicosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5916	 and <e1>hypothyroidism</e1> during re-treatment with <e2>amiodarone</e2> in a patient who previously experienced <e2>amiodarone</e2> -induced thyrotoxicosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5917	 and hypothyroidism during re-treatment with <e1>amiodarone</e1> in a patient who previously experienced <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5918	 <e1>Aphthous stomatitis</e1>, a common mucocutaneous disorder, is a well accepted complication of <e2>sirolimus</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5919	 We present an 11-year old male with Budd-Chiari syndrome who experienced profound <e1>worsening of chronic aphthous ulcers</e1> after immunosuppressive therapy was changed from tacrolimus to <e2>sirolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-

5920	 We present an 11-year old male with Budd-Chiari syndrome who experienced profound <e1>worsening of chronic aphthous ulcers</e1> after immunosuppressive therapy was changed from <e2>tacrolimus</e2> to sirolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-

5921	 aphthous stomatitis</e1> associated with oral <e2>calcineurin</e2> and mTOR inhibitors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5922	 findings mean that the effect of the <e1>MP</e1> pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an <e1>MP</e1> therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal-change nephrotic syndrome, may be responsible for the <e1>MP</e1> -induced <e2>transient renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5923	 nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of <e1>MP</e1> developed <e2>transient renal failure</e2> following an <e1>MP</e1> pulse therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5924	 nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of <e1>MP</e1> developed <e2>transient renal failure</e2> following an <e1>MP</e1> pulse therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5925	 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of <e1>severe cholestasis</e1> 3 months after initiation of <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5926	 is believed that this is the first reported case of reversible <e1>azathioprine</e1> -induced <e2>cholestasis</e2> associated with histological evidence of bile duct injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5927	 cholestasis with <e1>bile duct injury</e1> following <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5928	 <e1>cholestasis</e1> with bile duct injury following <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5929	 case of the Rett syndrome with <e1>acute encephalopathy</e1> induced during <e2>calcium hopantenate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5930	 report a girl with the Rett syndrome who had <e1>acute encephalopathy</e1> probably induced by <e2>calcium hopantenate</e2> (HOPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5931	 report a girl with the Rett syndrome who had <e1>acute encephalopathy</e1> probably induced by calcium hopantenate (<e2>HOPA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5932	 light reactivity</e1> from systemic <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5933	 <e1>photosensitivity</e1> is still present 3 years after the withdrawal of <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5934	 cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, <e2>doxorubicin</e2>, and mitomycin C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5935	 cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with <e2>etoglucid</e2>, doxorubicin, and mitomycin C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5936	 cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and <e2>mitomycin C</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5937	 patient with Wegener's granulomatosis rapidly developed a <e1>circumferential subglottic stenosis</e1> while on a <e2>cyclophosphamide</e2> regimen that had caused resolution of systemic symptoms and pulmonary infiltrates."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5938	 stenosis</e1> in Wegener's granulomatosis: development during <e2>cyclophosphamide</e2> treatment with response to carbon dioxide laser therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5939	 case is described of <e1>severe splenic hemorrhage and rupture</e1> which developed 3 h after completion of <e2>tPA</e2> infusion for suspected acute myocardial infarction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5940	 hemorrhage</e1>: a complication of <e2>tissue plasminogen activator</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5941	 therapy with <e1>tissue plasminogen activator</e1> (tPA) for acute myocardial infarction may result in major bleeding complications such as <e2>gastrointestinal or intracranial bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5942	 therapy with tissue plasminogen activator (<e1>tPA</e1>) for acute myocardial infarction may result in major bleeding complications such as <e2>gastrointestinal or intracranial bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5943	 case of <e1>severe acute hepatitis</e1> caused by <e2>cyproterone acetate</e2> in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5944	 of liver function tests should be mandatory in patients receiving high doses of <e1>cyproterone acetate</e1>; the drug should be withdrawn immediately if <e2>abnormal liver function tests</e2> are found."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5945	 hepatitis</e1> caused by <e2>cyproterone acetate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5946	 unique case of a transient, nonpigmenting <e1>fixed drug eruption</e1> caused by the radiopaque contrast medium <e2>iothalamate</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5947	 patient with systemic lupus erythematosus developed <e1>erythema multiforme</e1> after taking <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5948	 was discontinued until completion of radiotherapy, and the <e2>rash</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5949	 irradiation apparently enhanced the <e1>skin toxicity</e1> of <e2>aminoglutethimide</e2> or possibly <e2>aminoglutethimide</e2> had a radiosensitizing role in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5950	 report a case of radiotherapy-enhanced <e1>aminoglutethimide</e1> <e2>skin toxicity</e2> in a patient with metastatic breast cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5951	 have been published regarding the possibility that <e1>tamoxifen</e1> may be responsible for the subsequent development of <e2>carcinoma of the corpus uteri</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5952	 authors intend to carry out a case-control study on patients treated with <e1>tamoxifen</e1> for breast carcinoma to reveal the possible presence of <e2>endometrial carcinoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5953	 -induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5954	 patient had headache, mild fever, nausea, vomiting, rash, and <e1>eosinophilia</e1> after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5955	 patient had <e1>headache</e1>, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5956	 patient had headache, <e1>mild fever</e1>, nausea, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5957	 patient had headache, mild fever, <e1>nausea</e1>, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5958	 patient had headache, mild fever, nausea, vomiting, <e1>rash</e1>, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5959	 patient had headache, mild fever, nausea, <e1>vomiting</e1>, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5960	 reported a case of <e1>disulfiram</e1> -induced <e2>hepatitis</e2> with unique clinical features and compared our case with others in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5961	 episode of <e1>leukoencephalopathy</e1> is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 <e2>methotrexate</e2> and 12 mg intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5962	 episode of <e1>leukoencephalopathy</e1> is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 <e2>methotrexate</e2> and 12 mg intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5963	 -induced <e2>leukoencephalopathy</e2> is treatable with high-dose folinic acid: a case report and analysis of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5964	 <e1>heparin</e1> associated <e2>thrombocytopenia</e2> is a rare complication of <e1>heparin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5965	 <e1>heparin</e1> associated <e2>thrombocytopenia</e2> is a rare complication of <e1>heparin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5966	 report a patient who developed <e1>heparin</e1> associated <e2>thrombocytopenia</e2> during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5967	 <e2>alum</e2>inum toxicity after continuous intravesical <e2>alum</e2> irrigation for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5968	 encephalopathy and <e1>cardiomyopathy</e1> developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical <e2>aluminum</e2> infusion for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5969	 <e1>encephalopathy</e1> and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical <e2>aluminum</e2> infusion for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5970	 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, <e2>bleomycin</e2>, and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5971	 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of <e2>cisplatin</e2>, bleomycin, and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5972	 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5973	 of this route of intoxication might be important in patients in whom neurologic or <e1>psychiatric symptoms</e1> develop while large amounts of <e2>lidocaine</e2> cream are being used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5974	 -induced <e2>gingival hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5975	 is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced <e2>gingival hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5976	 using this "new" drug must be aware of the potential danger of <e1>sulfonamide</e1> -induced <e2>injury to the urinary tract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5977	 <e2>crystalluria</e2> revisited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5978	 describe two cases of <e1>sulfadiazine</e1> -induced <e2>crystalluria</e2> and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5979	 describe two cases of <e1>sulfadiazine</e1> -induced crystalluria and <e2>renal failure</e2> in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5980	 secondary to epithelial downgrowth and <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5981	 report a case of secondary <e1>glaucoma</e1> caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5982	 and <e1>sucralfate</e1> -induced <e2>hypophosphatemic osteomalacia</e2>: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5983	 of a <e1>hypersensitivity reaction</e1>, initial therapy with penicillin G and <e2>gentamicin</e2> was stopped and substituted with cefazolin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5984	 of a <e1>hypersensitivity reaction</e1>, initial therapy with <e2>penicillin G</e2> and gentamicin was stopped and substituted with cefazolin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5985	 cytomegalovirus (CMV) infection associated with severe <e1>brain damage</e1> was detected in an infant whose mother had been treated with prednisolone and <e2>azathioprine</e2> for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5986	 cytomegalovirus (CMV) infection associated with severe <e1>brain damage</e1> was detected in an infant whose mother had been treated with <e2>prednisolone</e2> and azathioprine for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5987	 cytomegalovirus (CMV) infection</e1> associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and <e2>azathioprine</e2> for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5988	 cytomegalovirus (CMV) infection</e1> associated with severe brain damage was detected in an infant whose mother had been treated with <e2>prednisolone</e2> and azathioprine for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5989	 coronary events</e1> following <e2>cisplatin</e2> -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5990	 patients with no previous signs or symptoms suggestive of coronary artery disease developed <e1>acute coronary ischemia</e1>/infarction shortly after <e2>cis-diamine-dichloroplatinum II</e2> (cisplatin) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5991	 patients with no previous signs or symptoms suggestive of coronary artery disease developed <e1>acute coronary ischemia</e1>/infarction shortly after cis-diamine-dichloroplatinum II (<e2>cisplatin</e2>) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5992	 patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/<e1>infarction</e1> shortly after <e2>cis-diamine-dichloroplatinum II</e2> (cisplatin) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5993	 patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/<e1>infarction</e1> shortly after cis-diamine-dichloroplatinum II (<e2>cisplatin</e2>) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5994	 perforation</e1> associated with intraperitoneal <e2>chromic phosphate</e2> instillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5995	 <e1>bowel injury</e1> is an infrequently observed complication of <e2>chromic phosphate</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5996	 report presents a case of <e1>colon perforation</e1> which occurred 4 months after treatment with intraperitoneal <e2>chromic phosphate</e2> for stage IB ovarian papillary serous cystadenocarcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5997	 a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent <e1>Ara-C</e1> treatment and led to <e2>death</e2> within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5998	 a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to <e2>death</e2> within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5999	 a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and <e1>loss of consciousness</e1> which worsened during subsequent <e2>Ara-C</e2> treatment and led to death within 3 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6000	 a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a progressive visual loss and <e2>loss of consciousness</e2> which worsened during subsequent Ara-C treatment and led to death within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6001	 a response of the meningeal tumor the patient developed in the third week of MTX treatment a <e1>progressive visual loss</e1> and loss of consciousness which worsened during subsequent <e2>Ara-C</e2> treatment and led to death within 3 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6002	 a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a <e2>progressive visual loss</e2> and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6003	 59-year-old woman with myasthenia gravis who received a large dose of <e1>pyridostigmine bromide</e1> developed postoperative psychosis and was diagnosed as having <e2>bromide intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6004	 59-year-old woman with myasthenia gravis who received a large dose of <e1>pyridostigmine bromide</e1> developed <e2>postoperative psychosis</e2> and was diagnosed as having bromide intoxication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6005	 intoxication</e1> secondary to <e2>pyridostigmine bromide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6006	 our knowledge , this is the first reported case of <e1>bromide intoxication</e1> due to <e2>pyridostigmine bromide</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6007	 use by pregnant women can be associated with a later presentation of <e2>withdrawal symptoms</e2> in the neonate than that induced by the use of other drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6008	 conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related <e1>ileus</e1> in patients treated with <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6009	 report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of <e1>adynamic ileus</e1>, while being treated with intravenous <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6010	 report on a patient with subarachnoid haemorrhage who developed an acute life-threatening <e1>pseudo-obstruction of the colon</e1>, a variant of adynamic ileus, while being treated with intravenous <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6011	 discontinuation of <e1>danazol</e1> the <e2>diabetes</e2> completely resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6012	 diabetes mellitus</e1> associated with <e2>danazol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6013	 diabetes mellitus</e1> developed in a young woman 8 weeks after the initiation of <e2>danazol</e2> for treatment of pelvic endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6014	 83-year-old man receiving <e1>glipizide</e1> 10 mg bid developed <e2>symptomatic hypoglycemia</e2> within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6015	 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/sulfamethoxazole (TMP/<e2>SMX</e2>) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6016	 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/<e2>sulfamethoxazole</e2> (TMP/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6017	 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/sulfamethoxazole (<e2>TMP</e2>/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6018	 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding <e2>trimethoprim</e2>/sulfamethoxazole (TMP/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6019	 hypoglycemia</e1> secondary to a <e2>glipizide</e2> -trimethoprim/sulfamethoxazole drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6020	 hypoglycemia</e1> secondary to a glipizide-trimethoprim/<e2>sulfamethoxazole</e2> drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6021	 hypoglycemia</e1> secondary to a glipizide-<e2>trimethoprim</e2>/sulfamethoxazole drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6022	 sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with <e1>anuria</e1>, the day after 5 g/m2 bolus <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6023	 sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an <e1>irreversible lethal renal failure</e1> with anuria, the day after 5 g/m2 bolus <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6024	 is a known nephrotoxic drug with demonstrated <e2>tubulopathies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6025	 anuria</e1> complicating high dose <e2>ifosfamide</e2> chemotherapy in a breast cancer patient with an impaired renal function."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6026	 strongly suspect that this <e1>lethal anuria</e1> was mainly due to <e2>ifosfamide</e2>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6027	 is one drug that has been reported to cause <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6028	 toxicities</e1> have been reported in less than one percent of the patients receiving <e2>ciprofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6029	 <e1>ciprofloxacin</e1> -induced <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6030	 article describes a patient with suspected <e1>ciprofloxacin</e1> -induced <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6031	 a female with acute lymphoblastic leukemia, inadvertent <e1>doxorubicin</e1> administration intrathecally caused severe, life-threatening, <e2>acute encephalopathy</e2> with high-pressure hydrocephalus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6032	 a female with acute lymphoblastic leukemia, inadvertent <e1>doxorubicin</e1> administration intrathecally caused severe, life-threatening, acute encephalopathy with <e2>high-pressure hydrocephalus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6033	 acute encephalopathy</e1> following inadvertent intrathecal <e2>doxorubicin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6034	 <e2>hepatotoxicity</e2> in an 8-month-old infant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6035	 hepatotoxicity</e1> from <e2>phenobarbital</e2> occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6036	 rash began after 2 weeks of treatment, and signs of <e1>hepatocellular failure</e1> developed 3 weeks after <e2>phenobarbital</e2> had been started."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6037	 rash</e1> began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after <e2>phenobarbital</e2> had been started."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6038	 -induced <e2>pseudolymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6039	 <e1>tardive dyskinesia</e1> is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with <e2>sulpiride</e2>, a selective D2-receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6040	 dyskinesia</e1> induced by <e2>sulpiride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6041	 cases indicate that <e1>sulpiride</e1> can cause <e2>tardive dyskinesia</e2> and that this drug should be administered with caution."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6042	 describe six patients who developed <e1>tardive dyskinesia</e1> after treatment with <e2>sulpiride</e2> for depression or gastrointestinal symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6043	 patient with seropositive rheumatoid arthritis developed <e1>ascites</e1> while taking weekly doses of <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6044	 patient with seropositive rheumatoid arthritis developed <e1>ascites</e1> while taking weekly doses of methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6045	 with <e1>bridging fibrosis</e1> and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6046	 with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6047	 with bridging fibrosis and <e1>reversible hepatic insufficiency</e1> in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6048	 is the third report of reversible <e1>hepatic decompensation</e1> associated with prolonged <e2>MTX</e2> therapy in patients with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6049	 discontinuation of <e1>MTX</e1>, her <e2>ascites</e2> resolved, and her arthritis became more active."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6050	 high-dose <e1>methotrexate</e1> has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a <e2>fatal rise in intracranial pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6051	 patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and <e1>brainstem herniation</e1> after she received a single dose of intravenous <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6052	 patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed <e1>fatal cerebral edema</e1> and brainstem herniation after she received a single dose of intravenous <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6053	 herniation caused by an <e1>intracranial mass lesion</e1> following high-dose <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6054	 herniation</e1> caused by an intracranial mass lesion following high-dose <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6055	 pulmonary infiltrates, and pleural effusion following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6056	 pulmonary infiltrates, and <e1>pleural effusion</e1> following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6057	 <e1>pulmonary infiltrates</e1>, and pleural effusion following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6058	 the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed <e2>fever</e2>, hemoptysis, and a pleural friction rub."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6059	 the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed fever, <e2>hemoptysis</e2>, and a pleural friction rub."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6060	 the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed fever, hemoptysis, and a <e2>pleural friction rub</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6061	 <e1>fever</e1> abated promptly following discontinuation of <e2>acyclovir</e2>, and radiographic abnormalities resolved over ten days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6062	 our knowledge, the syndrome of <e1>fever</e1>, pulmonary infiltrates, and pleural effusion following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6063	 our knowledge, the syndrome of fever, pulmonary infiltrates, and <e1>pleural effusion</e1> following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6064	 our knowledge, the syndrome of fever, <e1>pulmonary infiltrates</e1>, and pleural effusion following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6065	 -induced <e2>hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6066	 hearing loss</e1> due to <e2>quinine</e2> therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6067	 case of a 29-year-old man suffering from falciparum malaria disease who got a <e1>reversible hearing loss</e1> from <e2>quinine</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6068	 <e1>ototoxicity</e1> of <e2>quinine</e2> can accurately be studied with ultrahigh frequency audiometry (up to 20 kHz)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6069	 uremic syndrome</e1> in a patient on cis-platinum, vinblastine and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6070	 uremic syndrome</e1> in a patient on <e2>cis-platinum</e2>, vinblastine and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6071	 uremic syndrome</e1> in a patient on cis-platinum, <e2>vinblastine</e2> and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6072	 case of a 53-year-old man who developed <e1>acute pneumonitis</e1> after <e2>bleomycin</e2> and moderate oxygen administration is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6073	 case of a 53-year-old man who developed <e1>acute pneumonitis</e1> after bleomycin and moderate <e2>oxygen</e2> administration is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6074	 findings were consistent with <e1>bleomycin</e1> and oxygen-induced <e2>pulmonary damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6075	 findings were consistent with bleomycin and <e1>oxygen</e1> -induced <e2>pulmonary damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6076	 <e2>pneumonitis</e2> potentiated by oxygen administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6077	 potentiation of <e1>bleomycin</e1> -induced <e2>pulmonary toxicity</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6078	 potentiation of bleomycin-induced <e2>pulmonary toxicity</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6079	 patient with the Wolff-Parkinson-White syndrome presented with <e1>incessant orthodromic atrioventricular tachycardia</e1> following initiation of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6080	 atrial complexes, which occurred following junctional premature complexes, failed to initiate <e1>tachycardia</e1> in the control state but <e1>tachycardia</e1> was always reinitiated by an identical escape sequence after <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6081	 addition, the <e1>tachycardia</e1> persisted and was repeatedly spontaneously reinitiated for prolonged periods after <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6082	 -induced <e2>incessant supraventricular tachycardia</e2> in the Wolff-Parkinson-White syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6083	 <e1>pro-arrhythmic effects</e1> of <e2>procainamide</e2> may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6084	 hepatocellular carcinoma</e1> following <e2>phosphate diethylstilbestrol</e2> therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6085	 is a unique autopsy case of <e1>hepatocellular carcinoma</e1> closely related to diethylstilbestrol (<e2>DES</e2>) therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6086	 is a unique autopsy case of <e1>hepatocellular carcinoma</e1> closely related to <e2>diethylstilbestrol</e2> (DES) therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6087	 paper reports an autopsy case of a 78-year-old male with <e1>multiple nodules in the liver</e1> developed after long-termed administration of phosphate diethylstilbestrol (<e2>PDES</e2>) for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6088	 paper reports an autopsy case of a 78-year-old male with <e1>multiple nodules in the liver</e1> developed after long-termed administration of <e2>phosphate diethylstilbestrol</e2> (PDES) for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6089	 52-year-old woman developed symmetric sensorimotor polyneuropathy and <e1>cerebellar syndrome</e1> after 24 months of <e2>amiodarone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6090	 52-year-old woman developed <e1>symmetric sensorimotor polyneuropathy</e1> and cerebellar syndrome after 24 months of <e2>amiodarone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6091	 neuropathy and <e1>cerebellar syndrome</e1> associated with <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6092	 neuropathy</e1> and cerebellar syndrome associated with <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6093	 <e1>hyponatremia</e1> caused by <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6094	 most likely cause of such <e1>hyponatremic episode</e1> is <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6095	 this type of <e1>hyperpigmentation</e1> has been previously seen in patients with cancer who are receiving <e2>bleomycin</e2>, this is, to our knowledge, the first reported case of <e2>bleomycin</e2> -induced <e1>hyperpigmentation</e1> in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6096	 this type of <e1>hyperpigmentation</e1> has been previously seen in patients with cancer who are receiving <e2>bleomycin</e2>, this is, to our knowledge, the first reported case of <e2>bleomycin</e2> -induced <e1>hyperpigmentation</e1> in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6097	 report a case of <e1>hyperpigmentation</e1> due to <e2>bleomycin</e2> treatment in a patient with acquired immune deficiency syndrome (AIDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6098	 typical case of <e1>dextran-40</e1> associated <e2>acute renal failure</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6099	 failure</e1> associated with the use of <e2>dextran-40</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6100	 possible explanations of the mechanism of <e1>renal failure</e1> associated with the use of <e2>dextran-40</e2> are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6101	 the mechanism of <e1>dextran</e1> -associated <e2>renal failure</e2> remains unsolved, plasma exchange seems to be effective therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6102	 findings in <e1>methotrexate</e1> -induced <e2>CNS abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6103	 57-year-old man developed <e1>morphea</e1> while taking <e2>bromocriptine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6104	 after <e2>bromocriptine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6105	 35-year-old female with borderline lepromatous (BL) leprosy who suffered from <e1>dapsone</e1> -induced <e2>erythroderma</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6106	 -induced <e2>erythroderma</e2> with Beau's lines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6107	 appeared to be a common side effect of <e2>fluoxetine</e2> and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6108	 patients receiving <e1>fluoxetine</e1> for the treatment of obsessive compulsive disorder or major depression developed <e2>akathisia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6109	 -induced <e2>akathisia</e2>: clinical and theoretical implications."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6110	 authors suggest that <e1>fluoxetine</e1> -induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine</e1> -induced <e2>akathisia</e2> and tricyclic antidepressant-induced "jitteriness" may be identical."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6111	 authors suggest that <e1>fluoxetine</e1> -induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine</e1> -induced <e2>akathisia</e2> and tricyclic antidepressant-induced "jitteriness" may be identical."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6112	 typical <e1>fluoxetine</e1> -induced symptoms of restlessness, <e2>constant pacing</e2>, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6113	 typical <e1>fluoxetine</e1> -induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and <e2>marked anxiety</e2> were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6114	 typical <e1>fluoxetine</e1> -induced symptoms of restlessness, constant pacing, <e2>purposeless movements of the feet and legs</e2>, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6115	 typical <e1>fluoxetine</e1> -induced symptoms of <e2>restlessness</e2>, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6116	 patients who had experienced neuroleptic-induced <e1>akathisia</e1> in the past reported that the symptoms of <e2>fluoxetine</e2> -induced <e1>akathisia</e1> were identical, although somewhat milder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6117	 syndrome and <e1>demyelinating peripheral neuropathy</e1> caused by high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6118	 syndrome</e1> and demyelinating peripheral neuropathy caused by high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6119	 nerve dysfunction</e1> is a potentially serious complication of high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6120	 nervous system disturbances</e1> caused by <e2>cytosine arabinoside</e2> have rarely been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6121	 describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to <e1>death</e1> after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6122	 describe a patient with acute leukemia who developed <e1>Horner's syndrome</e1> and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6123	 describe a patient with acute leukemia who developed Horner's syndrome and a <e1>severe demyelinating peripheral neuropathy</e1> leading to death after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6124	 induced by <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6125	 <e1>nail-changes</e1> in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of <e2>penicillamine</e2> treatment are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6126	 of <e1>penicillamine</e1> treatment caused a recurrence thus proving a causal relationship between <e1>penicillamine</e1> and the described <e2>nail-changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6127	 -induced <e2>meningitis</e2>: detection of intrathecal IgG synthesis and immune complexes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6128	 report a case of <e1>ibuprofen</e1> -induced <e2>meningitis</e2> in an otherwise healthy individual."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6129	 -induced <e2>parkinsonism</e2> is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6130	 -induced <e2>parkinsonism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6131	 <e1>parkinsonism</e1> improved on discontinuation of <e2>metoclopramide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6132	 have reported six cases of <e1>metoclopramide</e1> -induced <e2>parkinsonism</e2> seen in consultation over a two-year period."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6133	 is suggested that the fatal stroke may have resulted from <e1>arterial spasm</e1> caused by <e2>ergotamine</e2> overdosage and possibly complicated by thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6134	 is suggested that the <e1>fatal stroke</e1> may have resulted from arterial spasm caused by <e2>ergotamine</e2> overdosage and possibly complicated by thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6135	 <e1>acute hyponatraemia</e1> induced by low dose <e2>cyclophosphamide</e2> and indomethacin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6136	 <e1>acute hyponatraemia</e1> induced by low dose cyclophosphamide and <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6137	 report the case of a patient with multiple myeloma who developed acute <e1>life-threatening water intoxication</e1> following treatment with oral indomethacin and low dose intravenous <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6138	 report the case of a patient with multiple myeloma who developed acute <e1>life-threatening water intoxication</e1> following treatment with oral <e2>indomethacin</e2> and low dose intravenous cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6139	 induced <e2>nail changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6140	 <e1>nail changes</e1> gradually disappeared when the dose of <e2>clofazimine</e2> was reduced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6141	 cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed <e2>discoloration of nail plate</e2>, subungual hyperkeratosis and onycholysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6142	 cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed discoloration of nail plate, subungual hyperkeratosis and <e2>onycholysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6143	 cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed discoloration of nail plate, <e2>subungual hyperkeratosis</e2> and onycholysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6144	 of <e1>asparaginase</e1> -induced <e2>hyperglycemia</e2> after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6145	 of <e1>persistent late onset asthma</e1> following treatment with <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6146	 describe the first case of de novo <e1>asthma</e1> following treatment with the angiotensin converting enzyme (ACE) inhibitor <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6147	 case report of a patient with probable cisplatin and <e1>bleomycin</e1> -induced <e2>TMA</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6148	 case report of a patient with probable <e1>cisplatin</e1> and bleomycin-induced <e2>TMA</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6149	 patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with <e2>ascites</e2>, oesophageal varices and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6150	 patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with ascites, oesophageal varices and <e2>jaundice</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6151	 patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with ascites, <e2>oesophageal varices</e2> and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6152	 patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and <e2>portal hypertension</e2> with ascites, oesophageal varices and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6153	 a lot of <e1>amiodarone</e1> -induced <e2>torsades de pointe</e2> have been published, a review of all these cases and the underlying risk-factors has never been made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6154	 induced <e2>torsades de pointe</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6155	 report three cases of <e1>amiodarone</e1> -induced <e2>torsades de pointe</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6156	 syndrome of irreversible <e1>lithium</e1> -effectuated <e2>neurotoxicity</e2> (SILENT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6157	 lasting <e1>respiratory depression</e1> induced by <e2>morphine-6-glucuronide</e2>?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6158	 report a case of long lasting <e1>respiratory depression</e1> after intravenous administration of <e2>morphine</e2> to a 7 year old girl with haemolytic uraemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6159	 -associated <e2>thrombocytopenia</e2> secondary to poor compliance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6160	 can be associated with severe adverse effects such as hepatitis, <e2>acute renal failure</e2>, hemolytic anemia, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6161	 can be associated with severe adverse effects such as hepatitis, acute renal failure, <e2>hemolytic anemia</e2>, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6162	 can be associated with severe adverse effects such as <e2>hepatitis</e2>, acute renal failure, hemolytic anemia, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6163	 can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6164	 article reports the occurrence of <e1>rifampin</e1> -associated <e2>thrombocytopenia</e2> in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6165	 present the first case of <e1>WES</e1> in an infant born to a mother taking <e2>haloperidol</e2> during her pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6166	 emergent syndrome</e1> in an infant associated with maternal <e2>haloperidol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6167	 report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to cyclophosphamide, methotrexate, and <e2>5-fluorouracil</e2> adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6168	 report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to <e2>cyclophosphamide</e2>, methotrexate, and 5-fluorouracil adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6169	 report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to cyclophosphamide, <e2>methotrexate</e2>, and 5-fluorouracil adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6170	 rarely causes lower <e2>gastrointestinal adverse reactions</e2> but has been implicated in systemic and local side effects in patients with lupus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6171	 proctitis</e1> in juvenile systemic lupus erythematosus after <e2>ibuprofen</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6172	 describe a case of <e1>ulcerative proctitis</e1> after <e2>ibuprofen</e2> treatment in a girl with juvenile systemic lupus erythematosus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6173	 <e1>cytarabine</e1> and methotrexate appear to act synergistically to enhance the potential for <e2>central nervous system toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6174	 cytarabine and <e1>methotrexate</e1> appear to act synergistically to enhance the potential for <e2>central nervous system toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6175	 present two children with acute lymphocytic leukemia who developed <e1>leukoencephalopathy</e1> following administration of a combination of intravenous <e2>ara = C</e2> and methotrexate during the consolidation phase of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6176	 present two children with acute lymphocytic leukemia who developed <e1>leukoencephalopathy</e1> following administration of a combination of intravenous ara = C and <e2>methotrexate</e2> during the consolidation phase of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6177	 treatment of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> (AIT) with or without persistent administration of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6178	 of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> (AIT) with thionamide, lithium or radioactive iodine is ineffective."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6179	 myelogenous leukemia</e1> in patients receiving <e2>chlorambucil</e2> as long-term adjuvant chemotherapy for stage II breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6180	 the <e1>chlorambucil</e1> was discontinued, the wbc count began to slowly rise and the patient developed clinical <e2>AML</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6181	 anxiety</e1> after abrupt discontinuation of <e2>mianserin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6182	 <e1>panic anxiety</e1> was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of <e2>mianserin</e2> 30 mg/day, and because of that the depressive symptom also disappeared."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6183	 neurologic illness and the syndrome of irreversible <e1>lithium</e1> -effectuated <e2>neurotoxicity</e2> (SILENT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6184	 neurologic illness or CNS insult of any kind is known to increase the vulnerability to <e1>neurotoxicity</e1> of <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6185	 authors describe a patient with hemiparesis who developed the syndrome of irreversible <e1>lithium</e1> -effectuated <e2>neurotoxicity</e2> (SILENT) while being treated with <e1>lithium</e1> for a manic episode."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6186	 accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and <e2>acute respiratory difficulties</e2>, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6187	 accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the <e2>cranial dystonia</e2> associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6188	 accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the cranial dystonia associated with <e2>inspiratory stridor</e2> and acute respiratory difficulties, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6189	 <e1>cranial dystonia</e1> following <e2>trihexyphenidyl</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6190	 findings in <e1>methotrexate</e1> -induced <e2>CNS abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6191	 of intrathecal <e1>Ara-C</e1> in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (<e2>paresthesias</e2>) in only one of 30 patients so treated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6192	 following intrathecal <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6193	 following prophylactic intrathecal cytosine arabinoside (<e2>Ara-C</e2>) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6194	 following prophylactic intrathecal <e2>cytosine arabinoside</e2> (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6195	 patients developed <e1>hypoadrenalism</e1> while on <e2>o,p'-DDD</e2> and apparently adequate dexamethasone replacement therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6196	 -induced <e2>mania</e2>: two clinical cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6197	 authors caution that treatment with <e1>alprazolam</e1> may be complicated by the induction of <e2>mania</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6198	 patients treated with <e1>alprazolam</e1> had histories suggestive of a bipolar disorder and developed lithium-responsive <e2>manic episodes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6199	 case is presented in which a 68-year-old man became <e1>delirious</e1> after being withdrawn from a low dosage of <e2>alprazolam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6200	 withdrawal <e2>delirium</e2> unresponsive to diazepam: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6201	 has been associated with <e2>bronchopulmonary complications of inflammatory bowel disease</e2> (IBD) in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6202	 has been associated with bronchopulmonary complications of inflammatory bowel disease (<e2>IBD</e2>) in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6203	 discuss a variety of bronchopulmonary complications of <e1>IBD</e1> and their association with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6204	 of <e1>amantadine</e1> was associated with <e2>psychotic decompensations</e2> in two schizophrenic patients being maintained on concomitant neuroleptic medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6205	 a postulated dopaminergic mechanism, there seems to have been only one previous report of <e1>amantadine</e1>'s <e2>precipitating psychosis</e2> in a schizophrenic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6206	 of <e1>schizophrenia</e1> associated with <e2>amantadine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6207	 after its introduction in 1952, <e1>chlorpromazine</e1> was noted to induce <e2>symptoms resembling Parkinson's disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6208	 is suggested that the patient had <e1>sulfasalazine</e1> -induced <e2>lupus</e2>, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6209	 is suggested that the patient had <e1>sulfasalazine</e1> -induced lupus, which manifested with serositis and <e2>pulmonary parenchymal involvement</e2> in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6210	 is suggested that the patient had <e1>sulfasalazine</e1> -induced lupus, which manifested with <e2>serositis</e2> and pulmonary parenchymal involvement in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6211	 who use <e1>sulfasalazine</e1> to treat patients with inflammatory bowel disease should be aware of the signs of <e1>sulfasalazine</e1> -induced <e2>lupus syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6212	 <e1>bilateral pleural effusions</e1>, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6213	 bilateral pleural effusions, echocardiographic evidence of <e1>cardiac tamponade</e1>, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6214	 bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6215	 bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and <e1>positive autoantibodies</e1> developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6216	 -induced <e2>lupus erythematosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6217	 myocardial infarction</e1> due to coronary spasm associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6218	 myocardial infarction due to <e1>coronary spasm</e1> associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6219	 findings and laboratory data indicated a diagnosis of <e1>acute myocardial infarction</e1> due to the <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6220	 believe this is the first report of myocardial infarction due to <e1>coronary spasm</e1>, demonstrated by angiography associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6221	 believe this is the first report of <e1>myocardial infarction</e1> due to coronary spasm, demonstrated by angiography associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6222	 study of in vitro reactivity to <e1>L-T4</e1>, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed <e2>leukopenia</e2> during treatment with <e1>L-T4</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6223	 -induced <e2>leukopenia</e2> in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6224	 -induced interstitial nephritis with <e2>generalised exfoliative dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6225	 -induced <e2>interstitial nephritis</e2> with generalised exfoliative dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6226	 there are few reports in the literature of <e1>ampicillin</e1> as a cause of <e2>acute interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6227	 the following case report, a patient developed <e1>acute interstitial nephritis</e1> with renal failure and exfoliative dermatitis following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6228	 the following case report, a patient developed acute interstitial nephritis with renal failure and <e1>exfoliative dermatitis</e1> following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6229	 the following case report, a patient developed acute interstitial nephritis with <e1>renal failure</e1> and exfoliative dermatitis following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6230	 diagnosis was based on the rapid onset of renal failure, presence of <e1>eosinophilia</e1>, skin rash, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6231	 diagnosis was based on the rapid onset of <e1>renal failure</e1>, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6232	 diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, <e1>skin rash</e1>, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6233	 patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and <e2>erythema of the cartilage of both ears</e2>, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6234	 patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and <e2>hemorrhagic lesions of the finger tips</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6235	 patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a <e2>lupus-like syndrome</e2> characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6236	 patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a <e2>malar rash</e2>, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6237	 patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, <e2>pain</e2> and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6238	 patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and <e2>tender erythematous</e2> and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6239	 possible development of a drug-induced vasculitis or <e1>lupus-like syndrome</e1> should be added to the list of rare toxic effects of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6240	 possible development of a drug-induced <e1>vasculitis</e1> or lupus-like syndrome should be added to the list of rare toxic effects of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6241	 -induced <e2>vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6242	 retinal function</e1> associated with <e2>isotretinoin</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6243	 of 50 patients treated with <e1>isotretinoin</e1> (1 mg/kg/day) for cystic acne complained of poor night vision and/or <e2>excessive glare sensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6244	 of 50 patients treated with <e1>isotretinoin</e1> (1 mg/kg/day) for cystic acne complained of <e2>poor night vision</e2> and/or excessive glare sensitivity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6245	 toxicity</e1> associated with hepatic artery infusion HAI of <e2>FUdR</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6246	 is frequently used in the treatment of tuberculosis, and, although <e2>optic neuropathies</e2> have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication."
DRUG-ADE(e1,e2)
Comment: DRUG-A

6247	 we recently saw two patients with renal tuberculosis treated with <e1>ethambutol</e1> in whom visual loss from <e2>toxic optic neuropathies</e2> was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6248	 we recently saw two patients with renal tuberculosis treated with <e1>ethambutol</e1> in whom <e2>visual loss</e2> from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6249	 neuropathy</e1> in <e2>ethambutol</e2> -treated renal tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6250	 <e1>ethambutol</e1> is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of <e1>ethambutol</e1> sufficient to produce <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6251	 57-year-old woman presented with a 3-week history of <e1>dysphagia for solids</e1>, 6 months after starting treatment with <e2>nifedipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6252	 reflux</e1> associated with <e2>nifedipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6253	 may induce, or aggravate, pre-existing, <e2>gastro-oesophageal reflux</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6254	 young diamond dealer developed visual impairment attributed to <e1>bilateral posterior subcapsular cataracts</e1> following only four courses of intermittent <e2>Decadron</e2> used as part of a five-drug antiemetic regimen for cisplatin-associated nausea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6255	 young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for <e1>cisplatin</e1> -associated <e2>nausea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6256	 young diamond dealer developed <e1>visual impairment</e1> attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent <e2>Decadron</e2> used as part of a five-drug antiemetic regimen for cisplatin-associated nausea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6257	 induced by intermittent <e2>Decadron</e2> used as an antiemetic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6258	 reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on <e1>cisplatin</e1> -induced <e2>vomiting</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6259	 <e1>phenytoin</e1> induced <e2>IgA deficiency</e2> and permanent IgE increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6260	 <e1>phenytoin</e1> induced IgA deficiency and permanent <e2>IgE increase</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6261	 pharmacology and toxicology of <e1>chloral hydrate</e1> are discussed with particular reference to the <e2>cardiac arrhythmias</e2> that are seen with overdosage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6262	 <e2>dacryolith</e2>: detection by ultrasound examination of the nasolacrimal duct."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6263	 examination of the <e1>dacryolith</e1> suggested its derivation from breakdown products of <e2>adrenaline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6264	 pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of <e1>valproic acid</e1>; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through <e1>valproic acid</e1> -induced <e2>hyperammonemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6265	 <e1>valproic acid</e1> -induced <e2>dementia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6266	 <e1>valproic acid</e1> -induced <e2>dementia</e2> was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6267	 <e2>red cell aplasia</e2> in leukaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6268	 <e1>co-trimoxazole</e1> was stopped the <e2>red cell aplasia</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6269	 patient developed <e1>optic neuropathy</e1> while being treated with isoniazid and <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6270	 patient developed <e1>optic neuropathy</e1> while being treated with <e2>isoniazid</e2> and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6271	 well-recognized complication of ethambutol use is optic neuropathy, but the potential <e1>ocular toxicity</e1> of <e2>isoniazid</e2> is often overlooked."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6272	 well-recognized complication of <e1>ethambutol</e1> use is <e2>optic neuropathy</e2>, but the potential ocular toxicity of isoniazid is often overlooked."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6273	 and <e1>ethambutol</e1> as a cause of <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6274	 and ethambutol as a cause of <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6275	 woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal <e1>Depo-Medrol</e1>, developed a <e2>spastic paraparesis at the lower limbs</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6276	 and ossification of the spinal arachnoid after intrathecal administration of <e2>Depo-Medrol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6277	 and <e1>ossification of the spinal arachnoid</e1> after intrathecal administration of <e2>Depo-Medrol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6278	 young woman with epilepsy had <e1>tonic-clonic seizures</e1> during antineoplastic therapy with <e2>adriamycin</e2> and cisplatin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6279	 young woman with epilepsy had <e1>tonic-clonic seizures</e1> during antineoplastic therapy with adriamycin and <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6280	 as a late side effect of prolonged <e2>adrenocorticotropic hormone</e2> therapy for infantile spasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6281	 infants developed <e1>hyperkalemia</e1> shortly after cessation of prolonged <e2>ACTH</e2> therapy for infantile spasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6282	 wish to call for cautious approach at time of cessation of prolonged <e1>ACTH</e1> therapy because of possible unexpected and only partially understood hazardous side effects such as <e2>hyperkalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6283	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and <e2>acute renal impairment</e2>) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6284	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and <e2>acute renal impairment</e2>) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6285	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, <e2>hyperkalaemia</e2> and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6286	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, <e2>hyperkalaemia</e2> and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6287	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and <e2>hyperphosphataemia</e2> with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6288	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and <e2>hyperphosphataemia</e2> with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6289	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (<e2>hyper-uricaemia</e2>, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6290	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (<e2>hyper-uricaemia</e2>, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6291	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with <e2>hypocalcaemia</e2> and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6292	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with <e2>hypocalcaemia</e2> and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6293	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with <e2>metabolic acidosis</e2> and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6294	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with <e2>metabolic acidosis</e2> and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6295	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the '<e2>phosphate shower syndrome</e2>' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6296	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the '<e2>phosphate shower syndrome</e2>' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6297	 patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and <e2>tetany</e2>, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6298	 patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and <e2>tetany</e2>, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6299	 <e1>camptocormia</e1> is a dose-dependent side effect of <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6300	 mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an <e1>abnormal posture of extreme forward flexion</e1>, called camptocormia, during <e2>valproate</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6301	 mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called <e1>camptocormia</e1>, during <e2>valproate</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6302	 a new side effect of <e2>sodium valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6303	 weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of <e2>carbamazepine</e2>, lynestrenol and sodium valproate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6304	 weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of carbamazepine, <e2>lynestrenol</e2> and sodium valproate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6305	 weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of carbamazepine, lynestrenol and <e2>sodium valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6306	 subsided after the cessation of <e2>carbamazepine</e2> and lynestrenol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6307	 subsided after the cessation of carbamazepine and <e2>lynestrenol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6308	 10-year-old girl with Lennox-Gastaut syndrome who received intravenous <e1>lorazepam</e1> for atypical absence status <e2>seizures</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6309	 precipitation of tonic seizures</e1> by <e2>lorazepam</e2> in a child with atypical absence seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6310	 fibrillation</e1> following <e2>methylprednisolone</e2> pulse therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6311	 a drug used for the treatment of acne, has been shown to have <e2>teratogenic effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6312	 <e2>teratogenicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6313	 report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and <e2>abnormalities of the corticospinal tracts</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6314	 report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had <e2>agenesis of the cerebellar vermis</e2>, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6315	 report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, <e2>hydrocephalus</e2>, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6316	 report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, <e2>multiple leptomeningeal neuroglial heterotopias</e2>, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6317	 report an additional case of <e1>isotretinoin</e1> <e2>teratogenicity</e2> in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6318	 case of <e1>allopurinol</e1> <e2>hypersensitivity</e2>, possibly the first in a black African, is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6319	 <e2>hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6320	 <e1>allopurinol</e1> <e2>hypersensitivity syndrome</e2> is a rare adverse drug reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6321	 formation</e1> induced in an infant by systemic <e2>prostaglandin-E2</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6322	 case of <e1>severe visual loss</e1> following a single dose of <e2>vincristine</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6323	 differential diagnostic alternatives can be considered in all described cases it is very likely that <e1>vincristine</e1> does cause <e2>severe visual loss</e2> in a small number of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6324	 visual loss</e1> after a single dose of <e2>vincristine</e2> in a patient with spinal cord astrocytoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6325	 literature of <e1>vincristine</e1> <e2>optic nerve toxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6326	 loss</e1> after a single small dose of <e2>vincristine</e2> has never been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6327	 causes a <e2>reversible toxic cystoid maculopathy</e2> that occurs in approximately 0.67% of patients taking high doses of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6328	 <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6329	 authors conclude that among patients taking high doses of oral <e1>niacin</e1> only those who experience <e2>visual symptoms</e2> need to be ophthalmologically evaluated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6330	 patients with <e1>niacin</e1> -induced visual symptoms had <e2>cystoid maculopathy</e2> without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6331	 patients with <e1>niacin</e1> -induced <e2>visual symptoms</e2> had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of <e2>visual symptoms</e2> upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6332	 patients with <e1>niacin</e1> -induced <e2>visual symptoms</e2> had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of <e2>visual symptoms</e2> upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6333	 case report of the <e1>hypersensitivity syndrome</e1> occurring in a patient being treated with <e2>dapsone</e2> for a brown recluse spider bite is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6334	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of <e2>fever</e2>, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6335	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, <e2>headache</e2>, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6336	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, <e2>hemolysis</e2>, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6337	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, <e2>hepatitis</e2>, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6338	 <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6339	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, <e2>leukopenia</e2>, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6340	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, <e2>lymphadenopathy</e2>, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6341	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and <e2>mononucleosis</e2>, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6342	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, <e2>nausea</e2>, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6343	 <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, <e2>vomiting</e2>, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6344	 report: <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2> associated with treatment of the bite of a brown recluse spider."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6345	 -induced <e2>adrenal insufficiency</e2> in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6346	 report the case of a patient with the acquired immunodeficiency syndrome treated with <e1>rifampicin</e1> who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of <e2>adrenal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6347	 cases of widespread <e1>cutaneous vasculitis</e1> are described in association with <e2>diltiazem</e2>, a recently introduced calcium antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6348	 <e1>cutaneous vasculitis</e1> associated with <e2>diltiazem</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6349	 <e1>nafcillin</e1> -induced <e2>seizures</e2> in a neonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6350	 report a premature infant who developed <e1>seizures</e1> associated with intraventricular administration of <e2>nafcillin</e2> and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6351	 58-year old patient is reported who developed an <e1>ischaemic cerebrovascular accident</e1> 22 hours after successful thrombolysis with <e2>streptokinase</e2> for life-threatening pulmonary emboli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6352	 complication</e1> after <e2>streptokinase</e2> therapy of pulmonary emboli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6353	 hypophosphatemia</e1> in this patient was caused by the erroneous intake of 1 g <e2>doxycycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6354	 clinically atypical, neuropathologically verified case of <e1>Creutzfeldt-Jakob disease</e1> is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with <e2>human growth hormone</e2> processed from pooled cadaveric pituitary glands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6355	 new case of <e1>Creutzfeldt-Jakob disease</e1> associated with <e2>human growth hormone</e2> therapy in New Zealand."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6356	 case of a 21-year-old woman who had developed mild <e1>hepatotoxicity</e1> while receiving <e2>choline magnesium trisalicylate</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6357	 associated with choline magnesium tri<e1>salicylate</e1>: case report and review of <e1>salicylate</e1> -induced <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6358	 associated with <e2>choline magnesium trisalicylate</e2>: case report and review of salicylate-induced hepatotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6359	 -induced <e2>hepatotoxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6360	 continued to rise for five more days before <e1>salicylate</e1> <e2>hepatotoxicity</e2> was suspected."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6361	 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when <e2>captopril</e2> was added to the nadolol and dyazide treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6362	 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when captopril was added to the nadolol and <e2>dyazide</e2> treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6363	 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when captopril was added to the <e2>nadolol</e2> and dyazide treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6364	 -related (and -induced?) <e2>asthma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6365	 confirmed the history of <e1>captopril</e1> -related <e2>asthma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6366	 also describe a case of <e1>timolol</e1> -induced <e2>ocular pemphigoid</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6367	 of plasma proteins in the skin</e1> during treatment with <e2>carbamazepine</e2> and diphenylhydantoin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6368	 of plasma proteins in the skin</e1> during treatment with carbamazepine and <e2>diphenylhydantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6369	 observations suggest that testicular swelling and <e1>pain</e1> are side effects of <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6370	 observations suggest that <e1>testicular swelling</e1> and pain are side effects of <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6371	 patients are described who developed testicular swelling and <e1>pain</e1> during treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6372	 patients are described who developed <e1>testicular swelling</e1> and pain during treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6373	 an ester-type local anesthetic, was believed responsible for apparent <e2>methemoglobinemia</e2> in a cat."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6374	 -induced <e2>methemoglobinemia</e2> has been reported in man, dogs, and cats."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6375	 associated with dermal application of <e2>benzocaine</e2> cream in a cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6376	 43-year-old white man developed a shallow <e1>erosion of a psoriatic plaque</e1> after chronic administration of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6377	 of psoriatic plaques</e1> after chronic <e2>methotrexate</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6378	 a six-week course of low-dose <e1>cyclosporine A</e1>, she developed a severe but reversible loss of glomerular filtration rate and <e2>effective renal plasma flow</e2> despite of low <e1>cyclosporine A</e1> plasma levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6379	 a six-week course of low-dose <e1>cyclosporine A</e1>, she developed a severe but reversible <e2>loss of glomerular filtration rate</e2> and effective renal plasma flow despite of low <e1>cyclosporine A</e1> plasma levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6380	 upon the observed <e1>fall of the filtration fraction</e1>, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6381	 upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the <e1>increase in proteinuria</e1>, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6382	 upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e1>cyclosporine A</e1> <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6383	 upon the observed fall of the filtration fraction, the <e1>rise in the relative clearance of 99Tc-dimercaptosuccinic acid</e1> and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6384	 severe reversible <e1>cyclosporine A</e1> -induced <e2>nephrotoxicity</e2> in a patient with systemic lupus erythematosus and tubulointerstitial renal disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6385	 patient is presented with typical <e1>hyperthyroidism</e1>, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for <e1>hyperthyroidism</e1> with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6386	 patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a <e1>raised creatine phosphokinase</e1> after treatment for hyperthyroidism with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6387	 patient is presented with typical hyperthyroidism, who developed a <e1>severe proximal muscle weakness</e1> and a raised creatine phosphokinase after treatment for hyperthyroidism with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6388	 after <e2>propylthiouracil</e2> treatment for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6389	 arrest</e1> following intravenous <e2>phenytoin</e2> loading."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6390	 obtained indicated that the Reye-like syndrome might be caused by <e1>calcium hopantenate</e1> possibly due to the induction of <e2>pantothenic acid deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

6391	 obtained indicated that the <e1>Reye-like syndrome</e1> might be caused by <e2>calcium hopantenate</e2> possibly due to the induction of pantothenic acid deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6392	 syndrome</e1> following treatment with the pantothenic acid antagonist, <e2>calcium hopantenate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6393	 senile patients developed <e1>fatal acute encephalopathy</e1> while receiving <e2>calcium hopantenate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6394	 possibly associated with controlled-release <e2>morphine sulfate</e2> tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6395	 ejaculation</e1> with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6396	 report two patients with <e1>anhedonic ejaculation</e1> (ejaculation without orgasm) associated with initiation of treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6397	 report two patients with anhedonic ejaculation (<e1>ejaculation without orgasm</e1>) associated with initiation of treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6398	 spasms</e1> following intrathecal <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6399	 case of <e1>halothane</e1> induced <e2>hepatitis</e2> is reported in a middle aged woman who underwent gastric surgery for morbid obesity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6400	 <e2>hepatitis</e2> and prompt resolution with methionine therapy: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6401	 of <e1>porphyria cutanea tarda</e1> after treatment with <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6402	 report a 46-yr-old woman with ovarian carcinoma who developed <e1>porphyria cutanea tarda</e1> while undergoing treatment with <e2>cisplatin</e2> and cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6403	 report a 46-yr-old woman with ovarian carcinoma who developed <e1>porphyria cutanea tarda</e1> while undergoing treatment with cisplatin and <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6404	 renal failure</e1> in a patient treated by continuous povidone-<e2>iodine</e2> mediastinal irrigation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6405	 renal failure</e1> in a patient treated by continuous <e2>povidone</e2> -iodine mediastinal irrigation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6406	 describe a 63 year old woman with a suppurative mediastinitis, treated with continuous <e1>PI</e1> irrigation who developed an <e2>acute oliguric renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6407	 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with <e1>epithelial crescents</e1> associated with hemoptysis after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6408	 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with <e1>hemoptysis</e1> after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6409	 56-year-old woman with scleroderma developed <e1>rapidly progressive glomerulonephritis</e1> with epithelial crescents associated with hemoptysis after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6410	 induced <e2>crescentic glomerulonephritis</e2>: report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6411	 9 other reported cases of <e1>D-penicillamine</e1> induced <e2>rapidly progressive glomerulonephritis</e2> have been reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6412	 -induced <e2>pneumonitis</e2> is a rare complication of gold salt therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6413	 -induced <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6414	 case supports the view that in <e1>gold</e1> -induced <e2>pneumonitis</e2> a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6415	 describe a patient with rheumatoid arthritis treated with <e1>gold</e1> salts, who developed <e2>bilateral interstitial pulmonary abnormalities</e2> and showed a dramatic response on corticosteroid therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6416	 -induced <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6417	 patients receiving <e1>gold</e1> salt treatment for rheumatoid arthritis developed severe <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6418	 determinants of <e1>6-mercaptopurine</e1> <e2>myelotoxicity</e2> and therapeutic failure in children with acute lymphoblastic leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6419	 the <e1>cerebellar toxicity</e1> may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of <e2>HDARAC</e2> is recommended."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6420	 -induced <e2>cerebellar syndrome</e2>: case report and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6421	 the first treatment, dysarthria and <e1>ataxia</e1> were seen after completion of the patient's eighth and final dose of <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6422	 the first treatment, <e1>dysarthria</e1> and ataxia were seen after completion of the patient's eighth and final dose of <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6423	 <e1>neurotoxicity</e1> seen with <e2>HDARAC</e2> is dose-related and has occurred in up to 60 percent of treated patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6424	 case report illustrates the <e1>neurotoxicity</e1> unique to <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6425	 infarction</e1> after endophthalmitis treated with vitrectomy and intravitreal <e2>gentamicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6426	 are concerned that the <e1>macular lesion</e1> was a retinal toxic effect of <e2>gentamicin</e2> because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6427	 woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a <e1>B-cell lymphoma</e1> of the lip following 4 1/2 years of treatment with <e2>razoxane</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6428	 immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed <e1>hypogammaglobulinemia</e1> in the course of <e2>gold</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6429	 associated with <e2>gold</e2> therapy: evidence for a partial maturation blockade of B cells."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6430	 <e1>leucopenia</e1> and thrombocytopenia associated with <e2>sodium nitroprusside</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6431	 leucopenia and <e1>thrombocytopenia</e1> associated with <e2>sodium nitroprusside</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6432	 simplex esophagitis</e1> in a renal transplant patient treated with <e2>cyclosporine A</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6433	 report the first case of <e1>herpes esophagitis</e1> in a renal transplant patient treated with <e2>Cyclosporine A</e2> while on chronic steroid therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6434	 the increasing use of <e1>Cyclosporine A</e1> in transplant patients, the incidence of <e2>herpes esophagitis</e2> may increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6435	 of excessive <e1>insulin</e1> induced <e2>hypoglycemia</e2> within 4 to 8 hours, followed by rebound hyperglycemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6436	 of excessive <e1>insulin</e1> induced hypoglycemia within 4 to 8 hours, followed by <e2>rebound hyperglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6437	 hyperglycemia</e1> (rebound hyperglycemia) after overdosing of <e2>insulin</e2> was diagnosed in 6 cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6438	 hyperglycemia (<e1>rebound hyperglycemia</e1>) after overdosing of <e2>insulin</e2> was diagnosed in 6 cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6439	 <e1>hyperglycemia</e1> following overdosing of <e2>insulin</e2> in cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6440	 hyperglycemia</e1> was observed with both intermediate (neutral <e2>protamine hagedorn</e2>) and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6441	 hyperglycemia</e1> was observed with both intermediate (neutral protamine hagedorn) and long-acting (<e2>protamine zinc iletin</e2>) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6442	 -induced <e2>lichen planus pemphigoides</e2> with pemphigus-like features."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6443	 report a case of a <e1>bullous lichenoid eruption</e1> due to the intake of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6444	 8-year-old girl, who had been vaccinated with <e1>BCG</e1> without subsequent regional reactions, developed <e2>osteomyelitis in the left calcaneus</e2> 7 months later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6445	 osteomyelitis</e1> following <e2>BCG</e2> vaccination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6446	 of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had hypertension and <e2>arteriosclerotic disease</e2> and the other died of a myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6447	 of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had <e2>hypertension</e2> and arteriosclerotic disease and the other died of a myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6448	 of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had hypertension and arteriosclerotic disease and the other died of a <e2>myocardial infarction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6449	 -induced <e2>cognitive impairment</e2> in two patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6450	 patients are described in whom subtle <e1>cognitive impairments</e1> are associated with therapeutic doses of <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6451	 23-year-old woman with systemic lupus erythematosus had a <e1>severe hypersensitivity reaction</e1> to the drug <e2>ibuprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6452	 systemic hypersensitivity reaction</e1> to <e2>ibuprofen</e2> occurring after prolonged therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6453	 brief review of reported cases of <e1>chloramphenicol</e1> <e2>hypersensitivity</e2> in the English-language literature, as well as possible alternative explanations in this case, are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6454	 reaction</e1> following <e2>chloramphenicol</e2> administration in a patient with typhoid fever."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6455	 reactions</e1> due to <e2>chloramphenicol</e2> are rarely reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6456	 present a case report of a patient with typhoid fever who experienced a <e1>hypersensitivity reaction</e1> subsequent to the infusion of <e2>chloramphenicol sodium succinate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6457	 brain magnetic resonance imaging examinations after six weeks and 11 months of <e1>penicillamine</e1> therapy documented the development of new <e2>brain lesions</e2> during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6458	 develop information on the relative rarity or frequency of neurologic worsening with the initiation of <e1>penicillamine</e1> therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with <e2>neurologic disease</e2> and having been treated with <e1>penicillamine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6459	 develop information on the relative rarity or frequency of <e1>neurologic worsening</e1> with the initiation of <e2>penicillamine</e2> therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6460	 describe a patient with Wilson's disease who presented with neurologic disease, was treated with <e1>D-penicillamine</e1>, and suffered sudden <e2>neurologic deterioration</e2> coincident with therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6461	 of neurologic syndrome</e1> in patients with Wilson's disease with initial <e2>penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6462	 <e1>upper tract neoplasms</e1> after <e2>cyclophosphamide</e2> are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6463	 tract urothelial malignancy</e1> after <e2>cyclophosphamide</e2> therapy: a case report and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6464	 report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and <e1>distal ureter without transitional cell carcinoma of the bladder</e1> occurring after chronic <e2>cyclophosphamide</e2> therapy for nonHodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6465	 report an unusual case of simultaneous <e1>transitional cell carcinoma of the renal pelvis</e1> and distal ureter without transitional cell carcinoma of the bladder occurring after chronic <e2>cyclophosphamide</e2> therapy for nonHodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6466	 pulmonary fibrosis</e1> complicating <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6467	 changes were progressive regardless of discontinuation of <e1>cyclophosphamide</e1> and led to <e2>severe restrictive ventilatory defect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6468	 de pointes</e1> during loading with <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6469	 de pointes</e1> represents a potential complication of chronic <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6470	 report a case of <e1>torsade de pointes</e1> following a single oral dose of <e2>amiodarone</e2> (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6471	 edema</e1> as a delayed complication of <e2>ritodrine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6472	 edema</e1> occurred 24 hours after intravenous <e2>ritodrine</e2> therapy and 10 hours after subcutaneous terbutaline therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6473	 edema</e1> occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous <e2>terbutaline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6474	 side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and <e2>abnormalities in liver function tests</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6475	 side effects included <e2>hirsutism</e2>, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6476	 side effects included hirsutism, <e2>hypertension</e2>, increased blood levels of urea and creatinine, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6477	 side effects included hirsutism, hypertension, <e2>increased blood levels of urea and creatinine</e2>, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6478	 of a cerebral aneurysm</e1> associated with <e2>nifedipine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6479	 describe <e1>rupture of a cerebral arterial aneurysm</e1> in a 32 year old hypertensive woman following the introduction of <e2>nifedipine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6480	 small initial dose of <e1>prazosin</e1> ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and <e2>severe drop in blood pressure</e2> after the administration of the first dose of <e1>prazosin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6481	 small initial dose of <e1>prazosin</e1> ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and <e2>severe drop in blood pressure</e2> after the administration of the first dose of <e1>prazosin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6482	 -induced first-dose phenomenon possibly associated with <e2>hemorrhagic stroke</e2>: a report of three cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6483	 <e1>fatal massive pulmonary embolus</e1> developed in a patient treated with <e2>streptokinase</e2> for acute deep vein thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6484	 pulmonary embolism</e1> complicating <e2>streptokinase</e2> treatment for deep vein thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6485	 <e2>digoxin</e2> poisoning: an unsuccessful resuscitation with use of <e2>digoxin</e2> -immune Fab."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6486	 case of <e1>phenytoin</e1> -induced <e2>hepatitis</e2> with mononucleosis is reported, and syndromes associated with <e1>phenytoin</e1> hypersensitivity reactions are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6487	 case of <e1>phenytoin</e1> -induced hepatitis with mononucleosis is reported, and syndromes associated with <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6488	 case of <e1>phenytoin</e1> -induced hepatitis with <e2>mononucleosis</e2> is reported, and syndromes associated with <e1>phenytoin</e1> hypersensitivity reactions are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6489	 -induced <e2>hypersensitivity reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6490	 was discontinued after admission; however, <e1>phenytoin</e1> 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and <e2>pruritus</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6491	 was discontinued after admission; however, <e1>phenytoin</e1> 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which <e2>swelling of the face and legs</e2> and pruritus developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6492	 <e1>phenytoin</e1> hypersensitivity reactions may appear as <e2>dermatologic, lymphoid, or hepatic syndromes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6493	 <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> may appear as dermatologic, lymphoid, or hepatic syndromes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6494	 was receiving phenytoin sodium 300 mg/day; <e1>carbamazepine</e1> 200 mg four times daily had been discontinued four days before admission because of <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6495	 was receiving <e1>phenytoin sodium</e1> 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6496	 possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly <e2>fever</e2>, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6497	 possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly <e2>fever</e2>, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6498	 possibility of <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6499	 possibility of <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6500	 possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and <e2>lymphadenopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6501	 possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and <e2>lymphadenopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6502	 possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, <e2>rash</e2>, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6503	 possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, <e2>rash</e2>, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6504	 was restarted 6 weeks later, and 10 weeks after that, the patient presented with <e1>fulminant hepatic failure</e1>, which resolved rapidly after cessation of <e2>nicotinic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6505	 acid</e1> -induced <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6506	 suggest that <e1>nicotinic acid</e1> was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6507	 suggest that <e1>nicotinic acid</e1> was the cause of his <e2>liver disease</e2>, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6508	 suggest that <e1>nicotinic acid</e1> was the cause of his <e2>liver disease</e2>, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6509	 infant girl with choanal atresia, <e1>athelia</e1>, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6510	 infant girl with choanal atresia, <e1>athelia</e1>, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6511	 infant girl with <e1>choanal atresia</e1>, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6512	 infant girl with <e1>choanal atresia</e1>, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6513	 infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate <e1>mental retardation</e1> was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6514	 infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate <e1>mental retardation</e1> was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6515	 atresia and <e1>athelia</e1>: <e2>methimazole</e2> teratogenicity or a new syndrome?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6516	 atresia</e1> and athelia: <e2>methimazole</e2> teratogenicity or a new syndrome?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6517	 atresia and athelia: <e1>methimazole</e1> <e2>teratogenicity</e2> or a new syndrome?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6518	 patient's defects may be due to <e1>methimazole</e1> <e2>teratogenicity</e2> or could represent a previously undescribed syndrome affecting ectodermal structures."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6519	 epidermal necrolysis</e1> resulted after 19 days of treatment with <e2>5-fluorocytosine</e2> and amphotericin B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6520	 epidermal necrolysis</e1> resulted after 19 days of treatment with 5-fluorocytosine and <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6521	 and one-half years after the diagnosis of myeloma, while in remission on <e1>cyclophosphamide</e1> therapy, the patient experienced severe <e2>abdominal right lower quadrant pain</e2> due to a large cecal lymphoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6522	 and one-half years after the diagnosis of myeloma, while in remission on <e1>cyclophosphamide</e1> therapy, the patient experienced severe abdominal right lower quadrant pain due to a large <e2>cecal lymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6523	 therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and <e2>fall in prothrombin time</e2>, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6524	 therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed <e2>jaundice</e2>, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6525	 therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, <e2>marked increase in serum transaminase levels</e2> and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6526	 therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of <e2>severe centrilobular necrosis</e2> were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6527	 patient with acute changes suggesting <e1>acute hepatitis</e1> after parenteral <e2>amiodarone</e2> administration is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6528	 early <e1>acute hepatitis</e1> with parenteral <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6529	 parenteral <e1>amiodarone</e1> was implicated as the cause of <e2>acute hepatitis</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6530	 became <e1>hyperkalemic</e1> on rechallenge with <e2>timolol</e2> and normokalemic following its withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6531	 hyperkalemia</e1> as a complication of <e2>timolol</e2>, a topically applied beta-adrenergic antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6532	 hyperkalemia</e1> occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning <e2>prednisone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6533	 pulmonary edema</e1> during intrabiliary infusion of <e2>mono-octanoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6534	 describe a patient in whom <e1>noncardiogenic pulmonary edema</e1> developed during intrabiliary infusion of <e2>monooctanoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6535	 supraventricular tachycardia</e1> during treatment with <e2>cisplatin</e2> and etoposide combination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6536	 supraventricular tachycardia</e1> during treatment with cisplatin and <e2>etoposide</e2> combination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6537	 report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed <e1>paroxysmal supraventricular tachycardia</e1> during <e2>cisplatin</e2> and etoposide combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6538	 report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed <e1>paroxysmal supraventricular tachycardia</e1> during cisplatin and <e2>etoposide</e2> combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6539	 case is reported of theophylline intoxication due to a dramatic <e1>decrease in theophylline clearance</e1> following concomitant administration of <e2>viloxazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6540	 case is reported of <e2>theophylline</e2> intoxication due to a dramatic decrease in <e2>theophylline</e2> clearance following concomitant administration of viloxazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6541	 case is reported of <e1>theophylline intoxication</e1> due to a dramatic decrease in theophylline clearance following concomitant administration of <e2>viloxazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6542	 intoxication following <e1>viloxazine</e1> induced <e2>decrease in clearance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6543	 intoxication following viloxazine induced decrease in clearance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6544	 intoxication</e1> following <e2>viloxazine</e2> induced decrease in clearance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6545	 pulmonary reactions to <e1>nitrofurantoin</e1> are not unusual, often presenting as <e2>eosinophilic pneumonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6546	 pulmonary reactions</e1> to <e2>nitrofurantoin</e2> are not unusual, often presenting as eosinophilic pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6547	 myocardial necrosis</e1> during administration of <e2>amsacrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6548	 addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of <e1>amsacrine</e1> -related <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6549	 addition to the recognized arrhythmic complications, the authors emphasize <e1>myocardial necrosis</e1> as a possible further manifestation of <e2>amsacrine</e2> -related cardiotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6550	 authors report a case of focal myocardial necrosis, presenting clinically as an <e1>acute myocardial infarction</e1> during the administration of the antineoplastic drug, <e2>amsacrine</e2>, in a patient without coronary artery disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6551	 authors report a case of <e1>focal myocardial necrosis</e1>, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, <e2>amsacrine</e2>, in a patient without coronary artery disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6552	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, <e2>alopecia</e2>, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6553	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, <e2>a pruritic desquamating erythrodermic rash</e2>, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6554	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of <e2>fever</e2>, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6555	 child in whom a <e1>phenobarbital</e1> <e2>hypersensitivity</e2> drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6556	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, <e2>icterus</e2>, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6557	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, <e2>myositis</e2>, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6558	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and <e2>nephritis</e2>, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6559	 child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, <e2>protein-losing enteropathy</e2>, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6560	 versus host-like illness</e1> in a child with <e2>phenobarbital</e2> hypersensitivity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6561	 versus host-like illness in a child with <e1>phenobarbital</e1> <e2>hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6562	 clinical findings and laboratory studies suggested an <e1>autoimmune cell-mediated hypersensitivity</e1> reaction triggered by <e2>phenobarbital</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6563	 ulceration</e1>: a complication of <e2>tolazoline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6564	 patients who were receiving <e1>Tolazoline</e1> by infusion developed <e2>duodenal ulceration</e2> and subsequent intestinal perforation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6565	 patients who were receiving <e1>Tolazoline</e1> by infusion developed duodenal ulceration and subsequent <e2>intestinal perforation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6566	 latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, <e2>acute and chronic pulmonary reactions</e2>, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6567	 latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and <e2>allergic reactions</e2> --and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6568	 latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, <e2>blood dyscrasias</e2> and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6569	 latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--<e2>liver damage</e2>, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6570	 latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, <e2>peripheral neuropathy</e2>, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6571	 pustular psoriasis</e1> precipitated by <e2>trazodone</e2> in the treatment of depression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6572	 report a patient in whom the anti-depressant trazodone hydrochloride (<e1>Molipaxin</e1>, Roussel), a serotonin antagonist, provoked <e2>generalized pustular psoriasis</e2> (GPP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6573	 report a patient in whom the anti-depressant <e1>trazodone hydrochloride</e1> (Molipaxin, Roussel), a serotonin antagonist, provoked <e2>generalized pustular psoriasis</e2> (GPP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6574	 report a patient in whom the anti-depressant trazodone hydrochloride (<e1>Molipaxin</e1>, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (<e2>GPP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6575	 report a patient in whom the anti-depressant <e1>trazodone hydrochloride</e1> (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (<e2>GPP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6576	 verapamil therapy in babies may cause <e1>apnea</e1>, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; <e2>quinidine</e2> may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6577	 <e1>verapamil</e1> therapy in babies may cause <e2>apnea</e2>, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6578	 <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of <e2>atrial flutter</e2> in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6579	 <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and <e2>bradycardia</e2>; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6580	 verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden <e1>death</e1>; <e2>quinidine</e2> may be related to the <e1>death</e1>; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6581	 <e1>verapamil</e1> therapy in babies may cause apnea, <e2>hypotension</e2>, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6582	 verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; <e1>quinidine</e1> may be related to the death; children with "familial seizure disorders" may in fact have the <e2>long QT interval syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6583	 <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause <e2>sudden death</e2>; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6584	 -associated <e2>cholestatic liver injury</e2>: case report and brief literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6585	 authors report a further case of <e1>methimazole</e1> -associated <e2>liver damage</e2> and present a brief review of eleven previous cases found in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6586	 main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and <e1>bile stasis</e1>, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6587	 main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and <e1>cholestasis</e1>, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6588	 main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of <e1>fatty liver parenchyma degeneration</e1> with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6589	 main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with <e1>granulocytic portal infiltration</e1> and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6590	 main clinical features of this 58-year-old female patient were laboratory evidence of <e1>leucopenia</e1> and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6591	 of corpus cavernosum</e1> after intracavernous injection of phentolamine/<e2>papaverine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6592	 of corpus cavernosum</e1> after intracavernous injection of <e2>phentolamine</e2>/papaverine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6593	 report a case of <e1>penile fibrosis</e1> after intracavernous self-injection of a combination of phentolamine and <e2>papaverine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6594	 report a case of <e1>penile fibrosis</e1> after intracavernous self-injection of a combination of <e2>phentolamine</e2> and papaverine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6595	 57-year-old woman developed <e1>pulmonary sarcoidosis</e1> during therapy with <e2>interferon beta</e2> for advanced renal cell carcinoma metastatic to mediastinal lymph nodes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6596	 possible role of <e1>interferon beta</e1> in the pathogenesis of <e2>sarcoidosis</e2> in this patient is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6597	 outcome</e1> of intravesical <e2>formalin</e2> instillation, with changes mimicking renal tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6598	 present a case report of a patient with alveolar hydatid disease, whose treatment with <e1>mebendazole</e1> was brief due to side effects of <e2>alopecia</e2> and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6599	 present a case report of a patient with alveolar hydatid disease, whose treatment with <e1>mebendazole</e1> was brief due to side effects of alopecia and <e2>granulocytopenia</e2>; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6600	 <e1>colitis</e1> (pseudomembranous <e1>colitis</e1>) developed in four patients with spinal cord injury and taking oral trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6601	 <e1>colitis</e1> (pseudomembranous <e1>colitis</e1>) developed in four patients with spinal cord injury and taking oral <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6602	 colitis (<e1>pseudomembranous colitis</e1>) developed in four patients with spinal cord injury and taking oral trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6603	 colitis (<e1>pseudomembranous colitis</e1>) developed in four patients with spinal cord injury and taking oral <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6604	 colitis</e1> readily occurs in at least certain population groups receiving trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6605	 colitis</e1> readily occurs in at least certain population groups receiving <e2>trimethoprim</e2> -sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6606	 <e1>lethal complication</e1> of peripheral vein <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6607	 condition should be suspected in patients who develop unexplained <e1>abdominal pain</e1> or collapse following <e2>vasopressin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6608	 condition should be suspected in patients who develop unexplained abdominal pain or <e1>collapse</e1> following <e2>vasopressin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6609	 adverse reactions to <e1>protamine</e1> are reported infrequently and are usually mild, we recently observed the first fatal case of <e2>type I anaphylaxis</e2> resulting from <e1>protamine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6610	 -induced <e2>fatal anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6611	 as a result of <e2>cis-platinum</e2> administration is well documented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6612	 concerning the <e1>nephrotoxicity</e1> of <e2>lithium</e2> is discussed, and recommendations for the evaluation of renal failure during <e2>lithium</e2> therapy are provided."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6613	 concerning the nephrotoxicity of <e1>lithium</e1> is discussed, and recommendations for the evaluation of <e2>renal failure</e2> during <e1>lithium</e1> therapy are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6614	 concerning the nephrotoxicity of <e1>lithium</e1> is discussed, and recommendations for the evaluation of <e2>renal failure</e2> during <e1>lithium</e1> therapy are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6615	 of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a <e2>decrease in blood flow</e2> that is best explained by an increase in pulmonary vascular resistance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6616	 of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an <e2>increase in pulmonary artery pressure</e2> associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6617	 of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an <e2>increase in pulmonary vascular resistance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6618	 pulmonary vasoconstriction</e1> induced by <e2>nitroglycerin</e2> in idiopathic pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6619	 block</e1> complicating <e2>amiodarone</e2> -induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6620	 block complicating <e1>amiodarone</e1> -induced <e2>hypothyroidism</e2> in a patient with pre-excitation and rate-dependent bilateral bundle branch block."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6621	 a case induced by <e1>hypothyroidism</e1> complicating long-term therapy with <e2>amiodarone</e2> in a 45 year old woman with pre-excitation is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6622	 increased the preexisting <e2>electrical decrement</e2> in three rabbits with experimental autoimmune myasthenia gravis while the drug had no deleterious effects in less affected or normal animals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6623	 may aggravate clinical and experimental <e2>myasthenia gravis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6624	 patients receiving <e1>ampicillin</e1> should be closely monitored for possible <e2>acute exacerbations</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6625	 patient had <e1>severe temporary weakness</e1> after an <e2>ampicillin sodium</e2> challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6626	 study following large patient groups on <e1>theophylline</e1> and a combination of <e1>theophylline</e1> and steroids might clarify the risk of <e2>ulcer</e2> formation in patients being treated with these medications for asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6627	 study following large patient groups on <e1>theophylline</e1> and a combination of <e1>theophylline</e1> and steroids might clarify the risk of <e2>ulcer</e2> formation in patients being treated with these medications for asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6628	 presented a patient with status asthmaticus treated with a combination of theophylline and <e1>prednisone</e1> who developed a <e2>perforated gastric ulcer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6629	 presented a patient with status asthmaticus treated with a combination of <e1>theophylline</e1> and prednisone who developed a <e2>perforated gastric ulcer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6630	 case of <e1>propranolol</e1> overdose complicated by <e2>esophageal spasm</e2> preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6631	 spasm</e1> following <e2>propranolol</e2> overdose relieved by glucagon."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6632	 and sinus arrest with <e2>nifedipine</e2> in pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6633	 and <e1>sinus arrest</e1> with <e2>nifedipine</e2> in pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6634	 patient presented with a <e1>painful, oedematous, cyanosed hand</e1> having injected a solution of <e2>diamorphine</e2> and methylphenidate into his radial artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6635	 patient presented with a <e1>painful, oedematous, cyanosed hand</e1> having injected a solution of diamorphine and <e2>methylphenidate</e2> into his radial artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6636	 following selfadministered intra-arterial injection of methylphenidate and <e2>diamorphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6637	 following selfadministered intra-arterial injection of <e2>methylphenidate</e2> and diamorphine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6638	 photosensitivity</e1> associated with <e2>hydrochlorothiazide</e2> ingestion occurred in four patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6639	 decompensation</e1> following <e2>verapamil</e2> therapy in infants with supraventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6640	 each infant demonstrated <e1>hemodynamic decompensation</e1> shortly after <e2>verapamil</e2> administration and required cardiopulmonary resuscitation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6641	 risk of <e1>cardiac decompensation</e1> in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6642	 with pleural and pericardial effusion and <e1>neuropathy</e1> during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6643	 with <e1>pleural and pericardial effusion</e1> and neuropathy during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6644	 with pleural and pericardial effusion and neuropathy during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6645	 of this and previously reported cases indicates the need for early diagnosis of <e1>amiodarone</e1> <e2>pneumonitis</e2>, immediate withdrawal of <e1>amiodarone</e1>, and prompt but continued steroid therapy to ensure full recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6646	 -induced <e2>hyperkalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6647	 findings suggest that <e1>hyperkalemia</e1> can develop with the use of low-dose <e2>heparin</e2>, within seven days of initiating <e2>heparin</e2> therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6648	 findings suggest that <e1>hyperkalemia</e1> can develop with the use of low-dose <e2>heparin</e2>, within seven days of initiating <e2>heparin</e2> therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6649	 present four cases in which the use of <e1>heparin</e1> was associated with <e2>hyperkalemia</e2> and discuss the pathophysiology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6650	 most physicians are aware of <e1>heparin</e1> -induced thrombocytopenia and skin necrosis, the association of <e1>heparin</e1> and <e2>hyperkalemia</e2> is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6651	 most physicians are aware of <e1>heparin</e1> -induced thrombocytopenia and <e2>skin necrosis</e2>, the association of <e1>heparin</e1> and hyperkalemia is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6652	 most physicians are aware of <e1>heparin</e1> -induced <e2>thrombocytopenia</e2> and skin necrosis, the association of <e1>heparin</e1> and hyperkalemia is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6653	 follow-up of so-called "self-limited" <e1>insulin</e1> <e2>edema</e2> is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6654	 -induced <e2>cardiac failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6655	 edema</e1> is a well-recognized complication of <e2>insulin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6656	 report describes the first case of <e1>insulin</e1> -induced <e2>cardiac failure</e2> in a patient without underlying heart disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6657	 case of <e1>pyridoxine</e1> -dependent <e2>seizures</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6658	 of <e1>pyridoxine</e1> to an infant after a long period of convulsions was followed by <e2>acute hypotonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6659	 <e1>severe cholestasis</e1> induced by <e2>oxacillin</e2> derivatives."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6660	 patients with osteomyelitis who developed <e1>reversible cholestatic jaundice</e1> during treatment with <e2>oxacillin</e2> derivatives are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6661	 all the patients, <e1>pellagra</e1> symptoms appeared during <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6662	 inhibits the conversion of tryptophan to niacin and may induce <e2>pellagra</e2>, particularly in poorly nourished patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6663	 encephalopathy</e1> among tuberculous patients: its relation to <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6664	 should be suspected whenever tuberculous patients under treatment with <e1>isoniazid</e1> develop <e2>mental, neurological or gastrointestinal symptoms</e2>, even in the absence of typical pellagra dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6665	 should be aware of the potential for the development of <e1>RS</e1> among children who are receiving long-term <e2>aspirin</e2> therapy for the treatment of systemic inflammatory illnesses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6666	 syndrome</e1> (RS) is believed to occur infrequently among children receiving long-term <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6667	 syndrome (<e1>RS</e1>) is believed to occur infrequently among children receiving long-term <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6668	 findings support previous studies that showed that the use of <e1>aspirin</e1> during the antecedent illness may be a risk factor for the development of <e2>RS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6669	 fibrillation</e1> was induced by <e2>diltiazem</e2> in two patients and verapamil induced syncope in one patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6670	 fibrillation was induced by diltiazem in two patients and <e1>verapamil</e1> induced <e2>syncope</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6671	 54-year-old man, treated with <e1>amiodarone</e1>, developed <e2>thyrotoxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6672	 -induced <e2>dysthyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6673	 <e1>propranolol</e1> was used as the initial treatment for his hyperadrenergic state, resulting in a <e2>decrease in heart rate</e2> but a paroxsymal increase in blood pressure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6674	 <e1>propranolol</e1> was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a <e2>paroxsymal increase in blood pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6675	 -induced <e2>hypertension</e2> in treatment of cocaine intoxication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6676	 to the literature, <e1>chlorambucil</e1> <e2>central nervous toxicity</e2> is found almost exclusively in childhood nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6677	 <e2>central nervous toxicity</e2>: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6678	 abnormalities</e1> were observed in two of the nine children during <e2>chlorambucil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6679	 35-year-old man with seropositive rheumatoid arthritis developed selective <e1>IgA deficiency</e1> during treatment with <e2>fenclofenac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6680	 -induced selective <e2>IgA deficiency</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6681	 case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by fenclofenac as well as <e2>aurothiomalate</e2> and sulphasalazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6682	 case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by <e2>fenclofenac</e2> as well as aurothiomalate and sulphasalazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6683	 case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6684	 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance <e1>lithium</e1> therapy developed a <e2>movement disorder</e2> following high doses of trazodone for treatment of an acute depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6685	 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a <e1>movement disorder</e1> following high doses of <e2>trazodone</e2> for treatment of an acute depression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6686	 the <e1>movement disorder</e1> could not with certainty be attributed to <e2>trazodone</e2> alone, the drug at least acted as an eliciting agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6687	 elicitation of a <e1>movement disorder</e1> by <e2>trazodone</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6688	 the <e1>trazodone</e1> was reduced, the <e2>involuntary movements</e2> promptly ceased."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6689	 review of the literature showed no previous description of this pattern in <e1>benzodiazepine</e1> <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6690	 coma</e1> in <e2>benzodiazepine</e2> toxicity: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6691	 reports of <e1>spindle coma</e1> are noted with alcohol and <e2>imipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6692	 literature review revealed 83 other reported cases of <e1>rifampicin</e1> -induced <e2>renal insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6693	 failure</e1> is a rare complication associated with the use of <e2>rifampicin</e2> for the treatment of tuberculosis, usually occurring well into the course of therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6694	 -induced <e2>renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6695	 following is a report of 2 cases of <e1>rifampicin</e1> -induced <e2>renal insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6696	 and ocular toxicity</e1> induced by <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6697	 in vivo/vitro studies clearly demonstrated that the <e1>neurological effects</e1> were due to a synergistic action of <e2>desferrioxamine</e2> and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6698	 in vivo/vitro studies clearly demonstrated that the <e1>neurological effects</e1> were due to a synergistic action of desferrioxamine and <e2>prochlorperazine</e2>, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6699	 of these patients, who also received the anti-emetic <e1>prochlorperazine</e1>, <e2>lost consciousness</e2> for 48-72 h and then fully recovered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6700	 other patients who did not receive prochlorperazine, developed <e1>retinal problems</e1> which later improved, one after only 15 g of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6701	 <e2>nephropathy</e2>: tissue analysis by X-ray fluorescent spectroscopy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6702	 findings are consistent with an immune-complex form of glomerulopathy in which <e1>gold</e1> is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by <e1>gold</e1> therapy may be a causative factor in the <e2>renal disease</e2> associated with <e1>gold</e1> therapy in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6703	 findings are consistent with an immune-complex form of glomerulopathy in which <e1>gold</e1> is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by <e1>gold</e1> therapy may be a causative factor in the <e2>renal disease</e2> associated with <e1>gold</e1> therapy in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6704	 patients developed <e1>proteinuria</e1> following <e2>gold</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6705	 cases of <e1>fat embolism</e1> are described in infants receiving prolonged intravenous infusion of fat (<e2>Intralipid</e2> 20%)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6706	 diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving <e1>methotrexate</e1> who develop <e2>bilateral pulmonary infiltrates</e2> seen on chest roentgenograms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6707	 <e1>diffuse interstitial pulmonary fibrosis</e1> should be considered in the differential diagnosis of patients receiving <e2>methotrexate</e2> who develop bilateral pulmonary infiltrates seen on chest roentgenograms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6708	 all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman-Rich syndrome, and <e1>methotrexate</e1> <e2>hepatotoxicity</e2> was present in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6709	 is suggested therefore that <e1>methotrexate</e1> be added to the list of agents capable of inducing <e2>diffuse interstitial pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6710	 -induced <e2>diffuse interstitial pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6711	 eosinophilia or <e1>granulomas</e1>, classically seen in previously reported cases of <e2>methotrexate</e2> pneumonitis, were not observed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6712	 eosinophilia or granulomas, classically seen in previously reported cases of <e1>methotrexate</e1> <e2>pneumonitis</e2>, were not observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6713	 eosinophilia</e1> or granulomas, classically seen in previously reported cases of <e2>methotrexate</e2> pneumonitis, were not observed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6714	 patients received respectively 190 mg, 175 mg, and 196 mg of <e1>methotrexate</e1> and developed <e2>bilateral pulmonary infiltrates</e2> without evidence of peripheral blood eosinophilia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6715	 patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound <e1>hyponatremia</e1> secondary to the administration of <e2>adenine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6716	 patient with disseminated herpes zoster developed a <e1>syndrome of inappropriate antidiuretic hormone</e1> and profound hyponatremia secondary to the administration of <e2>adenine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6717	 antidiuretic hormone</e1> following <e2>adenine arabinoside</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6718	 toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), <e2>abdominal pain</e2> (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6719	 toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), <e2>bone pain</e2> (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6720	 toxic effects of <e1>methotrexate</e1> included <e2>elevated liver transaminases</e2> (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6721	 toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), <e2>mild neutropenia</e2> (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6722	 toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and <e2>mild pruritus</e2> (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6723	 toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), <e2>nausea</e2> (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6724	 associated with <e2>carbamazepine</e2> administration: experience in brain-damaged children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6725	 one child, a second course of <e1>carbamazepine</e1> resulted in a return of the <e2>dystonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6726	 currently available clinical and neuropharmacologic data suggest that <e1>carbamazepine</e1> may be an antagonist of dopamine and that this property is responsible for the production of <e2>dystonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6727	 have cared for three children in whom four episodes of <e1>dystonia</e1> proceeding to opisthotonus occurred in association with <e2>carbamazepine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6728	 have cared for three children in whom four episodes of dystonia proceeding to <e1>opisthotonus</e1> occurred in association with <e2>carbamazepine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6729	 anemia and <e1>agranulocytosis</e1> in patients using <e2>methazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6730	 anemia</e1> and agranulocytosis in patients using <e2>methazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6731	 case reports of <e1>aplastic anemia</e1> with use of <e2>acetazolamide</e2>, and two cases with use of methazolamide, have appeared in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6732	 case reports of <e1>aplastic anemia</e1> with use of acetazolamide, and two cases with use of <e2>methazolamide</e2>, have appeared in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6733	 article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of <e1>methazolamide</e1>, and one case of <e2>agranulocytosis</e2> related to the use of <e1>methazolamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6734	 article describes two cases of <e1>aplastic anemia</e1>, at least one of which was almost certainly induced by the use of <e2>methazolamide</e2>, and one case of agranulocytosis related to the use of <e2>methazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6735	 carcinoma</e1> arising in a basal-cell epithelioma treated with <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6736	 report the development of <e1>squamous-cell carcinoma</e1> within a basal-cell epithelioma that was treated with intralesional injections of <e2>5-FU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6737	 extremity <e1>arterial insufficiency</e1> after long-term <e2>methysergide maleate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6738	 patient whose case is reviewed had <e1>migraine headaches</e1> and received <e2>methysergide</e2> maleate for 13 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6739	 case of <e1>Erythema Multiforme Bullosum</e1> in patient of lepromatous leprosy with pulmonary tuberculosis due to <e2>Rifampicin</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6740	 multiforme bullosum</e1> due to <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6741	 damage</e1> associated with long term use of <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6742	 authors report 2 cases of <e1>renal damage</e1> associated with <e2>lithium carbonate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6743	 two patients with mycosis fungoides, a <e1>squamous cell carcinoma</e1> developed during therapy with <e2>psoralens</e2> plus long-wave ultraviolet radiation (PUVA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6744	 and <e1>diabetic coma</e1>: possible relationship to diuretic-<e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6745	 and diabetic coma: possible relationship to diuretic-<e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6746	 patients developed <e1>diabetic coma</e1> when taking a combination of a thiazide diuretic and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6747	 patients developed <e1>diabetic coma</e1> when taking a combination of a <e2>thiazide</e2> diuretic and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6748	 insulin-dependent diabetic patient with nephropathy developed <e1>severe acidosis</e1> after treatment with <e2>acetazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6749	 acidosis</e1> from <e2>acetazolamide</e2> in a diabetic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6750	 progressed to <e1>tracheal compression</e1> with stridor after he had taken some <e2>aspirin</e2> for relief of the neck pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6751	 cases of <e1>clindamycin</e1> -associated <e2>pseudomembranous colitis</e2> in leukaemic patients are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6752	 infertile patient with amenorrhea-galactorrhea syndrome <e1>lost vision</e1> during a pregnancy occurring after <e2>Bromocryptine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6753	 acute tubular necrosis</e1> occurred in 1 patient in whom intravesical <e2>formalin</e2> was used to control massive persistent hemorrhage from radiation cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6754	 complication</e1> of intravesical <e2>formalin</e2> during control of intractable hemorrhage from radiation cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6755	 sodium bicarbonate appears to be indicated prophylactically in combating the associated <e1>metabolic acidosis</e1> due to absorbed <e2>formic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6756	 young woman developed <e1>galactorrhea</e1> during treatment with a new dibenzoxazepine antidepressant, <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6757	 young woman developed <e1>galactorrhea</e1> during treatment with a new <e2>dibenzoxazepine</e2> antidepressant, amoxapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6758	 <e1>15-kg weight gain</e1> developed in a patient during the third week of <e2>ibuprofen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6759	 associated with <e2>ibuprofen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6760	 should be recognized that <e1>ibuprofen</e1> may be associated with <e2>salt and water retention</e2> in the same fashion as previously described with phenylbutazone and indomethacin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6761	 should be recognized that ibuprofen may be associated with <e1>salt and water retention</e1> in the same fashion as previously described with phenylbutazone and <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6762	 should be recognized that ibuprofen may be associated with <e1>salt and water retention</e1> in the same fashion as previously described with <e2>phenylbutazone</e2> and indomethacin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6763	 -associated <e2>hand and foot deformities</e2> in chronic tophaceous gout."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6764	 digits of the hands and feet</e1> developed in a 69-year-old male with severe chronic tophaceous gout during <e2>allopurinol</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6765	 patient with coccidioidal meningitis was treated with intrathecally administered <e1>amphotericin B</e1>, and an <e2>acute toxic delirium</e2> with EEG abnormalities developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6766	 patient with coccidioidal meningitis was treated with intrathecally administered <e1>amphotericin B</e1>, and an acute toxic delirium with <e2>EEG abnormalities</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6767	 of intrathecal administration of <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6768	 keeping with findings in the literature, the <e1>aortic wall in this case was damaged</e1> by secondary changes following irradiation and <e2>Bleomycin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6769	 glycosides are thought to prevent <e1>doxorubicin</e1> <e2>cardiomyopathy</e2> by competitively inhibiting <e1>doxorubicin</e1> at its receptor sites, but ouabain has a much shorter half life than <e1>doxorubicin</e1> and its metabolites and so is less effective than digoxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6770	 <e2>cardiotoxicity</e2>: possible role of digoxin in its prevention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6771	 electrocardiographical changes</e1> were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving <e2>ouabain</e2>, and none of the 16 who were receiving digoxin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6772	 other patient on <e1>digoxin</e1> stopped taking it and developed <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6773	 patient on <e1>ouabain</e1> also developed <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6774	 healthy, 30-year-old man, exposed to <e1>sulindac</e1> on two separate occasions, had an incapacitating <e2>isolated idential sensory neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6775	 (<e1>Clinoril</e1>), a nonsteroidal anti-inflammatory agent, has few reported <e2>neurologic toxic effects</e2>, all of which have been associated with systemic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6776	 (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported <e2>neurologic toxic effects</e2>, all of which have been associated with systemic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6777	 our knowledge, we describe the first reported case of <e1>isolated paresthesia</e1> and peripheral neuropathy, without systemic involvement, secondary to <e2>sulindac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6778	 our knowledge, we describe the first reported case of isolated paresthesia and <e1>peripheral neuropathy</e1>, without systemic involvement, secondary to <e2>sulindac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6779	 addition, loading with one low oral dose of <e1>serine</e1> produced <e2>psychotic symptoms</e2> 5 h later which lasted 3-6 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6780	 of <e1>ergotamine</e1> -induced <e2>arteriospasm</e2> by mechanical intra-arterial dilatation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6781	 patients with imminent gangrene of the extremities caused by <e1>ergot</e1> -induced <e2>arteriospasm</e2> underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6782	 patients with imminent <e1>gangrene of the extremities</e1> caused by <e2>ergot</e2> -induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6783	 authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by <e2>hyperpyrexia</e2>, severe rigidity, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6784	 authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by <e2>hyperpyrexia</e2>, severe rigidity, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6785	 authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of <e2>irreversible tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6786	 authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of <e2>irreversible tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6787	 authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, severe rigidity, <e2>mutism</e2>, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6788	 authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, <e2>mutism</e2>, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6789	 authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, <e2>severe rigidity</e2>, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6790	 authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, <e2>severe rigidity</e2>, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6791	 authors postulate that two types of combined <e1>lithium</e1> -neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a <e1>lithium</e1> toxicity that occurs in combination with phenothiazines, primarily thioridazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6792	 authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a <e1>lithium toxicity</e1> that occurs in combination with phenothiazines, primarily <e2>thioridazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6793	 authors postulate that two types of combined <e1>lithium</e1> -neuroleptic toxicity occur: a <e2>neuroleptic malignant extrapyramidal syndrome</e2> and a <e1>lithium</e1> toxicity that occurs in combination with phenothiazines, primarily thioridazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6794	 authors postulate that two types of combined lithium-neuroleptic toxicity occur: a <e1>neuroleptic malignant extrapyramidal syndrome</e1> and a lithium toxicity that occurs in combination with phenothiazines, primarily <e2>thioridazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6795	 -induced <e2>chromosome damage</e2> to human lymphocytes is dose-dependent and cumulative."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6796	 reaction</e1> to 50% solution of <e2>dextrose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6797	 results suggest that the higher concentrations of <e1>dextrose</e1> induce <e2>increased histamine release</e2> from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6798	 patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an <e1>anaphylactoid reaction</e1> after the intravenous administration of 50% solution of <e2>dextrose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6799	 <e2>hepato toxicity</e2> in rheumatic fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6800	 children with rheumatic fever developed <e1>anicteric hepatitis</e1> while on high-dose <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6801	 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6802	 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6803	 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6804	 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6805	 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6806	 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6807	 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6808	 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6809	 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6810	 left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with cisplatinum, vinblastine, and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6811	 left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with <e2>cisplatinum</e2>, vinblastine, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6812	 left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with cisplatinum, <e2>vinblastine</e2>, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6813	 left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6814	 left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with <e2>cisplatinum</e2>, vinblastine, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6815	 left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with cisplatinum, <e2>vinblastine</e2>, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6816	 association of granulocytopenia, <e1>eosinophilia</e1>, skin reaction and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6817	 association of granulocytopenia, <e1>eosinophilia</e1>, skin reaction and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6818	 association of <e1>granulocytopenia</e1>, eosinophilia, skin reaction and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6819	 association of <e1>granulocytopenia</e1>, eosinophilia, skin reaction and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6820	 association of granulocytopenia, eosinophilia, skin reaction and <e1>hepatitis</e1> during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6821	 association of granulocytopenia, eosinophilia, skin reaction and <e1>hepatitis</e1> during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6822	 association of granulocytopenia, eosinophilia, <e1>skin reaction</e1> and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6823	 association of granulocytopenia, eosinophilia, <e1>skin reaction</e1> and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6824	 complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, <e2>eosinophilia</e2>, skin reaction and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6825	 complications of <e1>propylthiouracil</e1> treatment: <e2>granulocytopenia</e2>, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6826	 complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, skin reaction and <e2>hepatitis</e2> with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6827	 complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with <e2>lymphocyte sensitization</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6828	 complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, <e2>skin reaction</e2> and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6829	 toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and <e1>ataxia</e1> developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6830	 toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and <e1>ataxia</e1> developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6831	 toxic encephalopathy characterized by <e1>depressed level of consciousness</e1>, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6832	 toxic encephalopathy characterized by <e1>depressed level of consciousness</e1>, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6833	 toxic encephalopathy characterized by depressed level of consciousness, <e1>marked irritability</e1>, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6834	 toxic encephalopathy characterized by depressed level of consciousness, <e1>marked irritability</e1>, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6835	 <e1>toxic encephalopathy</e1> characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6836	 <e1>toxic encephalopathy</e1> characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6837	 neuropathy</e1> associated with <e2>penicillamine</e2> therapy in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6838	 neuropathy</e1> developed in a patient with rheumatoid arthritis who had been receiving <e2>D-penicillamine</e2> for about 1 year."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6839	 case resembles two previously reported cases of <e1>optic neuropathy</e1> which occurred in patients with Wilson's disease who were receiving <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6840	 patient developed transient, <e1>acute myopia</e1> while on isotretinoin (<e2>Accutane</e2>) therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6841	 patient developed transient, <e1>acute myopia</e1> while on <e2>isotretinoin</e2> (Accutane) therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6842	 was a clear relationship between restarting the <e1>Accutane</e1> and recurrence of the <e2>transient myopia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6843	 acute myopia</e1> resulting from isotretinoin (<e2>accutane</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6844	 acute myopia</e1> resulting from <e2>isotretinoin</e2> (accutane) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6845	 contact dermatitis</e1> to compound tincture of <e2>benzoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6846	 cases of <e1>allergic contact dermatitis</e1> to compound tincture of <e2>benzoin</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6847	 evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; <e2>Ara-C</e2>) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6848	 evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of <e2>cytarabine</e2> (cytosine arabinoside; Ara-C) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6849	 evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of cytarabine (<e2>cytosine arabinoside</e2>; Ara-C) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6850	 three of these patients the infection was clinically unsuspected; in the fourth, <e1>cutaneous herpes zoster</e1> developed after administration of 300 mg of <e2>cytarabine</e2> daily for the preceding five days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6851	 herpesvirus infections</e1> in leukemic patients receiving <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6852	 and morphological features of <e1>gold</e1> <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6853	 cases of <e1>gold</e1> -related <e2>neuropathy</e2> are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6854	 ceroid-like pigment</e1> following the treatment of lepromatous leprosy with clofazimine (<e2>B663</e2>; Lamprene)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6855	 ceroid-like pigment</e1> following the treatment of lepromatous leprosy with <e2>clofazimine</e2> (B663; Lamprene)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6856	 ceroid-like pigment</e1> following the treatment of lepromatous leprosy with clofazimine (B663; <e2>Lamprene</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6857	 of these was <e1>clofazimine</e1>, an aniline aposafranine derivative known to produce a <e2>ceroid-like pigment</e2> in the tissues of patients treated with this drug or lepromatous leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6858	 neurotoxicity</e1> with <e2>methyl G: CALGB</e2> experience."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6859	 young patient experienced marked <e1>sinus tachycardia</e1> while smoking marijuana and receiving therapeutic doses of <e2>nortriptyline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6860	 <e1>sinus tachycardia</e1> resulting from the synergistic effects of marijuana and <e2>nortriptyline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6861	 is concluded that '<e1>cerebral atrophy</e1>' on CT scans may represent an accumulative effect of <e2>ACTH</e2> and that <e2>ACTH</e2> should be given with the utmost discretion, and in as low a dose as possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6862	 reactions</e1> with newer cephalosporins: <e2>cefmenoxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6863	 is the first report of a <e1>disulfiram-like reaction</e1> with <e2>cefmenoxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6864	 bipolar manic-depressive patient, developed while on <e1>lithium</e1> prophylaxis, <e2>akathisia</e2> at therapeutic serum <e1>lithium</e1> levels and subsequently bucco-linguo-masticatory dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6865	 bipolar manic-depressive patient, developed while on <e1>lithium</e1> prophylaxis, akathisia at therapeutic serum <e1>lithium</e1> levels and subsequently <e2>bucco-linguo-masticatory dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6866	 leukopenia</e1> associated with <e2>silver sulfadiazine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6867	 from endemic areas referred to transplant centers may be at high risk for <e1>disseminated histoplasmosis</e1> when treated with long-term <e2>prednisone</e2> for graft-versus-host disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6868	 renal failure</e1> most likely was secondary to the nephrotoxic effect of <e2>captopril</e2> on chronically hypoperfused kidneys."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6869	 a patient with severe renovascular hypertension, <e1>nonoliguric acute renal failure</e1> developed after she received <e2>captopril</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6870	 acute renal failure</e1> after <e2>captopril</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6871	 -induced <e2>acute reversible renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6872	 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of <e1>captopril</e1> -induced <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6873	 report 5 cases of <e1>acute reversible renal failure</e1> coinciding with the onset of treatment with <e2>captopril</e2> in patients with severe drug-resistant hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6874	 case of <e1>mania</e1> associated with <e2>fluoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6875	 depressed woman with no history of bipolar illness developed a <e1>manic episode</e1> during treatment with <e2>fluoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6876	 nausea, and vomiting were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6877	 <e1>nausea</e1>, and vomiting were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6878	 nausea, and <e1>vomiting</e1> were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6879	 syndrome</e1> complicating long-term mitomycin C and <e2>5-fluorouracil</e2> therapy for gastric carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6880	 syndrome</e1> complicating long-term <e2>mitomycin C</e2> and 5-fluorouracil therapy for gastric carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6881	 cases of <e1>acute renal toxicity</e1> in patients receiving long-term therapy with mitomycin C and <e2>5-fluorouracil</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6882	 cases of <e1>acute renal toxicity</e1> in patients receiving long-term therapy with <e2>mitomycin C</e2> and 5-fluorouracil are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6883	 <e1>25-hydroxyvitain D3</e1> in treatment of osteomalacia associated with <e2>ileal resection</e2> and cholestyramine therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6884	 histological <e1>osteomalacia</e1> developed in a woman with Crohn's disease 2 years after ileal resection and the start of <e2>cholestyramine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6885	 of <e1>lithium</e1> <e2>tremor</e2> with metoprolol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6886	 patients with bipolar affective disorder and a history of bronchospastic phenomena experienced <e1>tremor</e1> during <e2>lithium carbonate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6887	 <e1>diazepam</e1> exacerbated the <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6888	 52-year-old Black woman on <e1>phenytoin</e1> therapy for post-traumatic epilepsy developed <e2>transient hemiparesis</e2> contralateral to the injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6889	 possible mechanism for <e1>focal neurological deficit</e1> in brain-damaged patients on <e2>phenytoin</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6890	 hemiparesis</e1> caused by <e2>phenytoin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6891	 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (<e2>2-propylpentanoic acid</e2>, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6892	 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (<e2>phenobarbitone</e2> therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6893	 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later <e2>valproate</e2> (2-propylpentanoic acid, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6894	 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, <e2>VPA</e2>) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6895	 therapy for Mycobacterium fortuitum bacteremia with associated <e2>granulomatous hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6896	 syndrome</e1> after <e2>gold sodium thiomalate</e2> induced vasomotor reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6897	 syndrome after <e1>gold sodium thiomalate</e1> induced <e2>vasomotor reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6898	 reactions</e1> after <e2>gold sodium thiomalate</e2> are well recognized."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6899	 nephropathy</e1> due to <e2>auranofin</e2> obscured by tolmetin pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6900	 nephropathy due to auranofin obscured by tolmetin pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6901	 nephropathy</e1> due to auranofin obscured by <e2>tolmetin</e2> pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6902	 nephropathy due to auranofin obscured by <e1>tolmetin</e1> <e2>pseudoproteinuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6903	 52-year-old, white female developed low-grade fever, <e1>cough</e1>, and dyspnea after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6904	 52-year-old, white female developed low-grade fever, cough, and <e1>dyspnea</e1> after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6905	 52-year-old, white female developed <e1>low-grade fever</e1>, cough, and dyspnea after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6906	 <e2>gold</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6907	 can rarely cause interstitial pneumonitis and <e2>fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6908	 can rarely cause <e2>interstitial pneumonitis</e2> and fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6909	 <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6910	 temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that <e1>cyclophosphamide</e1> was aetiologically responsible for the <e2>lung disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6911	 temporal sequence of the <e1>respiratory insufficiency</e1> and the histopathology, when compared to the previous examples in the literature, suggest that <e2>cyclophosphamide</e2> was aetiologically responsible for the lung disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6912	 <e1>reversible toxic liver damage</e1> was observed in a non-alcoholic woman treated with <e2>disulfiram</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6913	 hepatitis</e1> induced by <e2>disulfiram</e2> in a non-alcoholic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6914	 type of SMON is associated with <e1>acrodermatitis enteropathica</e1> which has a very high frequency of occurrence in association with administration of <e2>clioquinol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6915	 type of <e1>SMON</e1> is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of <e2>clioquinol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6916	 patients receiving high-dose <e1>tamoxifen</e1> for greater than 1 year have demonstrated similar <e2>retinal changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6917	 <e2>retinopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6918	 findings suggest that the <e1>corneal and retinal changes</e1> are the result of a toxic effect of <e2>tamoxifen</e2> when used in the doses and duration described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6919	 gigantism</e1> is a rare complication of <e2>D-penicillamine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6920	 they had complex medical problems, the high serum concentrations of <e1>ampicillin</e1> at the time of <e2>seizures</e2> without their recurrence after discontinuing the antibiotic suggest that the <e2>seizures</e2> were related to the <e1>ampicillin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6921	 they had complex medical problems, the high serum concentrations of <e1>ampicillin</e1> at the time of <e2>seizures</e2> without their recurrence after discontinuing the antibiotic suggest that the <e2>seizures</e2> were related to the <e1>ampicillin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6922	 -associated <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6923	 patients had <e1>ampicillin</e1> -associated <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6924	 the patient discontinued <e1>rifampicin</e1>, the <e2>skin lesions</e2> cleared completely within 5 weeks without any systemic medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6925	 foliaceus</e1> induced by <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6926	 foliaceus</e1> was seen in a patient with pulmonary tuberculosis during <e2>rifampicin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6927	 in patients treated with <e2>lorcainide</e2>, a new antiarrhythmic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6928	 eight patients, a mean <e1>decrease in serum Na+</e1> of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6929	 is concluded that <e1>SIADH</e1> is an important side effect of <e2>lorcainide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6930	 patient developed <e1>severe hyponatremia</e1> with serum Na+ of 108 mEq/L when <e2>hydrochlorothiazide</e2> was given to control hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6931	 of 33 patients developed significant <e1>hyponatremia</e1> and hypoosmolality during oral treatment with <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6932	 of 33 patients developed significant hyponatremia and <e1>hypoosmolality</e1> during oral treatment with <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6933	 intravascular hemolysis</e1> developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, <e2>chlorpropamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6934	 intravascular hemolysis</e1> developed when a diabetic patient, previously treated with <e2>glyburide</e2>, was started on another oral sulfonylurea drug, chlorpropamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6935	 -induced <e2>hemolytic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6936	 a 61-year-old man receiving chronic low-dosage <e1>amiodarone</e1> an <e2>interstitial pneumopathy</e2> was observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6937	 pneumopathy</e1> and low-dosage <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6938	 sinus rhythm</e1> and intermittent sinoatrial block induced by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6939	 sinus rhythm and <e1>intermittent sinoatrial block</e1> induced by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6940	 sinus rhythm</e1> and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg <e2>propranolol</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6941	 sinus rhythm and <e1>intermittent sinoatrial (S-A) block</e1> was observed in a 57-year-old woman, under treatment for angina with 80 mg <e2>propranolol</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6942	 <e1>abnormal rhythm</e1> disappeared with the withdrawal of <e2>propranolol</e2> and when the drug was restarted a 2/1 S-A block was seen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6943	 was accepted as evidence for <e1>propranolol</e1> being the cause of this <e2>conduction disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6944	 further case of <e1>anaphylactoid reaction</e1> to <e2>methylprednisolone</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6945	 reaction</e1> to <e2>methylprednisolone</e2> pulsed therapy for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6946	 lung specimens were lacking from these three patients, it is suggested that the <e1>pulmonary toxicity</e1> of <e2>CCNU</e2> may be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6947	 fibrosis</e1> subsequent to high doses of <e2>CCNU</e2> for chronic myeloid leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6948	 responsibility of <e1>CCNU</e1> in the pathogenesis of <e2>pulmonary fibrosis</e2> seems very likely."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6949	 patients treated for chronic myeloid leukemia with high doses of <e1>CCNU</e1> (1100 mg/m2 and 1240 mg/m2, respectively) developed a <e2>fatal pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6950	 pulmonary toxicity</e1> with melphalan and <e2>busulfan</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6951	 pulmonary toxicity</e1> with <e2>melphalan</e2> and busulfan therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6952	 report a 59-year-old patient with chronic myeloid leukemia, who developed <e1>severe interstitial lung fibrosis</e1> after short term and sequential treatment with melphalan and <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6953	 report a 59-year-old patient with chronic myeloid leukemia, who developed <e1>severe interstitial lung fibrosis</e1> after short term and sequential treatment with <e2>melphalan</e2> and busulfan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6954	 taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with lethargy, <e2>confusion</e2> and drowsiness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6955	 taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with lethargy, confusion and <e2>drowsiness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6956	 taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with <e2>lethargy</e2>, confusion and drowsiness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6957	 induced <e2>hyperchloremic metabolic acidosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6958	 is presumed that her <e1>hyperchloremic metabolic acidosis</e1> was secondary to <e2>cholestyramine</e2> because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6959	 first reported case, in an adult, of <e1>cholestyramine</e1> induced <e2>hyperchloremic metabolic acidosis</e2> is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6960	 myelosuppression is mild, <e1>immunosuppression</e1> and superinfection are potential hazards of treatment with <e2>DCF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6961	 myelosuppression is mild, immunosuppression and <e1>superinfection</e1> are potential hazards of treatment with <e2>DCF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6962	 ocular toxicity of <e1>DCF</e1>, previously described as <e2>conjunctivitis</e2>, appears to be a keratitis of moderate severity which requires further study."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6963	 ocular toxicity of <e1>DCF</e1>, previously described as conjunctivitis, appears to be a <e2>keratitis</e2> of moderate severity which requires further study."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6964	 <e1>ocular toxicity</e1> of <e2>DCF</e2>, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6965	 there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during <e1>vasopressin</e1> infusion, followed by release of myoglobin and <e2>renal damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6966	 there were no other obvious causes of renal failure in either patient, we propose that <e1>skeletal muscle ischemia</e1> developed during <e2>vasopressin</e2> infusion, followed by release of myoglobin and renal damage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6967	 and <e1>acute renal failure</e1> associated with intravenous <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6968	 and acute renal failure associated with intravenous <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6969	 and <e1>acute renal failure</e1> were observed in two patients with <e2>vasopressin</e2> -treated gastrointestinal hemorrhage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6970	 and acute renal failure were observed in two patients with <e2>vasopressin</e2> -treated gastrointestinal hemorrhage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6971	 major limitation in the use of <e1>amphotericin B</e1> is its potential to cause <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6972	 B</e1> <e2>nephrotoxicity</e2> in humans decreased by salt repletion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6973	 with five patients in whom <e1>impaired renal function</e1> developed early during <e2>amphotericin B</e2> therapy is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-A

6974	 developed in two epileptic patients some months after the addition of oral <e2>fluoresone</e2> 750 mg daily to the phenobarbital and phenytoin already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6975	 developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the <e2>phenobarbital</e2> and phenytoin already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6976	 developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and <e2>phenytoin</e2> already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6977	 in epileptics treated with phenobarbital, phenytoin and <e2>fluoresone</e2>: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6978	 in epileptics treated with <e2>phenobarbital</e2>, phenytoin and fluoresone: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6979	 in epileptics treated with phenobarbital, <e2>phenytoin</e2> and fluoresone: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6980	 report of withdrawal <e1>dyskinesia</e1> associated with <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6981	 of withdrawal <e1>dyskinesia</e1> indicates that the neuroleptic effects of <e2>amoxapine</e2> may be clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6982	 authors describe a case of <e1>oral-facial dyskinesia</e1> that occurred after discontinuation of <e2>amoxapine</e2>, and antidepressant which may also have neuroleptic effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6983	 case of <e1>toxic hepatitis</e1> caused by combination therapy with methotrexate and <e2>etretinate</e2> in the treatment of severe psoriasis is presented in a 47-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6984	 case of <e1>toxic hepatitis</e1> caused by combination therapy with <e2>methotrexate</e2> and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6985	 hepatitis</e1> due to combination therapy with methotrexate and <e2>etretinate</e2> in psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6986	 hepatitis</e1> due to combination therapy with <e2>methotrexate</e2> and etretinate in psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6987	 balance studies and rechallenge with <e1>hydrochlorothiazide</e1> were undertaken to investigate the mechanism of the thiazide-induced <e2>hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6988	 58-year-old woman developed <e1>unilateral acute angle-closure glaucoma</e1> four days after the application of a patch of transdermal <e2>scopolamine</e2> delivery system (TRANSDERM-V)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6989	 case history of a 15-year-old boy who developed incapacitating <e1>tardive dyskinesia</e1> that resolved during treatment with <e2>deanol</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6990	 are most likely associated with <e2>Vitamin K deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6991	 associated with the use of <e2>cephalosporin</e2> or moxalactam antibiotics in acute and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6992	 associated with the use of cephalosporin or <e2>moxalactam</e2> antibiotics in acute and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6993	 is more likely to be associated with <e2>platelet dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6994	 the <e1>coagulopathy</e1> seemed to be most closely associated with the administration of the <e2>cephalosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6995	 azotemic patients who developed a <e1>coagulopathy</e1> associated with the use of either <e2>cephalosporin</e2> or moxalactam antibiotics are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6996	 azotemic patients who developed a <e1>coagulopathy</e1> associated with the use of either cephalosporin or <e2>moxalactam</e2> antibiotics are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6997	 case is reported of a child with <e1>fatal pulmonary fibrosis</e1> following <e2>BCNU</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6998	 pulmonary fibrosis</e1> following <e2>1,3-bis(2-chloroethyl)-1-nitrosourea</e2> (BCNU) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6999	 pulmonary fibrosis</e1> following 1,3-bis(2-chloroethyl)-1-nitrosourea (<e2>BCNU</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7000	 thrombocytopenic purpura</e1> during <e2>penicillamine</e2> therapy in rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7001	 thrombocytopenic purpura</e1> (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7002	 thrombocytopenic purpura (<e1>TTP</e1>) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7003	 our knowledge, no prior cases of <e1>penicillamine</e1> -induced <e2>TTP</e2> in RA have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7004	 hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by <e2>cough</e2>, dyspnea and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7005	 hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and <e2>diffuse pulmonary infiltrates</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7006	 hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, <e2>dyspnea</e2> and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7007	 hydrochloride</e1>, a new antiarrhythmic agent, has been associated with <e2>pulmonary toxicity</e2> characterized by cough, dyspnea and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7008	 recurrence of <e1>amiodarone</e1> <e2>pulmonary toxicity</e2> following corticosteroid therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7009	 our knowledge, this recurrence of <e1>amiodarone</e1> <e2>pulmonary toxicity</e2> has not been reported previously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7010	 describe a case of <e1>fibrosing alveolitis</e1>, diagnosed by lung biopsy, in a patient receiving <e2>amiodarone</e2> which responded to corticosteroid therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7011	 61 year-old male patient developed <e1>gynecomastia</e1> after starting <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7012	 associated with <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7013	 other endogenous or exogenous cause for the <e1>gynecomastia</e1> could be found except for the <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7014	 <e1>gynecomastia</e1> regressed when the <e2>theophylline</e2> was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7015	 -induced <e2>sustained hypotension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7016	 incidence of oral-<e1>verapamil</e1> -induced <e2>hypotension</e2> in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7017	 report a case of <e1>sustained hypotension</e1> after administration of parenteral <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7018	 69-year-old man developed <e1>pure red cell aplasia</e1> after taking <e2>fenoprofen</e2> for ten months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7019	 red cell aplasia</e1> associated with <e2>fenoprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7020	 case represents the third example of <e1>erythroid aplasia</e1> associated with an anti-inflammatory agent and the first instance due to <e2>fenoprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7021	 <e1>psychosis</e1> resulted from the administration of <e2>quinacrine hydrochloride</e2> at a dosage of 100 mg twice daily for the treatment of discoid lupus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7022	 case of <e1>priapism</e1> associated with <e2>trazodone</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7023	 associated with <e2>trazodone</e2> therapy: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7024	 haemoperfusion and cysteamine therapy led to the rapid removal of the <e1>paracetamol</e1> from the body and consequently prevented the development of <e2>severe hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7025	 shock</e1>, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7026	 shock, disseminated intravascular coagulation, and <e1>anuric renal failure</e1> requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7027	 shock, <e1>disseminated intravascular coagulation</e1>, and anuric renal failure requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7028	 renal cortical necrosis</e1> associated with <e2>zomepirac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7029	 mechanism of <e1>anaphylactoid reaction</e1> to <e2>zomepirac</e2> in this case, therefore, remains unclear."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7030	 -induced <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7031	 is a rare cause of drug-induced <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7032	 56-year-old male parkinsonian patient developed a unique <e1>behavioral change</e1> following the oral administration of <e2>cinepazide</e2>, a cerebral vasodilator."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7033	 <e1>behavioral change</e1> with <e2>cinepazide</e2> in parkinsonism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7034	 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a <e1>small-bowel obstruction</e1> due to <e2>Amphojel</e2> concretions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7035	 patient with alcoholic cerebellar degeneration had <e1>periodic alternating nystagmus</e1> during a period of <e2>phenytoin</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7036	 the data indicate an immune-complex cause for <e1>gold-salt</e1> <e2>nephropathy</e2>, the incident antigen (or antigens) and mechanism of action remain unidentified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7037	 <e2>nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7038	 therapy may result in <e2>damage to proximal tubules</e2> that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7039	 <e1>nephrotic syndrome</e1> developed in a patient receiving therapy with <e2>gold</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7040	 cholestasis and <e1>cutaneous bullae</e1> associated with <e2>glibenclamide</e2> therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7041	 cholestasis</e1> and cutaneous bullae associated with <e2>glibenclamide</e2> therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7042	 cholestasis and <e1>cutaneous bullae</e1> associated with <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7043	 cholestasis</e1> and cutaneous bullae associated with <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7044	 features have not previously been reported as side effects of glibenclamide therapy, but <e1>intrahepatic cholestasis</e1> may occur with <e2>chlorpropamide</e2>, a similar sulphonylurea agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7045	 four patients, <e1>spasm</e1> occurred spontaneous and in one patient after 0.05 mg of <e2>ergonovine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7046	 authors describe a woman with chronic schizophrenia who experienced <e1>delirium</e1>, grand mal seizure, and photosensitivity after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7047	 authors describe a woman with chronic schizophrenia who experienced delirium, <e1>grand mal seizure</e1>, and photosensitivity after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7048	 authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and <e1>photosensitivity</e1> after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7049	 associated with <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7050	 mechanisms which aid in elucidating the role of <e1>disulfiram</e1> in the etiology of <e2>catatonia</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7051	 is the first report of a <e1>catatonic syndrome</e1> occurring in a patient receiving <e2>disulfiram</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7052	 reactions</e1> to <e2>cyclofenil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7053	 patients with <e1>hepatic reactions</e1> to <e2>cyclofenil</e2>, a non-steroidal drug with a stimulating effect on ovulation, are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7054	 early symptoms of the toxic effects of <e1>theophylline</e1> can mimic <e2>peptic ulcer disease</e2>, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of <e1>theophylline</e1> poisoning."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7055	 case of <e1>SIADH</e1> associated with <e2>desipramine</e2> treatment in an elderly depressed woman is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7056	 -associated <e2>SIADH</e2> in an elderly woman: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7057	 reports have emphasized the <e1>tubular and interstitial lesions</e1> associated with intermittent or discontinuous <e2>rifampin</e2> therapy for tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7058	 spectrum of <e1>renal lesions</e1> occurring during antituberculous therapy, particularly in association with <e2>rifampin</e2>, may be wider than previously suspected."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7059	 3 weeks of beginning continuous daily <e1>isoniazid</e1> and rifampin therapy for pulmonary tuberculosis, a patient developed <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7060	 3 weeks of beginning continuous daily isoniazid and <e1>rifampin</e1> therapy for pulmonary tuberculosis, a patient developed <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7061	 range pseudoproteinuria</e1> in a <e2>tolmetin</e2> -treated patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7062	 tuberculosis patients on <e1>isoniazid</e1> eat certain varieties of fish they may develop a <e2>histamine reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7063	 hepatitis</e1> associated with <e2>disulfiram</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7064	 report a case of <e1>fatal fulminant hepatitis</e1> caused by the use of <e2>disulfiram</e2> in a man with previously normal hepatocellular function."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7065	 45-year-old woman with thyrotoxicosis developed <e1>agranulocytosis</e1> after treatment with <e2>propylthiouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7066	 patient was given <e1>methimazole</e1> instead of propylthiouracil but, 10 weeks later, <e2>agranulocytosis</e2> again occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7067	 is, to the best of our knowledge, the first report of a case in which <e1>agranulocytosis</e1> followed treatment with both propylthiouracil and <e2>methimazole</e2> in the same patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7068	 is, to the best of our knowledge, the first report of a case in which <e1>agranulocytosis</e1> followed treatment with both <e2>propylthiouracil</e2> and methimazole in the same patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7069	 55-yr-old man developed <e1>prolonged jaundice</e1> and sicca complex after a course of <e2>thiabendazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7070	 55-yr-old man developed prolonged jaundice and <e1>sicca complex</e1> after a course of <e2>thiabendazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7071	 cholestasis</e1> and sicca complex after <e2>thiabendazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7072	 cholestasis and <e1>sicca complex</e1> after <e2>thiabendazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7073	 literature on <e1>thiabendazole</e1> -induced <e2>cholestasis</e2> and its association with sicca complex is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7074	 literature on <e1>thiabendazole</e1> -induced cholestasis and its association with <e2>sicca complex</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7075	 was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later died of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7076	 was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later died of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7077	 was placed on adjuvant Adriamycin (<e1>doxorubicin</e1>) chemotherapy, but 6 months later died of <e2>Adriamycin toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7078	 was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later <e2>died</e2> of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7079	 was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later <e2>died</e2> of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7080	 was placed on adjuvant Adriamycin (<e1>doxorubicin</e1>) chemotherapy, but 6 months later <e2>died</e2> of Adriamycin toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7081	 hemorrhage and <e1>focal seizures</e1> secondary to use of <e2>L-asparaginase</e2> during induction therapy of acute lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7082	 hemorrhage</e1> and focal seizures secondary to use of <e2>L-asparaginase</e2> during induction therapy of acute lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7083	 sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and <e2>asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7084	 sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, <e2>prednisone</e2>, and asparaginase."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7085	 sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with <e2>vincristine sulfate</e2>, prednisone, and asparaginase."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7086	 cause is presumed to be secondary to hypercoagulability due to <e1>asparaginase</e1> -induced <e2>antithrombin III deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7087	 patients with rheumatoid arthritis developed a syndrome resembling <e1>lupus erythematosus</e1> while being treated with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7088	 lupus erythematosus</e1> during <e2>penicillamine</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7089	 the amount of <e1>prednisone</e1> required to maintain normotension resulted in <e2>Cushingoid features</e2> and has been discontinued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7090	 should be aware of <e1>fasting hypoglycemia</e1> as an unusual but potentially serious complication of <e2>disopyramide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7091	 (Norpace)-induced <e2>hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7092	 (<e1>Norpace</e1>)-induced <e2>hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7093	 -associated <e2>renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7094	 other woman had rheumatoid arthritis and developed <e1>acute tubular necrosis</e1> after treatment with gentamicin and <e2>cefoxitin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7095	 other woman had rheumatoid arthritis and developed <e1>acute tubular necrosis</e1> after treatment with <e2>gentamicin</e2> and cefoxitin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7096	 elderly women suffered an <e1>acute deterioration of renal function</e1> after treatment with <e2>cefoxitin sodium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7097	 anuria</e1> following administration of angiotensin I-converting enzyme inhibitor (<e2>SQ 14225</e2>) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7098	 report on a patient with renal artery stenosis who had only 1 kidney and in whom <e1>acute renal impairment</e1> developed with transient anuria after the administration of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7099	 report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with <e1>transient anuria</e1> after the administration of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7100	 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7101	 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7102	 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7103	 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7104	 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7105	 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7106	 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7107	 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7108	 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7109	 was the third drug to induce <e2>AVT</e2> in this patient; she received 200 mg/day six days per week for six months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7110	 ventricular tachycardia (torsade de pointes) induced by amiodarone: <e1>arrhythmia</e1> previously induced by quinidine and <e2>disopyramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7111	 ventricular tachycardia (torsade de pointes) induced by amiodarone: <e1>arrhythmia</e1> previously induced by <e2>quinidine</e2> and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7112	 ventricular tachycardia</e1> (torsade de pointes) induced by <e2>amiodarone</e2>: arrhythmia previously induced by quinidine and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7113	 ventricular tachycardia (<e1>torsade de pointes</e1>) induced by <e2>amiodarone</e2>: arrhythmia previously induced by quinidine and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7114	 years later, 24 hours following an increase in the dose of <e1>disopyramide</e1> from 300 to 600 mg/day, <e2>AVT</e2> with syncope occurred; isoproterenol abolished the arrhythmia instantly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7115	 years later, 24 hours following an increase in the dose of <e1>disopyramide</e1> from 300 to 600 mg/day, AVT with <e2>syncope</e2> occurred; isoproterenol abolished the arrhythmia instantly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7116	 the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient <e1>coronary vasoconstriction</e1> induced by the <e2>dopamine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7117	 remission of the <e1>nephrosis</e1> occurred after discontinuation of <e2>hydroxychloroquine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7118	 following <e2>cimetidine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7119	 case of an adult who developed both <e1>hepatic dysfunction</e1> and an impaired macrophage migration after exposure to <e2>cimetidine</e2> is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7120	 case of an adult who developed both hepatic dysfunction and an <e1>impaired macrophage migration</e1> after exposure to <e2>cimetidine</e2> is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7121	 have been only two reports of <e1>cimetidine</e1> -induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7122	 66-year-old mand suffering from severe coronary heart disease took <e1>digoxin</e1> with suicidal intent an was treated for the ensuing <e2>complete atrioventricular block</e2> with <e1>digoxin</e1> -specific antibody fragments."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7123	 in effort-induced <e2>angina pectoris</e2> in patients with normal coronary arteries."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7124	 -associated <e2>diarrhea</e2> has been previously described in 6%-10% of patients receiving the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7125	 report describes a case of <e1>flucytosine</e1> -associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and <e2>marked separation of loops of bowel</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7126	 report describes a case of <e1>flucytosine</e1> -associated ulcerating enteritis in which the small bowel x-ray demonstrated <e2>severe luminal narrowing</e2>, ulceration, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7127	 report describes a case of <e1>flucytosine</e1> -associated <e2>ulcerating enteritis</e2> in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7128	 report describes a case of <e1>flucytosine</e1> -associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, <e2>ulceration</e2>, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7129	 enteritis</e1> associated with <e2>flucytosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7130	 without peripheral neuropathy in a patient taking <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7131	 adolescent male developed <e1>acute pancreatitis</e1> and pseudocyst of the pancreas 16 weeks after cessation of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7132	 adolescent male developed acute pancreatitis and <e1>pseudocyst of the pancreas</e1> 16 weeks after cessation of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7133	 pseudocyst of the pancreas</e1> can be a complication of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7134	 -induced <e2>pancreatitis</e2> has been reported during or closely following administration of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7135	 cases of <e1>pseudocyst of the pancreas</e1> in two women and one man have previously been reported with the use of intravenous <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7136	 one patient, treatment with <e1>DCA</e1> was associated with a <e2>decrease in blood lactate levels</e2> from 11.2 mM before treatment to 0.8 mM 16 h later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7137	 <e1>delirious</e1> patients suffering from <e2>lithium</e2> intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7138	 course of <e1>delirium</e1> due to <e2>lithium</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7139	 <e1>hyperkalemia</e1> induced by <e2>arginine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7140	 hyperkalemia</e1> was observed during and immediately after an infusion of <e2>arginine monohydrochloride</e2> in two patients with severe hepatic disease and moderate renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7141	 58-year-old man with rheumatoid arthritis developed <e1>lichen planus</e1> during treatment with <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7142	 provoked by <e2>gold</e2> seems not to have been described elsewhere."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7143	 planus and <e1>acne</e1> provoked by <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7144	 planus</e1> and acne provoked by <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7145	 case history confirms that <e1>gold</e1> treatment, even in the same patient, can give rise to a wide range of <e2>skin disturbances</e2>, which in many cases do not break out until long after the drug has been withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7146	 hyperparathyroidism in certain patients with <e1>lithium</e1> <e2>nephrotoxicity</e2> is also possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7147	 hyperparathyroidism</e1> in certain patients with <e2>lithium</e2> nephrotoxicity is also possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7148	 results indicate that <e1>lithium</e1> may cause <e2>biochemical hyperparathyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7149	 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (<e1>CHB</e1>) following administration of <e2>disopyramide phosphate</e2> (Norpace)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7150	 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (<e1>CHB</e1>) following administration of disopyramide phosphate (<e2>Norpace</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7151	 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed <e1>complete heart block</e1> (CHB) following administration of <e2>disopyramide phosphate</e2> (Norpace)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7152	 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed <e1>complete heart block</e1> (CHB) following administration of disopyramide phosphate (<e2>Norpace</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7153	 -induced <e2>heart block</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7154	 transient increases in ectopy after <e1>bretylium</e1> therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to <e2>cardiac arrest</e2> has not previously been emphasized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7155	 transient increases in ectopy after <e1>bretylium</e1> therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening <e2>ventricular arrhythmia</e2> leading to cardiac arrest has not previously been emphasized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7156	 the first patient, two episodes of <e1>ventricular tachycardia</e1> requiring cardioversion occurred in close temporal sequence with administering <e2>bretylium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7157	 the second case, five <e1>cardiac arrests</e1> due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7158	 the second case, five cardiac arrests due to ventricular tachycardia and <e1>fibrillation</e1> occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7159	 the second case, five cardiac arrests due to <e1>ventricular tachycardia</e1> and fibrillation occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7160	 ventricular tachycardia and <e1>fibrillation</e1> after intravenous <e2>bretylium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7161	 ventricular tachycardia</e1> and fibrillation after intravenous <e2>bretylium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7162	 is known to cause <e2>acute renal failure</e2> and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7163	 is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or <e2>nephrotic syndrome</e2> is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7164	 is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with <e2>proteinuria</e2> or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7165	 is known to cause acute renal failure and <e2>tubulo-interstitial disease</e2>, but the recently described association with proteinuria or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7166	 syndrome</e1> associated with <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7167	 patients on long-term <e1>lithium</e1> therapy developed the <e2>nephrotic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7168	 67-year-old man developed <e1>diarrhea</e1> shortly after a 10-day course of oral <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7169	 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, <e1>sensori-neural hearing loss</e1> after <e2>vincristine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7170	 acoustic nerve palsy</e1> associated with <e2>vincristine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7171	 acoustic (VIII) nerve palsy</e1> in this patient was most likely a manifestation of <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7172	 acoustic (VIII) nerve palsy in this patient was most likely a manifestation of <e1>vincristine</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7173	 case of <e1>timolol</e1> -associated <e2>heart failure</e2> in a 73-year old white man is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7174	 and congestive heart failure associated with ocular <e2>timolol maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7175	 and <e1>congestive heart failure</e1> associated with ocular <e2>timolol maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7176	 the second day of hospitalization, it was noted that the patient's <e1>dyspnea</e1> and sinus bradycardia could be related to a recent increase in his <e2>timolol</e2> dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7177	 the second day of hospitalization, it was noted that the patient's dyspnea and <e1>sinus bradycardia</e1> could be related to a recent increase in his <e2>timolol</e2> dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7178	 ventricular fibrillation</e1> after treatment with <e2>digoxin</e2> in a 27-year-old man with mitral leaflet prolapse syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7179	 was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and <e2>functional impairment</e2>; he died of ventricular fibrillation 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7180	 was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated <e2>left ventricular dilatation</e2> and functional impairment; he died of ventricular fibrillation 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7181	 was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of <e2>ventricular fibrillation</e2> 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7182	 of <e1>rapid mood cycling</e1> during <e2>L-dopa</e2> treatment in a bipolar patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7183	 authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which <e1>L-dopa</e1> <e2>shortened the manic-depressive cycle</e2> length when administered in a double-blind trial."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7184	 disease</e1> induced by <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7185	 paper reports a case of fatal <e2>perhexiline maleate</e2> liver injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7186	 non-lymphocytic leukemia</e1> in patients with ovarian carcinoma following long-term treatment with Treosulfan (= <e2>dihydroxybusulfan</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7187	 non-lymphocytic leukemia</e1> in patients with ovarian carcinoma following long-term treatment with <e2>Treosulfan</e2> (= dihydroxybusulfan)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7188	 non-lymphocytic leukemia</e1> occurred in eight women following long-term treatment with Treosulfan (= <e2>dihydroxybusulfan</e2>) for ovarian carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7189	 non-lymphocytic leukemia</e1> occurred in eight women following long-term treatment with <e2>Treosulfan</e2> (= dihydroxybusulfan) for ovarian carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7190	 of the eight cases of <e1>acute leukemia</e1> occurred in a series of 553 patients treated with <e2>Treosulfan</e2> for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7191	 probability of developing <e1>acute leukemia</e1> in this study was not significantly correlated to the total cumulative dosage of <e2>Treosulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7192	 -related <e2>bronchospasm</e2> in patients without history of asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7193	 of a negative history of asthma, therefore, life-threatening <e1>bronchospasm</e1> must be considered a possible complication of <e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7194	 the <e1>bronchospasm</e1> was relieved with discontinuation of <e2>propranolol</e2> and supportive bronchodilator therapy, the <e1>bronchospasm</e1> was believed to be caused by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7195	 the <e1>bronchospasm</e1> was relieved with discontinuation of <e2>propranolol</e2> and supportive bronchodilator therapy, the <e1>bronchospasm</e1> was believed to be caused by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7196	 patients with no history of asthma or allergy developed <e1>bronchospasm</e1> while taking <e2>propranolol</e2> for hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7197	 an unrecognized cause of <e2>central nervous system dysfunction</e2> in patients undergoing cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7198	 potential role of <e1>propranolol</e1> in inducing <e2>central nervous system disturbances</e2> is emphasized, and the literature on the subject is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7199	 fibrosis of the lung</e1> is a potential complication of <e2>methotrexate</e2> therapy for psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7200	 interstitial fibrosis</e1> with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of <e2>methotrexate</e2> for 18 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7201	 interstitial lung disease</e1> from prolonged <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7202	 of the pupil</e1> and visual-evoked potential in <e2>quinine</e2> amblyopia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7203	 of the pupil and visual-evoked potential in <e1>quinine</e1> <e2>amblyopia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7204	 transient tonic pupillary response, denervation supersensitivity, and <e1>abnormal visual-evoked potentials</e1> in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7205	 transient tonic pupillary response, <e1>denervation supersensitivity</e1>, and abnormal visual-evoked potentials in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7206	 <e1>transient tonic pupillary response</e1>, denervation supersensitivity, and abnormal visual-evoked potentials in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7207	 blindness with a transient tonic pupillary response, denervation supersensitivity, and <e1>abnormal visual-evoked potentials</e1> developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7208	 blindness with a transient tonic pupillary response, <e1>denervation supersensitivity</e1>, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7209	 blindness with a transient tonic pupillary response</e1>, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7210	 <e1>practolol</e1> induced <e2>sclerosing peritonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7211	 case of <e1>skeletal fluorosis</e1> induced by prolonged treatment with <e2>niflumic acid</e2>, a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7212	 ruling out a hydrotelluric source of fluorine, the patient's <e1>fluorosis</e1> was linked to chronic use of <e2>niflumic acid</e2>, following the publication in 1978 of the 2 previously reported cases affected by this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7213	 acid</e1> -induced <e2>skeletal fluorosis</e2>: iatrogenic disease or therapeutic perspective for osteoporosis?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7214	 fluorine contained in <e1>niflumic acid</e1> induced a marked <e2>densification of trabecular bone</e2> in all 3 cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7215	 associated with use of <e2>D-penicillamine</e2> in rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7216	 cases and a review of the literature suggested that <e1>hepatotoxicity</e1>, though rare, should be added to the list of adverse reactions to <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7217	 patients with rheumatoid arthritis developed evidence of <e1>hepatotoxicity</e1> while receiving <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7218	 62-year-old Indian with diabetic nephropathy controlled with <e1>metformin</e1>, developed <e2>miliary tuberculosis</e2> for which he was treated with rifampicin, isoniazid and ethambutol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7219	 acid</e1> -induced <e2>hypoglycaemia</e2> in a patient with diabetic nephropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7220	 induction of <e1>hypoglycaemia</e1> with <e2>PAS</e2> in this patient suggests a potential role for <e2>PAS</e2> in the treatment of diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7221	 introduction of <e1>para-aminosalicylic acid</e1> (PAS) led to <e2>hypoglycaemic coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7222	 introduction of para-aminosalicylic acid (<e1>PAS</e1>) led to <e2>hypoglycaemic coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7223	 patient developed papilloedema and <e1>hepatic dysfunction</e1> while being treated with <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7224	 patient developed <e1>papilloedema</e1> and hepatic dysfunction while being treated with <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7225	 and <e1>hepatic dysfunction</e1> apparently induced by <e2>perhexiline maleate</e2> (Pexid)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7226	 and <e1>hepatic dysfunction</e1> apparently induced by perhexiline maleate (<e2>Pexid</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7227	 and hepatic dysfunction apparently induced by <e2>perhexiline maleate</e2> (Pexid)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7228	 and hepatic dysfunction apparently induced by perhexiline maleate (<e2>Pexid</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7229	 <e1>increased pigmementation of skin</e1> immediately overlying veins used for multiple <e2>5-fluorouracil</e2> infusions was noted."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7230	 <e1>pigmentary changes</e1> associated with <e2>5-fluorouracil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7231	 useful in the management of chronic alcoholism, <e1>disulfiram</e1> is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include <e2>catatonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7232	 encephalopathy as a cause of the <e2>catatonia syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7233	 <e2>encephalopathy</e2> as a cause of the catatonia syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7234	 authors describe a case of the <e1>catatonia syndrome</e1> associated with <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7235	 antidiuretic hormone secretion</e1> after high dose <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7236	 report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of <e1>inappropriate secretion of antidiuretic hormone</e1> after receiving a high dose of <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7237	 cases of <e1>oesophageal damage</e1> associated with ingestion of the urinary anti-spasmodic agent <e2>emepronium bromide</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7238	 ulceration</e1> due to <e2>emepronium bromide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7239	 toxicity</e1> due to <e2>miconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7240	 of them had a history of cardiac disease, and with the possible exception of one case of <e1>cardiac arrest</e1>, where the patient received <e2>doxorubicin</e2>, no predisposing factors could be found."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7241	 patients with hematologic malignancies who were treated with <e1>miconazole</e1> for either suspected or proven fungal infections developed eight episodes of major adverse <e2>cardiorespiratory and anaphylactic reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7242	 -induced <e2>myopathy</e2> in patients with diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7243	 we have recently had four cases of <e1>clofibrate</e1> -induced <e2>myopathy</e2> in patients with diabetes insipidus due to hypothalamic lesions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7244	 should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with <e1>clofibrate</e1>, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of <e2>myopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7245	 of <e2>hycanthone</e2> in patients with metastatic breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7246	 a phase II study of <e1>hycanthone</e1> in patients with breast cancer we have recently observed <e2>severe hepatotoxicity</e2>, even at lower doses, which resulted in two drug-related deaths."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7247	 interstitial pneumonitis</e1> following high-dose intermittent <e2>chlorambucil</e2> therapy for chronic lymphocyte leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7248	 several of these courses of therapy, <e1>respiratory distress</e1> occurred 9 to 12 days after the <e2>chlorambucil</e2> was given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7249	 case of <e1>barbiturate</e1> -induced <e2>submassive hepatic necrosis</e2> is presented and the literature is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7250	 -induced <e2>submassive hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7251	 patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that <e1>barbiturates</e1> can be added to the list of agents which can cause <e2>submassive hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7252	 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited <e1>granulocytopenia</e1> 8 days following the administration of oral sustained-release <e2>procainamide</e2> (750 mg/day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7253	 <e1>procainamide</e1> -induced <e2>reversible granulocytopenia</e2> after myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7254	 frequency and relationship of <e1>granulocytopenia</e1> caused by sustained-release <e2>procainamide</e2> in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7255	 gammopathy</e1> and subsequent multiple myeloma in a patient on chronic <e2>diphenylhydantoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7256	 gammopathy and subsequent <e1>multiple myeloma</e1> in a patient on chronic <e2>diphenylhydantoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7257	 development of an <e1>IgG lambda-type monoclonal gammopathy</e1> and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (<e2>DILANTIN</e2>) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7258	 development of an <e1>IgG lambda-type monoclonal gammopathy</e1> and subsequent multiple myeloma in an epilepsy patient on <e2>diphenylhydantoin</e2> (DILANTIN) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7259	 development of an IgG lambda-type monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in an epilepsy patient on diphenylhydantoin (<e2>DILANTIN</e2>) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7260	 development of an IgG lambda-type monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in an epilepsy patient on <e2>diphenylhydantoin</e2> (DILANTIN) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7261	 recommended periodic examination of the serum proteins in patients receiving <e1>diphenylhydantoin</e1> in order to detect development of <e2>monoclonal gammopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7262	 <e1>Atovaquone</e1> should be added to the list of agents causing <e2>vortex keratopathy</e2> involving the corneal epithelium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7263	 We studied a case of <e1>vortex keratopathy</e1> that was associated with the use of <e2>atovaquone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7264	 Similar to previous findings of drug-induced <e1>vortex keratopathy</e1>, <e2>atovaquone</e2> <e1>vortex keratopathy</e1> is presumably caused by its lipophilic properties."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7265	 Similar to previous findings of drug-induced <e1>vortex keratopathy</e1>, <e2>atovaquone</e2> <e1>vortex keratopathy</e1> is presumably caused by its lipophilic properties."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7266	 keratopathy</e1> associated with <e2>atovaquone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7267	 injudiciously, <e1>naloxone</e1> can lead to withdrawal syndrome, return of <e2>severe pain</e2>, and other adverse effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7268	 injudiciously, <e1>naloxone</e1> can lead to <e2>withdrawal syndrome</e2>, return of severe pain, and other adverse effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7269	 there remain questions concerning whether these drugs, especially <e1>methimazole</e1> (MMI), may be associated with aplasia cutis congenita (<e2>ACC</e2>) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7270	 there remain questions concerning whether these drugs, especially methimazole (<e1>MMI</e1>), may be associated with aplasia cutis congenita (<e2>ACC</e2>) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7271	 there remain questions concerning whether these drugs, especially <e1>methimazole</e1> (MMI), may be associated with <e2>aplasia cutis congenita</e2> (ACC) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7272	 there remain questions concerning whether these drugs, especially methimazole (<e1>MMI</e1>), may be associated with <e2>aplasia cutis congenita</e2> (ACC) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7273	 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an <e1>acute reversible encephalopathy</e1> within 15 days of initiation of <e2>flecainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7274	 reversible ataxo-myoclonic encephalopathy</e1> with <e2>flecainide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7275	 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and <e1>bone marrow aplasia</e1> 4 and 7 days, respectively, following a single dose of 40 mg/m2 <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7276	 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and <e1>bone marrow aplasia</e1> 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7277	 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed <e1>severe skin rash</e1> and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7278	 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed <e1>severe skin rash</e1> and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7279	 marrow aplasia</e1> and severe skin rash after a single low dose of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7280	 marrow aplasia and <e1>severe skin rash</e1> after a single low dose of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7281	 of an <e1>extensive skin rash</e1> following a single dose of <e2>MTX</e2> may be an early warning sign for life-threatening bone marrow aplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7282	 the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or <e1>acute hypersensitivity reaction</e1> to <e2>MTX</e2> in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7283	 the absence of mucositis or diarrhea, <e1>severe dermatologic toxicity</e1> following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to <e2>MTX</e2> in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7284	 acetate</e1> <e2>withdrawal syndrome</e2> under combined androgen blockade for advanced prostate cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7285	 second had acute cystitis and was treated by sulphonamide and the third developed <e1>myopia</e1> coincident with <e2>metronidazole</e2> treatment for trichomonas vaginalis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7286	 second had acute cystitis and was treated by <e1>sulphonamide</e1> and the third developed <e2>myopia</e2> coincident with metronidazole treatment for trichomonas vaginalis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7287	 syndrome</e1> related to systemic lupus erythematosus after <e2>griseofulvin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7288	 syndrome related to <e1>systemic lupus erythematosus</e1> after <e2>griseofulvin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7289	 our knowledge, this is the first case of <e1>griseofulvin</e1> -exacerbated <e2>lupus</e2> in which nephrotic syndrome has been observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7290	 our knowledge, this is the first case of <e1>griseofulvin</e1> -exacerbated lupus in which <e2>nephrotic syndrome</e2> has been observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7291	 report a 16-year-old male who developed <e1>nephrotic syndrome</e1> related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7292	 report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of <e1>systemic lupus erythematosus</e1> after treatment with <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7293	 side effects</e1> in two patients receiving <e2>gold</e2> injections for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7294	 first patient developed <e1>mild nitritoid symptoms</e1> and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7295	 first patient developed <e1>mild nitritoid symptoms</e1> and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7296	 first patient developed mild nitritoid symptoms and <e1>pain</e1> in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7297	 first patient developed mild nitritoid symptoms and <e1>pain</e1> in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7298	 first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to <e1>T10-T12 dermatomes</e1>, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7299	 first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to <e1>T10-T12 dermatomes</e1>, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7300	 second patient experienced <e1>mild nitritoid symptoms</e1> following several <e2>GSTM</e2> injections prior experiencing a cerebrovascular accident within several hours of her next injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7301	 sensorineural hearing loss</e1> following intravenous <e2>ketoralac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7302	 PAN and <e1>methotrexate</e1> have been independently demonstrated to cause <e2>sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7303	 <e1>PAN</e1> and methotrexate have been independently demonstrated to cause <e2>sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7304	 recommend the cautious use of <e1>ketorolac</e1> in patients with underlying illnesses where NSAID-induced <e2>ototoxicity</e2> could result in adverse otologic consequences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7305	 report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed <e1>bilateral sensorineural hearing loss</e1> 25 minutes after receiving 30 mg of intravenous <e2>ketoralac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7306	 reactions</e1> with intraperitoneal <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7307	 SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal <e1>cisplatin</e1> and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit <e2>anaphylactoid reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

7308	 We conclude that a high dose combined with a short infusion time increases the risk of <e1>anaphylactoid reactions</e1> with the administration of intraperitoneal <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7309	 <e1>Anaphylactoid reactions</e1> have been described previously with <e2>cisplatin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7310	 her third cycle, she again received <e1>cisplatin</e1> <e2>100 mg/m2</e2> over 30 minutes and developed palmar pruritus, urticaria, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7311	 her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and <e2>edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7312	 her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed <e2>palmar pruritus</e2>, urticaria, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7313	 her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed palmar pruritus, <e2>urticaria</e2>, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7314	 To report the occurrence of <e1>anaphylactoid reactions</e1> to intraperitoneal <e2>cisplatin</e2> in 3 patients."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7315	 observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating <e1>anaphylactoid reactions</e1> with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7316	 -related <e2>myocardial infarction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

7317	 occurrence of a <e1>myocardial infarction</e1> is reported after chemotherapy containing <e2>etoposide</e2>, in a man with no risk factors for coronary heart disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7318	 9-year-old boy developed <e1>acute renal failure</e1> following intravenous <e2>acyclovir</e2> (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7319	 renal failure</e1> in a child associated with <e2>acyclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7320	 ischemic optic neuropathy</e1> secondary to <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7321	 <e1>Anterior ischemic optic neuropathy</e1> may complicate treatment with <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7322	 To report the occurrence of <e1>anterior ischemic optic neuropathy</e1> as a complication of treatment with <e2>interferon alfa</e2> and to consider the possible underlying mechanisms for this association."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7323	 Two patients, ages 40 and 51 years, undergoing treatment with <e1>interferon alfa</e1> for malignant neoplasms experienced <e2>sudden bilateral, sequential visual loss</e2> with disc-related field defects and segmental optic disc edema."
DRUG-ADE(e1,e2)
Comment: DRUG-

7324	 interval between initiating treatment with <e1>interferon alfa</e1> and onset of <e2>anterior ischemic optic neuropathy</e2> was similar to that of interferon-associated vascular retinopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7325	 interval between initiating treatment with <e1>interferon</e1> alfa and onset of anterior ischemic optic neuropathy was similar to that of <e1>interferon</e1> -associated <e2>vascular retinopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7326	 authors describe a case of <e1>neuroleptic malignant syndrome</e1> that occurred in a patient on <e2>amitriptyline</e2> and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7327	 authors describe a case of <e1>neuroleptic malignant syndrome</e1> that occurred in a patient on amitriptyline and <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7328	 SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with <e1>increased serum thyroid-stimulating hormone</e1> (TSH) concentrations after switching from 1 <e2>levothyroxine</e2> product to another."
DRUG-ADE(e2,e1)
Comment: DRUG-

7329	 is shown in this report that <e1>adenosine</e1> was associated with dangerous worsening of <e2>arrhythmia</e2> in patients with atrial flutter."
DRUG-ADE(e1,e2)
Comment: DRUG-A

7330	 <e1>alterations in heart rate</e1> after the use of <e2>adenosine</e2> in atrial flutter."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7331	 adverse effects, such as <e1>disorientation</e1> and temporary amnesia, have been reported in patients in the analogous agent, <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7332	 adverse effects, such as disorientation and <e1>temporary amnesia</e1>, have been reported in patients in the analogous agent, <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7333	 To describe a probable case of <e1>transient global amnesia</e1> caused by <e2>propafenone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7334	 <e1>propafenone</e1> -induced <e2>transient global amnesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7335	 case of <e1>acute subdural haematoma</e1> originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic <e2>aspirin</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7336	 haemorrhage</e1> from a meningioma in a patient receiving <e2>aspirin</e2> prophylaxis: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7337	 effect of low-dose mianserin on <e1>fluvoxamine</e1> -induced <e2>akathisia</e2> in an obsessive-compulsive patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7338	 side effects</e1> induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. <e2>fluoxetine</e2> and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7339	 side effects</e1> induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and <e2>sertraline</e2>, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7340	 the occurrence and management of <e1>akathisia</e1> induced by <e2>fluvoxamine</e2> have not been described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7341	 the presented case <e1>fluvoxamine</e1> -induced <e2>akathisia</e2> in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7342	 42 year old man, treated for testicular carcinoma with combination chemotherapy that included <e1>bleomycin</e1>, developed life threatening <e2>interstitial pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7343	 <e1>bleomycin</e1> <e2>lung toxicity</e2>: reversal with high dose corticosteroids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7344	 report suggests that <e1>bleomycin</e1> <e2>lung toxicity</e2> may be reversible if treated aggressively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7345	 of <e1>gold</e1> -induced <e2>neutropenia</e2> with granulocyte colony-stimulating factor (G-CSF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7346	 have successfully overcome <e1>severe neutropenia</e1> in an RA patient treated with <e2>gold</e2> salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7347	 and cardiac arrest have been reported during <e2>amphotericin B</e2> administration but no effective technique has been described to prevent them."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7348	 and <e1>cardiac arrest</e1> have been reported during <e2>amphotericin B</e2> administration but no effective technique has been described to prevent them."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7349	 of serum electrolyte imbalance prevents <e1>cardiac arrhythmia</e1> during <e2>amphotericin B</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7350	 saw two patients with kala-azar resistant to sodium stibogluconate who developed <e1>cardiac arrest</e1> after <e2>amphotericin</e2> infusion (in spite of tolerating a test dose)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7351	 describe two cases that illustrate the use of <e1>lithium</e1> in the treatment of veterans with PTSD who complained of serious problems with irritability or <e2>angry outbursts</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7352	 describe two cases that illustrate the use of <e1>lithium</e1> in the treatment of veterans with PTSD who complained of serious problems with <e2>irritability</e2> or angry outbursts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7353	 hyperthyroidism</e1> following transient thyrotoxicosis during <e2>interferon</e2> therapy for chronic hepatitis type C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7354	 hyperthyroidism following <e1>transient thyrotoxicosis</e1> during <e2>interferon</e2> therapy for chronic hepatitis type C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7355	 case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of <e1>Graves' hyperthyroidism</e1> during <e2>IFN</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7356	 report a case of <e1>Graves' hyperthyroidism</e1> induced by long-term interferon (<e2>IFN</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7357	 report a case of <e1>Graves' hyperthyroidism</e1> induced by long-term <e2>interferon</e2> (IFN) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7358	 <e1>INH</e1> <e2>neurotoxicity</e2> was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute <e1>INH</e1> <e2>neurotoxicity</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7359	 <e1>INH</e1> <e2>neurotoxicity</e2> was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute <e1>INH</e1> <e2>neurotoxicity</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7360	 <e1>isoniazid</e1> <e2>neurotoxicity</e2> in an urban hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7361	 We have seen an increased incidence of acute <e1>INH</e1> <e2>neurotoxicity</e2> because of the resurgence of TB in New York City."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7362	 patients with a known access to <e1>INH</e1>, <e2>seizures</e2> should be considered to be caused by <e1>INH</e1> toxicity unless proved otherwise."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7363	 To describe the presentation and treatment of acute isoniazid (<e1>INH</e1>) <e2>neurotoxicity</e2> appearing at an inner-city municipal hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-A

7364	 To describe the presentation and treatment of acute <e1>isoniazid</e1> (INH) <e2>neurotoxicity</e2> appearing at an inner-city municipal hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-A

7365	 pyridoxine, the specific antidote for <e1>INH</e1> -induced <e2>refractory seizures</e2>, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7366	 At our institution, no children appeared with acute <e1>INH</e1> <e2>neurotoxicity</e2> in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993."
DRUG-ADE(e1,e2)
Comment: DRUG-A

7367	 hypertension</e1> associated with topical ocular use of <e2>phenylephrine</e2> in dogs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7368	 <e1>Squamous metaplasia</e1> in these cases appears to be a consequence of <e2>progestin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7369	 To report the finding of <e1>squamous metaplasia within endometrial glands</e1> occurring as a result of <e2>progestin</e2> therapy of hyperplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7370	 Extensive <e1>squamous metaplasia</e1> was found in endometrial glands following <e2>progestin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

7371	 caused by the use of <e2>furosemide</e2> was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7372	 -associated <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7373	 dose-limiting toxicity of <e1>KW-2149</e1> is <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7374	 complaints</e1> were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7375	 complaints</e1> were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with <e2>ifosfamide</e2>, a derivative of cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7376	 of a potential drug-induced <e1>Fanconi syndrome</e1> is important when managing pediatric oncology patients previously treated with <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7377	 cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and <e2>cirrhosis</e2> related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7378	 cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and <e2>cirrhosis</e2> related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7379	 cases constitute the most severe cases of <e1>benzarone</e1> <e2>hepatotoxicity</e2> reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7380	 cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of <e2>(sub)fulminant hepatitis</e2> and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7381	 cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of <e2>(sub)fulminant hepatitis</e2> and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7382	 hepatotoxicity</e1> related to <e2>benzarone</e2>: a report of three cases with two fatalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7383	 report three cases of <e1>severe hepatotoxicity</e1> related to <e2>benzarone</e2>, a benzofuran derivative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

7384	 stress the potential of <e1>benzarone</e1> to cause <e2>hepatotoxicity</e2>, which usually resembles severe chronic active hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7385	 stress the potential of <e1>benzarone</e1> to cause hepatotoxicity, which usually resembles <e2>severe chronic active hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7386	 study: a modified topical treatment regimen for sodium <e1>warfarin</e1> -induced <e2>necrotizing fasciitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7387	 case study describes an atypical case of refractory, <e1>sodium warfarin</e1> -induced necrotizing fasciitis and <e2>myonecrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7388	 case study describes an atypical case of refractory, <e1>sodium warfarin</e1> -induced <e2>necrotizing fasciitis</e2> and myonecrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

